Sotsiaalministeerium · 18. detsember 2018
Sisu (failidest)
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
EUROPEAN COMMISSION
DIRECTORATE-GENERAL RESEARCH & INNOVATION
Health
Innovative and Personalised Medicine
GRANT AGREEMENT
NUMBER 825575 — EJP RD
This Agreement (‘the Agreement’) is between the following parties:
on the one part,
the European Union (‘the EU’), represented by the European Commission ('the Commission'),
represented for the purposes of signature of this Agreement by the Head of Unit, DIRECTORATE-
GENERAL RESEARCH & INNOVATION, Health, Administration and finance, Mila BAS
SANCHEZ,
and
on the other part,
1. ‘the coordinator’:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
established in RUE DE TOLBIAC 101, PARIS 75654, France, VAT number: FR31180036048,
represented for the purposes of signing the Agreement by Regional Delegate of Inserm,
Camille CHAUDONNERET
and the following other beneficiaries, if they sign their ‘Accession Form’ (see Annex 3 and Article 56):
2. FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG (FWF),
established in SENSENGASSE 1, WIEN 1090, Austria, VAT number: ATU37675903,
3. AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (AIT), established in
GIEFINGGASSE 4, WIEN 1210, Austria, VAT number: ATU14703506,
4. LUDWIG BOLTZMANN GESELLSCHAFT GMBH (LBG (LBI-RUD)), established in
NUSSDORFER STRASSE 64 6 STOCK, WIEN 1090, Austria, VAT number: ATU61640503,
5. FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FNRS), established in Rue
d'Egmont 5, BRUXELLES 1050, Belgium,
6. FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN (FWO),
established in EGMONTSTRAAT 5, BRUSSEL 1000, Belgium, VAT number: BE0880212840,
7. KATHOLIEKE UNIVERSITEIT LEUVEN (KU Leuven), established in OUDE MARKT 13,
LEUVEN 3000, Belgium, VAT number: BE0419052173,
1
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
8. MINISTRY OF EDUCATION YOUTH AND SPORTS (MEYS), established in Karmelitska 7,
Prague 118 12, Czech Republic,
9. SOTSIAALMINISTEERIUM (MOSAE), established in Suur-Ameerika 1, TALLINN 10122,
Estonia,
10. SUOMEN AKATEMIA (AKA), established in HAKANIEMENRANTA 6, HELSINKI 00531,
Finland, VAT number: FI02458939,
11. AGENCE NATIONALE DE LA RECHERCHE (ANR), established in 50 avenue Daumesnil,
PARIS 75012, France,
12. FONDATION MALADIES RARES (FFRD), established in RUE DIDOT 96, PARIS 75014,
France,
13. ASS FRANCAISE CONTRE LES MYOPATHIES (AFM), established in 47-83 47
BOULEVARD DE L'HOPITAL, INSTITUT DE MYOLO, PARIS 75013, France, VAT number:
FR00775609571,
14. IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES
FONDATION (IMAGINE), established in RUE DE VAUGIRARD 156, PARIS 75015, France,
15. DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV (DLR), established in
Linder Hoehe, KOELN 51147, Germany,
16. UNIVERSITAETSKLINIKUM AACHEN (UKA), established in Pauwelsstrasse 30, AACHEN
52074, Germany, VAT number: DE813100566,
17. CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE), established in Chariteplatz
1, BERLIN 10117, Germany, VAT number: DE228847810,
18. UNIVERSITAETSKLINIKUM FREIBURG (UKL-FR), established in HUGSTETTER
STRASSE 49, FREIBURG 79106, Germany, VAT number: DE811506626,
19. NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL (NKFIH), established
in KETHLY ANNA TER 1, BUDAPEST 1077, Hungary, VAT number: HU15831000,
20. THE HEALTH RESEARCH BOARD (HRB), established in LOWER BAGGOT STREET 73,
DUBLIN 2, Ireland, VAT number: IE4820764P,
21. MINISTERO DELLA SALUTE (IT-MOH), established in Via Giorgio Ribotta 5, ROMA
00144, Italy, VAT number: N/A,
22. REGIONE TOSCANA (TuscReg), established in Palazzo Strozzi Sacrati - Piazza del Duomo
10, FIRENZE 50122, Italy, VAT number: IT01386030488,
23. FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA (FRRB), established in
PIAZZA CITTA DI LOMBARDIA 1, MILANO 20124, Italy, VAT number: IT97608860157,
24. FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS (FGB),
established in VIA ABATE EUSTASIO 30, VALENZANO BARI 70010, Italy, VAT number:
IT06780820723,
2
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
25. FONDAZIONE TELETHON (FTELE), established in VIA VARESE 16/B, ROMA 00185,
Italy, VAT number: IT04879781005,
26. ISTITUTO SUPERIORE DI SANITA (ISS), established in Viale Regina Elena 299, ROMA
00161, Italy, VAT number: IT03657731000,
27. CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE (CVBF),
established in VIA NICOLO PUTIGNANI 178, BARI 70122, Italy, VAT number: IT01897720189,
28. TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL
RESEARCH (TEDDY), established in VIA LUIGI PORTA 14, PAVIA 231261, Italy, VAT number:
IT01825900184,
29. MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA (MIUR),
established in Via Michele Carcani 61, ROMA 00153, Italy, VAT number: IT97429780584,
30. VALSTS IZGLITIBAS ATTISTIBAS AGENTURA (VIAA), established in VALNU IELA 1,
RIGA 1050, Latvia,
31. Lietuvos mokslo taryba (LMT), established in Gedimino 3, Vilnius LT-01103, Lithuania,
32. VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS
(VUHSK), established in SANTARISKIU G 2, VILNIUS 08661, Lithuania, VAT number:
LT243645610,
33. FONDS NATIONAL DE LA RECHERCHE (FNR), established in 2 AVENUE DE
L'UNIVERSITE, ESCH-SUR-ALZETTE 4365, Luxembourg, VAT number: LU20686731,
34. ZORGONDERZOEK NEDERLAND ZON (ZonMw), established in Laan Van Nieuw Oost
Indie 334, DEN HAAG 2593CE, Netherlands,
35. ACADEMISCH ZIEKENHUIS GRONINGEN (UMCG), established in HANZEPLEIN 1,
GRONINGEN 9713 GZ, Netherlands, VAT number: NL800866393B01,
36. UNIVERSITEIT MAASTRICHT (UM), established in Minderbroedersberg 4-6,
MAASTRICHT 6200 MD, Netherlands,
37. NARODOWE CENTRUM BADAN I ROZWOJU (NCBR), established in UL.
NOWOGRODZKA 47A, WARSZAWA 00 695, Poland, VAT number: PL7010073777,
38. WARSZAWSKI UNIWERSYTET MEDYCZNY (MUW), established in UL. ZWIRKI I
WIGURY 61, WARSZAWA 02 091, Poland, VAT number: PL5250005828,
39. GDANSKI UNIWERSYTET MEDYCZNY (MUG), established in ULICA M
SKLODOWSKIEJ CURIE 3A, GDANSK 80210, Poland,
40. INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA (IPCZD), established in Aleja
Dzieci Polskich 20, WARSZAWA 04730, Poland, VAT number: PL9521143675,
41. FUNDACAO PARA A CIENCIA E A TECNOLOGIA (FCT), established in AVENIDA D
CARLOS I 126, LISBOA 1249 074, Portugal, VAT number: PT503904040,
3
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
42. INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE (INSA), established in
AVENIDA PADRE CRUZ, LISBOA 1600 560, Portugal, VAT number: PT501427511,
43. SLOVENSKA AKADEMIA VIED (SAS), established in STEFANIKOVA 49, BRATISLAVA
814 38, Slovakia, VAT number: N/A,
44. INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, VAT number: ESQ2827015E,
45. FUNDACIO CENTRE DE REGULACIO GENOMICA (CNAG-CRG), established in
CARRER DOCTOR AIGUADER 88, BARCELONA 08003, Spain, VAT number: ESG62426937,
46. UNIVERSIDAD POLITECNICA DE MADRID (UPM), established in CALLE RAMIRO DE
MAEZTU 7 EDIFICIO RECTORADO, MADRID 28040, Spain, VAT number: ESQ2818015F,
47. CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER),
established in CALLE MONFORTE DE LEMOS 5, MADRID 28029, Spain, VAT number:
ESG85296226,
48. VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL (SRC), established in
VASTRA JARNVAGSGATAN 3, STOCKHOLM 111 64, Sweden, VAT number: SE202100520801,
49. VERKET FÖR INNOVATIONSSYSTEM (VINNOVA), established in Mäster Samuelsgatan
56, STOCKHOLM 10158, Sweden, VAT number: SE202100521601,
50. UNIVERSITY OF LEICESTER (ULEIC), established in UNIVERSITY ROAD, LEICESTER
LE1 7RH, United Kingdom, VAT number: GB916583894,
51. THE UNIVERSITY OF LIVERPOOL (ULIV), established in BROWNLOW HILL
765 FOUNDATION BUILDING, LIVERPOOL L69 7ZX, United Kingdom, VAT number:
GB673598875,
52. UNIVERSITY OF NEWCASTLE UPON TYNE (UNEW), established in KINGS GATE,
NEWCASTLE UPON TYNE NE1 7RU, United Kingdom, VAT number: GB499672470,
53. ST. ANNA KINDERKREBSFORSCHUNG (CCRI), established in ZIMMERMANNPLATZ
10, WIEN 1090, Austria, VAT number: ATU16377105,
54. ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), established in 3 Avenue
Victoria, PARIS 75004, France, VAT number: FR95267500452,
55. HOPITAUX UNIVERSITAIRES DE STRASBOURG (HUS), established in PLACE DE L
HOPITAL 1, STRASBOURG CEDEX 67091, France, VAT number: FR47266700574,
56. CENTRE ANTICANCEREUX LEON BERARD (CLB), established in RUE LAENNEC 28,
LYON 69373, France,
57. UNIVERSITAETSKLINIKUM HEIDELBERG (UKL-HD), established in IM
NEUENHEIMER FELD 672, HEIDELBERG 69120, Germany, VAT number: DE143293939,
58. EBERHARD KARLS UNIVERSITAET TUEBINGEN (EKUT), established in
GESCHWISTER-SCHOLL-PLATZ, TUEBINGEN 72074, Germany, VAT number: DE812383453,
4
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
59. JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN (GUF),
established in THEODOR W ADORNO PLATZ 1, FRANKFURT AM MAIN 60629, Germany, VAT
number: DE114110511,
60. HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH (HSK), established in
LUDWIG ERHARD STRASSE 100, WIESBADEN 65199, Germany, VAT number: DE183092254,
61. ISTITUTO ORTOPEDICO RIZZOLI (IOR), established in VIA DI BARBIANO 1/10,
BOLOGNA 40136, Italy, VAT number: IT00302030374,
62. AZIENDA OSPEDALIERO UNIVERSITARIA PISANA (AOUP), established in VIA ROMA
67, PISA 56123, Italy, VAT number: IT01310860505,
63. AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (AOUS), established in STRADA
DELLE SCOTTE 14, SIENA 53100, Italy, VAT number: IT00388300527,
64. ACADEMISCH ZIEKENHUIS LEIDEN (LUMC), established in ALBINUSDREEF 2,
LEIDEN 2333 ZA, Netherlands, VAT number: NL003566213B01,
65. STICHTING KATHOLIEKE UNIVERSITEIT (Radboudumc), established in GEERT
GROOTEPLEIN NOORD 9, NIJMEGEN 6525 EZ, Netherlands, VAT number: NL002968721B01,
66. Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC), established in
MEIBERGDREEF 9, AMSTERDAM 1105AZ, Netherlands, VAT number: NL004627672B01,
67. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC),
established in DR. MOLEWATERPLEIN 40, ROTTERDAM 3015 GD, Netherlands, VAT number:
NL807181997B01,
68. SERVICIO MADRILENO DE SALUD (SERMAS), established in PLAZA CARLOS TRIAS
BERTRAN 7, MADRID 28020, Spain, VAT number: ESQ2801221I,
69. THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (NUTH),
established in FREEMAN HOSPITAL, HIGH HEATON, NEWCASTLE-UPON-TYNE NE7 7DN,
United Kingdom, VAT number: GB654968777,
70. GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH
SERVICE TRUST (GOSH), established in GREAT ORMOND STREET, LONDON WC1N 3JH,
United Kingdom, VAT number: GB654922910,
71. EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER
AISBL (EORTC), established in Avenue E. Mounier 83, Brussels 1200, Belgium, VAT number:
BE0408292992,
72. INFRAFRONTIER GMBH (INFRAFRONTIER), established in INGOLSTADTER
LANDSTRASSE 1, NEUHERBERG 85764, Germany, VAT number: DE291307064,
73. BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE
CONSORTIUM(BBMRI-ERIC) (BBMRI), established in NEUE STIFTINGTALSTRASSE 2/B/6,
GRAZ 8010, Austria, VAT number: ATU68520549,
5
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
74. ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
(ECRIN), established in 5 RUE WATT, PARIS 75013, France, VAT number: FR91801933235,
75. EATRIS ERIC (EATRIS), established in DE BOELELAAN 1118, AMSTERDAM 1081 HZ,
Netherlands, VAT number: NL853383054B01,
76. EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), established in
Meyerhofstrasse 1, HEIDELBERG 69117, Germany,
77. EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION
(EURORDIS), established in RUE DIDOT 96, Paris 75014, France,
78. MINISTRY OF HEALTH (CSO-MOH), established in YIRMIYAHU 39, JERUSALEM
9101002, Israel,
79. SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER
WISSENSCHAFTLICHEN FORSCHUNG (SNSF), established in Wildhainweg 3, Bern 3012,
Switzerland, VAT number: CH249693,
80. BLACKSWAN FOUNDATION (Blackswan), established in CHEMIN DE LA RIAZ 11,
VUARRENS 1418, Switzerland,
81. TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU (TUBITAK),
established in Ataturk Bulvari 221, ANKARA 06100, Turkey, VAT number: TR1750003600,
82. ACIBADEM UNIVERSITESI (ACURARE), established in ICERENKOY MAH.
KAYISDAGI CAD. NO/32 ATASEHIR, ISTANBUL 34752, Turkey, VAT number: TR0050521966,
83. HACETTEPE UNIVERSITESI (HUGEN), established in HACETTEPE UNIVERSITESI
BEYTEPE KAMPUSU REKTORLUK BINASI, CANKAYA ANKARA 06800, Turkey,
84. CANADIAN INSTITUTES OF HEALTH RESEARCH (CIHR), established in ELGIN STREET
9TH FLOOR ADDRESS LOCATOR 4809A 160, OTTAWA ONTARIO K1T 4H8, Canada, as
‘beneficiary not receiving EU funding’ (see Article 9),
85. FONDS DE RECHERCHE DU QUEBEC - SANTE (FRQS), established in RUE
SHERBROOKE OUEST 500, MONTREAL QUEBEC H3A3C6, Canada, as ‘beneficiary not receiving
EU funding’ (see Article 9),
86. INSERM TRANSFERT SA (IT), established in RUE WATT 7, PARIS 75013, France,
87. GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS (GSRT), established in
Mesogeion Avenue 14-18, ATHENS 11510, Greece,
88. DEUTSCHE FORSCHUNGSGEMEINSCHAFT (DFG), established in Kennedyallee 40,
BONN 53175, Germany, VAT number: DE122276357, as ‘beneficiary not receiving EU funding’ (see
Article 9),
Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator.
The parties referred to above have agreed to enter into the Agreement under the terms and conditions
below.
6
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to
implement it under their own responsibility and in accordance with the Agreement, with all the
obligations and conditions it sets out.
The Agreement is composed of:
Terms and Conditions
Annex 1 Description of the action
Annex 2 Estimated budget for the action
2a Additional information on the estimated budget
Annex 3 Accession Forms
Annex 4 Model for the financial statements
Annex 5 Model for the certificate on the financial statements
Annex 6 Model for the certificate on the methodology
Annex 7 Annual work plan for the next year
Annex 8 Model for the statement on the use of the previous pre-financing payment
7
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
TERMS AND CONDITIONS
TABLE OF CONTENTS
CHAPTER 1 GENERAL..............................................................................................................................................16
ARTICLE 1 — SUBJECT OF THE AGREEMENT.......................................................................................16
CHAPTER 2 ACTION................................................................................................................................................. 16
ARTICLE 2 — ACTION TO BE IMPLEMENTED ......................................................................................16
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION....................................................16
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS.......................................................16
4.1 Estimated budget................................................................................................................................ 16
4.2 Budget transfers..................................................................................................................................16
CHAPTER 3 GRANT...................................................................................................................................................16
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND FORMS OF
COSTS............................................................................................................................................16
5.1 Maximum grant amount..................................................................................................................... 16
5.2 Form of grant, reimbursement rates and forms of costs....................................................................16
5.3 Final grant amount — Calculation.....................................................................................................17
5.4 Revised final grant amount — Calculation....................................................................................... 19
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................19
6.1 General conditions for costs to be eligible........................................................................................ 19
6.2 Specific conditions for costs to be eligible........................................................................................20
6.3 Conditions for costs of linked third parties to be eligible................................................................. 27
6.4 Conditions for in-kind contributions provided by third parties free of charge to be eligible............. 27
6.5 Ineligible costs....................................................................................................................................27
6.6 Consequences of declaration of ineligible costs................................................................................ 27
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES........................................................................ 28
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION................ 28
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................28
7.1 General obligation to properly implement the action........................................................................ 28
7.2 Consequences of non-compliance...................................................................................................... 28
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE
ACTION.........................................................................................................................................28
ARTICLE 9 — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT RECEIVING EU
FUNDING...................................................................................................................................... 28
9.1 Rules for the implementation of action tasks by beneficiaries not receiving EU funding................. 28
8
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
9.2 Consequences of non-compliance...................................................................................................... 29
ARTICLE 10 — PURCHASE OF GOODS, WORKS OR SERVICES..........................................................29
10.1 Rules for purchasing goods, works or services............................................................................... 29
10.2 Consequences of non-compliance.................................................................................................... 29
ARTICLE 11 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES AGAINST
PAYMENT..................................................................................................................................... 30
11.1 Rules for the use of in-kind contributions against payment............................................................ 30
11.2 Consequences of non-compliance.................................................................................................... 30
ARTICLE 12 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES FREE OF
CHARGE........................................................................................................................................30
12.1 Rules for the use of in-kind contributions free of charge................................................................30
12.2 Consequences of non-compliance.................................................................................................... 31
ARTICLE 13 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................31
13.1 Rules for subcontracting action tasks.............................................................................................. 31
13.2 Consequences of non-compliance.................................................................................................... 32
ARTICLE 14 — IMPLEMENTATION OF ACTION TASKS BY LINKED THIRD PARTIES.................... 32
14.1 Rules for calling upon linked third parties to implement part of the action.................................... 32
14.2 Consequences of non-compliance.................................................................................................... 35
ARTICLE 14a — IMPLEMENTATION OF ACTION TASKS BY INTERNATIONAL PARTNERS........... 35
ARTICLE 15 — FINANCIAL SUPPORT TO THIRD PARTIES.................................................................. 35
15.1 Rules for providing financial support to third parties......................................................................35
15.2 Financial support in the form of prizes........................................................................................... 35
15.3 Consequences of non-compliance.................................................................................................... 36
ARTICLE 16 — PROVISION OF TRANS-NATIONAL OR VIRTUAL ACCESS TO RESEARCH
INFRASTRUCTURE.....................................................................................................................36
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION.............. 36
ARTICLE 17 — GENERAL OBLIGATION TO INFORM............................................................................36
17.1 General obligation to provide information upon request.................................................................36
17.2 Obligation to keep information up to date and to inform about events and circumstances likely to
affect the Agreement........................................................................................................................36
17.3 Consequences of non-compliance.................................................................................................... 37
ARTICLE 18 — KEEPING RECORDS — SUPPORTING DOCUMENTATION.........................................37
18.1 Obligation to keep records and other supporting documentation.................................................... 37
18.2 Consequences of non-compliance.................................................................................................... 38
ARTICLE 19 — SUBMISSION OF DELIVERABLES................................................................................. 38
19.1 Obligation to submit deliverables.................................................................................................... 38
9
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
19.2 Consequences of non-compliance.................................................................................................... 39
ARTICLE 20 — REPORTING — PAYMENT REQUESTS.......................................................................... 39
20.1 Obligation to submit reports............................................................................................................ 39
20.2 Reporting periods............................................................................................................................. 39
20.2a Request for a second pre-financing payment.................................................................................39
20.3 Periodic reports — Requests for interim payments.........................................................................39
20.4 Final report — Request for payment of the balance....................................................................... 41
20.5 Information on cumulative expenditure incurred.............................................................................41
20.6 Currency for financial statements and conversion into euro........................................................... 41
20.7 Language of reports..........................................................................................................................42
20.8 Consequences of non-compliance.................................................................................................... 42
ARTICLE 21 — PAYMENTS AND PAYMENT ARRANGEMENTS...........................................................42
21.1 Payments to be made....................................................................................................................... 42
21.2 Pre-financing payment — Amount — Amount retained for the Guarantee Fund........................... 42
21.3 Interim payments — Amount — Calculation..................................................................................42
21.4 Payment of the balance — Amount — Calculation — Release of the amount retained for the
Guarantee Fund................................................................................................................................ 43
21.5 Notification of amounts due.............................................................................................................44
21.6 Currency for payments..................................................................................................................... 44
21.7 Payments to the coordinator — Distribution to the beneficiaries....................................................44
21.8 Bank account for payments..............................................................................................................44
21.9 Costs of payment transfers...............................................................................................................45
21.10 Date of payment............................................................................................................................. 45
21.11 Consequences of non-compliance.................................................................................................. 45
ARTICLE 22 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF
FINDINGS..................................................................................................................................... 45
22.1 Checks, reviews and audits by the Commission..............................................................................45
22.2 Investigations by the European Anti-Fraud Office (OLAF)............................................................47
22.3 Checks and audits by the European Court of Auditors (ECA)........................................................48
22.4 Checks, reviews, audits and investigations for international organisations..................................... 48
22.5 Consequences of findings in checks, reviews, audits and investigations — Extension of
findings............................................................................................................................................. 48
22.6 Consequences of non-compliance.................................................................................................... 50
ARTICLE 23 — EVALUATION OF THE IMPACT OF THE ACTION....................................................... 50
23.1 Right to evaluate the impact of the action.......................................................................................50
23.2 Consequences of non-compliance.................................................................................................... 50
10
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
SECTION 3 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND AND RESULTS................. 50
SUBSECTION 1 GENERAL............................................................................................................................ 50
ARTICLE 23a — MANAGEMENT OF INTELLECTUAL PROPERTY...................................................... 50
23a.1 Obligation to take measures to implement the Commission Recommendation on the management
of intellectual property in knowledge transfer activities................................................................. 50
23a.2 Consequences of non-compliance.................................................................................................. 51
SUBSECTION 2 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND................................ 51
ARTICLE 24 — AGREEMENT ON BACKGROUND..................................................................................51
24.1 Agreement on background............................................................................................................... 51
24.2 Consequences of non-compliance.................................................................................................... 51
ARTICLE 25 — ACCESS RIGHTS TO BACKGROUND............................................................................ 51
25.1 Exercise of access rights — Waiving of access rights — No sub-licensing....................................51
25.2 Access rights for other beneficiaries, for implementing their own tasks under the action...............52
25.3 Access rights for other beneficiaries, for exploiting their own results............................................ 52
25.4 Access rights for affiliated entities.................................................................................................. 52
25.5 Access rights for third parties.......................................................................................................... 52
25.6 Consequences of non-compliance.................................................................................................... 53
SUBSECTION 3 RIGHTS AND OBLIGATIONS RELATED TO RESULTS............................................53
ARTICLE 26 — OWNERSHIP OF RESULTS...............................................................................................53
26.1 Ownership by the beneficiary that generates the results................................................................. 53
26.2 Joint ownership by several beneficiaries......................................................................................... 53
26.3 Rights of third parties (including personnel)................................................................................... 53
26.4 EU ownership, to protect results......................................................................................................54
26.5 Consequences of non-compliance.................................................................................................... 54
ARTICLE 27 — PROTECTION OF RESULTS — VISIBILITY OF EU FUNDING................................... 55
27.1 Obligation to protect the results.......................................................................................................55
27.2 EU ownership, to protect the results................................................................................................55
27.3 Information on EU funding..............................................................................................................55
27.4 Consequences of non-compliance.................................................................................................... 55
ARTICLE 28 — EXPLOITATION OF RESULTS..........................................................................................55
28.1 Obligation to exploit the results.......................................................................................................55
28.2 Results that could contribute to European or international standards — Information on EU
funding..............................................................................................................................................56
28.3 Consequences of non-compliance.................................................................................................... 56
ARTICLE 29 — DISSEMINATION OF RESULTS — OPEN ACCESS — VISIBILITY OF EU
FUNDING...................................................................................................................................... 56
11
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
29.1 Obligation to disseminate results..................................................................................................... 56
29.2 Open access to scientific publications............................................................................................. 56
29.3 Open access to research data........................................................................................................... 57
29.4 Information on EU funding — Obligation and right to use the EU emblem ..................................58
29.5 Disclaimer excluding Commission responsibility............................................................................58
29.6 Consequences of non-compliance.................................................................................................... 58
ARTICLE 30 — TRANSFER AND LICENSING OF RESULTS.................................................................. 58
30.1 Transfer of ownership...................................................................................................................... 58
30.2 Granting licenses.............................................................................................................................. 59
30.3 Commission right to object to transfers or licensing.......................................................................59
30.4 Consequences of non-compliance.................................................................................................... 59
ARTICLE 31 — ACCESS RIGHTS TO RESULTS....................................................................................... 59
31.1 Exercise of access rights — Waiving of access rights — No sub-licensing....................................59
31.2 Access rights for other beneficiaries, for implementing their own tasks under the action...............59
31.3 Access rights for other beneficiaries, for exploiting their own results............................................ 59
31.4 Access rights of affiliated entities....................................................................................................60
31.5 Access rights for the EU institutions, bodies, offices or agencies and EU Member States..............60
31.6 Access rights for third parties.......................................................................................................... 60
31.7 Consequences of non-compliance.................................................................................................... 60
SECTION 4 OTHER RIGHTS AND OBLIGATIONS.......................................................................................60
ARTICLE 32 — RECRUITMENT AND WORKING CONDITIONS FOR RESEARCHERS..................... 60
32.1 Obligation to take measures to implement the European Charter for Researchers and Code of
Conduct for the Recruitment of Researchers...................................................................................60
32.2 Consequences of non-compliance.................................................................................................... 61
ARTICLE 33 — GENDER EQUALITY.........................................................................................................61
33.1 Obligation to aim for gender equality..............................................................................................61
33.2 Consequences of non-compliance.................................................................................................... 61
ARTICLE 34 — ETHICS AND RESEARCH INTEGRITY.......................................................................... 61
34.1 Obligation to comply with ethical and research integrity principles............................................... 61
34.2 Activities raising ethical issues........................................................................................................ 62
34.3 Activities involving human embryos or human embryonic stem cells............................................62
34.4 Consequences of non-compliance.................................................................................................... 63
ARTICLE 35 — CONFLICT OF INTERESTS.............................................................................................. 63
35.1 Obligation to avoid a conflict of interests....................................................................................... 63
35.2 Consequences of non-compliance.................................................................................................... 63
12
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
ARTICLE 36 — CONFIDENTIALITY...........................................................................................................63
36.1 General obligation to maintain confidentiality................................................................................ 63
36.2 Consequences of non-compliance.................................................................................................... 64
ARTICLE 37 — SECURITY-RELATED OBLIGATIONS............................................................................. 64
37.1 Results with a security recommendation......................................................................................... 64
37.2 Classified information...................................................................................................................... 64
37.3 Activities involving dual-use goods or dangerous materials and substances...................................65
37.4 Consequences of non-compliance.................................................................................................... 65
ARTICLE 38 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................65
38.1 Communication activities by beneficiaries...................................................................................... 65
38.2 Communication activities by the Commission................................................................................ 66
38.3 Consequences of non-compliance.................................................................................................... 67
ARTICLE 39 — PROCESSING OF PERSONAL DATA...............................................................................67
39.1 Processing of personal data by the Commission............................................................................. 67
39.2 Processing of personal data by the beneficiaries............................................................................. 67
39.3 Consequences of non-compliance.................................................................................................... 68
ARTICLE 40 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE COMMISSION........... 68
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES — RELATIONSHIP
WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH PARTNERS OF A
JOINT ACTION........................................................................................................................................ 68
ARTICLE 41 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES —
RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH
PARTNERS OF A JOINT ACTION.............................................................................................68
41.1 Roles and responsibility towards the Commission.......................................................................... 68
41.2 Internal division of roles and responsibilities.................................................................................. 68
41.3 Internal arrangements between beneficiaries — Consortium agreement.........................................69
41.4 Relationship with complementary beneficiaries — Collaboration agreement.................................70
41.5 Relationship with partners of a joint action — Coordination agreement........................................ 70
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS
— DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE................................ 70
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY —
SANCTIONS.............................................................................................................................................. 70
ARTICLE 42 — REJECTION OF INELIGIBLE COSTS.............................................................................. 70
42.1 Conditions......................................................................................................................................... 70
42.2 Ineligible costs to be rejected — Calculation — Procedure............................................................70
42.3 Effects............................................................................................................................................... 70
ARTICLE 43 — REDUCTION OF THE GRANT......................................................................................... 71
13
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
43.1 Conditions......................................................................................................................................... 71
43.2 Amount to be reduced — Calculation — Procedure.......................................................................71
43.3 Effects............................................................................................................................................... 72
ARTICLE 44 — RECOVERY OF UNDUE AMOUNTS............................................................................... 72
44.1 Amount to be recovered — Calculation — Procedure....................................................................72
ARTICLE 45 — ADMINISTRATIVE SANCTIONS..................................................................................... 76
SECTION 2 LIABILITY FOR DAMAGES.........................................................................................................76
ARTICLE 46 — LIABILITY FOR DAMAGES.............................................................................................76
46.1 Liability of the Commission............................................................................................................ 76
46.2 Liability of the beneficiaries............................................................................................................ 76
SECTION 3 SUSPENSION AND TERMINATION............................................................................................76
ARTICLE 47 — SUSPENSION OF PAYMENT DEADLINE....................................................................... 76
47.1 Conditions......................................................................................................................................... 76
47.2 Procedure.......................................................................................................................................... 77
ARTICLE 48 — SUSPENSION OF PAYMENTS.......................................................................................... 77
48.1 Conditions......................................................................................................................................... 77
48.2 Procedure.......................................................................................................................................... 78
ARTICLE 49 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 78
49.1 Suspension of the action implementation, by the beneficiaries.......................................................78
49.2 Suspension of the action implementation, by the Commission....................................................... 79
ARTICLE 50 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR
MORE BENEFICIARIES..............................................................................................................80
50.1 Termination of the Agreement, by the beneficiaries........................................................................80
50.2 Termination of the participation of one or more beneficiaries, by the beneficiaries........................81
50.3 Termination of the Agreement or the participation of one or more beneficiaries, by the
Commission...................................................................................................................................... 83
SECTION 4 FORCE MAJEURE.......................................................................................................................... 87
ARTICLE 51 — FORCE MAJEURE.............................................................................................................. 87
CHAPTER 7 FINAL PROVISIONS...........................................................................................................................88
ARTICLE 52 — COMMUNICATION BETWEEN THE PARTIES...............................................................88
52.1 Form and means of communication.................................................................................................88
52.2 Date of communication.................................................................................................................... 88
52.3 Addresses for communication.......................................................................................................... 89
ARTICLE 53 — INTERPRETATION OF THE AGREEMENT.....................................................................89
53.1 Precedence of the Terms and Conditions over the Annexes............................................................89
53.2 Privileges and immunities................................................................................................................ 89
14
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
ARTICLE 54 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 89
ARTICLE 55 — AMENDMENTS TO THE AGREEMENT......................................................................... 89
55.1 Conditions......................................................................................................................................... 89
55.2 Procedure.......................................................................................................................................... 90
ARTICLE 56 — ACCESSION TO THE AGREEMENT............................................................................... 90
56.1 Accession of the beneficiaries mentioned in the Preamble............................................................. 90
56.2 Addition of new beneficiaries.......................................................................................................... 91
ARTICLE 57 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 91
57.1 Applicable law..................................................................................................................................91
57.2 Dispute settlement............................................................................................................................ 91
ARTICLE 58 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 92
15
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
CHAPTER 1 GENERAL
ARTICLE 1 — SUBJECT OF THE AGREEMENT
This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant
awarded to the beneficiaries for implementing the action set out in Chapter 2.
CHAPTER 2 ACTION
ARTICLE 2 — ACTION TO BE IMPLEMENTED
The grant is awarded for the action entitled ‘European Joint Programme on Rare Diseases’ —
‘EJP RD’ (‘action’), as described in Annex 1.
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION
The duration of the action will be 60 months as of 1 January 2019 (‘starting date of the action’).
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS
4.1 Estimated budget
The ‘estimated budget’ for the action is set out in Annex 2.
It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and linked
third party) and budget category (see Articles 5, 6, and 14). It also shows the estimated costs of the
beneficiaries not receiving EU funding (see Article 9).
4.2 Budget transfers
The estimated budget breakdown indicated in Annex 2 may be adjusted — without an amendment
(see Article 55) — by transfers of amounts between beneficiaries, budget categories and/or forms of
costs set out in Annex 2, if the action is implemented as described in Annex 1.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1,
unless such additional subcontracts are approved by an amendment or in accordance with Article 13.
CHAPTER 3 GRANT
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND
FORMS OF COSTS
5.1 Maximum grant amount
The ‘maximum grant amount’ is EUR 55 073 831.17 (fifty five million seventy three thousand eight
hundred and thirty one EURO and seventeen eurocents).
5.2 Form of grant, reimbursement rates and forms of costs
16
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The grant reimburses 70% of the action's eligible costs (see Article 6) (‘reimbursement of eligible
costs grant’) (see Annex 2).
The estimated eligible costs of the action are EUR 94 516 062.29 (ninety four million five hundred
and sixteen thousand sixty two EURO and twenty nine eurocents).
Eligible costs (see Article 6) must be declared under the following forms ('forms of costs'):
(a) for direct personnel costs:
- as actually incurred costs (‘actual costs’) or
- on the basis of an amount per unit calculated by the beneficiary in accordance with its
usual cost accounting practices (‘unit costs’).
Personnel costs for SME owners or beneficiaries that are natural persons not receiving a
salary (see Article 6.2, Points A.4 and A.5) must be declared on the basis of the amount per
unit set out in Annex 2a (unit costs);
(b) for direct costs for subcontracting: as actually incurred costs (actual costs);
(c) for direct costs of providing financial support to third parties: as actually incurred costs
(actual costs);
(d) for other direct costs:
- for costs of internally invoiced goods and services: on the basis of an amount per unit
calculated by the beneficiary in accordance with its usual cost accounting practices (‘unit
costs’);
- for all other costs: as actually incurred costs (actual costs);
(e) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2, Point E (‘flat-rate
costs’);
(f) specific cost category(ies): not applicable.
5.3 Final grant amount — Calculation
The ‘final grant amount’ depends on the actual extent to which the action is implemented in
accordance with the Agreement’s terms and conditions.
This amount is calculated by the Commission — when the payment of the balance is made (see
Article 21.4) — in the following steps:
Step 1 — Application of the reimbursement rates to the eligible costs
Step 2 — Limit to the maximum grant amount
Step 3 — Reduction due to the no-profit rule
Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach of
obligations
17
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
5.3.1 Step 1 — Application of the reimbursement rates to the eligible costs
The reimbursement rate(s) (see Article 5.2) are applied to the eligible costs (actual costs, unit costs
and flat-rate costs; see Article 6) declared by the beneficiaries and linked third parties (see Article 20)
and approved by the Commission (see Article 21).
5.3.2 Step 2 — Limit to the maximum grant amount
If the amount obtained following Step 1 is higher than the maximum grant amount set out in
Article 5.1, it will be limited to the latter.
5.3.3 Step 3 — Reduction due to the no-profit rule
The grant must not produce a profit.
‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total
receipts, over the action’s total eligible costs.
The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the
Commission.
The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see
Article 3).
The following are considered receipts:
(a) income generated by the action; if the income is generated from selling equipment or other
assets purchased under the Agreement, the receipt is up to the amount declared as eligible under
the Agreement;
(b) financial contributions given by third parties to the beneficiary or to a linked third party
specifically to be used for the action, and
(c) in-kind contributions provided by third parties free of charge and specifically to be used for the
action, if they have been declared as eligible costs.
The following are however not considered receipts:
(a) income generated by exploiting the action’s results (see Article 28);
(b) financial contributions by third parties, if they may be used to cover costs other than the eligible
costs (see Article 6);
(c) financial contributions by third parties with no obligation to repay any amount unused at the
end of the period set out in Article 3.
If there is a profit, it will be deducted from the amount obtained following Steps 1 and 2.
5.3.4 Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach
of obligations — Reduced grant amount — Calculation
If the grant is reduced (see Article 43), the Commission will calculate the reduced grant amount
by deducting the amount of the reduction (calculated in proportion to the seriousness of the errors,
18
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
irregularities or fraud or breach of obligations, in accordance with Article 43.2) from the maximum
grant amount set out in Article 5.1.
The final grant amount will be the lower of the following two:
- the amount obtained following Steps 1 to 3 or
- the reduced grant amount following Step 4.
5.4 Revised final grant amount — Calculation
If — after the payment of the balance (in particular, after checks, reviews, audits or investigations;
see Article 22) — the Commission rejects costs (see Article 42) or reduces the grant (see Article 43),
it will calculate the ‘revised final grant amount’ for the beneficiary concerned by the findings.
This amount is calculated by the Commission on the basis of the findings, as follows:
- in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs
approved by the Commission for the beneficiary concerned;
- in case of reduction of the grant: by calculating the concerned beneficiary’s share in the grant
amount reduced in proportion to the seriousness of the errors, irregularities or fraud or breach
of obligations (see Article 43.2).
In case of rejection of costs and reduction of the grant, the revised final grant amount for the
beneficiary concerned will be the lower of the two amounts above.
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS
6.1 General conditions for costs to be eligible
‘Eligible costs’ are costs that meet the following criteria:
(a) for actual costs:
(i) they must be actually incurred by the beneficiary;
(ii) they must be incurred in the period set out in Article 3, with the exception of costs relating
to the submission of the periodic report for the last reporting period and the final report
(see Article 20);
(iii) they must be indicated in the estimated budget set out in Annex 2;
(iv) they must be incurred in connection with the action as described in Annex 1 and necessary
for its implementation;
(v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s accounts
in accordance with the accounting standards applicable in the country where the beneficiary
is established and with the beneficiary’s usual cost accounting practices;
(vi) they must comply with the applicable national law on taxes, labour and social security, and
19
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(vii) they must be reasonable, justified and must comply with the principle of sound financial
management, in particular regarding economy and efficiency;
(b) for unit costs:
(i) they must be calculated as follows:
{amounts per unit set out in Annex 2a or calculated by the beneficiary in accordance with its usual cost
accounting practices (see Article 6.2, Point A and Article 6.2.D.5)
multiplied by
the number of actual units};
(ii) the number of actual units must comply with the following conditions:
- the units must be actually used or produced in the period set out in Article 3;
- the units must be necessary for implementing the action or produced by it, and
- the number of units must be identifiable and verifiable, in particular supported by records
and documentation (see Article 18);
(c) for flat-rate costs:
(i) they must be calculated by applying the flat-rate set out in Annex 2, and
(ii) the costs (actual costs or unit costs) to which the flat-rate is applied must comply with the
conditions for eligibility set out in this Article.
6.2 Specific conditions for costs to be eligible
Costs are eligible if they comply with the general conditions (see above) and the specific conditions
set out below for each of the following budget categories:
A. direct personnel costs;
B. direct costs of subcontracting;
C. direct costs of providing financial support to third parties;
D. other direct costs;
E. indirect costs;
F. not applicable.
‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be
attributed to it directly. They must not include any indirect costs (see Point E below).
‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot
be attributed directly to it.
A. Direct personnel costs
Types of eligible personnel costs
20
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
A.1 Personnel costs are eligible, if they are related to personnel working for the beneficiary under an
employment contract (or equivalent appointing act) and assigned to the action (‘costs for employees
(or equivalent)’). They must be limited to salaries (including during parental leave), social security
contributions, taxes and other costs included in the remuneration, if they arise from national law or
the employment contract (or equivalent appointing act).
Beneficiaries that are non-profit legal entities1 may also declare as personnel costs additional
remuneration for personnel assigned to the action (including payments on the basis of supplementary
contracts regardless of their nature), if:
(a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner
whenever the same kind of work or expertise is required;
(b) the criteria used to calculate the supplementary payments are objective and generally applied
by the beneficiary, regardless of the source of funding used.
‘Additional remuneration’ means any part of the remuneration which exceeds what the person would
be paid for time worked in projects funded by national schemes.
Additional remuneration for personnel assigned to the action is eligible up to the following amount:
(a) if the person works full time and exclusively on the action during the full year: up to EUR 8 000;
(b) if the person works exclusively on the action but not full-time or not for the full year: up to the
corresponding pro-rata amount of EUR 8 000, or
(c) if the person does not work exclusively on the action: up to a pro-rata amount calculated as
follows:
{{EUR 8 000
divided by
the number of annual productive hours (see below)},
multiplied by
the number of hours that the person has worked on the action during the year}.
A.2 The costs for natural persons working under a direct contract with the beneficiary other than
an employment contract are eligible personnel costs, if:
(a) the person works under conditions similar to those of an employee (in particular regarding
the way the work is organised, the tasks that are performed and the premises where they are
performed);
(b) the result of the work carried out belongs to the beneficiary (unless exceptionally agreed
otherwise), and
1 For the definition, see Article 2.1(14) of Regulation (EU) No 1290/2013 of the European Parliament and of the Council
of 11 December 2013 laying down the rules for the participation and dissemination in “Horizon 2020 – the Framework
Programme for Research and Innovation (2014-2020)” (‘Rules for Participation Regulation No 1290/2013’) (OJ L
347, 20.12.2013 p.81): ‘non-profit legal entity’ means a legal entity which by its legal form is non-profit-making or
which has a legal or statutory obligation not to distribute profits to its shareholders or individual members.
21
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(c) the costs are not significantly different from those for personnel performing similar tasks under
an employment contract with the beneficiary.
A.3 The costs of personnel seconded by a third party against payment are eligible personnel costs,
if the conditions in Article 11.1 are met.
A.4 Costs of owners of beneficiaries that are small and medium-sized enterprises (‘SME owners’)
who are working on the action and who do not receive a salary are eligible personnel costs, if they
correspond to the amount per unit set out in Annex 2a multiplied by the number of actual hours worked
on the action.
A.5 Costs of ‘beneficiaries that are natural persons’ not receiving a salary are eligible personnel
costs, if they correspond to the amount per unit set out in Annex 2a multiplied by the number of actual
hours worked on the action.
Calculation
Personnel costs must be calculated by the beneficiaries as follows:
{{hourly rate
multiplied by
the number of actual hours worked on the action},
plus
for non-profit legal entities: additional remuneration to personnel assigned to the action under the
conditions set out above (Point A.1)}.
The number of actual hours declared for a person must be identifiable and verifiable (see Article 18).
The total number of hours declared in EU or Euratom grants, for a person for a year, cannot be higher
than the annual productive hours used for the calculations of the hourly rate. Therefore, the maximum
number of hours that can be declared for the grant are:
{the number of annual productive hours for the year (see below)
minus
total number of hours declared by the beneficiary, for that person for that year, for other EU or Euratom
grants}
The ‘hourly rate’ is one of the following:
(a) for personnel costs declared as actual costs (i.e. budget categories A.1, A.2 and A.3): the hourly
rate is calculated per full financial year, as follows:
{actual annual personnel costs (excluding additional remuneration) for the person
divided by
number of annual productive hours}.
using the personnel costs and the number of productive hours for each full financial year
covered by the reporting period concerned. If a financial year is not closed at the end of the
22
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
reporting period, the beneficiaries must use the hourly rate of the last closed financial year
available.
For the ‘number of annual productive hours’, the beneficiaries may choose one of the following:
(i) ‘fixed number of hours’: 1 720 hours for persons working full time (or corresponding
pro-rata for persons not working full time);
(ii) ‘individual annual productive hours’: the total number of hours worked by the person in
the year for the beneficiary, calculated as follows:
{annual workable hours of the person (according to the employment contract, applicable
collective labour agreement or national law)
plus
overtime worked
minus
absences (such as sick leave and special leave)}.
‘Annual workable hours’ means the period during which the personnel must be
working, at the employer’s disposal and carrying out his/her activity or duties under the
employment contract, applicable collective labour agreement or national working time
legislation.
If the contract (or applicable collective labour agreement or national working time
legislation) does not allow to determine the annual workable hours, this option cannot
be used;
(iii) ‘standard annual productive hours’: the ‘standard number of annual hours’ generally
applied by the beneficiary for its personnel in accordance with its usual cost accounting
practices. This number must be at least 90% of the ‘standard annual workable hours’.
If there is no applicable reference for the standard annual workable hours, this option
cannot be used.
For all options, the actual time spent on parental leave by a person assigned to the action
may be deducted from the number of annual productive hours.
As an alternative, beneficiaries may calculate the hourly rate per month, as follows:
{actual monthly personnel cost (excluding additional remuneration) for the person
divided by
{number of annual productive hours / 12}}
using the personnel costs for each month and (one twelfth of) the annual productive hours
calculated according to either option (i) or (iii) above, i.e.:
- fixed number of hours or
- standard annual productive hours.
23
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Time spent on parental leave may not be deducted when calculating the hourly rate per month.
However, beneficiaries may declare personnel costs incurred in periods of parental leave in
proportion to the time the person worked on the action in that financial year.
If parts of a basic remuneration are generated over a period longer than a month, the
beneficiaries may include only the share which is generated in the month (irrespectively of the
amount actually paid for that month).
Each beneficiary must use only one option (per full financial year or per month) during each full
financial year;
(b) for personnel costs declared on the basis of unit costs (i.e. budget categories A.1, A.2, A.4 and
A.5): the hourly rate is one of the following:
(i) for SME owners or beneficiaries that are natural persons: the hourly rate set out in Annex 2a
(see Points A.4 and A.5 above), or
(ii) for personnel costs declared on the basis of the beneficiary’s usual cost accounting practices:
the hourly rate calculated by the beneficiary in accordance with its usual cost accounting
practices, if:
- the cost accounting practices used are applied in a consistent manner, based on objective
criteria, regardless of the source of funding;
- the hourly rate is calculated using the actual personnel costs recorded in the beneficiary’s
accounts, excluding any ineligible cost or costs included in other budget categories.
The actual personnel costs may be adjusted by the beneficiary on the basis of budgeted
or estimated elements. Those elements must be relevant for calculating the personnel
costs, reasonable and correspond to objective and verifiable information;
and
- the hourly rate is calculated using the number of annual productive hours (see above).
B. Direct costs of subcontracting (including related duties, taxes and charges such as non-
deductible value added tax (VAT) paid by the beneficiary) are eligible if the conditions in
Article 13.1.1 are met.
C. Direct costs of providing financial support to third parties
C.1 Direct costs of providing financial support are eligible if the conditions set out in Article 15.1.1
are met.
D. Other direct costs
D.1 Travel costs and related subsistence allowances (including related duties, taxes and charges
such as non-deductible value added tax (VAT) paid by the beneficiary) are eligible if they are in line
with the beneficiary’s usual practices on travel.
24
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
D.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand)
as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance with
Article 10.1.1 and written off in accordance with international accounting standards and the
beneficiary’s usual accounting practices.
The costs of renting or leasing equipment, infrastructure or other assets (including related duties,
taxes and charges such as non-deductible value added tax (VAT) paid by the beneficiary) are also
eligible, if they do not exceed the depreciation costs of similar equipment, infrastructure or assets and
do not include any financing fees.
The costs of equipment, infrastructure or other assets contributed in-kind against payment are
eligible, if they do not exceed the depreciation costs of similar equipment, infrastructure or assets, do
not include any financing fees and if the conditions in Article 11.1 are met.
The only portion of the costs that will be taken into account is that which corresponds to the duration
of the action and rate of actual use for the purposes of the action.
D.3 Costs of other goods and services (including related duties, taxes and charges such as non-
deductible value added tax (VAT) paid by the beneficiary) are eligible, if they are:
(a) purchased specifically for the action and in accordance with Article 10.1.1 or
(b) contributed in kind against payment and in accordance with Article 11.1.
Such goods and services include, for instance, consumables and supplies, dissemination (including
open access), protection of results, certificates on the financial statements (if they are required by the
Agreement), certificates on the methodology, translations and publications.
D.4 Capitalised and operating costs of ‘large research infrastructure’2 directly used for the action
are eligible, if:
(a) the value of the large research infrastructure represents at least 75% of the total fixed assets (at
historical value in its last closed balance sheet before the date of the signature of the Agreement
or as determined on the basis of the rental and leasing costs of the research infrastructure3);
(b) the beneficiary’s methodology for declaring the costs for large research infrastructure has been
positively assessed by the Commission (‘ex-ante assessment’);
(c) the beneficiary declares as direct eligible costs only the portion which corresponds to the
duration of the action and the rate of actual use for the purposes of the action, and
2 ‘Large research infrastructure’ means research infrastructure of a total value of at least EUR 20 million, for a
beneficiary, calculated as the sum of historical asset values of each individual research infrastructure of that beneficiary,
as they appear in its last closed balance sheet before the date of the signature of the Agreement or as determined on the
basis of the rental and leasing costs of the research infrastructure.
3 For the definition see Article 2(6) of the H2020 Framework Programme Regulation No 1291/2013: ‘Research
infrastructure’ are facilities, resources and services that are used by the research communities to conduct research and
foster innovation in their fields. Where relevant, they may be used beyond research, e.g. for education or public services.
They include: major scientific equipment (or sets of instruments); knowledge-based resources such as collections,
archives or scientific data; e-infrastructures such as data and computing systems and communication networks; and any
other infrastructure of a unique nature essential to achieve excellence in research and innovation. Such infrastructures
may be ‘single-sited’, ‘virtual’ or ‘distributed’.
25
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(d) they comply with the conditions as further detailed in the annotations to the H2020 grant
agreements.
D.5 Costs of internally invoiced goods and services directly used for the action are eligible, if:
(a) they are declared on the basis of a unit cost calculated in accordance with the beneficiary’s
usual cost accounting practices;
(b) the cost accounting practices used are applied in a consistent manner, based on objective
criteria, regardless of the source of funding;
(c) the unit cost is calculated using the actual costs for the good or service recorded in the
beneficiary’s accounts, excluding any ineligible cost or costs included in other budget
categories.
The actual costs may be adjusted by the beneficiary on the basis of budgeted or estimated
elements. Those elements must be relevant for calculating the costs, reasonable and correspond
to objective and verifiable information;
(d) the unit cost excludes any costs of items which are not directly linked to the production of the
invoiced goods or service.
‘Internally invoiced goods and services’ means goods or services which are provided by the
beneficiary directly for the action and which the beneficiary values on the basis of its usual cost
accounting practices.
E. Indirect costs
Indirect costs are eligible if they are declared on the basis of the flat-rate of 25% of the eligible direct
costs (see Article 5.2 and Points A to D above), from which are excluded:
(a) costs of subcontracting and
(b) costs of in-kind contributions provided by third parties which are not used on the beneficiary’s
premises and
(c) costs of providing financial support to third parties;
(d) not applicable.
Beneficiaries receiving an operating grant4 financed by the EU or Euratom budget cannot declare
indirect costs for the period covered by the operating grant, unless they can demonstrate that the
operating grant does not cover any costs of the action.
F. Specific cost category(ies)
4 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and
of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing
Council Regulation (EC, Euratom) No 1605/2002 (‘Financial Regulation No 966/2012’) (OJ L 218, 26.10.2012, p.1):
‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the
functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting
an EU policy.
26
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Not applicable
6.3 Conditions for costs of linked third parties to be eligible
Costs incurred by linked third parties are eligible if they fulfil — mutatis mutandis — the general
and specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 14.1.1.
6.4 Conditions for in-kind contributions provided by third parties free of charge to be
eligible
In-kind contributions provided free of charge are eligible direct costs (for the beneficiary or linked
third party), if the costs incurred by the third party fulfil — mutatis mutandis — the general and
specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 12.1.
6.5 Ineligible costs
‘Ineligible costs’ are:
(a) costs that do not comply with the conditions set out above (Article 6.1 to 6.4), in particular:
(i) costs related to return on capital;
(ii) debt and debt service charges;
(iii) provisions for future losses or debts;
(iv) interest owed;
(v) doubtful debts;
(vi) currency exchange losses;
(vii) bank costs charged by the beneficiary’s bank for transfers from the Commission;
(viii) excessive or reckless expenditure;
(ix) deductible VAT;
(x) costs incurred during suspension of the implementation of the action (see Article 49);
(b) costs declared under another EU or Euratom grant (including grants awarded by a Member
State and financed by the EU or Euratom budget and grants awarded by bodies other than the
Commission for the purpose of implementing the EU or Euratom budget); in particular, indirect
costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom
budget in the same period, unless it can demonstrate that the operating grant does not cover
any costs of the action.
6.6 Consequences of declaration of ineligible costs
Declared costs that are ineligible will be rejected (see Article 42).
This may also lead to any of the other measures described in Chapter 6.
27
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE
ACTION
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION
7.1 General obligation to properly implement the action
The beneficiaries must implement the action as described in Annex 1 and in compliance with the
provisions of the Agreement and all legal obligations under applicable EU, international and national
law.
7.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES
INVOLVED IN THE ACTION
The beneficiaries must have the appropriate resources to implement the action.
If it is necessary to implement the action, the beneficiaries may:
- purchase goods, works and services (see Article 10);
- use in-kind contributions provided by third parties against payment (see Article 11);
- use in-kind contributions provided by third parties free of charge (see Article 12);
- call upon subcontractors to implement action tasks described in Annex 1 (see Article 13);
- call upon linked third parties to implement action tasks described in Annex 1 (see Article 14);
- call upon international partners to implement action tasks described in Annex 1 (see
Article 14a).
In these cases, the beneficiaries retain sole responsibility towards the Commission and the other
beneficiaries for implementing the action.
ARTICLE 9 — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT
RECEIVING EU FUNDING
9.1 Rules for the implementation of action tasks by beneficiaries not receiving EU funding
Beneficiaries that (‘beneficiaries not receiving EU funding’) must implement the action tasks
attributed to them in Annex 1 in accordance with Article 7.1.
28
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Their costs are estimated in Annex 2 but:
- will not be reimbursed and
- will not be taken into account for the calculation of the grant (see Articles 5.2, 5.3 and 5.4,
and 21).
Chapter 3, Articles 10 to 15, 18.1.2, 20.3(b), 20.4(b), 20.6, 21, 23a, 26.4, 27.2, 28.1, 28.2, 30.3, 31.5,
40, 42, 43, 44, 47 and 48 do not apply to these beneficiaries.
They will not be subject to financial checks, reviews and audits under Article 22.
Beneficiaries not receiving EU funding may provide in-kind contributions to another beneficiary. In
this case, they will be considered as a third party for the purpose of Articles 11 and 12.
9.2 Consequences of non-compliance
If a beneficiary not receiving EU funding breaches any of its obligations under this Article, its
participation in the Agreement may be terminated (see Article 50).
Such breaches may also lead to any of the other measures described in Chapter 6 that are applicable
to it.
ARTICLE 10 — PURCHASE OF GOODS, WORKS OR SERVICES
10.1 Rules for purchasing goods, works or services
10.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services.
The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the
lowest price. In doing so, they must avoid any conflict of interests (see Article 35).
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
their contractors.
10.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC5 (or
2014/24/EU6) or ‘contracting entities’ within the meaning of Directive 2004/17/EC7 (or 2014/25/EU8)
must comply with the applicable national law on public procurement.
10.2 Consequences of non-compliance
5 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of
procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134,
30.04.2004, p. 114).
6 Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and
repealing Directive 2004/18/EC. (OJ L 94, 28.03.2014, p. 65).
7 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement
procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1)
8 Directive 2014/25/EU of the European Parliament and of the Council of 26 February 2014 on procurement by entities
operating in the water, energy, transport and postal services sectors and repealing Directive 2004/17/EC (OJ L 94,
28.03.2014, p. 243).
29
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the contract
concerned will be ineligible (see Article 6) and will be rejected (see Article 42).
If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES
AGAINST PAYMENT
11.1 Rules for the use of in-kind contributions against payment
If necessary to implement the action, the beneficiaries may use in-kind contributions provided by third
parties against payment.
The beneficiaries may declare costs related to the payment of in-kind contributions as eligible (see
Article 6.1 and 6.2), up to the third parties’ costs for the seconded persons, contributed equipment,
infrastructure or other assets or other contributed goods and services.
The third parties and their contributions must be set out in Annex 1. The Commission may however
approve in-kind contributions not set out in Annex 1 without amendment (see Article 55), if:
- they are specifically justified in the periodic technical report and
- their use does not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
the third parties.
11.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the costs related to the payment of
the in-kind contribution will be ineligible (see Article 6) and will be rejected (see Article 42).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 12 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES
FREE OF CHARGE
12.1 Rules for the use of in-kind contributions free of charge
If necessary to implement the action, the beneficiaries may use in-kind contributions provided by third
parties free of charge.
The beneficiaries may declare costs incurred by the third parties for the seconded persons, contributed
equipment, infrastructure or other assets or other contributed goods and services as eligible in
accordance with Article 6.4.
30
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The third parties and their contributions must be set out in Annex 1. The Commission may however
approve in-kind contributions not set out in Annex 1 without amendment (see Article 55), if:
- they are specifically justified in the periodic technical report and
- their use does not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
the third parties.
12.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the costs incurred by the third parties
related to the in-kind contribution will be ineligible (see Article 6) and will be rejected (see Article 42).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 13 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS
13.1 Rules for subcontracting action tasks
13.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the
implementation of certain action tasks described in Annex 1.
Subcontracting may cover only a limited part of the action.
The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate,
the lowest price. In doing so, they must avoid any conflict of interests (see Article 35).
The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex 1 and
the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The Commission
may however approve subcontracts not set out in Annex 1 and 2 without amendment (see Article 55),
if:
- they are specifically justified in the periodic technical report and
- they do not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
their subcontractors.
13.1.2 The beneficiaries must ensure that their obligations under Articles 35, 36, 38 and 46 also apply
to the subcontractors.
Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC (or
2014/24/EU) or ‘contracting entities’ within the meaning of Directive 2004/17/EC (or 2014/25/EU)
must comply with the applicable national law on public procurement.
31
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
13.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 13.1.1, the costs related to the subcontract
concerned will be ineligible (see Article 6) and will be rejected (see Article 42).
If a beneficiary breaches any of its obligations under Article 13.1.2, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14 — IMPLEMENTATION OF ACTION TASKS BY LINKED THIRD PARTIES
14.1 Rules for calling upon linked third parties to implement part of the action
14.1.1 The following affiliated entities10 and third parties with a legal link to a beneficiary11
(‘linked third parties’) may implement the action tasks attributed to them in Annex 1:
- INSTITUT ZA MOLEKULARNU GENETIKU I GENETICKO INZENJERSTVO (IMGGE),
affiliated or linked to INSERM
- STOCKHOLMS LANS LANDSTING (KI), affiliated or linked to INSERM
- UNIVERZITETNI KLINICNI CENTER LJUBLJANA (UMCL-UKCL), affiliated or linked to
INSERM
- Department of Health (PHE), affiliated or linked to INSERM
- MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES
FUND BY THE SHEBA MEDICAL CENTER (SHEBA), affiliated or linked to INSERM
- RINNEKOTI SAATIO (Rinnekoti), affiliated or linked to INSERM
- KLINIKA ZA DJECJE BOLESTI ZAGREB (KDBZ), affiliated or linked to INSERM
- TARTU ULIKOOL (UT), affiliated or linked to INSERM
10 For the definition see Article 2.1(2) Rules for Participation Regulation No 1290/2013: ‘affiliated entity’ means any
legal entity that is:
- under the direct or indirect control of a participant, or
- under the same direct or indirect control as the participant, or
- directly or indirectly controlling a participant.
‘Control’ may take any of the following forms:
(a) the direct or indirect holding of more than 50% of the nominal value of the issued share capital in the legal entity
concerned, or of a majority of the voting rights of the shareholders or associates of that entity;
(b) the direct or indirect holding, in fact or in law, of decision-making powers in the legal entity concerned.
However the following relationships between legal entities shall not in themselves be deemed to constitute controlling
relationships:
(a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect
holding of more than 50% of the nominal value of the issued share capital or a majority of voting rights of the
shareholders or associates;
(b) the legal entities concerned are owned or supervised by the same public body.
11 ‘Third party with a legal link to a beneficiary’ is any legal entity which has a legal link to the beneficiary implying
collaboration that is not limited to the action.
32
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- MEDIZINISCHE HOCHSCHULE HANNOVER (MHH), affiliated or linked to INSERM
- OSPEDALE PEDIATRICO BAMBINO GESU (OPBG), affiliated or linked to INSERM
- Ministry for Health - Government of Malta (DHIR), affiliated or linked to INSERM
- GEORGIAN FOUNDATION FOR GENETIC AND RARE DISEASES (GERAD), affiliated or
linked to INSERM
- BULGARIAN ASSOCIATION FOR PROMOTION OF EDUCATION AND SCIENCE
(BAPES), affiliated or linked to INSERM
- UNIVERZITA KARLOVA (CUNI), affiliated or linked to INSERM
- HEALTH SERVICE EXECUTIVE HSE (HSE), affiliated or linked to INSERM
- LES HOPITAUX UNIVERSITAIRES DE GENEVE (HUG), affiliated or linked to INSERM
- OSLO UNIVERSITETSSYKEHUS HF (OUS-HF), affiliated or linked to INSERM
- BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (CCUH), affiliated or linked
to INSERM
- UNIVERSITE D'AIX MARSEILLE (AMU), affiliated or linked to INSERM
- Center of Medical Genetics and Primary Health Care (CMG), affiliated or linked to INSERM
- MEDIZINISCHE UNIVERSITAET WIEN (MUW-AT), affiliated or linked to INSERM
- SCIENSANO (Sciensano), affiliated or linked to INSERM
- UNIVERSITATEA DE MEDICINA SI FARMACIE GRIGORE T.POPA IASI (UMF), affiliated
or linked to INSERM
- AGENZIA PER LA PROMOZIONE DELLA RICERCA EUROPEA (APRE), affiliated or
linked to IT-MOH
- FUNDACIO SANT JOAN DE DEU (FSJD), affiliated or linked to TEDDY
- UNIVERSITE LYON 1 CLAUDE BERNARD (UCBL), affiliated or linked to CLB
- Universitaetsklinikum Tuebingen (UKT), affiliated or linked to EKUT
- KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET (UKF), affiliated
or linked to GUF
- MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (MFT NHS TRUST), affiliated
or linked to AOUS
- CENTRE HOSPITALIER REG UNIVERSITAIRE DIJON (CHU DIJON), affiliated or linked
to AOUS
- UNIVERSITY OF GLASGOW (UoG), affiliated or linked to LUMC
33
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (UKSH), affiliated or linked to
LUMC
- INSTITUT CURIE (IC), affiliated or linked to Radboudumc
- STOCKHOLMS LANS LANDSTING (KUH), affiliated or linked to Radboudumc
- MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (MFT), affiliated or linked to
Radboudumc
- TERVEYDEN JA HYVINVOINNIN LAITOS (THL), affiliated or linked to BBMRI
- MEDIZINISCHE UNIVERSITAT GRAZ (MUG), affiliated or linked to BBMRI
- CENTRO DI RICERCA, SVILUPPO E STUDI SUPERIORI IN SARDEGNA SOCIETÀ A
RESPONSABILITÀ LIMITATA (CRS4), affiliated or linked to BBMRI
- KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN (TUM),
affiliated or linked to BBMRI
- UNIVERSITETET I OSLO (UiO), affiliated or linked to EATRIS
- FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
(VHIR), affiliated or linked to EATRIS
- UPPSALA UNIVERSITET (UU (ELIXIR-SE)), affiliated or linked to EMBL
- THE UNIVERSITY OF MANCHESTER (UNIMAN), affiliated or linked to EMBL
- UNIVERZA V LJUBLJANI (UL (ELIXIR-SI)), affiliated or linked to EMBL
- CSC-TIETEEN TIETOTEKNIIKAN KESKUS OY (CSC (ELIXIR-FI)), affiliated or linked to
EMBL
- BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE
SUPERCOMPUTACION (BSC (ELIXIR-ES)), affiliated or linked to EMBL
- DANMARKS TEKNISKE UNIVERSITET (DTU (ELIXIR-DK)), affiliated or linked to EMBL
- CONSIGLIO NAZIONALE DELLE RICERCHE (CNR (ELIXIR-IT)), affiliated or linked to
EMBL
- STICHTING DTL PROJECTS (DTL-Projects), affiliated or linked to EMBL
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF
CAMBRIDGE (UCAM), affiliated or linked to EMBL
- SIB INSTITUT SUISSE DE BIOINFORMATIQUE (SIB (ELIXIR-CH)), affiliated or linked to
EMBL
- Masarykova univerzita (MU-CERIT-SC), affiliated or linked to EMBL
The linked third parties may declare as eligible the costs they incur for implementing the action tasks
in accordance with Article 6.3.
34
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
their linked third parties.
14.1.2 The beneficiaries must ensure that their obligations under Articles 18, 20, 35, 36 and 38 also
apply to their linked third parties.
14.2 Consequences of non-compliance
If any obligation under Article 14.1.1 is breached, the costs of the linked third party will be ineligible
(see Article 6) and will be rejected (see Article 42).
If any obligation under Article 14.1.2 is breached, the grant may be reduced (see Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14a — IMPLEMENTATION OF ACTION TASKS BY INTERNATIONAL
PARTNERS
Not applicable
ARTICLE 15 — FINANCIAL SUPPORT TO THIRD PARTIES
15.1 Rules for providing financial support to third parties
15.1.1 The beneficiaries must provide financial support in accordance with the conditions set out in
Annex 1.
At a minimum, these conditions must include:
(a) the maximum amount of financial support for each third party.
The maximum amount may not exceed EUR 60 000 for each third party, unless it is necessary
to achieve the objectives of the action as described in Annex 1;
(b) the criteria for calculating the exact amount of the financial support;
(c) the different types of activity that qualify for financial support, on the basis of a closed list;
(d) the persons or categories of persons that may receive financial support, and
(e) the criteria for giving financial support.
The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the
European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards
the third parties receiving financial support.
15.1.2 The beneficiaries must ensure that their obligations under Articles 35, 36, 38 and 46 also apply
to the third parties receiving financial support.
15.2 Financial support in the form of prizes
35
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Not applicable
15.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Articles 15.1.1 or 15.2.1, the costs related to the
financial support or prize will be ineligible (see Article 6) and will be rejected (see Article 42).
If a beneficiary breaches any of its obligations under Articles 15.1.2 or 15.2.2, the grant may be
reduced (see Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 16 — PROVISION OF TRANS-NATIONAL OR VIRTUAL ACCESS TO
RESEARCH INFRASTRUCTURE
Not applicable
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT
ADMINISTRATION
ARTICLE 17 — GENERAL OBLIGATION TO INFORM
17.1 General obligation to provide information upon request
The beneficiaries must provide — during implementation of the action or afterwards and in accordance
with Article 41.2 — any information requested in order to verify eligibility of the costs, proper
implementation of the action and compliance with any other obligation under the Agreement.
17.2 Obligation to keep information up to date and to inform about events and
circumstances likely to affect the Agreement
Each beneficiary must keep information stored in the Participant Portal Beneficiary Register (via
the electronic exchange system; see Article 52) up to date, in particular, its name, address, legal
representatives, legal form and organisation type.
Each beneficiary must immediately inform the coordinator — which must immediately inform the
Commission and the other beneficiaries — of any of the following:
(a) events which are likely to affect significantly or delay the implementation of the action or the
EU's financial interests, in particular:
(i) changes in its legal, financial, technical, organisational or ownership situation or those
of its linked third parties and
(ii) changes in the name, address, legal form, organisation type of its linked third parties;
(b) circumstances affecting:
(i) the decision to award the grant or
(ii) compliance with requirements under the Agreement.
36
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
17.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 18 — KEEPING RECORDS — SUPPORTING DOCUMENTATION
18.1 Obligation to keep records and other supporting documentation
The beneficiaries must — for a period of five years after the payment of the balance — keep records
and other supporting documentation in order to prove the proper implementation of the action and
the costs they declare as eligible.
They must make them available upon request (see Article 17) or in the context of checks, reviews,
audits or investigations (see Article 22).
If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under
the Agreement (including the extension of findings; see Article 22), the beneficiaries must keep the
records and other supporting documentation until the end of these procedures.
The beneficiaries must keep the original documents. Digital and digitalised documents are considered
originals if they are authorised by the applicable national law. The Commission may accept non-
original documents if it considers that they offer a comparable level of assurance.
18.1.1 Records and other supporting documentation on the scientific and technical
implementation
The beneficiaries must keep records and other supporting documentation on scientific and technical
implementation of the action in line with the accepted standards in the respective field.
18.1.2 Records and other documentation to support the costs declared
The beneficiaries must keep the records and documentation supporting the costs declared, in particular
the following:
(a) for actual costs: adequate records and other supporting documentation to prove the costs
declared, such as contracts, subcontracts, invoices and accounting records. In addition, the
beneficiaries' usual cost accounting practices and internal control procedures must enable direct
reconciliation between the amounts declared, the amounts recorded in their accounts and the
amounts stated in the supporting documentation;
(b) for unit costs: adequate records and other supporting documentation to prove the number of
units declared. Beneficiaries do not need to identify the actual eligible costs covered or to keep
or provide supporting documentation (such as accounting statements) to prove the amount per
unit.
In addition, for unit costs calculated in accordance with the beneficiary's usual cost
accounting practices, the beneficiaries must keep adequate records and documentation to
prove that the cost accounting practices used comply with the conditions set out in Article 6.2.
37
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The beneficiaries and linked third parties may submit to the Commission, for approval, a
certificate (drawn up in accordance with Annex 6) stating that their usual cost accounting
practices comply with these conditions (‘certificate on the methodology’). If the certificate
is approved, costs declared in line with this methodology will not be challenged subsequently,
unless the beneficiaries have concealed information for the purpose of the approval.
(c) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility
of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs
covered or provide supporting documentation (such as accounting statements) to prove the
amount declared at a flat-rate.
In addition, for personnel costs (declared as actual costs or on the basis of unit costs), the beneficiaries
must keep time records for the number of hours declared. The time records must be in writing and
approved by the persons working on the action and their supervisors, at least monthly. In the absence
of reliable time records of the hours worked on the action, the Commission may accept alternative
evidence supporting the number of hours declared, if it considers that it offers an adequate level of
assurance.
As an exception, for persons working exclusively on the action, there is no need to keep time records,
if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively
on the action.
For costs declared by linked third parties (see Article 14), it is the beneficiary that must keep the
originals of the financial statements and the certificates on the financial statements of the linked third
parties.
18.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated
will be ineligible (see Article 6) and will be rejected (see Article 42), and the grant may be reduced
(see Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 19 — SUBMISSION OF DELIVERABLES
19.1 Obligation to submit deliverables
The coordinator must submit:
- 90 days before the end of each reporting period:
(a) the ‘annual work plan for the next year’ (see Annex 7), for approval by the
Commission and
(b) a summary progress report on the activities carried out during the on-going reporting
period.
This report must show how the activities proposed in the annual work plan for the next
year ensure continuity with the work already carried out.
38
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If the Commission considers that the annual work plan for the next year does not comply with
Annex 1, the coordinator must submit a revised version within 30 days from receiving formal
notification.
If the Commission considers that the revised annual work plan for the next year still does not
comply with Annex 1, it may terminate the Agreement (see Article 50.3).
- the other ‘deliverables’ identified in Annex 1, in accordance with the timing and conditions
set out in it.
19.2 Consequences of non-compliance
If the coordinator breaches any of its obligations under this Article, the Commission may apply any
of the measures described in Chapter 6.
ARTICLE 20 — REPORTING — PAYMENT REQUESTS
20.1 Obligation to submit reports
The coordinator must submit to the Commission (see Article 52) the technical and financial reports
set out in this Article. These reports include the requests for payment and must be drawn up using the
forms and templates provided in the electronic exchange system (see Article 52).
20.2 Reporting periods
The action is divided into the following ‘reporting periods’:
- RP1: from month 1 to month 12
- RP2: from month 13 to month 24
- RP3: from month 25 to month 36
- RP4: from month 37 to month 48
- RP5: from month 49 to month 60
20.2a Request for a second pre-financing payment
Not applicable
20.3 Periodic reports — Requests for interim payments
The coordinator must submit a periodic report within 60 days following the end of each reporting
period.
The periodic report must include the following:
(a) a ‘periodic technical report’ containing:
(i) an explanation of the work carried out by the beneficiaries;
(ii) an overview of the progress towards the objectives of the action, including milestones
and deliverables identified in Annex 1 and the annual work plan for the year (see
Annex 7).
39
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
This report must include explanations justifying the differences between work expected
to be carried out in accordance with Annex 1 and the annual work plan for the year (see
Annex 7) and that actually carried out.
The report must also detail the exploitation and dissemination of the results and — if
required in Annex 1 — an updated ‘plan for the exploitation and dissemination of
the results’;
The report must indicate the communication activities.
(iii) a summary for publication by the Commission;
(iv) the answers to the ‘questionnaire’, covering issues related to the action implementation
and the economic and societal impact, notably in the context of the Horizon 2020 key
performance indicators and the Horizon 2020 monitoring requirements;
(b) a ‘periodic financial report’ containing:
(i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each
linked third party, for the reporting period concerned.
The individual financial statement must detail the eligible costs (actual costs, unit costs
and flat-rate costs; see Article 6) for each budget category (see Annex 2).
The beneficiaries and linked third parties must declare all eligible costs, even if —
for actual costs, unit costs and flat-rate costs — they exceed the amounts indicated in
the estimated budget (see Annex 2). Amounts which are not declared in the individual
financial statement will not be taken into account by the Commission.
If an individual financial statement is not submitted for a reporting period, it may be
included in the periodic financial report for the next reporting period.
The individual financial statements of the last reporting period must also detail the
receipts of the action (see Article 5.3.3).
Each beneficiary and each linked third party must certify that:
- the information provided is full, reliable and true;
- the costs declared are eligible (see Article 6);
- the costs can be substantiated by adequate records and supporting documentation
(see Article 18) that will be produced upon request (see Article 17) or in the context
of checks, reviews, audits and investigations (see Article 22), and
- for the last reporting period: that all the receipts have been declared (see
Article 5.3.3);
(ii) an explanation of the use of resources and the information on subcontracting (see
Article 13) and in-kind contributions provided by third parties (see Articles 11 and
12) from each beneficiary and from each linked third party, for the reporting period
concerned;
40
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(iii) Not applicable;
(iv) a ‘periodic summary financial statement’, created automatically by the electronic
exchange system, consolidating the individual financial statements for the reporting
period concerned and including — except for the last reporting period — the request
for interim payment.
20.4 Final report — Request for payment of the balance
In addition to the periodic report for the last reporting period, the coordinator must submit the final
report within 60 days following the end of the last reporting period.
The final report must include the following:
(a) a ‘final technical report’ with a summary for publication containing:
(i) an overview of the results and their exploitation and dissemination;
(ii) the conclusions on the action, and
(iii) the socio-economic impact of the action;
(b) a ‘final financial report’ containing:
(i) a ‘final summary financial statement’, created automatically by the electronic
exchange system, consolidating the individual financial statements for all reporting
periods and including the request for payment of the balance and
(ii) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each linked third party, if it requests a total contribution of
EUR 325 000 or more, as reimbursement of actual costs and unit costs calculated on the
basis of its usual cost accounting practices (see Article 5.2 and Article 6.2).
20.5 Information on cumulative expenditure incurred
Not applicable
20.6 Currency for financial statements and conversion into euro
Financial statements must be drafted in euro.
Beneficiaries and linked third parties with accounting established in a currency other than the euro
must convert the costs recorded in their accounts into euro, at the average of the daily exchange
rates published in the C series of the Official Journal of the European Union, calculated over the
corresponding reporting period.
If no daily euro exchange rate is published in the Official Journal of the European Union for the
currency in question, they must be converted at the average of the monthly accounting rates published
on the Commission’s website, calculated over the corresponding reporting period.
Beneficiaries and linked third parties with accounting established in euro must convert costs incurred
in another currency into euro according to their usual accounting practices.
41
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
20.7 Language of reports
All reports (technical and financial reports, including financial statements) must be submitted in the
language of the Agreement.
20.8 Consequences of non-compliance
If the reports submitted do not comply with this Article, the Commission may suspend the payment
deadline (see Article 47) and apply any of the other measures described in Chapter 6.
If the coordinator breaches its obligation to submit the reports and if it fails to comply with this
obligation within 30 days following a written reminder, the Commission may terminate the Agreement
(see Article 50) or apply any of the other measures described in Chapter 6.
ARTICLE 21 — PAYMENTS AND PAYMENT ARRANGEMENTS
21.1 Payments to be made
The following payments will be made to the coordinator:
- a pre-financing payment;
- one or more interim payments, on the basis of the request(s) for interim payment (see
Article 20), and
- one payment of the balance, on the basis of the request for payment of the balance (see
Article 20).
21.2 Pre-financing payment — Amount — Amount retained for the Guarantee Fund
The aim of the pre-financing is to provide the beneficiaries with a float.
It remains the property of the EU until the payment of the balance.
The Commission will — within 30 days, either from the entry into force of the Agreement (see
Article 58) or from 10 days before the starting date of the action (see Article 3), whichever is the
latest — make a pre-financing payment to the coordinator of EUR 17 628 693.44 (seventeen million
six hundred and twenty eight thousand six hundred and ninety three EURO and forty four eurocents),
except if Article 48 applies.
From this amount, an amount of EUR 2 753 691.56 (two million seven hundred and fifty three
thousand six hundred and ninety one EURO and fifty six eurocents), corresponding to 5% of the
maximum grant amount (see Article 5.1), is retained by the Commission and transferred into the
‘Guarantee Fund’.
21.3 Interim payments — Amount — Calculation
Interim payments reimburse the eligible costs incurred for the implementation of the action during
the corresponding reporting periods.
The Commission will pay to the coordinator the amount due as interim payment within 90 days from
receiving the periodic report (see Article 20.3), except if Articles 47 or 48 apply.
42
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Payment is subject to the approval of the periodic report. Its approval does not imply recognition of
the compliance, authenticity, completeness or correctness of its content.
The amount due as interim payment is calculated by the Commission in the following steps:
Step 1 – Application of the reimbursement rates
Step 2 – Limit to 90% of the maximum grant amount
21.3.1 Step 1 — Application of the reimbursement rates
The reimbursement rate(s) (see Article 5.2) are applied to the eligible costs (actual costs, unit costs and
flat-rate costs; see Article 6) declared by the beneficiaries and the linked third parties (see Article 20)
and approved by the Commission (see above) for the concerned reporting period.
21.3.2 Step 2 — Limit to 90% of the maximum grant amount
The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant
amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as
follows:
{90% of the maximum grant amount (see Article 5.1)
minus
{pre-financing and previous interim payments}}.
21.4 Payment of the balance — Amount — Calculation — Release of the amount retained
for the Guarantee Fund
The payment of the balance reimburses the remaining part of the eligible costs incurred by the
beneficiaries for the implementation of the action.
If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the
payment of the balance takes the form of a recovery (see Article 44).
If the total amount of earlier payments is lower than the final grant amount, the Commission will
pay the balance within 90 days from receiving the final report (see Article 20.4), except if Articles
47 or 48 apply.
Payment is subject to the approval of the final report. Its approval does not imply recognition of the
compliance, authenticity, completeness or correctness of its content.
The amount due as the balance is calculated by the Commission by deducting the total amount of
pre-financing and interim payments (if any) already made, from the final grant amount determined
in accordance with Article 5.3:
{final grant amount (see Article 5.3)
minus
{pre-financing and interim payments (if any) made}}.
43
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
At the payment of the balance, the amount retained for the Guarantee Fund (see above) will be released
and:
- if the balance is positive: the amount released will be paid in full to the coordinator together
with the amount due as the balance;
- if the balance is negative (payment of the balance taking the form of recovery): it will be
deducted from the amount released (see Article 44.1.2). If the resulting amount:
- is positive, it will be paid to the coordinator
- is negative, it will be recovered.
The amount to be paid may however be offset — without the beneficiaries’ consent — against any
other amount owed by a beneficiary to the Commission or an executive agency (under the EU or
Euratom budget), up to the maximum EU contribution indicated, for that beneficiary, in the estimated
budget (see Annex 2).
21.5 Notification of amounts due
When making payments, the Commission will formally notify to the coordinator the amount due,
specifying whether it concerns a interim payment or the payment of the balance.
For the payment of the balance, the notification will also specify the final grant amount.
In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded
by the contradictory procedure set out in Articles 43 and 44.
21.6 Currency for payments
The Commission will make all payments in euro.
21.7 Payments to the coordinator — Distribution to the beneficiaries
Payments will be made to the coordinator.
Payments to the coordinator will discharge the Commission from its payment obligation.
The coordinator must distribute the payments between the beneficiaries without unjustified delay.
Pre-financing may however be distributed only:
(a) if the minimum number of beneficiaries set out in the call for proposals has acceded to the
Agreement (see Article 56) and
(b) to beneficiaries that have acceded to the Agreement (see Article 56).
21.8 Bank account for payments
All payments will be made to the following bank account:
44
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Name of bank: TRESOR PUBLIC
Full name of the account holder: ACS INSERM PARIS VI ST ANTOINE
IBAN code: FR7610071750000000100523686
21.9 Costs of payment transfers
The cost of the payment transfers is borne as follows:
- the Commission bears the cost of transfers charged by its bank;
- the beneficiary bears the cost of transfers charged by its bank;
- the party causing a repetition of a transfer bears all costs of the repeated transfer.
21.10 Date of payment
Payments by the Commission are considered to have been carried out on the date when they are
debited to its account.
21.11 Consequences of non-compliance
21.11.1 If the Commission does not pay within the payment deadlines (see above), the beneficiaries
are entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its
main refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate
is the rate in force on the first day of the month in which the payment deadline expires, as published
in the C series of the Official Journal of the European Union.
If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only
upon request submitted within two months of receiving the late payment.
Late-payment interest is not due if all beneficiaries are EU Member States (including regional and
local government authorities or other public bodies acting on behalf of a Member State for the purpose
of this Agreement).
Suspension of the payment deadline or payments (see Articles 47 and 48) will not be considered as
late payment.
Late-payment interest covers the period running from the day following the due date for payment (see
above), up to and including the date of payment.
Late-payment interest is not considered for the purposes of calculating the final grant amount.
21.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced
(see Article 43) and the Agreement or the participation of the coordinator may be terminated (see
Article 50).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 22 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION
OF FINDINGS
22.1 Checks, reviews and audits by the Commission
45
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
22.1.1 Right to carry out checks
The Commission will — during the implementation of the action or afterwards — check the proper
implementation of the action and compliance with the obligations under the Agreement, including
assessing deliverables and reports.
For this purpose the Commission may be assisted by external persons or bodies.
The Commission may also request additional information in accordance with Article 17. The
Commission may request beneficiaries to provide such information to it directly.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
22.1.2 Right to carry out reviews
The Commission may — during the implementation of the action or afterwards — carry out reviews
on the proper implementation of the action (including assessment of deliverables and reports),
compliance with the obligations under the Agreement and continued scientific or technological
relevance of the action.
Reviews may be started up to two years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the review is carried out on a third party (see Articles 10 to 16), the beneficiary concerned must
inform the third party.
The Commission may carry out reviews directly (using its own staff) or indirectly (using external
persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned of the
identity of the external persons or bodies. They have the right to object to the appointment on grounds
of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information and data in addition to deliverables and reports already submitted (including information
on the use of resources). The Commission may request beneficiaries to provide such information to
it directly.
The coordinator or beneficiary concerned may be requested to participate in meetings, including with
external experts.
For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the review findings, a ‘review report’ will be drawn up.
The Commission will formally notify the review report to the coordinator or beneficiary concerned,
which has 30 days to formally notify observations (‘contradictory review procedure’).
Reviews (including review reports) are in the language of the Agreement.
46
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
22.1.3 Right to carry out audits
The Commission may — during the implementation of the action or afterwards — carry out audits on
the proper implementation of the action and compliance with the obligations under the Agreement.
Audits may be started up to two years after the payment of the balance. They will be formally notified
to the coordinator or beneficiary concerned and will be considered to have started on the date of the
formal notification.
If the audit is carried out on a third party (see Articles 10 to 16), the beneficiary concerned must
inform the third party.
The Commission may carry out audits directly (using its own staff) or indirectly (using external
persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned of the
identity of the external persons or bodies. They have the right to object to the appointment on grounds
of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information (including complete accounts, individual salary statements or other personal data) to
verify compliance with the Agreement. The Commission may request beneficiaries to provide such
information to it directly.
For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the audit findings, a ‘draft audit report’ will be drawn up.
The Commission will formally notify the draft audit report to the coordinator or beneficiary concerned,
which has 30 days to formally notify observations (‘contradictory audit procedure’). This period
may be extended by the Commission in justified cases.
The ‘final audit report’ will take into account observations by the coordinator or beneficiary
concerned. The report will be formally notified to it.
Audits (including audit reports) are in the language of the Agreement.
The Commission may also access the beneficiaries’ statutory records for the periodical assessment
of unit costs or flat-rate amounts.
22.2 Investigations by the European Anti-Fraud Office (OLAF)
Under Regulations No 883/201313 and No 2185/9614 (and in accordance with their provisions and
13 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013
concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC) No
1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ L 248,
18.09.2013, p. 1).
14 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections
carried out by the Commission in order to protect the European Communities' financial interests against fraud and other
irregularities (OJ L 292, 15.11.1996, p. 2).
47
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation
of the action or afterwards — carry out investigations, including on-the-spot checks and inspections,
to establish whether there has been fraud, corruption or any other illegal activity affecting the financial
interests of the EU.
22.3 Checks and audits by the European Court of Auditors (ECA)
Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161
of the Financial Regulation No 966/201215, the European Court of Auditors (ECA) may — at any
moment during implementation of the action or afterwards — carry out audits.
The ECA has the right of access for the purpose of checks and audits.
22.4 Checks, reviews, audits and investigations for international organisations
In conformity with its financial regulations, the European Union, including the European Anti-Fraud
Office (OLAF) and the European Court of Auditors (ECA), may undertake, including on the spot,
checks, reviews, audits and investigations.
This Article will be applied in accordance with any specific agreement concluded in this respect by
the international organisation and the European Union.
22.5 Consequences of findings in checks, reviews, audits and investigations — Extension of
findings
22.5.1 Findings in this grant
Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead
to the rejection of ineligible costs (see Article 42), reduction of the grant (see Article 43), recovery of
undue amounts (see Article 44) or to any of the other measures described in Chapter 6.
Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final
grant amount (see Article 5.4).
Findings in checks, reviews, audits or investigations may lead to a request for amendment for the
modification of Annex 1 (see Article 55).
Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or
breach of obligations may also lead to consequences in other EU or Euratom grants awarded under
similar conditions (‘extension of findings from this grant to other grants’).
Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under
national law.
22.5.2 Findings in other grants
The Commission may extend findings from other grants to this grant (‘extension of findings from
other grants to this grant’), if:
15 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the
financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No
1605/2002 (OJ L 298, 26.10.2012, p. 1).
48
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar
conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of
obligations that have a material impact on this grant and
(b) those findings are formally notified to the beneficiary concerned — together with the list of
grants affected by the findings — no later than two years after the payment of the balance of
this grant.
The extension of findings may lead to the rejection of costs (see Article 42), reduction of the grant
(see Article 43), recovery of undue amounts (see Article 44), suspension of payments (see Article 48),
suspension of the action implementation (see Article 49) or termination (see Article 50).
22.5.3 Procedure
The Commission will formally notify the beneficiary concerned the systemic or recurrent errors and
its intention to extend these audit findings, together with the list of grants affected.
22.5.3.1 If the findings concern eligibility of costs: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings;
(b) the request to submit revised financial statements for all grants affected;
(c) the correction rate for extrapolation established by the Commission on the basis of the
systemic or recurrent errors, to calculate the amounts to be rejected if the beneficiary concerned:
(i) considers that the submission of revised financial statements is not possible or practicable
or
(ii) does not submit revised financial statements.
The beneficiary concerned has 90 days from receiving notification to submit observations, revised
financial statements or to propose a duly substantiated alternative correction method. This period
may be extended by the Commission in justified cases.
The Commission may then start a rejection procedure in accordance with Article 42, on the basis of:
- the revised financial statements, if approved;
- the proposed alternative correction method, if accepted
or
- the initially notified correction rate for extrapolation, if it does not receive any observations
or revised financial statements, does not accept the observations or the proposed alternative
correction method or does not approve the revised financial statements.
22.5.3.2 If the findings concern substantial errors, irregularities or fraud or serious breach of
obligations: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings and
(b) the flat-rate the Commission intends to apply according to the principle of proportionality.
49
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The beneficiary concerned has 90 days from receiving notification to submit observations or to
propose a duly substantiated alternative flat-rate.
The Commission may then start a reduction procedure in accordance with Article 43, on the basis of:
- the proposed alternative flat-rate, if accepted
or
- the initially notified flat-rate, if it does not receive any observations or does not accept the
observations or the proposed alternative flat-rate.
22.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs
will be ineligible (see Article 6) and will be rejected (see Article 42).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 23 — EVALUATION OF THE IMPACT OF THE ACTION
23.1 Right to evaluate the impact of the action
The Commission may carry out interim and final evaluations of the impact of the action measured
against the objective of the EU programme.
Evaluations may be started during implementation of the action and up to five years after the payment
of the balance. The evaluation is considered to start on the date of the formal notification to the
coordinator or beneficiaries.
The Commission may make these evaluations directly (using its own staff) or indirectly (using external
bodies or persons it has authorised to do so).
The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the
action, including information in electronic format.
23.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the Commission may apply the
measures described in Chapter 6.
SECTION 3 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND AND
RESULTS
SUBSECTION 1 GENERAL
ARTICLE 23a — MANAGEMENT OF INTELLECTUAL PROPERTY
23a.1 Obligation to take measures to implement the Commission Recommendation on the
management of intellectual property in knowledge transfer activities
50
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Beneficiaries that are universities or other public research organisations must take measures to
implement the principles set out in Points 1 and 2 of the Code of Practice annexed to the Commission
Recommendation on the management of intellectual property in knowledge transfer activities16.
This does not change the obligations set out in Subsections 2 and 3 of this Section.
The beneficiaries must ensure that researchers and third parties involved in the action are aware of
them.
23a.2 Consequences of non-compliance
If a beneficiary breaches its obligations under this Article, the Commission may apply any of the
measures described in Chapter 6.
SUBSECTION 2 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND
ARTICLE 24 — AGREEMENT ON BACKGROUND
24.1 Agreement on background
The beneficiaries must identify and agree (in writing) on the background for the action (‘agreement
on background’).
‘Background’ means any data, know-how or information — whatever its form or nature (tangible or
intangible), including any rights such as intellectual property rights — that:
(a) is held by the beneficiaries before they acceded to the Agreement, and
(b) is needed to implement the action or exploit the results.
24.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 25 — ACCESS RIGHTS TO BACKGROUND
25.1 Exercise of access rights — Waiving of access rights — No sub-licensing
To exercise access rights, this must first be requested in writing (‘request for access’).
‘Access rights’ means rights to use results or background under the terms and conditions laid down
in this Agreement.
Waivers of access rights are not valid unless in writing.
16 Commission Recommendation C(2008) 1329 of 10.4.2008 on the management of intellectual property in knowledge
transfer activities and the Code of Practice for universities and other public research institutions attached to this
recommendation.
51
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Unless agreed otherwise, access rights do not include the right to sub-license.
25.2 Access rights for other beneficiaries, for implementing their own tasks under the action
The beneficiaries must give each other access — on a royalty-free basis — to background needed to
implement their own tasks under the action, unless the beneficiary that holds the background has —
before acceding to the Agreement —:
(a) informed the other beneficiaries that access to its background is subject to legal restrictions or
limits, including those imposed by the rights of third parties (including personnel), or
(b) agreed with the other beneficiaries that access would not be on a royalty-free basis.
25.3 Access rights for other beneficiaries, for exploiting their own results
The beneficiaries must give each other access — under fair and reasonable conditions — to
background needed for exploiting their own results, unless the beneficiary that holds the background
has — before acceding to the Agreement — informed the other beneficiaries that access to its
background is subject to legal restrictions or limits, including those imposed by the rights of third
parties (including personnel).
‘Fair and reasonable conditions’ means appropriate conditions, including possible financial terms
or royalty-free conditions, taking into account the specific circumstances of the request for access, for
example the actual or potential value of the results or background to which access is requested and/or
the scope, duration or other characteristics of the exploitation envisaged.
Requests for access may be made — unless agreed otherwise — up to one year after the period set
out in Article 3.
25.4 Access rights for affiliated entities
Unless otherwise agreed in the consortium agreement, access to background must also be given
— under fair and reasonable conditions (see above; Article 25.3) and unless it is subject to legal
restrictions or limits, including those imposed by the rights of third parties (including personnel) —
to affiliated entities17 established in an EU Member State or ‘associated country’18, if this is needed
to exploit the results generated by the beneficiaries to which they are affiliated.
Unless agreed otherwise (see above; Article 25.1), the affiliated entity concerned must make the
request directly to the beneficiary that holds the background.
Requests for access may be made — unless agreed otherwise — up to one year after the period set
out in Article 3.
25.5 Access rights for third parties
Not applicable
17 For the definition, see ‘affiliated entity’ footnote (Article 14.1).
18 For the definition, see Article 2.1(3) of the Rules for Participation Regulation No 1290/2013: ‘associated country’
means a third country which is party to an international agreement with the Union, as identified in Article 7 of
Horizon 2020 Framework Programme Regulation No 1291/2013. Article 7 sets out the conditions for association of
non-EU countries to Horizon 2020.
52
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
25.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
SUBSECTION 3 RIGHTS AND OBLIGATIONS RELATED TO RESULTS
ARTICLE 26 — OWNERSHIP OF RESULTS
26.1 Ownership by the beneficiary that generates the results
Results are owned by the beneficiary that generates them.
‘Results’ means any (tangible or intangible) output of the action such as data, knowledge or
information — whatever its form or nature, whether it can be protected or not — that is generated in
the action, as well as any rights attached to it, including intellectual property rights.
26.2 Joint ownership by several beneficiaries
Two or more beneficiaries own results jointly if:
(a) they have jointly generated them and
(b) it is not possible to:
(i) establish the respective contribution of each beneficiary, or
(ii) separate them for the purpose of applying for, obtaining or maintaining their protection
(see Article 27).
The joint owners must agree (in writing) on the allocation and terms of exercise of their joint ownership
(‘joint ownership agreement’), to ensure compliance with their obligations under this Agreement.
Unless otherwise agreed in the joint ownership agreement, each joint owner may grant non-exclusive
licences to third parties to exploit jointly-owned results (without any right to sub-license), if the other
joint owners are given:
(a) at least 45 days advance notice and
(b) fair and reasonable compensation.
Once the results have been generated, joint owners may agree (in writing) to apply another regime
than joint ownership (such as, for instance, transfer to a single owner (see Article 30) with access
rights for the others).
26.3 Rights of third parties (including personnel)
If third parties (including personnel) may claim rights to the results, the beneficiary concerned must
ensure that it complies with its obligations under the Agreement.
53
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If a third party generates results, the beneficiary concerned must obtain all necessary rights (transfer,
licences or other) from the third party, in order to be able to respect its obligations as if those results
were generated by the beneficiary itself.
If obtaining the rights is impossible, the beneficiary must refrain from using the third party to generate
the results.
26.4 EU ownership, to protect results
26.4.1 The EU may — with the consent of the beneficiary concerned — assume ownership of results
to protect them, if a beneficiary intends — up to four years after the period set out in Article 3 — to
disseminate its results without protecting them, except in any of the following cases:
(a) the lack of protection is because protecting the results is not possible, reasonable or justified
(given the circumstances);
(b) the lack of protection is because there is a lack of potential for commercial or industrial
exploitation, or
(c) the beneficiary intends to transfer the results to another beneficiary or third party established
in an EU Member State or associated country, which will protect them.
Before the results are disseminated and unless any of the cases above under Points (a), (b) or (c)
applies, the beneficiary must formally notify the Commission and at the same time inform it of any
reasons for refusing consent. The beneficiary may refuse consent only if it can show that its legitimate
interests would suffer significant harm.
If the Commission decides to assume ownership, it will formally notify the beneficiary concerned
within 45 days of receiving notification.
No dissemination relating to these results may take place before the end of this period or, if the
Commission takes a positive decision, until it has taken the necessary steps to protect the results.
26.4.2 The EU may — with the consent of the beneficiary concerned — assume ownership of results
to protect them, if a beneficiary intends — up to four years after the period set out in Article 3 — to
stop protecting them or not to seek an extension of protection, except in any of the following cases:
(a) the protection is stopped because of a lack of potential for commercial or industrial exploitation;
(b) an extension would not be justified given the circumstances.
A beneficiary that intends to stop protecting results or not seek an extension must — unless any of
the cases above under Points (a) or (b) applies — formally notify the Commission at least 60 days
before the protection lapses or its extension is no longer possible and at the same time inform it of any
reasons for refusing consent. The beneficiary may refuse consent only if it can show that its legitimate
interests would suffer significant harm.
If the Commission decides to assume ownership, it will formally notify the beneficiary concerned
within 45 days of receiving notification.
26.5 Consequences of non-compliance
54
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to the any of the other measures described in Chapter 6.
ARTICLE 27 — PROTECTION OF RESULTS — VISIBILITY OF EU FUNDING
27.1 Obligation to protect the results
Each beneficiary must examine the possibility of protecting its results and must adequately protect
them — for an appropriate period and with appropriate territorial coverage — if:
(a) the results can reasonably be expected to be commercially or industrially exploited and
(b) protecting them is possible, reasonable and justified (given the circumstances).
When deciding on protection, the beneficiary must consider its own legitimate interests and the
legitimate interests (especially commercial) of the other beneficiaries.
27.2 EU ownership, to protect the results
If a beneficiary intends not to protect its results, to stop protecting them or not seek an extension of
protection, the EU may — under certain conditions (see Article 26.4) — assume ownership to ensure
their (continued) protection.
27.3 Information on EU funding
Applications for protection of results (including patent applications) filed by or on behalf of a
beneficiary must — unless the Commission requests or agrees otherwise or unless it is impossible
— include the following:
“The project leading to this application has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 825575”.
27.4 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 28 — EXPLOITATION OF RESULTS
28.1 Obligation to exploit the results
Each beneficiary must — up to four years after the period set out in Article 3 — take measures aiming
to ensure ‘exploitation’ of its results (either directly or indirectly, in particular through transfer or
licensing; see Article 30) by:
(a) using them in further research activities (outside the action);
(b) developing, creating or marketing a product or process;
55
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(c) creating and providing a service, or
(d) using them in standardisation activities.
This does not change the security obligations in Article 37, which still apply.
28.2 Results that could contribute to European or international standards — Information on
EU funding
If results are incorporated in a standard, the beneficiary concerned must — unless the Commission
requests or agrees otherwise or unless it is impossible — ask the standardisation body to include the
following statement in (information related to) the standard:
“Results incorporated in this standard received funding from the European Union’s Horizon 2020 research
and innovation programme under grant agreement No 825575”.
28.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced in
accordance with Article 43.
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 29 — DISSEMINATION OF RESULTS — OPEN ACCESS — VISIBILITY OF
EU FUNDING
29.1 Obligation to disseminate results
Unless it goes against their legitimate interests, each beneficiary must — as soon as possible —
‘disseminate’ its results by disclosing them to the public by appropriate means (other than those
resulting from protecting or exploiting the results), including in scientific publications (in any
medium).
This does not change the obligation to protect results in Article 27, the confidentiality obligations in
Article 36, the security obligations in Article 37 or the obligations to protect personal data in Article 39,
all of which still apply.
A beneficiary that intends to disseminate its results must give advance notice to the other beneficiaries
of — unless agreed otherwise — at least 45 days, together with sufficient information on the results
it will disseminate.
Any other beneficiary may object within — unless agreed otherwise — 30 days of receiving
notification, if it can show that its legitimate interests in relation to the results or background would
be significantly harmed. In such cases, the dissemination may not take place unless appropriate steps
are taken to safeguard these legitimate interests.
If a beneficiary intends not to protect its results, it may — under certain conditions (see Article 26.4.1)
— need to formally notify the Commission before dissemination takes place.
29.2 Open access to scientific publications
56
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Each beneficiary must ensure open access (free of charge online access for any user) to all
peer-reviewed scientific publications relating to its results.
In particular, it must:
(a) as soon as possible and at the latest on publication, deposit a machine-readable electronic
copy of the published version or final peer-reviewed manuscript accepted for publication in a
repository for scientific publications;
Moreover, the beneficiary must aim to deposit at the same time the research data needed to
validate the results presented in the deposited scientific publications.
(b) ensure open access to the deposited publication — via the repository — at the latest:
(i) on publication, if an electronic version is available for free via the publisher, or
(ii) within six months of publication (twelve months for publications in the social sciences
and humanities) in any other case.
(c) ensure open access — via the repository — to the bibliographic metadata that identify the
deposited publication.
The bibliographic metadata must be in a standard format and must include all of the following:
- the terms “European Union (EU)” and “Horizon 2020”;
- the name of the action, acronym and grant number;
- the publication date, and length of embargo period if applicable, and
- a persistent identifier.
29.3 Open access to research data
Regarding the digital research data generated in the action (‘data’), the beneficiaries must:
(a) deposit in a research data repository and take measures to make it possible for third parties to
access, mine, exploit, reproduce and disseminate — free of charge for any user — the following:
(i) the data, including associated metadata, needed to validate the results presented in
scientific publications, as soon as possible;
(ii) other data, including associated metadata, as specified and within the deadlines laid down
in the ‘data management plan’ (see Annex 1);
(b) provide information — via the repository — about tools and instruments at the disposal of the
beneficiaries and necessary for validating the results (and — where possible — provide the
tools and instruments themselves).
This does not change the obligation to protect results in Article 27, the confidentiality obligations in
Article 36, the security obligations in Article 37 or the obligations to protect personal data in Article 39,
all of which still apply.
57
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
As an exception, the beneficiaries do not have to ensure open access to specific parts of their research
data under Point (a)(i) and (iii), if the achievement of the action's main objective (as described in
Annex 1) would be jeopardised by making those specific parts of the research data openly accessible.
In this case, the data management plan must contain the reasons for not giving access.
29.4 Information on EU funding — Obligation and right to use the EU emblem
Unless the Commission requests or agrees otherwise or unless it is impossible, any dissemination of
results (in any form, including electronic) must:
(a) display the EU emblem and
(b) include the following text:
“This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 825575”.
When displayed together with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Commission.
This does not however give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
29.5 Disclaimer excluding Commission responsibility
Any dissemination of results must indicate that it reflects only the author's view and that the
Commission is not responsible for any use that may be made of the information it contains.
29.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 30 — TRANSFER AND LICENSING OF RESULTS
30.1 Transfer of ownership
Each beneficiary may transfer ownership of its results.
It must however ensure that its obligations under Articles 26.2, 26.4, 27, 28, 29, 30 and 31 also apply
to the new owner and that this owner has the obligation to pass them on in any subsequent transfer.
This does not change the security obligations in Article 37, which still apply.
Unless agreed otherwise (in writing) for specifically-identified third parties or unless impossible under
applicable EU and national laws on mergers and acquisitions, a beneficiary that intends to transfer
ownership of results must give at least 45 days advance notice (or less if agreed in writing) to the
58
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
other beneficiaries that still have (or still may request) access rights to the results. This notification
must include sufficient information on the new owner to enable any beneficiary concerned to assess
the effects on its access rights.
Unless agreed otherwise (in writing) for specifically-identified third parties, any other beneficiary
may object within 30 days of receiving notification (or less if agreed in writing), if it can show that
the transfer would adversely affect its access rights. In this case, the transfer may not take place until
agreement has been reached between the beneficiaries concerned.
30.2 Granting licenses
Each beneficiary may grant licences to its results (or otherwise give the right to exploit them), if:
(a) this does not impede the access rights under Article 31 and
(b) not applicable.
In addition to Points (a) and (b), exclusive licences for results may be granted only if all the other
beneficiaries concerned have waived their access rights (see Article 31.1).
This does not change the dissemination obligations in Article 29 or security obligations in Article 37,
which still apply.
30.3 Commission right to object to transfers or licensing
Not applicable
30.4 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 31 — ACCESS RIGHTS TO RESULTS
31.1 Exercise of access rights — Waiving of access rights — No sub-licensing
The conditions set out in Article 25.1 apply.
The obligations set out in this Article do not change the security obligations in Article 37, which still
apply.
31.2 Access rights for other beneficiaries, for implementing their own tasks under the action
The beneficiaries must give each other access — on a royalty-free basis — to results needed for
implementing their own tasks under the action.
31.3 Access rights for other beneficiaries, for exploiting their own results
The beneficiaries must give each other — under fair and reasonable conditions (see Article 25.3) —
access to results needed for exploiting their own results.
59
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Requests for access may be made — unless agreed otherwise — up to one year after the period set
out in Article 3.
31.4 Access rights of affiliated entities
Unless agreed otherwise in the consortium agreement, access to results must also be given — under
fair and reasonable conditions (Article 25.3) — to affiliated entities established in an EU Member
State or associated country, if this is needed for those entities to exploit the results generated by the
beneficiaries to which they are affiliated.
Unless agreed otherwise (see above; Article 31.1), the affiliated entity concerned must make any such
request directly to the beneficiary that owns the results.
Requests for access may be made — unless agreed otherwise — up to one year after the period set
out in Article 3.
31.5 Access rights for the EU institutions, bodies, offices or agencies and EU Member States
The beneficiaries must give access to their results — on a royalty-free basis — to EU institutions,
bodies, offices or agencies, for developing, implementing or monitoring EU policies or programmes.
Such access rights are limited to non-commercial and non-competitive use.
This does not change the right to use any material, document or information received from the
beneficiaries for communication and publicising activities (see Article 38.2).
31.6 Access rights for third parties
Not applicable
31.7 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
SECTION 4 OTHER RIGHTS AND OBLIGATIONS
ARTICLE 32 — RECRUITMENT AND WORKING CONDITIONS FOR RESEARCHERS
32.1 Obligation to take measures to implement the European Charter for Researchers and
Code of Conduct for the Recruitment of Researchers
The beneficiaries must take all measures to implement the principles set out in the Commission
Recommendation on the European Charter for Researchers and the Code of Conduct for the
Recruitment of Researchers20, in particular regarding:
20 Commission Recommendation 2005/251/EC of 11 March 2005 on the European Charter for Researchers and on a Code
of Conduct for the Recruitment of Researchers (OJ L 75, 22.3.2005, p. 67).
60
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- working conditions;
- transparent recruitment processes based on merit, and
- career development.
The beneficiaries must ensure that researchers and third parties involved in the action are aware of
them.
32.2 Consequences of non-compliance
If a beneficiary breaches its obligations under this Article, the Commission may apply any of the
measures described in Chapter 6.
ARTICLE 33 — GENDER EQUALITY
33.1 Obligation to aim for gender equality
The beneficiaries must take all measures to promote equal opportunities between men and women in
the implementation of the action. They must aim, to the extent possible, for a gender balance at all
levels of personnel assigned to the action, including at supervisory and managerial level.
33.2 Consequences of non-compliance
If a beneficiary breaches its obligations under this Article, the Commission may apply any of the
measures described in Chapter 6.
ARTICLE 34 — ETHICS AND RESEARCH INTEGRITY
34.1 Obligation to comply with ethical and research integrity principles
The beneficiaries must carry out the action in compliance with:
(a) ethical principles (including the highest standards of research integrity)
and
(b) applicable international, EU and national law.
Funding will not be granted for activities carried out outside the EU if they are prohibited in all
Member States or for activities which destroy human embryos (for example, for obtaining stem cells).
The beneficiaries must ensure that the activities under the action have an exclusive focus on civil
applications.
The beneficiaries must ensure that the activities under the action do not:
(a) aim at human cloning for reproductive purposes;
(b) intend to modify the genetic heritage of human beings which could make such changes heritable
(with the exception of research relating to cancer treatment of the gonads, which may be
financed), or
61
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(c) intend to create human embryos solely for the purpose of research or for the purpose of stem
cell procurement, including by means of somatic cell nuclear transfer.
In addition, the beneficiaries must respect the fundamental principle of research integrity — as set
out, for instance, in the European Code of Conduct for Research Integrity21.
This implies compliance with the following fundamental principles:
- reliability in ensuring the quality of research reflected in the design, the methodology, the
analysis and the use of resources;
- honesty in developing, undertaking, reviewing, reporting and communicating research in a
transparent, fair and unbiased way;
- respect for colleagues, research participants, society, ecosystems, cultural heritage and the
environment;
- accountability for the research from idea to publication, for its management and organisation,
for training, supervision and mentoring, and for its wider impacts
and means that beneficiaries must ensure that persons carrying out research tasks follow the good
research practices and refrain from the research integrity violations described in this Code.
This does not change the other obligations under this Agreement or obligations under applicable
international, EU or national law, all of which still apply.
34.2 Activities raising ethical issues
Activities raising ethical issues must comply with the ‘ethics requirements’ set out as deliverables
in Annex 1.
Before the beginning of an activity raising an ethical issue, each beneficiary must have obtained:
(a) any ethics committee opinion required under national law and
(b) any notification or authorisation for activities raising ethical issues required under national
and/or European law
needed for implementing the action tasks in question.
The documents must be kept on file and be submitted upon request by the coordinator to the
Commission (see Article 52). If they are not in English, they must be submitted together with
an English summary, which shows that the action tasks in question are covered and includes the
conclusions of the committee or authority concerned (if available).
34.3 Activities involving human embryos or human embryonic stem cells
Activities involving research on human embryos or human embryonic stem cells may be carried out,
in addition to Article 34.1, only if:
21 European Code of Conduct for Research Integrity of ALLEA (All European Academies)
http://ec.europa.eu/research/participants/data/ref/h2020/other/hi/h2020-ethics_code-of-conduct_en.pdf
62
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- they are set out in Annex 1 or
- the coordinator has obtained explicit approval (in writing) from the Commission (see
Article 52).
34.4 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43) and the Agreement or participation of the beneficiary may be terminated (see Article 50).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 35 — CONFLICT OF INTERESTS
35.1 Obligation to avoid a conflict of interests
The beneficiaries must take all measures to prevent any situation where the impartial and objective
implementation of the action is compromised for reasons involving economic interest, political or
national affinity, family or emotional ties or any other shared interest (‘conflict of interests’).
They must formally notify to the Commission without delay any situation constituting or likely to
lead to a conflict of interests and immediately take all the necessary steps to rectify this situation.
The Commission may verify that the measures taken are appropriate and may require additional
measures to be taken by a specified deadline.
35.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43) and the Agreement or participation of the beneficiary may be terminated (see Article 50).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 36 — CONFIDENTIALITY
36.1 General obligation to maintain confidentiality
During implementation of the action and for four years after the period set out in Article 3, the
parties must keep confidential any data, documents or other material (in any form) that is identified
as confidential at the time it is disclosed (‘confidential information’).
If a beneficiary requests, the Commission may agree to keep such information confidential for an
additional period beyond the initial four years.
If information has been identified as confidential only orally, it will be considered to be confidential
only if this is confirmed in writing within 15 days of the oral disclosure.
Unless otherwise agreed between the parties, they may use confidential information only to implement
the Agreement.
The beneficiaries may disclose confidential information to their personnel or third parties involved
in the action only if they:
63
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(a) need to know to implement the Agreement and
(b) are bound by an obligation of confidentiality.
This does not change the security obligations in Article 37, which still apply.
The Commission may disclose confidential information to its staff, other EU institutions and bodies.
It may disclose confidential information to third parties, if:
(a) this is necessary to implement the Agreement or safeguard the EU's financial interests and
(b) the recipients of the information are bound by an obligation of confidentiality.
Under the conditions set out in Article 4 of the Rules for Participation Regulation No 1290/201322,
the Commission must moreover make available information on the results to other EU institutions,
bodies, offices or agencies as well as Member States or associated countries.
The confidentiality obligations no longer apply if:
(a) the disclosing party agrees to release the other party;
(b) the information was already known by the recipient or is given to him without obligation of
confidentiality by a third party that was not bound by any obligation of confidentiality;
(c) the recipient proves that the information was developed without the use of confidential
information;
(d) the information becomes generally and publicly available, without breaching any
confidentiality obligation, or
(e) the disclosure of the information is required by EU or national law.
36.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 37 — SECURITY-RELATED OBLIGATIONS
37.1 Results with a security recommendation
Not applicable
37.2 Classified information
Not applicable
22 Regulation (EU) No 1290/2013 of the European Parliament and of the Council of 11 December 2013 laying down the
rules for participation and dissemination in "Horizon 2020 - the Framework Programme for Research and Innovation
(2014-2020)" (OJ L 347, 20.12.2013 p.81).
64
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
37.3 Activities involving dual-use goods or dangerous materials and substances
Not applicable
37.4 Consequences of non-compliance
Not applicable
ARTICLE 38 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING
38.1 Communication activities by beneficiaries
38.1.1 Obligation to promote the action and its results
The beneficiaries must promote the action and its results, by providing targeted information to multiple
audiences (including the media and the public) in a strategic and effective manner.
This does not change the dissemination obligations in Article 29, the confidentiality obligations in
Article 36 or the security obligations in Article 37, all of which still apply.
Before engaging in a communication activity expected to have a major media impact, the beneficiaries
must inform the Commission (see Article 52).
38.1.2 Information on EU funding — Obligation and right to use the EU emblem
Unless the Commission requests or agrees otherwise or unless it is impossible, any communication
activity related to the action (including in electronic form, via social media, etc.) and any
infrastructure, equipment and major results funded by the grant must:
(a) display the EU emblem and
(b) include the following text:
For communication activities:
“This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 825575”.
For infrastructure, equipment and major results:
“This [infrastructure][equipment][insert type of result] is part of a project that has received funding
from the European Union’s Horizon 2020 research and innovation programme under grant agreement
No 825575”.
When displayed together with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Commission.
This does not, however, give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
38.1.3 Disclaimer excluding Commission responsibility
65
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Any communication activity related to the action must indicate that it reflects only the author's view
and that the Commission is not responsible for any use that may be made of the information it contains.
38.2 Communication activities by the Commission
38.2.1 Right to use beneficiaries’ materials, documents or information
The Commission may use, for its communication and publicising activities, information relating
to the action, documents notably summaries for publication and public deliverables as well as any
other material, such as pictures or audio-visual material received from any beneficiary (including in
electronic form).
This does not change the confidentiality obligations in Article 36 and the security obligations in
Article 37, all of which still apply.
If the Commission’s use of these materials, documents or information would risk compromising
legitimate interests, the beneficiary concerned may request the Commission not to use it (see
Article 52).
The right to use a beneficiary’s materials, documents and information includes:
(a) use for its own purposes (in particular, making them available to persons working for the
Commission or any other EU institution, body, office or agency or body or institutions in EU
Member States; and copying or reproducing them in whole or in part, in unlimited numbers);
(b) distribution to the public (in particular, publication as hard copies and in electronic or digital
format, publication on the internet, as a downloadable or non-downloadable file, broadcasting
by any channel, public display or presentation, communicating through press information
services, or inclusion in widely accessible databases or indexes);
(c) editing or redrafting for communication and publicising activities (including shortening,
summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio
or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a
compilation);
(d) translation;
(e) giving access in response to individual requests under Regulation No 1049/200124, without
the right to reproduce or exploit;
(f) storage in paper, electronic or other form;
(g) archiving, in line with applicable document-management rules, and
(h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out
in Points (b), (c), (d) and (f) to third parties if needed for the communication and publicising
activities of the Commission.
If the right of use is subject to rights of a third party (including personnel of the beneficiary), the
24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43.
66
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by
obtaining the necessary approval from the third parties concerned).
Where applicable (and if provided by the beneficiaries), the Commission will insert the following
information:
“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the European Union (EU)
under conditions.”
38.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 43).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 39 — PROCESSING OF PERSONAL DATA
39.1 Processing of personal data by the Commission
Any personal data under the Agreement will be processed by the Commission under Regulation No
45/200125 and according to the ‘notifications of the processing operations’ to the Data Protection
Officer (DPO) of the Commission (publicly accessible in the DPO register).
Such data will be processed by the ‘data controller’ of the Commission for the purposes of
implementing, managing and monitoring the Agreement or protecting the financial interests of the
EU or Euratom (including checks, reviews, audits and investigations; see Article 22).
The persons whose personal data are processed have the right to access and correct their own personal
data. For this purpose, they must send any queries about the processing of their personal data to the
data controller, via the contact point indicated in the privacy statement(s) that are published on the
Commission websites.
They also have the right to have recourse at any time to the European Data Protection Supervisor
(EDPS).
39.2 Processing of personal data by the beneficiaries
The beneficiaries must process personal data under the Agreement in compliance with applicable EU
and national law on data protection (including authorisations or notification requirements).
The beneficiaries may grant their personnel access only to data that is strictly necessary for
implementing, managing and monitoring the Agreement.
The beneficiaries must inform the personnel whose personal data are collected and processed by the
Commission. For this purpose, they must provide them with the privacy statement(s) (see above),
before transmitting their data to the Commission.
25 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection
of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free
movement of such data (OJ L 8, 12.01.2001, p. 1).
67
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
39.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 39.2, the Commission may apply any of
the measures described in Chapter 6.
ARTICLE 40 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE
COMMISSION
The beneficiaries may not assign any of their claims for payment against the Commission to any
third party, except if approved by the Commission on the basis of a reasoned, written request by the
coordinator (on behalf of the beneficiary concerned).
If the Commission has not accepted the assignment or the terms of it are not observed, the assignment
will have no effect on it.
In no circumstances will an assignment release the beneficiaries from their obligations towards the
Commission.
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
— RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES —
RELATIONSHIP WITH PARTNERS OF A JOINT ACTION
ARTICLE 41 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
— RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES —
RELATIONSHIP WITH PARTNERS OF A JOINT ACTION
41.1 Roles and responsibility towards the Commission
The beneficiaries have full responsibility for implementing the action and complying with the
Agreement.
The beneficiaries are jointly and severally liable for the technical implementation of the action as
described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries
become responsible for implementing this part (without being entitled to any additional EU funding
for doing so), unless the Commission expressly relieves them of this obligation.
The financial responsibility of each beneficiary is governed by Article 44.
41.2 Internal division of roles and responsibilities
The internal roles and responsibilities of the beneficiaries are divided as follows:
(a) Each beneficiary must:
(i) keep information stored in the Participant Portal Beneficiary Register (via the electronic
exchange system) up to date (see Article 17);
(ii) inform the coordinator immediately of any events or circumstances likely to affect
significantly or delay the implementation of the action (see Article 17);
68
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(iii) submit to the coordinator in good time:
- individual financial statements for itself and its linked third parties and, if required,
certificates on the financial statements (see Article 20);
- the data needed to draw up the technical reports (see Article 20);
- ethics committee opinions and notifications or authorisations for activities raising
ethical issues (see Article 34);
- any other documents or information required by the Commission under the Agreement,
unless the Agreement requires the beneficiary to submit this information directly to the
Commission.
(b) The coordinator must:
(i) monitor that the action is implemented properly (see Article 7);
(ii) act as the intermediary for all communications between the beneficiaries and the
Commission (in particular, providing the Commission with the information described in
Article 17), unless the Agreement specifies otherwise;
(iii) request and review any documents or information required by the Commission and verify
their completeness and correctness before passing them on to the Commission;
(iv) submit the deliverables and reports to the Commission (see Articles 19 and 20);
(v) ensure that all payments are made to the other beneficiaries without unjustified delay (see
Article 21);
(vi) inform the Commission of the amounts paid to each beneficiary, when required under the
Agreement (see Articles 44 and 50) or requested by the Commission.
The coordinator may not delegate or subcontract the above-mentioned tasks to any other
beneficiary or third party (including linked third parties).
41.3 Internal arrangements between beneficiaries — Consortium agreement
The beneficiaries must have internal arrangements regarding their operation and co-ordination to
ensure that the action is implemented properly. These internal arrangements must be set out in a written
‘consortium agreement’ between the beneficiaries, which may cover:
- internal organisation of the consortium;
- management of access to the electronic exchange system;
- distribution of EU funding;
- additional rules on rights and obligations related to background and results (including whether
access rights remain or not, if a beneficiary is in breach of its obligations) (see Section 3 of
Chapter 4);
69
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- settlement of internal disputes;
- liability, indemnification and confidentiality arrangements between the beneficiaries.
The consortium agreement must not contain any provision contrary to the Agreement.
41.4 Relationship with complementary beneficiaries — Collaboration agreement
Not applicable
41.5 Relationship with partners of a joint action — Coordination agreement
Not applicable
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT —
RECOVERY — SANCTIONS — DAMAGES — SUSPENSION —
TERMINATION — FORCE MAJEURE
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— SANCTIONS
ARTICLE 42 — REJECTION OF INELIGIBLE COSTS
42.1 Conditions
The Commission will — after termination of the participation of a beneficiary, at the time of
an interim payment, at the payment of the balance or afterwards — reject any costs which are
ineligible (see Article 6), in particular following checks, reviews, audits or investigations (see Article
22).
The rejection may also be based on the extension of findings from other grants to this grant (see
Article 22.5.2).
42.2 Ineligible costs to be rejected — Calculation — Procedure
Ineligible costs will be rejected in full.
If the rejection of costs does not lead to a recovery (see Article 44), the Commission will formally
notify the coordinator or beneficiary concerned of the rejection of costs, the amounts and the reasons
why (if applicable, together with the notification of amounts due; see Article 21.5). The coordinator
or beneficiary concerned may — within 30 days of receiving notification — formally notify the
Commission of its disagreement and the reasons why.
If the rejection of costs leads to a recovery, the Commission will follow the contradictory procedure
with pre-information letter set out in Article 44.
42.3 Effects
If the Commission rejects costs at the time of an interim payment or the payment of the balance, it
will deduct them from the total eligible costs declared, for the action, in the periodic or final summary
70
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
financial statement (see Articles 20.3 and 20.4). It will then calculate the interim payment or payment
of the balance as set out in Articles 21.3 or 21.4.
If the Commission rejects costs after termination of the participation of a beneficiary, it will deduct
them from the costs declared by the beneficiary in the termination report and include the rejection in
the calculation after termination (see Article 50.2 and 50.3).
If the Commission — after an interim payment but before the payment of the balance — rejects
costs declared in a periodic summary financial statement, it will deduct them from the total eligible
costs declared, for the action, in the next periodic summary financial statement or in the final summary
financial statement. It will then calculate the interim payment or payment of the balance as set out
in Articles 21.3 or 21.4.
If the Commission rejects costs after the payment of the balance, it will deduct the amount rejected
from the total eligible costs declared, by the beneficiary, in the final summary financial statement. It
will then calculate the revised final grant amount as set out in Article 5.4.
ARTICLE 43 — REDUCTION OF THE GRANT
43.1 Conditions
The Commission may — after termination of the participation of a beneficiary, at the payment
of the balance or afterwards — reduce the grant, if :
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide requested information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 22.5.2).
43.2 Amount to be reduced — Calculation — Procedure
The amount of the reduction will be proportionate to the seriousness of the errors, irregularities or
fraud or breach of obligations.
Before reduction of the grant, the Commission will formally notify a ‘pre-information letter’ to the
coordinator or beneficiary concerned:
- informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons
why and
- inviting it to submit observations within 30 days of receiving notification
71
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If the Commission does not receive any observations or decides to pursue reduction despite the
observations it has received, it will formally notify confirmation of the reduction (if applicable,
together with the notification of amounts due; see Article 21).
43.3 Effects
If the Commission reduces the grant after termination of the participation of a beneficiary, it will
calculate the reduced grant amount for that beneficiary and then determine the amount due to that
beneficiary (see Article 50.2 and 50.3).
If the Commission reduces the grant at the time of the payment of the balance, it will calculate the
reduced grant amount for the action and then determine the amount due as payment of the balance
(see Articles 5.3.4 and 21.4).
If the Commission reduces the grant after the payment of the balance, it will calculate the revised
final grant amount for the beneficiary concerned (see Article 5.4). If the revised final grant amount
for the beneficiary concerned is lower than its share of the final grant amount, the Commission will
recover the difference (see Article 44).
ARTICLE 44 — RECOVERY OF UNDUE AMOUNTS
44.1 Amount to be recovered — Calculation — Procedure
The Commission will — after termination of the participation of a beneficiary, at the payment
of the balance or afterwards — claim back any amount that was paid, but is not due under the
Agreement.
Each beneficiary’s financial responsibility in case of recovery is limited to its own debt (including
undue amounts paid by the Commission for costs declared by its linked third parties), except for the
amount retained for the Guarantee Fund (see Article 21.4).
44.1.1 Recovery after termination of a beneficiary’s participation
If recovery takes place after termination of a beneficiary’s participation (including the coordinator), the
Commission will claim back the undue amount from the beneficiary concerned, by formally notifying
it a debit note (see Article 50.2 and 50.3). This note will specify the amount to be recovered, the terms
and the date for payment.
If payment is not made by the date specified in the debit note, the Commission will recover the
amount:
(a) by ‘offsetting’ it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Commission or an executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may
offset before the payment date specified in the debit note;
(b) not applicable;
(c) by taking legal action (see Article 57) or by adopting an enforceable decision under
72
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial regulation No 966/2012.
If payment is not made by the date specified in the debit note, the amount to be recovered (see above)
will be increased by late-payment interest at the rate set out in Article 21.11, from the day following
the payment date in the debit note, up to and including the date the Commission receives full payment
of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless
Directive 2007/64/EC26 applies.
44.1.2 Recovery at payment of the balance
If the payment of the balance takes the form of a recovery (see Article 21.4), the Commission will
formally notify a ‘pre-information letter’ to the coordinator:
- informing it of its intention to recover, the amount due as the balance and the reasons why;
- specifying that it intends to deduct the amount to be recovered from the amount retained for
the Guarantee Fund;
- requesting the coordinator to submit a report on the distribution of payments to the beneficiaries
within 30 days of receiving notification, and
- inviting the coordinator to submit observations within 30 days of receiving notification.
If no observations are submitted or the Commission decides to pursue recovery despite the
observations it has received, it will confirm recovery (together with the notification of amounts due;
see Article 21.5) and:
- pay the difference between the amount to be recovered and the amount retained for the
Guarantee Fund, if the difference is positive or
- formally notify to the coordinator a debit note for the difference between the amount to be
recovered and the amount retained for the Guarantee Fund, if the difference is negative. This
note will also specify the terms and the date for payment.
If the coordinator does not repay the Commission by the date in the debit note and has not submitted
the report on the distribution of payments: the Commission will recover the amount set out in the
debit note from the coordinator (see below).
If the coordinator does not repay the Commission by the date in the debit note, but has submitted the
report on the distribution of payments: the Commission will:
(a) identify the beneficiaries for which the amount calculated as follows is negative:
26 Directive 2007/64/EC of the European Parliament and of the Council of 13 November 2007 on payment services
in the internal market amending Directives 97/7/EC, 2002/65/EC, 2005/60/EC and 2006/48/EC and repealing
Directive 97/5/EC (OJ L 319, 05.12.2007, p. 1).
73
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
{{{{beneficiary’s costs declared in the final summary financial statement and approved by the
Commission multiplied by the reimbursement rate set out in Article 5.2 for the beneficiary concerned
plus
its linked third parties’ costs declared in the final summary financial statement and approved by the
Commission multiplied by the reimbursement rate set out in Article 5.2 for each linked third party
concerned}
divided by
the EU contribution for the action calculated according to Article 5.3.1}
multiplied by
}
the final grant amount (see Article 5.3) ,
minus
{pre-financing and interim payments received by the beneficiary} . }
(b) formally notify to each beneficiary identified according to point (a) a debit note specifying the
terms and date for payment. The amount of the debit note is calculated as follows:
{{amount calculated according to point (a) for the beneficiary concerned
divided by
the sum of the amounts calculated according to point (a) for all the beneficiaries identified according
to point (a)}
multiplied by
the amount set out in the debit note formally notified to the coordinator}.
If payment is not made by the date specified in the debit note, the Commission will recover the
amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Commission or an executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may
offset before the payment date specified in the debit note;
(b) by drawing on the Guarantee Fund. The Commission will formally notify the beneficiary
concerned the debit note on behalf of the Guarantee Fund and recover the amount:
(i) not applicable;
(ii) by taking legal action (see Article 57) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 21.11, from the day following the
74
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
payment date in the debit note, up to and including the date the Commission receives full payment
of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless
Directive 2007/64/EC applies.
44.1.3 Recovery of amounts after payment of the balance
If, for a beneficiary, the revised final grant amount (see Article 5.4) is lower than its share of the final
grant amount, it must repay the difference to the Commission.
The beneficiary’s share of the final grant amount is calculated as follows:
{{{beneficiary’s costs declared in the final summary financial statement and approved by the Commission
multiplied by the reimbursement rate set out in Article 5.2 for the beneficiary concerned
plus
its linked third parties’ costs declared in the final summary financial statement and approved by the Commission
multiplied by the reimbursement rate set out in Article 5.2 for each linked third party concerned}
divided by
the EU contribution for the action calculated according to Article 5.3.1}
multiplied by
}
the final grant amount (see Article 5.3) .
If the coordinator has not distributed amounts received (see Article 21.7), the Commission will also
recover these amounts.
The Commission will formally notify a pre-information letter to the beneficiary concerned:
- informing it of its intention to recover, the due amount and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If no observations are submitted or the Commission decides to pursue recovery despite the
observations it has received, it will confirm the amount to be recovered and formally notify to the
beneficiary concerned a debit note. This note will also specify the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Commission will recover the
amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Commission or an executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may
offset before the payment date specified in the debit note;
75
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(b) by drawing on the Guarantee Fund. The Commission will formally notify the beneficiary
concerned the debit note on behalf of the Guarantee Fund and recover the amount:
(i) not applicable;
(ii) by taking legal action (see Article 57) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 21.11, from the day following the
date for payment in the debit note, up to and including the date the Commission receives full payment
of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless
Directive 2007/64/EC applies.
ARTICLE 45 — ADMINISTRATIVE SANCTIONS
In addition to contractual measures, the Commission may also adopt administrative sanctions under
Articles 106 and 131(4) of the Financial Regulation No 966/2012 (i.e. exclusion from future
procurement contracts, grants, prizes and expert contracts and/or financial penalties).
SECTION 2 LIABILITY FOR DAMAGES
ARTICLE 46 — LIABILITY FOR DAMAGES
46.1 Liability of the Commission
The Commission cannot be held liable for any damage caused to the beneficiaries or to third parties
as a consequence of implementing the Agreement, including for gross negligence.
The Commission cannot be held liable for any damage caused by any of the beneficiaries or third
parties involved in the action, as a consequence of implementing the Agreement.
46.2 Liability of the beneficiaries
Except in case of force majeure (see Article 51), the beneficiaries must compensate the Commission
for any damage it sustains as a result of the implementation of the action or because the action was
not implemented in full compliance with the Agreement.
SECTION 3 SUSPENSION AND TERMINATION
ARTICLE 47 — SUSPENSION OF PAYMENT DEADLINE
47.1 Conditions
76
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The Commission may — at any moment — suspend the payment deadline (see Article 21.2 to 21.4)
if a request for payment (see Article 20) cannot be approved because:
(a) it does not comply with the provisions of the Agreement (see Article 20);
(b) the technical or financial reports have not been submitted or are not complete or additional
information is needed, or
(c) there is doubt about the eligibility of the costs declared in the financial statements and additional
checks, reviews, audits or investigations are necessary.
47.2 Procedure
The Commission will formally notify the coordinator of the suspension and the reasons why.
The suspension will take effect the day notification is sent by the Commission (see Article 52).
If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted
— and the remaining period will resume.
If the suspension exceeds two months, the coordinator may request the Commission if the suspension
will continue.
If the payment deadline has been suspended due to the non-compliance of the technical or financial
reports (see Article 20) and the revised report or statement is not submitted or was submitted but is also
rejected, the Commission may also terminate the Agreement or the participation of the beneficiary
(see Article 50.3.1(l)).
ARTICLE 48 — SUSPENSION OF PAYMENTS
48.1 Conditions
The Commission may — at any moment — suspend payments, in whole or in part and interim
payments or the payment of the balance for one or more beneficiaries, if:
(a) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 22.5.2).
If payments are suspended for one or more beneficiaries, the Commission will make partial payment(s)
for the part(s) not suspended. If suspension concerns the payment of the balance, — once suspension
77
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
is lifted — the payment or the recovery of the amount(s) concerned will be considered the payment
of the balance that closes the action.
48.2 Procedure
Before suspending payments, the Commission will formally notify the coordinator or beneficiary
concerned:
- informing it of its intention to suspend payments and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Commission does not receive observations or decides to pursue the procedure despite the
observations it has received, it will formally notify confirmation of the suspension. Otherwise, it will
formally notify that the suspension procedure is not continued.
The suspension will take effect the day the confirmation notification is sent by the Commission.
If the conditions for resuming payments are met, the suspension will be lifted. The Commission will
formally notify the coordinator or beneficiary concerned.
During the suspension, the periodic report(s) for all reporting periods except the last one (see
Article 20.3), must not contain any individual financial statements from the beneficiary concerned
and its linked third parties. The coordinator must include them in the next periodic report after the
suspension is lifted or — if suspension is not lifted before the end of the action — in the last periodic
report.
The beneficiaries may suspend implementation of the action (see Article 49.1) or terminate the
Agreement or the participation of the beneficiary concerned (see Article 50.1 and 50.2).
ARTICLE 49 — SUSPENSION OF THE ACTION IMPLEMENTATION
49.1 Suspension of the action implementation, by the beneficiaries
49.1.1 Conditions
The beneficiaries may suspend implementation of the action or any part of it, if exceptional
circumstances — in particular force majeure (see Article 51) — make implementation impossible or
excessively difficult.
49.1.2 Procedure
The coordinator must immediately formally notify to the Commission the suspension (see Article 52),
stating:
- the reasons why and
- the expected date of resumption.
The suspension will take effect the day this notification is received by the Commission.
Once circumstances allow for implementation to resume, the coordinator must immediately formally
78
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
notify the Commission and request an amendment of the Agreement to set the date on which the
action will be resumed, extend the duration of the action and make other changes necessary to adapt
the action to the new situation (see Article 55) — unless the Agreement or the participation of a
beneficiary has been terminated (see Article 50).
The suspension will be lifted with effect from the resumption date set out in the amendment. This
date may be before the date on which the amendment enters into force.
Costs incurred during suspension of the action implementation are not eligible (see Article 6).
49.2 Suspension of the action implementation, by the Commission
49.2.1 Conditions
The Commission may suspend implementation of the action or any part of it, if:
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles);
(b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 22.5.2), or
(c) the action is suspected of having lost its scientific or technological relevance.
49.2.2 Procedure
Before suspending implementation of the action, the Commission will formally notify the coordinator
or beneficiary concerned:
- informing it of its intention to suspend the implementation and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Commission does not receive observations or decides to pursue the procedure despite the
observations it has received, it will formally notify confirmation of the suspension. Otherwise, it will
formally notify that the procedure is not continued.
The suspension will take effect five days after confirmation notification is received (or on a later date
specified in the notification).
It will be lifted if the conditions for resuming implementation of the action are met.
The coordinator or beneficiary concerned will be formally notified of the lifting and the Agreement
will be amended to set the date on which the action will be resumed, extend the duration of the action
79
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
and make other changes necessary to adapt the action to the new situation (see Article 55) — unless
the Agreement has already been terminated (see Article 50).
The suspension will be lifted with effect from the resumption date set out in the amendment. This date
may be before the date on which the amendment enters into force.
Costs incurred during suspension are not eligible (see Article 6).
The beneficiaries may not claim damages due to suspension by the Commission (see Article 46).
Suspension of the action implementation does not affect the Commission’s right to terminate the
Agreement or participation of a beneficiary (see Article 50), reduce the grant or recover amounts
unduly paid (see Articles 43 and 44).
ARTICLE 50 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION
OF ONE OR MORE BENEFICIARIES
50.1 Termination of the Agreement, by the beneficiaries
50.1.1 Conditions and procedure
The beneficiaries may terminate the Agreement.
The coordinator must formally notify termination to the Commission (see Article 52), stating:
- the reasons why and
- the date the termination will take effect. This date must be after the notification.
If no reasons are given or if the Commission considers the reasons do not justify termination, the
Agreement will be considered to have been ‘terminated improperly’.
The termination will take effect on the day specified in the notification.
50.1.2 Effects
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the open reporting period until termination; see Article 20.3) and
(ii) the final report (see Article 20.4).
If the Commission does not receive the reports within the deadline (see above), only costs which are
included in an approved periodic report will be taken into account.
The Commission will calculate the final grant amount (see Article 5.3) and the balance (see
Article 21.4) on the basis of the reports submitted. Only costs incurred until termination are eligible
(see Article 6). Costs relating to contracts due for execution only after termination are not eligible.
Improper termination may lead to a reduction of the grant (see Article 43).
After termination, the beneficiaries’ obligations (in particular Articles 20, 22, 23, Section 3 of
Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply.
80
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
50.2 Termination of the participation of one or more beneficiaries, by the beneficiaries
50.2.1 Conditions and procedure
The participation of one or more beneficiaries may be terminated by the coordinator, on request of
the beneficiary concerned or on behalf of the other beneficiaries.
The coordinator must formally notify termination to the Commission (see Article 52) and inform the
beneficiary concerned.
If the coordinator’s participation is terminated without its agreement, the formal notification must be
done by another beneficiary (acting on behalf of the other beneficiaries).
The notification must include:
- the reasons why;
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in
writing);
- the date the termination takes effect. This date must be after the notification, and
- a request for amendment (see Article 55), with a proposal for reallocation of the tasks and the
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the
addition of one or more new beneficiaries (see Article 56). If termination takes effect after the
period set out in Article 3, no request for amendment must be included unless the beneficiary
concerned is the coordinator. In this case, the request for amendment must propose a new
coordinator.
If this information is not given or if the Commission considers that the reasons do not justify
termination, the participation will be considered to have been terminated improperly.
The termination will take effect on the day specified in the notification.
50.2.2 Effects
The coordinator must — within 30 days from when termination takes effect — submit:
(i) a report on the distribution of payments to the beneficiary concerned and
(ii) if termination takes effect during the period set out in Article 3, a ‘termination report’
from the beneficiary concerned, for the open reporting period until termination, containing
an overview of the progress of the work, an overview of the use of resources, the
individual financial statement and, if applicable, the certificate on the financial statement
(see Articles 20.3 and 20.4).
The information in the termination report must also be included in the periodic report for the next
reporting period (see Article 20.3).
If the request for amendment is rejected by the Commission (because it calls into question the decision
awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be
terminated according to Article 50.3.1(c).
81
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
If the request for amendment is accepted by the Commission, the Agreement is amended to introduce
the necessary changes (see Article 55).
The Commission will — on the basis of the periodic reports, the termination report and the report
on the distribution of payments — calculate the amount which is due to the beneficiary and if the
(pre-financing and interim) payments received by the beneficiary exceed this amount.
The amount which is due is calculated in the following steps:
Step 1 — Application of the reimbursement rate to the eligible costs
The grant amount for the beneficiary is calculated by applying the reimbursement
rate(s) to the total eligible costs declared by the beneficiary and its linked third parties
in the termination report and approved by the Commission.
Only costs incurred by the beneficiary concerned until termination takes effect are
eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
Step 2 — Reduction due to substantial errors, irregularities or fraud or serious breach of
obligations
In case of a reduction (see Article 43), the Commission will calculate the reduced
grant amount for the beneficiary by deducting the amount of the reduction (calculated
in proportion to the seriousness of the errors, irregularities or fraud or breach
of obligations, in accordance with Article 43.2) from the grant amount for the
beneficiary.
If the payments received exceed the amounts due:
- if termination takes effect during the period set out in Article 3 and the request for
amendment is accepted, the beneficiary concerned must repay to the coordinator the amount
unduly received. The Commission will formally notify the amount unduly received and
request the beneficiary concerned to repay it to the coordinator within 30 days of receiving
notification. If it does not repay the coordinator, the Commission will draw upon the
Guarantee Fund to pay the coordinator and then notify a debit note on behalf of the
Guarantee Fund to the beneficiary concerned (see Article 44);
- in all other cases, in particular if termination takes effect after the period set out in Article 3,
the Commission will formally notify a debit note to the beneficiary concerned. If payment
is not made by the date in the debit note, the Guarantee Fund will pay to the Commission the
amount due and the Commission will notify a debit note on behalf of the Guarantee Fund
to the beneficiary concerned (see Article 44);
- if the beneficiary concerned is the former coordinator, it must repay the new coordinator
according to the procedure above, unless:
- termination takes effect after an interim payment and
- the former coordinator has not distributed amounts received as pre-financing or
interim payments (see Article 21.7).
82
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
In this case, the Commission will formally notify a debit note to the former coordinator.
If payment is not made by the date in the debit note, the Guarantee Fund will pay to the
Commission the amount due. The Commission will then pay the new coordinator and notify
a debit note on behalf of the Guarantee Fund to the former coordinator (see Article 44).
If the payments received do not exceed the amounts due: amounts owed to the beneficiary
concerned will be included in the next interim or final payment.
If the Commission does not receive the termination report within the deadline (see above), only costs
included in an approved periodic report will be taken into account.
If the Commission does not receive the report on the distribution of payments within the deadline (see
above), it will consider that:
- the coordinator did not distribute any payment to the beneficiary concerned and that
- the beneficiary concerned must not repay any amount to the coordinator.
Improper termination may lead to a reduction of the grant (see Article 43) or termination of the
Agreement (see Article 50).
After termination, the concerned beneficiary’s obligations (in particular Articles 20, 22, 23, Section 3
of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply.
50.3 Termination of the Agreement or the participation of one or more beneficiaries, by the
Commission
50.3.1 Conditions
The Commission may terminate the Agreement or the participation of one or more beneficiaries, if:
(a) one or more beneficiaries do not accede to the Agreement (see Article 56);
(b) a change to their legal, financial, technical, organisational or ownership situation (or those
of its linked third parties) is likely to substantially affect or delay the implementation of the
action or calls into question the decision to award the grant;
(c) following termination of participation for one or more beneficiaries (see above), the necessary
changes to the Agreement would call into question the decision awarding the grant or breach
the principle of equal treatment of applicants (see Article 55);
(d) implementation of the action is prevented by force majeure (see Article 51) or suspended by
the coordinator (see Article 49.1) and either:
(i) resumption is impossible, or
(ii) the necessary changes to the Agreement would call into question the decision awarding
the grant or breach the principle of equal treatment of applicants;
(e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the
courts, has entered into an arrangement with creditors, has suspended business activities, or
is subject to any other similar proceedings or procedures under national law;
83
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
(f) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has been found guilty of professional misconduct, proven by any means;
(g) a beneficiary does not comply with the applicable national law on taxes and social security;
(h) the action has lost scientific or technological relevance;
(i) not applicable;
(j) not applicable;
(k) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed fraud, corruption, or is involved in a criminal organisation, money
laundering or any other illegal activity;
(l) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles);
(m) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions
— systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have
a material impact on this grant (extension of findings from other grants to this grant; see
Article 22.5.2);
(n) despite a specific request by the Commission, a beneficiary does not request — through the
coordinator — an amendment to the Agreement to end the participation of one of its linked
third parties or international partners that is in one of the situations under points (e), (f), (g),
(k), (l) or (m) and to reallocate its tasks.
50.3.2 Procedure
Before terminating the Agreement or participation of one or more beneficiaries, the Commission will
formally notify the coordinator or beneficiary concerned:
- informing it of its intention to terminate and the reasons why and
- inviting it, within 30 days of receiving notification, to submit observations and — in case of
Point (l.ii) above — to inform the Commission of the measures to ensure compliance with the
obligations under the Agreement.
If the Commission does not receive observations or decides to pursue the procedure despite the
observations it has received, it will formally notify to the coordinator or beneficiary concerned
confirmation of the termination and the date it will take effect. Otherwise, it will formally notify that
the procedure is not continued.
The termination will take effect:
84
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- for terminations under Points (b), (c), (e), (g), (h), (j), (l.ii) and (n) above: on the day specified
in the notification of the confirmation (see above);
- for terminations under Points (a), (d), (f), (i), (k), (l.i) and (m) above: on the day after the
notification of the confirmation is received.
50.3.3 Effects
(a) for termination of the Agreement:
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the last open reporting period until termination; see Article 20.3)
and
(ii) a final report (see Article 20.4).
If the Agreement is terminated for breach of the obligation to submit reports (see Articles 20.8
and 50.3.1(l)), the coordinator may not submit any reports after termination.
If the Commission does not receive the reports within the deadline (see above), only costs
which are included in an approved periodic report will be taken into account.
The Commission will calculate the final grant amount (see Article 5.3) and the balance (see
Article 21.4) on the basis of the reports submitted. Only costs incurred until termination takes
effect are eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
This does not affect the Commission’s right to reduce the grant (see Article 43) or to impose
administrative sanctions (Article 45).
The beneficiaries may not claim damages due to termination by the Commission (see
Article 46).
After termination, the beneficiaries’ obligations (in particular Articles 20, 22, 23, Section 3 of
Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply.
(b) for termination of the participation of one or more beneficiaries:
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a report on the distribution of payments to the beneficiary concerned;
(ii) a request for amendment (see Article 55), with a proposal for reallocation of the tasks and
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary,
the addition of one or more new beneficiaries (see Article 56). If termination is notified
after the period set out in Article 3, no request for amendment must be submitted unless
the beneficiary concerned is the coordinator. In this case the request for amendment must
propose a new coordinator, and
(iii) if termination takes effect during the period set out in Article 3, a termination
report from the beneficiary concerned, for the open reporting period until termination,
containing an overview of the progress of the work, an overview of the use of resources,
85
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
the individual financial statement and, if applicable, the certificate on the financial
statement (see Article 20).
The information in the termination report must also be included in the periodic report for the
next reporting period (see Article 20.3).
If the request for amendment is rejected by the Commission (because it calls into question the
decision awarding the grant or breaches the principle of equal treatment of applicants), the
Agreement may be terminated according to Article 50.3.1(c).
If the request for amendment is accepted by the Commission, the Agreement is amended to
introduce the necessary changes (see Article 55).
The Commission will — on the basis of the periodic reports, the termination report and the
report on the distribution of payments — calculate the amount which is due to the beneficiary
and if the (pre-financing and interim) payments received by the beneficiary exceed this amount.
The amount which is due is calculated in the following steps:
Step 1 — Application of the reimbursement rate to the eligible costs
The grant amount for the beneficiary is calculated by applying the
reimbursement rate(s) to the total eligible costs declared by the beneficiary
and its linked third parties in the termination report and approved by the
Commission.
Only costs incurred by the beneficiary concerned until termination takes effect
are eligible (see Article 6). Costs relating to contracts due for execution only
after termination are not eligible.
Step 2 — Reduction due to substantial errors, irregularities or fraud or serious breach
of obligations
In case of a reduction (see Article 43), the Commission will calculate
the reduced grant amount for the beneficiary by deducting the amount of
the reduction (calculated in proportion to the seriousness of the errors,
irregularities or fraud or breach of obligations, in accordance with Article 43.2)
from the grant amount for the beneficiary.
If the payments received exceed the amounts due:
- if termination takes effect during the period set out in Article 3 and the request for
amendment is accepted, the beneficiary concerned must repay to the coordinator the
amount unduly received. The Commission will formally notify the amount unduly
received and request the beneficiary concerned to repay it to the coordinator within
30 days of receiving notification. If it does not repay the coordinator, the Commission
will draw upon the Guarantee Fund to pay the coordinator and then notify a debit
note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44);
- in all other cases, in particular if termination takes effect after the period set out
in Article 3, the Commission will formally notify a debit note to the beneficiary
concerned. If payment is not made by the date in the debit note, the Guarantee Fund
86
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
will pay to the Commission the amount due and the Commission will notify a debit
note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44);
- if the beneficiary concerned is the former coordinator, it must repay the new
coordinator according to the procedure above, unless:
- termination takes effect after an interim payment and
- the former coordinator has not distributed amounts received as pre-financing
or interim payments (see Article 21.7).
In this case, the Commission will formally notify a debit note to the former
coordinator. If payment is not made by the date in the debit note, the Guarantee Fund
will pay to the Commission the amount due. The Commission will then pay the new
coordinator and notify a debit note on behalf of the Guarantee Fund to the former
coordinator (see Article 44).
If the payments received do not exceed the amounts due: amounts owed to the beneficiary
concerned will be included in the next interim or final payment.
If the Commission does not receive the termination report within the deadline (see above), only
costs included in an approved periodic report will be taken into account.
If the Commission does not receive the report on the distribution of payments within the
deadline (see above), it will consider that:
- the coordinator did not distribute any payment to the beneficiary concerned and that
- the beneficiary concerned must not repay any amount to the coordinator.
After termination, the concerned beneficiary’s obligations (in particular Articles 20, 22, 23,
Section 3 of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply.
SECTION 4 FORCE MAJEURE
ARTICLE 51 — FORCE MAJEURE
‘Force majeure’ means any situation or event that:
- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
- was not due to error or negligence on their part (or on the part of third parties involved in the
action), and
- proves to be inevitable in spite of exercising all due diligence.
The following cannot be invoked as force majeure:
- any default of a service, defect in equipment or material or delays in making them available,
unless they stem directly from a relevant case of force majeure,
87
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
- labour disputes or strikes, or
- financial difficulties.
Any situation constituting force majeure must be formally notified to the other party without delay,
stating the nature, likely duration and foreseeable effects.
The parties must immediately take all the necessary steps to limit any damage due to force majeure
and do their best to resume implementation of the action as soon as possible.
The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be
considered in breach of them.
CHAPTER 7 FINAL PROVISIONS
ARTICLE 52 — COMMUNICATION BETWEEN THE PARTIES
52.1 Form and means of communication
Communication under the Agreement (information, requests, submissions, ‘formal notifications’, etc.)
must:
- be made in writing and
- bear the number of the Agreement.
All communication must be made through the Participant Portal electronic exchange system and using
the forms and templates provided there.
If — after the payment of the balance — the Commission finds that a formal notification was not
accessed, a second formal notification will be made by registered post with proof of delivery (‘formal
notification on paper’). Deadlines will be calculated from the moment of the second notification.
Communications in the electronic exchange system must be made by persons authorised according to
the Participant Portal Terms & Conditions. For naming the authorised persons, each beneficiary must
have designated — before the signature of this Agreement — a ‘legal entity appointed representative
(LEAR)’. The role and tasks of the LEAR are stipulated in his/her appointment letter (see Participant
Portal Terms & Conditions).
If the electronic exchange system is temporarily unavailable, instructions will be given on the
Commission website.
52.2 Date of communication
Communications are considered to have been made when they are sent by the sending party (i.e. on
the date and time they are sent through the electronic exchange system).
Formal notifications through the electronic exchange system are considered to have been made when
they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party,
as indicated by the time stamp). A formal notification that has not been accepted within 10 days after
sending is considered to have been accepted.
88
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
Formal notifications on paper sent by registered post with proof of delivery (only after the payment
of the balance) are considered to have been made on either:
- the delivery date registered by the postal service or
- the deadline for collection at the post office.
If the electronic exchange system is temporarily unavailable, the sending party cannot be considered
in breach of its obligation to send a communication within a specified deadline.
52.3 Addresses for communication
The electronic exchange system must be accessed via the following URL:
https://ec.europa.eu/research/participants/portal/desktop/en/projects/
The Commission will formally notify the coordinator and beneficiaries in advance any changes to
this URL.
Formal notifications on paper (only after the payment of the balance) addressed to the Commission
must be sent to the official mailing address indicated on the Commission’s website.
Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries
must be sent to their legal address as specified in the Participant Portal Beneficiary Register.
ARTICLE 53 — INTERPRETATION OF THE AGREEMENT
53.1 Precedence of the Terms and Conditions over the Annexes
The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes.
Annex 2 takes precedence over Annex 1.
53.2 Privileges and immunities
Nothing in the Agreement may be interpreted as a waiver of any privileges or immunities accorded
to the EUROPEAN MOLECULAR BIOLOGY LABORATORY by its constituent documents or
international law.
ARTICLE 54 — CALCULATION OF PERIODS, DATES AND DEADLINES
In accordance with Regulation No 1182/7127, periods expressed in days, months or years are calculated
from the moment the triggering event occurs.
The day during which that event occurs is not considered as falling within the period.
ARTICLE 55 — AMENDMENTS TO THE AGREEMENT
55.1 Conditions
27 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods, dates
and time-limits (OJ L 124, 8.6.1971, p. 1).
89
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
The Agreement may be amended, unless the amendment entails changes to the Agreement which
would call into question the decision awarding the grant or breach the principle of equal treatment
of applicants.
Amendments may be requested by any of the parties.
55.2 Procedure
The party requesting an amendment must submit a request for amendment signed in the electronic
exchange system (see Article 52).
The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see
Annex 3).
If a change of coordinator is requested without its agreement, the submission must be done by another
beneficiary (acting on behalf of the other beneficiaries).
The request for amendment must include:
- the reasons why;
- the appropriate supporting documents, and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that
this opinion has been requested in writing).
The Commission may request additional information.
If the party receiving the request agrees, it must sign the amendment in the electronic exchange system
within 45 days of receiving notification (or any additional information the Commission has requested).
If it does not agree, it must formally notify its disagreement within the same deadline. The deadline
may be extended, if necessary for the assessment of the request. If no notification is received within
the deadline, the request is considered to have been rejected
An amendment enters into force on the day of the signature of the receiving party.
An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement,
on the date on which the amendment enters into force.
ARTICLE 56 — ACCESSION TO THE AGREEMENT
56.1 Accession of the beneficiaries mentioned in the Preamble
The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in
the electronic exchange system (see Article 52) within 30 days after its entry into force (see Article 58).
They will assume the rights and obligations under the Agreement with effect from the date of its entry
into force (see Article 58).
If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must
— within 30 days — request an amendment to make any changes necessary to ensure proper
90
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
implementation of the action. This does not affect the Commission’s right to terminate the Agreement
(see Article 50).
56.2 Addition of new beneficiaries
In justified cases, the beneficiaries may request the addition of a new beneficiary.
For this purpose, the coordinator must submit a request for amendment in accordance with Article 55.
It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic
exchange system (see Article 52).
New beneficiaries must assume the rights and obligations under the Agreement with effect from the
date of their accession specified in the Accession Form (see Annex 3).
ARTICLE 57 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES
57.1 Applicable law
The Agreement is governed by the applicable EU law, supplemented if necessary by the law of
Belgium.
As an exception, the Agreement is governed by a different applicable law for the following
beneficiaries:
- EUROPEAN MOLECULAR BIOLOGY LABORATORY: by the general principles governing
the law of international organisations and the rules of general international law
57.2 Dispute settlement
If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled
amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole
jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the
EU (TFEU).
As an exception, if such a dispute is between the Commission and MINISTRY OF HEALTH,
SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN
FORSCHUNG, BLACKSWAN FOUNDATION, TURKIYE BILIMSEL VE TEKNOLOJIK
ARASTIRMA KURUMU, ACIBADEM UNIVERSITESI, HACETTEPE UNIVERSITESI,
CANADIAN INSTITUTES OF HEALTH RESEARCH, FONDS DE RECHERCHE DU QUEBEC
- SANTE, the competent Belgian courts have sole jurisdiction.
As an exception, for the following beneficiaries:
- EUROPEAN MOLECULAR BIOLOGY LABORATORY
such disputes must — if they cannot be settled amicably — be referred to arbitration. Each party
must formally notify to the other party its intention of resorting to arbitration and the identity of the
arbitrator. The Permanent Court of Arbitration Optional Rules for Arbitration Involving International
Organisations and States in force at the date of entry into force of the Agreement will apply. The
appointing authority will be the Secretary-General of the Permanent Court of Arbitration following
a written request submitted by either party. The arbitration proceedings must take place in Brussels
91
Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD
H2020
Associated with MGARef.
document EJP Cofund — Multi:-v5.0
Ares(2018)6091977 28/11/2018
and the language used in the arbitral proceedings will be English. The arbitral award will be binding
on all parties and will not be subject to appeal.
If a dispute concerns administrative sanctions, offsetting or an enforceable decision under Article 299
TFEU (see Articles 44, 45 and 46), the beneficiaries must bring action before the General Court —
or, on appeal, the Court of Justice of the European Union — under Article 263 TFEU.
ARTICLE 58 — ENTRY INTO FORCE OF THE AGREEMENT
The Agreement will enter into force on the day of signature by the Commission or the coordinator,
depending on which is later.
SIGNATURES
For the coordinator For the Commission
[--TGSMark#signature-999997833_75_210--] [--TGSMark#signature-service_75_210--]
Camille CHAUDONNERET with ECAS id nchaucmi signed Signed by Mila BAS SANCHEZ with ECAS id bassami as
in the Participant Portal on 13/12/2018 at 02:13:21 an authorised representative on 13-12-2018 10:52:06
(transaction id SigId-95714- (transaction id SigId-101288-
7hpKIXbkMLMEP1K4BMAs5GcXMhBPsoHKapJcH8tPzl2 gGMrPJ5dlhgIczNLmKraWszOBb7NazPXa7tccKKhUPl3y
2AsRo8gJzzICO0dxlNDv5S7onKFuWJjTzg6oQ90XvMiW- nFzmnoKFc5bZNYquLMuP4ZAydwD0DBhopHTXG5hgn8-
PHslUMVSXYCzVB2usIRhDj- PHslUMVSXYCzVB2usIRhDj-
uQbPV0VdXOPxlSRwnfYHxXzHg5pMwzUzh8qdQY9zre4 iuJAhXWlZU3WKBBF1g04CCvelUhgIyxGKpKsaACx4zY)
y). Timestamp by third party at Thu Dec 13 10:52:10 CET 2018
Thu Dec 13 02:13:30 CET 2018
92
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
EUROPEAN COMMISSION
DIRECTORATE-GENERAL RESEARCH & INNOVATION
Innovative and Personalised Medicine
ANNEX 1 (part A)
COFUND (European Joint Programme)
NUMBER — 825575 — EJP RD
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Table of Contents
1.1. The project summary................................................................................................................................. 3
1.2. The list of beneficiaries..............................................................................................................................4
1.3. Workplan Tables - Detailed implementation..............................................................................................8
1.3.1. WT1 List of work packages........................................................................................................... 8
1.3.2. WT2 List of deliverables.............................................................................................................. 10
1.3.3. WT3 Work package descriptions................................................................................................. 34
Work package 1......................................................................................................................... 34
Work package 2......................................................................................................................... 43
Work package 3......................................................................................................................... 50
Work package 4......................................................................................................................... 54
Work package 5......................................................................................................................... 61
Work package 6......................................................................................................................... 65
Work package 7......................................................................................................................... 71
Work package 8......................................................................................................................... 74
Work package 9......................................................................................................................... 77
Work package 10....................................................................................................................... 82
Work package 11....................................................................................................................... 87
Work package 12....................................................................................................................... 95
Work package 13..................................................................................................................... 100
Work package 14..................................................................................................................... 104
Work package 15..................................................................................................................... 109
Work package 16..................................................................................................................... 113
Work package 17..................................................................................................................... 117
Work package 18..................................................................................................................... 120
Work package 19..................................................................................................................... 123
Work package 20..................................................................................................................... 128
Work package 21..................................................................................................................... 133
1.3.4. WT4 List of milestones.............................................................................................................. 137
1.3.5. WT5 Critical Implementation risks and mitigation actions......................................................... 143
1.3.6 WT6 Summary of project effort in person-months......................................................................149
1.3.7. WT7 Tentative schedule of project reviews...............................................................................161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.1. The project summary
Project Number 1 825575 Project Acronym 2 EJP RD
One form per project
General information
Project title 3
European Joint Programme on Rare Diseases
Starting date 4 01/01/2019
Duration in months 5 60
Call (part) identifier 6 H2020-SC1-2018-Single-Stage-RTD
SC1-BHC-04-2018
Topic
Rare Disease European Joint Programme Cofund
Fixed EC Keywords Health sciences
rare diseases, funding, data, omics, shared access, FAIR, patients, training,
Free keywords empowerment, translation, public-private partnerships, innovative methodologies for
clinical studies
Abstract 7
As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a
research area that can strongly profit from coordination on a European and international scale. RD research should
be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress
and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients.
In the specific context of the massive generation, need for reuse and efficient interpretation of data, introduction of
omics into care practice and the structuration of RD care centers in European Reference Networks, it appears crucial
and timely to maximize the potential of already funded tools and programmes by supporting them further, scaling up,
linking, and most importantly, adapting them to the needs of end-users through implementation tests in real settings.
Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care,
research and medical innovation. To achieve this goal, the European Joint Programme on RD (EJP RD) has two major
objectives: (i) To improve the integration, the efficacy, the production and the social impact of research on RD through
the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials,
processes, knowledge and know-how; (ii) To implement and further develop an efficient model of financial support
for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with
accelerated exploitation of research results for benefit of patients. To this end, the EJP RD actions will be organized
within four major Pillars assisted by the central coordination: (P1): Funding of research; (P2): Coordinated access
to data and services; (P3) Capacity building; (P4): Accelerated translation of research projects and improvement
outcomes of clinical studies.
Page 3 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.2. List of Beneficiaries
Project Number 1 825575 Project Acronym 2 EJP RD
List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
INSTITUT NATIONAL DE LA SANTE ET
1 INSERM France 1 60
DE LA RECHERCHE MEDICALE
FONDS ZUR FÖRDERUNG DER
2 FWF Austria 1 60
WISSENSCHAFTLICHEN FORSCHUNG
AIT AUSTRIAN INSTITUTE OF
3 AIT Austria 1 60
TECHNOLOGY GMBH
LUDWIG BOLTZMANN GESELLSCHAFT
4 LBG (LBI-RUD) Austria 1 60
GMBH
FONDS NATIONAL DE LA RECHERCHE
5 FNRS Belgium 1 60
SCIENTIFIQUE
FONDS VOOR WETENSCHAPPELIJK
6 FWO Belgium 1 60
ONDERZOEK-VLAANDEREN
7 KATHOLIEKE UNIVERSITEIT LEUVEN KU Leuven Belgium 1 60
MINISTRY OF EDUCATION YOUTH AND
8 MEYS Czech Republic 1 60
SPORTS
9 SOTSIAALMINISTEERIUM MOSAE Estonia 1 60
10 SUOMEN AKATEMIA AKA Finland 1 60
AGENCE NATIONALE DE LA
11 ANR France 1 60
RECHERCHE
12 FONDATION MALADIES RARES FFRD France 1 60
ASS FRANCAISE CONTRE LES
13 AFM France 1 60
MYOPATHIES
IMAGINE INSTITUT DES MALADIES
14 GENETIQUES NECKER ENFANTS IMAGINE France 1 60
MALADES FONDATION
DEUTSCHES ZENTRUM FUER LUFT -
15 DLR Germany 1 60
UND RAUMFAHRT EV
16 UNIVERSITAETSKLINIKUM AACHEN UKA Germany 1 60
CHARITE - UNIVERSITAETSMEDIZIN
17 CHARITE Germany 1 60
BERLIN
18 UNIVERSITAETSKLINIKUM FREIBURG UKL-FR Germany 1 60
NEMZETI KUTATASI FEJLESZTESI ES
19 NKFIH Hungary 1 60
INNOVACIOS HIVATAL
20 THE HEALTH RESEARCH BOARD HRB Ireland 1 60
21 MINISTERO DELLA SALUTE IT-MOH Italy 1 60
22 REGIONE TOSCANA TuscReg Italy 1 60
FONDAZIONE REGIONALE PER LA
23 FRRB Italy 1 60
RICERCA BIOMEDICA
Page 4 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
FONDAZIONE PER LA RICERCA
24 FARMACOLOGICA GIANNI BENZI FGB Italy 1 60
ONLUS
25 FONDAZIONE TELETHON FTELE Italy 1 60
26 ISTITUTO SUPERIORE DI SANITA ISS Italy 1 60
CONSORZIO PER VALUTAZIONI
27 CVBF Italy 1 60
BIOLOGICHE E FARMACOLOGICHE
TEDDY - EUROPEAN NETWORK
28 OF EXCELLENCE FOR PAEDIATRIC TEDDY Italy 1 60
CLINICAL RESEARCH
MINISTERO DELL'ISTRUZIONE,
29 MIUR Italy 1 60
DELL'UNIVERSITA' E DELLA RICERCA
VALSTS IZGLITIBAS ATTISTIBAS
30 VIAA Latvia 1 60
AGENTURA
31 Lietuvos mokslo taryba LMT Lithuania 1 60
VIESOJI ISTAIGA VILNIAUS
32 UNIVERSITETO LIGONINE SANTAROS VUHSK Lithuania 1 60
KLINIKOS
33 FONDS NATIONAL DE LA RECHERCHE FNR Luxembourg 1 60
34 ZORGONDERZOEK NEDERLAND ZON ZonMw Netherlands 1 60
ACADEMISCH ZIEKENHUIS
35 UMCG Netherlands 1 60
GRONINGEN
36 UNIVERSITEIT MAASTRICHT UM Netherlands 1 60
NARODOWE CENTRUM BADAN I
37 NCBR Poland 1 60
ROZWOJU
WARSZAWSKI UNIWERSYTET
38 MUW Poland 1 60
MEDYCZNY
39 GDANSKI UNIWERSYTET MEDYCZNY MUG Poland 1 60
INSTYTUT POMNIK CENTRUM
40 IPCZD Poland 1 60
ZDROWIA DZIECKA
FUNDACAO PARA A CIENCIA E A
41 FCT Portugal 1 60
TECNOLOGIA
INSTITUTO NACIONAL DE SAUDE DR.
42 INSA Portugal 1 60
RICARDO JORGE
43 SLOVENSKA AKADEMIA VIED SAS Slovakia 1 60
44 INSTITUTO DE SALUD CARLOS III ISCIII Spain 1 60
FUNDACIO CENTRE DE REGULACIO
45 CNAG-CRG Spain 1 60
GENOMICA
UNIVERSIDAD POLITECNICA DE
46 UPM Spain 1 60
MADRID
Page 5 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
CONSORCIO CENTRO DE
47 INVESTIGACION BIOMEDICA EN RED CIBER Spain 1 60
M.P.
VETENSKAPSRADET - SWEDISH
48 SRC Sweden 1 60
RESEARCH COUNCIL
49 VERKET FÖR INNOVATIONSSYSTEM VINNOVA Sweden 1 60
50 UNIVERSITY OF LEICESTER ULEIC United Kingdom 1 60
51 THE UNIVERSITY OF LIVERPOOL ULIV United Kingdom 1 60
UNIVERSITY OF NEWCASTLE UPON
52 UNEW United Kingdom 1 60
TYNE
53 ST. ANNA KINDERKREBSFORSCHUNG CCRI Austria 1 60
ASSISTANCE PUBLIQUE - HOPITAUX DE
54 AP-HP France 1 60
PARIS
HOPITAUX UNIVERSITAIRES DE
55 HUS France 1 60
STRASBOURG
CENTRE ANTICANCEREUX LEON
56 CLB France 1 60
BERARD
UNIVERSITAETSKLINIKUM
57 UKL-HD Germany 1 60
HEIDELBERG
EBERHARD KARLS UNIVERSITAET
58 EKUT Germany 1 60
TUEBINGEN
JOHANN WOLFGANG GOETHE-
59 GUF Germany 1 60
UNIVERSITATFRANKFURT AM MAIN
HELIOS DR. HORST SCHMIDT
60 HSK Germany 1 60
KLINIKEN WIESBADEN GMBH
61 ISTITUTO ORTOPEDICO RIZZOLI IOR Italy 1 60
AZIENDA OSPEDALIERO
62 AOUP Italy 1 60
UNIVERSITARIA PISANA
AZIENDA OSPEDALIERA
63 AOUS Italy 1 60
UNIVERSITARIA SENESE
64 ACADEMISCH ZIEKENHUIS LEIDEN LUMC Netherlands 1 60
STICHTING KATHOLIEKE
65 Radboudumc Netherlands 1 60
UNIVERSITEIT
Academisch Medisch Centrum bij de
66 AMC Netherlands 1 60
Universiteit van Amsterdam
ERASMUS UNIVERSITAIR MEDISCH
67 ERASMUS MC Netherlands 1 60
CENTRUM ROTTERDAM
68 SERVICIO MADRILENO DE SALUD SERMAS Spain 1 60
THE NEWCASTLE UPON TYNE
69 NUTH United Kingdom 1 60
HOSPITALS NHS FOUNDATION TRUST
Page 6 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
GREAT ORMOND STREET HOSPITAL
70 FOR CHILDREN NATIONAL HEALTH GOSH United Kingdom 1 60
SERVICE TRUST
EUROPEAN ORGANISATION FOR
71 RESEARCH AND TREATMENT OF EORTC Belgium 1 60
CANCER AISBL
72 INFRAFRONTIER GMBH INFRAFRONTIER Germany 1 60
BIOBANKS AND BIOMOLECULAR
RESOURCESRESEARCH
73 BBMRI Austria 1 60
INFRASTRUCTURE
CONSORTIUM(BBMRI-ERIC)
ECRIN EUROPEAN CLINICAL
74 RESEARCH INFRASTRUCTURE ECRIN France 1 60
NETWORK
75 EATRIS ERIC EATRIS Netherlands 1 60
EUROPEAN MOLECULAR BIOLOGY
76 EMBL Germany 1 60
LABORATORY
EURORDIS - EUROPEAN
77 ORGANISATION FOR RARE DISEASES EURORDIS France 1 60
ASSOCIATION
78 MINISTRY OF HEALTH CSO-MOH Israel 1 60
SCHWEIZERISCHER NATIONALFONDS
79 ZUR FORDERUNG DER SNSF Switzerland 1 60
WISSENSCHAFTLICHEN FORSCHUNG
80 BLACKSWAN FOUNDATION Blackswan Switzerland 1 60
TURKIYE BILIMSEL VE TEKNOLOJIK
81 TUBITAK Turkey 1 60
ARASTIRMA KURUMU
82 ACIBADEM UNIVERSITESI ACURARE Turkey 1 60
83 HACETTEPE UNIVERSITESI HUGEN Turkey 1 60
CANADIAN INSTITUTES OF HEALTH
84 CIHR Canada 1 60
RESEARCH
FONDS DE RECHERCHE DU QUEBEC -
85 FRQS Canada 1 60
SANTE
86 INSERM TRANSFERT SA IT France 1 60
GENIKI GRAMMATIA EREVNAS KAI
87 GSRT Greece 1 60
TECHNOLOGIAS
DEUTSCHE
88 DFG Germany 1 60
FORSCHUNGSGEMEINSCHAFT
Page 7 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3. Workplan Tables - Detailed implementation
1.3.1. WT1 List of work packages
WP Person- Start End
WP Title Lead beneficiary10
Number9 months11 month12 month13
WP1 Coordination and management 1 - INSERM 470.00 1 60
Integrative research and innovation
WP2 44 - ISCIII 64.00 1 60
strategy
Sustainability strategy and business
WP3 1 - INSERM 65.00 1 60
plan
Ethical, regulatory, legal and IPR
WP4 24 - FGB 63.00 1 60
framework of the EJP RD
WP5 Communication & dissemination 1 - INSERM 89.00 1 60
Joint Transnational Calls for
WP6 15 - DLR 133.60 1 60
collaborative research projects
Networking to share knowledge on
WP7 34 - ZonMw 21.40 1 60
rare diseases
WP8 Rare Disease Research Challenges 12 - FFRD 25.00 1 60
WP9 Monitoring of funded projects 78 - CSO-MOH 25.00 1 60
User-driven strategic planning and
WP10 transversal activities for Pillar 2 data 1 - INSERM 118.60 1 60
ecosystem
Common virtual platform for
WP11 discoverable data and resources for 1 - INSERM 1,330.70 1 60
RD research
Enabling sustainable FAIRness and
WP12 Federation at the record level for RD 50 - ULEIC 1,254.41 1 60
data, patients and samples
Enabling multidisciplinary,
WP13 holistic approaches for rare disease 36 - UM 297.90 1 60
diagnostics and therapeutics
Training on data management &
WP14 26 - ISS 185.00 1 60
quality
Capacity building and training of
WP15 patients and researchers in Rare 77 - EURORDIS 117.40 1 60
Disease research and processes
WP16 Online Academic education course 12 - FFRD 92.50 1 60
ERN RD training and support
WP17 58 - EKUT 63.00 1 60
programme
Development and adaptation of
WP18 32 - VUHSK 12.00 24 60
training activities
Facilitating partnerships and
WP19 accelerating translation for higher 75 - EATRIS 208.00 1 60
patient impact
Accelerating the validation, use
WP20 54 - AP-HP 251.00 1 60
and development of innovative
Page 8 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3. Workplan Tables - Detailed implementation
WP Person- Start End
WP Title Lead beneficiary10
Number9 months11 month12 month13
methodologies tailored for clinical
trials in RDs
WP21 Ethics requirements 1 - INSERM N/A 1 60
Total 4,886.51
Page 9 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.2. WT2 list of deliverables
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type 15 Date (in
Number14 number9 level16
months)17
Report from the Kick-
D1.1 WP1 1 - INSERM Report Public 2
off meeting
Confidential,
only for members
Helpdesk directory of of the consortium
D1.2 WP1 1 - INSERM Report 3
people and services (including the
Commission
Services)
First report from the
face-to-face ExCom
D1.3 WP1 1 - INSERM Report Public 7
and Policy Board
meeting
Second report from the
face-to-face ExCom
D1.4 WP1 1 - INSERM Report Public 19
and Policy Board
meeting
Third report from the
face-to-face ExCom
D1.5 WP1 1 - INSERM Report Public 31
and Policy Board
meeting
Fourth report from the
face-to-face ExCom
D1.6 WP1 1 - INSERM Report Public 43
and Policy Board
meeting
Fifth report from the
face-to-face ExCom
D1.7 WP1 1 - INSERM Report Public 55
and Policy Board
meeting
Confidential,
only for members
First Summary Progress
of the consortium
D1.8 Report and Annual WP1 1 - INSERM Report 9
(including the
Work Plan
Commission
Services)
Confidential,
only for members
Second Summary
of the consortium
D1.9 Progress Report and WP1 1 - INSERM Report 21
(including the
Annual Work Plan
Commission
Services)
Confidential,
only for members
Third Summary
of the consortium
D1.10 Progress Report and WP1 1 - INSERM Report 33
(including the
Annual Work Plan
Commission
Services)
Page 10 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
Fourth Summary
of the consortium
D1.11 Progress Report and WP1 1 - INSERM Report 45
(including the
Annual Work Plan
Commission
Services)
Confidential,
only for members
Fifth Summary
of the consortium
D1.12 Progress Report and WP1 1 - INSERM Report 57
(including the
Annual Work Plan
Commission
Services)
Confidential,
only for members
First Technical and of the consortium
D1.13 WP1 1 - INSERM Report 15
Financial Report (including the
Commission
Services)
Confidential,
only for members
Second Technical and of the consortium
D1.14 WP1 1 - INSERM Report 27
Financial Report (including the
Commission
Services)
Confidential,
only for members
Third Technical and of the consortium
D1.15 WP1 1 - INSERM Report 39
Financial Report (including the
Commission
Services)
Confidential,
only for members
Fourth Technical and of the consortium
D1.16 WP1 1 - INSERM Report 51
Financial Report (including the
Commission
Services)
Confidential,
only for members
Fifth Technical and of the consortium
D1.17 WP1 1 - INSERM Report 60
Financial Report (including the
Commission
Services)
Confidential,
only for members
Monitoring activities of the consortium
D1.18 WP1 51 - ULIV Report 2
handbook (including the
Commission
Services)
First EJP RD Confidential,
D1.19 WP1 27 - CVBF Report 12
Monitoring Report only for members
Page 11 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
of the consortium
(including the
Commission
Services)
Confidential,
only for members
Second EJP RD of the consortium
D1.20 WP1 27 - CVBF Report 24
Monitoring Report (including the
Commission
Services)
Confidential,
only for members
Third EJP RD of the consortium
D1.21 WP1 27 - CVBF Report 36
Monitoring Report (including the
Commission
Services)
Confidential,
only for members
Fourth EJP RD of the consortium
D1.22 WP1 27 - CVBF Report 48
Monitoring Report (including the
Commission
Services)
Confidential,
only for members
Fifth EJP RD of the consortium
D1.23 WP1 27 - CVBF Report 60
Monitoring Report (including the
Commission
Services)
Initial Data
D1.24 WP1 1 - INSERM Report Public 6
Management Plan
ORDP:
Updated Data Open
D1.25 WP1 1 - INSERM Public 6
Management Plan Research
Data Pilot
Final list of
D2.1 WP2 27 - CVBF Report Public 5
prioritization criteria
Prioritization scheme
D2.2 including decision- WP2 27 - CVBF Report Public 5
making process
Confidential,
First Summary only for members
document on mapped of the consortium
D2.3 WP2 44 - ISCIII Report 5
research and innovation (including the
needs Commission
Services)
Second Summary Confidential,
document on mapped only for members
D2.4 WP2 44 - ISCIII Report 17
research and innovation of the consortium
needs (including the
Page 12 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Commission
Services)
Confidential,
Third Summary only for members
document on mapped of the consortium
D2.5 WP2 44 - ISCIII Report 29
research and innovation (including the
needs Commission
Services)
Confidential,
Fourth Summary only for members
document on mapped of the consortium
D2.6 WP2 44 - ISCIII Report 41
research and innovation (including the
needs Commission
Services)
Confidential,
Fifth Summary only for members
document on mapped of the consortium
D2.7 WP2 44 - ISCIII Report 53
research and innovation (including the
needs Commission
Services)
D2.8 First Scoping paper WP2 26 - ISS Report Public 7
D2.9 Second Scoping paper WP2 26 - ISS Report Public 19
D2.10 Third Scoping paper WP2 26 - ISS Report Public 31
D2.11 Fourth Scoping paper WP2 38 - MUW Report Public 43
D2.12 Fifth Scoping paper WP2 38 - MUW Report Public 55
Confidential,
only for members
First List of refined JTC of the consortium
D2.13 WP2 44 - ISCIII Report 7
topics (including the
Commission
Services)
Confidential,
only for members
Second List of refined of the consortium
D2.14 WP2 44 - ISCIII Report 19
JTC topics (including the
Commission
Services)
Confidential,
only for members
Third List of refined of the consortium
D2.15 WP2 11 - ANR Report 31
JTC topics (including the
Commission
Services)
First List of research
D2.16 and innovation needs WP2 1 - INSERM Report Public 6
requiring medium- or
Page 13 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
long-term approach and
related Task Forces
Second List of research
and innovation needs
D2.17 requiring medium- or WP2 1 - INSERM Report Public 18
long-term approach and
related Task Forces
Third List of research
and innovation needs
D2.18 requiring medium- or WP2 1 - INSERM Report Public 30
long-term approach and
related Task Forces
Fourth List of research
and innovation needs
D2.19 requiring medium- or WP2 1 - INSERM Report Public 42
long-term approach and
related Task Forces
Fifth List of research
and innovation needs
D2.20 requiring medium- or WP2 1 - INSERM Report Public 54
long-term approach and
related Task Forces
First Analysis of
national state of play
D2.21 WP2 26 - ISS Report Public 9
and alignment process
with EJP RD
Second Analysis of
national state of play
D2.22 WP2 26 - ISS Report Public 21
and alignment process
with EJP RD
Third Analysis of
national state of play
D2.23 WP2 26 - ISS Report Public 32
and alignment process
with EJP RD
Fourth Analysis of
national state of play
D2.24 WP2 26 - ISS Report Public 55
and alignment process
with EJP RD
First Report from
D2.25 strategic workshop with WP2 26 - ISS Report Public 34
national policy makers
Second Report from
D2.26 strategic workshop with WP2 38 - MUW Report Public 58
national policy makers
Dynamic catalogue of
D3.1 EJP-RD sustainable WP3 1 - INSERM Report Public 36
resources including
Page 14 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Service Roadmap
Database
Confidential,
Study cases
only for members
of innovative
of the consortium
D3.2 sustainability solutions WP3 1 - INSERM Report 36
(including the
for specific EJP RD
Commission
outcomes
Services)
Confidential,
Analysis of structures,
only for members
business models
of the consortium
D3.3 and required WP3 75 - EATRIS Report 42
(including the
complementarity from
Commission
other relevant initiatives
Services)
Confidential,
First Proposal of
only for members
structure, governance
of the consortium
D3.4 and financial model and WP3 44 - ISCIII Report 46
(including the
global sustainability
Commission
roadmap
Services)
Confidential,
Second Proposal of
only for members
structure, governance
of the consortium
D3.5 and financial model and WP3 44 - ISCIII Report 54
(including the
global sustainability
Commission
roadmap
Services)
Confidential,
only for members
of the consortium
D4.1 First AREB report WP4 24 - FGB Report 6
(including the
Commission
Services)
Confidential,
only for members
First Periodic AREB of the consortium
D4.2 WP4 24 - FGB Report 19
report (including the
Commission
Services)
Confidential,
only for members
Second Periodic AREB of the consortium
D4.3 WP4 24 - FGB Report 31
report (including the
Commission
Services)
Confidential,
only for members
Third Periodic AREB of the consortium
D4.4 WP4 24 - FGB Report 43
report (including the
Commission
Services)
Page 15 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
Fourth Periodic AREB of the consortium
D4.5 WP4 24 - FGB Report 55
report (including the
Commission
Services)
Set of template
D4.6 agreements for EJP RD WP4 25 - FTELE Report Public 6
website
Confidential,
only for members
First Periodic IPR
of the consortium
D4.7 report (based on WP4 25 - FTELE Report 6
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Second Periodic
of the consortium
D4.8 IPR report (based on WP4 25 - FTELE Report 18
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Third Periodic IPR
of the consortium
D4.9 report (based on WP4 25 - FTELE Report 24
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Fourth Periodic IPR
of the consortium
D4.10 report (based on WP4 25 - FTELE Report 24
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Fifth Periodic IPR
of the consortium
D4.11 report (based on WP4 25 - FTELE Report 30
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Sixth Periodic IPR
of the consortium
D4.12 report (based on WP4 25 - FTELE Report 36
(including the
ExCom inputs)
Commission
Services)
Confidential,
Seventh Periodic
only for members
D4.13 IPR report (based on WP4 25 - FTELE Report 42
of the consortium
ExCom inputs)
(including the
Page 16 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Commission
Services)
Confidential,
only for members
Eighth Periodic IPR
of the consortium
D4.14 report (based on WP4 25 - FTELE Report 48
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Ninth Periodic IPR
of the consortium
D4.15 report (based on WP4 25 - FTELE Report 54
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
Tenth and final Periodic
of the consortium
D4.16 IPR report (based on WP4 25 - FTELE Report 60
(including the
ExCom inputs)
Commission
Services)
Confidential,
only for members
First IPR support of the consortium
D4.17 WP4 25 - FTELE Report 6
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Second IPR support of the consortium
D4.18 WP4 25 - FTELE Report 12
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Third IPR support of the consortium
D4.19 WP4 25 - FTELE Report 18
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Fourth IPR support of the consortium
D4.20 WP4 25 - FTELE Report 24
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Fifth IPR support of the consortium
D4.21 WP4 25 - FTELE Report 30
(monitoring) report (including the
Commission
Services)
Page 17 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
Sixth IPR support of the consortium
D4.22 WP4 25 - FTELE Report 36
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Seventh IPR support of the consortium
D4.23 WP4 25 - FTELE Report 42
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Eighth IPR support of the consortium
D4.24 WP4 25 - FTELE Report 48
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Ninth IPR support of the consortium
D4.25 WP4 25 - FTELE Report 54
(monitoring) report (including the
Commission
Services)
Confidential,
only for members
Tenth and final IPR
of the consortium
D4.26 support (monitoring) WP4 25 - FTELE Report 60
(including the
report
Commission
Services)
Websites,
D5.1 EJP RD website WP5 1 - INSERM patents Public 2
filling, etc.
Websites,
D5.2 EJP RD Newsletter WP5 1 - INSERM patents Public 2
filling, etc.
First RE(ACT)
D5.3 WP5 80 - Blackswan Report Public 16
Congress report
Second RE(ACT)
D5.4 WP5 80 - Blackswan Report Public 30
Congress report
Third RE(ACT)
D5.5 WP5 80 - Blackswan Report Public 54
Congress report
First Confidential Confidential,
Call documents: only for members
memorandum of of the consortium
D6.1 WP6 15 - DLR Report 1
understanding, (including the
governance Commission
of the call and Services)
Page 18 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
evaluation document
JTC2019-2022
Second Confidential
Call documents: Confidential,
memorandum of only for members
understanding, of the consortium
D6.2 WP6 11 - ANR Report 11
governance (including the
of the call and Commission
evaluation document Services)
JTC2019-2022
Third Confidential
Call documents: Confidential,
memorandum of only for members
understanding, of the consortium
D6.3 WP6 12 - FFRD Report 23
governance (including the
of the call and Commission
evaluation document Services)
JTC2019-2022
Fourth Confidential
Call documents: Confidential,
memorandum of only for members
understanding, of the consortium
D6.4 WP6 44 - ISCIII Report 35
governance (including the
of the call and Commission
evaluation document Services)
JTC2019-2022
First Public
Call documents
JTC2019-2022: call
D6.5 WP6 15 - DLR Report Public 1
text, guidelines for
applicants, proposal
templates
Second Public
Call documents
JTC2019-2022: call
D6.6 WP6 11 - ANR Report Public 11
text, guidelines for
applicants, proposal
templates
Third Public
Call documents
JTC2019-2022: call
D6.7 WP6 12 - FFRD Report Public 23
text, guidelines for
applicants, proposal
templates
Fourth Public
Call documents
JTC2019-2022: call
D6.8 WP6 44 - ISCIII Report Public 35
text, guidelines for
applicants, proposal
templates
Page 19 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
First Joint selection list
of the consortium
D6.9 of the projects to be WP6 15 - DLR Report 10
(including the
funded JTC2019-2022
Commission
Services)
Confidential,
only for members
Second Joint selection
of the consortium
D6.10 list of the projects to be WP6 11 - ANR Report 22
(including the
funded JTC2019-2022
Commission
Services)
Confidential,
only for members
Third Joint selection
of the consortium
D6.11 list of the projects to be WP6 12 - FFRD Report 24
(including the
funded JTC2019-2022
Commission
Services)
Confidential,
only for members
Fourth Joint selection
of the consortium
D6.12 list of the projects to be WP6 44 - ISCIII Report 46
(including the
funded JTC2019-2022
Commission
Services)
Confidential Call Confidential,
document for only for members
Evaluation Committee of the consortium
D7.1 WP7 34 - ZonMw Report 7
for Networking scheme (including the
including set of criteria Commission
for evaluation Services)
Public Call document
D7.2 WP7 34 - ZonMw Report Public 7
for Networking scheme
First List of
D7.3 funded networks in WP7 34 - ZonMw Report Public 21
Networking scheme
Second List of
D7.4 funded networks in WP7 34 - ZonMw Report Public 54
Networking scheme
Confidential,
First Confidential
only for members
Observers’ report on
of the consortium
D7.5 the evaluation of sets WP7 34 - ZonMw Report 12
(including the
of applications for the
Commission
Networking scheme
Services)
Second Confidential
Confidential,
Observers’ report on
only for members
D7.6 the evaluation of sets WP7 34 - ZonMw Report 30
of the consortium
of applications for the
(including the
Networking scheme
Page 20 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Commission
Services)
Confidential,
only for members
Report on multi- of the consortium
D8.1 WP8 77 - EURORDIS Report 8
stakeholder workshops (including the
Commission
Services)
Call documents for
D8.2 WP8 12 - FFRD Report Public 13
validation
List of first phase
D8.3 WP8 12 - FFRD Report Public 21
projects financed
Confidential,
only for members
List of second phase of the consortium
D8.4 WP8 12 - FFRD Report 43
projects financed (including the
Commission
Services)
Confidential,
Refined list of only for members
indicators for of the consortium
D9.1 WP9 78 - CSO-MOH Report 5
monitoring of JTC (including the
funded project Commission
Services)
Confidential,
First Year report on only for members
progress assessment of of the consortium
D9.2 WP9 78 - CSO-MOH Report 28
JTC 2019, 2020 and (including the
2021 projects Commission
Services)
Confidential,
Second Yearly reports only for members
on progress assessment of the consortium
D9.3 WP9 78 - CSO-MOH Report 40
of JTC 2019, 2020 and (including the
2021 projects Commission
Services)
Confidential,
Third Yearly reports only for members
on progress assessment of the consortium
D9.4 WP9 78 - CSO-MOH Report 52
of JTC 2019, 2020 and (including the
2021 projects Commission
Services)
First Final assessment Confidential,
report of E-Rare-3 only for members
JTC 2016, JTC 2017, of the consortium
D9.5 WP9 78 - CSO-MOH Report 35
JTC 2018 projects and (including the
the EJP RD JTC 2019 Commission
projects Services)
Page 21 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Second Final Confidential,
assessment report of only for members
E-Rare-3 JTC 2016, of the consortium
D9.6 WP9 78 - CSO-MOH Report 47
JTC 2017, JTC 2018 (including the
projects and the EJP Commission
RD JTC 2019 projects Services)
Third Final assessment Confidential,
report of E-Rare-3 only for members
JTC 2016, JTC 2017, of the consortium
D9.7 WP9 78 - CSO-MOH Report 59
JTC 2018 projects and (including the
the EJP RD JTC 2019 Commission
projects Services)
Confidential,
only for members
List of indicators
of the consortium
D9.8 for monitoring of WP9 78 - CSO-MOH Report 7
(including the
Networking grants
Commission
Services)
First Report on the
assessment of results of Confidential,
a 1st, 2nd and 3rd set only for members
of funded Networking of the consortium
D9.9 WP9 78 - CSO-MOH Report 24
events and a final (including the
general report on all Commission
funded Networking Services)
events
Second Report on the
assessment of results of Confidential,
a 1st, 2nd and 3rd set only for members
of funded Networking of the consortium
D9.10 WP9 78 - CSO-MOH Report 39
events and a final (including the
general report on all Commission
funded Networking Services)
events
Third Report on the
assessment of results of Confidential,
a 1st, 2nd and 3rd set only for members
of funded Networking of the consortium
D9.11 WP9 78 - CSO-MOH Report 59
events and a final (including the
general report on all Commission
funded Networking Services)
events
Confidential,
only for members
List of indicators for of the consortium
D9.12 WP9 78 - CSO-MOH Report 21
RD funded challenges (including the
Commission
Services)
Page 22 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
Report on the
of the consortium
D9.13 assessment of 1st phase WP9 78 - CSO-MOH Report 39
(including the
results of the challenges
Commission
Services)
Confidential,
Report on the only for members
assessment of 2nd of the consortium
D9.14 WP9 78 - CSO-MOH Report 54
phase results of the (including the
challenges Commission
Services)
First Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.1 reports, QMS of Pillar WP10 1 - INSERM Report Public 9
2 description, GDPR
compliance report and
sustainability planning
reporting
Second Annual
strategic report and
Action plan for Pillar 2,
including: Systematic
D10.2 surveys reports, QMS WP10 1 - INSERM Report Public 21
of Pillar 2 description,
GDPR compliance
report and sustainability
planning reporting
Third Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.3 reports, QMS of Pillar WP10 1 - INSERM Report Public 33
2 description, GDPR
compliance report and
sustainability planning
reporting
Fourth Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.4 reports, QMS of Pillar WP10 1 - INSERM Report Public 45
2 description, GDPR
compliance report and
sustainability planning
reporting
Page 23 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Report on the State
D10.5 of the Art of existing WP10 1 - INSERM Report Public 9
resources
First Ontological model
D11.1 WP11 76 - EMBL Other Public 12
of resources metadata
Second Ontological
D11.2 model of resources WP11 76 - EMBL Other Public 24
metadata
Third Ontological
D11.3 model of resources WP11 76 - EMBL Other Public 36
metadata
Fourth Ontological
D11.4 model of resources WP11 76 - EMBL Other Public 48
metadata
Fifth Ontological model
D11.5 WP11 76 - EMBL Other Public 60
of resources metadata
Virtual platform of RD
Websites,
resources annotated
D11.6 WP11 1 - INSERM patents Public 12
with EJP ontological
filling, etc.
model
First update Virtual
platform of RD Websites,
D11.7 resources annotated WP11 1 - INSERM patents Public 24
with EJP ontological filling, etc.
model
Second update Virtual
platform of RD Websites,
D11.8 resources annotated WP11 1 - INSERM patents Public 36
with EJP ontological filling, etc.
model
Third update Virtual
platform of RD Websites,
D11.9 resources annotated WP11 1 - INSERM patents Public 48
with EJP ontological filling, etc.
model
Fourth update Virtual
platform of RD Websites,
D11.10 resources annotated WP11 1 - INSERM patents Public 60
with EJP ontological filling, etc.
model
First version of
Additional facilities
integrated to resources
regarding data
D11.11 WP11 76 - EMBL Other Public 12
deposition and
access, including
user guidelines and
documentation
Page 24 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Second version
Additional facilities
integrated to resources
regarding data
D11.12 WP11 76 - EMBL Other Public 24
deposition and
access, including
user guidelines and
documentation
Third version
Additional facilities
integrated to resources
regarding data
D11.13 WP11 76 - EMBL Other Public 36
deposition and
access, including
user guidelines and
documentation
Fourth version
Additional facilities
integrated to resources
regarding data
D11.14 WP11 76 - EMBL Other Public 48
deposition and
access, including
user guidelines and
documentation
Fifth version Additional
facilities integrated to
resources regarding
D11.15 data deposition and WP11 76 - EMBL Other Public 60
access, including
user guidelines and
documentation
First Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.16 analysed, including WP11 45 - CNAG-CRG Report Public 12
description of new
cloud and online
analysis functionalities
and tools
Second Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.17 analysed, including WP11 45 - CNAG-CRG Report Public 24
description of new
cloud and online
analysis functionalities
and tools
Third Report on
D11.18 WP11 45 - CNAG-CRG Report Public 36
processed genome-
Page 25 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
phenome datasets and
multi-omics use cases
analysed, including
description of new
cloud and online
analysis functionalities
and tools
Fourth Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.19 analysed, including WP11 45 - CNAG-CRG Report Public 48
description of new
cloud and online
analysis functionalities
and tools
Fifth Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.20 analysed, including WP11 45 - CNAG-CRG Report Public 60
description of new
cloud and online
analysis functionalities
and tools
Report on core set
D12.1 of unified FAIR data WP12 50 - ULEIC Report Public 18
standards
First Report on core
set of FAIR software
tools and on extended
D12.2 WP12 3 - AIT Report Public 30
set of unified FAIR data
standards, applied in
EJP RD
Second Report on core
set of FAIR software
tools and on extended
D12.3 WP12 3 - AIT Report Public 48
set of unified FAIR data
standards, applied in
EJP RD
Report on extended
set of FAIR software
tools, applied in
D12.4 EJP,including overview WP12 64 - LUMC Report Public 60
of FAIRification
guidelines for RD data
managers
Collection of 20
D13.1 curated (sub)Portal on WP13 36 - UM Report Public 36
WikiPathways
Page 26 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Completed pathway
analysis workflow (data
analysis including both
D13.2 WP13 36 - UM Report Public 48
types of genetic variant
linking and network
creation)
Completed network
analysis workflow
(active node detection,
lifestyle factor network
D13.3 WP13 36 - UM Report Public 54
evaluation and extended
network analysis
for drugs and toxic
compounds)
First Report of
Orphanet nomenclature
D14.1 WP14 1 - INSERM Report Public 14
training for trainers and
national trainings
Second Report of
Orphanet nomenclature
D14.2 WP14 1 - INSERM Report Public 60
training for trainers and
national trainings
First Report on course
on interpretation of
D14.3 WP14 7 - KU Leuven Report Public 12
genetic variants and
quality standards
Second Report on
course on interpretation
D14.4 WP14 7 - KU Leuven Report Public 60
of genetic variants and
quality standards
First Report on
D14.5 International course on WP14 26 - ISS Report Public 24
undiagnosed diseases
Second Report on
D14.6 International course on WP14 26 - ISS Report Public 60
undiagnosed diseases
First Report on sample
D14.7 data management WP14 25 - FTELE Report Public 12
training workshops
Second Report
on sample data
D14.8 WP14 25 - FTELE Report Public 60
management training
workshops
First Report on
International course on
D14.9 Rare Disease Registries WP14 26 - ISS Report Public 12
and FAIRification of
data at source
Page 27 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Second Report on
International course on
D14.10 Rare Disease Registries WP14 26 - ISS Report Public 60
and FAIRification of
data at source
First Report on
D15.1 WP15 77 - EURORDIS Report Public 12
ExPRESS
Second Report on
D15.2 WP15 77 - EURORDIS Report Public 60
ExPRESS
First Report on
training of patient
representatives on
D15.3 WP15 77 - EURORDIS Report Public 24
scientific innovation
and translational
research in RD
Second Report on
training of patient
representatives on
D15.4 WP15 77 - EURORDIS Report Public 60
scientific innovation
and translational
research in RD
First Report on
D15.5 EURORDIS’ WP15 77 - EURORDIS Report Public 12
Leadership Programme
Second Report
D15.6 on EURORDIS’ WP15 77 - EURORDIS Report Public 48
Leadership Programme
Training plan for
D15.7 paediatric patients’ in WP15 28 - TEDDY Report Public 30
the EJP
Report on paediatric
D15.8 patients’ experts WP15 28 - TEDDY Report Public 60
training courses
Draft content of the
D16.1 WP16 12 - FFRD Report Public 9
online academic course
Content of the first 5
D16.2 WP16 12 - FFRD Other Public 24
online modules
Content of the full
D16.3 WP16 12 - FFRD Other Public 48
online course
Confidential,
only for members
First Impact assessment
of the consortium
D16.4 of the online academic WP16 76 - EMBL Report 36
(including the
course
Commission
Services)
Page 28 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
Second Impact
of the consortium
D16.5 assessment of the WP16 76 - EMBL Report 60
(including the
online academic course
Commission
Services)
Results of survey on
preferences, needs and
D17.1 WP17 64 - LUMC Report Public 4
resources from the
ERNs ecosystem
EJP RD ERN training
D17.2 WP17 57 - UKL-HD Report Public 7
programmes
First Annual report
D17.3 on implementation of WP17 58 - EKUT Report Public 13
training programs
Second Annual reports
D17.4 on implementation of WP17 58 - EKUT Report Public 60
training programs
Final report on
evaluation and
adaptation of training
programmes according
D18.1 WP18 32 - VUHSK Report Public 60
to EJP RD progress of
work, specific needs
of EU13 countries and
ERN developing needs
Confidential,
First Periodic report on only for members
mentoring and technical of the consortium
D19.1 WP19 75 - EATRIS Report 24
support for translational (including the
research projects Commission
Services)
Confidential,
Second Periodic report
only for members
on mentoring and
of the consortium
D19.2 technical support for WP19 75 - EATRIS Report 42
(including the
translational research
Commission
projects
Services)
Confidential,
Third Periodic report on only for members
mentoring and technical of the consortium
D19.3 WP19 75 - EATRIS Report 60
support for translational (including the
research projects Commission
Services)
Confidential,
Final report on follow-
only for members
D19.4 on funding and WP19 25 - FTELE Report 60
of the consortium
exploitation
(including the
Page 29 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Commission
Services)
User satisfaction and Confidential,
feasibility report on only for members
Facilitating partnerships of the consortium
D19.5 WP19 59 - GUF Report 48
and accelerating (including the
translation for higher Commission
patient impact Services)
Confidential,
only for members
Roadmap for EU
of the consortium
D19.6 investment platform for WP19 25 - FTELE Report 36
(including the
RDs
Commission
Services)
Confidential,
only for members
Terms of Reference of
of the consortium
D20.1 clinical studies support WP20 74 - ECRIN Report 6
(including the
office
Commission
Services)
Confidential,
only for members
First Report on the
of the consortium
D20.2 assessment of the WP20 74 - ECRIN Report 36
(including the
support office activity
Commission
Services)
Confidential,
only for members
Second Report on
of the consortium
D20.3 the assessment of the WP20 74 - ECRIN Report 48
(including the
support office activity
Commission
Services)
Confidential,
only for members
Third Report on the
of the consortium
D20.4 assessment of the WP20 74 - ECRIN Report 60
(including the
support office activity
Commission
Services)
Confidential,
First Report on only for members
options for long-term of the consortium
D20.5 WP20 74 - ECRIN Report 48
sustainability of the (including the
support office Commission
Services)
Confidential,
Second Report on only for members
options for long-term of the consortium
D20.6 WP20 74 - ECRIN Report 60
sustainability of the (including the
support office Commission
Services)
Page 30 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
List of topics for
of the consortium
D20.7 demonstration projects WP20 61 - IOR Report 6
(including the
call
Commission
Services)
Final Report of funded
D20.8 WP20 16 - UKA Report Public 50
demonstration projects
Final Report of funded
D20.9 new methodology WP20 16 - UKA Report Public 58
projects
Summary Report of
D20.10 WP20 54 - AP-HP Report Public 60
Task Force Group
Confidential,
only for members
of the consortium
D21.1 A - Requirement No. 1 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
NEC - Requirement No. of the consortium
D21.2 WP21 1 - INSERM Ethics 12
2 (including the
Commission
Services)
Confidential,
only for members
GEN - Requirement of the consortium
D21.3 WP21 1 - INSERM Ethics 12
No. 3 (including the
Commission
Services)
Confidential,
only for members
of the consortium
D21.4 H - Requirement No. 4 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
of the consortium
D21.5 H - Requirement No. 5 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
of the consortium
D21.6 H - Requirement No. 6 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Page 31 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Confidential,
only for members
of the consortium
D21.7 H - Requirement No. 7 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
of the consortium
D21.8 H - Requirement No. 8 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
of the consortium
D21.9 H - Requirement No. 9 WP21 1 - INSERM Ethics 12
(including the
Commission
Services)
Confidential,
only for members
POPD - Requirement of the consortium
D21.10 WP21 1 - INSERM Ethics 12
No. 10 (including the
Commission
Services)
Confidential,
only for members
POPD - Requirement of the consortium
D21.11 WP21 1 - INSERM Ethics 12
No. 11 (including the
Commission
Services)
Confidential,
only for members
POPD - Requirement of the consortium
D21.12 WP21 1 - INSERM Ethics 12
No. 12 (including the
Commission
Services)
Confidential,
only for members
POPD - Requirement of the consortium
D21.13 WP21 1 - INSERM Ethics 12
No. 13 (including the
Commission
Services)
Confidential,
only for members
GEN - Requirement of the consortium
D21.14 WP21 1 - INSERM Ethics 12
No. 14 (including the
Commission
Services)
GEN - Requirement Confidential,
D21.15 WP21 1 - INSERM Ethics 12
No. 15 only for members
Page 32 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
of the consortium
(including the
Commission
Services)
Page 33 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.3. WT3 Work package descriptions
Work package number 9 WP1 Lead beneficiary 10 1 - INSERM
Work package title Coordination and management
Start month 1 End month 60
Objectives
● Carry out the overall management of the initiative (capture, guide and lead all work related to the 5-year programme
and the annual work plans);
● Oversee and organize project-related meetings, including meetings of the General Assembly, Executive Committee,
Policy Board, ad hoc Scientific Board(s) and IRDiRC;
● Execute Scientific Secretariat of IRDiRC;
● Ensure appropriate financial administration (budgeting, planning, accounting);
● Report to the European Commission (including annual reports, annual summary progress reports, annual work plans
and deliverables);
● Ensure efficient internal communication (with help of dedicated tools);
● Ensure effective dialogue and coordination with project partners to assess progress and challenges in implementing
the annual work plans;
● Develop and implement the EJP RD Helpdesk;
● Ensure efficient decision making and manage conflicts in accordance with the rules set-out in the consortium
agreement;
● Implement the risk management strategy;
● Develop and implement the monitoring of the EJP RD activities
● Carry efforts to expand EJP RD consortium to new countries
Description of work and role of partners
WP1 - Coordination and management [Months: 1-60]
INSERM, DLR, CVBF, VUHSK, ZonMw, ULIV, AP-HP, UKL-HD, EATRIS, EMBL, EURORDIS
Task 1.1: Implementation and responsibilities of the coordination office (M1-M60)
TL: INSERM (Coo)
The Coordination Office based at INSERM will consist of the coordinator, two senior and two junior project managers,
communication officer, financial officer and assistant. The CO will be central point and carry out the day-to-day
operational management by supporting EJP RD partners. It will be the primary contact for the EJP RD partners,
Policy Board, IRDiRC, European Commission, and other interested parties. The CO will be responsible for an efficient
management of overall contractual obligations. It will ensure compliance by Beneficiaries with their obligations under
the Grant Agreement and Consortium Agreement in terms of administrative, legal and financial management. It will
monitor timely preparation and submission of the Deliverables to the European Commission, and coordinate preparation
and submission to the EC of the periodic Annual Progress Reports, Annual Work Plans, technical and financial reports
and Final Report. It will manage and coordinate any legal obligation such as Amendments to the Grant Agreement
when required.
SubTask 1.1.1: Scientific Secretariat of IRDiRC (M1-M60)
STL: INSERM (Coo)
The Scientific Secretariat (SciSec) of IRDiRC will be secured by EJP RD Project Managers seconded by the
Communication and Financial Officers. The integration of the SciSec in the EJP RD coordination is crucial as it
guarantees tight connection between EJP RD and IRDiRC necessary for common strategy, harmonized efforts and
critical position of Europe within IRDiRC Consortium. SciSec acts in service of and in response to the needs/requests of
the IRDiRC. The SciSec will provide support to the IRDiRC bodies (Consortium Assembly, Constituent Committees,
Scientific Committees, Operating Committee), manage the logistics of the meetings and reporting. It will ensure a liaison
between the EJP RD and IRDiRC members and Task Forces and other IRDiRC-specific Activities (see also WP2) to
optimize the complementarity and the coherence of their specific activities contributing to the common goals.
SubTask 1.1.2: Central Helpdesk (M1-M60)
STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS); ULiv
Page 34 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The proposed central Helpdesk will be the single-entry point for any inquiry related to the actions and services proposed
within the EJP RD. From the start, it will be managed by one of the EJP RD project managers that will be responsible
for providing of rapid response or re-directing the demand to the expert groups of a specific Pillar or connected projects
(in order to avoid duplication of efforts). It will function through the EJP RD website where contact information will be
provided. The project managers will be responsible for the registration and analysis of all incoming queries that will be
classified based on the “key” agreed with Helpdesk support groups formed by dedicated pillars’ members. The goal is
to monitor the incoming demands and adapt the service according to the needs. An analysis of incoming requests will
be performed every 3 months in connection to Task 1.3. A directory of people and services available within and outside
the EJP RD (via connected partners) will be created for the need of efficient management of demands and in support for
the Helpdesk. The Helpdesk will have close working relationships with similar elements of other initiatives like C4C
project or involved infrastructures in order to manage cross-referrals between initiatives.
Task 1.2: Coordination & support within and across pillars (M1-M60)
TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS)
In order to coordinate the support and swift communication within and across pillars, the pillar leaders together with
coordinator and project managers will form the Operating Group (OG). The OG is already a functioning body that has
gained experience, cohesion and efficacy during the preparation phase. Regular (twice a month) conference calls will
ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations and risk
management. The OG will participate in the preparation of the Executive Committee meetings and will be the driving
force for the elaboration of the Annual Work Plans (see also 1.2.1). The Pillar leaders will coordinate the activities
of WPs within their Pillars, will reflect on progress and engage in a collective brainstorming on future directions and
visions for the EJP RD. They will identify possible bottlenecks and report them to the CO. While the OG will be the
operative body, the Executive Committee (ExCom composed of the Coordinator, project officer, Pillar leaders, patients
and ERN representatives and all WP leaders) will be the forum to discuss details of the EJP RD progress, annual work
plans and related resource utilization. The ExCom will meet by conference call every month in the first year and every
two months in the following years of the project. It will also hold one face-to-face meeting per year: at M6, jointly with
the Policy Board (see 3.2) in order to discuss the priorities and work on the development of the Annual Work Plan to
be presented at the start of M9 at the Governance Board meeting.
SubTask 1.2.1: Development of Annual Progress Report and Annual Work Plans (M1-M60)
STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UK- HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS); ALL WP leaders
The development of the Annual Progress Report and Annual Work Plan will follow a structured process managed by
the Executive Committee:
● Each pillar will be responsible to capture outcomes and reflect them in the summary progress reports documenting
proposals and ideas, including input to the monitoring of EJP RD activities. These annual progress reports will be drafted
by each WP leader and compiled by the respective Pillar leaders. The CO jointly with relevant leaders of transversal
WPs will follow the same procedure;
● The CO will be responsible for the collation of the single summary progress reports to be complemented by the
outcomes of the monitoring and progress against established Key Performance Indicators captured within Task 1.3. The
final draft of the full Annual Progress Report will be presented to the Governing Board for validation before sending
to the Commission;
● At the same time the ExCom will be asked to propose tasks and deliverables based on the internal consultation of
WPs and in line with their implementation status. This will include update of the budgetary plan and proposition of
the redistribution of funds and new responsibilities. The collated draft will be discussed at the ExCom face-to-face
meeting (M6) and updated based on the inputs from the Policy Board and prioritization procedure. As for the Annual
Progress Report, the finalized version of Annual Plan will be presented for validation to the Governing Board (M9)
before sending to the Commission;
● The Annual Work Plan and Annual Progress Report will be complementary: the report will show how the activities
proposed in the annual work plan for the next year provide continuity with completed and ongoing work. The
Commission will thus be informed regarding project progress and compliance with commitments.
SubTask 1.2.2: Organization of EJP RD governance meetings (M1-M60)
STL: INSERM (Coo)
The CO will prepare and organize meetings of the Governing Board (once a year, M9/M21/M33/M45/M57), the highest-
decision making body (see also section 3.2), to approve the organization, work programme, the Annual Work Plan
of the following year, the structure and information flow and the political outcome of the EJP RD. The Governing
Board shall consist of one representative per participating country, one representative of ERNs, one representative of
participating EU infrastructures, 1 patient organization representative (EURORDIS), one representative of Orphanet
and one representative of other non-profit organizations. It will be up to each participating country/type of beneficiary
Page 35 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
to decide on the nomination procedure for their representative. Back-to-back to GB meeting, the CO will organize
meetings of the whole EJP RD Consortium (M9/M21/M33/M45/M57), to present yearly progress, oversee the needs
within the pillars (and respective work packages) and to ensure the efficient implementation of recommendations and/
or decisions taken by the Governing Board, the Executive Committee and the Policy Board. Finally, INSERM will
support WP2 leaders in organization of the Policy Board meetings (once a year, M6/M18/M30/M42/M54). All meetings
planned during the project will be held in different countries to raise visibility and encourage commitment. Joint or
back-to-back organization of these events with workshops or Task Forces planned in different WP will be privileged
in order to reduce the costs.
SubTask 1.2.3: EJP RD internal communication (M1-M60)
STL: INSERM (Coo)
Beside regular conference calls and meetings of the OG and ExCom, the whole EJP RD Consortium will meet at least
once a year, while each of the Pillars will follow its specific agenda according to planned activities. Due to the size of the
Consortium, direct communication (on regular basis) will be ensured through a dedicated internal monthly newsletter
including “EJP RD Actions Updates”. The internal Newsletter will summarize important timelines (conference calls,
activity reports, deliverables etc.) as well as specific events outside the consortium of high importance for partners. An
Intranet secured platform will be established for the exchange and deposit of project related documents accessible to
all partners.
SubTask 1.2.4: Initiating new partnerships (M1-M60)
STL : INSERM (Coo)
The EJP RD consortium includes 85 partners (and their linked third parties) from 33 countries. However, not all EU
countries or several members of IRDiRC are involved in the project. To maximize the impact of the programme, the
EJP RD coordination and partners will continue efforts to initiate new, long-term partnerships. This will be achieved
through the promotion of the EJP RD at different occasions (dedicated communication support will be deployed) and
the support of Pillar leaders as ambassadors of the programme will be key. IRDiRC members will be encouraged to get
involved and different modes of implication will be proposed: from “soft” collaboration to full engagement. Finally,
the official meetings of Policy Board, Programme Commitee meetings of the European Commission or events initiated
by the rotating presidency of the Council of the EU will be explored and used to speak for EJP RD and initiate new
collaborations.
Task 1.3: Monitoring of the EJP RD activities and achievements (M1-M60)
TL: CVBF, Participants: ELIXIR, ULiv
The aim of this task is to evaluate the quality of the EJP RD activities and the achievement of the expected project goals.
The identification of KPIs and suitable metrics to monitor the impact of EJP RD activities not otherwise monitored
within specific Pillars represents the first step of this task. The monitoring activities will include collecting and analyzing
relevant documents (reports from Helpdesk and Pillars) to measure the performance and evaluate if the expected targets
are reached. The results of the monitoring activities highlighting strengths and weaknesses of the EJP will be delivered
to the coordination bodies for the adaptation of the strategy, integration in the annual reports and work plans, and to
support risk management.
SubTask 1.2.4: Initiating new partnerships (M1-M60)
STL : INSERM (Coo)
The EJP RD consortium includes 85 partners (and their linked third parties) from 33 countries. However, not all EU
countries or several members of IRDiRC are involved in the project. To maximize the impact of the programme, the
EJP RD coordination and partners will continue efforts to initiate new, long-term partnerships. This will be achieved
through the promotion of the EJP RD at different occasions (dedicated communication support will be deployed) and
the support of Pillar leaders as ambassadors of the programme will be key. IRDiRC members will be encouraged to get
involved and different modes of implication will be proposed: from “soft” collaboration to full engagement. Finally,
the official meetings of Policy Board, Programme Commitee meetings of the European Commission or events initiated
by the rotating presidency of the Council of the EU will be explored and used to speak for EJP RD and initiate new
collaborations.
SubTask 1.3.1: Identification of key performance indicators (M1-M60)
STL: ULiv; Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS); CVBF, ELIXIR
Upon definition of the key processes to be monitored the related KPIs, the metrics and the methodology for the
monitoring of the project activities will be defined. The OG will participate to this subtask. To ensure an adequate quality
standard, the EJP RD activities will be monitored and evaluated considering three perspectives: (i) internal to the EJP;
(ii) the RD community; (iii) interfaces between the EJP and the broader health research community.
The KPIs and metrics will be defined (and adapted) on the basis of: (i) overall and yearly objectives of the EJP RD; (ii)
timeline of the milestones and deliverables; (iii) list of monitored procedures.
Page 36 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Criteria which will be considered for the KPIs definition are: 1) all activities will be directed towards sustainability and
5 years strategy; 2) all performance indicators will be SMART and context specific; 3) limited in number and scope.
The deliverable 1.7 “Monitoring activities Handbook” will contain: (i) the list of KPIs used for the monitoring of the
EJP RD as a whole; (ii) the list of other performance indicators used within specific Pillars/WPs; (iii) the process to alert
EJP to risks and issues (including mechanisms and timelines for escalation from Task to WP to Pillar to Coordination).
EJP RD performance will be evaluated in term of compliance with: (i) standards for all monitored activities; (ii) user
experience and assessment; (iii) review of “exceptions” when services do not meet standards.
A workshop will be organized at month 2 with the ExCom, in order to approve the final list of proposed KPIs and related
metrics, handbook of monitored procedures and methodology for the monitoring.
The Monitoring Activities Handbook will be available by the end of Month 3.
Since it may be necessary to revise and adapt KPIs and metrics during the project, in this workshop the responsible(s)
for KPIs and metrics revision will be designated. KPIs and metrics revision and approval will be performed yearly at
months 14, 26, 38 and 50 during the annual meeting or the coordinating board ExecCom meeting. A detailed description
of the monitoring methods and procedures, together with the specific roles and competencies, i.e., who does what and
how, will be included in the Handbook.
SubTask 1.3.2: Implementation of the monitoring process (M1-M60)
STL: CVBF, Participant: ULiv
The monitoring will be performed continuously and reported every 12 months (12-24-36-48-60) in period deliverables
called Monitoring Reports. The monitoring reports will serve to: (i) assess the quality and specificity of performed
activities; (ii) adjust the quality and specificity of planned activities; (iii) integrate the results of the monitoring in the up
scaling model and sustainability beyond the EJP RD; (iv) disseminate the EJP RD results. The first Monitoring Report
will be produced in the 1st AWP at Month 12 and will be used to monitor and assess the project progresses and to
promptly identify issues which need corrective actions.
Also, interim internal reports at month will be provided at month 6, 18, 30, 42, and 54 and will be used for drafting the
Annual Work Plans at months 9, 21, 33, 45 and 57, respectively.
Task 1.4: Data management plan (M1-M60)
TL: INSERM, Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS); (Pillar 2 WPLs)
As stated in the section 2.2.4 data management is one of the major activities of the EJP RD Pillar 2 and thus Pillar 2 can
be assimilated as DMP itself. All data activities will follow Open Research Data principles (which conform to FAIR
data principles), and comply with the GDPR and existing ethical and legal expectations for healthcare, research and
patient data. Nevertheless, it will be important to describe how data management will be extended and tackled under
other Pillars. That is why, EJP RD decided to deliver concise DMP at M6 taking the advantage of top-level experts of
Pillar 2. This initial DMP will be updated in line with Pillar 2 developments and its revised version will be delivered at
M42. Special attention will be given to the compliance with all regulatory and ethical aspects. Thus, the DMP will be
developed under the supervision of the Ethics Advisor and in collaboration AREB.
Participation per Partner
Partner number and short name WP1 effort
1 - INSERM 403.00
15 - DLR 6.00
27 - CVBF 16.00
32 - VUHSK 6.00
34 - ZonMw 6.00
51 - ULIV 8.00
54 - AP-HP 6.00
57 - UKL-HD 6.00
75 - EATRIS 6.00
76 - EMBL 0.00
Page 37 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP1 effort
DTL-Projects 1.00
77 - EURORDIS 6.00
Total 470.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Report from the Kick-off
D1.1 1 - INSERM Report Public 2
meeting
Confidential, only
for members of the
Helpdesk directory of
D1.2 1 - INSERM Report consortium (including 3
people and services
the Commission
Services)
First report from the
D1.3 face-to-face ExCom and 1 - INSERM Report Public 7
Policy Board meeting
Second report from the
D1.4 face-to-face ExCom and 1 - INSERM Report Public 19
Policy Board meeting
Third report from the
D1.5 face-to-face ExCom and 1 - INSERM Report Public 31
Policy Board meeting
Fourth report from the
D1.6 face-to-face ExCom and 1 - INSERM Report Public 43
Policy Board meeting
Fifth report from the
D1.7 face-to-face ExCom and 1 - INSERM Report Public 55
Policy Board meeting
Confidential, only
First Summary Progress for members of the
D1.8 Report and Annual Work 1 - INSERM Report consortium (including 9
Plan the Commission
Services)
Confidential, only
Second Summary for members of the
D1.9 Progress Report and 1 - INSERM Report consortium (including 21
Annual Work Plan the Commission
Services)
Confidential, only
Third Summary Progress for members of the
D1.10 Report and Annual Work 1 - INSERM Report consortium (including 33
Plan the Commission
Services)
Page 38 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
Fourth Summary for members of the
D1.11 Progress Report and 1 - INSERM Report consortium (including 45
Annual Work Plan the Commission
Services)
Confidential, only
Fifth Summary Progress for members of the
D1.12 Report and Annual Work 1 - INSERM Report consortium (including 57
Plan the Commission
Services)
Confidential, only
for members of the
First Technical and
D1.13 1 - INSERM Report consortium (including 15
Financial Report
the Commission
Services)
Confidential, only
for members of the
Second Technical and
D1.14 1 - INSERM Report consortium (including 27
Financial Report
the Commission
Services)
Confidential, only
for members of the
Third Technical and
D1.15 1 - INSERM Report consortium (including 39
Financial Report
the Commission
Services)
Confidential, only
for members of the
Fourth Technical and
D1.16 1 - INSERM Report consortium (including 51
Financial Report
the Commission
Services)
Confidential, only
for members of the
Fifth Technical and
D1.17 1 - INSERM Report consortium (including 60
Financial Report
the Commission
Services)
Confidential, only
for members of the
Monitoring activities
D1.18 51 - ULIV Report consortium (including 2
handbook
the Commission
Services)
Confidential, only
for members of the
First EJP RD Monitoring
D1.19 27 - CVBF Report consortium (including 12
Report
the Commission
Services)
Second EJP RD Confidential, only
D1.20 27 - CVBF Report 24
Monitoring Report for members of the
Page 39 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
consortium (including
the Commission
Services)
Confidential, only
for members of the
Third EJP RD
D1.21 27 - CVBF Report consortium (including 36
Monitoring Report
the Commission
Services)
Confidential, only
for members of the
Fourth EJP RD
D1.22 27 - CVBF Report consortium (including 48
Monitoring Report
the Commission
Services)
Confidential, only
for members of the
Fifth EJP RD Monitoring
D1.23 27 - CVBF Report consortium (including 60
Report
the Commission
Services)
Initial Data Management
D1.24 1 - INSERM Report Public 6
Plan
ORDP: Open
Updated Data
D1.25 1 - INSERM Research Public 6
Management Plan
Data Pilot
Description of deliverables
D1.1: Report from the Kick-off meeting (M2)
D1.2: Helpdesk directory of people and services (M3)
D1.3, D1.4, D1.5, D1.6 and D1.7: Report from the face-to-face ExCom and Policy Board meeting (M7, M19, M31,
M43, M55)
D1.8, D1.9, D1.10, D1.11 and D1.12: Summary Progress Report and Annual Work Plan (M9, 21, 33, 45, 57)
D1.13, D1.14, D1.15, D1.16 and D1.17: Technical and Financial Report (M15, 27, 39, 51, 63)
D1.18: Monitoring activities handbook (M3)
D1.19, D1.20, D1.21, D1.22 and D1.23: EJP RD Monitoring Report (M12, 24, 36, 48, 60)
D1.24: Initial Data Management Plan (M6)
D1.25: Updated DMP (M42)
D1.1 : Report from the Kick-off meeting [2]
Report from the Kick-off meeting
D1.2 : Helpdesk directory of people and services [3]
Helpdesk directory of people and services
D1.3 : First report from the face-to-face ExCom and Policy Board meeting [7]
Report from the face-to-face ExCom and Policy Board meeting due at M7
D1.4 : Second report from the face-to-face ExCom and Policy Board meeting [19]
Report from the face-to-face ExCom and Policy Board meeting due at M19
D1.5 : Third report from the face-to-face ExCom and Policy Board meeting [31]
Report from the face-to-face ExCom and Policy Board meeting due at Month 31
Page 40 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D1.6 : Fourth report from the face-to-face ExCom and Policy Board meeting [43]
Report from the face-to-face ExCom and Policy Board meeting due at Month 43
D1.7 : Fifth report from the face-to-face ExCom and Policy Board meeting [55]
Report from the face-to-face ExCom and Policy Board meeting due at month 55
D1.8 : First Summary Progress Report and Annual Work Plan [9]
Summary Progress Report and Annual Work Plan due at Month 9
D1.9 : Second Summary Progress Report and Annual Work Plan [21]
Summary Progress Report and Annual Work Plan due at month 21
D1.10 : Third Summary Progress Report and Annual Work Plan [33]
Summary Progress Report and Annual Work Plan due at month 33
D1.11 : Fourth Summary Progress Report and Annual Work Plan [45]
Summary Progress Report and Annual Work Plan due at month 45
D1.12 : Fifth Summary Progress Report and Annual Work Plan [57]
Summary Progress Report and Annual Work Plan due at month 57
D1.13 : First Technical and Financial Report [15]
Technical and Financial Report due at month 15
D1.14 : Second Technical and Financial Report [27]
Technical and Financial Report due at month 27
D1.15 : Third Technical and Financial Report [39]
Technical and Financial Report due at month 39
D1.16 : Fourth Technical and Financial Report [51]
Technical and Financial Report due at month 51
D1.17 : Fifth Technical and Financial Report [60]
Technical and Financial Report due at month 63
D1.18 : Monitoring activities handbook [2]
Other lead beneficiaries: ELIXIR (76) and CVBF (27) Monitoring activities handbook
D1.19 : First EJP RD Monitoring Report [12]
EJP RD Monitoring Report due at month 12
D1.20 : Second EJP RD Monitoring Report [24]
EJP RD Monitoring Report due at month 24
D1.21 : Third EJP RD Monitoring Report [36]
EJP RD Monitoring Report due at month 36
D1.22 : Fourth EJP RD Monitoring Report [48]
EJP RD Monitoring Report due at month 48
D1.23 : Fifth EJP RD Monitoring Report [60]
EJP RD Monitoring Report due at month 60
D1.24 : Initial Data Management Plan [6]
Initial Data Management Plan
D1.25 : Updated Data Management Plan [6]
Updated Data Management Plan including the Open Data Research Pilot information on how EJP RD will faciliatate
the access to data and resources
Page 41 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Coordination & governance Minutes of the 1st Operating
MS1 1 - INSERM 1
structures established Group conference call
MS2 Helpdesk entry point set up 1 - INSERM 3 Website
MS3 Policy Board established 1 - INSERM 3 List of Policy Board Members
Page 42 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP2 Lead beneficiary 10 44 - ISCIII
Work package title Integrative research and innovation strategy
Start month 1 End month 60
Objectives
This WP focuses on the development of EJP RD research and innovation strategy in connection to all related
stakeholders. Specific objectives are:
● To map the needs for RD research and innovation;
● To define the prioritization model for the EJP RD actions as part of the annual planning and in connection to WP3
(Sustainability) and WP4 (Ethical, Regulatory, Legal and IPR framework);
● To prioritize topics for the joint transnational calls (JTCs) to be implemented within Pillar;
● To feed the medium and long-term RD research and innovation strategy in collaboration with IRDiRC;
● To prepare a Scoping Paper to be promoted (and implemented) by the national mirror groups and within the current
and forthcoming EC Framework Programme.
Description of work and role of partners
WP2 - Integrative research and innovation strategy [Months: 1-60]
ISCIII, INSERM, ANR, DLR, IT-MOH, FTELE, ISS, CVBF, VUHSK, ZonMw, MUW, AP-HP, UKL-HD, EATRIS,
EURORDIS
Other lead beneficiary: ISS (26)
Task 2.1: Prioritization scheme for EJP RD actions (M1-M36)
TL: CVBF, FTELE; Participants: ISCIII, ISS
The prioritization scheme will be based on a set of criteria and procedure defining the decision-making process, by which
to order mapped needs and actions that contribute to the EJP RD objectives or that stand in need of further exploration.
The identified criteria will encompass scientific evidence aspects, demands of the RD community, regulatory and
societal concerns and take into account financial and technical feasibility. The criteria will be defined based on the input
collected (through a survey) from RD stakeholders representing research community, ERNs, patients and policy makers.
The ExCom will endorse the prioritization criteria and will submit the prioritization scheme for the input and validation
of the Governing Board to be finally adopted by the Policy Board during its first face-to-face meeting.
Task 2.2 Mapping the research and innovation needs (M1-M48)
TL: ISCIII, ISS, Participants: Operating Group (INSERM [Coo & Orpha], DLR, IT MoH, UKL-HD, APHP, VUHSK,
ZonMw, EURORDIS, EATRIS); DTL-Projects (ELIXIR-NL); MUW
The aim of this task is to identify and regularly update the research and innovation needs that will feed the EJP RD
Annual Plans and contribute to the development of the long-term strategy of the EJP RD.
This mapping exercise will include inputs from different type of stakeholders going beyond the EJP RD beneficiaries
and their Linked Third parties:
● Internal input from the EJP RD (Operating Group);
● National and EU needs represented by the EJP RD Policy Board and in connection to national mirror groups;
● Yearly analysis of the state of play of funded research and drug development, overlaps and trends at international
level (based on data collected in Pillar 2, WP11, Task 11.2);
● International research strategy developed by the International Rare Diseases Research Consortium (IRDiRC) and
represented by its scientific and constitutive committees.
Taking into account the overall objective of the EJP RD is to establish a sustainable structure for support of RD research
and innovation, the mapping shall expand beyond mere scientific requisites and encompass other connected domains
comprising: (i) Diagnosis & healthcare; (ii) Regulatory & ethics (including the open data & science issues); (iii) EU
competitiveness & innovation.
The inputs will be collected from all stakeholders on a yearly basis within the first trimester of every year. A summary
document will be generated and sent to the Policy Board and ExCom as basis for prioritization exercise. The Policy
Board will meet once a year (month 6) to deliberate, prioritize (according to prioritization scheme developed under Task
2.1) and issue recommendations to the EJP RD ExCom on the actions to implement within subsequent Annual Work
Plan and the ones that require medium and longer-term investigation. In addition to informing Annual Work Plan, the
outcomes of the mapping and prioritization will be reformulated in the form of Scoping Paper (prepared by the Task
2.2 leaders with help of CO) to be transmitted to the leaders of Task 2.3, 2.4 and 2.5 for complementary actions.
Page 43 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Task 2.3: Scientific programming of joint transnational calls (M1-M36)
TL: ISCIII, ANR, Participants: DLR, FFRD, IT MoH
The joint transnational calls (JTCs) to be implemented within Pillar 1 represent important resource of both funding
and research capacity. Firstly, because their goal is to integrate national investments into RD research under single,
common programme; secondly, because funded research projects not only advance knowledge, diagnosis and therapy
development for RDs in general, but also should significantly contribute to the development, improvement and
demonstration of the EJP RD infrastructure, tools and methodologies. Thus, programming of research topics for JTCs
will be treated with particular attention. The above-mentioned mapping and prioritization exercise will serve as basis to
produce JTC topics table that will be submitted for further refinement by the specific ad hoc Scientific Advisory Board
called on the demand of Pillar 1 Call Steering Committee(s). As result, a list of maximum 3 detailed topics will be
produced. Particular attention will be made to avoid any COI of Research Performing Organizations participating in the
EJP RD and that would be eligible to apply to JTCs. That is why, the final decision on topics will be taken independently
by the Board of Funders, in agreement with the established call rules and national prerogatives (see Pillar 1 WP6).
Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces
of IRDiRC (M1 – M60)
TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw,
EURORDIS, EATRIS); ISCIII, ISS
At present each of the IRDiRC Scientific (Diagnostics, Interdisciplinary, Therapies) or Constituent (Funders, Patients
Advocacy, Companies) Committees has the possibility to seize upon specific RD research need or bottleneck and
propose a Task Force aiming at issuing recommendations or concrete actions to overcome the identified obstacle. The
majority of EJP RD countries and the European Commission are also members of IRDiRC and participate actively in
different committees. Furthermore, the Chair and Vice-Chair of IRDiRC will be members of EJP RD Policy Board.
Such strong connection is a mutual advantage and will prevent duplication of efforts. Thus, any research strategic
question or need identified by the Policy Board as requiring medium or longer-term approach (Task 2.2) will be studied
in relation to the ongoing or future Task Forces planned within IRDiRC activities. Whenever an issue recognized by
Policy Board either of national or EU-specific nature, a dedicated, IRDiRC-independent Task Force(s) will be proposed.
The setting up of a Task Force will follow well-established scheme proposed by IRDiRC, composed of the following
steps: (i) Analysis and preparation of background document; (ii) Call for experts to constitute TF working group; (iii)
Establishment of TF work plan; (iv) Up to 6 months of work including regular conference calls; (v) Production of
final recommendations and/or roadmap to be followed by the engaged stakeholders (enquirers); (vi) Dissemination.
Any other issue with identified synergy to IRDiRC TF will be integrated and treated jointly. Finally, needs/questions
of international wingspan, not yet treated by IRDiRC will be proposed as subjects for new collective Task Forces. The
EJP RD Coordination office (including IRDiRC SciSec) will be responsible for the management of the TF.
Task 2.5: Translation/impact of prioritization on national and EU strategies (M6 – M60)
TL: ISS, MUW, Participants: EURORDIS, FTELE, ISCIII, IT MoH
It is expected that the European dimension of the EJP RD and involvement of the Policy Board should have impact
both ways - on the activities of the EJP RD itself but also on the undertakings at national and EU level. Thus, the T2.2
Scoping Paper will be promoted by the national mirror groups and within the current and forthcoming EC Framework
Programme. In addition, the Task leaders will be responsible for collection of information from EU Member States
(via a survey targeting national mirror groups) on the EJP RD relevant/complementary actions performed at national
level. Specific focus will be made on EU-13 countries in respect to their specific needs, obstacles and advancements. A
report analyzing national alignment with EJP RD will be produced annually and presented at the occasion of the Policy
Board & ExCom meetings. In addition, two Strategic Workshops with relevant policy stakeholders will be organized
(M33, M57).
Participation per Partner
Partner number and short name WP2 effort
1 - INSERM 13.00
11 - ANR 2.00
15 - DLR 1.00
21 - IT-MOH 2.00
25 - FTELE 1.00
Page 44 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP2 effort
26 - ISS 18.00
27 - CVBF 1.00
32 - VUHSK 1.00
34 - ZonMw 1.00
38 - MUW 4.00
44 - ISCIII 16.00
54 - AP-HP 1.00
57 - UKL-HD 1.00
75 - EATRIS 1.00
77 - EURORDIS 1.00
Total 64.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Final list of prioritization
D2.1 27 - CVBF Report Public 5
criteria
Prioritization scheme
D2.2 including decision- 27 - CVBF Report Public 5
making process
Confidential, only
First Summary document for members of the
D2.3 on mapped research and 44 - ISCIII Report consortium (including 5
innovation needs the Commission
Services)
Confidential, only
Second Summary
for members of the
document on mapped
D2.4 44 - ISCIII Report consortium (including 17
research and innovation
the Commission
needs
Services)
Confidential, only
Third Summary
for members of the
document on mapped
D2.5 44 - ISCIII Report consortium (including 29
research and innovation
the Commission
needs
Services)
Confidential, only
Fourth Summary
for members of the
document on mapped
D2.6 44 - ISCIII Report consortium (including 41
research and innovation
the Commission
needs
Services)
Fifth Summary document Confidential, only
D2.7 on mapped research and 44 - ISCIII Report for members of the 53
innovation needs consortium (including
Page 45 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
the Commission
Services)
D2.8 First Scoping paper 26 - ISS Report Public 7
D2.9 Second Scoping paper 26 - ISS Report Public 19
D2.10 Third Scoping paper 26 - ISS Report Public 31
D2.11 Fourth Scoping paper 38 - MUW Report Public 43
D2.12 Fifth Scoping paper 38 - MUW Report Public 55
Confidential, only
for members of the
First List of refined JTC
D2.13 44 - ISCIII Report consortium (including 7
topics
the Commission
Services)
Confidential, only
for members of the
Second List of refined
D2.14 44 - ISCIII Report consortium (including 19
JTC topics
the Commission
Services)
Confidential, only
for members of the
Third List of refined JTC
D2.15 11 - ANR Report consortium (including 31
topics
the Commission
Services)
First List of research
and innovation needs
D2.16 requiring medium- or 1 - INSERM Report Public 6
long-term approach and
related Task Forces
Second List of research
and innovation needs
D2.17 requiring medium- or 1 - INSERM Report Public 18
long-term approach and
related Task Forces
Third List of research
and innovation needs
D2.18 requiring medium- or 1 - INSERM Report Public 30
long-term approach and
related Task Forces
Fourth List of research
and innovation needs
D2.19 requiring medium- or 1 - INSERM Report Public 42
long-term approach and
related Task Forces
Fifth List of research
D2.20 and innovation needs 1 - INSERM Report Public 54
requiring medium- or
Page 46 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
long-term approach and
related Task Forces
First Analysis of
national state of play and
D2.21 26 - ISS Report Public 9
alignment process with
EJP RD
Second Analysis of
national state of play and
D2.22 26 - ISS Report Public 21
alignment process with
EJP RD
Third Analysis of
national state of play and
D2.23 26 - ISS Report Public 32
alignment process with
EJP RD
Fourth Analysis of
national state of play and
D2.24 26 - ISS Report Public 55
alignment process with
EJP RD
First Report from
D2.25 strategic workshop with 26 - ISS Report Public 34
national policy makers
Second Report from
D2.26 strategic workshop with 38 - MUW Report Public 58
national policy makers
Description of deliverables
D26: Final list of prioritization criteria (M5)
D27: Prioritization scheme including decision-making process (M5)
D28, D29, D30, D31 and D32: Summary document on mapped research and innovation needs (M5, 17, 29, 41, 53)
D33, D34, D35, D36 and D37: Scoping paper (M7, M19, M31, M42, M54)
D38, D39 and D40: List of refined JTC topics (M7, M19, M31)
D41, D42, D43, D44 and D45: List of research and innovation needs requiring medium- or long-term approach and
related Task Forces (M7, M18, M30, M42, M54)
D46, D47; D48 and D49: Analysis of national state of play and alignment process with EJP RD (M9, M21, M32,
M55)
D50 and D51: Report from strategic workshop with national policy makers (M34, M58)
D2.1 : Final list of prioritization criteria [5]
Other lead beneficiary FTELE (25) Final list of prioritization criteria
D2.2 : Prioritization scheme including decision-making process [5]
Other lead beneficiary FTELE (25) Prioritization scheme including decision-making process
D2.3 : First Summary document on mapped research and innovation needs [5]
Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs
D2.4 : Second Summary document on mapped research and innovation needs [17]
Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs
D2.5 : Third Summary document on mapped research and innovation needs [29]
Page 47 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 29
D2.6 : Fourth Summary document on mapped research and innovation needs [41]
Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 41
D2.7 : Fifth Summary document on mapped research and innovation needs [53]
Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 53
D2.8 : First Scoping paper [7]
Other lead beneficiaries: ISCIII (44) and INSERM (1) Scoping paper due at Month 7
D2.9 : Second Scoping paper [19]
Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 19
D2.10 : Third Scoping paper [31]
Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 31
D2.11 : Fourth Scoping paper [43]
Other lead beneficiaries: ISCIII (44) and INSERM (1) Scoping paper due at month 43
D2.12 : Fifth Scoping paper [55]
Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 55
D2.13 : First List of refined JTC topics [7]
Other lead beneficiary ANR (11) List of refined JTC topics due at month 7
D2.14 : Second List of refined JTC topics [19]
Other lead beneficiary ANR (11) List of refined JTC topics due at month 19
D2.15 : Third List of refined JTC topics [31]
Other lead beneficiary ANR (11) List of refined JTC topics due at month 31
D2.16 : First List of research and innovation needs requiring medium- or long-term approach and related Task Forces
[6]
List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month
6
D2.17 : Second List of research and innovation needs requiring medium- or long-term approach and related Task
Forces [18]
List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month
18
D2.18 : Third List of research and innovation needs requiring medium- or long-term approach and related Task
Forces [30]
List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month
30
D2.19 : Fourth List of research and innovation needs requiring medium- or long-term approach and related Task
Forces [42]
List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month
42
D2.20 : Fifth List of research and innovation needs requiring medium- or long-term approach and related Task Forces
[54]
List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month
54
D2.21 : First Analysis of national state of play and alignment process with EJP RD [9]
Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at
Month 9
D2.22 : Second Analysis of national state of play and alignment process with EJP RD [21]
Page 48 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month
21
D2.23 : Third Analysis of national state of play and alignment process with EJP RD [32]
Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month
32
D2.24 : Fourth Analysis of national state of play and alignment process with EJP RD [55]
Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month
55
D2.25 : First Report from strategic workshop with national policy makers [34]
Other lead beneficiary MUW (38) Report from strategic workshop with national policy makers due at month 34
D2.26 : Second Report from strategic workshop with national policy makers [58]
Other lead beneficiary MUW (38) Report from strategic workshop with national policy makers due at month 58
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Survey on prioritization
MS4 27 - CVBF 3 Survey document
criteria set up and launched
Prioritization scheme and
Minutes of the ExCom and
MS5 list of criteria validated by 44 - ISCIII 6
Policy Board meeting
ExCom and Policy Board
Page 49 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP3 Lead beneficiary 10 1 - INSERM
Work package title Sustainability strategy and business plan
Start month 1 End month 60
Objectives
The objective of WP3 is to prepare, and implement the EJP RD sustainability strategy in collaboration with the EJP-RD
boards, Pillars and relevant WP/Task leaders. The strategy will identify routes to sustainability and develop relevant
action plans.
Specific objectives:
● Identify elements of the EJP RD that are potentially sustainable by integrating information from the monitoring of EJP
activities (WP1) with feedback from targeted end-user groups and key stakeholders including entities that will provide
the resources for sustainability (ex. EU Member States);
● Identify potential sustainability models, including both ‘classic’ and innovative approaches to fund-raising activities,
business models and legal status of on-going European infrastructures and initiatives;
● Initiate efforts to promote the sustainable activities of the EJP-RD;
● In collaboration with WP4 (Ethical, regulatory & legal framework) formulate recommendations for the governance
of the organization(s) that will succeed EJP RD with a particular focus on intellectual property and access issues;
● Develop the sustainability roadmap of the EJP RD.
WP3 will ensure liaison with other strategic initiatives working on global sustainability issues (e.g. RDA, EOSC, EC-
funded e-Infrastructures, ESFRI Forum and its Health and Food Strategic Working Group, relevant H2020 projects and
other international initiatives) in view of aligning strategic sustainability activities and exploiting synergies.
Description of work and role of partners
WP3 - Sustainability strategy and business plan [Months: 1-60]
INSERM, DLR, VUHSK, ZonMw, ISCIII, ULIV, AP-HP, UKL-HD, EATRIS, EMBL, EURORDIS
Other lead beneficiaries: EATRIS (75) and ISCIII (44)
WP Methodology
Sustainability strategy encompasses several important aspects that will be addressed in this WP: (i) identification of
value propositions that emerge from EJP RD activities, taking into account effective segmentation of capabilities and
markets and the needs of resource holders; (ii) developing business plans for the activities of EJP RD that are sustainable,
including identification of necessary resources; (iii) scoping legal and governance issues relating to sustainability. The
experience and lessons learnt from the performance of E-RARE, RD-Connect, Orphanet, ERNs and other initiatives
indicate that long term sustainability is a serious issue necessary to be tackled by the EJP RD as early as possible.
Consultation with internal and external stakeholders will be essential to ensure that the approach to sustainability is
appropriate and that sustainability is considered throughout the programme.
Task 3.1: Service roadmap: alignment of the needs, expectations and engagement of the different RD research
stakeholders in Europe with respect to EJP RD sustainability (M1 – M36)
TL: INSERM (RaDiCo), ISCIII, Participants: ULiv, DTL-Projects, Operating Group (INSERM [Coo & Orpha], DLR,
UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS)
In close collaboration with the OG and transversal WPs 2 & 5, this task aims to integrate and maintain the information
collected on needs, expectations and possible contributions of: (i) National Programme Owners (PO) and Programme
Managers (PM) (Subtask 3.1.1 led by ISCIII) and (ii) other stakeholders (Subtask 3.1.2 led by INSERM-RaDiCo) to
define in a standard format value propositions that can drive sustainability perspectives. In a 360° perspective matrix-
based approach, the stakeholders will be segmented into specific subgroups (funders and public authorities, patients,
researchers and learned societies, care givers, industry) taking into account their needs, expectations and possible
contributions (including long term financial and/or in-kind commitment). This task will develop value propositions for
“viable” activities that will be prioritized via Task 3.2 and by stakeholders with resources that can sustain them.
Task 3.2: Preparation of the sustainable EJP-RD services catalogue, supporting the EJP-RD dissemination and
communication activities (M12 – M36)
TL: INSERM (RaDiCo), EATRIS, Participants: ISCIII, ULiv, DTL-Projects
Based on the results of Task 3.1 together with subsequent internal monitoring of EJP RD performance (WP1, Task
1.3), inputs from Pillars and Transversal WPs, and clear user demand, a catalogue of services will be compiled by WP3
and disseminated by WP5. The dissemination will include participation at dedicated events or channeling information
Page 50 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
to the ESFRI infrastructures, funding agencies and governmental bodies about the ‘catalogue’ and EJP RD plans and
successes. In addition, WP3 will support EJP RD components seeking resources to develop study cases of innovative
sustainability solutions.
Task 3.3: Preparation of the EJP-RD sustainability plan with business plan (M1 – M42)
TL: EATRIS, ISCIII, Participants: INSERM (RaDiCo), ULiv, DTL-Projects
The task will consist of benchmarking of sustainability strategies that exist in the EU research fields, such as European
ESFRI landmark research infrastructures and projects in the ESFRI Roadmap, European and national research data
hubs (e.g. EOSC / EDI), public and private institutes, foundations across the globe, with strong interconnections and
involvements of NGOs, private partners and public bodies. The results will be assessed, with high potential benchmark
strategies collated for possible use in the EJP sustainability roadmap. Then, the specific ecosystem in which the EJP
RD will operate will be evaluated: current state, target users, relevant unique value within-project take-up, post-project
take-up, financial aspects, and competitive analysis. The evaluation of the ecosystem will identify the expectations
and requirements of the member states (and other sources of sustainable resources) regarding: (i) expected benefits
and willingness to pay; (ii) constraints on operational structure, legal model, IP and other governance issues. The
potential sustainability models identified will be submitted to a SWOT analysis including their structure and governance
differences, budgetary needs, legal and tax-related environments, and the identification of potential financing sources
and their possible consequences on competing or synergistic interests. The sustainability cases will be based on a
business case with strategy of clients and combination of financial sources, including: national funds for availability
of e-Infrastructures, public funds and research grants, regional resource sharing and collaboration via Memorandum of
Understanding, public-private partnerships and exploration of pay-per-use and in-kind business models. Sustainability
models will be targeted to segments of resource holders. Finally, the most relevant sustainability models will be selected
with its business case, taking into account prioritization information from the EJP RD sustainable service catalogue
produced by Task 3.2, and presented to the EJP RD Governance and the stakeholders. The models will include the
following criteria: (i) open-access versus controlled availability of the EJP RD deliverables and outcomes in line with
European Open Science Cloud and European Data Infrastructure, (ii) design of services that enable researchers to make
the most of the EJP outcomes (iii) ensuring the possibility for accession of new members/contributors interested in
joining, (iv) identification of cash flow between the actors, (v) pricing of services, (vi) financial viability and (vii) buy-
in by the stakeholders. The selected sustainability models should include the Beneficiaries having contributed to the
considered deliverables and PO, PM and other key stakeholders that are involved in RD research (and beyond).
A first list of the relevant models addressing sustainability for key stakeholders will be delivered. This list will be
published for a public consultation. Following it, a refined list will be delivered to inform the Task 3.4.
Task 3.4: Sustainability roadmap (M36-M60)
TL: ISCIII, EATRIS, Participants: INSERM (RaDiCo), ULiv, DTL-Projects
This task will build on Tasks 3.1 – 3.3 to define the final sustainability roadmap for the EJP RD with all milestones
to be reached in order to roll out and implement the selected model to ensure sustainability of the integrated RD
research infrastructure at both EU and national levels. Upon the preferences and requirements expressed by Member
States a proposal with SWOT produced in T3.3 and future KPIs will be drafted and presented to Members States for
adoption after the EJP RD ends. A first version of the sustainability roadmap will be prepared and defined at M46. The
roadmap will be finalized at M54 with final decision after an iterative process taking into account associated deliverable
completion and evaluation by other WPs.
Participation per Partner
Partner number and short name WP3 effort
1 - INSERM 26.00
15 - DLR 1.00
32 - VUHSK 1.00
34 - ZonMw 1.00
44 - ISCIII 13.00
51 - ULIV 3.00
54 - AP-HP 1.00
57 - UKL-HD 1.00
Page 51 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP3 effort
75 - EATRIS 14.00
76 - EMBL 0.00
DTL-Projects 3.00
77 - EURORDIS 1.00
Total 65.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Dynamic catalogue of
EJP-RD sustainable
D3.1 resources including 1 - INSERM Report Public 36
Service Roadmap
Database
Confidential, only
Study cases of innovative
for members of the
sustainability solutions
D3.2 1 - INSERM Report consortium (including 36
for specific EJP RD
the Commission
outcomes
Services)
Analysis of structures, Confidential, only
business models and for members of the
D3.3 required complementarity 75 - EATRIS Report consortium (including 42
from other relevant the Commission
initiatives Services)
First Proposal of Confidential, only
structure, governance for members of the
D3.4 and financial model and 44 - ISCIII Report consortium (including 46
global sustainability the Commission
roadmap Services)
Second Proposal of Confidential, only
structure, governance for members of the
D3.5 and financial model and 44 - ISCIII Report consortium (including 54
global sustainability the Commission
roadmap Services)
Description of deliverables
D52: Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database (M36)
D53: Study cases of innovative sustainability solutions for specific EJP RD outcomes (M36)
D54: Analysis of structures, business models and required complementarity from other relevant initiatives (M42)
D55 and D56: Proposal of structure, governance and financial model and global sustainability roadmap (M46, M54)
D3.1 : Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database [36]
Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database Lead beneficiary
INSERM (RADICO)
D3.2 : Study cases of innovative sustainability solutions for specific EJP RD outcomes [36]
Page 52 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Study cases of innovative sustainability solutions for specific EJP RD outcomes Lead beneficiary ISNERM
(RADICO)
D3.3 : Analysis of structures, business models and required complementarity from other relevant initiatives [42]
Other lead beneficiary: EATRIS (75) Analysis of structures, business models and required complementarity from
other relevant initiatives
D3.4 : First Proposal of structure, governance and financial model and global sustainability roadmap [46]
Other lead beneficiary EATRIS (75) Proposal of structure, governance and financial model and global sustainability
roadmap due at month 46
D3.5 : Second Proposal of structure, governance and financial model and global sustainability roadmap [54]
Other lead beneficiary (EATRIS (75) Proposal of structure, governance and financial model and global sustainability
roadmap due at month 54
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Survey to national mirror
MS6 groups established and 26 - ISS 5 Survey document
launched
Proposed model approved by
Suitable structure and
the EJP-RD Governance and
MS7 sustainability model for the 75 - EATRIS 42
MS according to decision-
EJP RD proposed
making procedures
Final Business model and
Final proposal for decision on
MS8 44 - ISCIII 54 sustainability plan for
the sustainability roadmap
adoption
Page 53 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP4 Lead beneficiary 10 24 - FGB
Work package title Ethical, regulatory, legal and IPR framework of the EJP RD
Start month 1 End month 60
Objectives
This WP aims at providing all Pillars with the proper strategy to address ethical, regulatory (including GDPR), legal
and Intellectual Property Right (IPR) issues, and at ensuring that relevant rules are complied with within the course
of the EJP for RD.
The specific objectives include:
● Setting up an ‘Advisory Regulatory Ethics Board’;
● Advising on the regulatory procedures and ethical provisions to perform regulatory-compliant research and data
collection and to protect patient rights;
● Coordinating activities related to IPR issues of the EJP for RD as a whole.
This will allow EJP RD to perform not only ethically-sounded but also regulatory-compliant multi-national research.
Description of work and role of partners
WP4 - Ethical, regulatory, legal and IPR framework of the EJP RD [Months: 1-60]
FGB, INSERM, DLR, FTELE, CVBF, VUHSK, ZonMw, AP-HP, UKL-HD, BBMRI, ECRIN, EATRIS, EMBL,
EURORDIS
Other WP lead beneficiaries: FTELE (25)
Task 4.1. Advice and monitoring ethical/regulatory issues within EJP RD. (M1-M60)
TL: INSERM
With the aim to comply with the European ethical and legal frameworks, an independent expert will be appointed as an
“Ethics Advisor”. He/she will be in charge of advising on and monitoring ethical/legal/regulatory issues of the EJP RD,
of the Data Management Plan as well as of the projects founded within EJP RD to ensure that the ethics management
of the projects are carried out within the H2020 framework. He/she will closely work with the EJP RD operating group
and the Advisory Regulatory Ethics Board’ (AREB) that will be set up (see Task 4.2).
Task 4.2 Managing ethical and regulatory issues (M1-M60)
TL: FGB, Participants: BBMRI, ECRIN, ELIXIR, CVBF, INSERM, Operating Group (INSERM [Coo& Orpha], DLR,
UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS)
In order to ensure compliance of the project and its activities with ethical and regulatory requirements, a project
‘Advisory Regulatory Ethics Board’ (AREB) will be set up. It will be composed of internal EJP RD ethics/regulatory/
legal experts, including members with recognised expertise from involved European RIs. It will ensure compliance with
all international and European relevant rules and ethical norms, including but not limited to fundamental and patients’
rights, data management, protection and confidentiality, of the EJP RD as well as of the projects founded within EJP RD.
In particular, the AREB will be in charge of overseeing ethical issues and regulatory procedures envisaged in the EJP
RD four Pillars and by assisting partners. Specifically, the AREB will:
● Collaborate with Pillar 1 to ensure that the Joint Transnational Calls for collaborative research projects will include
all relevant requirements in the call text and guidelines for applicants;
● Verify that the collaborative research projects funded in Pillar 1 as well as pilot project/proof of concept foreseen in
Pillars 2 and 4 activities are regulatory- and ethically-compliant and that they will properly address patient rights and the
necessary regulatory procedures, e.g. ethical approval, authorisation from competent authorities, regulatory advice from
EMA or national agencies (Scientific Advice/Protocol Assistance, EMA qualification opinion, certification of ATMP
quality etc.), Paediatric Investigation Plan (PIP) or waiver, pharmacovigilance obligations;
● Ensure that data handling carried out in Pillars 2 and 4 and projects funded in Pillar 1 comply with GDPR and national
laws, including requirement for special declarations or authorisations;
● Inform and update EJP RD consortium partners on the advancements, changes and news from the regulatory, ethical
and legal framework during the yearly EJP RD Consortium meetings;
● Support EJP RD partners with ethical and legal advice whenever requested;
● Provide recommendations in case of detection of possible gap in the regulatory/ethical/legal framework to be applied
in multi-national biomedical research in the context of the EJP RD;
● Ensure that the H2020 framework for ethics is fully applied to the planned subsidiary projects, and the ethics
management of these should be carried out within the H2020 framework.
Page 54 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
A dialogue with the EMA and its committees as well as the national competent authorities will be established. Whenever
relevant, other regulatory agencies/authorities will be addressed as well, e.g. Food and Drug Administration (FDA, US)
and Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency
(PMDA).
Task 4.3. Managing legal and IPR issues (M1-M60)
TL: FTELE, Participant: FGB, BBMRI
Considering the high number of partners in the EJP RD consortium and the variety of planned activities, a one-size-
fits-all approach cannot be adopted. The Task Leader (TL) will therefore manage case by case the requests from EJP
RD beneficiaries and proactively monitor the IP relevant issues throughout the whole project duration. The IP support
report will serve as input to the Monitoring (Task 1.3) of the EJP RD activities and outcomes.
Every six months, the TL will interview the ExCom in order to:
● Collect emerging needs on IP issues in every WP;
● Identify the activities more likely to produce results that are expected to be commercially or industrially exploitable
and therefore needs IP protection;
● Keep track of the IP generated by each of the WPs, in particular in terms of copyrighted softwares or training materials
and patents (if any) and feed the WP3 Sustainability strategy.
Moreover, the TL will:
● Collect and archive any new or updated declaration on background IP by EJP-RD beneficiaries;
● Upon request, facilitate the contact and the negotiation between the Technology Transfer Offices and/or legal
departments of the relevant beneficiaries in case of joint ownership of the results;
● Make available, through the EJP RD website, a set of legal templates for Inter Institutional Agreements, Data Transfer
Agreement and Material Transfer Agreement compliant with EU rules, Grant Agreement and Consortium Agreement
provisions;
● Upon request, support EJP RD beneficiaries in the use and adaptation to their specific needs of the above mentioned
templates.
Participation per Partner
Partner number and short name WP4 effort
1 - INSERM 14.00
15 - DLR 1.00
24 - FGB 20.00
25 - FTELE 16.00
27 - CVBF 1.00
32 - VUHSK 1.00
34 - ZonMw 1.00
54 - AP-HP 1.00
57 - UKL-HD 1.00
73 - BBMRI 1.00
74 - ECRIN 1.00
75 - EATRIS 2.00
76 - EMBL 0.00
DTL-Projects 1.00
77 - EURORDIS 2.00
Total 63.00
Page 55 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
for members of the
D4.1 First AREB report 24 - FGB Report consortium (including 6
the Commission
Services)
Confidential, only
for members of the
First Periodic AREB
D4.2 24 - FGB Report consortium (including 19
report
the Commission
Services)
Confidential, only
for members of the
Second Periodic AREB
D4.3 24 - FGB Report consortium (including 31
report
the Commission
Services)
Confidential, only
for members of the
Third Periodic AREB
D4.4 24 - FGB Report consortium (including 43
report
the Commission
Services)
Confidential, only
for members of the
Fourth Periodic AREB
D4.5 24 - FGB Report consortium (including 55
report
the Commission
Services)
Set of template
D4.6 agreements for EJP RD 25 - FTELE Report Public 6
website
Confidential, only
for members of the
First Periodic IPR report
D4.7 25 - FTELE Report consortium (including 6
(based on ExCom inputs)
the Commission
Services)
Confidential, only
Second Periodic IPR for members of the
D4.8 report (based on ExCom 25 - FTELE Report consortium (including 18
inputs) the Commission
Services)
Confidential, only
for members of the
Third Periodic IPR report
D4.9 25 - FTELE Report consortium (including 24
(based on ExCom inputs)
the Commission
Services)
Fourth Periodic IPR Confidential, only
D4.10 report (based on ExCom 25 - FTELE Report for members of the 24
inputs) consortium (including
Page 56 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
the Commission
Services)
Confidential, only
for members of the
Fifth Periodic IPR report
D4.11 25 - FTELE Report consortium (including 30
(based on ExCom inputs)
the Commission
Services)
Confidential, only
for members of the
Sixth Periodic IPR report
D4.12 25 - FTELE Report consortium (including 36
(based on ExCom inputs)
the Commission
Services)
Confidential, only
Seventh Periodic IPR for members of the
D4.13 report (based on ExCom 25 - FTELE Report consortium (including 42
inputs) the Commission
Services)
Confidential, only
Eighth Periodic IPR for members of the
D4.14 report (based on ExCom 25 - FTELE Report consortium (including 48
inputs) the Commission
Services)
Confidential, only
for members of the
Ninth Periodic IPR report
D4.15 25 - FTELE Report consortium (including 54
(based on ExCom inputs)
the Commission
Services)
Confidential, only
Tenth and final Periodic for members of the
D4.16 IPR report (based on 25 - FTELE Report consortium (including 60
ExCom inputs) the Commission
Services)
Confidential, only
for members of the
First IPR support
D4.17 25 - FTELE Report consortium (including 6
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Second IPR support
D4.18 25 - FTELE Report consortium (including 12
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Third IPR support
D4.19 25 - FTELE Report consortium (including 18
(monitoring) report
the Commission
Services)
Page 57 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
for members of the
Fourth IPR support
D4.20 25 - FTELE Report consortium (including 24
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Fifth IPR support
D4.21 25 - FTELE Report consortium (including 30
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Sixth IPR support
D4.22 25 - FTELE Report consortium (including 36
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Seventh IPR support
D4.23 25 - FTELE Report consortium (including 42
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Eighth IPR support
D4.24 25 - FTELE Report consortium (including 48
(monitoring) report
the Commission
Services)
Confidential, only
for members of the
Ninth IPR support
D4.25 25 - FTELE Report consortium (including 54
(monitoring) report
the Commission
Services)
Confidential, only
Tenth and final IPR for members of the
D4.26 support (monitoring) 25 - FTELE Report consortium (including 60
report the Commission
Services)
Description of deliverables
D57 First AREB report (M6)
D58, D59, D60 and D61 Periodic AREB report (M19, M31, M43, M55)
D62 Set of template agreements for EJP RD website (M6)
D63 to D72 Periodic IPR report (based on ExCom inputs) (M6, 12, 18, 24, 30, 36, 42, 48, 54, 60)
D73 to D82 IPR support (monitoring) report (M6, M12, 18, 24, 30, 36, 42, 48, 54, 60).
D4.1 : First AREB report [6]
First AREB report
D4.2 : First Periodic AREB report [19]
Periodic AREB report due at month 19
Page 58 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D4.3 : Second Periodic AREB report [31]
Periodic AREB report due at month 31
D4.4 : Third Periodic AREB report [43]
Periodic AREB report due at month 43
D4.5 : Fourth Periodic AREB report [55]
Periodic AREB report due at month 55
D4.6 : Set of template agreements for EJP RD website [6]
Set of template agreements for EJP RD website
D4.7 : First Periodic IPR report (based on ExCom inputs) [6]
Periodic IPR report (based on ExCom inputs) due at month 6
D4.8 : Second Periodic IPR report (based on ExCom inputs) [18]
Periodic IPR report (based on ExCom inputs) due at month 18
D4.9 : Third Periodic IPR report (based on ExCom inputs) [24]
Periodic IPR report (based on ExCom inputs) due at month 24
D4.10 : Fourth Periodic IPR report (based on ExCom inputs) [24]
Periodic IPR report (based on ExCom inputs) due at month 24
D4.11 : Fifth Periodic IPR report (based on ExCom inputs) [30]
Periodic IPR report (based on ExCom inputs) due at month 30
D4.12 : Sixth Periodic IPR report (based on ExCom inputs) [36]
Periodic IPR report (based on ExCom inputs) due at month 36
D4.13 : Seventh Periodic IPR report (based on ExCom inputs) [42]
Periodic IPR report (based on ExCom inputs) due at month 42
D4.14 : Eighth Periodic IPR report (based on ExCom inputs) [48]
Periodic IPR report (based on ExCom inputs) due at month 48
D4.15 : Ninth Periodic IPR report (based on ExCom inputs) [54]
Periodic IPR report (based on ExCom inputs) due at month 54
D4.16 : Tenth and final Periodic IPR report (based on ExCom inputs) [60]
Final Periodic IPR report (based on ExCom inputs) due at month 60
D4.17 : First IPR support (monitoring) report [6]
IPR support (monitoring) report due at month 6
D4.18 : Second IPR support (monitoring) report [12]
IPR support (monitoring) report due at month 12
D4.19 : Third IPR support (monitoring) report [18]
IPR support (monitoring) report due at month 18
D4.20 : Fourth IPR support (monitoring) report [24]
IPR support (monitoring) report due at month 24
D4.21 : Fifth IPR support (monitoring) report [30]
IPR support (monitoring) report due at month 30
D4.22 : Sixth IPR support (monitoring) report [36]
IPR support (monitoring) report due at month 36
D4.23 : Seventh IPR support (monitoring) report [42]
IPR support (monitoring) report due at month 42
D4.24 : Eighth IPR support (monitoring) report [48]
Page 59 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
IPR support (monitoring) report due at month 48
D4.25 : Ninth IPR support (monitoring) report [54]
IPR support (monitoring) report due at month 54
D4.26 : Tenth and final IPR support (monitoring) report [60]
Final IPR support (monitoring) report due at month 60
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS9 AREB set up 24 - FGB 5 List of AREB members
1st Annual AREB meeting
MS10 24 - FGB 6 Meeting minutes
held
2nd Annual AREB meeting
MS11 24 - FGB 18 Meeting minutes
held
3rd Annual AREB meeting
MS12 24 - FGB 30 Meeting minutes
held
4th Annual AREB meeting
MS13 24 - FGB 42 Meeting minutes
held
Set of template agreements
Availability on-line (EJP RD
MS14 for IPR issues available to the 25 - FTELE 7
website)
community
Page 60 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP5 Lead beneficiary 10 1 - INSERM
Work package title Communication & dissemination
Start month 1 End month 60
Objectives
● Prepare and support the communication and dissemination strategy for the EJP RD as a whole and taking into account
the needs of each Pillar and transversal WPs
● Effectively communicate on activities of each Pillar/WP to a wide range of stakeholders and potential users in a
coherent, targeted and timely manner;
● Actively disseminate outputs from all work packages through a wide range of channels and tailored activities to target
audiences;
● Promote the initiative and ensure awareness by establishing dialogues with key stakeholders and potential partners
at national and EU level.
Description of work and role of partners
WP5 - Communication & dissemination [Months: 1-60]
INSERM, DLR, TEDDY, VUHSK, ZonMw, ULIV, AP-HP, UKL-HD, EATRIS, EURORDIS, Blackswan
Task 5.1: EJP RD external communication & dissemination of results (M1-M60)
TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP, VUHSK,
EATRIS, ZonMw), BLACKSWAN
Subtask 5.1.1: Implementation of the EJP RD communication strategy (M1-M60)
STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP,
VUHSK, EATRIS, ZonMw)
The operational day-to-day management of the communication & dissemination will be ensured by the Communication
Manager (CM) who will be part of the Coordination Office. The CM will collaborate closely with the Operating Group
to provide the interface between the partners participating in different pillars/WPs, collect their needs and provide
suitable communication and dissemination means to design communication actions targeted for the different audiences.
The CM will be responsible for the timely aggregation of items requiring communication/dissemination actions and
propose implementation, in line with the communication and dissemination plan provided in the proposal, and taking
advantage of the centrally provided tools (website, broadcast media, scientific support from project managers) coupled
with the extensive capacity and international coverage of the EJP RD partners (see also Task 5.2). The strategy will
be adapted to the type of stakeholders: general public, patients, policy makers and research community. The initially
proposed frequency and formats will be agreed and validated by the Executive Committee with the possibility of revision
whenever deemed necessary.
Impact of communication and dissemination activities will be assessed during the course of the project via the Task 1.3
(Monitoring). Dissemination activities will be tracked and evaluated regularly based on the criteria determined in the
Communication and Dissemination Plan to ensure an efficient impact and European-added value.
Subtask 5.1.2: Communication and dissemination tools (M1-M60)
STL: INSERM (Coo), Participants: BLACKSWAN
EJP RD website: the website will be established at the start of the project (M2). It will be a central tool to communicate,
disseminate the results but also serve as a single entry point for the EJP RD Helpdesk (see Subtask 1.1.2). The website
will be developed and maintained by INSERM under the responsibility of Coordination Unit and Communication
Manager in particular. The website will constantly updated and will feature individual pages dedicated to specific
activities developed within each Pillar and transversal WPs as well as sections focusing on promotion of relevant news
and activities of other EJP RD related initiatives. It will also encompass user-friendly interface for the EJP RD Helpdesk.
Newsletters: Project newsletters and flash news will be produced and disseminated through various listing of
stakeholders. The service used will be MailChimp, which has several reporting features such as download/access
statistics and breaking down the subscribers by country, age and gender etc. The newsletters will also be published on
the website.
Social media pack: The social media like Facebook, Twitter or LinkedIn are now part of the regular communication
and dissemination panoply. They will be also included in the EJP RD communication strategy. Special attention will be
given to the regular follow up and appropriate management (including privacy policy) of these tools to be subsumed
under duties of the CM.
Page 61 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Printed communication materials: leaflets, brochures presenting the goals and activities of the EJP RD for the
distribution during meetings and workshops; generic posters with the intention to reflect the status of the project and to
support the presentations at events and meetings. Whenever possible these communication materials will be translated
into the national languages of the EJP RD partner in order to facilitate and increase awareness.
Broadcast media: The audio and video support will be available to cover EJP RD events, interviews and preparation of
dedicated content (ex. general public, young patients, to feature new tools, etc.). EJP RD will pro-actively engage with
EC specific (e.g., Horizon Magazine, Cordis) and international media.
Scientific writing support: The experience gathered by the SciSec of IRDiRC (see also Task 1.1.1) showed that
centralized support for writing of reports, drafting of papers and preparation of scientific contents increases the efficiency
of the communication and dissemination of outputs produced by numerous Task Forces, workshops and working groups.
This model will be also implemented in the EJP RD. The scientific writing support will be provided by the CM and
EJP RD project managers. This core group may be reinforced on an ad hoc basis by experts mobilized from among
EJP RD partners.
Scientific Congresses:
The EJP RD intends to continue the collaboration initiated by E-Rare and IRDiRC with BlackSwan Foundation to
support and further expand RE(ACT) Congress. In addition, collaboration with other relevant events like ECRD,
ICORD, UDNI or ESHG congresses will be used to strengthen the dissemination capacity and exploit the potential of
these events to promote excellent research financed by Pillar 1 (and previously by E-Rare), outcomes of other Pillars and
provide stimulating environment for RD community. Joint targeted workshops fostering promotion and collaboration
with relevant stakeholders (regulatory bodies, patients or private investors) will be also organized at these occasions.
Subtask 5.1.3: Support of communication and dissemination activities of IRDiRC (M1-M60)
STL: INSERM
At present the communication and dissemination support of IRDiRC is ensured by its Scientific Secretariat. It includes
the maintenance and regular updates of the IRDiRC website, the development of a monthly newsletter, updates on
social media and development of suitable written content and organization of IRDiRC Congress. Since IRDiRC SciSec
will be integrative part of the EJP RD Coordination office, these activities and dedicated to IRDiRC communication
tools will be maintained (along with other responsibilities of the SciSec) and supported by Communication and
project Managers. Yearly communication and dissemination plan specific to IRDiRC will be presented at the IRDiRC
Consortium Assembly.
Task 5.2: Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders
(M1-M60)
TL: INSERM(Orphanet LTPs), Participants: EURORDIS, TEDDY, ULiv
The EJP RD gathers 85 partners from 32 EU, associated and non-European countries. Many involved beneficiaries
represent networks or projects that cover multitude of stakeholders like research communities (alliances, learned
societies), healthcare providers, patients (including young patients) or policy-makers (ministries, ethics and data
protection authorities, HTA). Thus, the internal potential of EJP RD partners should not be neglected, as it will serve
to vehicle unified information and multiply the communication and dissemination capacity of the EJP RD at regional
and national level. For this Task the Orphanet and EURORDIS networks already implemented in all of the EJP RD
countries will be used to link with national RD stakeholders and support EJP RD communication & dissemination
efforts. The TEDDY and C4C networks (ULiv), specifically dedicated to pediatric clinical research and having large
experience in communication to young patients will second EURORDIS and Orphanet. Finally, national networks of
collaborators (including voluntary helpers) will assist in adapting and translating the EJP RD newsletter, specific reports
or publication in national languages to reach wider public.
Participation per Partner
Partner number and short name WP5 effort
1 - INSERM 68.00
15 - DLR 1.00
28 - TEDDY 1.00
32 - VUHSK 1.00
34 - ZonMw 1.00
51 - ULIV 1.00
Page 62 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP5 effort
54 - AP-HP 1.00
57 - UKL-HD 1.00
75 - EATRIS 1.00
77 - EURORDIS 1.00
80 - Blackswan 12.00
Total 89.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Websites,
D5.1 EJP RD website 1 - INSERM patents Public 2
filling, etc.
Websites,
D5.2 EJP RD Newsletter 1 - INSERM patents Public 2
filling, etc.
First RE(ACT) Congress
D5.3 80 - Blackswan Report Public 16
report
Second RE(ACT)
D5.4 80 - Blackswan Report Public 30
Congress report
Third RE(ACT)
D5.5 80 - Blackswan Report Public 54
Congress report
Description of deliverables
D83: EJP RD website (M2)
D84: EJP RD Newsletter (M2)
D85, D86 and D87: RE(ACT) Congress report (M16, M30, M54)
D5.1 : EJP RD website [2]
EJP RD website
D5.2 : EJP RD Newsletter [2]
EJP RD Newsletter
D5.3 : First RE(ACT) Congress report [16]
First RE(ACT) Congress report due at M16
D5.4 : Second RE(ACT) Congress report [30]
Second RE(ACT) Congress report due at Month 30
D5.5 : Third RE(ACT) Congress report [54]
Third RE(ACT) Congress report due at month 54
Page 63 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
EJP RD social media pack set Relevant social media
MS15 1 - INSERM 2
up and running accounts
Decision on the organization
Minutes of the relevant
MS16 of the RE(ACT) 2020 1 - INSERM 4
ExCom conference call
congress
Decision on the organization
Minutes of the relevant
MS17 of the RE(ACT) 2022 1 - INSERM 18
ExCom conference call
congress
Decision on the organization
Minutes of the relevant
MS18 of the RE(ACT) 2024 1 - INSERM 42
ExCom conference call
congress
Target countries and
List of target countries and
MS19 voluntary helpers for 1 - INSERM 2
voluntary helpers
translated Newsletter agreed
Page 64 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP6 Lead beneficiary 10 15 - DLR
Work package title Joint Transnational Calls for collaborative research projects
Start month 1 End month 60
Objectives
The funding of transnational collaborative research is critical to enhance the cooperation between scientists working
on rare diseases across Europe and beyond, and thus reduce the fragmentation of research in this field. Therefore, the
central Pillar 1 activity is providing financial support to third parties.
WP1 will foster the implementation of four joint transnational calls for research projects combining national/regional
funding and EC co-funding. Transnational calls including basic, translational, clinical, social and health economic
research topics will be included in the overall research agenda for the five years of the EJP RD. The first two calls
should have broad topics to enable the widest participation of funding organizations. It is expected that at least 60 Mio
€ will be spent to research projects in the four calls.
Specific objectives are:
Implementation of four joint transnational calls for research projects combining national/regional funding and EC co-
funding which include the tasks:
● Topic selection
● Preparation of the call and establishment of the joint call secretariat
● Evaluation of the joint call and funding decision
● Quality management of call procedures
Description of work and role of partners
WP6 - Joint Transnational Calls for collaborative research projects [Months: 1-60]
DLR, FWF, FNRS, MOSAE, AKA, ANR, FFRD, NKFIH, HRB, IT-MOH, TuscReg, FRRB, MIUR, LMT, FNR,
ZonMw, NCBR, FCT, SAS, ISCIII, SRC, VINNOVA, EURORDIS, CSO-MOH, SNSF, TUBITAK, GSRT, DFG
The Joint Transnational Calls (JTCs) will be implemented using the “virtual common pot” funding mode. This means
that national/regional funding will be made available through national/regional funding organisations according to their
own regulations. In addition, in two Joint Transnational Calls the EC will also provide funding that will maximize
the number of selected projects that can be funded. Each country/region will fund only their own national/regional
component of the transnational research project. Funding from the EC will be distributed through the national/regional
funding agencies. The participation in each call will be negotiated between the EJP Pillar 1 funding agency partners
on the basis of their possible funding commitments, taking into account the principle of variable geometry (i.e. that
each partner decides to join one, several or all planned calls on the basis of their political and financial possibilities and
commitments). Moreover, funding bodies (agencies, patient organizations, charities) not belonging to the EJP RD will
also have the possibility to support the calls and provide additional funding.
The representatives of the participating funding agencies in a joint call will constitute the call steering committee (CSC),
which is in charge of deciding on the final topic (based on inputs from Task 2.3) selection and the specific design of the
joint call. The CSC will also be the monitoring body for all actions taken by the acting joint call secretariat (JCS). The
implementation of transnational research funding will be streamlined according to the lessons learned in the previous
E-Rare JTCs and will be built on the established procedures and underlying documents. Due to the yearly overlapping
of the joint calls the JCS responsibility will be shared between four partners (DLR-PT, Germany; ANR, France; FFRD,
France; ISCIII, Spain) in order to distribute the workload and ensure good practice. Three partners have experience in
managing joint transnational calls in several ERA-Nets, including E-Rare, or other transnational initiatives.
Most importantly, the incorporation of the joint transnational calls within the broader EJP RD ecosystem provides a
unique opportunity for synergies between the individual research projects (Pillar 1) and the supporting resources and
tools (Pillars 2-4) since successful research projects will be supported by and will make use of the methodologies, tools
and resources made available through Pillars 2-4 (strong recommendations on Data Management Plan, use of Pillar 2
Virtual Platform and links to other relevant activities of the EJP RD will be explicit).
Task 6.1 1st co-funded Joint Transnational Call (JTC 2019) (M1-M12)
TL: DLR; Participants: all participants in the call
Subtask 6.1.1 Topic selection and eligibility criteria (M1)
TL: DLR; Participants: all partners joining the call
Page 65 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
As indicated above the topics of co-funded calls will be broad topics to enable the widest participation of funding
organizations. The call will focus on implementing IRDiRC objectives. Special consideration will be given to avoid
duplication with Horizon 2020 calls in the area of rare diseases. The final formulation of the topics will be undertaken
by the CSC pending approval by the EC Project Officer.
Subtask 6.1.2 Preparation of the call and establishment of the joint call secretariat (M1-M2)
STL: DLR; Participants: all partners joining the call
The task leader will be responsible for drafting and finalizing all necessary documents: Memorandum of Understanding,
Call text, Governance and evaluation procedures, Guidelines for applicants and Proposal templates. Previous versions
of these documents already established within E-Rare-3 ERA-Net and validated by the Commission, will efficiently be
used as templates. In addition, the task leader will set up the JCS. The JCS will act as central support to the applicants
regarding all aspects of proposal drafting and submission. Finally, each participating funding organization will establish
its national contact point. Potential applicants will be strongly encouraged to contact their national representative for
advice on national rules and regulations, including eligibility and financial budget regulations.
The call for proposals will be published on the EJP RD website and by the national funding organizations via their
national publishing routines such as websites, newsletters, press announcements. The publishing instruments of the EC
like the Participant Portal and ERA-LEARN will be used as well. If feasible and necessary, a call pre-announcement
will be published to maximize the early mobilization of the rare diseases research community. The EC will be duly
notified of the call and its content at least 30 days before the expected date of publication. The call will be opened for
the submission of proposals for at least 60 days.
Subtask 6.1.3 Evaluation of the joint call (M1-M10)
STL: DLR; Participants: all partners joining the call
The evaluation will be implemented in a two-step procedure according to the Horizon 2020 rules. The eligible
applications will first undergo national eligibility check and then be submitted to the transnational peer review Scientific
Evaluation Committee (SEC) composed of independent expert scientists chosen for their scientific, technical and/or
disease-specific expertise, as well as patient representatives. The Committee will be as far as possible gender and
geographically balanced, including experts from countries participating and not participating in the call, experienced
(i.e. previous SEC members) as well as new members. Reviewers will be carefully selected with regard to any potential
conflict of interest. Each pre-proposal will be reviewed by two SEC members with expertise in line with the proposal.
The full proposals will be reviewed by at least five independent experts: two (remote) external specialists of the disease
and/or approach and three members of the previously established SEC. In addition, an independent expert will be invited
as official observer to the second SEC meeting to assess the conformity of the general implementation of the joint call
and specifically the proper implementation of the international peer review and establishment of the ranking list of
transnational projects. The evaluation and selection process will ensure that the H2020 framework for ethics is fully
applied to the funded projects. The assessment of the observer will be provided in a report to the European Commission.
Subtask 6.1.4: Funding decision (M10-M12)
STL: DLR; Participants: all partners joining the call
The CSC will take its final funding decision based strictly on the scientific recommendation of the SEC (ranking list). As
many full proposals as possible with a clear funding recommendation will be funded, taking into account the available
budget. Each eligible applicant will be funded by the organization of the country from which the applicants have applied
and according to the national administrative regulations (virtual common pot model). The final distribution of the EC
contribution will be discussed and agreed by the CSC in order to maximize the number of high quality proposals to
be funded by filling funding gaps and/or topping up the national contributions (mixed model). This will be done in
accordance to the general criteria fixed in advance to the launch of the call to avoid the underestimation of national
budgets and to permit a balanced distribution of the EC contribution in line with the national funding. If proposals have
identical scores, the proposals coming from participating Member States or associated countries with still available
funding will be given precedence, in order to further maximize the number of selected projects. The joint selection list of
projects to be funded will be communicated to the EC. The applicants will be informed about the final funding decision
and the national negotiations will commence. The final funding list will be prepared by the JCS and provided to WP5
for publication on the EJP RD website and Newsletter, the relevant EC portals as well as the IRDiRC webpage.
Subtask 6.1.5 Quality management of call procedures (M1-M12)
STL: DLR; Participants: all partners joining the call
The practicability of administrative and operational mechanisms used for implementation of calls, peer review, funding
of projects and scientific follow up will be monitored by the JCS with feedback from all participating stakeholders.
The lessons learned will feed the call design and implementation of the next joint calls. Thus, the evolution of robust
and functional administrative and operational practices will be facilitated and continual process improvement will
be implemented. Results of this quality management process will be incorporated in the lessons learned reports for
individual calls and presented to the CSC. In addition, detailed statistics and information of the submitted, pre-selected,
recommended and funded proposals will be collected and made available on the demand of the European Commission.
Page 66 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Task 6.2 – 6.4 Joint Transnational Calls 2020-22
TL: DLR
In general, the description of work for the other calls is analogous to the first call described above. Lessons learned from
the first call and strategic input from the other work packages will be taken into account for all the steps included in
these calls. Identification of topics for subsequent calls (2020 – 2022) will be based on the procedure described in the
transversal strategy WP and will include multi-stakeholder input from the rare disease community inside and outside
the EJP as well as IRDiRC and lessons learned from previous E-Rare calls. Each time the topics and call procedures
will be submitted in advance to the EC for validation.
Task 6.2 2nd co-funded Joint Transnational Call (JTC 2020) (M4-M24)
TL: ANR; Participants: all participants in the call
Task 6.3 3rd Joint Transnational Call (JTC 2021) not co-funded by the EC (M16-M36)
TL: FFRD; Participants: all partners joining the call
Task 6.4 4th Joint Transnational Call (JTC 2022) not co-funded by the EC (M28-M48)
TL: ISCIII; Participants: all partners joining the call
Participation per Partner
Partner number and short name WP6 effort
2 - FWF 3.00
5 - FNRS 3.00
9 - MOSAE 3.00
10 - AKA 3.00
11 - ANR 15.40
12 - FFRD 12.40
15 - DLR 21.40
19 - NKFIH 3.00
20 - HRB 3.00
21 - IT-MOH 3.00
22 - TuscReg 3.00
23 - FRRB 3.00
29 - MIUR 3.00
31 - LMT 3.00
33 - FNR 3.00
34 - ZonMw 3.00
37 - NCBR 3.00
41 - FCT 3.00
43 - SAS 3.00
44 - ISCIII 12.40
48 - SRC 3.00
49 - VINNOVA 3.00
77 - EURORDIS 3.00
78 - CSO-MOH 3.00
79 - SNSF 3.00
Page 67 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP6 effort
81 - TUBITAK 3.00
87 - GSRT 3.00
88 - DFG 3.00
Total 133.60
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
First Confidential
Call documents: Confidential, only
memorandum of for members of the
D6.1 understanding, 15 - DLR Report consortium (including 1
governance of the call the Commission
and evaluation document Services)
JTC2019-2022
Second Confidential
Call documents: Confidential, only
memorandum of for members of the
D6.2 understanding, 11 - ANR Report consortium (including 11
governance of the call the Commission
and evaluation document Services)
JTC2019-2022
Third Confidential
Call documents: Confidential, only
memorandum of for members of the
D6.3 understanding, 12 - FFRD Report consortium (including 23
governance of the call the Commission
and evaluation document Services)
JTC2019-2022
Fourth Confidential
Call documents: Confidential, only
memorandum of for members of the
D6.4 understanding, 44 - ISCIII Report consortium (including 35
governance of the call the Commission
and evaluation document Services)
JTC2019-2022
First Public
Call documents
D6.5 JTC2019-2022: call text, 15 - DLR Report Public 1
guidelines for applicants,
proposal templates
Second Public
Call documents
D6.6 JTC2019-2022: call text, 11 - ANR Report Public 11
guidelines for applicants,
proposal templates
Page 68 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Third Public
Call documents
D6.7 JTC2019-2022: call text, 12 - FFRD Report Public 23
guidelines for applicants,
proposal templates
Fourth Public
Call documents
D6.8 JTC2019-2022: call text, 44 - ISCIII Report Public 35
guidelines for applicants,
proposal templates
Confidential, only
First Joint selection list for members of the
D6.9 of the projects to be 15 - DLR Report consortium (including 10
funded JTC2019-2022 the Commission
Services)
Confidential, only
Second Joint selection for members of the
D6.10 list of the projects to be 11 - ANR Report consortium (including 22
funded JTC2019-2022 the Commission
Services)
Confidential, only
Third Joint selection for members of the
D6.11 list of the projects to be 12 - FFRD Report consortium (including 24
funded JTC2019-2022 the Commission
Services)
Confidential, only
Fourth Joint selection for members of the
D6.12 list of the projects to be 44 - ISCIII Report consortium (including 46
funded JTC2019-2022 the Commission
Services)
Description of deliverables
D88 to D91: Confidential Call documents: memorandum of understanding, governance of the call and evaluation
document JTC2019-2022 (M1, M11, M23, M35)
D92 to D95: Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates (M1, M11,
M23, M35)
D96 to D99: Joint selection list of the projects to be funded JTC2019-2022 (M10, M22, M24, M46)
D6.1 : First Confidential Call documents: memorandum of understanding, governance of the call and evaluation
document JTC2019-2022 [1]
Other lead beneficiaries: ANR (11), FFRD (12), ISCIII (44) Confidential Call documents: memorandum of
understanding, governance of the call and evaluation document JTC2019-2022 due at month 1
D6.2 : Second Confidential Call documents: memorandum of understanding, governance of the call and evaluation
document JTC2019-2022 [11]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of
understanding, governance of the call and evaluation document JTC2019-2022 due at month 11
D6.3 : Third Confidential Call documents: memorandum of understanding, governance of the call and evaluation
document JTC2019-2022 [23]
Page 69 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of
understanding, governance of the call and evaluation document JTC2019-2022 due at month 23
D6.4 : Fourth Confidential Call documents: memorandum of understanding, governance of the call and evaluation
document JTC2019-2022 [35]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of
understanding, governance of the call and evaluation document JTC2019-2022 due at month 35
D6.5 : First Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [1]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text,
guidelines for applicants, proposal templates due at month 1
D6.6 : Second Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [11]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text,
guidelines for applicants, proposal templates due at month 11
D6.7 : Third Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [23]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text,
guidelines for applicants, proposal templates due at mont 23
D6.8 : Fourth Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [35]
Other lead beneficiaries ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text,
guidelines for applicants, proposal templates due at month 35
D6.9 : First Joint selection list of the projects to be funded JTC2019-2022 [10]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded
JTC2019-2022 due at month 10
D6.10 : Second Joint selection list of the projects to be funded JTC2019-2022 [22]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded
JTC2019-2022 due at month 22
D6.11 : Third Joint selection list of the projects to be funded JTC2019-2022 [24]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded
JTC2019-2022 due at month 24
D6.12 : Fourth Joint selection list of the projects to be funded JTC2019-2022 [46]
Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded
JTC2019-2022 due at month 46
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Page 70 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP7 Lead beneficiary 10 34 - ZonMw
Work package title Networking to share knowledge on rare diseases
Start month 1 End month 60
Objectives
The main objective of this work package is to encourage sharing of knowledge on rare diseases of clinicians,
(biomedical) scientists and patient (organization[s]) by implementing a Networking support scheme. The scheme will
provide financial support to third parties for fostering organization of workshops or conferences to support new research
networks or strengthening existing research networks, to enable exchange of knowledge. It is expected that these new
or improved networks may lead to future collaborative research efforts, e.g. by applying to research funding within the
EJP RD (e.g. Joint Transnational Calls), to COST actions or Marie Skłodowska-Curie Actions (mobility and training
calls). A budget of 2 M€ is foreseen to finance about 70 networking grants.
Specific objectives are:
● Establishment of the Networking scheme
● Early assessment of the Networking scheme and further improvement
Description of work and role of partners
WP7 - Networking to share knowledge on rare diseases [Months: 1-60]
ZonMw, VIAA, SRC, EURORDIS, CSO-MOH, TUBITAK
Task 7.1: Development of the Networking scheme (M1-M7)
TL: CSO-MoH, ZonMw, Participants: CIHR, TUBITAK
The experience of several countries (e.g. Netherlands or France) shows that networking schemes developed at national
scale are of added value and generate positive results . Taking the example of these initiatives, the EJP RD proposes
to implement the support for networking at European/international level. Financial support will be provided through
competitive calls to foster networking of rare disease stakeholders to (list not exhaustive):
• Share existing knowledge on a specific (group of) rare disease(s) or on cohorts of undiagnosed patients that are
suspected of suffering from a rare disease/rare diseases;
• Improve the knowledge on rare disease(s);
• Encourage further innovation and research, e.g. by preparing an application for another networking grant, training
grant or research grant in an EC or other international programme;
• Share knowledge and best practices on data sharing (Pillar 2) and /or to promote novel/validated methodological
approaches for clinical research (including clinical trials) (Pillar 4).
It is expected that networks of researchers/clinicians and patient organizations from countries involved in the EJP RD
will be eligible to apply. The consortia should include beneficiaries from at least three different eligible countries at the
time of application. Additional partners, from countries not involved in the EJP RD, may be also part of the consortium,
depending on the scope of the networking event. However, they will not be eligible to directly receive funds. There
will be no limitation in the number of participants. Nonetheless, the maximum grant amount will be limited to 30 000
€ for each funded networking event.
Documents for the application and evaluation procedure will be developed within the first semester of the EJP RD and
will be submitted for validation of the EC before opening of the call. The call will be published widely through the
same channels as the Joint Transnational Calls (WP6).
Task 7.2: Application and evaluation of proposals for the Networking Scheme (M7-M60)
TL: ZonMw, Participants: CSO-MOH, EURORDIS, VIAA, SRC, TUBITAK
An existing electronic submission system provided by one of the involved participants will be chosen and modified
to the needs of the Networking scheme. The application system will be open permanently, but the proposals will be
collected every three months for evaluation by a Committee of independent experts issued from funding agencies and
EURORDIS. The dates of collection of the proposals for each evaluation session as well as changes will be clearly
communicated to interested applicants. Applicants may apply for a budget for a networking event more than once. The
principal investigator will receive the funding on behalf of the consortium and will be the responsible person for the
internal management of the consortium. The budget has to be spent within a year after receiving the grant. Funded
applicants will be bound to communicate the dates and information on the organized event at least two months in
advance for the dissemination purposes by the EJP RD (WP5). In addition, the funded applicants will have to deliver
Page 71 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
a final (public) report after the meeting. These reports will be monitored and assessed (Pillar 1 Task WP9.2) and used
for dissemination and communication purposes (WP5).
The evaluation procedure will respect Horizon 2020 rules and evaluation criteria (excellence, impact & quality and
efficiency of implementation). Proposals will be ranked according to the evaluation results. It is expected that about
15 projects will be granted per year. An independent expert will be invited as official observer to the evaluation
session after the first subsidy round and after the fifth subsidy round (see Task 7.3) to assess the conformity of the
general implementation of the Networking scheme and establishment of the ranking list of transnational networks. The
assessments of the observer will be provided in a report to the European Commission.
The management of grants will be ensured by ZonMw that will be responsible for collection of the applications at each
deadline, supporting the Evaluation Committee and communication with the applicants, including sending the budget
for the meetings to the granted applicants. The ZonMw grant terms and conditions will be applied for the management
of the grants.
Task 7.3 Early assessment of the Networking scheme (M21-M24)
TL: CSO-MOH, ZonMw; Participants: CIHR, TUBITAK
After four subsidy rounds the Networking scheme will be assessed to analyze whether it meets its objectives. This will be
done in collaboration with WP1 Task 1.3 (Monitoring). In addition, “lessons learned” from the quarterly implementation
and evaluation process will serve for improvement of next rounds
Participation per Partner
Partner number and short name WP7 effort
30 - VIAA 1.00
34 - ZonMw 13.20
48 - SRC 1.00
77 - EURORDIS 1.00
78 - CSO-MOH 3.20
81 - TUBITAK 2.00
Total 21.40
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential Call
Confidential, only
document for Evaluation
for members of the
Committee for
D7.1 34 - ZonMw Report consortium (including 7
Networking scheme
the Commission
including set of criteria
Services)
for evaluation
Public Call document for
D7.2 34 - ZonMw Report Public 7
Networking scheme
First List of funded
D7.3 networks in Networking 34 - ZonMw Report Public 21
scheme
Second List of funded
D7.4 networks in Networking 34 - ZonMw Report Public 54
scheme
Page 72 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
First Confidential Confidential, only
Observers’ report on for members of the
D7.5 the evaluation of sets 34 - ZonMw Report consortium (including 12
of applications for the the Commission
Networking scheme Services)
Second Confidential Confidential, only
Observers’ report on for members of the
D7.6 the evaluation of sets 34 - ZonMw Report consortium (including 30
of applications for the the Commission
Networking scheme Services)
Description of deliverables
D100: Confidential Call documents for Evaluation Committee for Networking scheme, including set of criteria for
evaluation (M7)
D101: Public Call document for Networking scheme (M7)
D102 and D103: List of funded networks in Networking scheme (M21, M54)
D104 and D105: Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme
(M12, M30)
D7.1 : Confidential Call document for Evaluation Committee for Networking scheme including set of criteria for
evaluation [7]
Confidential Call document for Evaluation Committee for Networking scheme including set of criteria for evaluation
D7.2 : Public Call document for Networking scheme [7]
Other lead beneficiary: CSO/MOH (78) Public Call document for Networking scheme
D7.3 : First List of funded networks in Networking scheme [21]
List of funded networks in Networking scheme due at month 21
D7.4 : Second List of funded networks in Networking scheme [54]
List of funded networks in Networking scheme due at month 54
D7.5 : First Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme [12]
Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme due at month 12
D7.6 : Second Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme
[30]
Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme due at month 30
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Public Call document on
Implementation of
MS20 34 - ZonMw 7 website and announcement of
Networking scheme
the first round
Page 73 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP8 Lead beneficiary 10 12 - FFRD
Work package title Rare Disease Research Challenges
Start month 1 End month 60
Objectives
Main objectives:
● To solve specific Rare Disease Research (RDR) Challenges in the field of therapeutic development.
● To facilitate collaboration between academia and industry.
Description of work and role of partners
WP8 - Rare Disease Research Challenges [Months: 1-60]
FFRD, DLR, ZonMw, EATRIS, EURORDIS
Task 8.1: Development of the scheme (M1-M8)
TL: EURORDIS; Participants: FFRD, DLR, ZonMw, EATRIS, AFM
The RDR Challenges will be created based on the successful examples of other funding opportunities such as the
challenge-driven innovation scheme of Vinnova (https://www.vinnova.se/en/m/challenge-driven-innovation/) and UK
Crack-IT scheme (https://crackit.org.uk/crack-it-challenges)
The goal is to set up an innovative, rapid and efficient call for projects involving both industry and academia and
with strong incentive for all participants: facilitated pathway for academics to exploit their research and access to
scientific and technological innovations emerging from academic research for industry. The concept of the RDR
Challenge will need to be fit for the rare diseases field. This will be addressed in 2 multi-stakeholder workshops
gathering experienced/interested funders, experts in public-private partnerships from Pillar 4, industry representatives
and independent scientific experts. Industry representatives will be drawn from the EURORDIS Round Table of
Companies (ERTC; http://www.eurordis.org/ertc consisting of about 70 private companies), the companies that are
members of IRDiRC and/or EFPIA. Special attention will be given to alleviate risks of lengthy negotiations about
intellectual property rights, economical use of the results and safeguarding utilization, for example by developing a
model cooperation agreement. IP developed within the project will be the property of the contractor (Challenge winner)
and its sub-contractors. This WP will be closely connected to the Pillar 4 efforts aiming at public-private collaborations.
It is expected that industry will provide input by co-funding and/or in-kind contributions to the projects.
Task 8.2: Identification of challenges (M9-M12)
TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM
A multidisciplinary stakeholder committee including industry participants will be established to propose the Challenges
solvable in a short time period of 18 months with a possible 12-month extension.The final choice of challenges will be
based on predefined criteria e.g. viability, impact and time to impact, commercial potential/potential for uptake of the
technology, alignment with external activities, risk of Challenge not being solved, added value for RD community. The
Challenges that meet the criteria will be approved by the multidisciplinary stakeholder committee for use in the call.
The final chosen challenge(s) will be used to develop call documents.
Task 8.3: The call for projects, eligibility criteria and evaluation (M13-M56)
TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM
The opening of the RDR Challenges is foreseen for Year 2. As specified above the scheme will be refined and proposed
for validation of the Commission within Annual Work Plan for Y2. However, general principles and eligibility criteria
are presented below:
The RDR Challenges scheme foresees selection and funding of projects in a 4-stage process: (i) selection of most
promising proofs of concept (POCs) responding to the proposed challenge(s); (ii) funding of POCs for maximum of 18
months; (iii) evaluation of results of funded POCs and selection of projects passing to the second stage; (iv) funding
of selected projects for additional 12 months to finalize the challenge. All projects should involve the sponsor as co-
investor from the start. The expected co-funding from sponsors should be of at least 30%.
Financial support to third parties will be provided to academia and SMEs from countries participating in the EJP RD.
Since each application will have to involve the sponsor, EJP RD will organize a face-to-face networking meeting
for academia, SMEs and industry to initiate formation of future consortia in advance of the opening of the call.
The evaluation process will follow Horizon 2020 rules and criteria (Excellence, Impact, Quality and efficiency of
implementation). Projects will be assessed by a multidisciplinary Review Panel composed of independent experts.
Special attention will be given that the expertise of the review panel matches the challenges that will be addressed.
Page 74 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The two-stage selection process will be done by the same Review Panel.The projects will be financed based on the
established ranking list.
Task 8.4: Management of the funding resources, establishment of contracts and distribution of funding to selected
projects (M17-M50)
TL: FFRD
The maximum grant amount for the phase 1 POCs will be of 150 000 € and for the 2nd phase of 100 000 € The
administrative and legal action necessary for the distribution of the funding to the successful applicants of the call will
be performed by FFRD. The contractual obligations applied will be the ones of Horizon 2020 and will take into account
the necessary regulations including the required ethical, legal and data protection approvals.
Participation per Partner
Partner number and short name WP8 effort
12 - FFRD 16.50
15 - DLR 1.50
34 - ZonMw 1.50
75 - EATRIS 1.50
77 - EURORDIS 4.00
Total 25.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Confidential, only
for members of the
Report on multi-
D8.1 77 - EURORDIS Report consortium (including 8
stakeholder workshops
the Commission
Services)
Call documents for
D8.2 12 - FFRD Report Public 13
validation
List of first phase
D8.3 12 - FFRD Report Public 21
projects financed
Confidential, only
for members of the
List of second phase
D8.4 12 - FFRD Report consortium (including 43
projects financed
the Commission
Services)
Description of deliverables
D106: Report on multi-stakeholder workshops for RDR Challenges (M8)
D107: Call documents for RDR Challenge scheme for validation (M13)
D108: List of first phase challenge projects financed (M21)
D109: List of second phase challenge projects financed (M43)
D8.1 : Report on multi-stakeholder workshops [8]
Report on multi-stakeholder workshops
D8.2 : Call documents for validation [13]
Page 75 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Call documents for validation
D8.3 : List of first phase projects financed [21]
List of first phase projects financed
D8.4 : List of second phase projects financed [43]
List of second phase projects financed
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Multi-stakeholder workshops
Report from RDR Challenges
MS21 to set-up RDR Challenges 77 - EURORDIS 8
workshops
scheme
Page 76 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP9 Lead beneficiary 10 78 - CSO-MOH
Work package title Monitoring of funded projects
Start month 1 End month 60
Objectives
The proposed subsidy schemes, granted projects and granted networks in Pillar 1 and the previous E-Rare projects have
to be monitored for progress and results of Pillar 1 funding schemes. Monitoring of the results of the different granted
projects is necessary to measure their outcomes and ensure an adequate use of resources. The results of the monitoring
will be communicated to the coordination and communication office for further dissemination in the transversal activities
within the EJP and for dissemination outside the EJP. In addition, there will be a close collaboration with Pillar 4 to
enhance the translational development of the funded project results from WP1.
Description of work and role of partners
WP9 - Monitoring of funded projects [Months: 1-60]
CSO-MOH, FNRS, FFRD
Task 9.1 Monitoring of Joint Transnational Calls for collaborative research projects (M1-M60)
TL: CSO-MoH, DLR; Participants: FNRS, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the
monitored calls participate with 100% in kind personnel contribution for this activity)
All funded projects of WP6 will be required to complete an on-line questionnaire for monitoring annual progress and
a final report at the end of the funding period. The results of the projects follow-up and assessment will be presented
to the EJP RD funding partners every year. In addition, the coordinators and/or national/regional group leaders will be
asked to present the results of their projects at a mid-term monitoring meeting. In this midterm meeting, experts will
be invited to evaluate the progress of the funded projects. Representatives of the funding agencies will participate in
the meetings as well.
Subtask 9.1.1 Definition/Update of the indicators for ex-post evaluation of funded projects in each call (M1-M60)
STL: CSO-MoH, Participants: FNRS; DLR, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the
monitored calls participate with 100% in kind personnel contribution for this activity
Within the frame of E-Rare-3 a list of indicators was developed and applied to design the template for periodic and final
reports of funded projects. This set indicators will serve to establish and refine indicators for the EJP funded projects
and will need to be adapted to the specificities of the different call topics. The selected indicators will be embedded in
the design of the online reporting forms to be used in the follow-up and monitoring activities. Some examples include:
number of project-related publications, patents, new employees, established collaborations, etc.
Subtask 9.1.2 Adaptation of the monitoring tool for follow-up and assessment of funded projects (M1-M60)
STL: FNRS
The aim of this task is to adapt the online tool for reporting, monitoring, and assessment of all funded projects that was
developed in E-Rare-3. It will enable an easy collection and management of the reports of funded projects.
Subtask 9.1.3 Follow-up, monitoring and assessment of funded projects in WP6, including organization of mid-term
monitoring meetings for each Call (M1-M60)
STL: CSO-MoH, Participants: FCT, DLR, ANR, FFRD, ISCIII and all partners participating in the monitored calls
participate with 100% in kind personnel contribution for this activity
This task aims at both evaluating the progress and assessing the outputs of granted projects. It will be carried out in
close collaboration with the co-funded call secretariats (WP6). The funded projects will be followed up and monitored
through brief online annual progress reports and a final report at the end of the funding period. The results of the WP6
projects follow up and assessment will be analyzed by the STL and the summary of this analysis will be presented to
the WP6 partners every year. These results will also be available for analysis in the P4 innovation support activities.
Relevant outputs (e.g. publications, patents etc.) will be communicated through the central dissemination activities. In
addition, mid-term monitoring meetings will be set up for each call.
Subtask 9.1.4 Assessment of E-Rare 3 Joint Call Funding programme (M1-M48)
STL: CSO-MoH, Participants: FCT, ANR, ISCIII, ZonMw and all partners participating in the monitored calls
participate with 100% in kind personnel contribution for this activity
Analogous to subtask 9.1.3, the monitoring of projects funded in the E-Rare calls of 2017 and 2018 will be continued
and completed in this task.
Task 9.2 Monitoring of networking grants to share knowledge on rare diseases (M1-M60)
TL: CSO-MoH, ZonMw; Participants: FNRS, SRC, TUBITAK, VIAA, EURORDIS.
Page 77 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The granted applicants of all funded networking grants in P1WP7 will have to complete a short, standardized report
after the meeting has taken place. These reports will be monitored and also used for dissemination purposes (WP5 -
Communication and Dissemination). The report format will be customized using indicators (developed in Subtask 9.2.1)
and a specific on-line reporting form on an existing monitoring tool (adapted in subtask 9.2.2). The monitoring team
(consisting of the Task 9.2 leaders) will contact the granted applicant directly for information delivery and reporting
requests.
Subtask 9.2.1 Definition of indicators for ex-post evaluation of funded networking events (M1-M7)
STL: CSO-MoH, ZonMw; Participants: FNR,. SRC, TUBITAK, VIAA, EURORDIS
The monitoring team will define indicators for the ex-post evaluation of funded networking grants with help of the
Evaluation Committee that evaluates the applications of the networking scheme (Task 7.2).
Subtask 9.2.2 Adaptation of monitoring tool for follow-up and assessment of funded networking events (M1-M7)
STL: FNRS
For each call, a reporting template will be developed to be implemented within online existing monitoring tool. These
templates will facilitate the collection of the reports of the funded projects, their analysis and subsequent reporting.
Subtask 9.2.3 Assessment of the funded networking events (M13-M60)
STL: CSO-MoH, ZonMw
Follow-up, analysis and assessments of results of the networking grants and communication of the results to the EJP
RD management for dissemination. This monitoring of the results of the networking grants will regularly take place:
a report on the assessment of the first set of funded meetings will be written after four subsidy rounds for the early
assessment of the networking scheme (Task 7.3). Subsequently, two midterm monitoring reports will be written on the
assessment of the results of the second and third set of funded meetings and a final monitoring report.
Task 9.3. Monitoring of Rare Disease Research Challenge (M17-M56)
TL: CSO-MoH, FFRD; Participants: FNRS, EURORDIS, DLR, ZonMw, EATRIS, AFM participate with 100% in kind
personnel contribution for this activity
The granted applicants of the Rare Disease Challenges in WP8 will have to complete a report after finalizing the
two stages of the project. The report format will be customized using relevant indicators (to be established). In
addition, the achievement of defined milestones will be closely monitored. The monitoring team will contact directly
the granted applicants for information delivery and reporting request. The reports will be used to facilitate the uptake,
implementation or further development of the solutions by industry or other stakeholders.
Participation per Partner
Partner number and short name WP9 effort
5 - FNRS 4.00
12 - FFRD 1.00
78 - CSO-MOH 20.00
Total 25.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
Refined list of indicators for members of the
D9.1 for monitoring of JTC 78 - CSO-MOH Report consortium (including 5
funded project the Commission
Services)
Confidential, only
First Year report on
D9.2 78 - CSO-MOH Report for members of the 28
progress assessment of
consortium (including
Page 78 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
JTC 2019, 2020 and 2021 the Commission
projects Services)
Confidential, only
Second Yearly reports on
for members of the
progress assessment of
D9.3 78 - CSO-MOH Report consortium (including 40
JTC 2019, 2020 and 2021
the Commission
projects
Services)
Confidential, only
Third Yearly reports on
for members of the
progress assessment of
D9.4 78 - CSO-MOH Report consortium (including 52
JTC 2019, 2020 and 2021
the Commission
projects
Services)
First Final assessment
Confidential, only
report of E-Rare-3
for members of the
JTC 2016, JTC 2017,
D9.5 78 - CSO-MOH Report consortium (including 35
JTC 2018 projects and
the Commission
the EJP RD JTC 2019
Services)
projects
Second Final assessment
Confidential, only
report of E-Rare-3
for members of the
JTC 2016, JTC 2017,
D9.6 78 - CSO-MOH Report consortium (including 47
JTC 2018 projects and
the Commission
the EJP RD JTC 2019
Services)
projects
Third Final assessment
Confidential, only
report of E-Rare-3
for members of the
JTC 2016, JTC 2017,
D9.7 78 - CSO-MOH Report consortium (including 59
JTC 2018 projects and
the Commission
the EJP RD JTC 2019
Services)
projects
Confidential, only
List of indicators for members of the
D9.8 for monitoring of 78 - CSO-MOH Report consortium (including 7
Networking grants the Commission
Services)
First Report on the
assessment of results of Confidential, only
a 1st, 2nd and 3rd set for members of the
D9.9 of funded Networking 78 - CSO-MOH Report consortium (including 24
events and a final general the Commission
report on all funded Services)
Networking events
Second Report on the Confidential, only
assessment of results of for members of the
D9.10 a 1st, 2nd and 3rd set 78 - CSO-MOH Report consortium (including 39
of funded Networking the Commission
events and a final general Services)
Page 79 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
report on all funded
Networking events
Third Report on the
assessment of results of Confidential, only
a 1st, 2nd and 3rd set for members of the
D9.11 of funded Networking 78 - CSO-MOH Report consortium (including 59
events and a final general the Commission
report on all funded Services)
Networking events
Confidential, only
for members of the
List of indicators for RD
D9.12 78 - CSO-MOH Report consortium (including 21
funded challenges
the Commission
Services)
Confidential, only
Report on the assessment for members of the
D9.13 of 1st phase results of the 78 - CSO-MOH Report consortium (including 39
challenges the Commission
Services)
Confidential, only
Report on the assessment for members of the
D9.14 of 2nd phase results of 78 - CSO-MOH Report consortium (including 54
the challenges the Commission
Services)
Description of deliverables
D110: Refined list of indicators for monitoring of JTC funded project (M5)
D111 to D113: Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects (M28, M40, M52)
D114 to D116: Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC
2019 projects (M35, M47, M59)
D117: List of indicators for monitoring of Networking grants (M7)
D118 to D120: Reports on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final
general report on all funded Networking events (M24, M39, M59)
D121: List of indicators for RD funded Challenges (M21)
D122: Report on the assessment of 1st phase results of the RD challenges (M39)
D123: Report on the assessment of 2nd phase results of the RD challenges (M54)
D9.1 : Refined list of indicators for monitoring of JTC funded project [5]
Refined list of indicators for monitoring of JTC funded project
D9.2 : First Year report on progress assessment of JTC 2019, 2020 and 2021 projects [28]
Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 28
D9.3 : Second Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects [40]
Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 40
D9.4 : Third Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects [52]
Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 52
D9.5 : First Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019
projects [35]
Page 80 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
First Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects
due at month 35
D9.6 : Second Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC
2019 projects [47]
Second Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019
projects due at month 47
D9.7 : Third Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019
projects [59]
Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects at
month 59
D9.8 : List of indicators for monitoring of Networking grants [7]
Other lead beneficiary: ZonMW (34) List of indicators for monitoring of Networking grants
D9.9 : First Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final
general report on all funded Networking events [24]
Other lead beneficiary: ZonMW (34) Reports on the assessment of results of a 1st, 2nd and 3rd set of funded
Networking events and a final general report on all funded Networking events due at month 24
D9.10 : Second Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final
general report on all funded Networking events [39]
Other lead beneficiary: ZonMW (34) Second Report on the assessment of results of a 1st, 2nd and 3rd set of funded
Networking events and a final general report on all funded Networking events due at month 39
D9.11 : Third Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final
general report on all funded Networking events [59]
Other lead beneficiary: ZonMW (34) Third Report on the assessment of results of a 1st, 2nd and 3rd set of funded
Networking events and a final general report on all funded Networking events due at month 59
D9.12 : List of indicators for RD funded challenges [21]
List of indicators for RD funded challenges
D9.13 : Report on the assessment of 1st phase results of the challenges [39]
Other lead beneficiary FFRD (12) Report on the assessment of 1st phase results of the challenges
D9.14 : Report on the assessment of 2nd phase results of the challenges [54]
Other lead beneficiary: FFRD (12) Report on the assessment of 2nd phase results of the challenges
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Adapted monitoring tool
Link to monitoring tool
MS22 implemented for collaborative 5 - FNRS 9
released to granted applicants
research projects
Adapted monitoring tool
Link to monitoring tool
MS23 implemented for Networking 5 - FNRS 9
released to granted applicants
grants
Final reports of Rare disease
MS24 challenge projects delivered 78 - CSO-MOH 54 Final reports
to monitoring tool
Page 81 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP10 Lead beneficiary 10 1 - INSERM
Work package title User-driven strategic planning and transversal activities for Pillar 2 data ecosystem
Start month 1 End month 60
Objectives
The overall objective of this WP is to provide a unifying coordination effort that places users, not least ERNs, in a central
strategic position in Pillar 2. Research Infrastructures (RIs) will be key in addressing quality and sustainability/upscaling
challenges. WP10 will have special importance in optimising the activities and the quality of work conducted by WP11
(about metadata and centralised data resources), WP12 (about record level and federated solutions), and WP13 (about
filling gaps in data and analysis methods regarding heterogeneous RD data). This WP will thus help Pillar 2 to build
and iteratively test the desired Virtual Platform (VP) for efficient deposition, discoverability, access, and advanced use
of RD data, samples, patients, tools and resources. EJP RD will thereby progressively reduce fragmentation of effort,
accelerate scientific progress, shorten the diagnostic odyssey, and expand treatment possibilities.
Specific objectives include:
● Continuously track the utility of Pillar 2 outputs compared to RD community needs
● Iteratively refine a strategic plan guiding Pillar 2 activities to meet real-world needs
● Establish and apply quality management and GDPR compliance by design for WP11/12/13 operations
● Evaluate models to sustain and scale-up the use of the virtual platform and FAIRification support services
Description of work and role of partners
WP10 - User-driven strategic planning and transversal activities for Pillar 2 data ecosystem [Months: 1-60]
INSERM, FTELE, ISS, UM, INSA, CNAG-CRG, ULEIC, UKL-HD, LUMC, BBMRI, EMBL
WP Methodology
WP10 will base its work on methodologies that consult and empower the relevant RD communities, in particular ERNs.
Actions will be ongoing, but based around annual cycles of tracking progress and needs in parallel (via TCs, surveys,
interviews, virtual platform impact and quality assessments, etc), with a final bringing together of all these aspects in an
large community retreat, to produce guidance on prioritizations and adjustments for the following year. Annual retreats
will also entail field-testing of developed systems, by working on specific use-cases proposed by ERNs and by Pillar 4
partners. Hence listening, distilling and strategic planning are core elements of this WP.
Task 10.1: Convene yearly retreats leading to Pillar 2 annual strategic plans (M1-M60)
TL:INSERM (Orph) [STLs: ISS, INSERM (Orph), ULEIC] Other: [contribute to annual retreat, design and draft annual
strategic plan] All ERNs, CNAG-CRG, LUMC, UM, UKL-HD
This Task will ensure that the direction of developments in WP11 and WP12 are iteratively adjusted to meet the needs
of the RD community. Additionally, and critically, in the first two years of the project, the goal will also be to identify
and ensure prioritisation of work towards proof of principle demonstrators to validate the core functionalities that Pillar
2 seeks to create, and to prioritize proof-of-concept studies to be performed in WP13 allowing for integrative systems
biology approaches for rare diseases.
Based on the lessons learned during the continuous monitoring of pillar 2 WPs, and on the feedback from the community
provided in Task 10.2, as well as on the needs and expectations of the ERNs community, back-and-forth discussions will
be organized between the users and builders of Pillar 2, so that gaps, risks and opportunities can be agreed and specific
actions triggered. This will occur via a transparent and inclusive process, with ERNs in the driving seat for making
these decisions (as main users of the data and resource ecosystem created in Pillar 2). The mechanism will involve two
activities, both occurring once per year: Subtask 10.1.1 (“Whole-RD-community annual retreat”) will take place over
approximately 3 days each May, involve 24 ERNs plus Pillar 2 WPs contributors and Pillar 4 representatives, and be
open to others who wish to attend (space allowing); and Subtask 10.1.2 (“Annual strategic plan for Pillar 2”) whereby a
multi-stakeholder strategy board will refine the Pillar 2 workplan, guided by recommendations from the annual retreat,
as well on the analysis of the state of the art of resources that already exist, to be put into action by WP leaders. The
updated Pillar 2 workplan will itself contribute to the EJP RD Annual workplan (Coordination WP2). In addition, annual
retreats will include field-testing exercises, by organizing use case based, end-users live tests of the virtual platform
functionalities in order to adjust developments and to monitor usefulness.
Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60)
TL: ULEIC [STL: FTELE, CNAG-CRG] Other: [conduct surveys/interviews, contribute to TCs and surveys/interviews]
All ERNs, INSERM (Orph), LUMC, UM, INSA, UKL-HD
Page 82 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
This Task will gather and summarize the information needed to simultaneously assess Pillar 2 WPs outputs against RD
community needs. Specifically, we will undertake Subtask 10.2.1 (”Bi-monthly TCs and reports with WPs leaders”),
leading to regular progress reports that are properly documented and made promptly available to the EJP consortium. In
parallel, to expose and track the evolving needs of the RD community, we will undertake Subtask 10.2.2 (”Community
surveys and structured interviews”) on a continual basis throughout the project, focused on technical, scientific and
strategic requirements and how the outputs of Pillar 2 are or are not serving the community. ERNs will be centrally
involved in advising, designing and responding to these activities, as well as Pillar 4 partners, in order to ensure Pillar
2 activities are optimised to enable innovation.
Task 10.3: Coordination of technical GDPR implementation (M1-M60)
TL: BBMRI, ELIXI;, Other: [explore and advise re GDPR] INSERM (RaDiCo), CNAG-CRG, LUMC, ULEIC
In collaboration with all the Pillar 2 contributors and according to the EJP policy established in Transversal WP4,
this task will identify and document personal data processing, including legal basis and technical and organizational
safeguards implemented. Methodology will be developed for risk assessment, including assistance with DPIA to the
extent needed. The task will provide technical guidance to WP11, WP12 and WP13 to ensure consistent implementation
of security and privacy by design in the software and services delivered by Pillar 2.
Task 10.4: Quality oversight (M1-M60)
TL: BBMRI, ELIXIR; Other: [establish & deploy formalised quality policy] All ERNs, INSERM (RaDiCo), INSERM
(Orph), CNAG-CRG, LUMC, ULEIC
This task will analyze processes and services delivered within Pillar 2 and propose a quality management system (QMS)
to assist with complying with user requirements and to ensure quality of services delivered. Specific aspects include
documenting user requirements, software design and development (including software development best practice ),
operation of services. The FitSM lightweight IT service management standard will be assessed for this purpose, as it
has been already used in EOSCpilot and EOSC-hub projects. The QMS will define performance indicators and monitor
them in regular improvement cycles. The code developed within the project will undergo peer review in order to provide
feedback to developers.
Task 10.5: Sustainability and scaling up (M1-M60)
TL: DTL-Projects (ELIXIR-NL), Other: [design sustainability options] ELIXIR, FTELE, INSERM (RaDiCo), INSERM
(Orph), BBMRI, CNAG-CRG, LUMC, ISS, ULEIC
This task will investigate financing models to sustain and scale up the development and use of the virtual platform (VP)
and its support services, in close collaboration with sustainability experts in the EJP RD transversal WP3, the RIs, the
European Open Science Cloud project (EOSC), experts associated with RDA, and the international GO FAIR offices
(currently in the Netherlands, Germany, and France, with an RD implementation network starting in 2018). This task
will explore needs, opportunities and methods for sustaining and scaling up each VP component and service judged
to be useful by the EJP RD community, and map this to a financing model matrix developed by Transversal WP3. By
eliciting real costs of the VP activities, selected models will be simulated and evaluated with sustainability experts,
potential payers (e.g. funders, ERN HCPs, patient organizations), and suppliers (e.g. SMEs).
Participation per Partner
Partner number and short name WP10 effort
1 - INSERM 13.40
25 - FTELE 25.10
26 - ISS 6.00
36 - UM 1.10
42 - INSA 1.10
45 - CNAG-CRG 5.70
50 - ULEIC 13.50
57 - UKL-HD 0.50
64 - LUMC 5.20
73 - BBMRI 23.10
Page 83 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP10 effort
76 - EMBL 0.00
DTL-Projects 23.90
Total 118.60
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
First Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.1 reports, QMS of Pillar 1 - INSERM Report Public 9
2 description, GDPR
compliance report and
sustainability planning
reporting
Second Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.2 reports, QMS of Pillar 1 - INSERM Report Public 21
2 description, GDPR
compliance report and
sustainability planning
reporting
Third Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.3 reports, QMS of Pillar 1 - INSERM Report Public 33
2 description, GDPR
compliance report and
sustainability planning
reporting
Fourth Annual strategic
report and Action plan
for Pillar 2, including:
Systematic surveys
D10.4 reports, QMS of Pillar 1 - INSERM Report Public 45
2 description, GDPR
compliance report and
sustainability planning
reporting
Report on the State of the
D10.5 1 - INSERM Report Public 9
Art of existing resources
Description of deliverables
Page 84 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D124 to D127: Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of
Pillar 2 description, GDPR compliance report and sustainability planning reporting (M9, updates M21,M33, 45)
D10.1 : First Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of
Pillar 2 description, GDPR compliance report and sustainability planning reporting [9]
Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2
description, GDPR compliance report and sustainability planning reporting due at M9
D10.2 : Second Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of
Pillar 2 description, GDPR compliance report and sustainability planning reporting [21]
Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2
description, GDPR compliance report and sustainability planning reporting update at month 21
D10.3 : Third Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of
Pillar 2 description, GDPR compliance report and sustainability planning reporting [33]
Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2
description, GDPR compliance report and sustainability planning reporting update at month 33
D10.4 : Fourth Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of
Pillar 2 description, GDPR compliance report and sustainability planning reporting [45]
Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2
description, GDPR compliance report and sustainability planning reporting update at month 45
D10.5 : Report on the State of the Art of existing resources [9]
Report on the State of the Art of existing resources
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
1st Annual retreat of Pillar 2
MS25 1 - INSERM 6 and Pillar 4 representative
completed
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
2nd Annual retreat of Pillar 2
MS26 1 - INSERM 18 and Pillar 4 representative
completed
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
3rd Annual retreat of Pillar 2
MS27 1 - INSERM 30 and Pillar 4 representative
completed
organized and achieved,
including background
documents
Annual meeting involving
4th Annual retreat of Pillar 2 all ERNs, Pillar 2 WPs co-
MS28 1 - INSERM 42
completed leaders, WP10 partners
and Pillar 4 representative
Page 85 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
5th Annual retreat of Pillar 2
MS29 1 - INSERM 54 and Pillar 4 representative
completed
organized and achieved,
including background
documents
Pillar 2 WP10: Online
MS30 1st End-users surveys done 50 - ULEIC 5 surveys developed, sent and
results analyzed.
Pillar 2 WP10 : Online
MS31 2nd End-users surveys done 50 - ULEIC 17 surveys developed, sent and
results analyzed.
Pillar 2 WP10 : Online
MS32 3rd End-users surveys done 50 - ULEIC 29 surveys developed, sent and
results analyzed.
Pillar 2 WP10: Online
MS33 4th End-users surveys done 50 - ULEIC 41 surveys developed, sent and
results analyzed.
Pillar 2 WP10: Online
MS34 5th End-users surveys done 50 - ULEIC 53 surveys developed, sent and
results analyzed.
Financing models for Matrix and support document
sustaining and scaling listing the appropriateness
up FAIRification support of financing models for
MS35 65 - Radboudumc 18
services assessed with sustaining and scaling up
sustainability experts and RD virtual platform components
community stakeholders and support services
Simulations of financing
models for sustaining and
scaling up FAIRification Results of the simulations
MS36 support services executed and 65 - Radboudumc 48 of financing models for
evaluated with sustainability FAIRification services listed
experts and RD community
stakeholders
Page 86 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP11 Lead beneficiary 10 1 - INSERM
Work package title Common virtual platform for discoverable data and resources for RD research
Start month 1 End month 60
Objectives
The overall objectives of this WP are i) to build a comprehensive, FAIR-compliant virtual platform describing
resources (including registries, biobanks, research infrastructures, genome-phenome repositories, methods, standards,
etc) allowing for these resources to be findable online via a central access point and ii) to provide researchers the means
to deposit, share and analyse phenotypic, genomic and multi-omics data building on and scaling up existing resources.
The specific objectives of this WP are:
● To produce an ontological model to represent fine-grained metadata describing existing and future resources relevant
for RD research.
● To build a comprehensive suite of catalogs based on this ontological model to allow queries through a central facility.
● To facilitate data generated from RD research to be deposited in existing repositories by improving their capacity,
interoperability, privacy protection, and security compliance.
● To facilitate user access to resources by adopting a common Authentication and Authorization Interface (AAI)
● To improve and scale up genomic, phenomic and multi-omics analysis, integration and sharing capabilities
Description of work and role of partners
WP11 - Common virtual platform for discoverable data and resources for RD research [Months: 1-60]
INSERM, AIT, LBG (LBI-RUD), CHARITE, UKL-FR, FTELE, ISS, VUHSK, UMCG, UM, IPCZD,
ISCIII, CNAG-CRG, UPM, CIBER, ULEIC, CCRI, UKL-HD, GUF, HSK, LUMC, Radboudumc, AMC,
INFRAFRONTIER, BBMRI, EMBL, ACURARE
Other lead beneficiary: CNAG (45)
Methodology
WP11 will build on and scale up existing catalogs (Orphanet, BBMRI, RD-Connect Biobank and Registry Finder, JRC’s
ERDRI and ELIXIR bio.tools) to develop a comprehensive suite of catalogs using standardized metadata and utilizing
existing recommended ontologies (i.e. Orphanet rare disease ontology (ORDO), Human Phenotype Ontology (HPO).
It will allow registries, biobanks, data repositories, and other resources and tools to be findable by queries in terms of
disease, genes, phenotypes, sample types, and other data element types. Queries may expand to federated queries at data
record-level through the FAIRIfication process of WP12. This centralized metadata system will be FAIR compliant.
Furthermore, WP11 will improve, adapt, scale up and document existing RD data deposition and analysis resources
(such as the RD-Connect GPAP and Sample Catalogue, DECIPHER, INFRAFRONTIER, hPSCreg, Cellosaurus, EGA,
Metabolights or Pride), and make them findable through the EJP virtual platform, to serve researchers’ deposition and
analysis needs (i.e. for the projects funded in Pillar 1, Solve-RD and others). Access will be simplified by adopting a
common Authentication and Authorization Infrastructure (AAI), and a system to link anonymised data from the same
patient in different projects will be deployed via Privacy Preserving Record Linkage (PPRL). Functionality of resources
will be expanded by improving their usability. Additional experimental data issued from WP4 will be included.
Task 11.1: Metadata and ontological model definition for cataloging resources for RD research (M1-M60)
TL: EMBL-EBI, GUF [STL: SIB (ELIXIR-CH), GUF, AMC] Other: [metadata definition and modelisation] JRC,
INSERM(Orph), BBMRI, UMCG, UPM, LUMC, ULEIC, Charité, ACU/ACURARE, UM, ISCIII, CIBER
Subtask 11.1.1: A set of metadata will be defined to describe each RD resource to be included in the virtual platform
following prioritization provided by WP10. This set of metadata will be based on, and expand, metadata already
developed by Orphanet, BBMR-ERIC (for biobanks), RD-Connect (for registries and biobanks), and JRC’s ERDRI
(European Rare Disease Registry Infrastructure, including the registries Central Metadata Repository and the European
Directory of Registries). Schemas such as MIABIS (biobanks), and Bioschema.org, and standard ontologies (Orphanet
Rare Disease Ontology ORDO, Human Phenotype Ontology HPO, OBIB) and standard nomenclatures (HGNC,
Uniprot/neXtProt, Cellosaurus etc) will be used to improve interoperability. This will provide a unified way to describe
a range of includable resources in the centralized suite of catalogs built in Task 11.2. Accessibility metadata will be
included based on ADA-M tool as well as provenance information about the metadata itself. These metadata will serve
as a starting point for metadata description at record level in WP12. Metadata will be organized as application ontology
integrated with other standard ontologies (Subtask 11.1.2). Resources to be included will be prioritized following WP10
Page 87 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
strategic decisions, and the model will be updated and extended every year in order to include new resources (subtask
11.1.3). Prioritized resources will be financially supported to provide their metadata.
Task 11.2: FAIR-compliant virtual platform for discovery of RD resources (M1-M60)
TL: INSERM(Orph) [STL: INSERM(Orph), UMCG, DTU (ELIXIR-DK), BSC (ELIXIR-ES), GUF] Other:
[integration and extension of catalogs and development of central query point] JRC, BBMRI, CNAG-CRG, UPM,
LUMC, UM, CIBER, VUHSK, IPCZD (CMHI), ULEIC
A database of RD-specific expert resources is already maintained by Orphanet by the collection, manual curation and
quality control of expert centres (including ERNs), diagnostic tests, patient organizations, infrastructures, registries and
databases and RD research projects and clinical trials and orphan drugs in 35 countries. These are described with a
set of metadata and organized around the elements of ORDO, which allows these resources to be findable by disease
and by gene. Task 11.2 aims at building a virtual platform using and expanding this catalog based on the metadata
model developed in Task 11.1, integrating it with catalogs already developed by BBMRI-ERIC and RD-Connect for
biobanks and registries (using MOLGENIS) and JRC’s ERDRI (for registries), and ensuring manual curation, quality
and updates (subtask 11.2.1). In order to provide analytical data to inform the research strategic agenda elaborated by
Transversal WP2, an international RD specific database of research projects, clinical trials and developing therapies
will be enriched by national data and by IRDiRC members (subtask 11.2.2). To make relevant RD analysis tools and
methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation for the RD community initiated in
EXCELERATE (subtask 11.2.3). The virtual platform built in Task 11.2 will be optimized to allow queries using the
underlying ontological model. Query facilities will provided online and to the EJP-RD helpdesk (Subtask 11.2.4).
Task 11.3: Data deposition and access to data infrastructures for RD research (M1-M60)
TL: EMBL-EBI [STL: CSC (ELIXIR-FI), MU-CERIT-SC (ELIXIR-CZ), ELIXIR, BSC (ELIXIR-ES), UU
(ELIXIR-SE), INSERM (RaDiCo), AIT] Other: [develop and document secure linked data deposition and access
capabilities] INFRAFRONTIER, UKL-HD (ERKnet), APHP (PaedCan), LUMC(Endo-ERN), GUF(ERN-Lung), HSK
(MetabERN), FTELE, UMCG, BBMRI, CNAG-CRG, GUF, Charité, INSERM (AMU), ISCIII, ISS, UKLFR, CIBER,
ULEIC, WTSI (Associated partner)
Task 11.3 aims to serve the needs for depositing, integrating and storing quality controlled (meta)data produced
by the EJP and the overall RD community building on existing resources including registries (JRC-ERDRI, RD-
Connect Registry and Biobank Finder, known also as IDcards), patient cohorts (RadiCo, BBMRI-ERIC Directory),
biobanks (RD-Connect Sample Catalogue, RD-Connect Registry and Biobank Finder, BBMRI-ERIC Directory), cell
lines (hPSCreg, Cellosaurus), mouse models (INFRAFRONTIER), raw omics data (EGA, Pride, MetaboLights) and
genome-phenome platforms (DECIPHER, RD-Connect GPAP). Subtask 11.3.1 will support resources by improving
and/or expanding their deposition and access mechanisms (Application Programming Interfaces, APIs, and Graphical
User Interfaces, GUIs) and deploying mechanisms to ensure quality of datasets, evaluating GDPR compliance and
implementing transparency measures and means to monitor data re-usability following Pillar 2 Task 10.3 guidance.
BBMRI-ERIC Negotiator, used for implementing access pipeline for biobanks and registries will be extended to support
resources integrated in WP12. The LifeScience AAI (converging from ELIXIR and BBMRI-ERIC Authorization and
Authentication Infrastructure), enabling users to access several resources using the same credential while controlling
access permissions, will be implemented (subtask 11.3.2). To overcome issues associated with patient identification and
duplication, subtask 11.3.3. will deploy a GDPR compliant PPRL (Privacy Preserving Record Linkage) solution based
on EUPID, aligned with the proposals from the joint GA4GH/IRDiRC PPRL working group. General and resource
specific documentation and guidelines including user registration, data deposition, data access, data security, policies,
transparency, incentives for data submitters and usage of ontologies and standards will be published online via EJP RD
website (subtask 11.3.4).
Task 11.4: Provision of RD analysis and data sharing capabilities through online resources (M1-M60)
TL: CNAG-CRG [STL: UMCG, CNAG-CRG, BSC (ELIXIR-ES), SIB (ELIXIR-CH), EMBL-EBI, CSC (ELIXIR-
FI), UU (ELIXIR-SE), LBG (LBI-RUD)] Other: [phenotype, genotype and multi-omics integrated analysis facilities ]
LUMC (Endo-ERN), FTELE, INSERM (RaDiCo), BBMRI, RUMC, LUMC, INSERM (AMU), ISS, UM, ACU/
ACURARE, ISCIII, CIBER, UKLFR, WTSI, (Associated partner)
To contribute to the achievement of the IRDiRC diagnostics goals and provide analysis and data sharing capabilities
to the EJP platform, task 11.4 will support and upscale user friendly software and tools for the analysis of omics data
together with rich standardised clinical and phenotypic data. To create a comprehensive suite of online analysis tools,
they will be made compatible with the models developed in T11.1, included in T11.2 and linked to key resources
from T11.3. The capacity to identify causative genetic variants and discover new pathogenic genes will be provided
by building on the online RD-Connect genome-phenome analysis platform (GPAP) (subtask 11.4.1). The GPAP is
a recognised IRDiRC resource that provides secure user-friendly deposition, access, analysis and interpretation of/to
integrated genotype (whole genomes, exomes and panels) and standardised phenotype information. The GPAP will
play a central role in the Solve-RD project. In subtask 11.4.2, methods and tools for integrative bioinformatics analysis
will be developed and implemented in alignment with WP13, including user-friendly interfaces for easy access and
Page 88 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
interactive analysis. This collaborative, integrated analysis of multi-omics data will be provided to projects funded in
Pillar 1 generating multi-omics datasets and to WP13 selected use cases, being leveraging also on the multi-omics
datasets generated within Solve-RD. Furthermore, a pilot cloud computing capability will be piloted for custom analyses
from funded projects in Pillar 1 (subtask 11.4.3). Main raw omics data resources such as the EGA or MetaboLights
will be connected building on the developments from Solve-RD. Newly developed analysis methods and tools will be
integrated or linked to in the analysis systems following a user-driven prioritisation, and improvements on the usability
of the resources will be made according to the EJP and ERN needs (subtask 11.4.4).
Participation per Partner
Partner number and short name WP11 effort
1 - INSERM 431.40
3 - AIT 26.80
4 - LBG (LBI-RUD) 22.30
17 - CHARITE 31.30
18 - UKL-FR 17.40
25 - FTELE 9.90
26 - ISS 6.80
32 - VUHSK 5.00
35 - UMCG 74.00
36 - UM 11.00
40 - IPCZD 10.00
44 - ISCIII 9.90
45 - CNAG-CRG 181.70
46 - UPM 10.60
47 - CIBER 14.70
50 - ULEIC 12.60
53 - CCRI 5.00
57 - UKL-HD 2.80
59 - GUF 76.80
60 - HSK 3.90
64 - LUMC 42.10
65 - Radboudumc 10.70
66 - AMC 5.70
72 - INFRAFRONTIER 39.00
73 - BBMRI 65.80
76 - EMBL 0.00
DTL-Projects 194.10
82 - ACURARE 9.40
Total 1,330.70
Page 89 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
First Ontological model
D11.1 76 - EMBL Other Public 12
of resources metadata
Second Ontological
D11.2 model of resources 76 - EMBL Other Public 24
metadata
Third Ontological model
D11.3 76 - EMBL Other Public 36
of resources metadata
Fourth Ontological
D11.4 model of resources 76 - EMBL Other Public 48
metadata
Fifth Ontological model
D11.5 76 - EMBL Other Public 60
of resources metadata
Virtual platform of RD Websites,
D11.6 resources annotated with 1 - INSERM patents Public 12
EJP ontological model filling, etc.
First update Virtual
Websites,
platform of RD resources
D11.7 1 - INSERM patents Public 24
annotated with EJP
filling, etc.
ontological model
Second update Virtual
Websites,
platform of RD resources
D11.8 1 - INSERM patents Public 36
annotated with EJP
filling, etc.
ontological model
Third update Virtual
Websites,
platform of RD resources
D11.9 1 - INSERM patents Public 48
annotated with EJP
filling, etc.
ontological model
Fourth update Virtual
Websites,
platform of RD resources
D11.10 1 - INSERM patents Public 60
annotated with EJP
filling, etc.
ontological model
First version of
Additional facilities
integrated to resources
D11.11 regarding data deposition 76 - EMBL Other Public 12
and access, including
user guidelines and
documentation
Second version
Additional facilities
integrated to resources
D11.12 regarding data deposition 76 - EMBL Other Public 24
and access, including
user guidelines and
documentation
Page 90 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Third version Additional
facilities integrated to
resources regarding data
D11.13 76 - EMBL Other Public 36
deposition and access,
including user guidelines
and documentation
Fourth version
Additional facilities
integrated to resources
D11.14 regarding data deposition 76 - EMBL Other Public 48
and access, including
user guidelines and
documentation
Fifth version Additional
facilities integrated to
resources regarding data
D11.15 76 - EMBL Other Public 60
deposition and access,
including user guidelines
and documentation
First Report on processed
genome-phenome
datasets and multi-omics
use cases analysed,
D11.16 45 - CNAG-CRG Report Public 12
including description of
new cloud and online
analysis functionalities
and tools
Second Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.17 45 - CNAG-CRG Report Public 24
analysed, including
description of new cloud
and online analysis
functionalities and tools
Third Report on
processed genome-
phenome datasets and
multi-omics use cases
D11.18 45 - CNAG-CRG Report Public 36
analysed, including
description of new cloud
and online analysis
functionalities and tools
Fourth Report on
processed genome-
phenome datasets and
D11.19 45 - CNAG-CRG Report Public 48
multi-omics use cases
analysed, including
description of new cloud
Page 91 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
and online analysis
functionalities and tools
Fifth Report on processed
genome-phenome
datasets and multi-omics
use cases analysed,
D11.20 45 - CNAG-CRG Report Public 60
including description of
new cloud and online
analysis functionalities
and tools
Description of deliverables
D128 to D132: Ontological model of resources metadata (M12, 24, 36, 48, 60)
D133 to D137: Virtual platform of RD resources annotated with EJP ontological model and updated regularly (M12,
24, 36, 48, 60)
D138 to D142: Additional facilities integrated to resources regarding data deposition and access, including User
guidelines and documentation for data deposition and access (M12, M24, M36, M48, M60)
D143 to D147: Report on processed genome-phenome datasets and multi-omics use cases analysed, including
Description of new cloud and online analysis functionalities and tools (M12, M24, M36, M48, M60)
D11.1 : First Ontological model of resources metadata [12]
First Ontological model of resources metadata due at mont 12
D11.2 : Second Ontological model of resources metadata [24]
Second Ontological model of resources metadata due at month 24
D11.3 : Third Ontological model of resources metadata [36]
Third Ontological model of resources metadata due at month 36
D11.4 : Fourth Ontological model of resources metadata [48]
Fourth Ontological model of resources metadata due at month 48
D11.5 : Fifth Ontological model of resources metadata [60]
Fifth Ontological model of resources metadata due at month 60
D11.6 : Virtual platform of RD resources annotated with EJP ontological model [12]
First version of the Virtual platform of RD resources annotated with EJP ontological model due at month 12
D11.7 : First update Virtual platform of RD resources annotated with EJP ontological model [24]
First update of the Virtual platform of RD resources annotated with EJP ontological model due at month 24
D11.8 : Second update Virtual platform of RD resources annotated with EJP ontological model [36]
Second update of the Virtual platform of RD resources annotated with EJP ontological model due at month 36
D11.9 : Third update Virtual platform of RD resources annotated with EJP ontological model [48]
Third update of the Virtual platform of RD resources annotated with EJP ontological model due at month 48
D11.10 : Fourth update Virtual platform of RD resources annotated with EJP ontological model [60]
Fourth update of the Virtual platform of RD resources annotated with EJP ontological model due at month 60
D11.11 : First version of Additional facilities integrated to resources regarding data deposition and access, including
user guidelines and documentation [12]
Other lead beneficiary ELIXIR (76) First version of Additional facilities integrated to resources regarding data
deposition and access, including user guidelines and documentation due at month 12
Page 92 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D11.12 : Second version Additional facilities integrated to resources regarding data deposition and access, including
user guidelines and documentation [24]
Other lead beneficiary: ELIXIR (76) Second version of Additional facilities integrated to resources regarding data
deposition and access, including user guidelines and documentation due at month 24
D11.13 : Third version Additional facilities integrated to resources regarding data deposition and access, including
user guidelines and documentation [36]
Other lead beneficiary: ELIXIR (76) Third version of Additional facilities integrated to resources regarding data
deposition and access, including user guidelines and documentation due at month 36
D11.14 : Fourth version Additional facilities integrated to resources regarding data deposition and access, including
user guidelines and documentation [48]
Other lead beneficiary: ELIXIR (76) Fourth version of the Additional facilities integrated to resources regarding data
deposition and access, including user guidelines and documentation due at month 48
D11.15 : Fifth version Additional facilities integrated to resources regarding data deposition and access, including
user guidelines and documentation [60]
Other lead beneficiary: ELIXIR (76) Fifth version of the Additional facilities integrated to resources regarding data
deposition and access, including user guidelines and documentation due at month 60
D11.16 : First Report on processed genome-phenome datasets and multi-omics use cases analysed, including
description of new cloud and online analysis functionalities and tools [12]
Other lead beneficiary UMCG (35) First Report on processed genome-phenome datasets and multi-omics use cases
analysed, including description of new cloud and online analysis functionalities and tools due at month 12
D11.17 : Second Report on processed genome-phenome datasets and multi-omics use cases analysed, including
description of new cloud and online analysis functionalities and tools [24]
Other lead beneficiary UMCG (35) Second Report on processed genome-phenome datasets and multi-omics use cases
analysed, including description of new cloud and online analysis functionalities and tools due at month 24
D11.18 : Third Report on processed genome-phenome datasets and multi-omics use cases analysed, including
description of new cloud and online analysis functionalities and tools [36]
Other lead beneficiary: UMCG (35) Third Report on processed genome-phenome datasets and multi-omics use cases
analysed, including description of new cloud and online analysis functionalities and tools due at month 36
D11.19 : Fourth Report on processed genome-phenome datasets and multi-omics use cases analysed, including
description of new cloud and online analysis functionalities and tools [48]
Other lead beneficiary: UMCG (35) Fourth Report on processed genome-phenome datasets and multi-omics use cases
analysed, including description of new cloud and online analysis functionalities and tools due at month 48
D11.20 : Fifth Report on processed genome-phenome datasets and multi-omics use cases analysed, including
description of new cloud and online analysis functionalities and tools [60]
Other lead beneficiary: UMCG (35) Fifth Report on processed genome-phenome datasets and multi-omics use cases
analysed, including description of new cloud and online analysis functionalities and tools due at month 60
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
First Metadata sets of
Prioritized resources having
MS37 identified and prioritized 76 - EMBL 9
validated metadata sets
resources
Second Metadata sets of Prioritized resources having
MS38 identified and prioritized 76 - EMBL 21 validated metadata sets
resources updated at month 21
Page 93 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Third Metadata sets of Prioritized resources having
MS39 identified and prioritized 76 - EMBL 33 validated metadata sets
resources updated at month 33
Fourth Metadata sets of Prioritized resources having
MS40 identified and prioritized 76 - EMBL 45 validated metadata sets
resources updated at month 45
Fifth Metadata sets of Prioritized resources having
MS41 identified and prioritized 76 - EMBL 57 validated metadata sets
resources updated at month 57
Common AAI integrated in 3 3 resources integrated with
MS42 76 - EMBL 24
resources LifeScience/ELIXIR AAI
PPRL available to link data
PPRL in production for 3
MS43 76 - EMBL 36 between at least 3 projects/
projects/resources
resources
Pilot cloud computing
infrastructure available for
MS44 Pilot cloud deployed 45 - CNAG-CRG 24
deploying workflows at
UCMG and BSC(ELIXIR-SI)
Page 94 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP12 Lead beneficiary 10 50 - ULEIC
Enabling sustainable FAIRness and Federation at the record level for RD data, patients
Work package title
and samples
Start month 1 End month 60
Objectives
This WP will ensure the availability of standards, inter-operable tools, and networks of expert support for biological,
clinical and preclinical data, samples, and patient information, to create maximal utility as per the FAIR paradigm.
Specific objectives of this WP are:
● To identify, refine and expose core standards for dataset interoperability, asset (data, sample, subject) discovery, and
responsible data sharing (via Task 12.1), concentrating on data level rather than resource level information, guided by
the needs of EJPRD stakeholders from pillar 1 and 4, including ERNs towards the overall EJPRD objectives.
● To improve and deploy open-source tools, by multi-site teams, made maximally interoperable and compliant with
EJPRD agreed standards, to enable RD data to be made FAIR in practice (via Task 12.2).
● To coordinate and deploy broad expertise and practical support for data ‘FAIRification’, including options for
data hosting and brokering (via Task 12.3), with a path towards a self-propagating and self-sustaining ecosystem for
provisioning of FAIR data stewardship.
Description of work and role of partners
WP12 - Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples
[Months: 1-60]
ULEIC, INSERM, AIT, CHARITE, FTELE, UMCG, UM, MUW, ISCIII, CNAG-CRG, UPM, CIBER, UKL-HD,
GUF, LUMC, Radboudumc, AMC, BBMRI, EMBL, ACURARE
Other lead beneficiary: LUMC (64)
To progressively ‘FAIRify’ RD resources at the record-level to support innovative basic, translational and clinical
research, our efforts will synergise with and extend those of WP11 (which has a resource level focus) and WP13
(which has a data integration focus) – with guidance from WP10. The approach assumes that RD research data, samples
and clinical information gathered from patients will typically be distributed, heterogeneous and sensitive. By joint
research, development, services and sharing of expertise we will enhance and apply extant capabilities to support RD
data custodians, biobanks, and registries. Relevant standards will be identified and refined for WP12 by a community
wide effort (Task 12.1), existing software will be improved to stress interoperability and functionalities needed by WP12
(Task 12.2), and expertise for practical FAIRification support and FAIR data hosting services for EJP RD projects will
be leveraged via user workshops and engagement (Task 12.3) – whilst reflecting users’ needs back to Tasks 12.1 &
12.2, and maturing everything towards a sustainable model.
Task 12.1: Compare and align core interoperability standards of relevance (M1-M60)
TL: ULEIC [STLs: BBMRI, UMCG, LUMC, AMC, ULEIC] Other: [TC/Workshop attendance, info gathering, design/
testing] UKL-HD (ERK-net), JRC, INSERM (Orph), EMBL-EBI, CSC (ELIXIR-FI), SIB (ELIXIR-CH), UPM, UM,
ACU/ACURARE, INSERM (RaDiCo), GUF, AIT, FTELE, Charité, ISCIII, MUW, CIBER
This task will underpin the Virtual Platform by defining the standards required to maximise interoperability and
federation potential. This will span RD genotype-phenotype databases, RD biobanks, RD patient registries, ERN
networks, and ultimately (as guided by WP13) extend to clinical and digital health data, PROM information, natural
history and environmental data. The aim is not to invent new standards. Instead, we will engage a broad community
of stakeholders to jointly survey the standards that already exist, establish how/where they are being used, and thereby
define overlaps, conflicts and gaps that exist. We will then establish what is needed to map and translate between
alternatives, and devise refinements and extensions as necessary. Undertaking this work along with the existing
producers and users of today’s most relevant standards, and publishing our results (along with Transversal WP5), will
ensure they are accepted and employed by the field’s practitioners (who will have been involved in their creation).
To this end, we will arrange regular teleconferences and workshops between teams that presently develop or use
standards in this space, and encourage external groups to join in. Key external partners would be IRDiRC, ELIXIR,
BBMRI, Solve-RD and GA4GH, which have overlapping membership with EJP. Topic priorities will be guided by
WP12 tool developments (Task 12.2) and FAIRification activities (Task 12.3), and by WPs 10, 11 and 13. Task 12.1 will
be adaptive, but organised around five domains, each having its own expert leadership team coordinating subgroups
on specific standards: “Metadata and data models” (Subtask 12.1.1) to provide syntactic and semantic targets that
Page 95 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
FAIRification procedures would target to improve Findability and Interoperability, beyond the resource-level models of
WP11; “Federation architectures and network registers” (Subtask 12.1.2) to underpin a growing federated arrangement
of RD resources; “Automated Accessibility and Reusability elements” (Subtask 12.1.3), not least machine-readable
consent & use conditions, governance policies, patient/sample/data identifiers, and anonymization methods; “Query
languages and data exchange formats” (Subtask 12.1.4) to provide a 'lingua franca' for databases and data discovery
platforms to translate from and to, so that they can (with suitable permissions) interpret and respond to mutual queries
and promote Findability and Interoperability; and “Ontologies & semantics for record-level clinical and preclinical
information” (Subtask 12.1.5), to steadily improve our ability to feed complex medical data into the research world.
Task 12.2: Multi-team software development to enable the FAIR ecosystem (M1-M60)
TL: AIT [STL: BBMRI, GUF, AIT, ULEIC] Other: [developers and service providers] JRC, INSERM (Orph), UMCG,
CNAG-CRG, UPM, LUMC, AMC, MUW, FTELE, INSERM (AMU), RUMC
A wide array of technologies and capabilities are needed to make RD datasets and resources FAIR, and so in Task
12.2 we will work with RD communities to improve existing Open Source software. The goal will be to enhance their
utility, their interoperability and their compatibility with standards defined by Task 12.1, driven by priorities defined
in WP10. We will use these tools in Task 12.3, assist the community in adopting them, and thereby validate them and
inform iteratively cycles of further optimisation. Task 12.2 activities will be guided by tool users and by feedback at
annual retreats organised by WP10. More specifically, we will start each cycle of tool development by first defining an
unmet need, and assess the effectiveness of the developed software by evaluating its ability to address the targeted need
- all in conjunction with real-world users. The work will also be undertaken by multi-team efforts, addressing four key
topics, namely: “Semantic and syntactic harmonisation of data records” (Subtask 12.2.1) which is a core need when
making datasets, samples and patients precisely Findable and maximally Interoperable; “Data extraction, obfuscation,
anonymisation and disclosure control” (Subtask 12.2.2) to appropriately manage the confidentiality of sensitive patient-
level data; “Metadata-level, data-level and sample-level discovery support” (Subtask 12.2.3) which extends the resource
level Findability work of WP11 and includes new approaches to RD patient matchmaking that give the person making
the query more influence over what constitutes a real match; and “Management of consent and data use conditions,
plus automated access control (Subtask 12.2.4) to ensure data discovery and sharing are made more efficient and more
responsibly conducted. Awareness of and access to these tools will be facilitates in conjunction with the main EJP RD
Helpdesk.
Task 12.3: Combining expertise for practical FAIRification support (M1-M60)
TL: LUMC [STLs: UMCG, LUMC, AMC, ULEIC] Other: [TC/Expertise gathering, hosting services, FAIR Services]
INSERM (Orph), CNAG-CRG, INSERM (RaDiCo), BBMRI, EMBL-EBI, SIB (ELIXIR-CH), INSERM (AMU),
Charité, UPM, RUMC, ISS
Widespread implementation of FAIR data principles requires interdisciplinary collaboration and practical support to
ensure a good flow of standards, technologies and capabilities out to the community. Developing guidelines, protocols,
and support services to aid the RD community with practical implementation of FAIR data principles is the goal
of Task 12.3. Specifically, Subtask 12.3.1 (“Coordinating teams of experts”) will organise online and face-to-face
meetings to engage dispersed experts and integrate RD infrastructural activities with bodies such as IRDiRC, GA4GH,
ELIXIR and BBMRI. A liaison program will involve early-career representatives of EJPRD stakeholders in developing
FAIR infrastructure and best data stewardship practices. Subtask 12.3.2 (“Brokered hosting service”) will establish
a data hosting service to support data discovery in FAIRification efforts. This will include new forms of RD patient
matchmaking for use within networks of authorised users, and place the queryer in full control of the matching
criteria. Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities. Dedicated FAIR
data stewards, engaged via Subtask 12.3.1 will work with stakeholders to implement standards (Task 12.1) and tools
(Task 12.2) to make selected data more FAIR compliant, in order to solve real-world problems from pillars 1 and 4 and
external users. Formalised, objective FAIR metrics will be used to monitor progress. Each FAIRification undertaking
will address a different set of challenges and different cross-resource questions to ensure that FAIRification guidelines,
standards and tools cover a sufficient range of practical applications of the EJPRD. The FAIRification process and
reusable artefacts, such as an application ontology, will be documented and shared with the wider RD community, and
fed into the training program of Pillar 3. The actual total costs of FAIRification in practice will be analysed as input for
developing financial models for a sustainable FAIRification service for the RD community (Task 10.5).
Participation per Partner
Partner number and short name WP12 effort
1 - INSERM 47.90
Page 96 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP12 effort
3 - AIT 106.50
17 - CHARITE 9.00
25 - FTELE 36.60
35 - UMCG 162.40
36 - UM 2.50
38 - MUW 11.70
44 - ISCIII 2.51
45 - CNAG-CRG 11.00
46 - UPM 54.80
47 - CIBER 2.90
50 - ULEIC 193.90
57 - UKL-HD 2.80
59 - GUF 121.50
64 - LUMC 151.60
65 - Radboudumc 32.90
66 - AMC 94.30
73 - BBMRI 180.80
76 - EMBL 25.90
82 - ACURARE 2.90
Total 1,254.41
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Report on core set
D12.1 of unified FAIR data 50 - ULEIC Report Public 18
standards
First Report on core
set of FAIR software
tools and on extended
D12.2 3 - AIT Report Public 30
set of unified FAIR data
standards, applied in EJP
RD
Second Report on core
set of FAIR software
tools and on extended
D12.3 3 - AIT Report Public 48
set of unified FAIR data
standards, applied in EJP
RD
Page 97 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Report on extended
set of FAIR software
tools, applied in
D12.4 EJP,including overview 64 - LUMC Report Public 60
of FAIRification
guidelines for RD data
managers
Description of deliverables
D148: Report on core set of unified FAIR data standards (M18)
D149 and D150: Report on core set of FAIR software tools and on extended set of unified FAIR data standards,
applied in EJP RD, available (M30, M48)
D151: Report on extended set of FAIR software tools, applied in EJP RD, including overview of FAIRification
guidelines for RD data managers (M60)
D12.1 : Report on core set of unified FAIR data standards [18]
Report on core set of unified FAIR data standards
D12.2 : First Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in
EJP RD [30]
First Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP
RD due at month 30
D12.3 : Second Report on core set of FAIR software tools and on extended set of unified FAIR data standards,
applied in EJP RD [48]
Second Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP
RD due at month 48
D12.4 : Report on extended set of FAIR software tools, applied in EJP,including overview of FAIRification guidelines
for RD data managers [60]
Other lead beneficiary: LUMC (64) Report on extended set of FAIR software tools, applied in EJP,including overview
of FAIRification guidelines for RD data managers
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Core standards teams Lists of teams and target
MS45 assembled and working 50 - ULEIC 12 standards in place, plus shared
actively document storage
Multi-team software
Lists of teams and target goals
MS46 collaborations working on 50 - ULEIC 18
and standards in place
agreed goals and standards
Communication established
List of experts and
between experts and
stakeholders in place, plus
MS47 stakeholder representatives 64 - LUMC 12
means of communication and
involved in practical
shared document storage
FAIRification support
Page 98 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
First update FAIRification Guidelines document updated
MS48 guidelines for RD data 64 - LUMC 6 by the latest FAIRification
managers experiences at month 6
Second update FAIRification Guidelines document updated
MS49 guidelines for RD data 64 - LUMC 30 by the latest FAIRification
managers experiences at month 30
Third update FAIRification Guidelines document updated
MS50 guidelines for RD data 64 - LUMC 42 by the latest FAIRification
managers experiences
Guidelines document updated
Fourth update FAIRification
by the latest FAIRification
MS51 guidelines for RD data 64 - LUMC 54
experiences updated at month
managers
54
Page 99 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP13 Lead beneficiary 10 36 - UM
Enabling multidisciplinary, holistic approaches for rare disease diagnostics and
Work package title
therapeutics
Start month 1 End month 60
Objectives
Extend the virtual platform with workflows that allow holistic research based on rare disease data and biological
knowledge. Fill gaps in technologies identified in previously performed explorative studies and perform proof of
principle studies to evaluate the results and improve and optimise the approach. Thereby, improve the understanding of
the etiology and progression or rare diseases and support the discovery of biomarkers and the identification of druggable
pathways and targets, and allow the study of disease modifiers such as nutrition, and metabolism (exercise) aspects of
lifestyle and exposure to toxicants. Provide content for training in pillar 3 to make these new workflows available for
the community.
Description of work and role of partners
WP13 - Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics [Months:
1-60]
UM, INSERM, LBG (LBI-RUD), UKL-FR, ISS, UMCG, ISCIII, CNAG-CRG, UKL-HD, EKUT, LUMC,
Radboudumc, EMBL, ACURARE
Other lead beneficiary: UKL-HD (57)
Methodology:
The approach will include the following steps: (i) Knowledge structuring based on text and data mining and expert
curation; (ii) creation of technical links for integration (database ID linksets, FAIR format conversions from repository
data to tool ready data, links between biological entities (e.g. gene variants and their effects); (iii) create disease specific
pathways and networks with flexible data representations based on i and ii; (iv) Allow extension of these networks with
relevant regulatory information (e.g. transcription factors and miRNAs) and evaluation for intrinsic lifestyle factors
(e.g. micronutrient targets) and epigenetic factors and allow extension with external environmental factors like chemical
exposure (toxicology) and allow subsequent active node analysis to evaluate these; (v) Create complete workflows.
As part of the whole process continuously perform small proof of principle studies that help to drive the work forward,
help show the relevance of what is done and help identify problems with the effectiveness of what is being done and to
adapt that to the next level. Basically implementing an agile approach as known in software development for this WP.
Some of the outcomes of WP13 will be applied and tested within the collaborative analyses of multi-omics datasets
performed in WP11 task 11.4.2 on existing data, data provided by the ERNs and data generated from Pillar 1 funded
projects and the Solve-RD project. Work with Pillar 3 to develop training, especially on creating pathways, using the
pathways, networks and complete workflows for discovery of diagnostic and therapeutic activities and for inference of
lifestyle and environmental factors.
Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (M1-
M60)
TL: UM, LUMC, [STLs: LUMC, RUMC, UM, INSERM (AMU), ISS Other: EKUT, ACU/ACURARE, EMBL-EBI,
SIB (ELIXIR-CH), UMCG, CNAG-CRG, UK-LFR, ISCIII, LBG/LBI-RUD (mentioned at the end of subtasks they are
involved in, subtask leaders in bold)
Subtask 13.1.1: Pathways created and expert curated. Build a knowledge base of relevant rare diseases biological
pathways for the existing pathway portal available on WikiPathways. Select relevant diseases in collaboration with
ERNs (via WP10) and Solve-RD. For diseases where pathways that can be used by analytical tools are not yet available,
use literature review including FAIR text-mining predictive methods, data mining and expert input from ERNs and FAIR
to identify disease-relevant genes and use the knowledge available in neXtProt and other resources, e.g. protein-protein
interactions, co-expression, co-localisation, etc. to create a network structure. Annotate those network structures and
make them available for integrated omics analysis in pathway and network tools and in BioPax ontology based pathway
RDF format contributed to the Open PHACTS platform and WikiData. (UM, LUMC, ACU/ACURARE; M1-36)
Subtask 13.1.2 Mapping to genes: Allow gene directed mapping of rare disease gene variants to genes (and then to
pathways) based on mappings available in external resources. Update mapping databases and allow access to a location-
based gene mapping service. Work with WP11/12 to get interoperable gene variant descriptions (correct identifiers
including genome locations) that allow these mappings to be used, use genomics platform annotation pipeline from RD-
connect. (UM, LUMC; M1-36; develop, updates 1-60)
Page 100 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Subtask 13.1.3 Mapping (combinations) of variants to function: Mapping of (combinations of) variants to functional
gene regulatory sequences and protein domains operationalized for the rare disease community and allow use of that to
evaluate edges (interactions and reactions in pathways), linking this to the edgetic concept. (RUMC, LUMC, CNAG-
CRG, EMBL-EBI, SIB(ELIXIR-CH); M1-60)
Subtask 13.1.4 Link to external FAIR data: Leverage on the data generated by Solve-RD and the funded projects in
Pillar 1 and work with WP11/12 to allow integration, and thereby analysis, of FAIRified experimental multi-omics data
with knowledge based pathways and networks derived from FAIRified external data sources (e.g. using ELIXIR core
repositories and resources respectively), and using the fact that it was already linked to FAIR genotype and phenotype
data within the RD-Connect platform, provide specific scripts/tools. (RUMC, LUMC, CNAG-CRG, UMCG, UM,
EKUT; M13-60)
Subtask 13.1.5 Network repository: For a limited number of diseases create evaluated and documented networks and
deposit in the network repository NDEX (for analysis in Cytoscape). (UM, LUMC; M37-60)
Subtask 13.1.6 Environmental lifestyle: Allow network analysis to discover identify possibly relevant environmental
factors (such as exercise and nutrition including factors affecting epigenetics) from multi-omics networks. (INSERM-
AMU, RUMC, UM; M19-60)
Subtask 13.1.7 Treatment drugs: Allow and describe network analysis and single pathway approaches to compare rare
diseases with to known treatable diseases and to add drugs to networks and explore sub paths using network directionality
for target selection using methods that will be developed in collaboration with external EFPIA partners. (LUMC, UM,
UK-LFR, M1-36)
Subtask 13.1.8 Environmental toxicology: Allow and describe network enrichment analysis and single pathway
approaches and connect environmental (toxicology based) data via the OpenRiskNet and eNanomapper APIs, thereby
allowing links between (epi)genetics and exposure. (ISS, UM, ISCIII; M1-48)
Subtask 13.1.9 Workflow leading to understanding of disease mechanisms and diagnosis: Describe workflow for
(multi)omics data analysis finding (sub)pathways, building networks and describing basic network analysis (up to
finding affected sub pathways and active nodes and thereby diagnostic biomarker (Subtasks 1 to 4) and extended
workflows for Subtasks 6, 7 and 8. (UM, INSERM-AMU, LBG/LBI-RUD, LUMC, RUMC; M25-60)
Subtask 13.1.10 Link to Adverse Outcome Pathway approach: Harmonize the rare disease pathways (from 1) to be
linked with events that occur in Adverse Outcome Pathways (AOPs) created by the EUToxRisk flagship project as made
available on the OECD AOPWiki. (LUMC, ISS, UM; M13-36)
Task 13.2: Organise proof of principle studies to identify efficacy of the work done and identify remaining (including
new) gaps (M1-M60)
TL: RUMC Other: LUMC (data linking), UM (integrating 4,1 tasks, network building, extension and evaluation), ACU/
ACURARE (active sub-paths and effects thereon for MS2)
The proof of principle studies form an essential element in the agile approach for the pathway and workflow development
in task 13.1. They steer the pathway selection in task 13.1.1 and set targets for the other 13.1 tasks. The developed
elements are continually tested in these studies and where possible improved. The topics for the studies will be selected
based on the strategic annual plan established in WP10 together with ERNs and with the participation of Solve-RD and
EuRenOmics. With their input we will identify relevant resources and select the pathways that need to be developed. We
expect to carry out 5 rare disease related proof of principle studies for relevant parts of the WP work plan. The first study
will help select and create datasets to link and analyse and pathways to be developed and in the second study we will
use these pathways to analyse omics data. In a third study we will evaluate advanced omics analysis: evaluate genetics
mappings and protein structure effects. These will contribute to MS1.The final two studies will evaluate nutritional
lifestyle effects in disease networks and links between disease network and toxicology data and will contribute to MS2.
A second group of studies, possibly for different diseases, will aim at research questions relevant for multi-omics linkage
to known drug targets, lifestyle nutrition and metabolism (exercise) relations and to environmental toxicology resources
for MS13.2. All studies will combine data FAIRified in WP12, in part selected for this purpose, with the pathways from
task 13.1.1 leading to the selection of enriched pathways which are then combined in networks, we will then use the 13.1
subtasks to define the workflow to answer research questions and we will identify gaps in available technology. The
operational, tested, workflows, tools and pathway- and mapping data that result after the pilot studies will be integrated
in the Pillar 2 virtual platform and will form the basis for tutorial development with pillar 3. After having conducted
these studies, the remaining gaps will be reported to the strategic research agenda transversal activity, for possible
implementation in research calls through Pillar 1.
Participation per Partner
Page 101 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP13 effort
1 - INSERM 17.30
4 - LBG (LBI-RUD) 0.70
18 - UKL-FR 5.60
26 - ISS 12.20
35 - UMCG 3.60
36 - UM 88.40
44 - ISCIII 5.00
45 - CNAG-CRG 6.60
57 - UKL-HD 5.60
58 - EKUT 3.10
64 - LUMC 63.70
65 - Radboudumc 54.80
76 - EMBL 2.80
82 - ACURARE 28.50
Total 297.90
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Collection of 20
D13.1 curated (sub)Portal on 36 - UM Report Public 36
WikiPathways
Completed pathway
analysis workflow (data
analysis including both
D13.2 36 - UM Report Public 48
types of genetic variant
linking and network
creation)
Completed network
analysis workflow (active
node detection, lifestyle
D13.3 factor network evaluation 36 - UM Report Public 54
and extended network
analysis for drugs and
toxic compounds)
Description of deliverables
D152: Collection of 20 curated pathways in (sub)portal on WikiPathways (M36)
D153: Completed pathway analysis workflow (data analysis including both types of genetic variant linking and
network creation) (M48)
D154: Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended
network analysis for drugs and toxic compounds) (M54)
Page 102 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D13.1 : Collection of 20 curated (sub)Portal on WikiPathways [36]
Collection of 20 curated (sub)Portal on WikiPathways
D13.2 : Completed pathway analysis workflow (data analysis including both types of genetic variant linking and
network creation) [48]
Completed pathway analysis workflow (data analysis including both types of genetic variant linking and network
creation)
D13.3 : Completed network analysis workflow (active node detection, lifestyle factor network evaluation and
extended network analysis for drugs and toxic compounds) [54]
Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended
network analysis for drugs and toxic compounds)
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
D153 (D13.2) workflow used
in proof of concepts study Peer reviewed paper or report
MS52 evaluated and improved, 36 - UM 48 in BioRXiv. Plus plans on
with project plans for future GitHub
updates and release scheme.
D13.3 workflow used in proof
of concepts study evaluated Peer reviewed paper or report
MS53 and improved, with project 36 - UM 60 in BioRXiv. Plus plans on
plans for future updates and GitHub
release scheme
Page 103 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP14 Lead beneficiary 10 26 - ISS
Work package title Training on data management & quality
Start month 1 End month 60
Objectives
The main objectives of WP14 are to decrease RD data fragmentation and increase data quality through training activities
on data management & quality which will raise the level of capacities and help data sharing and networking within the
RD community. The training activities of WP14 will focus on (i) Standardization of rare disease data; (ii) Standards
and quality in genetic testing; (iii) Strategies to foster solutions of undiagnosed rare disease cases; (iv) Biological rare
disease sample data management, and sharing; (v) Establishment and long term sustainability of International, FAIR and
high quality rare disease registries and (vi) Learn components and interoperability tools of the European Rare Diseases
Registry Infrastructure
Description of work and role of partners
WP14 - Training on data management & quality [Months: 1-60]
ISS, INSERM, LBG (LBI-RUD), KU Leuven, IMAGINE, CHARITE, FTELE, VUHSK, UMCG, MUG, IPCZD,
ISCIII, CNAG-CRG, EKUT, HSK, IOR, LUMC, AMC, BBMRI, EMBL, EURORDIS, ACURARE, HUGEN
Methodology
WP14 will achieve the objectives through (i) the integration and implementation of existing and successful training
activities and (ii) development of new specific trainings to address all objectives. This will ensure appropriate
coverage of relevant aspects on data management & quality under a joint programme for meaningful interaction and
comprehensive training across RD community in Europe.
Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research (M1-M60)
TL: INSERM (Orph), Participants: LUMC, LBG (LBI-RUD), MUW
An Orphanet nominated training manager will develop a novel training module on the Orphanet nomenclature and
RD ontologies for RD research for clinicians and scientists. This work will be done in collaboration with a scientific
committee. The novel course will be translated and adapted to country-specific needs by the Orphanet Network teams,
in order to organise ‘National trainings’ in their national languages (free for participants). The training manager will
also organise a 'Training for Trainers' which will be dispensed to the Orphanet Network teams, enabling them to acquire
efficient training techniques and thus in turn dispense effective ‘National trainings’ in their country. Participation in this
training will help clinicians and researchers to exploit the full potential of the Orphanet database integrated data through
ORDO and Orphanet nomenclature use thus enabling them to generate additional knowledge in their field.
Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice (M1-M60)
TL: KULeuven, Participants: EKUT, ACU/ACURARE, ISS, IPCZD (CMHI), CNAG-CRG, INSERM (AMU), UMCG
‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are
increasingly confronted with the complexity of genomic data. It is of importance to provide training on the interpretation
of genetic variants and quality standards. Courses for scientists, bio-informaticians and clinicians with an interest in
genomic technologies and applications will be developed. The aim is to teach participants about the evaluation of the
pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis
pipelines and on the use of international databases. The course will build on expertise gained by EuroGentest and help
in the translation of research tools to diagnostic applications (in line with the IRDiRC objectives). The impact is on the
quality and reliability of NGS results, obtained through rare disease research. Over the years, the course content will
shift to total genome interpretation, which will entail novel disease molecular mechanisms. Annual 3-day residential
training courses typically host 20 participants and will travel across Europe (KULeuven, EKUT, ACU/ACURARE, ISS
and IPCZD (CHMI)).
Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases (M12-M60)
TL: ISS, Participants: EKUT, LBG (LBI-RUD), ACU/ACURARE, ISCIII, INSERM (AMU), FTELE, UMCG,
IMAGINE, CNAG-CRG, IPCZD (CMHI)
This task will implement a new 3-day residential training course that will provide newly-developed strategies and
tools based on phenotypic and molecular analysis to foster solutions for undiagnosed rare disease cases for researchers
and clinicians. The course will be organised and hosted in ISS in close collaboration with task partners, “Solve-RD”,
and the Undiagnosed Network International (UDNI). The course will guide participants on novel molecular strategies,
functional analysis, integrative multi-omics interpretation and clinical utility (EKUT, linked with Pillar 3 Task 14.1, and
with Pillar 2 WP13). In particular, a selected number of cases will be presented (in rotation by the following partners LBG
Page 104 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
(LBI-RUD), EKUT, ACU/ACURARE, ISCIII, IMAGINE, UMCG, FTELE, INSERM (AMU). Moreover participants
during the course will learn how to use tools such as the RD-Connect genome-phenome analysis platform (CNAG-
CRG and linked with Pillar 2 WP11) and other bio-informatic resources (INSERM-AMU). Participants at the end of
the course will be better equipped with specific knowledge enabling them to solve undiagnosed cases.
Task 14.4: Training for biobanks and researchers/clinicians on sample data management (M1-M60)
TL: FTELE; Participants: UMCG, BBMRI, CHARITE, ISCIII, MUG, HUGEN (HACETTEPE), VUHSK
Biological samples from RD patients are precious resources for research. Due to their intrinsic rarity, these samples
are often dispersed in multiple biobanks and are difficult to locate. Moreover, samples collected by researchers within
projects are often not available for reuse or processed with adequate standards. Such practices do not facilitate research
reproducibility and are not in the best interest of the patients. Biobanks have begun to share RD datasets to centralised
sample catalogues (e.g. RD-Connect, EuroBioBank) to facilitate access, and support the change towards best practice
with their special position interfacing patients, clinicians and researchers. However, RD samples and associated data
pose particular management challenges for their high variety of data types (e.g. disease names, genetic variants,
phenotypes, clinical data), as well as balancing the need to share while preserving privacy and rights of patients. The
goals of this task are to train (subtask 14.4.1) researchers/clinicians on how to use biobanks to support their projects
for sample management, and (subtask 14.4.2) to train biobank staff how to share and link individual RD samples and
data, using existing platforms and standards developed by Pillar 2. The latest ethical and legal requirements including
privacy/data protection provisions will be covered (linked with Transversal activities in WP4). Two annual workshops
(developed by FTELE, BBMRI, UMCG, CHARITE), rotating in different locations including EU-13 countries, will be
organised (ISCIII, MUG, HUGEN (HACETTEPE), VUHSK).
Task 14.5: Training on rare disease registries and FAIRification of data at the source (M1-M60)
TL: ISS; Participants: LUMC (also for Endo-ERN); Bond-ERN (IOR), Metab-ERN (HK) EURORDIS, ISCIII, LUMC,
INSERM (RaDiCo); UMCG, DTL-Projects (ELIXIR-NL), CNR (ELIXIR -IT), AMC
Since 2013 this course has been organised and hosted in ISS with the collaboration and support of key partners including
RD-Connect, ELIXIR, LUMC, and EURORDIS. The enhanced and expanded course provided by this task will be an
annual residential training course for the establishment of Findable, Accessible, Interoperable, and Reusable, for humans
and computers, (FAIR) Rare Disease (RD) registries. The course, organised and hosted in ISS in close collaboration
with task partners, is open to the international researcher community, patients, registry curators, database managers,
healthcare professionals and students and takes place over 5 days split into two main parts. In the first 3 days, participants
learn (a) what resources are needed for the establishment / maintenance of a high-quality registry; (b) the features of
successful strategies to ensure (i) long-time sustainability of the registry, (ii) including quality, (iii) legal and ethical
issues in compliance with the EU General Data Protection Regulation, and (iv) FAIR principles (most of the speakers
from task partners). The final two days of the course are a hands-on tutorial (Bring Your Own Data, BYOD) where the
attendees work with IT-Trainers and use a set of light-weight tools to make use cases FAIR (mainly from LUMC, and
ELIXIR, link with Pillar 2 WP12 in particular task 12.3). Use cases are brought by task partners (ENDO-ERN, BOND-
ERN and METAB-ERN) and in part by participants.
Task 14.6: Training on the European Rare Diseases Registry Infrastructure (ERDRI) (M1-M60)
TL: JRC; Participants: INSERM (Orph), AIT; Other (external collaborators for JRC) UMC Frankfurt, University of
Mainz
The task will be in accordance to the JRC's contribution to Pillar 2 WP11 and WP12. Accordingly, the JRC
and its partners for this task will provide trainings to all interested stakeholders on the ERDRI components and
other interoperability tools including the Central Metadata Repository: structure, functioning, access by registries,
implementation (JRC and UMC Frankfurt); the European Directory of Registries: structure, functioning, access by
registries, implementation (JRC and University of Mainz); the implementation of the Set of Common Data Elements
for Rare Disease Registration (JRC) and linked element sources (codification, ontologies - Orphanet) and the EUPID
Pseudonymisation tool for RD registries : functioning, access, implementation (JRC and AIT).
Participation per Partner
Partner number and short name WP14 effort
1 - INSERM 28.00
4 - LBG (LBI-RUD) 2.00
7 - KU Leuven 12.00
14 - IMAGINE 2.00
Page 105 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Partner number and short name WP14 effort
17 - CHARITE 8.00
25 - FTELE 27.00
26 - ISS 43.00
32 - VUHSK 1.00
35 - UMCG 10.00
39 - MUG 1.00
40 - IPCZD 4.00
44 - ISCIII 6.00
45 - CNAG-CRG 1.00
58 - EKUT 7.00
60 - HSK 2.00
61 - IOR 2.00
64 - LUMC 7.00
66 - AMC 1.00
73 - BBMRI 5.00
76 - EMBL 0.00
CNR (ELIXIR-IT) 3.00
DTL-Projects 4.00
77 - EURORDIS 3.00
82 - ACURARE 5.00
83 - HUGEN 1.00
Total 185.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
First Report of Orphanet
nomenclature training
D14.1 1 - INSERM Report Public 14
for trainers and national
trainings
Second Report of
Orphanet nomenclature
D14.2 1 - INSERM Report Public 60
training for trainers and
national trainings
First Report on course on
interpretation of genetic
D14.3 7 - KU Leuven Report Public 12
variants and quality
standards
Page 106 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Second Report on course
on interpretation of
D14.4 7 - KU Leuven Report Public 60
genetic variants and
quality standards
First Report on
D14.5 International course on 26 - ISS Report Public 24
undiagnosed diseases
Second Report on
D14.6 International course on 26 - ISS Report Public 60
undiagnosed diseases
First Report on sample
D14.7 data management 25 - FTELE Report Public 12
training workshops
Second Report on
D14.8 sample data management 25 - FTELE Report Public 60
training workshops
First Report on
International course on
D14.9 Rare Disease Registries 26 - ISS Report Public 12
and FAIRification of data
at source
Second Report on
International course on
D14.10 Rare Disease Registries 26 - ISS Report Public 60
and FAIRification of data
at source
Description of deliverables
D155 and D156: Reports of Orphanet nomenclature training for trainers and national trainings (M14 and M60)
D157 and D158: Report on course on interpretation of genetic variants and quality standards (M12 and M60)
D159 and D160: Report on International course on undiagnosed diseases (M24 and M60)
D161 and D162: Report on sample data management training workshops (M12 and M60)
D163 and D164: Report on International course on Rare Disease Registries and FAIRification of data at source (M12
and M60)
D14.1 : First Report of Orphanet nomenclature training for trainers and national trainings [14]
First Report of Orphanet nomenclature training for trainers and national trainings due at month 14
D14.2 : Second Report of Orphanet nomenclature training for trainers and national trainings [60]
Second Report of Orphanet nomenclature training for trainers and national trainings due at month 60
D14.3 : First Report on course on interpretation of genetic variants and quality standards [12]
First Report on course on interpretation of genetic variants and quality standards due at month 12
D14.4 : Second Report on course on interpretation of genetic variants and quality standards [60]
Second Report on course on interpretation of genetic variants and quality standards due at month 60
D14.5 : First Report on International course on undiagnosed diseases [24]
First Report on International course on undiagnosed diseases due at month 24
Page 107 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D14.6 : Second Report on International course on undiagnosed diseases [60]
Second Report on International course on undiagnosed diseases due at month 60
D14.7 : First Report on sample data management training workshops [12]
First Report on sample data management training workshops due at month 12
D14.8 : Second Report on sample data management training workshops [60]
Second Report on sample data management training workshops due at month 60
D14.9 : First Report on International course on Rare Disease Registries and FAIRification of data at source [12]
First Report on International course on Rare Disease Registries and FAIRification of data at source due at month 12
D14.10 : Second Report on International course on Rare Disease Registries and FAIRification of data at source [60]
Second Report on International course on Rare Disease Registries and FAIRification of data at source due at month
60
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Report of scientific committee
Orphanet training content
MS54 1 - INSERM 10 meeting validated and
defined
available
Definition of the training
MS55 Training Roadmap established 26 - ISS 1
schedule
Page 108 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP15 Lead beneficiary 10 77 - EURORDIS
Capacity building and training of patients and researchers in Rare Disease research and
Work package title
processes
Start month 1 End month 60
Objectives
The overall objective of this WP is to address one key component of the EJP on RD that is to improve RD research
and innovation and to enhance the uptake of research results by building the capacity of the patient community and
other key stakeholders.
The specific objectives of this WP include:
● Gaining an understanding of therapeutic development and regulatory processes for medicinal products in the field of
rare diseases for patients and researchers;
● Providing the knowledge and skills required for patients to become legitimate collaborators in RD scientific &
translational research hence enabling the implementation of the strategy supported by the EJP on education of patients;
● Empowering the patient community and specifically patient representatives in their roles as equal, valued, and efficient
partners in research and scientific project / ERNs governance bodies;
● Applying appropriate methods in the empowerment process of the paediatric patients to provide them with knowledge,
skills and educational comprehensive tools covering some of the main knowledge gaps related to the paediatric
developmental specificities.
Description of work and role of partners
WP15 - Capacity building and training of patients and researchers in Rare Disease research and processes
[Months: 1-60]
EURORDIS, IMAGINE, ISS, TEDDY, MUG, ACURARE
Methodology
This WP will apply a blended approach to deliver the existing and new training activities (e-learning and face to face for
T15.1, T15.2 and T15.3) open and free to all participants that will be integrated within the EURORDIS Open Academy .
The T15.4 will develop gamified training material adapted to the paediatric target audience and deliver its course via
short workshops in year 4 and 5 organised in synergy with the TEDDY Network, FSJD and the IMI2-funded project
C4C (i.e. Conect4Children).
Task 15.1: ExPRESS Expert Patients and Researchers EURORDIS Summer School (M1-M60)
TL: EURORDIS, Participant: LUMC
One of the ultimate aims of research is to bring innovative, life-transforming therapeutic options to patients who are also
taking on ever increasing roles in advocating for medicines development, equal access to treatments across Europe and
ensuring that medical information is clear, accurate and comprehensible. ExPRESS Expert Patients and Researchers
EURORDIS Summer School (ExPRESS) is an annual training programme organised by EURORDIS. The face-to-face
course trains 45 expert patients and 15 researchers annually as part of an intensive 4.5-day course held in Barcelona. It
was demonstrated that joint training of patients and researchers is of great benefit for both type of stakeholders helping
to raise awareness and sharpen advocacy skills and gain an understanding of therapeutic development and regulatory
processes for medicinal products in the field of rare diseases. Joint training enable both stakeholders to become more
active in this ecosystem. This task will support the human resources necessary to organize, develop and carry out all
activities as well as the operational support needed to ensure participation of researchers. The EJP for RD’s contribution
is being requested pro-rata thus leveraging on complementary and diverse sources of funding raised by EURORDIS.
Task 15.2: Training for patient advocates on scientific innovation and translational research aspects in rare diseases
(M12-M60)
TL: EURORDIS; Participant: IMAGINE
This task will enable further development of a new 5-day annual residential training workshop for 30 patient
representatives, focused on scientific innovation and translational research organised by EURORDIS since 2018.
The programme will introduce trainees to translational research, genetics, the latest advances in diagnostic tools and
pathways including those developed within the large European project called Solve-RD, disease model systems, data
(collection, sharing, and protection), patient-reported outcomes and the use of novel technologies in the context of
rare diseases research. Training will be delivered by experts in research coming from academia and industry, along
with patient groups who will provide case studies in successful research engagement. The course will also provide
Page 109 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
information on research funding in the EU, research funding strategies for patient groups and corporate collaborations.
The course will take place at the Imagine Institute for Genetic Diseases in Paris which will enable daily on site visits
to relevant laboratories and interactive discussion between research teams and participants. This task will support the
development of the programme in line with scientific breakthrough in RD research and implementation of the course
from Y2 (2020) to Y5 (2023) of the EJP (the 2018 and 2019 editions are funded through Solve-RD).
Task 15.3: Training for patient representatives and advocates on leadership and communication skills (M1-M48)
TL: EURORDIS; Participants: ISS, ACU/ACURARE and MUG
This task uses a unique strategy of engagement and integration of patients at all levels of leadership, design, training,
coaching and communication. The brand new Leadership Programme aims to provide patient representatives including
but not limited to members of the European Patient Advocacy Groups (ePAGs) involved in the 24 European Reference
Networks with a comprehensive overview of working processes involved in various advisory, management and steering
research committees, governance processes and terminology, fostering meaningful communication, cooperation, and
coordination strategies and helping patient representatives carefully consider strategic health and research advocacy
processes, roles, and responsibilities. The EURORDIS leadership programme will be developed and implemented for the
first time within the course of the EJP and will combine 4 modules (Personal Impact, Building Partnerships, Leadership
Style and Knowledge Generation) that will help nurture individual personal authority to better act on behalf of others,
influence decisions and set the strategic direction within ERNs and European-wide disease specific and infrastructure
research initiatives and projects. This task will support the development of the annual face-to-face 2 days training
programme for 30 participants. The location will be rotating each year between France (EURORDIS), Italy (ISS),
Turkey (ACU/ACURARE) and Poland (MUG).
Task 15.4: Educational materials and activities for paediatric patients (M25-M60)
TL: TEDDY & LTP (FSJD); Participant: EURORDIS
Due to the paediatric specific developmental characteristics, specifically tailored methods should be applied to the
training and empowerment process of paediatric patients. The activities undertaken in this task will be conducted based
on the experience carried out within the FP6 TEDDY Network of Excellence coordinated by CVBF, as further developed
in the context of the Category 1 Enpr-EMA member “TEDDY Network of Excellence for Paediatric Clinical Trial”.
There will also be relevant links and synergies with the ongoing H2020 project EPTRI European Paediatric Translational
Research Infrastructure, coordinated by CVBF, the H2020 project PEDCRIN Paediatric Clinical Research Infrastructure
Network coordinated by ECRIN and with the IMI2 C4C project. These are both collaborative projects, in which ad
hoc actions for paediatric patients’ empowerment are foreseen, involving also Foundation Sant Joan de Deu (FSJD).
The planned activities include short workshops in collaboration with EURORDIS and the eYPAGnet (the European
Young Persons' Advisory Group network) for 15 patients’ representatives focusing on the following areas: (i) Genetic /
rare disease characteristics and evolution; (ii) Role for paediatric patients and relevance of clinical and translational
research (including patients’ engagement in clinical trials, the consent issue, the patient-reported outcomes in the context
of paediatric rare diseases); (iii) Orphan Medicinal Products availability and access for paediatric patients on the EU
market, pharmacovigilance and off-label use in paediatric setting. The Face to Face ‘paediatric patient experts training
course’ will start in year 3 and will be hosted in Italy (TEDDY), Spain (JSJD) and France (EURORDIS).
Participation per Partner
Partner number and short name WP15 effort
14 - IMAGINE 0.40
26 - ISS 2.00
28 - TEDDY 22.00
39 - MUG 2.00
77 - EURORDIS 89.00
82 - ACURARE 2.00
Total 117.40
Page 110 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
D15.1 First Report on ExPRESS 77 - EURORDIS Report Public 12
Second Report on
D15.2 77 - EURORDIS Report Public 60
ExPRESS
First Report on training
of patient representatives
D15.3 on scientific innovation 77 - EURORDIS Report Public 24
and translational research
in RD
Second Report on
training of patient
representatives on
D15.4 77 - EURORDIS Report Public 60
scientific innovation and
translational research in
RD
First Report on
D15.5 EURORDIS’ Leadership 77 - EURORDIS Report Public 12
Programme
Second Report on
D15.6 EURORDIS’ Leadership 77 - EURORDIS Report Public 48
Programme
Training plan for
D15.7 paediatric patients’ in the 28 - TEDDY Report Public 30
EJP
Report on paediatric
D15.8 patients’ experts training 28 - TEDDY Report Public 60
courses
Description of deliverables
D165 and D166: Report on ExPRESS (M12 and M60)
D167 and D168: Report on training of patient representatives on scientific innovation and translational research in
RD (M24 and M60)
D169 and D170: Report on EURORDIS’ Leadership Programme (M12 and M48)
D171: Training plan for paediatric patients’ in the EJP (M30)
D172: Report on paediatric patients’ experts training courses (M60)
D15.1 : First Report on ExPRESS [12]
First Report on ExPRESS EURORDIS Summer School due at month 12
D15.2 : Second Report on ExPRESS [60]
Second Report on ExPRESS EURORDIS Summer School due at month 60
D15.3 : First Report on training of patient representatives on scientific innovation and translational research in RD
[24]
First Report on training of patient representatives on scientific innovation and translational research in RD due at
month 24
D15.4 : Second Report on training of patient representatives on scientific innovation and translational research in RD
[60]
Page 111 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Second Report on training of patient representatives on scientific innovation and translational research in RD due at
month 60
D15.5 : First Report on EURORDIS’ Leadership Programme [12]
First Report on EURORDIS’ Leadership Programme due at month 12
D15.6 : Second Report on EURORDIS’ Leadership Programme [48]
Second Report on EURORDIS’ Leadership Programme due at month 48
D15.7 : Training plan for paediatric patients’ in the EJP [30]
Other beneficiary: FSJD Training plan for paediatric patients’ in the EJP
D15.8 : Report on paediatric patients’ experts training courses [60]
Other beneficiary: FSJD Report on paediatric patients’ experts training courses
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Page 112 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP16 Lead beneficiary 10 12 - FFRD
Work package title Online Academic education course
Start month 1 End month 60
Objectives
Most of the currently available trainings and courses are either focusing on a group of RD, a specific technology or
developed for a national/university audience. The overall objective of this WP is to provide a EU-wide streamlined
education programme on RD research to all interested stakeholders via an e-learning established service provider that
will combine both certificated courses and MOOC. The modules of the e-learning course will be created and/or adapted
from existing/available content together with top-tier RD experts. Education being part of the future activities to be
developed by ERNs, this WP will also provide complimentary access to the e-learning platform facilities, as well as
visibility to the research training activities and educational material developed by the ERNs and other relevant clinical
networks. Educational material developed within the online academic education course is focussed on the transversal
aspects across RDs and is non-redundant with that of the ERNs.
The specific objectives of this WP are to:
● Ensure a thorough EU-wide benchmark and assessment of RD academic trainings and e-learning courses in order
to prevent any duplication of existing content and favour relevant adaptation and inclusion of existing courses in the
future EJP-RD online course;
● Develop a comprehensive, high-quality e-learning course, both available to an academic audience but also to a wider
public in coordination with a professional service provider;
● Closely monitor the impact of the course in order to implement the relevant modifications throughout the EJP-RD
lifetime and ensure its widest impact.
Description of work and role of partners
WP16 - Online Academic education course [Months: 1-60]
FFRD, INSERM, FGB, VUHSK, ISCIII, AP-HP, UKL-HD, AOUS, Radboudumc, SERMAS, NUTH, GOSH,
EATRIS, EMBL, EURORDIS
Task 16.1: Assess the needs, target audience, main topics of the academic education course (M1-M6),
TL: FFRD; Participants: SERMAS (ERN TransplantChild), RUMC (LTP-Curie Institute for ERN GENTURIS),
VUHSK, NUTH (EURO-NMD), EURORDIS, UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE),
APHP (for MetabERN and Endo-ERN)
This task will be performed through a thorough benchmark of existing RD academic courses at EU level by i) building
on the outcome of task 17.1 in Pillar 3 regarding ERNs needs and ii) working with other relevant stakeholders (EU
Universities, Patients’ Organizations, Learned Societies, EU Infrastructures, Industry stakeholders having developed
trainings on RD, etc.). Aside the content, the benchmark will also include targeted audiences of the current available
courses as well as experts and lecturers involved in those courses. As far as possible shareable feedbacks from lecturers,
students, developers and providers of the courses will be collected. This benchmark will enable to identify gaps and
specific needs as well as the main topics to address with the most relevant lecturers to involve. Priority areas of training
will be identified in order to implement the course in the most relevant way.
Task 16.2: Developing the online course (M6-M48),
TL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP-
Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS,
NUTH (ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (for ERN
MetabERN and Endo-ERN), FGB, UU (ELIXIR-SI), FutureLearn (subcontractor)
Subtask 16.2.1: Format, technical issues, status, and accreditation
STL: FFRD, Participant: FutureLearn (subcontractor)
The most suitable format and options/tools for the course will be discussed in close coordination with the e-learning
platform provider and the coordinators of the modules. European Credit Transfer System eligibility (ECTS) will be
sought, as it will be an incentive to target students more specifically. Based on existing e-learning courses, the envisioned
length for each module of the course would be 10 to 15 hours, over two to five weeks. The most-suited number of
sessions/year/modules will also be defined, with a minimum of one session/year/module. Based on the success of each
module, they could be run as many times a year as relevant with no added-fee. The selected e-learning platform is
totally scalable and enables to adapt content for different audiences and to provide in parallel free-MOOC open to
Page 113 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
everyone and programme certification for enrolled students/learners. The partners will rely on a renowned e-learning
platform with track record working with EU projects and top-ranked EU Universities together with a strong expertise
in Health. The platform will help promote the course and disseminate it, in close coordination with WP5. The platform
will be actively involved in managing lecturers of the different modules. Practical issues such as filming, e-tutoring,
collaborative learning, virtual classroom will be further defined in collaboration with coordinators of the modules and
the lecturers whilst keeping within the service provider contract.
Subtask 16.2.2: Identify and work with relevant European universities, learned societies and other institutions to develop
the content of the academic course
STL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP-
Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS,
NUTH (for ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (ERN
MetabERN andENDO-ERN), FGB, UU (ELIXIR-SI),FutureLearn (subcontractor)
Top-tier EU RD experts will be involved in the definition of the course content together with the most relevant
lecturers. 10 to 12 modules have been envisioned but will be challenged by task 16.1 outputs. Each module will
be built in close collaboration with two co-coordinators (objectives, content, e-learning options, lecturers, detailed
programme, evaluation options, etc.). Co-coordinators of the modules are bringing diverse expertise that will enrich
the approach: eight ERNs, Universities, Research Institutes (VUHSK, ISCIII, Inserm-AMU, Inserm-ORPHANET),
Patients’ Organisations (EURORDIS), EU Infrastructures (EATRIS, ELIXIR, Charities (FFRD, FGB). Modules will
be launched progressively: five modules would be implemented by M24, five more by M36 and the rest of them by
M48, with the full course running by the end of M48 with several sessions per year per module. The modules to be
launched at first will be selected based on task 16.1 outputs. The list of coordinators will also be enriched based on task
16.1 outputs. Modules will encompass a wide variety of subjects taking into consideration a bench-to-bedside approach.
Whenever possible and relevant, a three-fold perspective will be followed including patients’ testimonies, clinicians’
perspective and researchers’ expertise. The course will be developed with the ability to link and flag ERN own research
e-learning training activities. Access to the e-learning platform facilities to ERNs will also be facilitated.
Task 16.3: Follow-up, assessment and monitoring of the e-learning course (M18-M60)
TL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK), Participants: FFRD and FutureLearn ( subcontractor)
A close and regular follow-up will be necessary to adapt the online course and ensure its effectiveness. Assessment
will encompass both qualitative and quantitative and a strategy for the uptake of suggested improvements to the course
itself. Evaluation activities to be performed in this task will be developed in collaboration and shared with transversal
WP1 (task 1.3: Monitoring of the EJP RD activities). Objectivity will also be ensured with the task 16.3 leader not being
involved in the development of the course’s content.
Subtask 16.3.1 Quantitative assessment
STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK, Participant: FutureLearn (subcontractor)
The quantitative follow-up and monitoring will be ensured by the e-learning platform as part of its basic contract (no
extra fee). The platform will be capturing, in real time, demographic data (e.g. gender, geographic distribution, age,
carrier stage, etc.) as well as students’ performance. De-identified raw data would need further interpretation that will
be handled by ELIXIR-UK.
Subtask 16.3.2 Follow-up of the assessment, feedback of coordinators/lecturers/attendees
STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK)
Students’ assessment and evaluation will be defined in collaboration with coordinators and lecturers and will allow for
a measure of training quality and impact. Metrics and Key Performance Indicators (KPIs) developed by ELIXIR will
be used in order to adopt and refine a common benchmark mechanism for the different modules. This will be done in
close collaboration with WP1/Task 1.3 and WP5. The application of a common feedback collection approach across
all modules’ coordinators and lecturers will guarantee that the same core data will be gathered, allowing for an easy
comparison between modules. This will provide not only a benchmarking process for training providers to use but also
the ability (through the collection of appropriate metrics and KPIs) to determine the quality and impact of the training
being delivered. A combination of short and long-term post-course feedback surveys will be fostered to measure the
quality (short term) and impact (long term) of the course. This will be done in close links with WP1 and WP3 of the
EJP RD transversal activities.
Subtask 16.3.3 Monitoring/adaptation of the course
STL: FFRD
The modules of the course will be adapted in the subsequent sessions for a given module taken into consideration
impact assessment studies. The e-learning platform enabling to run modules separately, improvements could be brought
module/module and in a very flexible way. The adaptation of the course will be done in close collaboration with the
modules co-coordinators and lecturers.
Page 114 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Participation per Partner
Partner number and short name WP16 effort
1 - INSERM 2.50
12 - FFRD 47.00
24 - FGB 1.00
32 - VUHSK 4.00
44 - ISCIII 3.50
54 - AP-HP 4.50
57 - UKL-HD 1.50
63 - AOUS 1.00
65 - Radboudumc 1.50
68 - SERMAS 1.50
69 - NUTH 1.50
70 - GOSH 1.50
75 - EATRIS 3.50
76 - EMBL 0.00
UU (ELIXIR-SE) 1.00
UNIMAN 6.00
UCAM 8.00
77 - EURORDIS 3.00
Total 92.50
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Draft content of the
D16.1 12 - FFRD Report Public 9
online academic course
Content of the first 5
D16.2 12 - FFRD Other Public 24
online modules
Content of the full online
D16.3 12 - FFRD Other Public 48
course
Confidential, only
First Impact assessment for members of the
D16.4 of the online academic 76 - EMBL Report consortium (including 36
course the Commission
Services)
Second Impact Confidential, only
D16.5 assessment of the online 76 - EMBL Report for members of the 60
academic course consortium (including
Page 115 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
the Commission
Services)
Description of deliverables
D173: Draft content of the online academic course (M9)
D174: Content of the first 5 online modules (M24)
D175: Content of the full online course (M48)
D176 and D177: Impact assessment of the course (M36 and M60)
D16.1 : Draft content of the online academic course [9]
Draft content of the online academic course
D16.2 : Content of the first 5 online modules [24]
Content of the first 5 online modules
D16.3 : Content of the full online course [48]
Content of the full online course
D16.4 : First Impact assessment of the online academic course [36]
First Impact assessment of the online academic course Lead beneficiary: UCAM (ELIXIR-UK)
D16.5 : Second Impact assessment of the online academic course [60]
Second Impact assessment of the online academic course due at month 60 Lead beneficiary: UCAM (ELIXIR-UK)
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Overview/benchmark Draft content course for
MS56 of online courses on RD 12 - FFRD 9 the academic online course
completed available
Follow-up with the service
Technical platform developed
provider closely monitored
MS57 and ready for online academic 12 - FFRD 18
and tracked through regular
course deployment
calls/emails
Course accreditations
Official feedbacks from
MS58 obtained for the RD online 12 - FFRD 18
relevant organisations
academic course
First 5 modules of the RD 5 modules available online
MS59 online academic course 12 - FFRD 24 and accessible to an EU-wide
developed audience
12 modules available online
Full online course available
MS60 12 - FFRD 48 and accessible to an EU-wide
online
audience
Page 116 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP17 Lead beneficiary 10 58 - EKUT
Work package title ERN RD training and support programme
Start month 1 End month 60
Objectives
The overall objective of this WP is to deliver research training programs for the European Reference Networks (ERNs)
focusing on cross-cutting and over-arching research themes.
The specific objectives of this WP are:
● To map and assess the existing landscape of the training programs in the ERN training networks in terms of needs,
target groups, formats, contents, and existing resources regarding cross-cutting and overarching research themes
● To develop and deliver tailored research training activities that will be periodically adjusted to current needs to support
RD research in the formed ERN training groups
● To accredit the training activities across Europe.
Description of work and role of partners
WP17 - ERN RD training and support programme [Months: 1-60]
EKUT, UKL-HD, LUMC, Radboudumc
Methodology
In order to implement training programs that provide a cross-ERN added value, the 24 ERNs will be divided into four
training groups according to research topics that are shared by the ERNs of each group. The following training groups
have been formed:
• Group 1 “Neuro” will integrate: ERN-RND (coordination), EURO-NMD, EpiCare, ERN-Eye, ERN-CRANIO, and
ERN-ITHACA,
• Group 2 “Neoplasm and Malformation” will integrate: GENTURIS, EURACAN, PaedCan, ReCONNECT, EuroBlood
Net, ERN RITA, and ERNICA.
• Group 3 “Organs” will integrate: ERKNet, Rare-Liver, TransplantChild, Guard-Heart, ERN Lung, and ERN eUrogen,
• Group 4 “Systemic” will integrate: Endo-ERN, METABERN, VASCERN, ERN Skin and BOND.
These training groups represent the very first integration of ERNs on operational level. The ERN coordinators belonging
to the respective groups will jointly introduce a decision-making process to decide on and review funded training
activities. Matter of factly, the WP will coordinate its activities with the established ERN CG Working Group on
guidelines, education and training. By date, there has not been coordination activities of this group as regards ERN
training activities meaning that this WP will act as the main driver.
Task 17.1: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem (M1-M3)
TL: LUMC, Participants: UKL-HD, EKUT, RUMC
The goal of this online survey is for the first time to gather and assess information on cross-cutting and overarching
research training interests, activities and themes to feed into the development of research training programs to be
delivered in the ERN training groups. Four ERN training groups have been formed based common research topics. Such
a mapping has not been done yet and will provide novel data as well as the basis for implementing the ERN training
groups. Information and data have been collected by some ERNs with a focus on ERN specific content, although not in
a coordinated fashion across ERNs. These data might nevertheless serve as a starting point.
Research training needs and added value, target groups, formats, contents and existing resources will be taken into
account when implementing a structured survey. The survey will contain overarching questions and questions tailored
to the respective ERN groups. The results will also inform Pillar 3 Task 16.1 specifically regarding ERN training needs.
Task 17.2: Development of training programs for the ERN training networks based on the results of survey, (M4-M6)
TL: UKL-HD, Participants: EKUT, LUMC, RUMC;
This task will develop bespoke training programs for the ERN groups based on the results of the survey performed
in task 1 focusing on identified cross-cutting and overarching research topics. We will use focus group meetings to
develop and consent on the training programs. Focus groups will be composed of ERN coordinators, ERN training
leads and ePAG representatives. The output of the focus groups that is the consented training program will be delivered
through task 17.3. Such training programs present a level of integration not yet achieved on operational level between
the existing ERNs. So far ERNs have operationally focused on their respective networks.
Task 17.3: Deliver training programs through the ERN training networks, (M7-M60)
TL: EKUT, Participants: UKL-HD, RUMC, LUMC
Page 117 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Based on the training programs produced in task 17.2, the ERN training groups will be planning, organizing and
delivering research training activities. Based on the identified cross-cutting and overarching themes task forces will be
formed that are composed of the ERN clinicians and researcher that are experts in the respective theme. Notably, no
such cross-cutting ERN task forces on operational level exist yet and will thus bring about a new level of collaboration
of the ERNs. The task forces will develop fitting training activities that might comprise formats like fellow exchange,
clinical workshops, and further formats to be determined through the mapping exercise. Fellow exchanges might focus
on performance of (i) small bilateral research projects linking partners from different ERNs through using cutting-edge
methodologies and approaches and/or (ii) training of novel research methodologies that provide added value beyond the
single ERN level. Clinical workshops will be directed towards multidisciplinary multi-disciplinary research themes that
might have the potential to play a disruptive role in medical practise such as big data based care, tissue engineering and
stem cell technologies as well as mind-machine interface. Primary addressees of the training activities are healthcare
professionals from ERNs interested or active in research.
Task 17.4 Accreditation of training activities, (M7-M60)
TL: EKUT, Participants: UKL-HD, LUMC, RUMC
The objectives of this task will be to seek the recognition of the training activities to be accredited by respective
accreditation organisations such as the European Union of Medical Specialists (UEMS) to allow the participants to get
CME accredited training activities recognised in their respective home countries.
Participation per Partner
Partner number and short name WP17 effort
57 - UKL-HD 15.00
58 - EKUT 18.00
64 - LUMC 15.00
65 - Radboudumc 15.00
Total 63.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Results of survey on
preferences, needs and
D17.1 64 - LUMC Report Public 4
resources from the ERNs
ecosystem
EJP RD ERN training
D17.2 57 - UKL-HD Report Public 7
programmes
First Annual report
D17.3 on implementation of 58 - EKUT Report Public 13
training programs
Second Annual reports
D17.4 on implementation of 58 - EKUT Report Public 60
training programs
Description of deliverables
D178: Results of survey on preferences, needs and resources from the ERNs ecosystem (M4)
D179: EJP RD ERN training programmes (M7)
D180 and D181: Periodic reports on implementation of training programs (M13 and M60)
Page 118 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
D17.1 : Results of survey on preferences, needs and resources from the ERNs ecosystem [4]
Results of survey on preferences, needs and resources from the ERNs ecosystem
D17.2 : EJP RD ERN training programmes [7]
EJP RD ERN training programmes
D17.3 : First Annual report on implementation of training programs [13]
First Annual reports on implementation of training programs due at month 13
D17.4 : Second Annual reports on implementation of training programs [60]
Second Annual reports on implementation of training programs due at month 60
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Consent by respective ERN
MS61 ERN training groups formed 58 - EKUT 1
coordinators
Training programs of ERN Confirmed research training
MS62 58 - EKUT 6
training groups consented programs for ERN groups
Page 119 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP18 Lead beneficiary 10 32 - VUHSK
Work package title Development and adaptation of training activities
Start month 24 End month 60
Objectives
The overall objective of this WP is to ensure that capacity building activities within Pillar 3 address the
developing education and training needs in RD research of key stakeholders (including clinicians, researchers, patient
representatives, but also paramedical sector), across different EU countries. Fostering the constant flow of knowledge
and know-how, arising from the activities of Pillars 2 and 4 and reaching out to RD research community as a whole will
enhance usage of best practices and standards in RD research. These activities will be done in close collaboration and
shared with WP1 Task1.3. These activities will decrease fragmentation of RD research education and training activities
across universities, countries, infrastructures, and networks (such as ERNs).
The specific objectives of this WP include:
● Adaptation of capacity building activities according to progress of work in Pillar 2 and Pillar 4;
● Adaptation of capacity building activities according to specific needs of EU-13 countries;
● Adaptation of capacity building activities according to specific ERN training and support needs (closely linked to the
work of WP17 of Pillar 3 and WP20 of Pillar 4).
Description of work and role of partners
WP18 - Development and adaptation of training activities [Months: 24-60]
VUHSK, FFRD, FTELE, ISS, IPCZD, EKUT, EURORDIS
Other co-lead beneficiaries: IPCZ (40) and EURORDIS (77)
Methodology
Careful evaluation of different information sources on RD education and training needs will be performed including
evaluation of Pillar 3 training users and developers’ experience surveys, self-assessments and reports. Internal (Pillar
1, 2 and 4 leaders, ERNs, EURORDIS) and external sources such as the Association of Medical Schools in Europe and
European Union of Medical Specialists, will be consulted for the identification of areas for further development required
to address specific emerging needs of the rare disease community (VUHSK, EURORDIS, ISS, FTELE, FFRD, EKUT).
In addition, particular attention will be given to the specific adaptation of training activities for EU-13 countries (IPCZD
(CHMI), VUHSK, UU (ELIXIR-SI)) with the aims of enhancing EU-13 inclusion into RD communities. Reports of
identified gaps and needs will be shared with WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning
and with WP5 for dissemination purposes.
Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of
training activities (M24-M60)
TL: EURORDIS and FFRD, Participants: EKUT, ISS, VUHSK, FTELE;
Task 18.1 will work in synergy with the Operating Group and the Executive Committee (EURORDIS, VUHSK) to
review progress, report and identify training areas in need of further development and/or not previously addressed within
Pillar 3. For example, close attention will be given to ensure continuous relevance and alignment of training topics and
areas of Pillar 3 WP14 (ISS), WP15 (EURORDIS) and WP16 (FFRD) with progress of work in WP10 and WP13 of
Pillar 2 (ISS, FTELE, EKUT). Furthermore, it is envisaged that a new training activity will be developed to provide
capacity building of the different stakeholders on the use of the common platform to be developed under WP11 of
Pillar 2.
Task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs
of EU-13 countries, (M24-M60)
TL: IPCZD (CHMI) and VUHSK, Participants: EURORDIS, FFRD, EKUT, ISS, UU (ELIXIR-SI);
Currently, EU-13 countries still lag behind in RD research and their wider participation is hindered by challenges such as
lack of RD research and training funding and economic constraints for attending international conferences/workshops.
Task 18.2 will provide the driving force to make available wider possibilities of education and training to participants
from EU-13 (including rotation of courses and fellowships for EU-13 participants), hence contributing to their wider,
more active and consistent participation in RD research. Additional efforts to disseminate the free on-line academic
courses (WP16) within EU-13 countries will be made to increase visibility and accessibility of these resources. Task 18.2
co-leaders (IPCZD (CHMI) and VUHSK) supported by Pillar 3 leaders and partners (EURORDIS, ISS, FTELE, FFRD,
EKUT, Univ of Ljubljana) will carefully evaluate strategic priorities in capacity building needs of EU-13 countries and
Page 120 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
will transfer their assessment to WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning and to WP5
for dissemination purposes.
Task 18.3: Evaluation of developing ERN training and support needs and adaptation of training activities in WP17,
(M24-M60)
TL: EKUT, Participants: EURORDIS, VUHSK, FFRD
Task 18.3 will work in synergy with WP17 of Pillar 3 (EKUT) and WP19, Task 19.2 of Pillar 4 to adapt ERN training
and support programmes to the emerging and developing needs of ERNs including but not limited to training in
methodologies for clinical trials (WP20 of Pillar 4). The 4 core training networks composed of representatives from all
ERNs in WP17 will ensure relevance of the adaptation across rare diseases and facilitate implementation of the new
methodologies in the different ERNs.
Participation per Partner
Partner number and short name WP18 effort
12 - FFRD 1.00
25 - FTELE 1.00
26 - ISS 1.00
32 - VUHSK 4.00
40 - IPCZD 2.00
58 - EKUT 1.00
77 - EURORDIS 2.00
Total 12.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Final report on evaluation
and adaptation of training
programmes according
D18.1 to EJP RD progress of 32 - VUHSK Report Public 60
work, specific needs of
EU13 countries and ERN
developing needs
Description of deliverables
D182: Final report on evaluation and adaptation of training programmes according to Pillar 2 and 3 progress of work,
specific needs of EU-13 countries and developing needs of ERNs (M60)
D18.1 : Final report on evaluation and adaptation of training programmes according to EJP RD progress of work,
specific needs of EU13 countries and ERN developing needs [60]
Other lead beneficiaries: EURORDIS (77), IPCZD (40) and EKUT (58) Final report on evaluation and adaptation of
training programmes according to EJP RD progress of work, specific needs of EU13 countries and ERN developing
needs
Page 121 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Page 122 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP19 Lead beneficiary 10 75 - EATRIS
Work package title Facilitating partnerships and accelerating translation for higher patient impact
Start month 1 End month 60
Objectives
The overall aim of this work package is to provide researchers the mix of competences (drug/diagnostic development,
regulatory, methodological, pre-clinical and clinical development, IPR) needed to support rigorous translational
research, to secure follow-on funding and find partners for the development of new treatments and diagnostics for rare
diseases. To move a research project across all the compulsory steps that lead to market authorization and reimbursement,
and remove the well-known difficulties, a multitude of different actions and different sets of competencies are
necessary. This WP will support the RD community to more effectively translate high quality research into high impact
interventions for the RD patient community, by creating a bridge between basic research and medical innovation,
otherwise known as the “bench to bed-side” approach.
The specific objectives are:
● Empower researchers to conduct rigorous translational research by providing self-help resources and active project
mentoring and technical support;
● Improve the uptake of successful research projects towards clinical implementation with active exploitation and
follow-on funding support;
● Improve efficiency and outcomes of translational research, and develop novel funding concept to reduce the ‘valley
of death’ funding gap.
Description of work and role of partners
WP19 - Facilitating partnerships and accelerating translation for higher patient impact [Months: 1-60]
EATRIS, FFRD, FGB, FTELE, CVBF, UNEW, CCRI, CLB, GUF, HSK, HUGEN
Other lead beneficiary: FTELE (25)
Task 19.1: Accelerating translation
TL: CVBF, EATRIS, Participants: FTELE, UNEW, GUF (ERN LUNG), CCRI (PAEDCAN)
Subtask 19.1.1: Innovation Management Toolbox (M1-M60)
In this task, a toolbox will be established as an online virtual library that provides self-help resources that will be openly
accessible to the RD research community, and will be utilised by the WP partners and Innovation Managers to implement
documents and guidance for projects supported here. This library will be accessible through the virtual platform in
Pillar 2. Via electronic surveys of the ERN and basic research community conducted by ERNLUNG, the pressing
needs for self-help resources and templates will be ascertained, to drive the population of the library. The toolbox will
include technical guidance (such as target validation techniques, use of molecular imaging for drug development, and
- drawing upon the work done in other pillars, especially Pillar 2 - patient confidentiality and data handling, animal
welfare, biorepositories, plus intellectual property management and contract templates), a project management manual,
and regulatory guidance. Many of these materials have already been created in other contexts and will be available after
collation. Particular attention to the Paediatric Regulation will be given by CVBF and a handbook will be created by
UNEW, to develop an ‘ACT’ (Advisory Committee on Therapeutics) model for Rare Diseases, based on the successful
TACT model in the muscular dystrophy field. WP19 will make this library accessible through the Central Helpdesk
and Virtual Platform of the EJP RD. It will also provide guidance to Pillar 2 on special requirements for translational/
clinical research.
Subtask 19.1.2: Assessment of translational research projects (M1-M54)
All projects selected for funding through Pillar 1 and ongoing projects from E-Rare-3 will be analyzed to establish
the development stage of the project and the likely product classification of the concept. In so doing, the future
developmental needs should be confirmed including the regulatory pathway (in collaboration with the regulatory
transversal WP4). This analysis will be undertaken by FTELE and EATRIS, and Paediatric projects will be assessed by
CVBF, all of which are expert organizations in innovation management and translational research, and comprise experts
with basic science, product development, regulatory, commercial and intellectual property expertise.
Projects eligible for IM support are:
● Translational research projects funded in Pillar 1;
● Successful RDR Challenge projects from WP8 of Pillar 1;
Page 123 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
● Ongoing projects (with 2 years or more still to run at time of application) from E-RARE 3 that request support and
are identified as translational.
Subtask 19.1.3: Real-time mentoring and technical support for translational research projects (M1-M60)
All projects that are translational will be offered the support of a dedicated Innovation Manager (IM) that will utilise
the innovation management toolbox (T 19.1) and the extensive networks of the partners in the EJP RD. These networks
include those of the ESFRI infrastructures (BBRMI, ECRIN, EATRIS, ELIXIR), the ERNs, global partners in and
outside of IRDiRC (especially those with drug, medtech and diagnostics development expertise, such as NIH NCATS,
CDRD, LifeArc, AFM Telethon, FTELE), and the paediatric research community through CVBF-EPTRI. Projects will
be supported until IM capacity is exhausted and so will be on a first-come-first-serve basis. The assigned Innovation
Manager will be the permanent contact point for the supported project, granting access to expertise, facilities and
tools. From M1 IM will build a pool of mentors by approaching individuals to request involvement. The mentors
enrolled in WP19 will be from industry and regulatory organisations, providing excellent contact between research,
industry and regulatory sectors. Consenting experts will be added to a database and will sign a mentoring agreement
to establish the rules of engagement. Experts subsequently recruited into support of specific projects will mentor team
in a longitudinal, distance format, via regular conference call meetings and occasional face-to-face as needed, and will
verify the achievement of milestones, advise on further steps and issue recommendations on technical progress, in order
to maximise the project’s potential of success and further development towards the clinic. Finally, on ad hoc basis, the
IM and mentors will provide guidance to Pillar 2 on special requirements for translational/clinical research if demanded.
Task 19.2: Support in exploitation and follow-on funding (M1-M60)
TL:FTELE; Participants: EATRIS, CVBF, FFRD, FGB, HUGEN (HACETTEPE), CLB (ERN-EURACAN), HSK
(MetabERN), AFM
This task is aimed at providing support and guidance to projects approaching the end of EJP RD funding, in particular
on the definition and implementation of a development and exploitation plan.
Activities in this task are accessible to principal investigators:
● Funded through the transnational calls of Pillar 1 and that have been indicated as candidates to receive IM
support in subtask 19.1.3
● Originated from the PoC challenges in P1WP8
● Funded through E-Rare calls upon request and with minimum technology readiness level (TRL) 4.
Subtask 19.2.1: Assessing the potential of projects (M1-M54)
The aim of this sub-task is to provide Pillar 1 translational projects and those from PoC RDR Challenges approaching
their term, the opportunity to discuss envisaged next steps with a panel of experts in drug development, IP and business
development, potentially including also relevant experts in the specific disease area (ERNs). Special attention will be
paid in selecting the experts for the assessment panel in order to avoid any conflict of interest. The aim of this assessment
is to identify the best strategy to bring the projects forward in development depending on the data obtained, TRL reached
and expertise required to further development.
Subtask 19.2.2: Development and exploitation plan (M3-M60)
Based on the assessment conducted in the subtask above, PIs will receive support in the definition of a suitable plan to
implement the identified strategy, potentially using a limited part of the remaining funding to cover initial development
activities. The plan will encompass:
● Research activities mainly aimed at validating data obtained in the project
● IP strategy
● Definition of the unmet need filled by the project (analysis of the disease field, epidemiology, available treatments/
diagnostics, main players)
● Sustainability plan (follow on funding, partnership with industry, company creation).
Subtask 19.2.3: Follow-on funding (M5-M60)
In order to implement the plan defined above, in the cases where further funding is needed to reach proof of concept,
support in identifying suitable funding opportunities (either through public or private funding) and guidance in preparing
the application will be provided through the expertise in technology transfer, pre-clinical and clinical development as
well as in regulatory affairs.
Subtask 19.2.4: Partnering support (M6-M60)
This task will support projects that meet the requirements to be uptaken by companies/investors for the achievement
of their development plan. FTELE has established over the years a number of partnerships with commercial partners
that have allowed to bring one advanced therapy to patients (i.e. Strimvelis, approved by EMA in 2016) and to support
clinical trials for 5 genetic diseases. This expertise, combined with that of the other partners in the task, will be made
available to PIs to support them in approaching companies. In addition to the identification of the best candidate partners,
a guide to the preparation of appropriate project presentations (both confidential and non-confidential) will be provided,
including layout models.
Task 19.3: Evaluation of Innovation Management and exploitation support tasks (M44-M48)
Page 124 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
TL: GUF (ERN-LUNG)
On the basis of surveys and - if needed - interviews of users of the services provided in T19.1-T19.4, ERN-LUNG
will assess the user satisfaction and added value of both services and the library. A report will be created utilizing the
Transversal Sustainability matrix provided by WP3, to inform sustainability planning and monitoring Task 1.3.
Task 19.4: Roadmap for a European investment platform for RD (M2-M44)
TL: FTELE, EATRIS
Expanding on specific examples of novel investment platforms in RD and elsewhere, this task will assess feasibility
and define a roadmap for the creation of a pan-European funding platform with a focus on RDs, to optimize the path
to the patent and sustain the important innovation activities of the EJP RD. The roadmap will feed the sustainability
strategy of the EJP RD as a whole performed in WP3.
Participation per Partner
Partner number and short name WP19 effort
12 - FFRD 7.00
24 - FGB 12.00
25 - FTELE 74.00
27 - CVBF 28.00
52 - UNEW 10.00
53 - CCRI 3.00
56 - CLB 2.00
59 - GUF 5.00
60 - HSK 3.00
75 - EATRIS 53.00
83 - HUGEN 11.00
Total 208.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
First Periodic report on
for members of the
mentoring and technical
D19.1 75 - EATRIS Report consortium (including 24
support for translational
the Commission
research projects
Services)
Second Periodic report Confidential, only
on mentoring and for members of the
D19.2 technical support for 75 - EATRIS Report consortium (including 42
translational research the Commission
projects Services)
Third Periodic report on
Confidential, only
mentoring and technical
D19.3 75 - EATRIS Report for members of the 60
support for translational
consortium (including
research projects
Page 125 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
the Commission
Services)
Confidential, only
for members of the
Final report on follow-on
D19.4 25 - FTELE Report consortium (including 60
funding and exploitation
the Commission
Services)
User satisfaction and
Confidential, only
feasibility report on
for members of the
Facilitating partnerships
D19.5 59 - GUF Report consortium (including 48
and accelerating
the Commission
translation for higher
Services)
patient impact
Confidential, only
Roadmap for EU for members of the
D19.6 investment platform for 25 - FTELE Report consortium (including 36
RDs the Commission
Services)
Description of deliverables
D183 to D185: Periodic reports on mentoring and technical support for translational research projects (M24, M42,
M60)
D186: Final report on follow-on funding and exploitation (M 60)
D187: User satisfaction and feasibility report (M48)
D188: Roadmap for EU investment platform for RDs (M36)
D19.1 : First Periodic report on mentoring and technical support for translational research projects [24]
Other lead beneficiary: CVBF (27) First Periodic report on mentoring and technical support for translational research
projects due at month 24
D19.2 : Second Periodic report on mentoring and technical support for translational research projects [42]
Other lead beneficiary: CVBF (27) First Periodic report on mentoring and technical support for translational research
projects due at month 42
D19.3 : Third Periodic report on mentoring and technical support for translational research projects [60]
Other lead beneficiary: CVBF (27) Third Periodic report on mentoring and technical support for translational research
projects due at month 60
D19.4 : Final report on follow-on funding and exploitation [60]
Other lead beneficiary: FGB (24) Final report on follow-on funding and exploitation
D19.5 : User satisfaction and feasibility report on Facilitating partnerships and accelerating translation for higher
patient impact [48]
User satisfaction and feasibility report on Facilitating partnerships and accelerating translation for higher patient
impact
D19.6 : Roadmap for EU investment platform for RDs [36]
Other lead beneficiary: EATRIS (75) Roadmap for EU investment platform for RDs
Page 126 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Innovation Management
MS63 75 - EATRIS 8 Toolbox available on website
Toolbox openly accessible
User satisfaction survey Internal report on collected
MS64 75 - EATRIS 46
completed survey results
Benchmarking of investment Internal report on
MS65 75 - EATRIS 30
platform models completed benchmarking
Page 127 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP20 Lead beneficiary 10 54 - AP-HP
Accelerating the validation, use and development of innovative methodologies tailored
Work package title
for clinical trials in RDs
Start month 1 End month 60
Objectives
The overall objective of this WP is to foster the development of innovative methodologies tailored for clinical studies
in RDs. The specific objectives are to map the best methodologies for clinical studies in RDs and to validate innovative
and promising design and analysis methodologies for therapy evaluation in some specific rare diseases. This WP will
support ERNs to use the most adapted methodologies improving clinical trial studies in RDs. Moreover innovative
design and analysis methodologies in RD areas should be developed in fields with unmet need in order to fill the gaps.
Once validated, agreed and accepted by all stakeholders, the innovative methodologies will foster the achievement of
IRDiRC goals.
Description of work and role of partners
WP20 - Accelerating the validation, use and development of innovative methodologies tailored for clinical
trials in RDs [Months: 1-60]
AP-HP, UKA, CCRI, UKL-HD, HSK, IOR, SERMAS, GOSH, ECRIN
Other lead beneficiaries: UKA (16) and HSK (60)
Task 20.1: Task Force Group (M1-M60)
TL: UKA, APHP, HSK (Metab-ERN), Participants: UKA, APHP, CCRI (Ped-Can), IOR (ERN-Bond), UKL-HD
(ERKnet), GOSH (EPICARE), ECRIN, EURORDIS, ULiv, AFM
The main activities within the WP20 will be coordinated and monitored by a Task Force Group (TFG) of experts which
will be established during the first month of the EJP RD project (subtask 20.1.1) and represented by the WP leaders
with additional scientific, clinical and methodological experts and representative(s) of patients from EURORDIS. The
TFG will be responsible for review of the existing state-of-the-art methodologies at European and international levels in
specific topics related to clinical trials in rare diseases. Whenever needed the TFG will expand its capacity by including
additional experts from ERNs and other external specialists covering different disciplines. The TFG will review the
standard of clinical studies methodology usable in RD research and deliver the roadmap of available methodologies
promising to gain efficiency for a given RD or a group of RDs. The duties of the TFG will include: (i) coordination of
activities within WP20; (ii) identification of promising areas for the demonstration projects and innovative methodology
projects; (iii) preparation of detailed internal call (topic) description for internal call for demonstration projects and
innovative methodology projects (Tasks 20.3 & 20.4); (iv) writing of the final report summarizing main results of the
WP20 including recommendations roadmap.
The Group will start the work by a concise knowledge interchange and identification of highly promising areas for
validation of recent promising methodologies and areas in need of further innovation. The TFG will be responsible for
the monitoring of the progress of the projects and annual progress reports will serve as input to the EJP RD Annual
Progress Report. The TFG will also identify the items/findings ready for dissemination to the RD community through
Transversal WP5 but also through the clinical trials support office with ECRIN (task 20.2) and through training activities
of WPs 15 and 16. The main results of the WP20 of the TFG roadmap will be disseminated via a peer review publications,
e.g. summarized in a “Points to Consider” paper by the regulators (EMA, etc.).
Task 20.2: Support in design and planning of RD clinical studies (M1-M60)
TL: ECRIN, Participants: APHP (ERN-Skin), SERMAS (ERN Child Transplant)
To support the RD/ERN clinical investigators in the preparation of clinical studies for the development of new
treatments, for drug or device repurposing, or for diagnostic studies a support office will be set up (task 20.2.1). The
support office will benefit from the current ECRIN organization reinforced by a dedicated RD clinical manager who
will be the permanent contact point for the ERN clinical investigators and partners, collecting information on the
projects, organizing and facilitating their access to the specific expertise and ensuring timely delivery of support. The
(ECRIN) RD clinical manager will be supported by the (ECRIN) Clinical Operation Manager and medical expert(s).
The support will include design and methodological aspects of the study and statistical methodology adapted to the
small sample size. The office will offer support to ERN investigators to plan trials testing new treatments or new
strategies for the benefit of the patients. Beside ECRIN specialists, it will include two representatives of ERNs, and
a methodology expert (from the TFG). Additional experts from the TFG will provide specific input upon request. A
“Terms of Reference” document will describe the mission, composition and activities of the support office, and the
Page 128 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
eligibility of the investigators requesting support (first restricted to members of ERNs, then expanded to the Pillar 1
calls or projects on clinical studies). The support office will meet through teleconferences, inviting the investigators
to present and discuss their project proposals. For each project, the office will propose a spectrum of support in the
planning of clinical studies on RDs including: (i) the site and country selection; (ii) patient recruitment strategies; (iii)
information on regulatory and ethical aspects; (iv) informed consent and insurance requirements on the management of
samples and IMP; (v) recommendations on monitoring plan, on data management, sharing and analysis; (vi) support on
cost evaluation; (vii) recommendations on consortium and study management and governance; (viii) recommendations
on contracting, together with risk assessment and mitigation. Further design aspects will include recommendations on
the choice the most efficient study design, the choice of primary endpoint, the comparator, inclusion and exclusion
criteria, and on all aspects of the statistical methodology of the study. The requests and nature of support provided will
be recorded for evaluation of efficiency (Task 1.3) and incoming needs towards the reinforcement of the capacity of
ERNs to initiate and conduct clinical studies, independently of industry sponsors.
Task 20.3: Demonstration projects on existing statistical methodologies to improve RD clinical trials (M9-M48)
TL: IOR (ERN BOND); GOSH (EPICARE), Participants: APHP, UKA
By M9 WP20 will organize call for 6 demonstration projects. This will be done with support from Pillar 1 chosen
partner to ensure transparent and efficient call implementation and evaluation process. Recent developments suggest
that traditional methodologies do not result in cost effective and efficient trials supporting RD research as needed. A
major source of innovative methodologies are recently published by IDeAl , asterix and InSPiRe . However, validation
of these new methodologies is still missing. Thus, the overall aim of the 6 small scale demonstration projects will be to
validate in practical settings the existing, most recently presented innovative methodologies, in practil settings to provide
necessary proofs of their efficacy and thereby raise awareness and usage of these methodologies. The demonstration
will be based on existing RD data or running co-funded pilot studies (with industry or private partners) to proof the
feasibility for possible use of these methods. The main source for these data will be completed clinical trials data of
ERNs. As result, the investigation will show the benefit of these innovative methodologies for therapy evaluation in RD
and thereby foster better treatment evaluation with efficient analysis techniques. Taking into account, that the various
design aspects, like definition of endpoints, trial layout, randomization techniques and power calculation are related
to analysis techniques, the result of this task will be pivotal in influencing design and implementation of clinical trials
in RD at large scale. The progress and results of the demonstration projects will be followed and referred to the TFG
during the monthly meetings. Finally, these results will be communicated to Pillar 4, Task 20.2, to Pillar 3 WP18 and to
the communication manager of the EJP RD. It is expected that with the launch of the call in M9 demonstrators should
start in month 15 with 30 months (2.5 years) working period. Thus, the final results of these validation projects will
be expected at M45.
Task 20.4: Projects on innovative methodologies to improve RD clinical trials in limited populations (M12-M56)
TL: CCRI (PAEDCan) & HSK (Metab ERN), Participants: APHP, UKA
Recently, the IRDiRC Task Force for ‘Small population Clinical Trials’ tackled the issue of optimization and
improvement of commonly adopted approaches to reach agreement between the different stakeholders on appropriate
small population studies. Based on the inputs from this Task Force, the TFG together with other relevant experts will
identify the most promising areas of research on missing methodologies to close the gaps in clinical studies on limited
populations. The internal call will be organized similarly to the one on demonstrators, with the input from the TFG on the
detailed call text and factual implementation by partners (from Pillar 1) possessing expertise in launching, implementing
and evaluating call for projects.
The proposed areas for innovative methodology projects will include:
From the clinical perspectives:
● Finding more appropriate endpoints for clinical studies in RDs which allow assessing clinically meaningful responses
as PCOMs
● Validation of possible composite end points and surrogates
● Capture in the cohorts of natural history studies efficacy and important safety information through life span.
And from statistical methodologies perspectives:
● Level of evidence assessment associated with randomization in limited populations
● Efficient designing and analysis of bridging studies for RD
● Pharmacometric modeling for design and analysis in limited populations
The involvement of clinicians, patients and methodologists will be considered as the best configuration to meaningful
results to customized methodological development of clinical studies matching the patients need (and not only focusing
on testing of a given therapy). The internal call for the innovative methodology projects will be launched in month 12
and will start in month 18 with the 36-month working period. Thus the results are expected by M54.
Page 129 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Participation per Partner
Partner number and short name WP20 effort
16 - UKA 59.00
53 - CCRI 10.00
54 - AP-HP 68.00
57 - UKL-HD 4.00
60 - HSK 17.00
61 - IOR 6.00
68 - SERMAS 4.00
70 - GOSH 6.00
74 - ECRIN 77.00
Total 251.00
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Confidential, only
Terms of Reference of for members of the
D20.1 clinical studies support 74 - ECRIN Report consortium (including 6
office the Commission
Services)
Confidential, only
First Report on the for members of the
D20.2 assessment of the support 74 - ECRIN Report consortium (including 36
office activity the Commission
Services)
Confidential, only
Second Report on the for members of the
D20.3 assessment of the support 74 - ECRIN Report consortium (including 48
office activity the Commission
Services)
Confidential, only
Third Report on the for members of the
D20.4 assessment of the support 74 - ECRIN Report consortium (including 60
office activity the Commission
Services)
Confidential, only
First Report on
for members of the
options for long-term
D20.5 74 - ECRIN Report consortium (including 48
sustainability of the
the Commission
support office
Services)
Confidential, only
Second Report on
D20.6 74 - ECRIN Report for members of the 60
options for long-term
consortium (including
Page 130 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
sustainability of the the Commission
support office Services)
Confidential, only
List of topics for for members of the
D20.7 demonstration projects 61 - IOR Report consortium (including 6
call the Commission
Services)
Final Report of funded
D20.8 16 - UKA Report Public 50
demonstration projects
Final Report of funded
D20.9 new methodology 16 - UKA Report Public 58
projects
Summary Report of Task
D20.10 54 - AP-HP Report Public 60
Force Group
Description of deliverables
D189: “Terms of Reference” for clinical studies support office group (M6)
D190 to D192: Report on the assessment of the support office activity (M36, M48, M60)
D193 and D194: Report on options for long-term sustainability of the support office (M48 and M60)
D195: List of topics for demonstration projects call (M6)
D196: Final Report of funded Demonstration Projects’ (M50)
D197: Final Report of funded methodology Projects (M58
D198: Summary Report of TFG (M60)
D20.1 : Terms of Reference of clinical studies support office [6]
Terms of Reference of clinical studies support office
D20.2 : First Report on the assessment of the support office activity [36]
First Report on the assessment of the support office activity due at month 36
D20.3 : Second Report on the assessment of the support office activity [48]
Second Report on the assessment of the support office activity due at month 48
D20.4 : Third Report on the assessment of the support office activity [60]
Third Report on the assessment of the support office activity due at month 60
D20.5 : First Report on options for long-term sustainability of the support office [48]
First Report on options for long-term sustainability of the support office due at month 48
D20.6 : Second Report on options for long-term sustainability of the support office [60]
Second Report on options for long-term sustainability of the support office due at month 60
D20.7 : List of topics for demonstration projects call [6]
Other lead beneficiary AP-HP (54) List of topics for demonstration projects call
D20.8 : Final Report of funded demonstration projects [50]
Other lead beneficiaries: AP-HP (54), IOR (61) and GOSH (70) Final Report of funded demonstration projects
D20.9 : Final Report of funded new methodology projects [58]
Other lead beneficiaries: AP-HP (54), CCRI (10) and HSK (60) Final Report of funded new methodology projects
D20.10 : Summary Report of Task Force Group [60]
Page 131 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Other lead beneficiary: AP-HP (54) Summary Report of the Task Force Group
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS66 Task Force Group set up 16 - UKA 1 Task Force Appointment list
6 demonstration of
MS67 methodologies projects 61 - IOR 15 List of demonstration projects
launched
6 innovative methodologies
MS68 53 - CCRI 18 List of innovative projects
projects launched
Report about Kick-off of
Clinical trials support office
MS69 54 - AP-HP 3 clinical trials office support
established
group
Page 132 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Work package number 9 WP21 Lead beneficiary 10 1 - INSERM
Work package title Ethics requirements
Start month 1 End month 60
Objectives
The objective is to ensure compliance with the 'ethics requirements' set out in this work package.
Description of work and role of partners
WP21 - Ethics requirements [Months: 1-60]
INSERM
This work package sets out the 'ethics requirements' that the project must comply with.
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Confidential, only
for members of the
D21.1 A - Requirement No. 1 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
NEC - Requirement No.
D21.2 1 - INSERM Ethics consortium (including 12
2
the Commission
Services)
Confidential, only
for members of the
GEN - Requirement No.
D21.3 1 - INSERM Ethics consortium (including 12
3
the Commission
Services)
Confidential, only
for members of the
D21.4 H - Requirement No. 4 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
D21.5 H - Requirement No. 5 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
D21.6 H - Requirement No. 6 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Page 133 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
for members of the
D21.7 H - Requirement No. 7 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
D21.8 H - Requirement No. 8 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
D21.9 H - Requirement No. 9 1 - INSERM Ethics consortium (including 12
the Commission
Services)
Confidential, only
for members of the
POPD - Requirement No.
D21.10 1 - INSERM Ethics consortium (including 12
10
the Commission
Services)
Confidential, only
for members of the
POPD - Requirement No.
D21.11 1 - INSERM Ethics consortium (including 12
11
the Commission
Services)
Confidential, only
for members of the
POPD - Requirement No.
D21.12 1 - INSERM Ethics consortium (including 12
12
the Commission
Services)
Confidential, only
for members of the
POPD - Requirement No.
D21.13 1 - INSERM Ethics consortium (including 12
13
the Commission
Services)
Confidential, only
for members of the
GEN - Requirement No.
D21.14 1 - INSERM Ethics consortium (including 12
14
the Commission
Services)
Confidential, only
for members of the
GEN - Requirement No.
D21.15 1 - INSERM Ethics consortium (including 12
15
the Commission
Services)
Description of deliverables
Page 134 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The 'ethics requirements' that the project must comply with are included as deliverables in this work package.
D21.1 : A - Requirement No. 1 [12]
5.4. The applicant must provide a general guidance on Directive 2010/63/EU, the nature of the experiments, the
procedures to ensure the welfare of the animals, the principle of the three Rs will be applied, and training requirement
for researchers, whenever animal research is involved 5.7. The applicant must clarify whether non-human primates
will be involved in this study and justify their inclusion in the research.
D21.2 : NEC - Requirement No. 2 [12]
6.1. A statement with the applicant's commitment not to transfer any personal data/material from or to the EU before
obtaining the relevant authorisations must be provided. 6.2. The applicant must confirm that the ethical standards and
guidelines of Horizon2020 will be rigorously applied, regardless of the country in which the research is carried out.
6.4. The applicant must provide details on the material which will be imported to/exported from EU and adequate
authorisation must be provided.
D21.3 : GEN - Requirement No. 3 [12]
12.2. An Ethics Board (AREB WP4) is to be established which must include the relevant independent expertise to
monitor the ethical concerns of this project. A periodic report from the Ethics Board must be submitted.
D21.4 : H - Requirement No. 4 [12]
2.1. Details on the procedures and criteria that will be used to identify/recruit research participants must be provided.
D21.5 : H - Requirement No. 5 [12]
2.2. Detailed information on the informed consent procedures that will be implemented for the participants must be
provided.
D21.6 : H - Requirement No. 6 [12]
2.3. Templates of the informed consent forms and information sheet must be provided. They have to be in the
language and terms understandable by the participants.
D21.7 : H - Requirement No. 7 [12]
2.4. The applicant must clarify whether children and/or adults unable to give informed consent will be involved and,
if so, justification for their participation must be provided.
D21.8 : H - Requirement No. 8 [12]
2.5. The applicant must clarify how consent/assent will be ensured in case children and/or adults unable to give
informed consent are involved.
D21.9 : H - Requirement No. 9 [12]
2.11. Copies of ethics approvals for the research with humans must be submitted.
D21.10 : POPD - Requirement No. 10 [12]
4.1. The applicant must check if a declaration on compliance and/or authorisation is required under national law for
collecting and processing personal data as described in the proposal. If yes, the declaration on compliance and/or
authorisation must be [kept on file (to be specified in the grant agreement)] [submitted as a deliverable].
D21.11 : POPD - Requirement No. 11 [12]
4.2. If no declaration on compliance or authorisation is required under the applicable national law, a statement from
the designated Data Protection Officer that all personal data collection and processing will be carried out according to
EU and national legislation must be [kept on file (to be specified in the grant agreement)] [submitted as a deliverable].
D21.12 : POPD - Requirement No. 12 [12]
4.4. Detailed information on the procedures for data collection, storage, protection, retention, and destruction, and
confirmation that they comply with national and EU legislation must be [included in the grant agreement before
signature] [kept on file (to be specified in the grant agreement)] [submitted as a deliverable].
D21.13 : POPD - Requirement No. 13 [12]
4.9. In case of further processing of previously collected personal data, relevant authorisations must be [kept on file
(to be specified in the grant agreement)] [submitted as a deliverable].
D21.14 : GEN - Requirement No. 14 [12]
Page 135 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
12.1. An Ethics Advisor with the relevant independent expertise to monitor the ethical concerns in this project must
be appointed. A periodic report from the Ethics Advisor must be submitted.
D21.15 : GEN - Requirement No. 15 [12]
12.1. An Ethics Advisor with the relevant independent expertise to monitor the ethical concerns in this project
must be appointed. A periodic report from the Ethics Advisor must be submitted. 12.2. An Ethics Board must be
established which includes the relevant independent expertise to monitor the ethics concerns of this project. A
periodic report from the Ethics Board must be submitted. The Ethics Board should make sure the H2020 framework
for ethics is fully applied to the planned subsidiary projects, and the ethics management of these should be carried out
within the H2020 framework.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Page 136 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.4. WT4 List of milestones
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
Coordination &
Minutes of the 1st Operating
MS1 governance structures WP1 1 - INSERM 1
Group conference call
established
Helpdesk entry point
MS2 WP1 1 - INSERM 3 Website
set up
Policy Board
MS3 WP1 1 - INSERM 3 List of Policy Board Members
established
Survey on prioritization
MS4 criteria set up and WP2 27 - CVBF 3 Survey document
launched
Prioritization scheme
and list of criteria Minutes of the ExCom and
MS5 WP2 44 - ISCIII 6
validated by ExCom Policy Board meeting
and Policy Board
Survey to national
mirror groups
MS6 WP3 26 - ISS 5 Survey document
established and
launched
Proposed model approved by
Suitable structure and
the EJP-RD Governance and
MS7 sustainability model for WP3 75 - EATRIS 42
MS according to decision-
the EJP RD proposed
making procedures
Final proposal for Final Business model and
MS8 decision on the WP3 44 - ISCIII 54 sustainability plan for
sustainability roadmap adoption
MS9 AREB set up WP4 24 - FGB 5 List of AREB members
1st Annual AREB
MS10 WP4 24 - FGB 6 Meeting minutes
meeting held
2nd Annual AREB
MS11 WP4 24 - FGB 18 Meeting minutes
meeting held
3rd Annual AREB
MS12 WP4 24 - FGB 30 Meeting minutes
meeting held
4th Annual AREB
MS13 WP4 24 - FGB 42 Meeting minutes
meeting held
Set of template
agreements for IPR Availability on-line (EJP RD
MS14 WP4 25 - FTELE 7
issues available to the website)
community
EJP RD social media Relevant social media
MS15 WP5 1 - INSERM 2
pack set up and running accounts
Decision on the
organization of the Minutes of the relevant
MS16 WP5 1 - INSERM 4
RE(ACT) 2020 ExCom conference call
congress
Page 137 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
Decision on the
organization of the Minutes of the relevant
MS17 WP5 1 - INSERM 18
RE(ACT) 2022 ExCom conference call
congress
Decision on the
organization of the Minutes of the relevant
MS18 WP5 1 - INSERM 42
RE(ACT) 2024 ExCom conference call
congress
Target countries and
voluntary helpers for List of target countries and
MS19 WP5 1 - INSERM 2
translated Newsletter voluntary helpers
agreed
Public Call document on
Implementation of
MS20 WP7 34 - ZonMw 7 website and announcement of
Networking scheme
the first round
Multi-stakeholder
workshops to set- Report from RDR Challenges
MS21 WP8 77 - EURORDIS 8
up RDR Challenges workshops
scheme
Adapted monitoring
tool implemented for Link to monitoring tool
MS22 WP9 5 - FNRS 9
collaborative research released to granted applicants
projects
Adapted monitoring
Link to monitoring tool
MS23 tool implemented for WP9 5 - FNRS 9
released to granted applicants
Networking grants
Final reports of Rare
disease challenge
MS24 WP9 78 - CSO-MOH 54 Final reports
projects delivered to
monitoring tool
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
1st Annual retreat of
MS25 WP10 1 - INSERM 6 and Pillar 4 representative
Pillar 2 completed
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
2nd Annual retreat of
MS26 WP10 1 - INSERM 18 and Pillar 4 representative
Pillar 2 completed
organized and achieved,
including background
documents
Annual meeting involving
3rd Annual retreat of all ERNs, Pillar 2 WPs co-
MS27 WP10 1 - INSERM 30
Pillar 2 completed leaders, WP10 partners
and Pillar 4 representative
Page 138 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
4th Annual retreat of
MS28 WP10 1 - INSERM 42 and Pillar 4 representative
Pillar 2 completed
organized and achieved,
including background
documents
Annual meeting involving
all ERNs, Pillar 2 WPs co-
leaders, WP10 partners
5th Annual retreat of
MS29 WP10 1 - INSERM 54 and Pillar 4 representative
Pillar 2 completed
organized and achieved,
including background
documents
Pillar 2 WP10: Online
1st End-users surveys
MS30 WP10 50 - ULEIC 5 surveys developed, sent and
done
results analyzed.
Pillar 2 WP10 : Online
2nd End-users surveys
MS31 WP10 50 - ULEIC 17 surveys developed, sent and
done
results analyzed.
Pillar 2 WP10 : Online
3rd End-users surveys
MS32 WP10 50 - ULEIC 29 surveys developed, sent and
done
results analyzed.
Pillar 2 WP10: Online
4th End-users surveys
MS33 WP10 50 - ULEIC 41 surveys developed, sent and
done
results analyzed.
Pillar 2 WP10: Online
5th End-users surveys
MS34 WP10 50 - ULEIC 53 surveys developed, sent and
done
results analyzed.
Financing models for
sustaining and scaling Matrix and support document
up FAIRification listing the appropriateness
support services of financing models for
MS35 WP10 65 - Radboudumc 18
assessed with sustaining and scaling up
sustainability experts virtual platform components
and RD community and support services
stakeholders
Simulations of
financing models
for sustaining
Results of the simulations
and scaling up
MS36 WP10 65 - Radboudumc 48 of financing models for
FAIRification support
FAIRification services listed
services executed
and evaluated with
sustainability experts
Page 139 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
and RD community
stakeholders
First Metadata sets
Prioritized resources having
MS37 of identified and WP11 76 - EMBL 9
validated metadata sets
prioritized resources
Second Metadata Prioritized resources having
MS38 sets of identified and WP11 76 - EMBL 21 validated metadata sets
prioritized resources updated at month 21
Third Metadata sets Prioritized resources having
MS39 of identified and WP11 76 - EMBL 33 validated metadata sets
prioritized resources updated at month 33
Fourth Metadata Prioritized resources having
MS40 sets of identified and WP11 76 - EMBL 45 validated metadata sets
prioritized resources updated at month 45
Fifth Metadata sets Prioritized resources having
MS41 of identified and WP11 76 - EMBL 57 validated metadata sets
prioritized resources updated at month 57
Common AAI
3 resources integrated with
MS42 integrated in 3 WP11 76 - EMBL 24
LifeScience/ELIXIR AAI
resources
PPRL available to link data
PPRL in production for
MS43 WP11 76 - EMBL 36 between at least 3 projects/
3 projects/resources
resources
Pilot cloud computing
infrastructure available for
MS44 Pilot cloud deployed WP11 45 - CNAG-CRG 24
deploying workflows at
UCMG and BSC(ELIXIR-SI)
Core standards teams Lists of teams and target
MS45 assembled and working WP12 50 - ULEIC 12 standards in place, plus
actively shared document storage
Multi-team software
collaborations working Lists of teams and target goals
MS46 WP12 50 - ULEIC 18
on agreed goals and and standards in place
standards
Communication
established between List of experts and
experts and stakeholder stakeholders in place, plus
MS47 WP12 64 - LUMC 12
representatives means of communication and
involved in practical shared document storage
FAIRification support
First update
Guidelines document updated
FAIRification
MS48 WP12 64 - LUMC 6 by the latest FAIRification
guidelines for RD data
experiences at month 6
managers
Guidelines document updated
Second update
MS49 WP12 64 - LUMC 30 by the latest FAIRification
FAIRification
experiences at month 30
Page 140 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
guidelines for RD data
managers
Third update
Guidelines document updated
FAIRification
MS50 WP12 64 - LUMC 42 by the latest FAIRification
guidelines for RD data
experiences
managers
Fourth update Guidelines document updated
FAIRification by the latest FAIRification
MS51 WP12 64 - LUMC 54
guidelines for RD data experiences updated at month
managers 54
D153 (D13.2)
workflow used in
proof of concepts Peer reviewed paper or report
MS52 study evaluated and WP13 36 - UM 48 in BioRXiv. Plus plans on
improved, with project GitHub
plans for future updates
and release scheme.
D13.3 workflow used
in proof of concepts
Peer reviewed paper or report
study evaluated and
MS53 WP13 36 - UM 60 in BioRXiv. Plus plans on
improved, with project
GitHub
plans for future updates
and release scheme
Report of scientific
Orphanet training
MS54 WP14 1 - INSERM 10 committee meeting validated
content defined
and available
Training Roadmap Definition of the training
MS55 WP14 26 - ISS 1
established schedule
Overview/benchmark Draft content course for
MS56 of online courses on WP16 12 - FFRD 9 the academic online course
RD completed available
Technical platform Follow-up with the service
developed and ready provider closely monitored
MS57 WP16 12 - FFRD 18
for online academic and tracked through regular
course deployment calls/emails
Course accreditations
Official feedbacks from
MS58 obtained for the RD WP16 12 - FFRD 18
relevant organisations
online academic course
First 5 modules of the 5 modules available online
MS59 RD online academic WP16 12 - FFRD 24 and accessible to an EU-wide
course developed audience
12 modules available online
Full online course
MS60 WP16 12 - FFRD 48 and accessible to an EU-wide
available online
audience
ERN training groups Consent by respective ERN
MS61 WP17 58 - EKUT 1
formed coordinators
Page 141 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
Training programs of
Confirmed research training
MS62 ERN training groups WP17 58 - EKUT 6
programs for ERN groups
consented
Innovation
MS63 Management Toolbox WP19 75 - EATRIS 8 Toolbox available on website
openly accessible
User satisfaction survey Internal report on collected
MS64 WP19 75 - EATRIS 46
completed survey results
Benchmarking of
Internal report on
MS65 investment platform WP19 75 - EATRIS 30
benchmarking
models completed
Task Force Group set
MS66 WP20 16 - UKA 1 Task Force Appointment list
up
6 demonstration of
MS67 methodologies projects WP20 61 - IOR 15 List of demonstration projects
launched
6 innovative
MS68 methodologies projects WP20 53 - CCRI 18 List of innovative projects
launched
Report about Kick-off of
Clinical trials support
MS69 WP20 54 - AP-HP 3 clinical trials office support
office established
group
Page 142 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.5. WT5 Critical Implementation risks and mitigation actions
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
● High quality of the coordination team with
Incapacity or departure of
1 WP1 possibility of interim by one of the Pillar leaders ●
coordinator
Strong commitment of the Coordinator
Underestimation of
● Close follow up of the work progress (regular
workload to be shared by
meetings, detailed management plan) ● Possibility
2 project managers between WP1
to receive temporary support from IRDiRC
Coordination office and
members during rush periods
IRDiRC SciSec
● The plan for 5 years already in place ● Strategy,
Delay in delivery of Annual
prioritization and monitoring procedures well
3 Work Plan and Annual WP1
organized ● Close follow up of the yearly agenda
Progress Report
by Pillar and WP leaders
● Most partners’ institutions are experiences
and equipped with internal financial accounting
4 Misuse of resources WP1 and auditing office ● The Coordination financial
officer will advise and partners in preparation of
financial documents when necessary
● Detailed business plan prepared before launch
Financial bottleneck due
of the project including 15% risk of budget
to underestimation of
loss ● Financial management issues set up in
5 contribution capacity of WP1
Consortium Agreement ● Emergency mitigation
partner(s) and/or withdrawal
procedure set up – possibility to adjust the work
of major partner
plan and align budget
● Efficient management strategy put in place, with
Failure to adapt to events reactive Operating Group ● Careful monitoring
6 WP1
(opportunities, threats, risks) process put in place to be able to react on time and
adapt
● EJP RD partners are highly committed to the
Programme and will contribute actively to the
strategy development ● The analysis that will be
provided by Orphanet/UBER Research is a good
Difficulty in collection of
7 WP2 alternative that demands a limited effort from the
input from stakeholders
stakeholders and shall provide detailed overview
of the funded previous and ongoing research
and capture the overlaps and trends to be used as
recommendations for prioritization
Special attention will be put to differentiate
Generalization in the between the needs in EU countries with a higher
8 WP2
definition of needs or lower development of national research plans
on RD
Special attention will be put to establish a
Generalization in the
prioritization scheme of actions, taking into
9 prioritization scheme for WP2
account the needs in countries with less developed
actions
national research plans on RD
Insufficient coordination • Criteria and process of prioritization agreed
10 of priorities / unresolved WP2 at the start of the project and validated by
conflicts about strategy GB • Possibility to call for Policy Board
Page 143 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
recommendations • Flexibility of Annual Work
Plans
● Participation of the RPOs in the prioritization
Difficulty in the management process will be separated from the topic choice
of the Conflict of Interest of that will be reserved to funding bodies ●
11 WP2
EJP RD research performing Necessary scientific support for the detailed
organizations (RPOs) definition of the topics will be ensure by the ad
hoc Advisory Boards called by the funders
IRDiRC SciSec being part of the EJP RD Coo
Office will ensure strong connection with IRDiRC
Problem of the alignment In addition, many EJP RD partners are members
12 between EJP RD proposed WP2 of IRDiRC and therefore can help in alignment.
TF and IRDiRC TF Finally, IRDiRC chair and VC will be part of the
EJP RD Policy Board to further strengthen the
collaboration
● Participation of countries will be ensured at
Low participation of some multiple levels: Policy Board, Governing Board
countries in collecting state and Mirror Groups ● The majority of EJP RD
of play information and in countries is represented in the programme by
13 WP2
the process for translation of more that one beneficiary and reflects well
prioritization on national and different type of beneficiaries (RFOs, RPOs,
EU strategies ERN, infrastructures, etc.), which guarantees good
potential of translation at national level
Incomplete/poor quality ● Provide guidance and templates to WP leaders
information on added value for sustainability/user demand reporting ●
14 WP3
of services and resources, Perform independent assessment of value of
creates misinformed roadmap services
Difficult to achieve
● Monitor external risk factors related to
sustainable collaboration
sustainability ● Update Sustainability Roadmap as
between the service
15 WP3 living document ● Give specific attention to other
providers and the associated
initiatives for agreements on equitable principles
communities beyond the
and realistic planning for adoption
project
● WP dedicated to sustainability planned ●
Sustainability activities tackled from the start of
Failure to prepare for the project ● Good knowledge of beneficiaries,
16 WP3
sustainability their capacities and weaknesses ● Important
commitment of Member States and direct contact
and dialogue ensured via the Policy Board
AREB will include the necessary expertise to
cover the different topics of the regulatory and
ethical framework. To this aim, members with
AREB unable to respond to
17 WP4 recognized expertise and the relevant European
the needs of the consortium
RIs will join the board. Furthermore, EMA and
national competent authorities will be addressed if
necessary
Inputs and feedback from ● AREB will participate whenever necessary in
pillars to verify that the the OG conference calls and will be in contact
18 WP4
projects and activities will with the CO for routine updates ● AREB will
be regulatory- and ethically- collaborate closely with Pillar 1 Joint Call
Page 144 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
compliant not delivered to Secretariats during the period of call preparation
AREB and contractualization of projects
Ethical, regulatory and legal
documentation collated and
Awareness raising at meetings, conferences and
19 made available through the WP4
via transversal WP5 and Pillar 3
EJP RD is not used by the
community
Ensure awareness and understanding of the
Few/no requests for support
20 WP4 support and of its value with support from OG and
from EJP RD beneficiaries
WP leaders
● Strong commitment of BF and EJP RD
to collaborate supported by long-lasting
Breach of collaboration with
collaboration history and congress reputation ●
Blackswan Foundation and/
Possibility to partner with other organizations
21 or impossible to organize WP5
like ESHG or EURORDIS (ECRD Congress) ●
RE(ACT) congress due to
Support from EJP RD Communication Manager
low budget or interest
to BF team for communication and partnership
search
● Earmarking adequate national budgets in line
National financial with national research capacity and costs ● Post-
bottlenecks for funding evaluation negotiations on increasing national
22 WP6
joint transnational research budget and/or budget negotiations with applicants
projects ● Use of EC co-funding to adjust national budget
shortcomings
Incentives will be set up to facilitate the use of
Lack of contributions Pillar 2 components. Also the projects will be
and utilization of Pillar 2 informed regularly about the possibilities of
23 WP6
components by Pillar 1 use of P2 components. Finally, they will also
research projects be encouraged to participate in Pillar 3 WP 14
trainings on data management and quality.
Low number of applications After four subsidy rounds an early evaluation of
24 WP7
for Networking scheme the scheme is foreseen
No challenges are brought
Multi-stakeholder workshops, consisting of
up that can be solved up to
representatives of industry, academia and patient
the stage of proof of concept
25 WP8 organisations will be organised to discuss
within the projected time
potential challenges and the chosen time period
frame of 18 months with a
for proof of concept of solutions
possible 12-month extension
● Potential access to some 70 companies
No interest from who are ERTC (EURORDIS Round Table of
26 pharmaceutical companies in WP8 Companies)members confronted with specific
the project hurdles in rare diseases ● Effort also be made to
attract industry in Pillar 4
Approved challenges at A face-to-face networking meeting for academia,
27 risk of not finding relevant WP8 SMEs and industry will be organized to speed up
applicants collaboration and increase quality of applications.
A two-stage process makes it possible to put
Selected projects don’t get
additional resources at month 18 on the projects
28 expected results with the risk WP8
which would have been best developed during the
of challenge not being solved
first period. Moreover, in case the phase one has
Page 145 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
taken some delay in starting, a 5-month window is
scheduled between the completion of the second
phase and the closing of the EJP at year 5.
Routine procedure of messages and reminders
will be implemented in collaboration with call
Missing / incomplete
secretariats and respective funding agencies.
29 reporting by coordinators of WP9
Several funding agencies will only sent the final
projects funded within WP6
payment after receiving the final report of their
national research group.
A routine procedure of messages and reminders
will be implemented in collaboration with the
Missing / incomplete
Networking scheme Secretariat. The applicants
30 reporting by coordinators of WP9
will receive 80% of the grant before the meeting.
Networking scheme grants
The final payment of 20% will be sent by ZonMw
after receiving the report.
Maintain constant dialog with the ERNs
ERNs not involved in the Research group through Pillar 2 co-leader (ERN
31 WP10
Pillar 2 strategy coordinator) and incentivisation to bring their use
cases and research questions
Annual retreats and other means of regular contact
32 Poor WP10 surveys feedback WP10
will be also used to generate user’s feedback
Regular communication (TCs, workshops) will
33 WPs divergent developments WP10
maintain the alignment between both parallel WPs
Engage at least 2 partners in the metadata model
Failure to deliver metadata
34 WP11 development and extend a metadata model already
model to the virtual platform
in place
Failure to deliver single
Engage at least 2 partners in the query point
35 coordinated query point to WP11
development and extend a catalog already in place
resources
Research projects automated
Replace by manual collection and curation by
36 database subcontractor WP11
Orphanet network teams
failure
Provide support and expertise to encourage
Common AAI not deployed resources to adopt common AAI to be
37 WP11
in all resources recommended as deposition platform by the EJP
RD
Resources for some
of the virtual platform Resources for some of the virtual platform
38 infrastructures not sufficient WP11 infrastructures not sufficient to serve high EJP
to serve high EJP community community needs
needs
Failure to deliver suitable
Engage many partners and external groups,
39 standards recommended for WP12
already developing and using relevant standards
software to be based upon
Failure to deliver support
Engage at least two 2 software teams per topic,
40 software for making data WP12
working together and to WP12 standards
FAIR
Page 146 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
Funded projects in Pillar 1, Solve-RD and other
Few Multi-omics datasets not
41 WP13 already producing multi-omics data: provide
available for analysis
analysis to the data producers
All ERNs engaged in driving and testing the
VP; WP13 providing and promoting re-use by
Slow adoption of the EJP ERNs; strong communication through WP5 and
42 RD Virtual platform (VP) WP10 trainings provided through WP14 achieving
facilities by the community a large outreach of the RD community; new
trainings proposed through WP18 on the use and
value of the VP.
If such difficulties are encountered, the position
Problem in recruiting a
could be considered as full time for 2.5 years
43 half time position training WP14
in order to develop the training modules and
manager
organize the first round of national trainings
Availability of experts/
Enlarge recruitment base for teachers, link to
44 teachers for each of the 3 WP14
national societies via EuroGentest
courses
● Extension of deadline for registration
and increased dissemination. Pre-workshop
questionnaires sent do potential participants to
Insufficient number of partly guide workshop content; Promotion through
45 WP14
participants ERNs, biobanks, etc. ● Increase dissemination in
coordination with relevant WP/task leaders in EJP
+ adjust format and content based on feedbacks
received
Insufficient number of use
A number of use cases to be used for this purpose
46 cases, databases for the WP14
already available
course
Incomplete implementation ● Post workshop follow-up (3 months, 6 months,
of workshop guidelines by etc.) with all workshop participants to get
47 workshop participants once WP14 feedback. ● Common roadblocks should be
they return to their home addressed in future workshops to enable working
institutions solutions
Decrease of co-funding
48 supporting the overall WP15 Decrease the number of participants
participation of patients
Decrease or loss of the in-
kind support of Imagine Alternative on-site venues and on-site visits
49 WP15
Institute that provides the provided by other EJP RD Partners
venue and on-site visits
Increase dissemination in coordination with
Course not engaging
50 WP16 relevant WP/task leaders in EJP + adjust format
sufficient number of students
and content based on feedbacks received
Not all ERNs commit to Formation of training groups with committing
51 WP17
ERN training Networks ERNs
Funding not sufficient to Given the size and scope of the ERNs all ERN
52 deliver training programs of WP17 training groups will significantly contribute
sufficient scope additional training resources
Page 147 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
Training needs for Pillar
Close monitoring ensured through transversal
53 2 platform users not fully WP18
activities and link with Pillar 2
defined in time
Funding not sufficient to
Maximizing resources allocated to training
54 adapt training programs of WP18
activities in WP14-WP17 to enable adaptation
sufficient scope
Awareness raising at meetings, conferences and
The online resources are not
55 WP19 via transversal WP communication and education
utilized by the community
of Pillar 3
Few/no project teams request
Ensure awareness and understanding of the
56 support of Innovation WP19
support and the value of mentoring
Manager (IM)
Few projects reach stage of
● Support project teams via IM to ensure max
need for exploitation, few/no
57 WP19 chance of technical success ● Ensure max
projects request exploitation
awareness of support available
support
Delay of implementation of The TFG will implement the support office with
58 WP20
clinical study support office another member of the ECRIN network
Delay in demonstration or The TFG will select the next best demonstration
59 WP20
methodological project start project of applicant list
A rule will be defined by the TFG that each
Project not finished in due
60 WP20 beneficiary will provide sufficient funding for
time
finishing the project
Deviation from expected Tight monitoring of the research progress by the
61 WP20
research progress TFG will minimize the risk
Tight monitoring of the research progress
will minimize the risk of delay. In case of an
Deliverable are delayed or
62 WP20 unachievable deliverable the TFG will develop a
cannot be achieved
solution in agreement with the EJP coordinator
taking care of the success of the project
Page 148 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.6. WT6 Summary of project effort in person-months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
1 - INSERM 403 13 26 14 68 0 0 0 0 13.40 431.40 47.90 17.30 28 0 2.50 0 0 0
· IMGGE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· KI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· UMCL-UKCL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· PHE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· SHEBA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· Rinnekoti 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· KDBZ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· UT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· MHH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· OPBG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· DHIR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· GERAD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· BAPES 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· CUNI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· HSE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· HUG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· OUS-HF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· CCUH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· AMU 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· CMG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· MUW-AT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· Sciensano 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· UMF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Page 149 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
2 - FWF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
3 - AIT 0 0 0 0 0 0 0 0 0 0 26.80 106.50 0 0 0 0 0 0 0
4 - LBG (LBI-
0 0 0 0 0 0 0 0 0 0 22.30 0 0.70 2 0 0 0 0 0
RUD)
5 - FNRS 0 0 0 0 0 3 0 0 4 0 0 0 0 0 0 0 0 0 0
6 - FWO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 - KU Leuven 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0
8 - MEYS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 - MOSAE 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
10 - AKA 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
11 - ANR 0 2 0 0 0 15.40 0 0 0 0 0 0 0 0 0 0 0 0 0
12 - FFRD 0 0 0 0 0 12.40 0 16.50 1 0 0 0 0 0 0 47 0 1 7
13 - AFM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
14 - IMAGINE 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0.40 0 0 0 0
15 - DLR 6 1 1 1 1 21.40 0 1.50 0 0 0 0 0 0 0 0 0 0 0
16 - UKA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
17 - CHARITE 0 0 0 0 0 0 0 0 0 0 31.30 9 0 8 0 0 0 0 0
18 - UKL-FR 0 0 0 0 0 0 0 0 0 0 17.40 0 5.60 0 0 0 0 0 0
19 - NKFIH 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
20 - HRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
21 - IT-MOH 0 2 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
· APRE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
22 - TuscReg 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
23 - FRRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
24 - FGB 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 1 0 0 12
25 - FTELE 0 1 0 16 0 0 0 0 0 25.10 9.90 36.60 0 27 0 0 0 1 74
26 - ISS 0 18 0 0 0 0 0 0 0 6 6.80 0 12.20 43 2 0 0 1 0
Page 150 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
27 - CVBF 16 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 28
28 - TEDDY 0 0 0 0 1 0 0 0 0 0 0 0 0 0 22 0 0 0 0
· FSJD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
29 - MIUR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
30 - VIAA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
31 - LMT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
32 - VUHSK 6 1 1 1 1 0 0 0 0 0 5 0 0 1 0 4 0 4 0
33 - FNR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
34 - ZonMw 6 1 1 1 1 3 13.20 1.50 0 0 0 0 0 0 0 0 0 0 0
35 - UMCG 0 0 0 0 0 0 0 0 0 0 74 162.40 3.60 10 0 0 0 0 0
36 - UM 0 0 0 0 0 0 0 0 0 1.10 11 2.50 88.40 0 0 0 0 0 0
37 - NCBR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
38 - MUW 0 4 0 0 0 0 0 0 0 0 0 11.70 0 0 0 0 0 0 0
39 - MUG 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0
40 - IPCZD 0 0 0 0 0 0 0 0 0 0 10 0 0 4 0 0 0 2 0
41 - FCT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
42 - INSA 0 0 0 0 0 0 0 0 0 1.10 0 0 0 0 0 0 0 0 0
43 - SAS 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
44 - ISCIII 0 16 13 0 0 12.40 0 0 0 0 9.90 2.51 5 6 0 3.50 0 0 0
45 - CNAG-CRG 0 0 0 0 0 0 0 0 0 5.70 181.70 11 6.60 1 0 0 0 0 0
46 - UPM 0 0 0 0 0 0 0 0 0 0 10.60 54.80 0 0 0 0 0 0 0
47 - CIBER 0 0 0 0 0 0 0 0 0 0 14.70 2.90 0 0 0 0 0 0 0
48 - SRC 0 0 0 0 0 3 1 0 0 0 0 0 0 0 0 0 0 0 0
49 - VINNOVA 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
50 - ULEIC 0 0 0 0 0 0 0 0 0 13.50 12.60 193.90 0 0 0 0 0 0 0
51 - ULIV 8 0 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Page 151 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
52 - UNEW 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10
53 - CCRI 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 3
54 - AP-HP 6 1 1 1 1 0 0 0 0 0 0 0 0 0 0 4.50 0 0 0
55 - HUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
56 - CLB 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2
· UCBL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
57 - UKL-HD 6 1 1 1 1 0 0 0 0 0.50 2.80 2.80 5.60 0 0 1.50 15 0 0
58 - EKUT 0 0 0 0 0 0 0 0 0 0 0 0 3.10 7 0 0 18 1 0
· UKT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
59 - GUF 0 0 0 0 0 0 0 0 0 0 76.80 121.50 0 0 0 0 0 0 5
· UKF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
60 - HSK 0 0 0 0 0 0 0 0 0 0 3.90 0 0 2 0 0 0 0 3
61 - IOR 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0
62 - AOUP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
63 - AOUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
· MFT NHS
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TRUST
· CHU DIJON 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
64 - LUMC 0 0 0 0 0 0 0 0 0 5.20 42.10 151.60 63.70 7 0 0 15 0 0
· UoG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· UKSH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
65 - Radboudumc 0 0 0 0 0 0 0 0 0 0 10.70 32.90 54.80 0 0 1.50 15 0 0
· IC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· KUH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· MFT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
66 - AMC 0 0 0 0 0 0 0 0 0 0 5.70 94.30 0 1 0 0 0 0 0
Page 152 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
67 - ERASMUS
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MC
68 - SERMAS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0
69 - NUTH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0
70 - GOSH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0
71 - EORTC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
72 -
0 0 0 0 0 0 0 0 0 0 39 0 0 0 0 0 0 0 0
INFRAFRONTIER
73 - BBMRI 0 0 0 1 0 0 0 0 0 23.10 65.80 180.80 0 5 0 0 0 0 0
· THL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· MUG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· CRS4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· TUM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
74 - ECRIN 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
75 - EATRIS 6 1 14 2 1 0 0 1.50 0 0 0 0 0 0 0 3.50 0 0 53
· UiO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· VHIR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
76 - EMBL 0 0 0 0 0 0 0 0 0 0 0 25.90 2.80 0 0 0 0 0 0
· UU (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
SE)
· UNIMAN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0
· UL (ELIXIR-SI) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
· CSC (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FI)
· BSC (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ES)
· DTU (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
DK)
Page 153 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19
· CNR (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0
IT)
· DTL-Projects 1 0 3 1 0 0 0 0 0 23.90 194.10 0 0 4 0 0 0 0 0
· UCAM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 0 0 0
· SIB (ELIXIR-
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CH)
· MU-CERIT-SC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
77 - EURORDIS 6 1 1 2 1 3 1 4 0 0 0 0 0 3 89 3 0 2 0
78 - CSO-MOH 0 0 0 0 0 3 3.20 0 20 0 0 0 0 0 0 0 0 0 0
79 - SNSF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
80 - Blackswan 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0
81 - TUBITAK 0 0 0 0 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0
82 - ACURARE 0 0 0 0 0 0 0 0 0 0 9.40 2.90 28.50 5 2 0 0 0 0
83 - HUGEN 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 11
84 - CIHR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
85 - FRQS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
86 - IT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
87 - GSRT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
88 - DFG 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0
Total Person/ 470 64 65 63 89 133.60 21.40 25 25 118.60 1330.70 1254.41 297.90 185 117.40 92.50 63 12 208
Months
Page 154 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
1 - INSERM 0 1064.50
· IMGGE 0 0 0
· KI 0 0 0
· UMCL-UKCL 0 0 0
· PHE 0 0 0
· SHEBA 0 0 0
· Rinnekoti 0 0 0
· KDBZ 0 0 0
· UT 0 0 0
· MHH 0 0 0
· OPBG 0 0 0
· DHIR 0 0 0
· GERAD 0 0 0
· BAPES 0 0 0
· CUNI 0 0 0
· HSE 0 0 0
· HUG 0 0 0
· OUS-HF 0 0 0
· CCUH 0 0 0
· AMU 0 0 0
· CMG 0 0 0
· MUW-AT 0 0 0
· Sciensano 0 0 0
· UMF 0 0 0
2 - FWF 0 3
3 - AIT 0 133.30
Page 155 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
4 - LBG (LBI-RUD) 0 25
5 - FNRS 0 7
6 - FWO 0 0
7 - KU Leuven 0 12
8 - MEYS 0 0
9 - MOSAE 0 3
10 - AKA 0 3
11 - ANR 0 17.40
12 - FFRD 0 84.90
13 - AFM 0 0
14 - IMAGINE 0 2.40
15 - DLR 0 32.90
16 - UKA 59 59
17 - CHARITE 0 48.30
18 - UKL-FR 0 23
19 - NKFIH 0 3
20 - HRB 0 3
21 - IT-MOH 0 5
· APRE 0 0 0
22 - TuscReg 0 3
23 - FRRB 0 3
24 - FGB 0 33
25 - FTELE 0 190.60
26 - ISS 0 89
27 - CVBF 0 46
28 - TEDDY 0 23
Page 156 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
· FSJD 0 0 0
29 - MIUR 0 3
30 - VIAA 0 1
31 - LMT 0 3
32 - VUHSK 0 24
33 - FNR 0 3
34 - ZonMw 0 27.70
35 - UMCG 0 250
36 - UM 0 103
37 - NCBR 0 3
38 - MUW 0 15.70
39 - MUG 0 3
40 - IPCZD 0 16
41 - FCT 0 3
42 - INSA 0 1.10
43 - SAS 0 3
44 - ISCIII 0 68.31
45 - CNAG-CRG 0 206.00
46 - UPM 0 65.40
47 - CIBER 0 17.60
48 - SRC 0 4
49 - VINNOVA 0 3
50 - ULEIC 0 220
51 - ULIV 0 12
52 - UNEW 0 10
53 - CCRI 10 18
Page 157 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
54 - AP-HP 68 82.50
55 - HUS 0 0
56 - CLB 0 2
· UCBL 0 0 0
57 - UKL-HD 4 42.20
58 - EKUT 0 29.10
· UKT 0 0 0
59 - GUF 0 203.30
· UKF 0 0 0
60 - HSK 17 25.90
61 - IOR 6 8
62 - AOUP 0 0
63 - AOUS 0 1
· MFT NHS TRUST 0 0 0
· CHU DIJON 0 0 0
64 - LUMC 0 284.60
· UoG 0 0 0
· UKSH 0 0 0
65 - Radboudumc 0 114.90
· IC 0 0 0
· KUH 0 0 0
· MFT 0 0 0
66 - AMC 0 101
67 - ERASMUS MC 0 0
68 - SERMAS 4 5.50
69 - NUTH 0 1.50
Page 158 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
70 - GOSH 6 7.50
71 - EORTC 0 0
72 - INFRAFRONTIER 0 39
73 - BBMRI 0 275.70
· THL 0 0 0
· MUG 0 0 0
· CRS4 0 0 0
· TUM 0 0 0
74 - ECRIN 77 78
75 - EATRIS 0 82
· UiO 0 0 0
· VHIR 0 0 0
76 - EMBL 0 28.70
· UU (ELIXIR-SE) 0 0 1
· UNIMAN 0 0 6
· UL (ELIXIR-SI) 0 0 0
· CSC (ELIXIR-FI) 0 0 0
· BSC (ELIXIR-ES) 0 0 0
· DTU (ELIXIR-DK) 0 0 0
· CNR (ELIXIR-IT) 0 0 3
· DTL-Projects 0 0 227
· UCAM 0 0 8
· SIB (ELIXIR-CH) 0 0 0
· MU-CERIT-SC 0 0 0
77 - EURORDIS 0 116
78 - CSO-MOH 0 26.20
Page 159 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP20 WP21 Total Person/Months per Participant
79 - SNSF 0 3
80 - Blackswan 0 12
81 - TUBITAK 0 5
82 - ACURARE 0 47.80
83 - HUGEN 0 12
84 - CIHR 0 0
85 - FRQS 0 0
86 - IT 0 0
87 - GSRT 0 3
88 - DFG 0 3
Total Person/Months 251 4886.51
Page 160 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.3.7. WT7 Tentative schedule of project reviews
Review Tentative Planned venue
Comments, if any
number 19 timing of review
RV1 25 Remote Mid term
Page 161 of 161
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1. Project number
The project number has been assigned by the Commission as the unique identifier for your project. It cannot be
changed. The project number should appear on each page of the grant agreement preparation documents (part A
and part B) to prevent errors during its handling.
2. Project acronym
Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should
appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its
handling.
3. Project title
Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are
possible if agreed during the preparation of the grant agreement.
4. Starting date
Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement,
the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into
force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a
written justification.
5. Duration
Insert the duration of the project in full months.
6. Call (part) identifier
The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated
in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the
Commission in the letter inviting to prepare the grant agreement.
7. Abstract
8. Project Entry Month
The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start
dates being relative to this start date.
9. Work Package number
Work package number: WP1, WP2, WP3, ..., WPn
10. Lead beneficiary
This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this
work package
11. Person-months per work package
The total number of person-months allocated to each work package.
12. Start month
Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other
start dates being relative to this start date.
13. End month
Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.
14. Deliverable number
Deliverable numbers: D1 - Dn
15. Type
Please indicate the type of the deliverable using one of the following codes:
R Document, report
DEM Demonstrator, pilot, prototype
DEC Websites, patent fillings, videos, etc.
OTHER
ETHICS Ethics requirement
ORDP Open Research Data Pilot
16. Dissemination level
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Please indicate the dissemination level using one of the following codes:
PU Public
CO Confidential, only for members of the consortium (including the Commission Services)
EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
17. Delivery date for Deliverable
Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates
being relative to this start date.
18. Milestone number
Milestone number:MS1, MS2, ..., MSn
19. Review number
Review number: RV1, RV2, ..., RVn
20. Installation Number
Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be
used independently from the rest.
21. Installation country
Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is
an international organization, an ERIC or a similar legal entity.
22. Type of access
VA if virtual access,
TA-uc if trans-national access with access costs declared on the basis of unit cost,
TA-ac if trans-national access with access costs declared as actual costs, and
TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of
unit cost.
23. Access costs
Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access
fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the
basis of unit cost will result from the unit cost by the quantity of access to be provided.
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
HISTORY OF CHANGES
nVer DateDD Changes
2.0 Annex 1 Part A
Annex 1 Part B
08.09.2018 The tables 3.1a, 3.1 b, 3.1c, 3.2a, 3.2b, 3.4a were removed
08.09.2018 The History of changes table was added
08.09.2018 The table of content was updated
08.09.2018 The number, acronym and specification Part B was added in the footer
08.09.2018 In response to the ESR comment a short description on expansion of the EJP RD to
new countries was added on Page 6. Furthermore, a new “Subtask:1.2.4: Initiating
new partnerships” was added to WP1.
08.09.2018 In response to the ESR comment a paragraph dedicated to the EU13 countries was
added on Page 35 in the section EJP RD “Consortium as a whole”.
08.09.2018 In response to the ESR comment an explanation on the estimated number of trainees
and capacity building enhancement was added under paragraph “Pillar 3” on page 9.
In addition, a paragraph was added under IMPACT section “Specific impact 6:
Follow the policies and contribute to the objectives of the International Rare
Diseases Research Consortium (IRDiRC)” for Pillar 4 anticipated results on page 16.
08.09.2018 In response to the ESR comment the representative of EuropaBio was added to the
Policy Board composition on page 33. An explanation on the involvement of private
stakeholders (industry and venture capitals) was added in the paragraph “The route
to exploitation of EJP RD results at policy and industrial levels” on page 35. A
short paragraph explaining the composition of mentoring support boards was added
in the WP19 under subtask 19.1.3.
08.09.2018 In response to the ESR comment the description of the Operating Group on page 32
was modified. In addition, an explanation on the voting rules to avoid silencing of
minority opinion was added on page 29 under the “Governing Board” paragraph. In
addition, the governance structure figure on page 30 was modified in order to better
reflect the origin of the Operating Group (as part of the ExCom).
08.09.2018 In response to the ESR comment extended explanation on the budget and PM share
was added on page 37.
08.09.2018 In response to the ESR comment a new deliverable D10.2 “Report on the State of the
Art of existing resources” (M9) was added to the WP10.
26.09.2018 A table specifying the status of each of the beneficiaries (Programme Owner,
Programme Manager or Other) was added under 4.1 (Participants) on page 45
26.09.2018 The table 3.4 b was updated – the numbers of beneficiaries were added.
27. 09.2018 The Gantt chart was removed as not manageable (readable) after the update of all
Milestones in Part A
27.09.2018 The AWP was updated: Gantt chart, numbers of deliverables for each action, Subtask
1.2.4 was added to Action 1.
02.11.2018 The description of all Linked Third Parties was updated. The following LTPs were
removed: Partner 54 (APHP) – all LTPs were removed; Partner 70 (GOSH) – all
LTPs were removed; Partner 83 (HUGEN) – HT-TTM LTP was removed.
02.11.2018 The description of Financial support to third parties was updated. The details on
maximum amounts of financial support and criteria for determining exact amount
were added. Details of open calls were provided.
02.11.2018 3 new beneficiaries were added: N°86 (Inserm Transfert – IT) will assist the
coordination of INSERM to comply with INSERM internal rules and support
INSERM in development of new collaborations related to EJP RD during the
lifetime of the project. N°87 (GSRT, Greece) - funding body, will provide 1 M€ for
the Pillar 1 co-funded call but from structural costs, so their contribution will not be
accounted for the EC reimbursement. N°88 (DFG, Germany) - funding body, will
provide 3 M€ for the Pillar 1 co-funded call but does not want to claim any EC
825575 – EJP RD – Part B 1
reimbursement. The participation ofAssociated
DFG is crucial as it doubles
with document the German budget
Ref. Ares(2018)6091977 - 28/11/2018
for JTC 2019 call.
02.11.2018 Section 5 – Ethics was updated according to the comments of Ethics experts review.
13.11.2018 Section 4 – the explanation of the COI avoidance for INSERM and ISCIII was
added.
13.11.2018 The participation of Ethics Advisor was updated in WP1 and WP4.
13.11.2018 Section 5 – Ethics was updated according to the comment of EC Project Officer.
13.11.2018 The information on the subject of beneficiaries to the jurisdiction of Belgain courts
was updated.
13.11.2018 The information on the LTP of partner N°56 (CLB) was added in the table.
13.11.2018 The use of in kind contributions provided by third parties was updated according to
the requirements sent by the Ec Financial and administrative officer.
825575 – EJP RD – Part B 2
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
HISTORY OF CHANGES ........................................................................................................................................... 1
1. EXCELLENCE ........................................................................................................................................................ 6
1.1 Rare Diseases burden in Europe ............................................................................................................................. 6
1.2 Efforts deployed by the European Union and Member States so far ..................................................................... 6
1.3 Key policy recommendations ................................................................................................................................. 7
1.4 Major challenges to overcome................................................................................................................................ 7
1.5 Objectives of the European Joint Programme on Rare Diseases ........................................................................... 8
1.6. Relation to the work programme ........................................................................................................................... 8
1.7. Concept and methodology ..................................................................................................................................... 9
1.8 Ambition 14
2. IMPACT 15
2.1 Expected impacts .................................................................................................................................................. 15
2.1.1. Barriers / obstacles........................................................................................................................................... 20
2.1.2. Framework conditions ...................................................................................................................................... 21
2.2 Measures to maximize impact .............................................................................................................................. 21
2.2.1 Dissemination and exploitation of results ......................................................................................................... 21
2.2.2 Communication activities .................................................................................................................................. 22
2.2.3 Data Management Plan...................................................................................................................................... 22
2.2.4 Dissemination and communication Plan ........................................................................................................... 22
3. IMPLEMENTATION ............................................................................................................................................ 30
3.2. Management structure, milestones and procedures ............................................................................................. 32
3.3: Consortium as a whole ........................................................................................................................................ 37
3.4: Resources to be committed.................................................................................................................................. 39
Table 3.4a: Summary of staff effort (per participants and per WP) ........................................................................... 40
Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research infrastructures) 41
4.1. Participants (applicants) ...................................................................................................................................... 45
01-INSERM (A) ......................................................................................................................................................... 48
01-INSERM (B) ......................................................................................................................................................... 50
01-INSERM (C) ......................................................................................................................................................... 52
01-INSERM (D) ......................................................................................................................................................... 56
02-FWF....................................................................................................................................................................... 58
03-AIT ........................................................................................................................................................................ 59
04-LBG ....................................................................................................................................................................... 61
05-FNRS ..................................................................................................................................................................... 63
06-FWO ...................................................................................................................................................................... 64
07-KU LEUVEN ........................................................................................................................................................ 64
08-MEYS .................................................................................................................................................................... 67
09-MOSAE ................................................................................................................................................................. 68
10-AKA ...................................................................................................................................................................... 69
11-ANR ...................................................................................................................................................................... 69
12-FFRD ..................................................................................................................................................................... 71
13-AFM ...................................................................................................................................................................... 73
14-IMAGINE ............................................................................................................................................................. 74
15-DLR ....................................................................................................................................................................... 75
16-UKA ...................................................................................................................................................................... 77
17-CHARITE ............................................................................................................................................................. 78
18-UKLFR .................................................................................................................................................................. 80
825575 – EJP RD – Part B 3
19-NKFIH...................................................................................................................................................................
Associated with document Ref. Ares(2018)6091977 - 28/11/2018 82
20-HRB....................................................................................................................................................................... 84
21-IT MOH ................................................................................................................................................................. 85
22-TUSCREG............................................................................................................................................................. 86
23-FRRB..................................................................................................................................................................... 88
24-FGB ....................................................................................................................................................................... 90
25-FTELE ................................................................................................................................................................... 92
26-ISS ......................................................................................................................................................................... 94
27-CVBF .................................................................................................................................................................... 97
28-TEDDY ............................................................................................................................................................... 100
29-MIUR .................................................................................................................................................................. 104
30-VIAA ................................................................................................................................................................... 105
31-LMT .................................................................................................................................................................... 106
32-VUHSK ............................................................................................................................................................... 106
33-FNR ..................................................................................................................................................................... 108
34-ZONMW ............................................................................................................................................................. 109
35-UMCG ................................................................................................................................................................. 110
36-UM ...................................................................................................................................................................... 113
37-NCBR .................................................................................................................................................................. 114
38-MUW................................................................................................................................................................... 115
39-MUG ................................................................................................................................................................... 117
40-IPCZD ................................................................................................................................................................. 119
41-FCT ..................................................................................................................................................................... 122
42-INSA ................................................................................................................................................................... 123
43-SAS ..................................................................................................................................................................... 125
44-ISCIII................................................................................................................................................................... 126
45-CNAG-CRG ........................................................................................................................................................ 131
46-UPM .................................................................................................................................................................... 133
47-CIBER ................................................................................................................................................................. 135
48-SRC ..................................................................................................................................................................... 137
49-VINNOVA .......................................................................................................................................................... 137
50-ULEIC ................................................................................................................................................................. 138
51-ULIV ................................................................................................................................................................... 140
52-UNEW ................................................................................................................................................................. 141
53-CCRI ................................................................................................................................................................... 143
54-APHP (A) ............................................................................................................................................................ 145
54-APHP (B) ............................................................................................................................................................ 146
54-APHP (C) ............................................................................................................................................................ 148
54-APHP (D) ............................................................................................................................................................ 150
54-APHP (E) ............................................................................................................................................................ 153
825575 – EJP RD – Part B 4
54-APHP (F) .............................................................................................................................................................
Associated with document Ref. Ares(2018)6091977 - 28/11/2018 155
54-APHP (G) ............................................................................................................................................................ 155
55-HUS ..................................................................................................................................................................... 157
56-CLB ..................................................................................................................................................................... 159
57-UKL-HD ............................................................................................................................................................. 161
58-EKUT .................................................................................................................................................................. 162
59-GUF ..................................................................................................................................................................... 164
60-HSK ..................................................................................................................................................................... 165
61-IOR ...................................................................................................................................................................... 166
62-AOUP .................................................................................................................................................................. 169
63-AOUS .................................................................................................................................................................. 172
64-LUMC ................................................................................................................................................................. 174
65-RABOUDUMC ................................................................................................................................................... 180
66-AMC .................................................................................................................................................................... 184
67-ERASMUS MC ................................................................................................................................................... 187
68-SERMAS ............................................................................................................................................................. 188
69-NUTH .................................................................................................................................................................. 190
70-GOSH .................................................................................................................................................................. 192
71-EORTC ................................................................................................................................................................ 194
72-INFRAFRONTIER ............................................................................................................................................. 196
73-BBMRI ................................................................................................................................................................ 197
74-ECRIN/PEDCRIN............................................................................................................................................... 199
75-EATRIS ............................................................................................................................................................... 201
76-ELIXIR ................................................................................................................................................................ 203
77-EURORDIS ......................................................................................................................................................... 208
78-CSO-MOH .......................................................................................................................................................... 210
79-SNSF ................................................................................................................................................................... 210
80-BLACKSWAN ................................................................................................................................................... 211
81-TUBITAK ........................................................................................................................................................... 212
82-ACU/ACURARE ................................................................................................................................................ 213
83-HUGEN ............................................................................................................................................................... 215
84-CIHR ................................................................................................................................................................... 217
85-FRQS ................................................................................................................................................................... 218
86-IT ......................................................................................................................................................................... 219
87-GSRT................................................................................................................................................................... 220
88-DFG ..................................................................................................................................................................... 223
4.2. Third parties involved in the project (including use of third party resources) ................................. 224
4.3: Financial support to third parties ....................................................................................................................... 254
SECTION 5: ETHICS AND SECURITY ................................................................................................................... 272
5.1 Ethics ................................................................................................................................................. 272
5.2 SECURITY ....................................................................................................................................................... 279
825575 – EJP RD – Part B 5
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1. EXCELLENCE
1.1 Rare Diseases burden in Europe
Rare Diseases (RDs) are life threatening or chronically debilitating conditions from which fewer than five affected
persons per 10,000 citizens in the European Union (EU) suffer. It is estimated that 6,000-8,000 different RDs exist,
affecting between 6% and 8% of the population in the course of their lives. Many RDs manifest in childhood, affect
patient’s life-long and are not curable with current interventions or medications, resulting in high medical need and
immense costs for health care system, society and families. Whereas the rarity of each disease, the extreme
variability of the clinical manifestation, the common affection of different organs, and the lack of broad recognition
of RDs would call for clustering of expertise, research on RD remains scarce and scattered in different research and
care organizations throughout the EU. This translates into delayed diagnosis, few medicinal products and difficult
access to care. That is why RDs are a prime example of a research area that can strongly profit from coordination
on a European and international scale. This was recognized in the Council Recommendation of June 8, 2009 on an
action in the field of RD (2009/C 151/02), which specifically emphasized that the coordination of Community,
national and regional programmes for RD research should be improved.
1.2 Efforts deployed by the European Union and Member States so far
Between 2007 and 2017 the European Commission (EC) invested over 874 M€1 in research on RD. The European
Commission has supported not only key actions to produce data necessary to improve identification and knowledge
on RD under the form of large multinational scientific projects but also strategic and coordination initiatives to
provide recommendations on specific areas to support and guide Member States policies on RD.
In particular, the EC has supported the International RD Research Consortium (IRDiRC2), a global consortium
of funders and organizations (including patient organizations) involved in RD research to address RD grand
challenges through collaborative actions such as establishing and providing access to harmonized data and samples,
performing the molecular and clinical characterization of RDs, boosting translational, preclinical and clinical
research, and streamlining ethical and regulatory procedures. The ambitious goal to deliver 200 new therapies for
RDs by 2020 has already been met and means for RD diagnosis have greatly improved since IRDiRC was founded.
IRDiRCs new vision is to provide diagnosis for most RD patients within a year of first sub-specialty medical
consultation and 1000 new therapies by 2027.
The EC supports several associated projects like RD-Connect3, a global infrastructure project that links up omics
databases, registries, biobanks and clinical bioinformatics data used in RD research into a central resource for
researchers worldwide or RareBestPractices4, which is a platform to improve the management of RD patients by
disseminating trustworthy guidelines globally, identifying and prioritizing RD research needs and facilitating
timely, effective and efficient translation of research results into patient oriented strategy on the clinical as well as
the public health level. Finally, the European Rare Diseases Registries Infrastructure (ERDRI) being
developed by the DG Joint Research Centre (JRC) in collaboration with DG SANTE will promote and support
European-level solutions ensuring interoperability for registries established at the European, national and/or
regional level. It will provide a source of information on rare disease patient data with a large transnational
coverage.
Part of the EC’s comprehensive approach to tackle the RD burden in Europe is to co-finance projects and actions
with Member States. An example is the Rare Diseases Joint Action5 (continuation of EUCERD Joint Action
initiated in 2011) that has the general objectives to (i) support further development and sustainability of the
Orphanet6 database on RD (the biggest repository of information about RD globally co-funded by the EC since
2000), (ii) contribute to solutions to ensure an appropriate codification of RD in health information systems; (iii)
continue implementation of the priorities identified in the 2009 Council Recommendation and the 2008
Commission Communication on RD, and (iv) support the work of the Commission Expert Group on Rare
Diseases7 by gathering expertise and producing data necessary to its action.
An additional important initiative for research on and healthcare for RD is the current development of European
Reference Networks8 (ERNs) in which specialists in various disciplines in different countries in Europe join their
1 Communicated by the EC for FP7 and H2020 2014-2015
2 http://www.irdirc.org
3 http://www.irdirc.org
2 rd-connect.eu/
4 rd-connect.eu/
3 www.rarebestpractices.eu/
5 www.rarebestpractices.eu/
4 www.rd-action.eu
6 www.rd-action.eu
5 www.orpha.net/
7 www.orpha.net/
6 http://ec.europa.eu/health/rare_diseases/expert_group_en
7 http://ec.europa.eu/health/rare_diseases/expert_group_en
8 http://ec.europa.eu/health/ern/policy/index_en.htm
825575 – EJP RD – Part B 6
efforts to treat RD that require highly specialized healthcare and a concentration
Associated ofRef.
with document knowledge and resources.
Ares(2018)6091977 - 28/11/2018
Although their primary goal is the development of cross-border health care, ERNs have often evolved from
European research networks and their outstanding gathering of expertise has the potential, in the future, to support
and facilitate translational research in areas such as quality assurance mechanisms for laboratory testing;
development of good practice guidelines for diagnosis and care; natural history studies; support to cross-national
clinical trials; registries; etc.
The landscape cannot be complete without mentioning important efforts of Member States that integrate on one
hand direct research funding and on the other support for medical infrastructures providing services to the research
community. Since at present, only few European countries fund research on RD through specific dedicated
programmes, the funding of transnational collaborative research is the most effective joint activity to enhance the
cooperation between scientists working on RD in Europe and beyond, and thus reducing fragmentation of research
in this field. The E-Rare, ERA-Net for Research Programmes on Rare Diseases9, was established in 2006 to
link responsible funding organizations and ministries that combine the scarce resources for research and thus
enable the participation of many researchers to transnational projects via Joint Transnational Calls (JTCs). At the
start of E-Rare-1 in 2006 the consortium consisted of eight countries and extended in the following years. Today,
E-Rare-3 is a network of twenty-eight partners – public bodies, ministries and research funding organizations –
from twenty countries: Member States (Austria, Belgium, Czech Republic, Finland, France, Germany, Greece,
Hungary, Italy, Latvia, Poland, Portugal, Romania, Spain, The Netherlands), three Associate States (Switzerland,
Israel and Turkey) and two non-European countries (Canada and Japan). In addition E-Rare is member of IRDiRC
and strongly contributes to its objectives.
RD research also benefits from several biomedical and life sciences European Research Infrastructures such as
BBMRI, ELIXIR, EU-Openscreen, Eatris, or Infrafrontier and ECRIN, which were developed in the past years
through collaborative efforts of Member States. Although not specific for RDs, these infrastructures aim at
development of services facilitating researchers access to resources and knowledge and to contribute to sharing of
data and avoiding duplication of efforts. Finally, Rare disease research can take full advantage of cutting-edge data-
focused initiatives in current European policy, including the European Open Science Cloud (EOSC)10, which
aims to accelerate and support the current transition to more effective Open Science and Open Innovation in the
Digital Single Market and to enable trusted access to services, systems and the re-use of shared scientific data
across disciplinary, social and geographical borders. The very rarity of RD means that the field has a vast amount
to gain from opening up and reuse of research data, and tapping into such major flagship initiatives will help
maximize gains for the RD community as early adopters of these cutting edge data stewardship initiatives.
1.3 Key policy recommendations
In 2017 report “Rare Diseases - a major unmet medical need”11 the European Commission pinpoints five key
policy recommendations:
● Support integration and networking among EU research, patient and healthcare organisations;
● Adapt implementation of regulatory requirements, especially for clinical trials in rare diseases;
● Develop legally and ethically robust agreements for collecting and exchanging health and genetic data;
● Support health technology assessment, standards and evidence-base for guiding public health policy;
● Collaborate globally through the International Rare Diseases Research Consortium (IRDiRC) to accelerate
research on improving the lives of patients with rare diseases.
These recommendations, together with identified challenges are the main driving force of the EJP RD.
1.4 Major challenges to overcome
Despite significant developments in the RD field over the past years, several challenges still remain. To achieve an
integrated strategy for RD research and care there is a need for:
● Sustainable and interoperable organization with established, accepted standards to govern the collection,
organisation, sharing and reuse of (health) data and resources that are currently fragmented and/or duplicated
(information or samples, omics data, registries and cohorts, national history studies, biobanks, ontologies,
inventories, the ethical framework, trial readiness). This includes advanced data sharing and linkage mechanism
according to FAIR (Findable, Accessible, Interoperable, Reusable);
● Structured connection of research efforts with European Reference Networks (ERNs). These networks
should be well placed to show how standards and tools supported by European infrastructures or developed by
the RD community can be efficiently implemented and integrated into healthcare while improving the equity of
9 www.e-rare.eu
10 http://ec.europa.eu/research/openscience/index.cfm?pg=open-science-cloud
11 https://ec.europa.eu/info/sites/info/files/rarediseases_p4p-report_2017.pdf
825575 – EJP RD – Part B 7
healthcare provision across the EU on rare diseases, and to improve HTA
Associated methodologies
with document so that they can
Ref. Ares(2018)6091977 also
- 28/11/2018
be fully applied specifically to interventions addressing rare diseases;
● High quality research to identify novel disease mechanisms and to lump diseases based on common pathways;
● Enhanced uptake of research results for translation into tangible outcomes for better health and effective
transfer of exploitable results to SMEs and relevant industry sectors, in particular for drug development or
repurposing, humanized models, preclinical trials, biomarker development, patient trial readiness and clinical
trials;
● Centralized planning and coordination that takes the overall responsibility and disposes necessary means to
support the needs of the RD community and reach a greater level of integration, including in EU-13 countries
and ensures active and broad participation of European and international research stakeholders in IRDiRC
activities and the wide uptake of collaborative results;
● Systematic implication of patient organizations in the design of research and care programming and actions
at national and regional levels;
● Effective interaction and training across RD community at all different levels (researchers, practitioners and
patients).
1.5 Objectives of the European Joint Programme on Rare Diseases
RD research in Europe can be improved to overcome fragmentation, leading to efficacious use of data and
resources, faster scientific progress and increase of competitiveness, and most importantly to decrease unnecessary
hardship and prolonged suffering of RD patients. In the specific context of the massive generation and need for
reuse and efficient interpretation of data, introduction of omics into care practice and the ongoing structuration of
RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of
already funded tools, projects and programmes by supporting them further, scaling them up, linking them together,
and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a
concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care,
research and medical innovation.
To achieve this goal, the European Joint Programme on RD will have two major objectives:
• To improve the integration, the efficacy, the production and the social impact of research on RD through the
development, demonstration and promotion of Europe-wide and even world-wide sharing of research and
clinical data, materials, processes, knowledge and know-how;
• To implement and further develop an efficient model of financial support for all types of research on RD
(fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation
of research results for benefit of patients.
Figure 1. The EJP RD concept
1.6. Relation to the work programme
The proposed joint programme of activities ranging from research to coordination and networking activities,
including training, demonstration and dissemination activities will be structured along five main components
ensuring the implementation of a comprehensive and cohesive research and innovation bench to bedside pipeline,
fully in line with the Work Programme call SC1-BHC-04-2018 “Rare Disease European Joint Programme
Cofund”:
825575 – EJP RD – Part B 8
● Pillar 1 “funding collaborative research on RD” will foster jointAssociated
transnational calls Ref.
with document for Ares(2018)6091977
collaborative research
- 28/11/2018
projects resulting in financial support to third parties encompassing various aspects of rare diseases. In
addition, the financial support actions will be extended to the Networking Scheme (to encourage sharing of
knowledge on rare diseases between clinicians, (biomedical) scientists and patient organizations) and the Rare
Disease Research Challenges (innovative funding scheme to foster private-public partnerships and multi-
stakeholder collaborations). All calls will be implemented according to standards and good practice of Horizon
2020 including international peer review, Horizon 2020 evaluation criteria, proposal selection following the
ranking list etc.;
● Pillar 2 “innovative coordinated access to data and services for transformative RD research” aiming at
rationalized, optimized and increased potential of existing resources and services, will develop a FAIR
virtual platform for RD information encompassing research data, samples, tools and standards to support and
accelerate rare diseases research. The usefulness of the developed tools and their upscaling will be ensured
through the direct links with funded research projects (Pillar 1) and new connections across the rare diseases
community in particular with European Reference Networks (ERNs). In addition, pilot and proof-of-concept
projects will be put in place to enable multidisciplinary, holistic approaches for rare disease diagnostics and
therapeutics and fostering creation of complete diseases pathways;
● Pillar 3 “capacity building and empowerment” will be raising the level of knowledge and know-how within
the RD research and care community, including through ERNs and RD patient representatives and advocates.
To this end, a comprehensive programme of training courses will tackle areas such as research data
management, orphan drug development, HTA & regulatory processes, scientific innovation & translational
research, best practice guidelines and ERN cross-cutting themes & needs. Activities will involve large groups of
stakeholders including adult and paediatric patients. Furthermore, training courses will be developed and
adapted to address the specific needs of EU13 countries and to provide capacity building of the different
stakeholders on the use of the common platform developed within Pillar 2. Finally, Pillar 3 aims at first-in-
Europe online academic course to provide an EU-wide streamlined education programme on RD research to all
interested stakeholders;
● Pillar 4 concentrates on“ accelerating the translation of high potential projects and improving outcomes of
clinical studies in small populations”. By creating a bridge between basic research and medical innovation,
otherwise known as the “bench to bedside” approach, this pillar aims to support the RD community to more
effectively translate high quality research into high impact interventions for the RD patient community.
To demonstrate its efficiency, research projects funded through Pillar 1 and previously by E-Rare will be
selected for their translational potential and specifically supported and guided throughout this process. In
addition, Pillar 4 will foster the development of innovative methodologies tailored for clinical studies in RDs by
specifically supporting ERNs to use the most adapted methodologies improving trial studies in RDs.
Demonstration studies will be funded to validate existing and most recently presented innovative methodologies
as well as most promising new statistical methodologies;
● Finally, the strategic coordination and management of the EJP RD will constitute the foundation linking all
the Pillars together, enabling cross-communication, prioritisation and alignment between different activities. It
will encompass annual programming including gap-analysis and identification of research priorities and
policy questions in demand for evidence generation, as well as monitoring of the outcome of the EJP RD.
Close linkage with IRDiRC will be ensured by integration of the IRDiRC Secretariat in the EJP RD
Coordination Office. A specific WP will be dedicated to provide all Pillars with the proper strategy to address
ethical, regulatory, legal and Intellectual Property Right (IPR) issues, and will ensure that relevant rules are
complied with within the course of the project. Finally, exploitation of EJP RD results, its innovative potential
and sustainability will be key aspects, tackled from the start and throughout the course of the programme.
1.7. Concept and methodology
The linked approaches and complementary strategic orientation of the four core pillars together with that of the
coordination and transversal activities create an overall comprehensive and cohesive structure that will deliver and
ensure implementation of the wide range of jointly related activities bridging the gaps and adding value to existing
resources and initiatives. The schematic concept of EJP RD is presented in Figure 2.
825575 – EJP RD – Part B 9
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Figure 2. Structure of the EJP RD (coordination, transversal activities and four pillars)
COORDINATION AND TRANSVERSAL ACTIVITIES:
The EJP RD will be based on the concerted action of 88 beneficiaries and their linked third parties from 24
European (AT, BE, CZ, DE, ES, EE, FI, FR, HU, IE, IT, NL, NO, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4
associated (AM, CH, IL, TK) and 1 non-EU country (CA). In addition institutions from Japan and Australia will
participate as “associated partners or “observers”. EJP RD will strive for further inclusion and “openness” at all
levels including funding opportunities, Virtual Platform of resources and services, trainings and translation and
innovation services. RD stakeholders from all countries involved in the EJP RD will be eligible to profit from
offered support and the Virtual Platform will be constructed as fully open source for the benefit of the whole RD
community. The EJP RD will be structured around centralised coordination and management, which will focus not
only on active and efficient support of the EJP RD partners and planned activities but also will allow necessary
overarching governance and implementation of transversal actions that require convergent approach, like
communication, EJP RD research and innovation strategy, tackling of ethical, legal and regulatory issues,
exploitation of results and IPR and closely related sustainability plan. Furthermore, direct collaboration with Policy
Board of relevant high-level stakeholders (ministries, EC directorates, industry, regulatory agencies and European
infrastructures forum) will ensure decisive alignment of national and European strategies and policies. Finally,
despite the fact that the process of integration of Member States in the EJP RD covered an almost 2 year period in
advance of the application, not all EU countries decided to get involved. However, the efforts on expansion of the
EJP RD consortium will be pursued by the coordination to ensure meaningful involvement of new partners.
PILLAR 1: COLLABORATIVE RESEARCH FUNDING
Notwithstanding the important progress in the Rare Diseases (RD) field, many aspects remain without solutions.
The need for fundamental, translational, clinical, social and health services research and most efficient modes of
fostering them are therefore still topical. The interdisciplinary cooperative approaches to be addressed through
national and EC programmes should be promoted. Since at present, only few European countries fund research on
RD through specific dedicated programmes, the funding of transnational collaborative research is the most
effective joint activity to enhance the cooperation between scientists working on RD in Europe and beyond, and
thus reducing fragmentation of research in this field.
Pillar 1 will be based on the strong previous collaboration and reputation of the E-Rare ERA-Net. The activities of
E-Rare demonstrated that continuous cooperation of funding organizations, particularly for the implementation of
joint transnational calls, influences the alignment of processes, funding procedures and timelines in addition to the
gained common knowledge. The high number of proposals received in response to the calls of E-Rare highlights
the great potential and diversity of the European RD research community and the need for funding of collaborative
projects. The ex-post analysis of projects financed between 2007 and 2011 showed that all of them were able to
achieve critical mass of resources necessary to complete their goals. In addition, the consortia demonstrated
intensive exchange of samples as well as creation of databases, biobanks, or registries. These “infrastructures” were
created either from scratch or by pooling the existing, but disconnected sources. The transnational collaboration
within projects translated also through the training and exchange of personnel. Finally, the number of joint
825575 – EJP RD – Part B 10
publications also confirmed this success: 525 peer review articles were published
Associated byRef.
with document 37Ares(2018)6091977
consortia with -a28/11/2018
mean
impact factor of 7.32 (range from 0.5 to 59). This confirms that joint research funding and support of RD research
is considered as “stimulator” of transnational, enduring partnerships and should be further developed. However,
some weaknesses were also pointed out, namely (i) insufficient level of interactions between different types of
stakeholders (not only scientists) for the benefit of RD research and (ii) lack of commitment from private investors
and industry.
Pillar 1 will engage 29 funding bodies from 22 countries and will be open for further integration of new partners.
At the moment of submission of this proposal the commitment to two first joint transnational calls reached 37 M€.
Further engagement of at least 20 M€ for calls 2021-22 is also planned. Most importantly Pillar 1 takes into
account lessons and recommendations learned during previous (E-Rare) years. Therefore, the proposed funding
support will be extended beyond joint transnational calls and will encompass the Networking scheme (2 M€) and
the Rare Diseases Research Challenges (1.5 M€ of public funding), the latter targeting public-private partnerships.
Foreseen funding activities will not only strengthen rare diseases research but also increase its exploitation
potential by implementing innovative mechanism of public-private support. Pillar 1 will also expand the
collaboration potential beyond the national and EU borders by enabling RD networks and events including partners
from and outside EJP RD participating countries.
PILLAR 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR
TRANSFORMATIVE RARE DISEASE RESEARCH
Despite the significant resources already in place (knowledge bases, databases, registries and infrastructures), the
fragmentation and duplication of effort and resources in relation to data, information or samples persist, making
efficient and timely use of these resources in RD research challenging. In order to overcome these bottlenecks
Pillar 2 will create a sustainable and interoperable ecosystem of resources (the EJP RD virtual platform), coupled to
robust standards, tools and procedures that will infuse FAIR principles into advanced and secure forms of data
discovery, linkage and sharing. It will allow flexible, real-time access to data (under suitably controlled conditions),
with supporting tools and services that serve the ultimate goal of increasing the efficiency and efficacy of RD
research. Driven by concrete use-cases and needs arising from the RD clinical and research community, it will
provide the means to harmonise and standardise the way RD relevant data, samples and tools are made findable,
accessible, interoperable and re-usable, and the means to query the progressively increasing number of resources
and repositories connected to the EJP RD virtual platform through a central facility.
The EJP RD Pillar 2 will establish a stronger and broader collaboration between the RD community and European
Research Infrastructures and global consortia than ever before. This will have major mutual benefit and impact. On
one hand RD research, supported by highly motivated patient representatives and ERNs, presents an exemplar
challenge and opportunity for research infrastructures to create common solutions and stimulate collaboration. On
the other hand, progress in RD research depends on the strongest possible infrastructure to address its needs
towards efficient information retrieval and analysis across its distributed data resources. The increased capacity of
infrastructures and their seamless integration with RD community will ultimately translate to higher innovation
potential and benefit for patients.
To that point, Pillar 2 will develop three parallel and complementary axes of work, all three governed by consistent
quality, regulations and compliance with agreed standards requirements. Moreover, all axes will be driven by
research and clinical user community, ensuring that Virtual Platform is built for and adopted by this community.
The axes are:
• Centralized metadata repository describing pre-existing resources (including catalogs, data repositories, tools
and infrastructures12) with RD-specific semantic standards and metadata that conforms to an ontological,
machine-readable model that also encompasses consent and data use conditions. This will make resources
Findable, and their Accessibility conditions to be known. Furthermore, it will provide guidance and services to
produce, store and share phenotype-genotype data for researchers, as well as standards for data processing,
generation and deposition of multi-omics data, relevant for RD. More importantly, the involvement of key
partner resources to normalise their metadata models, and to harmonise data deposition is already secured;
• Federated ecosystem of FAIR-at-the-source resources, in order to enable data discovery, sharing and analysis
down to the record level. This axis of work organizes partnering with target resources to make them FAIR
compliant, as well as the required interdisciplinary collaboration between RD experts and data experts. Beyond
achieving FAIRification of resources in the VP, Pillar 2 will offer to the RD community at large the means and
support, including training, to enlarge the scope of the federated ecosystem, by building a sustainable
FAIRification service.
12
Catalogs: Orphanet, BBMRI, ERDRI, ELIXIR’s bio.tools; Data repositories: ERNs’ registries, biobanks, RD-Connect’s GPAP; Infrastructures:
INFRAFRONTIER, ECRIN, are examples of those.
825575 – EJP RD – Part B 11
• Extension of the virtual platform with workflows that allow Associated
holistic research based
with document Ref.on rare disease data
Ares(2018)6091977 and
- 28/11/2018
biological knowledge, by filling gaps in data on disease modifiers such as nutrition and metabolism, aspects of
lifestyle and exposure to toxicants with the final aim to improve the understanding of the etiology and
progression or rare diseases and to support the discovery of biomarkers and the identification of druggable
pathways and targets. This axis of work requires exploitation of previously performed explorative studies and
the conduction of proof of principle studies specific for RD. It will be based on important collaboration between
European Research Networks and top-level research teams excelling in data mining and interpretation. Relevant
connection to Solve-RD project will be also ensured.
PILLAR 3: CAPACITY BUILDING & EMPOWERMENT
Critical to ensuring equity and optimizing outcomes for people living with rare diseases is integrating RD activities
under a common joint education & training programme to raise the level of knowledge and build capacity within
the RD community. This is what Pillar 3 of the EJP RD is aiming to achieve by working closely and collaboratively
with 45 partners including RD patient representatives (e.g. ePAGs involved in ERNs and young RD patient
representatives), several ERNs, academics, researchers, clinical scientists, European Networks (e.g. Orphanet) and
European research infrastructures (e.g. BBMRI, ELIXIR).
The pooling of existing resources, training initiatives, relevant expertise and experience in RD trainings from the
different partners within the central place of the EJP RD will meaningfully facilitate the engagement of the RD
community with regulatory bodies, the private sector and the biomedical industry in order to fast-track access and
provide diagnosis to unsolved cases as well as facilitate clinical trials and boost drug development of RD therapies.
Patient-centered health service is increasingly recognized as a priority in medicines R&D and is a founding
principle of the common values in European Union Health Systems, spanning from research to healthcare. In order
to build and reinforce partnerships between patients and researchers, current practices need to evolve. This holistic
approach will ultimately deliver the improved outcomes for patients and the health system. The key success factor
for patient researcher partnerships is building the capability of researchers to engage meaningfully with patients,
maintain transparency and build trust thus empowering them to contribute proactively with researchers and help
inform research objectives. Consequently, a crucial element for sustainable research and the translation of new
knowledge into the health system is to invest in capacity building for effective engagement among all stakeholders.
Through this investment, significant opportunities will be created that will enhance the research and innovation
capability among all stakeholders, thus enabling effective, patient centered outcomes that address RD patient needs
and can be readily adopted within healthcare systems.
Pillar 3 will concentrate its activities on developing and delivering a seamless flow of training programmes on key
aspects relevant for rare disease research across the RD community. Existing training courses will be expanded
further and new ones developed to adequately suit the needs of the RD research community with a specific
attention to the needs of ERNs and EU13 countries. Pillar 3 has secured an essential and key asset which is
represented by the inclusion of the major players in the European RD landscape as EJP RD partners responsible for
developing and updating the training courses according to emerging needs from the community.
The methodology chosen consists of a blended approach of face-to-face courses ranging from short 1 or 2-day
workshops to 3 or 5 days residential training and a comprehensive EU-wide online academic RD research training
programme. All training courses will be open to all and offered free of charge to interested participants.
Researchers funded through Pillar 1 funding schemes and Pillar4- supported researchers and clinicians with
specific issues (e.g. IP, regulatory, etc.) will be encouraged to apply and register for the training activities. In
addition, 10 to 15% of selected participants will be offered travel and accommodation fellowships enabling a more
equitable level of participation among less wealthy EU countries. Successful applicants will be selected using an
eligibility matrix including a scoring system based on pre-identified criteria which will be adapted along the course
of the EJP RD. Furthermore, several training courses will be changing location each year, hosted by EJP partners
based in different countries to ensure wide participation across Europe. Within Pillar 3, the face-to-face capacity
building activities plan to train around 1,500 participants over the course of the EJP [WP14:1006 trainees including
WP14.1: 23x12=276; WP14.2: 20x5=100; WP14.3: 30x4=120; WP14.4:310; WP14.5: 40x5=200); WP15=335
including WP15.1: 10x5=50; WP15.2: 30x4=120; WP15.3: 30x4=120; WP15.4: 15x3=45; WP17:72 trainees;
WP18: 80 trainees]. It is important to highlight that this estimation does not take into account the online academic
course within WP16, which has the potential to train an unlimited number of interested stakeholders in the long
term. Furthermore, WP15 also includes pre-training online modules which will grow in content over the years and
will be open access to anyone interested in the topics addressed, in particular but not restricted to, rare disease
patient representatives. Finally, the ambition and mission of Pillar 3 is capacity building of all RD stakeholders and
as such many trained participants will be able in turn to transfer to knowledge and skills gained through the EJP to
their own networks with a potential downstream impact of inestimable value. Thus, the EJP RD represents the
unique opportunity to showcase all the relevant education and empowerment activities for RD research under one
umbrella.
825575 – EJP RD – Part B 12
PILLAR 4: ACCELERATING THE TRANSLATION OF HIGH
Associated with POTENTIAL PROJECTS- 28/11/2018
document Ref. Ares(2018)6091977 AND
IMPROVING OUTCOMES OF CLINICAL STUDIES IN SMALL POPULATIONS
The improvement of outcomes in translational and clinical research by providing on one hand suitable support,
mentoring, expertise and improved industrial uptake and on the other hand direct innovative methodologies for RD
clinical studies is one of the main goals of the EJP RD. This will be achieved with Pillar 4, which aims to structure
a long-term sustainable strategy for improving pipeline productivity and translational research capacities on
therapies of RDs working closely with ERNs and other actors in the RD community. There are two main areas in
need of urgent attention in the development pathway. Firstly, due to the historical lack of academic incentives,
expertise and funding opportunities to perform translational research in all but a handful of RDs combined with
large pharmaceutical industry’s retreat from performing early translation (due to the biological complexity and high
failure rates), there is a substantial gap that slows or even prevents good science from being efficiently translated
into effective interventions for society. Secondly, clinical development of novel interventions for rare diseases is
particularly challenging, as they are complex and heterogeneous with lack of suitable patient cohorts, incomplete
understanding of outcome measures and natural history. In addition, the small size of many ultra-rare disease
populations make pivotal clinical trials difficult and at the same time commercially less viable despite the
incentives for the development of therapies for RDs. Improving the development pathway for rare diseases through
an integrated development methodology with innovative clinical trial design and statistical analysis methods will
help encourage more successful development of life changing drugs for more rare diseases. To achieve these goals
Pillar 4 will promulgate three hallmarks of sounds translational research, namely mindset, professional
management, and mentoring. This will be achieved through a combination of self-help resources and active in-
project support from diverse fields, such as product development, regulatory and commercial. To do so, the
expertise of several partners (EATRIS, FTELE, ECRIN, ERNs), will be utilised. An active mentoring programme
coordinated by an Innovation Manager assigned to project teams, investigators and funders of Pillar 1 will benefit
from active guidance and input into design, development and help in the execution of cutting edge translational and
clinical studies. In addition, in close connection with RDR Challenges Pillar 4 will support high potential projects
to find resources and expertise of private and for-profit funders and developers, in order to complete the
development pathway to the patient. In Europe, several cases show that, despite the limited size of the market, the
field of rare diseases is attractive to investors. On the basis of recent examples in Italy, the Netherlands and France,
the Pillar 4 will create a roadmap for innovation funding in RD, utilizing blended investment modes that will feed
also sustainability strategy.
Acceleration of arrival of new therapeutic options to patients passes also by more efficient and reliable clinical
studies. Pillar 4 is particularly well armed to tackle this issue as it gathers the capacity and expertise of the
European Reference Networks strengthened by know-how of ECRIN and high-level methodologists from IDeAl
project. This will be done at three levels: (i) through identification of already existing but not sufficiently used
highest methodological standard for clinical trials in RDs and their direct promotion via the powerful network of
ERNs and other relevant EJP RD partners; (ii) via demonstrators projects focusing on validation of recently
developed methodologies for design and analysis of clinical trials and finally (iii) via design of innovative
methodologies in parts of clinical design that were not adequately addressed until now (e.g. more appropriate
endpoints allowing better assessment of clinically meaningful responses as PCOMs; validation of composite end
points and surrogates; capture in the cohorts of natural history studies efficacy and important safety information
through life span; evidence assessment associated with randomization in limited populations; pharmacometric
modeling, extrapolation modelling). Pillar 4 will collaborate closely with Pillar 2 to exploit existing data and to
deliver validated or new methodological standards to enhance the panel of tools for RD community. Finally, the
involvement of funds from the private sector (pharma, SMEs, start ups) and the promotion of rare disease therapies
as the future of personalized medicine based on particular characteristics of each individual or each small group of
individuals will be extensively addressed in this Pillar.
Gender/sex aspects:
EJP-RD will respect the gender equality and work to keep on a gender balance throughout the project. Sex and
gender are captured in the EJP RD project at three levels:
In the project management and governance: The gender representation of the partners’ involved at the EJP-RD
is well balanced (M/F=52/42). Attention will be taken to keep gender balance in the governance structures
(Governing Board and Policy Board) as well as Advisory Ethics, Regulatory & Legal Board.
With regards to conduct of research: gender perspective will be integrated in all EJP RD activities in support of
gender justice, based on the recognition that a systematic approach to gender in research enhances quality and
excellence. All partners, and the consortium as an entity, are committed to recruiting collaborators to the program
or training activities without bias of race or gender. Furthermore, gender will be one of the indicators for the
assessment of the funded projects in the calls of Pillar 1 and in the pilot projects of Pillar 2 and 4. Special attention
will be paid to ensure that extra effort will be performed to try and recruit more women researchers in these
825575 – EJP RD – Part B 13
projects, and to avoid the loss of women scientists during the transition between
Associated junior
with document and
Ref. higher positions.
Ares(2018)6091977 The
- 28/11/2018
equality will be also applied to the trainings offered by Pillar 3.
Sex and gender aspects in research activities to be performed: Most rare diseases do not discriminate between
males and females. Even for the X-linked diseases that seem to affect mainly males there is more and more
evidence that also female carriers may suffer from these conditions. However, sex/gender aspects will be taken into
account whenever considered relevant, e.g. (i) in Pillar 1 funded projects; (ii) in Pillar 2 with respect to influence of
gender on disease mechanisms being taking into account together with environmental factors in POCs (WP13), as
well as gender being represented in metadata describing data collection (WP11&12); (iii) in Pillar 2 for the
development of tools of virtual platform that will serve research community; (iv) in Pillar 4 (WP20) demonstration
and innovation projects for innovative methodologies to improve outcomes of clinical studies, where sex and
gender are crucial elements for natural history registries, PCOMs, etc.
1.8 Ambition
The European Joint Programme Cofund is a supreme instrument to grant high-level strategic organization and
performance of research activities in an organized and transversal manner. EJP RD will maximize the potential of
this European tool, by expanding the panel and potential of involved stakeholders. The commonly involved
Programme Owners (ministries) and Programme Managers (Research Performing Organizations) will be
accompanied for the first time by funders (Research Funding Organizations), European Research Infrastructures,
European Reference Networks, patient organizations, education institutions, and will reach regulatory bodies and
private sector. This will ensure the necessary level of integration and unique strategy to efficiently tackle
societal challenges specific and relevant for the field of rare diseases.
The overarching ambition of the EJP RD is to establish an urgently needed comprehensive strategy covering
research, data, tools and clinics leading to optimization and exploitation of results, higher and timely diagnostic
rates, faster drug discovery at reduced costs, improved patients’ care, empowering all stakeholders as well as
giving Europe a leading role in the field of RD in the coming years.
To do so, rare diseases need efficient research paths from patient to “product” (product being standardized
diagnostic guidelines, methodological and technology approaches, biomarkers, tools, medicines or devices). Thus,
the EJP RD will formalise the development “value chain” for RD in terms of diagnosis and therapies. All
stakeholders will have access to a seamless pipeline from patient needs to effective intervention through relevant
resources. The current state of the organization of the path from patient to product and respective EJP RD elements
are summarised in Figure 3..
In this path, the first step is to identify relevant patients and populations. The second step is to gather information
about them. Information gathering involves clinical information, phenotyping and genotyping, but also information
beyond the exome (which is integrated through the deployment of multiple –omic technologies). The third step is
to extract actionable insights from the information. Then useful insights are harnessed to develop products that are
subsequently evaluated. At each step in the value chain there are three key determinants of a success: (i) input
(access to facilities); (ii) resources (capability and capacity of staff, equipment and facilities); (iii) outputs and
connections to the next step. Currently, for RDs, this value chain is fragmented which leads to gaps, delays,
inefficiencies and diseconomies of scale. It also causes significant barriers to entry for the RD patients, researchers
and funders. Finally, the challenges are magnified by the dispersed nature of rare diseases patients and expertise.
Figure 3: Current generic value chain for RD “product” development.
825575 – EJP RD – Part B 14
The EJP RD will develop innovative services through a combination of: (i)
Associated withimprovement of existing components
document Ref. Ares(2018)6091977 - 28/11/2018
of the value chain (and their adaptation to RD when needed – mainly working with small populations and large
effects); (ii) integration through developing a systematic approach to inputs and outputs to each service that
improves the accessibility of all services to the RD community. Improvement and integration will be driven by
funding projects, pilots and by supporting stakeholders at each step of the value chain. The experience of these
projects and pilots will promote changes to the services used during RD products development and the connections
between services. The future state is shown in Figure 4.
Figure 4: Impact of EJP RD on value chain for RD “product” development.
Therefore, the work done by EJP RD will promote consistent links that facilitate collaboration. In addition, these
linkages will reduce the risks arising from dispersal and fragmentation providing a robust platform for judgments
about funding allocation by research funders and third sector organizations (such as patient organizations funding
research). The EJP RD will lead directly to at least 165 projects (transnational, networking, RDR challenges, POCs,
demonstrators) that will each push forward the state of the art in their respective topic areas. More fundamentally,
these projects will provide proof-of-concept for the joined-up approach that EJP RD will champion. This work will
a) reduce barriers to entry for all contributors to the value chain; b) reduce the costs of collaboration; c) increase the
benefits gained at each step of the value chain by focusing methodologies on the needs of RD. EJP-RD will
increase the value of investment through a combination of shortened timelines, targeted collaborations and
optimised methods. This will provide a step change in the value of work on RD product development and increase
the productivity of existing investment in RD. It will build a comprehensive research environment. It will also
attract new funding because of the increased likelihood of good returns on investment. Thus, the EJP RD 360°
approach will be a true game changer in a way RD is conducted so as to allow realistic achievement of IRDiRC
new ambitious goals.
2. IMPACT
2.1 Expected impacts
EJP RD will contribute to:
Overall impact: Improved alignment of national/regional activities and policies in RD
Rare diseases are capital example where pooling of expertise and resources together with coordination of national
and European efforts are game changers. Despite significant efforts employed so far, RD research in Europe can be
further improved, to overcome fragmentation, leading to efficacious use of data and resources, faster scientific
progress and increase of competitiveness, and most importantly to decrease unnecessary hardship and prolonged
suffering of RD patients. To that extent, EJP RD will be the first initiative gathering over ninety partners (and their
825575 – EJP RD – Part B 15
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
networks, e.g. only the ERNs by themselves cover 900 healthcare units from near all EU Member States) from 32
countries representing key stakeholders in RD field. The strength of the EJP RD consortium lies not only in the
number and diversity of its partners but also in its capacity to exploit the existing elements, detect their weaknesses,
improve, innovate and deliver novel more efficient solutions. To efficiently transcribe EJP RD activities and
outcomes at regional, national, EU and international levels the EJP RD already involved and will maintain strong
connection with relevant policy makers. The governance, research & innovation strategy and prioritization process
will be organized around the Policy Board gathering ministries of research & health, relevant EC directorates and
other key high-level stakeholders (see section 3.2). In addition, each country will be urged to put in place National
Mirror Group (NMG) bringing national partners participating directly in the EJP RD and additional actors of the
RD field. The NMDs will be central in identifying, discussing and bringing the national needs to the upper level.
Each country will speak with united and single voice. This will be also reflected in the EJP RD Governing Board
where each country will possess one vote (in the name of all national stakeholders). The same rule will apply to the
EU Research Infrastructures, Patient Organizations, ERNs and charities. Once again EJP RD will capitalize on
already existing seminal configurations (e.g. at national level around National Plans for Rare Diseases; for EU
research infrastructures within CORBEL project; for ERNs within ERN Board of Coordinators, etc.) and reinforce
their (gathering) potential through the EJP RD governance. Such explicit organization fortified by extraordinary
commitment of EJP RD partners and RD community in general will be the key to successful alignment of
regional/national and EU activities and policies in the field of rare diseases.
Specific impact 1: Improve lives of rare disease patients by providing new and optimised treatment options
and diagnostic tools for these diseases
The contribution of the EJP RD to the improvement of lives of RD patients by providing new and optimised
treatment options and diagnostic tools will be achieved as a sum of efforts provided within different pillars and
transversal activities strengthened by the central coordination and close linkage with relevant policy stakeholders to
translate these efforts at regional, national and EU levels.
New and optimised treatment options and diagnostic tools can only emerge from well-organized, coordinated
science that includes basic, translational, clinical, social and health economic research. These different types of
research will be financed and closely monitored in Pillar 1 thereby accelerating development of diagnostic tools
and treatments.
Pillar 2 aims at removing obstacles, for both humans and computers, to finding, accessing under well defined
conditions, analysing and reusing data across the many resources that are relevant for clinical and biological
research on rare diseases. The power of Pillar 2 virtual platform will lie in enabling RD data and tool providers to
make their data as usable as possible through FAIR principles. RD researchers and experts will be able to find and
exploit most relevant data and tools more rapidly to perform advanced and reproducible analysis allowing better
understanding of RD causes, mechanisms and determinants, which will improve ways to diagnose and to treat RD.
The successful delivery and implementation of Pillar 3 training courses will result in the systematic implication of
patient representatives in the design of research, treatment strategies and developments, as well as care
programming and actions at European, national and regional levels.
By creating an end-to-end pipeline of support and expertise for RD research, Pillar 4’s focus on translating
excellent science into effective interventions for RD patients will maximise the patient impact of the EJP RD
efforts. By ensuring access to expertise, facilities and funding, the complexities to translation will be ameliorated,
while the efforts to develop, demonstrate and disseminate improved clinical study methodologies with a support
desk available will substantially improve our ability to develop valuable interventions for small populations and
enhance the involvement of ERNs in clinical studies.
Specific impact 2: Decrease fragmentation of rare diseases expertise and research resources
Through the participation of 87 partners including policy makers, funders, research organizations, ERNs,
infrastructures and patients from 32 countries, EJP RD programme is unique in achieving centralised critical mass
of expertise and research resources from Europe and beyond.
825575 – EJP RD – Part B 16
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The long standing collaboration (2006 – 2019) of funding agencies in EU member, associated and non-EU states in
the ERA-Net E-Rare resulted in ten Joint Transnational Calls funding 117 projects including 556 research teams.
Each of these projects proved the capacity to achieve critical mass in pooling resources (data, samples, expertise
and patients) to perform high quality research. At least 77% of these projects established long-lasting
collaborations, often extended to other research groups and countries. Progressive joining of new countries allowed
pooling of national resources and better coordination of research programmes on rare diseases. EJP RD goes
beyond E-Rare by integrating of 11 new agencies (total of 29 covering 22 countries) and expanding further the
power of international collaboration of funders to support and encourage excellent (national/regional) research
groups to collaborate transnationally in the area of rare diseases. Thus, activities of Pillar 1 will be major leverage
action to decrease fragmentation and increase potential of expertise and research resources.
All Pillar 2 activities focus on centralization and uniform access to resources and expertise. The Virtual Platform of
Pillar 2 will provide a single access point to find and query resources through the most important catalogues for RD
(e.g. Orphanet, biobank and patient registry catalogues) and tools (customized ELIXIR bio.tools). It will create an
ecosystem of RD resources that are FAIR from resource level down to data element level and encompass
interoperable solutions for centralised but also decentralised resources. For the first time research resources: data,
infrastructures and tools will be accessible in an integrated way. In addition, Pillar 2 will be working through
networks of experts from and across different disciplines to address a specific bottleneck (e.g. an interoperability
standards, adoption of FAIR principles for particular health data sets).
Pillar 3 will provide the training opportunities to a large panel of RD stakeholders: researchers, healthcare
providers and patients, thereby contributing to strengthening knowledge and creating new experts. In addition, it
will decrease the fragmentation by structuring the organization and access to already available and relevant
trainings for the RD community in Europe.
Multi-disciplinary, multi-sector collaboration is a hallmark of the Pillar 4 approach, and thus will bring together
experts from basic research, product development, ESFRI infrastructures, ERNs, regulatory science, financing and
more, and make these available to EJP RD and E-RARE projects to maximise their chance to reach the patient. In
so doing, not only European but global level efforts to bring people together RD community will occur. Moreover,
P4 brings together clinical and methodological experts from around the world to drive the improvement of clinical
study design for small populations and enhance the development of clinical studies for very rare diseases.
Specific impact 3: Increase the EU's capacity to innovate in the field of rare diseases
The EJP RD programme combines massive amount of expertise and capacity not only through its direct partners
but also through hundreds of rare disease researchers that will be financed in the joint transnational projects. This
increases the opportunities for innovation and for translation into improved diagnostic tools and new or optimized
treatments. In addition, the discoveries brought by RD field may serve and be expanded to other medical domains,
as the underlying disease mechanisms may also be useful for improved diagnostic and therapeutic solutions for
more common diseases.
All funding activities of Pillar 1 foster the increase of research and knowledge capacity for rare diseases in Europe.
The dedicated Rare Disease Challenge funding scheme will specifically aim at removing general obstacles for
innovation in the field of therapeutic research in rare diseases by bringing together public and private stakeholders
(academia, SMEs, industry and funders). In addition, the support provided from Pillar 4 to detect exploitation
potential in funded projects of Pillar 1 and subsequent accompanying of these projects through translation to clinic
steps will contribute to the increase of innovation and competitiveness potential of EU.
Pillar 2 will support the increase of EU’s capacity to innovate at different levels: (i) it will maximize the potential
of already existing, EU funded facilities and tools, both RD-specific and broader ones (RD-Connect, Orphanet,
HPO, ELIXIR, BBMRI, EATRIS, INFRAFRONTIER, etc.) by supporting them further, scaling them up, linking
them together and fully tuning them to the needs of end-users; (ii) it will set mechanisms to continuous integration
of new data elements, standards and tools so as to provide European research with a unique ecosystem that will
efficiently translate research into better care and medical innovation; (iii) by working hand in hand with the
European Reference Networks it will bring a unique opportunity to efficiently link healthcare and research opening
the road to diagnostics innovation; (iv) furthermore, as omics becomes more prevalent in clinical practice Pillar 2
will develop novel tools and pathways for comprehensive interpretation of data and setting of standards thereby
accelerating means to tackle undiagnosed diseases.
825575 – EJP RD – Part B 17
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Providing state-of-the-art education and bringing together different type of stakeholders will enhance the
innovation potential of the RD community. In addition, empowering patients and promoting patients’ centered
approaches brings attention back to their needs, helps in focusing on relevant priorities and thereby accelerates the
process of innovation. In addition, Pillar 3 itself will be source of innovation in training and education field by
creating the first EU e-learning academic education programme on RD.
EJP RD is structured specifically to improve innovation, and Pillar 4 creates the bridge from basic research to the
clinic and back, in the bench-to-bedside-and-back approach. By both supporting the best projects to get to the
patient more effectively, and working on some longstanding bottlenecks, such as methodological challenges in
design and analysis of clinical studies of small populations, and access to proof-of-concept funding for preclinical
projects, this pillar will allow immediate systemic improvement to Europe’s ability to innovate in RD and
accelerate the reach for therapies.
Specific impact 4: Improve healthcare systems' capacity to take up research results
The EJP RD pipeline translated by its interlocked Pillars and transversal activities fosters effective and efficient
implementation of research and innovation outcomes in the daily life of rare disease patients. The participation and
strong involvement of the European Reference Networks, linking centres of expertise and professionals in different
countries, will be the key element to improve the uptake of research results into health care.
The funding of socio-economic and health care/health services related projects in Pillar 1 (WP6) will facilitate a
better understanding of the real life problems and possible solutions for better uptake of research results in the
general practice. In addition, the expected exchange of knowledge facilitated through the Networking schemes
(WP7) and close connections between researchers, doctors and patients will also lead to an increased uptake of
research results by providing the space to share diagnostic practices and guidelines, put more light on research
results and innovative solutions and strengthen the collaborations by different stakeholders.
The Pillar 2 strategy is based on giving the European Reference Networks a leading role in driving the way VP is
built, with the ultimate aim to accelerate the take up of research results in clinical practice for the benefit of
patients. ERNs will ensure the usability and the usefulness of the VP by continuously testing it against real-life use
cases, by bringing research questions and establishing, together with Pillar 2 partners, sustainable mechanisms for
ensuring a virtuous cycle between care and research.
The translation from research to healthcare cannot be done without relevant education. Pillar 3 will train on how
research results can be exploited in other settings like diagnosis, drug development, etc. It will also provide
dedicated trainings developed by and targeted to ERNs, thus closely connecting the needs of healthcare providers
and research.
Pillar 4 is dedicated to patient-centrism, and in so doing will ensure that all projects traversing the chasm between
lab and clinic are designed for optimal patient uptake. This will be achieved by ensuring strong technical, product
development, regulatory, HTA and funding support is available, so that projects are structured with patient uptake
at their heart, and can benefit from follow-on funding to get them closer to the patient. Moreover, the
methodological work being done to improve statistical methods for small populations will allow clinical uptake for
interventions designed for rare diseases, thereby also improving ability to implement results into the clinic. The
involvement of ERNs and of patients group will be a key factor for this implementation.
Specific impact 5: Reinforce the EU's role as a global leader for rare diseases
The EJP RD is exemplary to the world in bringing together the various expertise on research and innovation of rare
diseases from so many institutions, clinicians, researchers and patient organisations in one programme to
investigate and implement the results into the life of rare disease patients in Europe and beyond.
The joint funding activity of Pillar 1 bringing 23 countries and the European Commission is key to speed up rare
diseases research in Europe. The joint effort leveraging national funding resources in addition to the EC funding
capacity is estimated at more than 60M € for 5 years. The variety of proposed funding schemes fostering
transnational research, Networks and Rare Disease Challenges will be essential to enhance excellence and thus
European leadership in the field of rare diseases.
825575 – EJP RD – Part B 18
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
European Pillar 2 partners are already leading global endeavours (Orphanet, HPO, FAIR data principles and
metrics) or are deeply involved in global initiatives (IRDiRC, MME, Beacon, GA4GH). Consolidating their efforts
into the Pillar 2 work will maximize their impact and constitute an unprecedented resource that will establish a new
paradigm for conducting research in the RD field, and could be a model for other domains. Europe will
demonstrate that synergizing efforts by building a structuring long-lasting ecosystem of data and resources across
domains (healthcare and research) but also linking national and transnational levels has a direct impact in clinically
applicable discovery and innovation.
As for the other EJP RD elements, the strength of Pillar 3 is based on bringing together yet fragmented but already
existing EU capacities and organizing them in a coherent and efficient RD training and education landscape.
Furthermore, the EU potential will be expanded by seizing and creation of novel, first-in-class trainings.
The highly multi-disciplinary, outcome-oriented approach to the EJP RD in general, and specifically in Pillar 4,
will augment Europe’s world class output in RD research and development. The outstanding outputs to be expected
from the efforts in Pillars 1,2 and 3 will create a rich seedbed of knowledge, which will supported by Pillar 4 on the
long journey from publication to patient. P4’s combination of active support to today’s projects, combined with a
systematic tackling of serious systemic roadblocks to innovation, will cement Europe’s lead in RD research and
innovation.
Specific impact 6: Follow the policies and contribute to the objectives of the International Rare Diseases
Research Consortium (IRDiRC)
The organization of the EJP RD consortium reflects well the organization of IRDiRC by bringing under single
umbrella funders, research performing institutions, healthcare providers, patients and linking to industry. In
addition, the majority of EJP RD partners are also members of IRDiRC. This will not only allow but also accelerate
the follow up of IRDiRC policies and contribution to its objectives. Furthermore, constant connection to IRDiRC
will be maintained by the integration of IRDiRC chair and vice chair in the EJP RD Policy Board, incorporation of
IRDiRC Scientific Secretariat in the EJP RD Coordination Office, implementation of joint Task Forces and
participation of rare diseases experts and other EJP RD members in IRDiRC scientific and constituent committees.
The large part of funders involved in the EJP RD are members of IRDiRC. Funding bodies participate either with
“individual” status or through the “E-Rare group of funders” that joined IRDiRC in 2012 and were strongly
involved in determining the vision and goals of IRDiRC for the period 2017-2027. The support to IRDiRC policies
and objectives is already translated through introduction of IRDiRC recommendations in guidelines for researchers
as well as implementation of joint transnational calls targeting topics identified by IRDiRC as of most importance.
This will be continued and further expanded within Pillar 1 activities.
The Pillar 2 main goal is to provide access to data and services to allow better research towards diagnostics as well
as new and more effective therapies for rare diseases. Thus, the overall Pillar 2 was designed towards IRDiRC
2017 – 2027 goals, namely (i) provision of a diagnosis within one year to all patients coming to medical attention
with a suspected rare disease if their disorder is known in the medical literature or integrating of all currently
undiagnosable individuals into a globally coordinated diagnostic and research pipeline and (ii) to develop 1000
therapies. These new IRDiRC goals can only be achieved with fundamental changes to the way science is
conducted, shared, and applied to the care of rare disease patients. By creating an innovative VP and by putting in
place mechanisms for constant improvement and continuous integration of new data, standards and resources,
Pillar 2 realizes the commitment of Europe to catalyse those qualitative changes. Based on real-life use cases and
needs brought by ERNs, Pillar 2 will help generating new knowledge on disease mechanisms towards better
diagnosis and identification of druggable targets and disease modifiers to be used in research, by bringing together
data and resources (expanding beyond RD), so as to take the best advantage of the most cutting-edge research
across domains.
Although IRDiRC recommendations do not target specifically education and training activities, its overarching and
specific goals will be followed within Pillar 3. This will include for example raising awareness of complexity in
diagnostics of unsolved patients with RD in the healthcare system or enhanced uptake of research results for
translation into tangible outcomes, diagnosis and therapy development.
With a central aim of IRDiRC being therapies and diagnostics, the patient-centric approach to Pillar 4 will directly
contribute to its goals. A key focus of the activities in Pillar 4 is to improve and accelerate the productivity of
825575 – EJP RD – Part B 19
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
translational and clinical research, which represents the critical path of new diagnostics and therapies to clinical
implementation. The pillar will seek to address systemic weaknesses in the current development pathway by
(among others) accelerating the validation and dissemination of high potential (statistical) methodologies tailored
for small patient populations and proposing new approaches dedicated for RD. In so doing, the EJP RD will push
for faster uptake of novel methodologies that have been shown to have utility for clinical rare disease R&D. In
addition, the vast pool of resources, expertise and projects that will be created by EJP RD will be supported by P4
to take the outstanding discoveries and bring them towards the patient in form of a novel product. The outcomes in
translational research will be improved by creating tailored mentoring boards for each applied research project
funded in the EJP and E-RARE 3 funding programmes, the research community will avail of expert support in
fields that are critical to success, including preclinical studies, product development, manufacturing,
implementation of the trials regulatory affairs, and more. Such a mentoring system will be unique in Europe, and
serve to improve outputs and increase cross-sectoral collaboration through organic public-private
interaction. Finally, further leveraging other funding sources (by supporting researchers in defining follow-on
financing opportunities) as well as creating a roadmap for a future innovation fund in Europe, the systemic funding
deficiency in R&D in Europe will be partially addressed. Hereby individual projects will be more immune to the
stop-start dysfunction of public financing, while providing access to expert support in innovation.
Other substantial impact(s): Contribution to the European Open Science Cloud
EJP RD will increase its impact by actively contributing to the European Open Science Cloud (EOSC) by: (i)
supporting the EOSC in its stated desire to apply FAIR Principles (in league with the GO FAIR network), given
that establishing FAIR Rare Disease data is a cornerstone of the EJP RD (Pillar 2 WP12); (ii) aligning with EOSC
on the respective data plus software quality assurance approaches and the data governance principles (Pillar 2
WP10); (iii) developing the EJP RD data Virtual Platform to be a multi-tenant federated architecture able to
support a plurality of service providers and service consumers, as needed for EOSC (Pillar 2 WP11); and (iv)
exploring cross-fertilising sustainability models for the life science ecosystem with EJP RD being the leader on rare
diseases aspects of this ecosystem (Pillar 2 WPs10 & 12, transversal WP3). In particular, this work will begin with
EJP RD building on the previous European investments into the EOSC, e.g., by utilizing outcomes of EOSCpilot
and EOSC-hub projects. Outcomes of these projects, such as policies for dealing with sensitive data or common
metadata models and guidelines, will be adopted and promoted to help their expansion on European scale within
the communities relevant to EJP RD.
2.1.1. Barriers / obstacles
The key barriers to achieving the expected impacts are the dispersal of patients and fragmentation of expertise.
Overcoming dispersal of patients involves interacting with relevant umbrella organisations at national (National
Alliances for Rare Diseases existing in most EU countries and members of EURORDIS) and European level
(European Federations for specific Rare Diseases, also members of EURORDIS) which can then interact with their
members reaching a large number of individuals. However, each interaction could provide an obstacle to the work
of the EJP RD because of the need to address specific anxieties, concerns, and institutional processes. Hospitals
that provide care for people with RD may derive a number of benefits from working in isolation (tangible revenue
streams, intangible reputational benefits). These obstacles will be balanced against the direct benefits of
collaboration to patients and hospitals. RD cannot be addressed locally and the European patient advocacy groups
that participate in the EJP RD will reinforce this message as appropriate. The improved value chain for RD product
development developed by EJP RD will provide the trusted environment that allows individual institutions and
persons to realise the benefits of collaboration. In the long-term, improved treatments will reduce the overall costs
to society of RDs and will promote the reputations of hospitals that provide innovative treatments.
Overcoming fragmentation of expertise involves obtaining buy-in, and institutional approval, from researchers and
their host organizations. Obtaining buy-in could prove to be an obstacle because of competing opportunities and
perceptions about the low value of RD research. The work done by EJP RD to improve the efficiency and
effectiveness of RD research will redress the balance in favour of RD research. Institutional approval for research
is equally difficult for RD and other types of research: all EJP RD participants are extremely skilled in seeking
institutional approvals and will be further supported by dedicated services developed under the EJP RD.
These barriers and obstacles are unlikely to have a material effect on the ability of EJP RD to achieve impact
because a critical mass of collaborating individuals, advocacy groups, hospitals, and academic organizations
already exists. The uncertainty about achievement relates to the scale and breadth of success beyond the groups that
are already committed. Direct investment of 25 countries through funded calls in Pillar 1 will promote scale and
825575 – EJP RD – Part B 20
breadth of involvement. Progress will be monitored in WP1 Task 1.3.with
Associated The Operating
document Group and Executive
Ref. Ares(2018)6091977 - 28/11/2018
Committee will have sufficient information to identify and address deficiencies.
2.1.2. Framework conditions
A number of regulatory frameworks are relevant and will be addressed comprehensively: information governance
(WP1, WP4 & Pillar 2); research conduct (WP4, WP19); transfer of biological material (WP4) and data (GDPR);
national divergence (WP1). The regulatory context is relatively stable so that direct work on these topics is likely to
lead to predictable achievement of the expected impacts. Many relevant standards are missing or incomplete but
will be developed as needed, with full participation of EJP RD and its members in all similar initiatives. The
standards environment is established and key players are included in the consortium (Orphanet, Human Phenotype
Ontology -HPO-, FAIR principles conceivers) so that effort in this domain is highly likely to lead to the anticipated
impacts.
Public acceptance of the need for research in RD may vary. Past efforts of the RD community have increased the
visibility of research and acceptance of the specific features of RD in many European countries. There is a risk that
this growing acceptance will stall and that countries without RD programmes do not develop them or that member
states with RD programmes will not support continued growth of those programmes. This risk would only be
material to the impact of the EJP RD programme if public acceptance is reduced: this is highly unlikely. A subtler
risk is the possibility that collaboration about RDs reduces the likelihood of public donations because of less direct
emotional impact arising from reduced awareness of individual cases. This risk is already well-managed by
umbrella groups such as EURORDIS or Telethon advocacy organizations and this know-how can be further shared.
All of these risks to public acceptance of RD research and the specific actions of the EJP RD are actively mitigated
by efforts made by EJP RD participants in parallel to EJP RD. Acceptance of research and methods by RD patients
and their families will not change.
Workforce considerations relate to the number of researchers involved in RD; the skills-mix of those researchers
and the lack of support for collaboration in academic settings (that can reduce the drivers and incentives for
academics to collaborate in the way proposed by this application). At present, the workforce is not a rate-limiting
step in the RD product development value chain. As the current rate-limiting steps of dispersal of patients and
fragmentation of expertise are addressed during the EJP RD, the skills-mix will become more important,
particularly the adaptation of generic skills to the needs of RD research. The programme is designed to promote
appropriate skills through Pillar 3 but also through the dedicated incentives within Pillar 1 joint transnational calls
and Networking scheme. The number of researchers and the involvement of academic institutions will be increased
by the increased flow of projects prompted by the EJP RD actions and organizational legacy provided by the EJP
RD. The clearer relationship between effort and reward provided by improvements in the RD product development
value chain is likely to improve the return on investment for individual researchers (as career pathways become
more obvious) and for academic institutions (as the number and value of collaborative projects increase). Thus,
attention to supply and demand elements of workforce management will promote the success of the EJP RD. The
only way that workforce considerations could reduce impact would be a general reduction in the scientific
workforce. This possibility is highly unlikely and the effects of a general reduction in the scientific workforce
would be mitigated for RDs by the effects on supply and demand outline here.
Finance of follow-up steps is directly addressed in Pillar 4, WP19. This will be directly facilitated by work to
reduce costs and increase benefits.
Finally, cooperation of other links in the value chain is built into the EJP RD through the extensive partnerships
that beneficiaries are involved in. The EJP RD value chain starts with diagnosed patients and ends with evaluated
products. Before the EJP RD value chain starts, patients are diagnosed and given clinical care. The ERNs are
positioned to improve diagnosis and clinical management and will embed their work in the EJP RD. Products
developed by the EJP RD value chain are fed into health care systems. ERNs will do this at the level of clinical
management. EJP RD participants from national funding agencies and policy organizations will provide links to
relevant national intersectoral networks.
2.2 Measures to maximize impact
2.2.1 Dissemination and exploitation of results
The dissemination of outputs (new knowledge, tools, services, trainings, etc.) and achievements obtained by the
EJP RD program is essential for the visibility, outreach, impact and sustainability beyond the five year of the
programme. The plan on dissemination and exploitation of results is designed to maximize the impact and serves
three goals: (i) increase awareness on the EJP RD in order to involve more partner countries in joining EJP RD
activities resulting in a substantial contribution to the overall goals of IRDiRC and inducing changes in the RD
landscape at regional/national/EU and international level; (ii) to increase knowledge on and understanding of rare
diseases, accelerate diagnosis and therapy development; and, finally (iii) to engage key stakeholders to support a
825575 – EJP RD – Part B 21
sustainability scenario for EJP RD ecosystem as a whole and for individual “products”.
Associated with TheAres(2018)6091977
document Ref. results of EJP RD will
- 28/11/2018
be disseminated at different levels by means specifically tailored to the needs of the targeted audience. On one hand
the consortium will take advantage of its extensive network of partners, their powerful outreach and excellent
reputation, on the other hand it will develop new instruments that will serve to increase the impact. The
dissemination plan is presented in the table below.
2.2.2 Communication activities
Strengthening the communication and interactions between different stakeholders is essential to raise awareness on
the importance and benefits of rare diseases research. EJP RD communication activities will include such elements
as workshops/briefings to stakeholders, webinars, educational sessions with patients, practitioners and/or policy
makers or scientific meetings. The communication tools will comprehend portals, newsletters, networking
platforms, official reports and strategic publications, videos and social media. In order to multiply the impact
special attention will be given to encourage consortia financed through Pillar 1 to organize open events to
disseminate their results and knowledge as well a mandatory publication in open access journals. Scientific
congresses will be organized [RE(ACT) & IRDiRC] and dedicated RD sessions will be put in place in
collaboration with other European or international congresses (ESHG, ECRD, DIA BIO, etc.).
2.2.3 Data Management Plan
EJP RD will contribute to the European Open Science Cloud and data management will be dealt with extensively.
All data activities will follow Open Research Data principles (which conform to FAIR data principles), and comply
with the GDPR and existing ethical and legal expectations for healthcare, research and patient data. Whenever
possible, datasets managed by EJP RD will have no access restrictions, though more sensitive data will be
provisioned in a responsible and secure manner such that discovery, access and use (analysis and linking) will be
controlled based on reasonable regulatory conditions, all of which will be fully transparent. Processes for
requesting data will be maximally streamlined and progressively automated. A clear commitment to the above
principles will be included in the Consortium Agreement. It is important to underline that the whole of Pillar 2
relates to professional IT and RD data management, emphasizing Open data and FAIR data principles, by means of
an advanced Virtual Platform (VP). Pillar 2 will provide the technology, standards, access/analysis capabilities,
utility/quality assurance and GDPR guidelines for local, hosted and centralised data management. All of this shall
be coordinated by Pillar 2 WP10, with monitoring and strategic guidance provided by the RD research and
healthcare community. More details are provided in Pillar 2 description of the Implementation and Annual Work
Plan parts.
Ongoing data management in the EJP RD will be a shared responsibility. All data-related activities (existing, new
and derived data) will exploit and align with the data management systems provided by Pillar 2. In Pillar 1 this
pertains to the projects that are financed within joint transnational calls. In Pillar 4 this applies to generated and
derived data that supports translational research. In Pillar 3, in close collaboration with Pillar 2, it is relevant to
educating data custodians, stewards and users about how to apply best data management practices and how to use
the Pillar 2 VP. Finally, the EJP RD extends its data management ambition to long term data support through its
sustainability and scaling-up activities (transversal WP3 and Pillar 2).
2.2.4 Dissemination and communication Plan
Table 1. Dissemination and communication plan including expected effects of planned activities
825575 – EJP RD – Part B 22
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
EJP RD planned Expected effects of dissemination Target Audience Means of dissemination and WP Date
Activity/Outputs and communication communication tools
INTERNAL COMMUNICATION
EJP RD internal ● EJP RD partners informed of all ● EJP RD partners ● Monthly internal NL including EJP RD 1 Continuous
communication actions on time Action Updates
● Timely delivery of expected ● Regular conference calls
outputs by partners ● Consortium assembly meetings
EXTERNAL DISSEMINATION & COMMUNICATION
Central Helpdesk ● Timely communication between ● All stakeholders ● Website Continuous
providers of RD research ● Multimedia marketing campaigns targeted Every year
services and consumers of at users of RD research services
research services
SRIA ● National and EU needs and ● Ministries of Research & Health ● Policy Board meetings 2 Every year
recommendations well captured ● Relevant EU directorates (DG RTD, ● Annual SRIA Scoping paper & M33, M57
● EJP RD annual priorities Santé, Connect) ● State of play of funded research and drug for strategic
defined by Transparent ● IRDiRC development, overlaps and trends at workshops
decision-making process ● ESFRI representatives international level report
● Alignment and enhancement of ● Regulatory authorities ● SoA of Member States activities related to
national, EU and international ● Patient Organisations the EJP RD
RD research activities (funding, ● National Mirror Groups ● Strategic workshops targeted to EU13 and
support to sharing of data and EU15 needs & interactions
resources, training, accelerated
exploitation of research results)
Medium and long-term ● Joint (with IRDiRC) ● Research and health policy makers ● Publication of outcomes on IRDiRC and 2 Continuous
strategy - Task Forces identification of gaps and ● Research funders EJP RD websites
bottlenecks in RD research → ● Industry ● Targeted reports or/and publications in peer
alignment of strategies ● Patient(s)/Organisations review journals
● Adoption and endorsement of ● RD researchers ● Presentation at relevant workshops and
TF recommendations conferences
● Integration of relevant elements
in the EJP RD activities (e.g.
trainings)
825575 – EJP RD – Part B 23
Management of EJP ● Implementation of EJP RD ● EJP RD partners ● Presentation of ethics, regulatory
Associated 4 Every -year
& legal Ref. Ares(2018)6091977
with document or
28/11/2018
RD ethics, regulatory activities in line with ethical, ● RD stakeholders at large updates to partners Continuous
& legal issues regulatory and legal guidelines ● Regulatory agencies ● Dissemination via dedicated Flash News or
● Establishment of efficient NL
dialogue with regulatory ● Short update reports to be published at EJP
agencies RD website and redistributed to relevant
● Become an “information stakeholders for further dissemination
reference” for legal, ethical and
regulatory issues in RD field
EJP RD service ● Detection and promotion of ● Researchers on rare diseases ● EJP RD website and Helpdesk 3 M24-M36 then
catalogue useful services complying with ● ERNs / care givers ● Dedicated events continuous
interoperability objectives in ● Patients’ organizations ● Channeling to ESFRI, funding bodies,
RD research activities ● SMEs and industry (pharma, medical governmental bodies
● Increased interest and adhesion devices, ICT)
of the research community / end ● Public funders and authorities
users, ● Other funders
● Public and private support to ● Learned societies
sustain most acclaimed services ● Regulators
Sustainability roadmap ● Action in engaging key ● Policy makers ● Business plan 3 From M24
stakeholders ● Ministries ● Reports on innovative sustainability
● Program owners and managers solutions & sustainability models
● European Commission ● EJP-RD service catalogue
● SMEs and industry ● EJP RD dedicated strategic reports
● Foundations and learned societies ● Meetings with Policy Board
● Patients’ organizations
Funded research ● Critical mass of ● Clinicians and heads of reference centers ● OA publications 6 Continous
projects data/samples/patients achieved ● Researchers on rare diseases ● EJP RD and IRDiRC websites
● Increased knowledge on and ● Technology platforms ● EJP RD and partner organizations
understanding of rare diseases ● European infrastructures Newsletter
● Improved diagnosis ● Patients organizations ● Scientific meetings and congresses
● Accelerated therapy ● SMEs and industry (RE(ACT), IRDiRC Congress, ECRD,
development ● Program owners and managers ESHG)
● Data sharing and networking ● European Commission ● Targeted workshops (also at national level)
● Input for EJP RD virtual ● All other rare diseases related initiatives ● Pillar 3 trainings
platform ● General public ● RE(ACT) platform
● Contribution to the objectives of ● EJP RD public reports and brochures
IRDiRC ● EC Cordis & ERA-LEARN
Networking projects ● New RD networks ● RD researchers & clinicians ● Networking events publicized on EJP RD 7 Continuous
● Increased collaboration of RD ● Patients website, Newsletter and through partner from Y2
825575 – EJP RD – Part B 24
researchers, clinicians and ● European Reference Networks organizations channels
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
patients ● Healthcare providers ● Reports from organized events published
● Increased sharing of knowledge on EJP RD website, Newsletter
on undiagnosed patients ● OA publications (when relevant)
● Expanded geographical
coverage (e.g. networks
covering more EU13 countries
or new collaboration with
Africa, South America, etc.)
RDR Challenge ● Effective academia-industry ● Industry/pharmaceutical ● ERTC specific communication 8 Case by case
projects collaboration companies/SMEs (EURORDIS) basis (from
● Outputs with patenting, IP ● Venture capitals ● EFPIA website M36)
potential ● Academic RD researchers ● IRDiRC website and Newsletter
● New (technology) solutions
● Creation of valuable know-how
● POCs
Virtual Platform for ● Increased visibility of resources ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from
federated FAIR data ● Resources and FAIRdata P1 funded projects) ● EJP RD and related partners newsletter 12 M12
and resources (record level) findable at a ● ERNs and national reference ● Scientific OA publications &
central point centers/hospitals ● Strategic reports 13
● Increased interoperability ● Patients ● IRDiRC Recognized resource label
between resources ● Policy makers/ministries ● Inclusion in dedicated trainings
● Accelerated access to data and ● Funders ● Congresses and workshops
resources ● Industry (EFPIA) ● Recommendations on use in calls for
● Integration in national and EU ● SMEs (EUCOPE) projects of Pillar 1
recommendations (e.g. RD ● EJP RD Sustainability Roadmap
national plans) ● EJP RD catalogue of services
● EOSC
RD analysis tools and ● Improved usability of ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from
data sharing genomics/phenomics/multi- P1 funded projects) ● EJP RD and related partners newsletter 13 M12
capabilities omics data deposition and ● Systems Biologists and Data scientists ● Scientific OA publications (pathway
analysis resources ● ERNs and national reference ● Strategic reports portal will start
● Facilitated and secure centers/hospitals ● Guidelines and recommendations month 1)
deposition of data ● Policy makers ● IRDiRC Recognized resource label
● Higher number of submissions ● Funders ● Inclusion in dedicated trainings
● Higher number of accessible ● Industry (including pharma) ● Congresses and workshops
datasets for research ● Recommendations on use in calls for
● Faster identification of projects of Pillar 1
causative genes and variants ● EJP RD catalogue of services
● Accelerated diagnosis including ● Presentations and workshops in ELIXIR
undiagnosed or misinterpreted SME events
cases ● Tutorials on pathway creation and multi-
825575 – EJP RD – Part B 25
● Increased EU innovation omics workflows(with pillarwith
Associated 3) document Ref. Ares(2018)6091977 - 28/11/2018
capacity ● Pathway portal on WikiPathways
● Better disease mechanism ● Network deposition on NDEX
descriptions (on pathway portal)
● New ideas for drug targets and
drug repositioning
Organisation of data ● Good flow of standards, ● RD researchers and clinicians ● EJP RD website and Helpdesk 12 & Starting from
stewarding technologies and capabilities ● Research institutes and hospitals ● IRDiRC Recognized resource label 14 M1
collaborations, between infrastructures, data ● Infrastructures ● Guidelines and protocols
advocacy, and self-help experts and RD experts ● Funders ● OA publications
networks for practical ● Emergence of self-helping data ● Policy makers ● Webinars
FAIRification support stewarding networks within the ● Industry ● Trainings
RD community ● Tailored service support
● Increased awareness and better ● Collaboration with international expert
FAIR data stewardship groups (e.g. organised through IRDiRC,
capacity planning by RD ELIXIR, GA4GH, BBMRI-ERIC, EOSC,
resource managers GO FAIR, NIH, OHDSI, etc.)
● Model for FAIRification ● Recommendations for FAIR data
support as a service by and for stewardship in Data Management plans in
the RD community, including calls for projects of Pillar 1
public-private-partnership ● EJP RD Sustainability Roadmap
● Project-based and on-site engagement with
exemplar stakeholders to seed
FAIRification capacity in RD networks
(e.g. ERNs)
● Online communication channels, telephone
conferencing, and workshops for FAIR
experts and interdisciplinary
communication
● Support for advocacy and networking by
stakeholder data stewards at EJPRD
meetings and international conferences for
RD
Innovative holistic ● Reduced product attrition ● RD researchers and clinicians ● EJP RD website and Helpdesk 13 From M36 and
approaches for rare ● More rapid completion of ● Research institutes and hospitals ● EJP RD and related partners newsletter then continous
diseases diagnosis and product development ● Infrastructures ● Scientific OA publications
therapeutics ● Funders ● Strategic reports
● Policy makers ● IRDiRC Recognized resource label
● Industry (EFPIA) ● Inclusion in dedicated trainings
● SMEs (EUCOPE) ● Congresses and workshops
● Recommendations on use in calls for
projects of Pillar 1
825575 – EJP RD – Part B 26
● EJP RD Sustainability Roadmap
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Training on data ● All potential participants ● Academic researchers and clinicians ● EJP RD website and Helpdesk 14 Every year
management and interested in training course(s) ● Biobank managers ● EJP RD and related partners websites &
quality informed in time for registration ● Laboratory scientists & technicians newsletter
● Clinical geneticists ● Universities websites, and social media
● Applicants of EJP RD joint transnational ● EU-funded projects’ Newsletters (Solve-
calls RD, RD-Connect, Share4Rare, Orphanews,
● ERNs etc.)
● ePAGs (RD patient rep involved in ERNs ● Recommendations on use in calls for
for task 14.5) projects of Pillar 1 and Pillar 4
● ePAGs online communities
● ERN specific Newsletters
● ERN specific websites
● Communication channels of Learned
Societies
● Other relevant EU and international
networks (UDNI, EuroBioBank website,
ESBB etc.)
● Journals listing (e.g Nature Events)
Training of patients ● All potential participants ● Rare disease patients and representatives ● EJP RD website and Helpdesk 15 Every year
and researches in rare interested in training course(s) ● ePAGs (RD patient rep involved in ● EJP RD and related partners newsletter,
diseases research and informed in time for registration ERNs) websites and social media (twitter,
processes ● Increase of knowledge and ● YPAGs (young patient advisory groups LinkedIn, facebook)
awareness within the targeted representatives) ● ePAGs online communities
community ● Academic researchers ● EURORDIS website (Open Academy), e-
News, ePAGs Newsletter and EURORDIS
working groups/Task Force mailing lists
(e.g. DITA, Summer School Alumni, TAG,
SWAN Europe etc.)
● TEDDY and, EPTRI and eYPAGnet
mailing lists/Newsletters/website
● C4C Website/Newsletter
Online academic RD ● Increase awareness of the online ● Academic clinicians and researchers ● EJP RD website and Helpdesk 16 Every year and
education course course among several ● Medical & biomedical students ● EJP RD and related partners (e.g. more starting
stakeholder groups ● Industry researchers/scientists universities) newsletters M12
● RD patient representatives and advocates ● Dedicated printed materials (leaflets,
● Industry posters) to be distributed by partner
● Lecturers organizations
● University managers ● FutureLearn platform and Newsletter
● Professional organizations ● Communication channels of Learned
● Organizations of academic institutions Societies
(like UEMS) ● Scientific meetings and congresses
825575 – EJP RD – Part B 27
(RE(ACT), IRDiRC Congress,
Associated with ECRD,
document Ref. Ares(2018)6091977 - 28/11/2018
ESHG
● Conferences and events dedicated to
academic education
ERN training & ● All potential participants ● Academic clinicians and researchers ● ERNs specific Newsletters 17 Every year
support interested in training involved in ERNs ● ERNs specific websites
programme informed in time for ● Mailing list ERN training and education
registration working groups
Development and ● Needs of RD research ● Ministries of Research & Health ● Policy Board meetings 18 Every year
adaptation of training community as a whole and ● National Mirror Groups ● EJP RD website and Helpdesk from year 2
activities relevant groups of stakeholders ● Patient Organizations ● EJP RD and related partners newsletter and
(ERN, countries) well captured ● ERNs websites
● Transparent decision-making ● Organizations of academic institutions ● Conferences and events dedicated to
process for EJP RD annual academic education
priorities
Innovation ● Appropriate and timely ● RD research community especially ● ERNs, website and roadshows 19 Continuous
Management Toolbox connections between innovators researchers with a potential product ● EJP RD website and Helpdesk
and facilitators of innovation ● ERNs ● EJP RD and related partners newsletter &
● Self-help resources openly ● RD research community websites
accessible to RD research ● Institutional innovation managers
community
Real-time mentoring ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 19 Continuous
and technical support identification for researchers ● E-Rare & Pillar 1 funded projects ● EJP RD website and Helpdesk
for translational ● EJP RD and related partners newsletters
projects
Support in exploitation ● Timely match between investors ● Researchers with an evaluated product ● ERNs, website and roadshows 19 Continuous
of research results and and product ● Investors (industry, venture capitals, ● EJP RD website and Helpdesk
follow-up funding charities, etc.) ● EJP RD and related partners newsletter
● Dedicated meetings and congresses
Roadmap for EU ● Shared agenda for research in ● Funders ● Publication of outcomes on EJP RD 19 M36
investment platform RD and clear entry points for ● Clinicians and heads of reference centers websites
investors ● Researchers on rare diseases ● Targeted reports or/and publications in peer
● Technology platforms review journals
● European infrastructures ● Presentation at relevant workshops and
● Patients organizations conferences
● SMEs
Activity: Support in ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 20 Continuous
design and planning of identification for clinical studies ● clinicians with a potential project of a ● EJP RD website and Helpdesk
RD clinical studies clinical study ● EJP RD and related partners newsletter
●
Demonstration studies ● Increased range of ● Funders ● Publication of outcomes on EJP RD 20 M12 – M48
to validate promising methodologies that have been ● Clinicians and heads of reference centers websites
825575 – EJP RD – Part B 28
methodologies to validated for use in RD clinical ● Researchers on rare diseases ● Targeted reports or/and publications
Associated in peer
with document Ref. Ares(2018)6091977 - 28/11/2018
improve RD clinical trials ● methodologists involved in RDs review journals
trials ● Large pharma and SMEs ● Presentation at relevant workshops and
● Regulators conferences
● diffusion through clinical trials help desk
Innovative ● Increased range of innovative ● Funders ● Publication of outcomes on EJP RD 20 M15 – M56
methodologies to methodologies and new ● Clinicians and heads of reference centers websites
improve RD clinical statistical designs for use in RD ● Researchers on rare diseases ● Targeted reports or/and publications in peer
trials in limited clinical studies to fill the urgent ● Methodologists involved in RDs review journals
populations gaps ● Large pharma and SMEs ● Presentation at relevant workshops and
● Regulators conferences
● Webinars
EJP RD project as a ● Increased use of EJP RD ● RD community at large (researchers, ● Creation of unique, recognizable identity 1 Continuous
whole tools and services healthcare providers, patients) ● Annual Progress Report
● More knowledgeable RD ● Policy makers ● EJP RD website, newsletter and printable
stakeholders ● Research institutions and infrastructures publicity elements
● Better connected RD ● Funders ● Presentations at national, EU and
stakeholders ● Industry and SMEs international congresses
● Improved alignment of ● Patient Organisations ● Targeted videos adapted to different types
national, EU and ● General public of stakeholders
international strategies ● Scientific and strategic publications
825575 – EJP RD – Part B 29
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
3. IMPLEMENTATION
A more detailed description of the specific activities to be carried out in the first year will be included in Annex 7
Figure 6. EJP RD implementation structure (interactions being represented in the table below)
825575 – EJP RD – Part B 30
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Table 2: Description of interactions between different work packages of the EJP RD
825575 – EJP RD – Part B 31
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
3.2. Management structure, milestones and procedures
An initiative such as EJP RD, aiming at developing into an ambitious sustainable structure, needs to establish clear
roles and responsibilities in order to meet the objectives, build trust from the wider rare diseases community and
mechanisms to solve potential conflicts. The management structure aims at transparent decision-making process
with well-defined responsibilities in pillars, WPs and tasks. It will provide efficient and adaptive structure,
necessary to capture and deal with emerging strengths and weaknesses. It will manage the strategy planning, annual
work (plans) and allocation of resources. It will be responsible for interactions with external (policy and political)
stakeholders.
It is developed according to the principles of subsidiarity and should stimulate co-decision of each partner and co-
creation of knowledge, be it at the EU-level, the national level or at the level of the scientific community. The
management structure of the EJP RD will be defined to:
● Plan, organize and monitor the effort to achieve the EJP RD’s objectives within constraints of time schedule and
budget.
● Define clearly the decision-making procedures and bodies.
● Run performance control procedures leading to the expected quality of achievements and deliverables described
in the work plan.
● Continually inform the partners on the project status and progress.
● Drive the project implementation in accordance with administrative, financial and legal issues defined by the
European regulations and national specificities.
● Guarantee that the rights and obligations of the partners are kept compliant with the Grant Agreement signed
with the European Commission and the Consortium Agreement.
A Consortium Agreement will be signed between the partners to specify the project governance, the internal
organization of the consortium, the management of the project and any other critical aspects such as liability and
confidentiality.
The proposed organizational structure of the consortium is as follows:
● The General Assembly will be the ultimate decision-making body of the EJP RD and will take major decisions
with regards to its implementation. General Assembly members will liaise with Policy Board and National
Mirror Groups established at national level and outside the framework of this EJP.
● The Coordinator will monitor compliance by the partners with their obligations under the Grant Agreement and
will be the intermediary between the European Commission and the consortium. He/she will be responsible for
the EJP overall management and coordination as well as the supervision of transversal activities. Given the
important size of the EJP RD, the Coordinator will be assisted in these tasks by a Management Office composed
of experienced project managers, communication and administrative support.
● Pillar leaders and Work package Leaders will be the operational arms of the EJP. They will be responsible for
the EJP proper implementation and the follow up of annual work plans. Together with the chair of ERN
coordinators and representative of EURORDIS they will form the Executive Committee (ExCom) that provides
assistance to the Coordinator for the monitoring of the programme.
825575 – EJP RD – Part B 32
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Figure 6. EJP RD governance structure
Strategy level:
General Assembly:
GA will be composed of ALL beneficiaries of the EJP RD. GA will be the ultimate decision making body dealing
with extraordinary decision requiring vote of all members like inclusion of new ones or exclusion of a non-
performing partner. For other decisions the vote will be centralized and put in hands of Governing Board.
Voting procedure: The GA will strive to reach consensus and if consensus cannot be reached, the GA will vote on
different options. GA Quorum and voting arrangements will be elaborated on in the Consortium Agreement.
Governing Board (GB)
GB composition: The Governing Board shall consist of one representative per participating country, one
representative of ERNs, one representative of participating EU infrastructures, 1 patient organization representative
(EURORDIS), one representative of Orphanet and one representative of other non-profit organizations. Such
distribution of representation will reflect and incentivize the need for agreement between stakeholders representing
specific country and/or type of beneficiaries (ex. ERNs or infrastructures) on one hand and limit the unbalance that
could be provoked by over-representation or a single country or type of beneficiary. It will be up to each
participating country/type of beneficiary to decide on the nomination procedure for their representative. One
country = one vote will ensure equality between bigger and smaller countries or less numerous type of stakeholders
825575 – EJP RD – Part B 33
and avoid inappropriate silencing of minority opinions. In addition, the representatives
Associated ofAres(2018)6091977
with document Ref. EC DG RTD and DG
- 28/11/2018
Santé will be invited as “observers”. The GB will elect a chair and set down its rules for procedures (Terms of
Reference) as well as Rules for Participation in advance of the official start of the EJP RD. It will be convened by
the Coordinator in collaboration with the Executive Committee. The GB will validate the decisions proposed by the
Executive Committee such as the annual work plan, the budget, internal calls etc. In particular, the GB will:
● Approve the initial 5-year work plan before submission of the proposal;
● Approve the annual work plans and annual summary reports;
● Monitor and approve the achievement of the most significant milestones;
● Approve ethical, legal and data management frameworks developed;
● Support the Executive Committee in developing a long-term sustainability plan for the EJP RD.
Voting procedure: The GB will strive to reach consensus and if consensus cannot be reached, the GB will vote on
different options. GB Quorum and voting arrangements for the GB will be elaborated on in the Consortium
Agreement.
Meetings: once a year.
Coordination level:
The Coordinator
Role: The Coordinator will be in charge of the day-to-day overall scientific, administrative and financial
management of the project and will be the primary contact point for the European Commission. In particular, the
Coordinator will:
● Prepare the Consortium Agreement to be signed by the partners, with the support of the Executive Committee;
● Update and maintain the Consortium Agreement and submit amendment requests to Grant Agreement;
● Oversee deadlines and milestones of activities, and quality control of deliverables;
● Report on the implementation of the initiative and challenges encountered to the Executive Committee, the
Consortium, General Assembly and the European Commission;
● Chair the Executive Committee and act as the scientific secretariat for their meetings;
● Ensure cooperation across WPs and Pillars;
● Ensure technical and financial reporting to the European Commission and budget management;
● Organize the General Assembly Meeting once a year;
● Ensure transversal activities of the EJP on RDs;
● Supervise the Scientific Secretariat of IRDiRC;
● Represent the EJP on RDs at the EU and international level;
● Together with the Executive Committee manage the project reserve budget.
● The Coordinator will be supported in all these tasks by the Management Office.
The Coordination Office
The Coordination Office will be under the responsibility of the Coordinator and will be constituted by four project
managers, one Communication manager, one financial and administrative manager and one assistant. The project
manager will share their time between direct support of EJP RD and of the scientific secretariat of the International
Rare Diseases Research Consortium (IRDiRC).
Role: The Coordination Office (CO) will be responsible for the day-to-day operational management of the EJP
and the Scientific Secretariat of IRDiRC. The financial and administrative officer will provide financial advice
support to all partners.
Members of the CO will
continuously
support the Operating
Group, Executive
Committee and all
other partners of the
consortium in
fulfilling their obligations
according to the work plan.
825575 – EJP RD – Part B 34
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Figure 7: Structure of the EJP RD coordination office
Operational level:
The Executive Committee (ExCom)
The ExCom will consist of the Coordinator, Pillar Leaders and all WP Leaders. It will be chaired by the
Coordinator. The ExCom will set down its rules for procedures (Terms of Reference) in advance of the official start
of the EJP RD.
Role: The ExCom will ensure the implementation of the EJP RD according to the overall 5-year plan of the
initiative and the individual annual work plans. It will monitor progress according to the milestones as set out in the
5-year plan and the annual work plan. The ExCom will be responsible for the overall quality control of deliverables
and reports. The ExCom will be in charge of adopting solutions to problems encountered during the
implementation and can refer to the Governing Board if no agreement can be found or if the solution will imply
major deviations from the work plans agreed by the GB. In this case, the Coordinator is in charge of duly informing
the European Commission about expected deviations. The ExCom will oversee how resources are spent and
propose changes if needed. The ExCom will be the entity preparing the basis for the decisions to be taken in the
GB based on input from the Operating Group (see below) and WP leaders. The ExCom will also inform the GB
about connections established with sister initiatives at national, EU- and international level and can ask for the GB
's assistance to establish contacts if needed.
Meetings: every two months, starting month 1 (physical or web conference), adapting the number of meetings to
the necessary the following years.
The Operating Group (OG)
Since the ExCom will count about thirty persons a more restricted group is necessary for the efficient
administration of day-to-day activities. The Operating Group is part of the ExCom and will be composed of
members of Coordinator, projects managers and eight Pillar leaders. The representation of funders, ERNs, patients
and EU infrastructures is currently ensured via the Pillar 1, 2, 3 and 4 leaders respectively. Pillar leaders are
nominated for the lifetime of the project. However, in case of change attention will be taken to keep fair
representation of respective groups in the Operating Group. The OG will be responsible for close communication
and coordination of activities between different pillars and WPs. The OG will reflect on progress and engage in a
collective brainstorming on future directions and visions for the EJP RD. Regular (twice a month) conference calls
will ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations
and risk management. The OG will participate in the preparation of the Executive Committee meetings and will be
the driving force for the elaboration of the Annual Work Plans.
Pillar Leaders (PL)
Pillar leaders (PL) will support the coordination and interaction of Work Package Leaders (WPL) within their
respective Pillars, as well as across the Pillars. The tasks of the PLs are to:
● Ensure the coordination of activities across the WPs in the pillar to deliver a coherent set of results both within
the pillar, and with respect to the outputs generated under the other pillars. This will ensure that the overall
outcomes of the EJP for RDs are coherent and complementary and together generate a robust and harmonized
rare diseases platform and ecosystem;
● Ensure good communication with the coordinator and management office;
● Ensure coordination and collaboration across pillars and promote knowledge transfer within and across pillars
(via the Operating Group activities);
825575 – EJP RD – Part B 35
● Ensure that tasks are not duplicated and promote complementarity and
Associated withsynergies. The
document Ref. main forum -for
Ares(2018)6091977 this
28/11/2018
process will be the ExCom meetings;
● Organization of regular management meetings (telephone conferences and/or personal meetings) with the
respective WP leaders to ensure that work within the WPs is in line with the annual work plans and contributes
to the development of annual work plans for upcoming years;
● Collecting training needs from the respective pillar WPs and reporting them to the Pillar 3 leaders;
● Participate in the OG and ExCom meetings and teleconferences;
● Feed into the development of the annual communication plan.
Work Package Leaders (WPL)
Work Package Leaders (WPL) will be in charge of implementing the tasks of the WPs as agreed in the annual work
plans, cross-coordinating with other WPLs, informing the PL about any deviations to the annual work plan and
developing contingency plans. The WPL will be supported by a number of Task and Subtask leaders who are
responsible for the implementation of a specific task within the work package. The tasks of the WPL therefore are:
● Manage implementation of the WP and tasks, and ensure good communication within the WP in order to ensure
efficient flow of information;
● Ensure that work within the WP is in line with the annual work plans;
● Identify any bottlenecks or obstacles, as well as links, synergies and overlaps across WPs, and report them to
the Pillar Leaders.
● Formal reporting of progress to the Pillar Leaders and the Coordinator for discussion at the Executive
Committee meetings, and contributing the sections of the annual report for their WP;
● Draft the WP descriptions for upcoming annual work plans;
● Provide input to training measures;
● Participate in the Pillar and ExCom meetings and teleconferences.
Advisory Regulatory Ethics Board
The Advisory Regulatory Ethics Board (AREB) will be set up in order to ensure compliance of the project and its
activities with ethical and regulatory requirements. It will be composed of internal EJP RD ethics/regulatory/legal
experts, including members with recognised expertise from involved European RIs and the Independent Ethics
Advisor. It will ensure compliance with all international and European relevant rules and ethical norms, including
but not limited to fundamental and patients’ rights, data management, protection and confidentiality, of the EJP RD
as well as of the projects founded within EJP RD. The Independent Ethics Advisor will supervise the actions of
AREB and will be in charge of advising on and monitoring ethical/legal/regulatory issues of the EJP RD, of the
Data Management Plan as well as of the projects founded within EJP RD to ensure that the ethics management of
the projects are carried out within the H2020 framework.
Satellite Boards
Policy Board
The members of the EJP RD are aware of the importance of continuous feedback and dialogue with relevant
national, European and international stakeholders. This is necessary to translate efficiently the specific needs and
strategy represented by countries or European Commission as well as the outcomes of the EJP RD. The Policy
Board will have a major role in ensuring this dialogue and translation through its participation is EJP RD strategy
and sustainability development. The Policy Board will be constituted from:
● Representatives of national ministries of research and health;
● Representatives of European Commission Directorates: DG RTD, DG Santé, DG Connect;
● Representative of the pharmaceutical industry and public-private initiatives (e.g. European Federation of
Pharmaceutical Industries and Associations, EFPIA; Innovative Medicines Initiative, IMI);
● Representative of EuropaBio;
● Representative of regulatory authorities (e.g. European Medicines Agency, EMA, esp. Committee for Orphan
Medicinal Products, COMP, EuNetHTA);
● Chair of the European Strategy Forum on Research Infrastructures (ESFRI);
● Chair and vice-chair of the International Rare Diseases Research Consortium (IRDiRC).
Meetings: Once a year.
National mirror groups (NMG)
Participating countries will be strongly advised to constitute NMG, bringing together the national representatives of
the EJP RD and other relevant RD stakeholders. The role of the NMGs will be to ensure national coordination,
contribute to the objectives of the EJP RD and benefit from it. The creation and composition of a NMG is at the
discretion of each participating country. It is expected that NMGs will include representatives of the National plan
825575 – EJP RD – Part B 36
for RD, national nodes of the European Reference Networks, relevant national
Associated authorities
with document Ref. and research institutions
Ares(2018)6091977 - 28/11/2018
(whether participating to the EJP RD or not), as well as the relevant national partners of the EJP RD and GB
member that will report NMG views and positions during GB meetings. Although not mandatory, it is expected
that the establishment of National Mirror Groups will ensure that national activities, strategies and needs are taken
into account when taking decisions at the EJP RD level and when designing the annual work plans.
Board of funders
In order to ensure the independence of joint transnational calls management (Pillar 1), the final decisions on call
topics and implementation of calls will be taken autonomously by the Board of Funders (BOF). The composition of
Board of Funders will be variable depending on the configuration of funding bodies participating in the joint
transnational calls. BOF will be chaired by the Pillar 1 leaders.
Meetings: Ad hoc meetings before and after the launch of each joint transnational call for proposals.
Ad hoc Advisory Board (AB)
The ad hoc Advisory Board(s) will be constituted on demand of BOF or Pillar 2 and 4 leaders in relation to pilot
projects foreseen. The AB will consist of international experts and RD stakeholders to include their knowledge and
experience and use their input for the definition of the research strategy for joint transnational calls or pilot
projects.
3.3: Consortium as a whole
The objectives of the EJP RD, namely improvement of integration, efficacy, production and social impact of
research on rare diseases and its translation into clinical applications and uptake in healthcare for the benefit of
patients can only be achieved by bringing together key actors and stakeholders thus guaranteeing integrity of the
pipeline. The EJP RD consortium is composed of 87 (full) partners from 23 European (AT, BE, CZ, DE, ES, EE,
FI, FR, GR, HU, IE, IT, NL, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4 associated (AM, CH, IL, TK) and 1
non-EU country (CA) bringing together expertise necessary to fulfill set aims. The majority of EJP RD’ partners
have existing collaborations established through previous projects or are united within existing (infra)structures.
Funding: All Pillar 1 members are leading organizations that fund, manage and implement strategically planned
focused research programmes in the field of health. They put into action and fund international collaborative
research programmes, (e.g. bi-lateral, multi-lateral), and participate into numerous international and European
initiatives that match their national strategic issues on research. Most of these funding bodies (20) have previously
worked under the ERA-Net E-Rare. At present twenty-nine funding agencies/ministries in Life Science and Health,
from twenty-two countries, are part of the EJP RD consortium. The addition of Estonia, Ireland, Luxembourg,
Slovakia, Sweden and two Italian regions (Lombardy and Tuscany), enables further European expansion of the
programme.
Most importantly, the engagement of funders will be translated through strong commitment, that all funding bodies
made during the preparation phase of this application, to participate to the two co-funded and subsequent joint
calls. Providing financial support to projects is crucial for acceleration of collaborative research on rare diseases
and enhancement of knowledge sharing between different national teams. Previous experience of E-Rare has
demonstrated that such projects structure the community via long-lasting collaborations and bring direct and
meaningful benefit for patients via discovery of new genes, establishment of diagnostic guidelines and
development of new treatments. Furthermore, projects financed in Pillar 1 will take advantage of additional tools
and support provided within Pillars 2, 3 and 4 creating an optimal ecosystem for accelerated diagnosis and
exploitation of results for therapy development.
In addition to the well-established joint transnational calls, EJP RD will profit from the know-how of new partners
to build novel initiatives needed by the RD community.
The proposition of support to Networking scheme stems from numerous demands expressed by the RD research
community and (additonal) stakeholders including addressing the need for reinforcement of cooperation and
knowledge sharing between EU13 and EU15 countries and stronger integration of patients in research. The
management of the Networking scheme will be based on the past experience of ZonMw (NL) complemented by
knowledge of partners representing different regions (Latvia, Israel, Sweden, Turkey, Canada) and rare disease
patients (EURORDIS).
EJP RD will also benefit from the extensive experience and management capacities of new partners (FFRD, AFM
Telethon & EATRIS) to implement a unique support to the so-called RD Research Challenges to accelerate
innovation through public-private partnerships. Moreover, the scheme will be closely connected to Pillar 4 and
collaborate with other members of the consortium (EURORDIS, FTELE, IMAGINE, ERNs) to set up effective
portfolio of private partners and sponsors interested in challenges.
Resources: The development of the virtual platform for rare diseases information and research data, based on
existing resources (samples, tools and standards), linked directly with funded research projects to support and
accelerate rare diseases research can only be achieved with extensive contribution of research performing
825575 – EJP RD – Part B 37
organizations and infrastructures. This will be achieved through participation
Associated withof 20 institutions
document and 24 ERNs
Ref. Ares(2018)6091977 and 5
- 28/11/2018
European research infrastructures (members of ESFRI). Again, EJP RD capitalizes on the previously acquired
experience, know-how and, most importantly, standards, resources and tools created by projects and infrastructures
including Orphanet, RD-Connect, HPO, RaDiCo, or ERDRI. This will be complemented by strong commitment of
several biomedical European Research Infrastructures such as BBMRI, ELIXIR, EATRIS, Infrafrontier and
ECRIN, which were developed in the past years through collaborative efforts of Member States. Although not
specific for RDs, these infrastructures aim to develop services facilitating access for researchers to resources and
knowledge and to enhance data sharing thus avoiding duplication of efforts. Their direct involvement will be key to
achieve harmonized user access to biological and medical technologies, samples and services for rare diseases.
Even if findable under single virtual platform, the resources can only be efficiently used if they are made accessible
and interoperable. That is why EJP RD will be armed with know-how of top-level institutions focusing on the
development and implementation of FAIR approaches in Europe. LUMC, UMCG, University of Leicester, CNAG-
CRG, AIT and BBMRI will be the driving force to “FAIRification” of key RD resources and enabling FAIR
ecosystem at larger scale by assisting the RD community. Furthermore, the capacities of EJP RD research
institutions (UM, RUMC, ISCIII, ISS, ACU/ACURARE, INSERM (AMU)) coupled with potential of external
projects (Solve-RD, UDNI) as well as European Reference Networks, will extend the platform with workflows that
allow holistic research based on rare disease data and biological knowledge, closing the circle between initial data
production and its reutilization in explorative studies. The participation of above-mentioned institutions will not be
limited to activities foreseen in Pillar 2 but also expanded to, and strongly connected with Pillars 3 and 4.
Education and empowerment: In Pillar 3, infrastructures will join leading players to anchor and expand rare
diseases education and empowerment programmes. This is where national universities, charities and patient
organizations bring their competences, taking advantage of the already established education/trainings and creating
a new, coherent landscape for education on rare diseases. The courses on data/resources management and quality
initiated by institutions including INSERM (Orph), KULeuven, ISS, FTELE, LUMC and JRC will be enriched by
contributions of new partners (EKUT, IPCZD (CMHI), IMAGINE, Charité, LBG (LBI-RUD), HUGEN
(HACETTEPE) and more) and also made specifically accessible to EU13 countries in order to enhance capacity
and knowledge sharing across Europe. Participation of EURORDIS, TEDDY, FSJD and C4C will be central to
further engage and empower rare disease patients into research and provide them with the tools required to
apprehend and actively contribute to innovation and therapy development. Furthermore, EJP RD will work with
universities, learned societies and ERNs to design first the European rare diseases academic course. Once more, the
consortium will take advantage of already existing capacities within national institutions and transform them for the
benefit of all. This innovation in education will seek the active participation of the European Reference Networks
fostering crosscutting needs of healthcare professionals interested or active in research.
Translation: EJP RD can only fully contribute to IRDiRC goals, namely delivery of diagnosis within one year for
patients coming to medical attention and development of 1000 new therapies for rare diseases by 2027, by
including the participation of the European Reference Networks. All twenty-four ERNs will be part of the
consortium. The majority will participate through their coordinating institutions representing the tremendous
potential of 900 units from 300 hospitals. ERNs will be the driving wheel of translation of research results into
clinical diagnosis and treatment of patients. Accompanied by RPOs, they will be responsible for guidance of Pillar
2 in identification of key resources to be FAIRified and creation of new tools for efficient exploitation and
interpretation of data. The know-how of ERNs will command the process of development and validation of
methodologies and approaches in clinical research (endpoints, trial layout, randomisation techniques, power
calculation, patient centred outcomes, etc.) leading to their dissemination and increased implementation in
healthcare systems. Finally, the enhanced uptake of research results and improved innovation potential will be
achieved with mentoring and solid support for translational research projects. This link (between Pillar 1 and Pillar
4) will be ensured by the group of partners (EATRIS, FTELE, FGB, CVBF, AFM, HUGEN (HACETTEPE) and
UNEW) experienced in drug/diagnostic, regulatory, pre-clinical and clinical development. Research projects
financed in joint transnational calls will have access to innovation management tools and accompanying of
innovation manager allowing maximization of exploitation potential and opening routes to follow-on funding.
EU 13 countries: The participation of EU13 countries was tailored to progressively increase their capacity and go
beyond the initially available resources (budgetary, administrative and scientific). For Pillar 1 the budgets
dedicated to joint transnational calls reflect not only the financial capacities of different countries but also, are
adapted to the size and success rate of their scientific community. Furthermore, previous experience (E-Rare)
confirmed that an increase in budget is not sufficient (and most often unnecessary) while the strategies to increase
the success rate and capacity building are better adapted. That is why the focus of EJP RD is on increased capacity
building, continuation and expansion of already approved strategies. This will be done and pursued for joint
transnational calls but also further expanded through the Networking scheme. In addition, the EU13 play leading
role in the training activities of Pillar 3 as creators, providers and strategic advisors to develop tailored capacities.
825575 – EJP RD – Part B 38
They will contribute to databasing activities in Pillar 2 as most ofAssociated
them arewith
constituents ofAres(2018)6091977
document Ref. the Orphanet Network.
- 28/11/2018
Finally, the EU13 needs will be translated through the prioritization strategy based, among others, on the feedback
received from the EU 13 mirror groups and RD stakeholders.
Other (international) collaborations: Although one of the main goals of the EJP RD is to strengthen European
capacity in the field of rare diseases, it does not mean that the ecosystem should be closed to international
collaborations. Actually, the linkage with international partners will be ensured at different levels. First of all,
through the integration of IRDiRC Scientific Secretariat in the Coordination Office of the EJP RD and joint
management of research and innovation strategy (via the participation of IRDiRC Chair and Vice chairs in the EJP
RD Policy Board and organization of common Task Forces). Secondly, through the already established
collaboration with partners like Australia (Western Australian Department of Health) that expressed interest to
participate as so-called Associated Partners contributing to and aligning with research and training activities
proposed under Pillars 2, 3 and 4. The status of Associated Partner will be also granted to DECIPHER (Sanger
Institute, UK) and ChemBioNet (DE) that could not join EJP RD as full beneficiaries but expressed their
willingness to contribute to the EJP RD goals.
Finally, EJP RD intends to pursue efforts in expanding the collaboration and integration of other countries willing
to join with their knowledge and resources to achieve shared benefits for rare diseases patients. At present, the
possibility of cooperation with Japan Agency for Medical Research and Development (AMED) is being discussed.
AMED is a key player in rare disease research field, member of IRDiRC since 2015 and would be an invaluable
partner for EJP RD bringing the unique opportunity to build the bridges for Japanese-European actions covering
research, sharing of resources and acceleration of drug development.
The route to exploitation of EJP RD results at policy and industrial levels: Creating an efficient and stable rare
diseases research ecosystem will be efficient and productive if it can realistically be translated at the policy-makers
level. Therefore, from the very start, EJP RD will be accompanied by the Policy Board composed of
representatives of research and health ministries, relevant Commission directorates and other central policy
stakeholders. The Board will have the responsibility to consciously contribute in prioritization strategy of the EJP
RD by orienting towards the imperatives and at the same time aligning its own activities to support outcomes of the
EJP RD. This will be further strengthened by the creation of national Mirror Groups guaranteeing proficient
dialogue at national level. The Board will be also primary interlocutor of the EJP RD sustainability work package
and recipient of the business plan and sustainability roadmap. The involvement of different types of stakeholders
will be kept at different level and goes beyond the Policy Board. More specifically the potential investors and
industrial partners will be implicated directly in establishment and participation of RD Challenges fostering
unexploited potential of academic/SME partners. The representatives of industry and specialists in venture capitals
will assist Innovation Manager (WP19) in real-time mentoring of funded projects with high translation potential.
Furthermore, the contact with EFPIA or EuropaBio will be exploited to prepare and promote candidate projects at
public-private partnerships events. Finally, the EJP RD will be advised by the Companies Constituent Committee
of IRDiRC to maximize the development and exploitation of EJP RD “products” stemming from the activities of
Pillars 2 and 4 (registries, natural history studies, FAIRified resources, clinical trials methodologies). Thus, the
integrated connection with relevant stakeholders at both public (policy) and private (industry, venture capitals)
levels will provide the route to proficient exploitation of EJP RD results.
3.4: Resources to be committed
The EJP RD consortium members are strongly committed and will support the programme with in cash or in kind
contributions. This includes: personnel, resources like data infrastructures, tools, training and education materials,
meeting rooms and high level expertise. The initial, earmarked (in cash) budget of EJP RD involved funders is
about 37 M€ and further commitments of at least 20 M€ are foreseen (to support non-cofunded joint transnational
calls). Due to the large span of proposed activities and related capacity to generate in cash or in kind support, the
consortium agreed to apply, rather than fixed 70%, different reimbursement rates and redistribute EC contribution
accordingly. The table below details the settled reimbursement percentage per activity and maximum budget per
pillar agreed by the consortium:
Type of activity Reimbursement rate Max budget per Pillar
Central coordination, management and transversal activities (WP1 – 100% 8 929 031 €
WP5)
825575 – EJP RD – Part B 39
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 1 co-funded joint transnational calls (WP6) Variable depending on the 15 978 333 €
result of calls (max. 33%)
Pillar 1 Networking scheme and RDR Challenge (WP7 – WP8) 100%
Pillar 1 all management costs (WP6 – WP9) 100%
Pillar 2 all activities (WP10 – WP13) 70% 17 765 609 €
Pillar 3 training activities (WP14 – WP18) 80 – 90% 5 934 160 €
Pillar 3 subcontracting of e-learning platform (WP16) 100%
Pillar 4 all activities (WP19 – WP20) 70% 6 477 306 €
TOTAL EJP RD budget 55 084 438 €
In addition, each of the WPs identified activities to be implemented at later stage for which the budget was pre-
defined but the allocation to specific partners will take place in subsequent years, based on the agreed Annual Work
Plans. It was agreed that the “non-assigned” budget would remain for the time being with the coordination
(INSERM):
WP Details Reimbursement rate (%) Non-assigned EC
contribution (overhead
included)
WP6 Evaluation meetings 100 % 280 000 €
WP8 RDR Challenge scheme 100 % 1 500 000 €
WP9 Monitoring meetings 100 % 80 000 €
WP10 Workshops & meetings 70 % 49 720 €
WP11 FAIRification costs 70 % 100 000 €
WP12 FAIRification costs 70 % 900 000 €
WP13 Proof of concept projects – data provision by ERNs 70 % 150 000 €
WP20 Evaluation of internal calls for demonstration and innovation in 70 % 40 000 €
methodologies projects
WP20 Demonstration & new methodologies pilot projects 70 % 3 600 000 €
TOTAL non-assigned to be kept with coordination (INSERM) 6 699 720 €
It is important to note that by reason of different reimbursement rates, the exact redistribution of budget per partner
has been defined and will be different from the one presented on the ECAS platform. The real budget redistribution
agreed will be part of the Consortium Agreement.
Table 3.4a: Summary of staff effort (per participants and per WP)
Explanation of allocation of PM:
Pillar 1: the number of PM allocated for the majority of the funding bodies correspond to the “basic” participation
in funding activities consisting of participation in the process of joint transnational call(s). The number of PMs was
calculated based on the solid previous experience (12 years) of running the same activity in ERA-Net E-Rare.
Specific case of European Reference Network: the consortium took the decision to involve ALL ERNs from the
start of the project even if many of the activities in which ERNs will be fully involved (like WP13 or WP20) will
take place at later stage (starting from year 2). However, it is crucial that ERNs are involved from the start via their
825575 – EJP RD – Part B 40
participation in Annual Retreats of Pillar 2, dedicated Task Forces or meetings
Associated of General
with document Assembly, as they
Ref. Ares(2018)6091977 are
- 28/11/2018
the key actors to guide the work of Pillars 2 and 4, as well as the driving force for the trainings of Pillar 3 WP17.
All partners of the EJP RD agreed that any work related to the participation in the meetings will be done as in kind
contribution (accountable or not) and thus no PM are allocated to this type of activities for any of the EJP RD
partners. This results also in a low number of PM allocated to ERNs. In WP13 and WP20, where extensive
participation of ERNs is expected, the distribution of budget will be done at later stage and thus also the
distribution of respective PMs. Therefore, the low budget or number of PM of some partners are often related to the
fact that these partners are expected to take more active participation from year 2 onwards and the budget related to
the planned actions has not been yet distributed. In addition, a business plan with detailed share of budget was
made during the proposal preparation and all partners agreed on this defined allocation of funds and confirmed
their strong commitment.
Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research
infrastructures)
N° Cost (€) Justification
WP1 Travel to 5 GA meetings ; WP1 Travels policy board (X5);
WP3 travel (6 meetings 6 pax) ; WP4 travel (5 meetings 11 pax) ;
WP1 travel to 5 EX Com meetings + Kick off; PL2 Travel costs
1 INSERM Travel 218 910
(Radico, Orphanet+LTP, AMU); WP10 Travel to annual retreat
(ORPHANET); WP14 Task 14.1 Travel costs; WP20 Travel costs of
experts
WP20 PL4 ERN Pilot projects (to be allocated); WP1 General
assembly meetings org (X5)
; WP1 Executive com meetings org (X5) ; WP1 ERN CHAIR costs
to be assigned; WP1 Policy Board+Ethics+ExecCom joint meetings
org (X5); WP1 Monitoring meetings org (X5); WP2 Irdirc Task
Forces: Workshops organisation; WP3 meeting org (6 meetings 6
pax) ; WP4 meeting org (5 meetings 11 pax) ; WP5 EJP website;
WP5 Printing/translation/publication/video; WP6 Evaluation
Other 6 735 027
meetings (2/year x 4 calls) at average cost 35 000 € (to be
allocated); WP9 Meeting costs (to be allocated); WP10 PL2 Annual
retreats from year 2 (to be allocated); WP10 PL2 Workshop
Orphanet; WP11 Fairification costs (to be allocated); WP12
Fairification costs (to be allocated); WP13 Data provision by ERNs
(to be allocated); WP14 Task 14.1 Catering costs; WP20
Organisation of 2 evaluation meetings (to be allocated); WP20 Task
Force meetings and experts
TOTAL 6 953 937
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
2 FWF Travel 14 850
costs;
Other 4 000 CFS Cost
TOTAL 18 850
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
5 FNRS Travel 14 850
costs
TOTAL 14 850
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
6 FWO Travel 2 000
costs
Other 4 000 CFS Cost
TOTAL 6 000
7 KULeuven Travel 12 730 WP1 Travel to 5 GA meetings ; PL3 Task 14.2 Travel costs ;
Other 4 056 PL3 Task 14.2 Catering
TOTAL 16 786
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
9 MOSAE Travel 14 610
costs
TOTAL 14 610
825575 – EJP RD – Part B 41
WP1 Travel to 5 GAAssociated
meetings ; WP6
with Travel
document costs ; WP9 Travel
Ref. Ares(2018)6091977 - 28/11/2018
10 AKA Travel 14 850
costs
Other 4 000 CFS Cost
TOTAL 18 850
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
11 ANR Travel 16 850
costs
Other 4 000 CFS Cost
TOTAL 20 850
WP1 Travel to 5 GA meetings; WP1 travel to 5 EX Com meetings +
12 FFRD Travel 49 510 Kick off; WP6 Travel costs ; WP8 Travel costs ; WP9 Travel costs ;
WP16 Task 16.2 Travel costs; WP16 Task 16.3 Travel costs
WP8 1 meeting call development; WP8 2 Evaluation meetings for
Other 50 006 RD challenge ; WP8 Networking event for RDR challenge; WP16
Task 16.2 Catering costs; WP16 Task 16.3 Catering costs CFS Cost
TOTAL 99 516
13 AFM Travel 5 900 WP1 Travel to 5 GA meetings
TOTAL 5 900
14 IMAGINE Travel 5 900 WP1 Travel to 5 GA meetings
TOTAL 5 900
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
NKFIH Travel 14 850
19 costs
Other 0
TOTAL 14 850
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
HRB Travel 14 610
20 costs
Other 4 000 CFS Cost
TOTAL 18 610
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
IT MoH Travel 14 850
21 costs
Other 4 000 CFS Cost
TOTAL 18 850
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
RT (TuscReg) Travel 14 610
22 costs
TOTAL 14 610
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
FRRB Travel 14 610
23 costs
Other 4 000 CFS Cost
TOTAL 18 610
WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax);
WP1 travel to 5 EX Com meetings + Kick off; PL2 travel costs; PL3
ISS Travel 185 880
Task 14.2 Travel costs; PL3 Task 14.3 Travel costs; PL3 Task 14.5
26 Travel costs; PL3 Task 15.3 Travel costs
WP2 meeting org (1 meeting 50 pax); PL2 annual retreat year 1
(meeting costs); PL3 Task 14.2 Catering costs; PL3 Task 14.3
Other 136 893
Catering costs; PL3 Task 14.5 Catering costs; PL3 Task 15.3
Catering costs ; CFS Cost
TOTAL 322 773
WP1 Travel to 5 GA meetings ; FSJD (LTP TEDDY) -Task 15.4
TEDDY Travel 30 440
28 Travel costs; TEDDY -Task 15.4 Travel costs
FSJD (LTP TEDDY) -Task 15.4 Catering costs; TEDDY -Task 15.4
Other 15 404
Catering costs ;
TOTAL 45 844
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
MIUR Travel 14 610
29 costs
TOTAL 14 610
30 VIAA Travel 6 140 WP1 Travel to 5 GA meetings ; WP9 Travel costs ;
825575 – EJP RD – Part B 42
TOTAL 6 140 Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
LMT Travel 14 610
31 costs
TOTAL 14 610
WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings +
VUHSK Travel 44 480
32 Kick off; PL3 Task 14.4 travel costs; PL3 WP18 travel costs;
Other 28 686 PL3 Task 14.4 catering costs; PL3 WP18 catering costs ;
TOTAL 73 166
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
FNR Travel 14 610
33 costs
TOTAL 14 610
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
NCBR Travel 14 850
37 costs
Other 4 000 CFS Cost
TOTAL 18 850
WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax); PL2
MUW Travel 34 400
38 travel costs
Other 6 650 WP2 meeting org (1 meeting 50 pax)
TOTAL 41 050
WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs; PL3
MUG Travel 24 840
39 Task 15.3 Travel costs
Other 7 263 PL3 Task 14.4 Catering costs; PL3 Task 15.3 Catering costs ;
TOTAL 32 103
WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings +
IPCZD Travel 15 550
40 Kick off; PL3 Task 14.2 travel costs
Other 4 056 PL3 Task 14.2 catering costs
TOTAL 19 606
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
FCT Travel 14 850
41 costs
TOTAL 14 850
42 INSA Travel 10 900 WP1 Travel to 5 GA meetings ; PL2 travel costs ;
TOTAL 10 900
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
SAS Travel 14 610
43 costs
TOTAL 14 610
47 CIBER Travel 10 900 WP1 Travel to 5 GA meetings; PL2 travel costs ;
TOTAL 10 900
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
SRC Travel 14 610
48 costs
Other 4 000 CFS Cost
TOTAL 18 610
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
Vinnova Travel 14 610
49 costs
Other 4 000 CFS Cost
TOTAL 18 610
ERN EYE Travel and subsistence for WP20 PL4; WP1 Travel to 5
HUS Travel 13 600
55 GA meetings ; ERN EYE PL2 Travel costs
TOTAL 13 600
EURACAN Travel and subsistence for WP20 PL4; WP1 Travel to 5
CLB Travel 14 070
56 GA meetings ; EURACAN PL2 Travel costs
TOTAL 14 070
ERN KNET Travel and subsistence for WP20 PL4; WP1 Travel to 5
UKL-HD Travel 25 560 GA meetings (2 teams); ERKnet WP1 travel to 5 EX Com
57 meetings + Kick off; ERKnet PL2 Travel costs ;
PL3 WP17 Training delivery for 4,5 years; 4 training networks with
Other 409 000
6 ERNs each; 90.000 per training network per year (15k€ per ERN)
825575 – EJP RD – Part B 43
CFS Cost Associated with document Ref. Ares(2018)6091977 - 28/11/2018
TOTAL 434 560
ERN RND Travel and subsistence WP20 PL4 ; .WP1 Travel to 5
GA meetings (X2, ERN+nonERN)
EKUT Travel 63 460 .WP1 travel to 5 EX Com meetings + Kick off (Holm); ERN RND
PL2 Travel costs ; PL3 Task 14.2 travel Costs; PL3 WP17 ERN RD
58 training and support programme travel
PL3 Task 14.2 catering; PL3 WP17 ERN RD training and support
programme catering; PL3 WP7: Training delivery for 4,5 years; 4
Other 422 632
training networks with 6 ERNs each; 90.000 per training network
per year (15k€ per ERN) CFS Cost
TOTAL 486 092
ERN Bond Travel and subsistence for WP20 PL4; WP1 Travel to 5
IOR Travel 15 840
61 GA meetings ; ERN Bond PL2 Travel costs
TOTAL 15 840
ERN Reconnect Travel and subsistence WP20 PL4 ; WP1 Travel to
AOUP Travel 14 070
62 5 GA meetings ; ERN Reconnet PL2 Travel costs
TOTAL 14 070
ERN Ithaca Travel and subsistence WP20 PL4 ; WP1 Travel to 5
AOUS Travel 14 070
63 GA meetings ; Ithaca PL2 Travel costs
TOTAL 14 070
ENDO Ern Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA
meetings (all LUMC teams X2); WP1 travel to 5 EX Com
LUMC Travel 30 490
meetings + Kick off (M Roos); Travel costs to PL2 meetings (all
64 LUMC teams X2);
PL2 workshop costs (M Roos); WP17 Training delivery for 4,5
Other 429 000 years; 4 training networks with 6 ERNs each; 90.000 per training
network per year (15k€ per ERN) ; CFS Cost
TOTAL 459 490
ERN Genturis&Eurogen Travel and subsistence WP20 PL4 ; WP1
RUMC Travel 39 040 Travel to 5 GA meetings (X3 RUMC teams); ERN
65 Genturis&Eurogen Travel for PL2 ; Travel for PL2 (non ERN);
Equipment 0
PL2 workshop costs (non ERN); PL3 WP17 Training delivery for
Other 426 500 4,5 years; 4 training networks with 6 ERNs each; 90.000 per training
network per year (15k€ per ERN) ; CFS Cost
TOTAL 465 540
ERN Cranio & ERNICA Travel and subsistence WP20 PL4 ; WP1
Erasmus MC Travel 28 140 Travel to 5 GA meetings (X2 ERN); PL2 travel costs (Cranio &
67 ERNICA)
TOTAL 28 140
ERN Transplant staff for WP20 PL4; ERN Transplant WP1 Travel
SERMAS Travel 14 070
68 to 5 GA meetings ; ERN Transplant PL2 travel
TOTAL 14 070
ERN Rare Liver,Rita, EuroNMD Travel and subsistence WP20 PL4
NUTH Travel 42 210 ; WP1 Travel to 5 GA meetings (X3 ERNs); ERN Rare Liver,Rita,
69 EuroNMD Travel for PL2
TOTAL 42 210
EPICARE travel and subsistence for WP20 PL4; WP1 Travel to 5
GOSH Travel 15 840
70 GA meetings ; EPICARE travel for PL2
TOTAL 15 840
71 EORTC Travel 5 900 WP1 Travel to 5 GA meetings
TOTAL 5 900
Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA
EURORDIS Travel 180 850 meetings;
77 WP1 Travel to 5 EX Com meetings + Kick off; WP6 Travel costs ;
825575 – EJP RD – Part B 44
WP8 Travel costs; WP9 Travel
Associated withcosts; WP14
document Ref. Task 14.5 Travel- costs;
Ares(2018)6091977 28/11/2018
WP15 Task 15.1 Travel costs; WP15 Task 15.2 Travel costs; WP15
Task 15.3 Travel costs
WP8 2 Multi-stakeholder workshops for set-up RDR challenge
Other 89 547 scheme ; WP15 Task 15.1 Catering costs; WP15 Task 15.2 Catering
costs; WP15 Task 15.3 Catering costs ; CFS Cost
TOTAL 270 397
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
SNSF Travel 14 850
79 costs
Other 4 000 CFS Cost
TOTAL 18 850
80 BLACKSWAN Travel 5 900 WP1 Travel to 5 GA meetings
Other 150 000 WP5 - REACT congress organisation costs
TOTAL 155 900
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
TUBITAK Travel 14 850
81 costs
Other 4 000 CFS Cost
TOTAL 18 850
WP1 Travel to 5 GA meetings ; PL2 travel costs; PL3 Task 14.2
ACURARE Travel 34 550
82 travel costs; PL3 Task 15.3 travel costs;
Other 9 243 PL3 Task 14.2 catering; PL3 Task 15.3 catering ;
TOTAL 43 793
83 HUGEN Travel 8 020 WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs
Other 2 076 PL3 Task 14.4 Catering costs
TOTAL 10 096
WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel
GSRT Travel 14 610
87 costs
TOTAL 14 610
4.1. Participants (applicants)
Type of partner
(Programme owner
N° Partner Acronym Participant organisation name Country
[PO], Programme
manager [PM], other [O]
INSTITUT NATIONAL DE LA SANTE DE DE PM
1 INSERM FR
LA RECHERCHE MEDICALE
FONDS ZUR FÖRDERUNG DER PO & PM
2 FWF AT
WISSENSCHAFTLICHEN FORSCHUNG
AIT AUSTRIAN INSTITUTE OF O
3 AIT AT
TECHNOLOGY GMBH
LUDWIG BOLTZMANN GESELLSCHAFT O
4 LBG (LBI-RUD) AT
GMBH
FOND DE LA RECHERCHE SCIENTIFIQUE- PO & PM
5 FNRS BE
FNRS
FONDS VOOR WETENSCHAPPELIJK PO & PM
6 FWO BE
ONDERZOEK - VLAANDEREN
7 KULeuven KU LEUVEN (UNIVERSITY OF LEUVEN) BE O
MINISTRY OF EDUCATION YOUTH AND PO & PM
8 MEYS CZ
SPORT
MINISTRY OF SOCIAL AFFAIRS OF PO & PM
9 MoSAE EE
ESTONIA
10 AKA SUOMEN AKATEMIA FI PO & PM
11 ANR AGENCE NATIONALE DE LA RECHERCHE FR PM
FONDATION MALADIES RARES - FRENCH PO & PM
12 FFRD FR
FOUNDATION FOR RARE DISEASES
825575 – EJP RD – Part B 45
ASSOCIATION FRANÇAISE CONTRE LES O
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
13 AFM FR
MYOPATHIES
IMAGINE - INSTITUT DES MALADIES O
14 IMAGINE FR
GENETIQUES NECKER ENFANTS MALADES
DEUTSCHES ZENTRUM FUER LUFT - UND PM
15 DLR DE
RAUMFAHRT EV
16 UKA UNIVERSITAETSKLINIKUM AACHEN DE O
17 CHARITE CHARITE - UNIVERSITÄTSMEDIZIN BERLIN DE O
18 UKLFR (Freiburg) UNIVERSITAETSKLINIKUM FREIBURG DE O
NEMZETI, KUTATASI, FEJLESZTESI ES PO & PM
19 NKFIH HU
INNOVACIOS HIVATAL
20 HRB HEALTH RESEARCH BOARD IE PO & PM
21 IT MoH MINISTRY OF HEALTH IT PO & PM
22 RT (TuscReg) TUSCANY REGION - REGIONE TOSCANA IT PO & PM
FONDAZIONE REGIONALE PER LA PO & PM
23 FRRB IT
RICERCA BIOMEDICA
FONDAZIONE PER LA RICERCA O
24 FGB IT
FARMACOLOGICA GIANNI BENZI ONLUS
25 FTELE FONDAZIONE TELETHON IT O
26 ISS ISTITUTO SUPERIORE DI SANITA IT PO & PM
CONSORZIO PER VALUTAZIONI O
27 CVBF IT
BIOLOGICHE E FARMACOLOGICHE
TEDDY- EUROPEAN NETWORK OF O
28 TEDDY EXCELLENCE FOR PAEDIATRIC CLINICAL IT
RESEARCH
MINISTERO DELL'ISTRUZIONE, PO & PM
29 MIUR IT
DELL'UNIVERSITA E DELLA RICERCA
VALSTS IZGLITIBAS ATTISTIBAS PO & PM
30 VIAA (SEDA) LV
AGENTURA
31 LMT (RCL) LIETUVOS MOKSLO TARYBA LT PO & PM
VILNIUS UNIVERSITY HOSPITAL O
32 VUHSK LT
SANTAROS KLINIKOS
33 FNR FONDS NATIONAL DE LA RECHERCHE LU PO & PM
34 ZON (ZonMw) ZORGONDERZOEK NEDERLAND NL PO & PM
35 UMCG ACADEMISCH ZIEKENHUIS GRONINGEN NL O
36 UM UNIVERSITEIT MAASTRICHT NL O
NATIONAL CENTRE FOR RESEARCH AND PM
37
NCBR DEVELOPMENT PL
MEDICAL UNIVERSITY OF WARSAW O
38
MUW (POLAND) PL
GDANSKI UNIWERSYTET MEDYCZNY O
39
MUG (MEDICAL UNIVERSITY GDANSK) PL
INSTYTUT "POMNIK- CENTRUM ZDROWIA O
40
IPCZD (CMHI) DZIECKA" PL
FUNDAÇÃO PARA A CIENCIA E A PO & PM
41
FCT TECNOLOGIA PT
INSTITUTO NACIONAL DE SAUDE DOUTOR PM
42
INSA RICARDO JORGE, I.P. PT
43 SAS SLOVAK ACADEMY OF SCIENCES SK PO & PM
INSTITUTO DE SALUD CARLOS III / PO & PM
44
ISCIII INSTITUTE OF HEALTH CARLOS III ES
FUNDACIO CENTRE DE REGULACIO O
45
CNAG-CRG GENOMICA ES
46 UPM UNIVERSIDAD POLITECNICA DE MADRID ES O
CONSORCIO CENTRO DE INVESTIGACION O
47
CIBER BIOMEDICA EN RED, M.P. ES
48 SRC SWEDISH RESEARCH COUNCIL SE PO & PM
49 Vinnova VINNOVA SE PO & PM
825575 – EJP RD – Part B 46
50 ULEIC UNIVERSITY OF LEICESTER UK O
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
51 ULIV UNIVERSITY OF LIVERPOOL UK O
52 UNEW UNIVERSITY OF NEWCASTLE UPON TYNE UK O
53 CCRI ST. ANNA KINDERKREBSFORSCHUNG AT O
ASSISTANCE PUBLIQUE HOPITAUX DE O
54
APHP PARIS FR
HOPITAUX UNIVERSITAIRES DE O
55
HUS STRASBOURG FR
56 CLB CENTRE LEON BERARD FR O
57 UKL-HD UNIVERSITAETSKLINIKUM HEIDELBERG DE O
EBERHARD KARLS UNIVERSITÄT O
58
EKUT TÜBINGEN DE
59 GUF GOETHE UNIVERSITÄT FRANKFURT DE O
HELIOS DR. HORST SCHMIDT KLINIK O
60
HSK GMBH DE
61 IOR ISTITUTO ORTOPEDICO RIZZOLI - IRCCS IT O
AZIENDA OSPEDALIERO UNIVERSITARIA O
62
AOUP PISANA IT
AZIENDA OSPEDALIERA UNIVERSITARIA O
63
AOUS SENESE IT
ACADEMISCH ZIEKENHUIS LEIDEN / O
64
LUMC LEIDEN UNIVERSITY MEDICAL CENTER NL
65 RUMC STICHTING KATHOLIEKE UNIVERSITEIT NL O
ACADEMISCH MEDISCH CENTRUM BIJ DE O
66
AMC UNIVERSITEIT VAN AMSTERDAM NL
ERASMUS UNIVERSITAIR MEDISCH O
67
Erasmus MC CENTRUM ROTTERDAM NL
68 SERMAS SERVICIO MADRILEÑO DE SALUD ES O
THE NEWCASTLE UPON TYNE HOSPITALS O
69
NUTH NHS FOUNDATION TRUST UK
70 GOSH GREAT ORMOND STREET HOSPITAL UK O
EUROPEAN ORGANISATION FOR O
71
EORTC RESEARCH AND TREATMENT OF CANCER EU org
EU O
72
INFRAFRONTIER INFRAFRONTIER GMBH Infra
73 BBMRI BBMRI-ERIC EU Infra O
EUROPEAN CLINICAL RESEARCH O
74
ECRIN/PedCRIN INFRASTRUCTURE NETWORK EU Infra
75 EATRIS EATRIS-ERIC EU Infra O
EUROPEAN MOLECULAR O
76 BIOLOGYLABORATORY (FORELIXIR
ELIXIR ANDEMBL-EBI) EU Infra
77 EURORDIS EURORDIS-RARE DISEASES EUROPE EU org O
CHIEF SCIENTIST OFFICE - MINISTRY OF PO & PM
78
CSO/MoH HEALTH IL
79 SNSF SWISS NATIONAL SCIENCE FOUNDATION CH PO & PM
80 BLACKSWAN BLACKSWAN CH O
TÜBITAK TURKIYE BILIMSEL VE PO & PM
81
TUBITAK TEKNOLOJIK ARASTIRMA KURUMU TK
82 ACU/ACURARE ACIBADEM UNIVERSITY TK O
HUGEN O
83
(HACETTEPE) HACETTEPE UNIVERSITY TK
CANADIAN INSTITUTES OF HEALTH PO & PM
84
CIHR RESEARCH CA
FONDS DE RECHERCHE DU QUEBEC - PO & PM
85
FRQS SANTE CA
86 IT INSERM TRANSFERT FR O
87 GSRT GENERAL SECRETARIAT OF RESEARCH GR PO & PM
825575 – EJP RD – Part B 47
AND TECHNOLOGY Associated with document Ref. Ares(2018)6091977 - 28/11/2018
DEUTSCHE PO & PM
88
DFG FORSCHUNGSGEMEINSCHAFT DE
01-INSERM (a)
INSERM-ITGGB (Institut Thématique Génétique, Génomique et Bioinformatique)
Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale
(INSERM)
Principal investigator Catherine Nguyen
Relevant Network
INSERM is the only public research organization in France entirely dedicated to human health. Its objective is to
promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health
research. Inserm brings together 15,000 researchers, engineers, technicians, and administrative staff around one
common goal: to improve the health of all by advancing knowledge of life and disease, innovation in treatment, and
public health research. Since its foundation in 1964, Inserm has played a part in many key medical advances,
including the first prenatal diagnostic tests, understanding of the HLA system, the first in vitro fertilization,
identification of the AIDS virus, radiotherapy for cancer, the first skin graft, deep brain stimulation, and gene
therapy. Inserm is the leading European academic biomedical research institution, and with nearly 12,000
publications a year; is second in the world only to the National Institutes of Health (NIH). According to the 2016
ranking by Thomson-Reuters, Inserm is also the world’s 9th most innovative public research organization.
Inserm plays a crucial role in the structure of the European Research Area and its international position is
strengthened by close collaborations (teams abroad and associated international laboratories). In 2015, the Institute
had 22 associated international laboratories at its disposal, 9 mixed international units set up abroad and around
thirty international cooperation agreements. With involvement in more than 400 European projects financed by the
European Commission within the 7th Research and Development Framework Programme, Inserm has been
confirmed as one of the principal European players in the area of research into life sciences and health. Inserm has
also been one of the foremost European research institutions in terms of IMI (Innovative Medicines Initiative)
financing of public/private research partnerships with a strong presence in the European Research Council.
Its mission is supported by the work of 9 theme-based institutes, whose role is to monitor progress and take a lead
on research in their respective fields.
The Institute of Genetics, Genomics and Bioinformatics (IT GGB) covers genetics and genomics in all living
organisms, from viruses, micro-organisms and plants to humans. Scientific projects are focused on organization,
evolution, genome variability, gene expression regulation, population genetics as well as genetic and
epigenetic determinism of diseases and treatments of genetic diseases.
The Institute coordinates discussions and research in the following fields:
• Bioinformatics, setup of intermediate platforms to existing national centers relying on mass sequencing
platforms,
• Genomic diversity, rare diseases, population genomics, metagenomics, evolution,
• Molecular genetics, genetic regulation: from transcriptomics to epigenetics,
• Genome dynamics, transposable elements, mutations,
• Quantitative genetics, multifactorial diseases, rare diseases, complex traits.
This Institute liaises with thematic institutes for cross-disciplinary purposes, but particularly with the Cell biology,
development and evolution, Molecular and structural bases of living organisms and Cancer.
Main tasks in the project per Pillar/WP:
Coordination and transversal activities:
WP1: Inserm-ITGGB will be responsible for the overall coordination, management and strategy of the EJP
RD. It will establish a coordination office composed of: coordinator (Daria Julkowska, PhD), four project
managers, communication manager, financial officer and assistant. It will be responsible for the coordination and
support within and across all pillars and transversal work packages. Inserm-ITGGB will be also in charge of the
Scientific Secretariat of IRDiRC.
WP2: Inserm-ITGGB will be involved in Task 2.2 and 2.4 where it contribute to the mapping of research and
innovation needs and establishment of short, medium and long-term research and innovation strategy.
Inserm-ITGGB will also ensure interaction and common strategy with IRDiRC by organization of joint Task
Forces.
825575 – EJP RD – Part B 48
WP3: Inserm-ITGGB will participate in Task 3.1 and focus on alignment of needs,
Associated with expectations
document and engagement
Ref. Ares(2018)6091977 - 28/11/2018
of different RD stakeholders in Europe with respect to EJP RD sustainability.
WP4: Inserm-ITGGB will support the Advisory Regulatory Ethics Board in management of ethical and regulatory
issues of the EJP RD.
WP5: Inserm-ITGGB will be leading this work package dedicated to communication and dissemination of EJP
RD. It will be in charge of the implementation of communication and dissemination strategy as set in the Annex 1.
It will develop and provide various communication tools in line with the needs of EJP RD partners. It will liaise
and strengthen the integration of EJP RD communication and dissemination strategy with the strategies of involved
stakeholders at national and international level. Finally, Inserm-ITGGB will support IRDiRC in its communication
and dissemination activities as agreed within the responsibilities of IRDiRC Scientific Secretariat.
Previous experience relevant to the Tasks:
Inserm-ITGGB is strongly involved in the coordination of national strategic vision and actions of different
stakeholders in the field of genetics, genomics and bioinformatics. It represents INSERM in actions related to rare
diseases and accompanies the 3rd National Plan for Rare Diseases. It is strongly involved in the implementation of
National Plan of Genomic Medicine through the reorganization of French Institute of Bioinformatics to meet
specific needs of institutions and organizations involved in biology and health research. It is responsible for
animation of scientific community and organization of dedicated events like annual bioinformatics school, advance
epigenetics conference or rare diseases and personalized medicine meetings.
Short Profile of key Staff Members who will be undertaking the work
Dr. Daria Dr. Daria Julkowska has over 15 years of experience in research and management. She is
Julkowska responsible for the management of several European and international funding programmes.
(Female) Among others, since 2010 she is involved in E-Rare, the ERA-Net for Research programmes on
rare diseases, where for the first two years she occupied the position of the project manager to
finally (April 2013) take over the coordination of the programme. As the coordinator she
developed and put into action a set of collaborations facilitating rare diseases research, including
the partnerships with European Research Infrastructures and Patients’ Organizations. She has an
extensive knowledge and understanding of European funding schemes and programmes. Since
February 2017 she serves as the chair of the Funders Constituent Committee of IRDiRC.
Of Polish origin, Dr. Julkowska obtained her international PhD in molecular biology at the
University of Paris XI, France and University of Gdansk, Poland in 2005. She pursued her
scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris
and extensive training in communication and European Union counselling. She also holds MSc in
Management of Research from the University of Paris Dauphine (FR).
D.Julkowska was also responsible for coordination and preparation of the EJP RD proposal and
will be the coordinator of the EJP RD.
Dr. Catherine
Nguyen Dr.Catherine Nguyen is the director of the INSERM Genomic, Genetic and Bioinformatic
(Female) Thematic Institute. She has extensive training in genetics and functional genomics. Between 2002
and 2018 she was leading the Inserm TAGC Transcriptome laboratory in Marseille, France. Her
unit dedicated to functional genomics studies (TAGC laboratory) with a transcriptome facility at
the Luminy campus, which is nationally recognized as a platform for functional genomics studies
within different research organizations in France, focused on bioinformatics analysis of data
collected from DNA microarrays and other (bio)informatics fields.
Domains of expertise or consultancy: Genomic, transcriptome, immunology and cancer
research, DNA chips, splicing, molecular biology. Member (vice chairwoman) authorities of
valuation of INSERM (ICSS3 then CT2), of the commission of reflection STIC-INSERM, of the
committee of piloting of transcriptome of Marseilles Génopole, of jury of INSERM,-CNRS
engineers recruitment. Member of the Committee of Strategic Organization AGENAE INRA.
Member of the CHSHS PACA, INSERM.
Expert for the authorities of evaluation for the Ministry of research and New Technologies
(MRNT), employment and solidarity (PHRC), CNRS (Action DNA chips), Genopoles, the
National Association of Technical Research (ANRT), National Network Technologies and Health
(RNTS), of IMTSSA Tropical Institute of Medicine dependent of the army office, the French
society against myopathies (AFM), the national Research fund (FNR) of Luxembourg, of the
French-Indian centre for the promotion of advanced Research (CEFRIPRA), System of Research
825575 – EJP RD – Part B 49
Grants Council, (CERG) Hong Kong), of the Mission ofwith
Associated expertise
documentfor
Ref.the Ministry for French-
Ares(2018)6091977 - 28/11/2018
Korean Research, Edition in Immunology of the Medical Research Council, MRC, UK, of ANR
(INCA, PNANO), FRM (bioinfo).
Member of HUGO (Human Genome Organisation) since 1995, member of SFI (French Society
of Immunology) since 1997, coordinator ESF network on technologies for functional genomics,
member of scientific comity of the Forum 2000- 2006 (Industrial meeting organization).
Patents: 1-N°US 10-007 926 (sight entry): gene expression profiling of primary breast
carcinomas using arrays of candidates genes. International Extension PCT/IB01/02811. 2-
European Number.EP: 02290949.9 « gene expression profiling of blood tumors using
polynucleotides arrays.
Grants: since 1999, 35 grants from fundations (ARC, LNCC, AFM, ANRS), from MNRT, from
the industry (GALDERMA, IPSOGEN, GENSODI,) and 3 european grant (5th- 7th PCRD);
Student training: >30 courses in a frame of National and InterNational university (Pasteur
Institut, Paris, Faculty of Sciences St Jérôme, Marseille; ESIL GBMA Marseille, Welcome trust
summer schools, UK; European School of Haematology (ESH) Dublin, Irland; University of St
Joseph, Lebanon, USTH Vietnam .45 master, 24 PhD student supervision.
Publications: 102 research articles in international journals, 31 reviews and 6 book chapters. 43
invited lecturer; more than 100 oral communications in national & international meeting, up to
120 communications in national and international conferences.
Personnel to INSERM will recruit four project managers; communication officer, financial officer and assistant
be recruited to support the coordinator in management and coordination responsibilities under EJP RD.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Analysis of ERA-NET Cofund actions under Horizon 2020. Final report of the expert group. Niels Gøtke
(Chairperson), Effie Amanatidou (Rapporteur), Ioana Ispas, Daria Julkowska, Joaquín Serrano. Directorate-
General for Research and Innovation. Publications Office of the European Union, 2016.
2. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Austin CP, Cutillo CM, Lau LPL,
Jonker AH, Rath A, Julkowska D, Thomson D, Terry SF, de Montleau B, Ardigò D, Hivert V, Boycott KM,
Baynam G, Kaufmann P, Taruscio D, Lochmüller H, Suematsu M, Incerti C, Draghia-Akli R, Norstedt I, Wang L,
Dawkins HJS; International Rare Diseases Research Consortium (IRDiRC). ; Clin Transl Sci. 2018 Jan;11(1):21-
27.
3. The importance of international collaboration for rare diseases research: a European perspective.
Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I,
Rath A, Schuster R, Simelyte E, van Weely S. ; Gene Ther. 2017 Sep;24(9):562-571.
4. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health
Framework. Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki
K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A,
Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger
ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochmüller H,
Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le
Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R,
Weeramanthri TS, Molster C, Dawkins HJS. ; Adv Exp Med Biol. 2017;1031:55-94.
List of relevant previous projects or activities, connected to the subject of this proposal
E-Rare-1 (2007 – 2011), GA036248
E-Rare-2 (2011 – 2014), GA266608
01-INSERM (b)
INSERM-US14
Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale
(INSERM), France
Principal investigator Ana Rath
Relevant Network Orphanet Network
Description of the legal entity/department/laboratory/group:
The INSERM-US14 houses Orphanet, the knowledge base of rare diseases and orphan drugs. Its goal is to
825575 – EJP RD – Part B 50
contribute to improve the diagnosis, management and treatmentAssociated of rare with
diseases. For
document Ref.these purposes, the
Ares(2018)6091977 unit
- 28/11/2018
produces, compiles and conveys information as well as scientific and medical data with added value, complete,
validated and updated for researchers, clinicians, the general public and all the actors in the field of rare diseases
(researchers, patients, industrialists, decision-makers, professionals in the medico-social sector).
INSERM-US14 has been acting as coordinator of the Orphanet network (41 countries in 2018) since the beginning
of the European projects in 2001. The INSERM-US14 also acted as coordinator of the Joint Action on RD (RD-
ACTION) 2015-2018 and of the HIPBI-RD project. He currently coordinates SUPPORT-IRDiRC (2012-2018) and
has acted as the coordinator of the Rare Diseases Task Force (2004-2009) and the European Union Committee of
Experts on Rare Diseases (EUCERD)(2010-2013).
Main tasks in the project per Pillar/WP:
Pillar 2:
Dr. Ana Rath will act as Pillar 2 co-leader.
WP10: Inserm-Orphanet will co-lead the WP and lead the Task 10.1 Convene yearly retreats leading to Pillar 2
annual strategic plans (in particular being co-responsible for subtask 10.1.2 Annual strategic plan for Pillar 2)
WP11: Inserm-Orphanet will co-lead the WP and lead Task 11.2: FAIR-compliant virtual platform for
discovery of RD resources (in particular subtasks 11.2.1 and 11.2.2). Orphanet TLP will contribute to subtasks
11.2.1 Collaboratively assemble and curate metadata into the Orphanet catalog, on an ongoing basis, to represent
all key databases and resources and 11.2.2. Create a catalog of research projects and clinical trials, on an ongoing
basis, to inform funders (IRDiRC Roadmap priority)
WP12: Orphanet will contribute to subtasks related to the generation and maintenance of semantic standards and
metadata (subtasks 12.1.1, 12.1.5., 12.2.1., 12.3.1.)
Pillar 3:
WP 14: Training on data management and quality. Inserm-Orphanet will lead the Task 14.1: Developement of a
novel training modules for clinicians and scientists involved in various rare disease research fields. After some
adaptation to country-specific needs, the Orphanet Network teams will organise trainings in their countries in their
national language. Orphanet will contribute also to the Task 14.6. Training on the European RD Registry
Infrastructure (ERDRI) and to the Task 14.2 Developing the online course in WP3: Online academic education
course
Coordination and transversal activities
Inserm-Orphanet will contribute to subtasks in the WP1 Coordination and Management, as Pillar 2 co-leader and as
Coordinator of the pan-European Orphanet network.
Inserm-Orphanet will co-lead the Task 2.1: Mapping and prioritizing the needs in the WP2: Integrative research
strategy.
Inserm-Orphanet will lead and Orphanet TLP will contribute to the Task 5.2: Integrating EJP RD communiation
and dissemination strategies with the strategies of involved stakeholders in the WP5: Communication &
dissemination.
Previous experience relevant to the Tasks:
Orphanet produces the standard nomenclature, classification and ontology for rare diseases including genomic
and phenomic data, is a IRDiRC recognized resource and is also recognized as a Human Variome Project
recommended system.
Orphanet maintains a database of RD-specific expert resources since 1997 by the collection, manual curation and
quality control of expert centres (including ERNs), diagnostic tests, patient organisations, infrastructures,
registries and databases and RD research projects and clinical trials and orphan drugs in 35 countries of the 41
countries in the Orphanet network.
Orphanet has maintained, and contributes to maintain in the frame of RD-Action, the State of the Art of activities
related on RD, based on the work of national Orphanet hubs covering all EU countries.
Orphanet coordinates RD-Action, the DG Santé Joint action for RD, dealing with data and policies, including
codification of RD in health information systems.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Orphanet database owned by Inserm, with its access services and formats :
www.orpha.net
825575 – EJP RD – Part B 51
www.orphadata.org (XML, JSON, OWL) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
www.orpha.net/sparql/ SPARQL Endpoint
ORDO http://bioportal.bioontology.org/ontologies/ORDO (OWL, CSV, RDF/XML)
HOOM http://www.orphadata.org/cgi-bin/inc/hoom_orphanet.inc.php
Orphanet is hosted at CINES (National Computing Center for Higher Education, a French public institution). The
Orphanet IT infrastructure is managed both by US14 Inserm unit and by Inserm Department of Information System
and has productions, pre-production and development servers organized in several Virtual Machines.
Short Profile of key Staff Members who will be undertaking the work
Dr. Ana Rath, Ana Rath is a medical doctor with a background in general surgery and a Masters degree in
(Female) Philosophy. She oriented her career to medical information in 1997 and joined Orphanet
(www.orpha.net) in 2005. She acts as managing editor of the Topic Advisory Group on rare
diseases at the World Health Organization. She chairs the Orphanet rare diseases ontology
(ORDO:http://bioportal.bioontology.org/ontologies/ORDO). Ana is the current Director of
Orphanet and the coordinator of RD-ACTION, the EU Joint Action for rare diseases (2015-2018)
and of the HIPBI-RD project. She chairs the Orphanet Rare Disease Ontology (ORDO).
Marc Marc Hanauer is an engineer at INSERM and Chief Technology Officer at Orphanet since 2007
Hanauer, and Orphanet Deputy director since 2017. He is also in charge of managing Orphanet's innovation
(Male) strategy. Previous to his current position, Marc worked for different internet start-ups from 2000
on-wards. He has an academic background in information and communication sciences."
Sylvie Maiella Sylvie Maiella has a PhD in Human Immunology and has been trained to Transversal
(Female) management. She oriented her career to scientific project management in 2010 and since 2011 she
has been acting as Orphanet international coordinator and project manager of the previous
Orphanet- Inserm coordinated Joint actions (OEJA 2011-2014 and RD-ACTION 2015-2018).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. orphadata.org
2. ORDO (http://www.orphadata.org/cgi-bin/inc/ordo_orphanet.inc.php/)
3. Harmonising phenomics information for a better interoperability in the rare disease field.
Maiella S, Olry A, Hanauer M, Lanneau V, Lourghi H, Donadille B, Rodwell C, Köhler S, Seelow D, Jupp S,
Parkinson H, Groza T, Brudno M, Robinson PN, Rath A. Eur J Med Genet. 2018 Feb 7. pii: S1769-
7212(17)30506-2. doi: 10.1016/j.ejmg.2018.01.013. [Epub ahead of print] Review. PMID:29425702
4. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective.
Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, et al; International Rare Diseases Research Consortium
(IRDiRC). Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23. Review.
PMID:28796445
5. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
Boycott KM, Rath A, et al Am J Hum Genet. 2017 May 4;100(5):695-705. doi: 10.1016/j.ajhg.2017.04.003.
List of relevant previous projects or activities, connected to the subject of this proposal
Harmonising phenomics information for a better interoperability in the RD field (HIPBI-RD) 2016 – 2019, project
financed by ERA-Net E-Rare-3.
Promoting implementation of recommendations on policy, information and data for RD Joint action (RD-
ACTION); 2015-2018
SUPPORT-IRDiRC; 2012 – 2018, FP7 GA N°: 305207
01-INSERM (c)
INSERM-U993/RaDiCo
Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale
(INSERM), France
Principal investigator Serge Amselem
Relevant Network
Description of the legal entity/department/laboratory/group: The research unit UMR_S933 from INSERM
“Pathophysiology of Paediatric Genetic Diseases”, led by Prof. Serge Amselem is subdivided into two distinct
825575 – EJP RD – Part B 52
components: the Genetic research group and the RaDiCo French national platform
Associated on RD
with document cohorts.
Ref. Ares(2018)6091977 - 28/11/2018
The genetic research group of the UMRS 933 INSERM/UPMC is devoted to the study of the pathophysiology of
several human Mendelian disorders, including auto-inflammatory disorders, primary ciliary dyskinesia, growth
disorders of endocrine origin, and disorders of sex development & infertility. It has access to several cohorts of
patients with these disorders, which are exceptional, both in their size and their phenotypic characterization. For
each pathology investigated, the group develops on the top of the genetic profile (identification of new genetic
factors involved the studied diseases), a functional profile with the design of disease-specific studies aimed at:
developing disease-specific cell models,
characterizing the molecular networks to which the proteins involved belong,
evaluating, using different model systems, the consequences of the mutations identified in patients,
and opening up new therapeutic avenues. The research conducted in this team leads to clinical implications with
diagnostic, prognostic and therapeutic repercussions (translational research).
The RaDiCo national platform on RD cohorts: RaDiCo (for Rare Disease Cohorts, see www.radico.fr) is a
French platform and programme coordinated and administratively managed by the French Institute of Health and
Medical Research (Inserm / UMR S 933). Its activities started in November 2013 and are funded within the scope
of the ‘Investissements d’Avenir’ (Investments for the Future) programme implemented by the MESR (French
Ministry for Higher Education and Research), the Agence Nationale pour la Recherche (ANR, the French National
Research Agency). The aim of RaDiCo is to bring in-kind services and large spectrum of expertise to the RD
community in France and in Europe to optimizing the design and implementation of high quality multicentric RD
cohorts with clearly defined scientific objectives: describing natural history of RDs, establishing genotype-
phenotype correlations, assessing the impact of environmental factors, elucidating their physiopathology,
identifying new therapeutic approaches and diagnostic / prognostic / theranostic biomarkers, or assessing their
medical, economical and societal impacts. To date, RaDiCo is involved in sixteen RD cohort studies, all selected
following a national call for proposals by independent experts. Two of them (RaDiCo-ECYSCO and RaDiCo-
EURBIO Alport) are already of European. One original cohort (RaDiCo-GenIDA) proposes to the patient
community an international social network for data collection on the natural history of rare monogenic forms of
intellectual disabilities. Several Public-Private Partnerships with big pharma industries have already been
initiated for the use of certain cohort resources through Specific Research Projects. To summarise, the major
activities performed by the RaDiCo team are the following:
eHealth
Ø Interoperability with pre-existing local databases and information sources, FAIRification
Ø Webservices and e-form building (eCRF, questionnaires)
Ø Integration of data from mobile-health and connected devices
Ø Secure-by-design, GDPR-compliant electronic infrastructure / IS resource orchestration and maintenance
Transversal affairs
Ø Training courses on regulatory, ethical and standardization issues
Ø Preparation of legal documents
Ø Intellectual property and data access management
Ø Communication
Ø Public-private partnerships agreements
Ø Dissemination and exploitation plans / cohort resource access management (data and bio-collections)
Ø European and international collaborations
Ø Cohort infrastructure as a service: sustainability solutions
Research
Ø Cohort longitudinal study design and methodology
Ø Design of the case report forms and patient questionnaires
Ø Preparation of the regulatory dossiers
Ø Real time data monitoring and management
Ø Biostatistical expertise and scientific valorisation of the data/knowledge
Main tasks in the project per Pillar/WP:
Coordination and transversal activities:
WP3: Co-leader of WP3 “Sustainability strategy and business plan”, leader of Task 3.1, joint development of a
dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database and Study cases of
innovative sustainability solutions for specific EJP RD outcomes
825575 – EJP RD – Part B 53
WP4: Participant in WP4 “Ethical, regulatory, legal and IPR framework
Associatedof the
with EJP RD”
document Ref. (expertise in ethical
Ares(2018)6091977 and
- 28/11/2018
regulatory issues in the MS related to RD patient databases, secure by design information systems and GDPR
obligations in Europe, expertise in IPR issues and collaborative contractual frameworks (eg Consortium
Agreement, Public-Private contracts, involving use and exploitation of data).
Pillar 2:
WP10: “User-driven strategic planning and transversal activities for Pillar 2 data ecosystem”: Participant in Task
10.3: Coordination of technical GDPR implementation (expert), Task 10.4: Quality oversight (expert), Task 10.5:
Sustainability and scaling up (to coordinate with WP3 activities).
WP11: “Common virtual platform for discoverable data and resources for RD research”: Participant in notably
Task 11.3: Data deposition and access to data infrastructures for RD research (concerning patient cohort data),
Task 11.4: Provision of RD analysis and data sharing capabilities through online resources.
WP12: “Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples”:
Participant in notably in Task 12.1: Compare and align core interoperability standards of relevance and Task 12.3:
Combining expertise for practical FAIRification: experience and PoCs based on RaDiCo cohorts’ databases.
Pillar 3:
WP14: “Training on data management & quality”: in Task 14.5: Training on rare disease registries and
FAIRification of data at the source: trainer in data management and data quality best practices and approaches,
next generation registries and database governance models, integration of IoTs, valorisation and exploitation
activities.
Pillar 4:
Involvement in WP20 “Accelerating the validation, use and development of innovative methodologies tailored for
clinical trials in RDs” due to strong expertise in clinical trial and study design and implementation at European
level within transnational RD patient cohorts.
Previous experience relevant to the Tasks:
RaDiCo team: 16 fully dedicated employees act within 3 different sub-units: Clinical research, e-Health and
Information System. They are bringing complementary expertise and tools since 2014 enabling RD cohorts’
design and implementation. 16 RD cohorts were conceived and are currently managed by the RaDiCo platform at
national and European levels, covering more than 40 different rare diseases. The team composition, expertise and
organisation has been continuously adapted to cope with the evolution of RaDiCo activities for the supported
cohorts.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work : The Inserm-RaDiCo platform has selected the free, secured, web-based, and user-friendly
electronic data capture (EDC) tool REDCap as its clinical research software suite for electronic data capture and
management. All information systems proposed by RaDiCo run in a virtual, redundant and supervised, GDPR-
compliant architecture in a certified health data hosting and facilities management centre (HADS in French) in the
framework of a service contract with the Inserm. Security audits are performed each year. The equipment is
dedicated and isolated. The required operating system is LINUX long term support, Apache, the MySQL database
engine and the PhP application scripting language, i.e. the LAMP suite.
Short Profile of key Staff Members who will be undertaking the work
Prof. Serge Prof. Serge Amselem (Male) - MD (paediatrician), PhD, Professor of human genetics at Université
Amselem Pierre et Marie Curie (UPMC) in Paris (France) and director of the U933 Inserm research unit
(Male) (UMR_S933 INSERM/UPMC) dedicated to the study of the pathophysiology of several Mendelian
disorders. He is the scientific coordinator of the RaDiCo program ~ 150 papers in peer-reviewed
journals (first / corresponding author in several international journals, including Nat Genet, New
Engl J Med, Am J Hum Genet, J Clin Invest, PNAS, EMBO J, PLoS Genet, Hum Mol Genet).
Prof. Paul Landais (Male) - Professor of Public Health, Clinical Epidemiologist and Nephrologist
Prof. Paul (MD). Director of the UPRES EA2415 Research Unit, Clinical Research Institute, Montpellier
Landais University. Founded the French Renal Epidemiology and Information Network (REIN), the
(Male) SCETIDE program with Pr A. Fischer, the CEMARA platform for rare diseases (RD) & past-
coordinator of the French national Rare Diseases Data Bank (BNDMR). Co-Coordinator of the
national RaDiCo program for RD cohorts. Founder of the Institute for clinical evaluation of medical
devices (IDIL).
Prof. Prof. Annick Clement (Female) – MD (paediatrician) PhD, Professor of pediatricsSorbonne
Annick Université, Paris, France. Director of the pediatric pulmonary department of the Eastern university
Clement hospital of Paris. Coordinator of the national reference centre for rare respiratory diseases.
Coordinator of the national nework for rare lung diseases. Team leader of national and international
825575 – EJP RD – Part B 54
research programs in the field of rare lung diseases. Co-Coordinator
Associated with document Ref.ofAres(2018)6091977
the national RaDiCo
- 28/11/2018
program for RD cohorts.
Dr. Sonia Dr. Sonia Gueguen (Female) - Science & Operations Director of the RaDiCo platform at the
Gueguen French National Institute of Health and Medical Research (Inserm). PhD degree in Epidemiology
(Female) and Public Health from Faculté de Pharmacie, Nancy I University. Fifteen years of experience in
clinical research. Deputy Director of Clinical Research Department of the French National Institute
of Health and Medical Research (Inserm) which had 146 ongoing projects with 5 % of international
or European studies over the past five years (2012-2018).
Dr. Laure Dr. Laure Jamot (Female) Head of RaDiCo’s Clinical Research Department. PhD degree in neuro-
Jamot genetics from Paris V René Descartes University in Paris. After 5 years of basic research on rare
(Female) neurodegenerative diseases (Mount Sinaï hospital, Toronto Canada), moved to the Trophos
biotechnology company in 2001, in Marseille to set up the R&D programme on Huntington’s
disease. In 2008, joined the Alfact Innovation company, based in Paris, as head of pre-clinical and
clinical research programmes. Backed by her team of clinical research project and data-managers,
biostatistician and methodologist, she now takes advantage of her 13 year experience in the private
sector for dealing with all aspects of translational and clinical research for the benefit of the RaDiCo
programme and its cohorts.
List of the most relevant publications
- Olcese C*, Patel MP*, Shoemark A*, Kiviluoto S*, Legendre M*, Hayward J, Goldenberg A, Emes RD, …
Armengot M, Escudier E,Hogg C; UK10K Rare Group., Amselem S*, Sun Z*, Bartoloni L*, Blouin JL*,
Mitchison HM* X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein
assembly factor PIH1D3. Nat Commun. 2017 Feb 8;8:14279. (*co-first and co-last authors)
- El Khouri E, Lucie L, Jeanson L, Bequignon E, Vallette V, Duquesnoy P, Montantin G, Copin B, Dastot-Le Moal
F, Blanchon S, Papon JF, Lorès P, Yuan L, Collot N, Tissier S, Faucon C, Gacon G, Patrat C, Wolf JP, Dulioust E,
Crestani B, Escudier E, Coste A, Legendre M, Touré A, Amselem S. Mutations in DNAJB13, which encodes an
HSP40 family member, cause primary ciliary dyskinesia and male infertility Am J Hum Genet. 2016 Aug
4;99(2):489-500
- Jeanson L, Copin B, Papon JF, Dastot-Le Moal F, et al., Clement A, Escudier E, Amselem S (corresp author),
Legendre M. RSPH3 mutations cause primary ciliary dyskinesia with a near absence of radial spokes and central
complex defects. Am J Hum Genet. 2015 Jul 2;97(1):153-62.
- Kott E, Legendre M, Copin B, Papon JF, Dastot-Le Moal F, et al., Clement A, Housset B, Louis B, Escudier E,
Amselem S. Loss-of-function mutations in RSPH1 cause primary ciliary dyskinesia with central-complex and
radial-spoke defects. Am J Hum Genet. 2013 Sep 5;93(3):561-70.
- Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O. How should we approach classification of
autoinflammatory diseases? Nat Rev Rheumatol. 2013 Oct;9(10):624-9.
- Kott E, Duquesnoy P., Copin B, Dastot-Le Moal F, Montantin G, Jeanson L, Tamamlet A, Papon JF, Rives N,
Mitchell V, de Blic J, Coste A, Clement A, Escalier D, Touré A, Escudier E, Amselem S. Loss-of-function
mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary
ciliary dyskinesia. Am J Hum Genet. 2012, 91(5):958-64.
- Merveille A.C., Davis E.E., Becker-Heck A., Legendre M., et al., Georges M., Lequarré A.S., Katsanis N., Omran
H., Amselem S. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for
normal ciliary motility in humans and dogs. Nat Genet., 2011, 43(1):72-79.
- Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe:
entering a new century, do we do better? Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, et al., Neven B,
Blanche S, Fischer A, Cavazzana-Calvo M, Landais P. Inborn Errors Working Party of the European Group for
Blood and Marrow Transplantation; European Society for Immunodeficiency. J Allergy Clin Immunol. 2010
Sep;126(3):602-10.e1-11.
- Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar
HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ. Haemopoietic stem-cell
transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep
12;374(9693):912-20.
- Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, .. , Bredius R, Schulz A, Landais P, Fischer A;
European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term
survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience
1968-99. Lancet. 2003 Feb 15;361(9357):553-60.
- Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P. A methodology for a minimum data set
for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc.
2015 Jan;22(1):76-85.
825575 – EJP RD – Part B 55
- Kodra Y, Posada de la Paz M, Coi A, Santoro M, Bianchi F, Ahmed F, Rubinstein
Associated YR,
with document Weinbach
Ref. J, Taruscio
Ares(2018)6091977 D.
- 28/11/2018
Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017;1031:149-164.
- Kodra Y, Weinbach J, Posada-de-la-Paz M, Bros-Facer V, .., Landais P, .., Reis R, Rubinstein YR, Ambrosini
A and Taruscio D. Recommendations for Improving Quality of Rare Disease Registries. Int J Environ Res Public
Health. 2018 Aug 3;15(8). pii: E1644.
- Taruscio D, Vittozzi L, Choquet R, Heimdal K, Iskrov G, Kodra Y, Landais P, Posada M, Stefanov R,
Steinmueller C, Swinnen E, Van Oyen H. National registries of rare diseases in Europe: an overview of the current
situation and experiences. Public Health Genomics. 2015;18(1):20-5.
List of relevant previous projects or activities, connected to the subject of this proposal MINDDS – a pan-
European network for Neurodevelopmental Disorder research - supported as a European COST Action. COST
(European Cooperation in Science and Technology) – 26 countries participating. RaDiCo represents France in this
project.
01-INSERM (d)
INSERM-AMU (LTP)
Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale
(INSERM), France
Principal investigator Christophe Béroud
Relevant Network RD-Connect, IRDiRC, ELIXIR
Description of the legal entity/department/laboratory/group:
The “Marseille Medical Genetics” (MMG, JRU 1251) is a JRU between INSERM and AMU, headed by Pr.
Nicolas Levy, with employees from INSERM, AMU and CNRS. The main areas of research investigated by MMG
teams are the genetic and cellular mechanisms involved in rare genetic disorders, and exploration of the phenotypic
consequences of these mutations. Our research Center is part of the Timone campus that comprises fundamental
research laboratories at the School of Medicine and the Children's Hospital in Marseille – la Timone. Research
activities led by the different teams are closely connected to clinical research conducted in the Department of
Medical Genetics. MMG occupies 2150 m2 of research space that was designed specifically for its mission. MMG
gathers in a fully equipped space over 150 people shared out among 8 research teams.
AMU manages this JRU, as confirmed by the INSERM and AMU framework agreement. AMU is thus Linked
third Party of INSERM to handle this project
Main tasks in the project per Pillar/WP:
Pillar 2:
WP11: AMU will contribute to the WP: Common virtual platform for discoverable data and resources for RD
research (in particular subtasks 11.3 and 11.4). The "Genetics and Bioinformatics" Team (led by Prof. Christophe
Béroud) has a strong expertise in the Rare Disease management of data and resources and is a key partner of the
RD-Connect platform that will be central for the EJP platform. All team members (Dr. David Salgado, Dr.
Gwenaëlle Collod-Béroud, Jean-Pierre Desvignes, Marc Garibal and Céline Guien as well as a new Research
Engineer specifically hired for the EJP-RD, will be involved in this WP as well as WP12, 13, 14 and 16).
WP12: AMU will contribute to the WP: Enabling sustainable FAIRness and Federation at the record level for
RD data, patients and samples (in particular subtasks 12.2 and 12.3). Inserm-AMU has a strong expertise in
software and tool developments for the analysis of genomics and other types of -omics data, and various groups
may contribute to this WP. The team led by Prof. C. Béroud has an international recognized expertize in the
development of NGS pipelines and tools, expertise in RNA-seq and CHIP-seq analyses, NGS data management
and analysis, in Locus Specific Databases (GEN2PHEN, TREAT-NMD, NMD-CHIP). Overall, Inserm-AMU will
participate to the demonstration that the application of the FAIR principles to various existing resources developed
and hosted at AMU, as the TREAT-NMD global registries, is feasible in practice.
WP13: AMU will contribute to the WP: Enabling multidisciplinary, holistic approaches for rare disease
diagnostics and therapeutics. The MMG Network and Systems Biology group (NSBD, led by Dr. Anaïs Baudot
(see Partner CNRS), a member of Nicolas Lévy's group, has a strong expertize in modeling, mining and integration
of multi-omics data in the disease contexts. Two post-doctoral fellows from AMU of the group (Pooya Zakeri and
post-doc to be recruited in January 2019) will be involved. The group collaborates closely with the MABIOS team
led by Dr. Elisabeth Remy (see Partner CNRS), from the Marseille Mathematic Institute, composed of
mathematicians and computer scientists, to develop algorithms to study biological networks. The MABIOS team
includes two AMU associate researchers (Laurent Tichit and Brigitte Mossé) as well as an AMU post-doctoral
fellow (Léo Pio-Lopez) who will be implicated in the project.
825575 – EJP RD – Part B 56
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 3: AMU, the largest worldwide French speaking University, has all requirements to become a partner in
training workpackages.
WP 14: Training on data management & quality. Inserm-AMU will contribute to the "Training on-omics"
thanks to C. Béroud team, which has long experience in international training sessions (3Gb-test, VEP, ELIXIR,
RD-Connect, TREAT-NMD, HGVS …). Inserm-AMU will also contribute to the training on undiagnosed once
again thanks to "Genetics and Bioinformatics" Team's long experience on this topic. They regularly give
international conferences on mutations and their effects on splicing signals. They are also leading the ELIXIR
Human-CNV community that is also highly relevant for this task. Moreover, the A Baudot's group, expert in
systems biology, is specifically dealing with undiagnosed and multi-omics data analysis.
WP16: Online Academic education course. The MMG unit hosts various key teachers involved in general
trainings on rare diseases, bioinformatics, databases and registries (DIU "rare diseases", Master 2 "Human
pathologies"). Thanks to this recognized expertise, the MMG will be responsible for the "Bioinformatics" part of
the "Developing the online course".
Previous experience relevant to the Tasks:
C. Béroud's team is leading the European RD-Connect WP dedicated to "Clinical Bioinformatics"; international
"TREAT-NMD global registries"; national databases BANCCO and RDVD dedicated to the collection of NGS
mutations; and various national and international patients' registries and mutations databases. In the context of NGS
data analysis, the team developed multiple reference systems including (UMD-Predictor, Human Splicing Finder
and VarAFT); Internationally recognized Locus Specific Database (LSDB) for various genes. The team has been
involved in multiple international projects such as TREAT-NMD, GEN2PHEN, NMD-CHIP, RD-Connect.
Complementarily, the NSBD group develops tools and approaches with strong theoretical bases and apply them to
biological questions related to human diseases. It will bring its expertise in networks and systems biology that will
address complementary aspects of the project.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed
work :
C. Beroud team: Leading Elixir human CNV Community, Elixir French node/IFB (French bioinformatics institute)
platform, Share memory supercomputer (SGI UV 2000, 256 cores, 1Tb RAM), its HPC cluster node (3 x 64Gb
RAM, 16 cores nodes) as well as its storage capacity (∼1Pb).
Short Profile of key Staff Members who will be undertaking the work
Prof. C. Béroud has over 20 years of experience in research laboratories. He is a Pharmacist, geneticist,
Christophe bioinformatician, and professor of Human Genetics at the AMU. He leads the Genetics and
Béroud, Bioinformatics" research team at INSERM U1251, which is labeled "Platform of the French
(Male) Bioinformatics Institute" and a French node of ELIXIR. His team has become an internationally
recognized center for the creation and management of genetic databases and analysis systems. C.
Béroud is a member of the scientific committee of the "Human Genome Variation Society" and an
expert in the evaluation of research proposals for the French Ministry of Research and various
international organizations.
Prof. Nicolas Nicolas Lévy is Professor of Medical Genetics (MD, PhD) at the Aix-Marseille Faculty of
Levy (Male) Medicine and Chief of Service Department of Medical Genetics and Director of the research unit
Aix-Marseille University / INSERM UMR_S910 "Marseille Medical Genetics"
Author of 189 publications, 90 invited conferences since 2010, and co-inventor of 10 patents with
four operated licenses, Nicolas Levy won the Grand Research Robert Debré Award in 2013 and
the Prix Rose Lamarca assigned by the FRM (Foundation for Medical Research) in 2014.
Specialist of rare diseases, he established the Rare Diseases Foundation of which he has been the
director until November 2015. Specialist in genetics of neuromuscular diseases and
laminopathies, he identified the mutation responsible for the progeria in 2003, and since then, the
pathophysiological mechanisms and genes associated withProgeria and related premature aging
syndromes.
Dr. Anaïs A. Baudot is a bioinformatician with more than 14 years of expertize in network biology, both in
Baudot biology, cancer and mathematics research centers. She is leading the NSBD group dedicated to
(Female) the development of systems and network approaches to better understand human diseases, and
rare monogenic diseases in particular. She leads and participates to various national projects.
Dr David D. Salgado is a computer scientist with 12 years experience in research laboratories. Since 2012
Salgado, he is a Research Engineer in C. Béroud's research team, and is responsible of the MMG
825575 – EJP RD – Part B 57
(Male) Bioinformatics platform. He has contributed to the development
Associated of multiple
with document Ref. bioinformatics
Ares(2018)6091977 - 28/11/2018
systems including pathogenicity prediction system, rare disease patient registries and therapeutic
tools, all dedicated to translational research in human rare diseases.
Dr Elisabeth After initial training and a PhD in applied mathematics, E. Remy joined the CNRS in 2002. She
Remy, has several years of experience in modeling and analysis of logical regulatory networks. She is
(Female) now heading the MABIOS group (Mathematics and Algorithms for Systems Biology) in the
Marseilles Institute of Mathematics (I2M), working in close collaboration with the NSBD group.
She participated in several national/international projects and managed young researcher ANR
grant.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
• F.-O. Desmet, D. Hamroun, M. Lalande, G. Collod-Beroud, M. Claustres, and C. Béroud, “Human Splicing
Finder: an online bioinformatics tool to predict splicing signals.,” Nucleic Acids Res., vol. 37, no. 9, p. e67, May
2009. (Highly Cited paper: 902 citations Web of Science)
• D. Salgado, J.-P. Desvignes, G. Raï, A. Blanchard, M. Miltgen, A. Pinard, N. Lévy, G. Collod-Beroud, and C.
Béroud, “UMD-Predictor: a High Throughput Sequencing Compliant System for Pathogenicity Prediction of any
Human cDNA Substitution.,” Hum. Mutat., vol. 37, no. 5, pp. 439–446, Feb. 2016.
• Didier G, Brun C and Baudot A. Identifying communities from multiplex biological networks. PeerJ 2015. 2015.
• Bladen CL, Salgado D,et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne
muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395-402. doi: 10.1002/humu.22758.
• C. Béroud, G. Collod-Beroud, C. Boileau, T. Soussi, and C. Junien, “UMD (Universal mutation database): a
generic software to build and analyze locus-specific databases.,” Hum. Mutat., vol. 15, no. 1, pp. 86–94, 2000.
List of relevant previous projects or activities, connected to the subject of this proposal
EU FP7 (01.02.2008 – 31.01.2013), GEN2PHEN (partner)
EU-FP7 (01.12.2009 – 30.11.2012), BIO-NMD (WP leader)
EU-FP7 (01.11.2012 – 30.10.2018), RD-CONNECT (WP leader)
02-FWF
Full legal name (Acronym) – Country Fonds zur Förderung der wissenschaftlichen Forschung (FWF),
Austria
Principal investigator Stephanie Resch
Relevant Network
Description of the legal entity/department/laboratory/group:
The Austrian Science Fund (FWF) is Austria's main funding organisation for basic research. The FWF supports the
ongoing development of top-notch Austrian science and basic research based on international standards. In this
way, the organisation makes a significant contribution to cultural development, to the advancement of our
knowledge-based society, and thus to the creation of added value and prosperity in Austria. One of the FWF's key
objectives is to strengthen Austria's international performance and capabilities in science and research as well as the
country's attractiveness as a location for high-level research. This is achieved primarily by funding top-quality
projects for individuals and teams, and by enhancing the competitiveness of Austria's innovation system and
research facilities. Guided by the principle of research-driven education, the FWF also works to develop Austria's
human resources for science and research in both qualitative and quantitative terms. In addition, the organisation
strives to emphasize and enhance the interaction of science and research with all other areas of society, culture and
the economy, and in particular to increase the acceptance of science and research through concerted public relations
activities. The FWF's annual funding budget came to EUR 197.8 million in 2016.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will join the transnational calls for collaborative research projects (task 6.1, 6.2, 6.3, 6.4)
In WP9, we will contribute to the monitoring activities (task 9.1)
Previous experience relevant to the Tasks:
One of the key objectives guiding the FWF’s activities at the international level is to enhance Austria’s
international visibility as a research location. The FWF’s international programmes include a variety of funding
instruments which are essentially designed to support bilateral and multilateral research projects as well as
825575 – EJP RD – Part B 58
international networking. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Since 2003, the FWF has participated in more than 130 bilateral and multilateral international calls, including some
60 ERA-Net calls. The FWF’s funding volume for international programmes amounted to EUR 22.1 million in
2016.
The FWF will use its prior experience to make an active contribution to the activities related to the joint calls. The
FWF’s Department of Biology and Medical Sciences has participated actively in the following ERA-Nets: E-Rare-
1; E-Rare-2; E-RARE-3; TRANSCAN; TRANSCAN-2; EUROPOLAR; ERA-CAPS; Pathogenomics; Infect-ERA;
NEURON I, II and III; BIODIVERSA 1, 2 and 3; ERASynBio; New Indigo; ERA-CVD; ERACoSysMed and ERA
PerMed.
As a partner in EJP RD, the FWF will be represented on the Network Steering Committee. The FWF will also
participate in the COFUND calls as well as other joint calls in the coming years.
The personnel involved have vast experience in running joint calls for projects, and in monitoring and strategic
activities.
Short Profile of key Staff Members who will be undertaking the work
Dr. Stephanie Diploma and PhD in microbiology and genetics. Co-founder and R&D manager of a biotech
Resch(female) company focusing on vaccine development (Germany and USA). Head of the Department of
Biology and Medicine at the FWF since 2005. Participant in various ERA-Nets (e.g. E-RARE,
TRANSCAN, ERA-PerMed).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Funding of 17 Austrian sub-projects with a total budget of 3.6M€ within the framework of E-RARE (sum
of all three running periods).
List of relevant previous projects or activities, connected to the subject of this proposal :
. E-RARE-1; Funder; 2009-2010: promoting transnational funding activities by active participation in the JTC
2009 as well as participation in strategic research funding policy
. E-RARE-2; Funder; 2010-2014: promoting transnational funding activities by active participation in the JTC
2011, JTC 2012, JTC 2013, JTC 2014 as well as participation in strategic research funding policy
. E-RARE-3; Funder; 2015-2019: promoting transnational funding activities by active participation in the JTC
2015, JTC 2016, JTC 2018 as well as participation in strategic research funding policy
.
03-AIT
Full legal name (Acronym) – Country AIT Austrian Institute of Technology GmbH (AIT), Austria
Principal investigator Günter Schreier
Relevant Network
Description of the legal entity/department/laboratory/group:
AIT Austrian Institute of Technology is Austria’s largest non-university research institute with more than 1.300
employees, structured in 8 centres. AIT’s vision is to bridge the gap between basic research and applied science.
Its Digital Health Information Systems (HIS) research team is part of the Center for Health & Bioresources and has
comprehensive experience, infrastructure, tools and skills for the design, development and operation of ICT
solutions for healthcare and biomedical research – from rapid prototyping through feasibility studies to proof-of-
concept and clinical evaluation trials. The interdisciplinary HIS team consists of about 45 scientists and engineers
and has been a key partner in numerous EC funded projects and a variety of funding schemes (SIOPEN-R-NET,
CARE-MAN, RegIonCo, iStoppFalls, FoSIBLE, ENVIROFI, ENCCA, ExPO-r-Net, CARE, SymbIoTe, …). AIT
is currently running various ICT infrastructures for clinical trials and research networks, e.g. in the fields of
paediatric oncology, as well as eHealth infrastructures and healthcare IT systems that provide direct links to
patients in telehealth settings and to collect so called patient reported outcomes (ePRO). Several large-scale
telehealth systems have been developed and operated by AIT, adding up to more than 1.000.000 patient monitoring
days so far. More recently, the team has been instrumental in a number of Big Healthcare Data predictive analytics
activities, e.g. to predict hospital re-admission, delirium or the need for blood transfusions. The HIS team is
supported by AIT’s administrative, financial, legal and marketing units, which provide the ideal project
management environment for carrying out also large collaborative research projects. AIT operates the EUropean
Patient IDentity management (EUPID) service and will provide this as a basis and key element for
pseudonymisation and privacy preserving record linkage in the present project (see also https://eupid.eu).
825575 – EJP RD – Part B 59
Main tasks in the project per Pillar/WP: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 2:
In WP11, we will be leading subtask 11.3.3, with a focus on providing EUPID based registration/pseudonymisation
services for the network of EJP partners.
In WP12, we will be leading the task 12.2 “Multi-team software development to enable the FAIR ecosystem” and
contribute to improving existing software solutions, previously developed in the RD community.
Pillar 3:
In WP14, we will be contributing to the “Training on the European Rare Diseases Registry Infrastructure
(ERDRI)”, in particular regarding patient registration and pseudonymisation with EUPID (task 14.6).
Previous experience relevant to the Tasks:
In preceding projects, AIT has been leading IT tasks similar to the ones required in the present project in general,
both in funding and industrial settings. In particular, the AIT team has already managed EUPID pilot integration
projects with partners from the rare disease and paediatric oncology community. AIT has been an IT partner to
those communities for many years, and in charge of different kinds of tasks relevant to the present project,
including development of IT solution architectures, managing interdisciplinary and cross-institutional system
development efforts and providing demonstrations and trainings to end users in face 2 face and virtual sessions.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
AIT operates the EUropean Patient IDentity management (EUPID) services which, in its version 1.0, implements
the basic UPID concept descripted below in [4] and mainly consists of a database containing the necessary
metadata and functionalities, a RESTful web service (EUPID App Service) providing the EUPID
Pseudonymisation Service to clients and the utilisation of an Identity Provider Service allowing to manage users,
their authentication and authorisation to use EUPID Services (see https://eupid.eu for up-to-date information).
Short Profile of key Staff Members who will be undertaking the work
Guenter Günter’s Role in the project will be to manage AIT’s activities in the project. He will provide his
Schreier expertise in related ICT / Biomedical Informatics fields, ranging from dataset standardisation,
(Male) standards-based interoperability, identity management and data linkage, to security and privacy
aspects as well as mHealth and Big Healthcare Data. Günter serves as an advisor to the Austrian
Ministry of Health and as a member of the IT advisory board for EC’s European Reference
Networks. He is the founder and president of the annual scientific conference on “Medical
Informatics and eHealth” in Vienna (www.eHealth20xx.at).
Michael Michael will contribute to the IT system architecture and will be leading AIT’s implementation
Nitzlnader, activities. He will coordinate related software developments and operational activities, i.e.
(Male) adapting, extending, setting-up and operating the core components of the EUropean Patient
Identity management (EUPID) system. He will also be involved in linking the existing sources
systems and responsible for the overall security and privacy concept. Michael holds a number of
IT certificates highly relevant to the present project and related to IT security, requirements
engineering and data protection.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1: Hayn D, Falgenhauer M, Kropf M, Nitzlnader M, Welte S, Ebner H, Ladenstein R, Schleiermacher G, Hero B,
Schreier G. IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research
Networks. Stud Health Technol Inform. 2016;228:287-91. PubMed PMID: 27577389.
2: Hochedlinger N, Nitzlnader M, Falgenhauer M, Welte S, Hayn D, Koumakis L, Potamias G, Tsiknakis M,
Saraceno D, Rinaldi E, Ladenstein R, Schreier G. Standardized data sharing in a paediatric oncology research
network—a proof-of-concept study. Stud Health Technol Inform. 2015;212:27-34. PubMed PMID: 26063254.
3: Nitzlnader M, Falgenhauer M, Gossy C, Schreier G. Architecture for an advanced biomedical collaboration
domain for the European paediatric cancer research community (ABCD-4-E). Stud Health Technol Inform.
2015;212:167-74. PubMed PMID: 26063273.
4: Nitzlnader M, Schreier G. Patient identity management for secondary use of biomedical research data in a
distributed computing environment. Stud Health Technol Inform. 2014;198:211-8. PubMed PMID: 24825705.
5: Schreier G, Messmer J, Rauchegger G, Modre-Osprian R, Ladenstein R. A Web-based platform for
interdisciplinary biomedical research. Front Biosci (Landmark Ed). 2009 Jan 1;14:2738-46. PubMed PMID:
19273232.
List of relevant previous projects or activities, connected to the subject of this proposal (max 5):
1. ENCCA (www.encca.eu) – European Network for Cancer Research in Children and Adolescents – FP7 (2011
– 2015) Network of excellence project to establish a Virtual Institute for cancer research in Europe. AIT served
as the IT work package leader and guided the development of the information portal of the Virtual Institute.
825575 – EJP RD – Part B 60
Some elements developed in ENCCA were the starting point forAssociated
developments of important
with document ICT infrastructure
Ref. Ares(2018)6091977 - 28/11/2018
for data sharing, in particular EUPID.
2. ExPO-r-Net (www.expornet.eu) - European Expert Paediatric Oncology Reference Network for Diagnostics
and Treatment - ExPO-r-Net (EC, Health Programme, 2014 – 2017) was the pilot project for the European
Reference Network (ERN) for Paediatric Oncology, now established as Paediatric Cancer ERN (PaedCan). AIT
was responsibility for the overall IT architecture and the interoperability strategyy and lead the development of a
Virtual Tumour Board application.
3. RegIonCo (http://www.regionco.eu) – ERDF project (2008-2012) to foster collaboration between Austria and
Hungary regarding the new Ion Therapy facility MedAustron which is currently being established in Austria. AIT’s
role has been to design and build a prototype of an interoperable IT infrastructure for cross-border transfer of
medical images in order to facilitate continuity of care in accordance with European and international
interoperability concepts.
4. SIOPEN-R-NET (www.siopen-r-net.org) –SIOP Europe Neuroblastoma Research Network – FP5 (2002-2006)
Thematic Network project to link European Neuroblastoma research – AIT was the IT partner and responsible for
design, development and operation of this tailored ICT platform to support research activities on the basic science
as well as the clinical level. The resulting SIOPEN-R-NET system is still up and running until today with almost
5000 patients being registered in the system in the course of five different clinical trials.
04-LBG
Full legal name (Acronym) – Country Ludwig Boltzmann Gesellschaft (LBG) GmbH, Austria
Principal investigators Kaan Boztug, Christoph Bock
Relevant Network Orphanet, UDNI (Undiagnosed Diseases Network International),
International Human Epigenome Consortium, Human Cell Atlas
Description of the legal entity/department/laboratory/group:
The Ludwig Boltzmann Society is a research institution, with a strong focus on medicine, hosting 18 research
institutes of various disciplines in Austria. The Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases
(LBI-RUD) is Austria’s first and leading research institute dedicated to a broad spectrum of rare and undiagnosed
diseases research. LBI-RUD consist of 4 groups focusing on the identification and characterization of inborn errors
of the immune and nervous system, the development and improvement of bioinformatics tools for next generation
sequencing and safe data exchange, and the ethical and societal implications of rare diseases and rare diseases
research.
Main tasks in the project per Pillar/WP:
Pillar 2: we will make some contributions (limited by budget allocation) to the following specific tasks:
- Collaborative integrated analysis of multi-omics data from selected use cases
- Provide capabilities for custom analyses through cloud-based solutions
- User-driven implementation of new analysis functionalities and tools
Pillar 3: we will contribute to training (limited by budget allocation) for clinicians and scientists about the
Orphanet database, the Orphanet nomenclature, genetic data prioritization using bioinformatics tools developed in
LBI-RUD.
We will participate in training activities sharing our expertise in functional dissection of molecular patomechanisms
of rare disease patients using a through specific case-studies.
Previous experience relevant to the Tasks:
LBI-RUD is well-connected in Austria and several Eastern European countries and together with its clinical
partners established well-studied patient cohorts of rare and ultra-rare diseases. LBI-RUD has built an effective
bioinformatics infrastructure for processing, interpreting, and securely sharing genome/exome/panel sequencing
data (e.g. Müller et al. 2017 Nucleic Acids Res). LBI-RUD scientists have a strong track record in the functional
dissection of rare disease mechanisms especially in the area of hematopoietic, immune, and neurological
disorders (e.g. Dobbs et al. NEJM 2015, Salzer et al. Nat Immunol 2016; Ozen et al. NEJM 2017). LBI-RUD
developed and applied advanced multi-omics technology including epigenome mapping (e.g. Farlik et al. Cell
Stem Cell 2016, Sheffield et al. Nat Med 2017), proteomics, metabolomics, and single-cell sequencing (e.g. Bock
et al. Trends Biotechnol 2016, Mass et al. Science 2016).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Computational infrastructure. LBI-RUD and CeMM maintain a powerful scientific computing cluster that is
upgraded annually to keep pace with steeply increasing data generation (current status: >100 CPUs, >1,000 cores,
>10 TB memory, >1,000 TB storage). For even more computation-intensive tasks, CeMM researchers have
825575 – EJP RD – Part B 61
institutional access to the Vienna Scientific Cluster, a global TOP500 supercomputer
Associated with documentoperated by a consortium
Ref. Ares(2018)6091977 of
- 28/11/2018
universities and research institutes in Vienna.
Biomedical Sequencing Facility (BSF). The BSF is a large technology platform dedicated to next generation
sequencing in biomedicine. It is jointly operated by CeMM and the Medical University of Vienna under the
scientific leadership of Christoph Bock. It is equipped with the following machines: (i) three large-scale sequencing
machines (1x NovaSeq 6000, 1x HiSeq 4000, 1x HiSeq 3000) for production sequencing; (ii) two medium-scale
sequencing machines (1x NextSeq, 1x MiSeq) for technology development; (iii) a PerkinElmer Sciclone NGS (pre-
PCR) and Zephyr (post-PCR) supporting 96-well automated library preparation for RNA-seq (PolyA+, RiboZero,
and 3’mRNA fingerprinting), RRBS, and ChIP-seq; (iv) a 10x Genomics Single Cell Controller, a Silicon
Biosystems DEPArray and a Fluidigm C1 for single-cell sequencing.
Short Profile of key Staff Members who will be undertaking the work
Dr. Kaan Boztug Kaan Boztug studied Medicine in Düsseldorf, Freiburg and London, followed by his graduate
(male) training with Iain Campbell at the Scripps Research Institute (La Jolla, USA), and clinical
training and postgraduate research with Christoph Klein at Hannover Medical School
(Germany). He joined CeMM in 2011 and holds a dual appointment as Associate Professor at
the Department of Paediatrics and Adolescent Medicine at the Medical University of Vienna.
Since 2016, Kaan Boztug is director of the LBI-RUD and the CeRUD Vienna Center for Rare
and Undiagnosed Diseases and joint director of the Jeffrey Modell Foundation Center for
Immunodeficiencies at the Medical University of Vienna and St. Anna Children’s Hospital.
Dr. Christoph Christoph Bock is a principal investigator at LBI-RUD and the CeMM Research Center for
Bock / male Molecular Medicine of the Austrian Academy of Sciences. His research focuses on disease
genomics/epigenomics and on high-throughput technologies for precision medicine. He is
also a guest professor at the Medical University of Vienna, scientific coordinator of the
Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the
Max Planck Institute for Informatics. He has received several research awards, including the
Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the
Overton Prize of the International Society of Computational Biology (2017).
Dr. David David Medgyesi studied molecular biology and received his PhD in immunology at the
Medgyesi / male Eötvös Loránd University Budapest, Hungary. He was a postdoctoral fellow and project
leader at Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. He
joined LBI-RUD as a senior research associate in 2017.
Dr. Matthias Matthias Haimel studied bioinformatic engineering at Upper Austria University of Applied
Haimel / male Sciences at Hagenberg and completed his PhD studies in 2017 at the Department of Medicine,
University of Cambridge, UK. He joined LBI-RUD as a bioinformatician in 2018.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Ozen A et al. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. (2017) N Eng J
Med, 377(1): 52-61.
2. Sheffield NC et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. (2017) Nat
Med, 23(3):386-395.
3. Müller H et al. VCF.Filter: Interactive prioritization of disease-linked genetic variants from sequencing data.
(2017) Nucleic Acids Res, 45, W567–W572.
4. Salzer E et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. (2016),
Nat Immunol, 17 (12), 1352-60.
5. Dobbs K et al. Inherited DOCK2 deficiency in patients with early-onset invasive infections. (2015) N Eng J
Med, 372(25): 2409-22.
List of relevant previous projects or activities, connected to the subject of this proposal:
. Precise PID; Vienna Science and Technology Fund (WWTF); 2017-2020, leader; using PIDs as model diseases
to rationalize patient-specific workflows from gene discovery and pathomechanisms to targeted treatments.
. Immuno Core; European Research Council (ERC); 2013-2018, leader; using systems genomics tools to uncover
primary deficiencies with a focus on phagocyte deficiencies such as congenital neutropenia syndromes.
. Epigenome Programming; European Research Council (ERC); 2013-2018, leader; development methods for
targeted (and potentially therapeutic) editing of epigenetic alterations
825575 – EJP RD – Part B 62
05-FNRS Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Fond de la Recherche Scientifique-FNRS (F.R.S.-FNRS) –
Belgium
Principal investigator Florence Quist
Relevant Network E-RARE, NEURON, JPIAMR,
Description of the legal entity/department/laboratory/group:
The Fund for Scientific Research - FNRS (F.R.S.-FNRS) is a research funding agency that promotes and supports
basic scientific research in the French-speaking Community of Belgium. Founded in 1928, it mainly receives
public subsidies, currently from the French-speaking Community of Belgium, the Walloon Region and the Federal
Government of Belgium. The Fund supports individual researchers on the basis of the criterion of excellence by
offering temporary or permanent positions; funding to research teams; grants and credits for international
collaboration and scientific prizes. F.R.S.-FNRS fosters research in all scientific fields, following a bottom-up
approach of investigator-driven research. Further, the Fund supports researchers in an ever growing context of
internationalisation through facilitating their mobility, allowing for collaborative transnational projects and
supporting a high level international working environment. Since October 2008, Dr. Ir. Véronique Halloin is the
Secretary-General of F.R.S.-FNRS.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate in the Joint Transnational Calls for collaborative research projects (tasks 6.1, 6.2, 6.3
and 6.4)
In WP9, we will participate in the Monitoring of funded projects (tasks 9.1, 9.2 and 9.3)
Previous experience relevant to the Tasks:
The Fund for Scientific Research - FNRS runs a programme supporting mainly basic research through project-
based funding for the French speaking community of Belgium. Research projects are funded through a bottom-up
principle following an open competition in a yearly call for research proposals and grants.
The F.R.S.-FNRS is currently involved in various European initiatives and bilateral agreements at the
international level. The Fund is and has been full partner in several FP7 ERA-Nets (CHIST-ERA, ERA-CAPS,
FLAG-ERA, GENDER-NET, PASTEUROA, HERA, E-RARE 2) and has participated in numerous ERANET
calls (JPND, Neuron, JPI-AMR, ERANET-LAC, Inno Indigo, SEA-EU NET, among others). The F.R.S.-FNRS
participated in the E-RARE Joint Transnational Calls in 2011, 2013, 2015 and 2017.
Moreover, the F.R.S.-FNRS is also part of practically all the ERANET COFUND initiatives that permit to
perform basic science in H2020 (EURONANOMED III, ERA-CVD, M-ERANET 2, NEURON, TRANSCAN,
among others) not in the least those that support the Joint Programming Initiatives such as WaterWorks 2014;
WaterWorks 2015; WaterWorks 2017; JPCofund; Urban Europe (Smart Cities and Urban Futures); and FACCE
Surplus and SusCrop.
The F.R.S.-FNRS has been involved in the monitoring of funded projects for E-RARE 2 and is in charge of the
whole monitoring work package for E-RARE 3.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Due to its responsibilities in E-RARE 2 and E-RARE 3, the F.R.S.-FNRS has developed an online monitoring tool,
which will be adapted to perform the monitoring of the EJP-RD projects.
Short Profile of key Staff Members who will be undertaking the work
Dr. Florence Dr. Florence Quist, PhD in Chemistry, is a scientific officer at the Unit of International and
Quist / Female European Affairs in charge of European cooperation, evaluation and monitoring processes. She
has extensive experience in material science through several post-docs and as head of R&D
Development in an SME specialized in recycling photovoltaic material. In this capacity, she was
also responsible for several projects financed by the Walloon region and the European
Commission. Florence complements these experiences with a solid background in management
through a complementary Certificate at Solvay Business School. Florence participates in many
different ERANETs, including E-RARE III, in which the F.R.S.-FNRS is responsible for project
monitoring activities.
Mr. Joël Joël Groeneveld, M.A. in Political Science, is a policy officer at the Unit of International and
Groeneveld / European Affairs in charge of international cooperation and bilateral agreements. He acquired a
Male thorough understanding of project management, monitoring and reporting while working as
Finance and Program Officer for the Institute for Historical Justice and Reconciliation. Prior to
this experience, he successfully pursued a degree in journalism in The Netherlands and performed
extensive editing work as media analyst for Report International in Paris for several years while
studying history. Joël has a wide ranged experience in participating in ERANETs, in particular the
825575 – EJP RD – Part B 63
geographically based FP7 ERANETS, and GENDERNET PLUS
Associated with and E-RARE
document III, where FNRS
Ref. Ares(2018)6091977 is
- 28/11/2018
responsible for monitoring activities.
Dr. Arnaud Dr. Arnaud Goolaerts, PhD in Respiratory physiology/Biophysics and MSc in Geochemistry, is a
Goolaerts / scientific officer at the Unit of International and European Affairs in charge of European
Male cooperation and evaluation and monitoring processes. Prior to coming to the F.R.S.-FNRS, he
was a doctoral fellow at the University of California San Francisco and a Marie Curie Fellow at
the European Respiratory Society in Paris. Arnaud co- leads the monitoring of projects in E-
RARE III and is involved in all biomedical ERANETs. His background in Geochemistry also
allows him to work in more climate related topics. He also leads 2 Scientific Commissions in Life
Sciences and Natural Sciences in the programmes executed by the F.R.S.-FNRS.
List of relevant previous projects or activities, connected to the subject of this proposal
. E-RARE III; ERANET; 2014-2019 – WP Leader for Monitoring of funded projects
. E-RARE II; ERANET; 2010-2014 – Task Leader for Monitoring of funded projects
. Gendernetplus; 2017-2021 – Participant in Monitoring of funded projects
06-FWO
Full legal name (Acronym) – Country Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO) –
Belgium (Flanders)
Principal investigator Dr. Alain Deleener
Relevant Network N/A
Description of the legal entity/department/laboratory/group:
The Research Foundation - Flanders (FWO) is the agency that supports ground-breaking fundamental and strategic
research at the universities and research centres of the Flemish Community. The FWO also stimulates cooperation
between the Flemish universities and other research institutes.
Main tasks in the project per Pillar/WP:
The FWO will limit its active participation to Pillar 1, as project funding – similar to the ERA-NET scheme - is the
main goal of our participation. The FWO will not take up specific tasks within the consortium.
Previous experience relevant to the Tasks:
The FWO participated in several ERA-NETs up to now, on a so-called ‘remote’ basis. This implies that we don’t
take up any ‘Work Packages’. Our participation is mostly limited to the actual funding of our national/regional
research community, besides the administrative basic modalities for participation, e.g.: verifying call docs,
eligibility check, acting as national contact point, providing input for deliverables, etc.
Additionally, the FWO has the required experience with project funding due to its management of application
rounds for projects, fellowships and mobility grants on a yearly basis, and as already mentioned, also the
participation in past joint ERA-calls.
Short Profile of key Staff Members who will be undertaking the work
Dr. Alain Science Policy Advisor Strategic Research Programmes at FWO and responsible - among other
Deleener/ things - for the European SBO-projects (Strategic Basic Research) policy and cooperation within
male FWO.
Dr. Olivier Coordinator Strategy and Policy Cell at FWO and responsible - among other things - for European
Boehme/ male joint programming and cooperation within FWO.
Toon Advisor Research Affairs at FWO and responsible for the general, daily follow-up of joint
Monbaliu/ programming, especially ERA-NET and JPI.
male
07-KU Leuven
Full legal name (Acronym) – Country Katholieke Universiteit Leuven (KU Leuven) – Belgium
Principal investigator Gert Matthijs
Relevant Network EuroGentest-ESHG, MetabERN, EURO-CDG(2), IRDiRC,
Description of the legal entity/department/laboratory/group:
825575 – EJP RD – Part B 64
KU Leuven boasts a rich tradition of education and research thatAssociated
dates back
with six centuries.
document The university’s
Ref. Ares(2018)6091977 basic
- 28/11/2018
research orientation has always been and will remain fundamental research From a basis of social responsibility
and scientific expertise, KU Leuven provides high-quality, comprehensive health care, including specialised
tertiary care, in its University Hospitals. In doing so it strives toward optimum accessibility and respect for all
patients.
KU Leuven is currently by far the largest university in Belgium in terms of research funding and expenditure (EUR
466.55 million in 2016), and is a charter member of LERU. KU Leuven conducts fundamental and applied research
in all academic disciplines with a clear international orientation. In the Times Higher Education ranking KU
Leuven is ranked as the 14th European university, while in the Reuters Top 100 of the World’s most innovative
institutions, KU Leuven is listed as the first European university.
Leuven participates in over 540 highly competitive European research projects (FP7, 2007-2013), ranking sixth in
the league of HES institutions participating in FP7. In Horizon 2020, KU Leuven currently has been approved more
than 260 projects and is ranked sixth HES institution with regard to number of signed grants. To date, the 107 ERC
Grantees (including affiliates with VIB and IMEC) in our midst confirm that KU Leuven is a breeding ground (55
Starting Grants) and attractive destination for the world’s best researchers. In our 229 Actions, of which 111
Initial/European Training Networks, hundreds of young researchers have been trained through research and have
acquired the necessary skills to transfer their knowledge into the world outside academia. In Horizon 2020, KU
Leuven is ranked first institution of higher education with regard to number of MSCA-ITNs ‘(54) and second for
all entities. KU Leuven employs 8,084 researchers on its academic staff (2015). To strengthen international
collaboration, KU Leuven has its own international research fellowship programme and supports international
scholars in international funding applications. KU Leuven Research & Development (LRD) is the technology
transfer office (TTO) of the KU Leuven. Since 1972 a multidisciplinary team of experts guides researchers in their
interaction with industry and society, and the valorisation of their research results (110 spin offs, …) .
The Center for Human Genetics is the largest genetics department in Belgium. The staff includes clinical
geneticists, genetic counsellors, psychologists, laboratory geneticists, principal investigators in research, post-docs,
PhD students, masters, bio-informaticians and technicians (over 200 co-workers in total). The diagnostic activities
focus on rare diseases, with specific interests in intellectual disabilities, multiple congenital anomalies, neurological
and neuro-muscular diseases, nephropathies,cardiopathies, immune deficiencies, genodermatoses, metabolic
diseases and familial cancer syndromes. The laboratories also offer testing for (rare) cancers. The translation
research focusses on the introduction of genomics into medicine.
Main tasks in the project per Pillar/WP:
Pillar 3 WP14 – task 14.2
Standards and quality of genetics/genomics data in laboratory and clinical research practice ;
Leader KU Leuven, Contributor University of Tubingen, ACU RARE, ISS, CMHI, CNAG, INSERM-AMU,
UMCG;
‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are
increasingly confronted with the complexity of genomic data. It is of importance to provide training on the
interpretation of genetic variants and quality standards. We will therefore organize residential courses for scientists,
bio-informaticians and clinicians with an interest in genomic technologies and applications. The aim is to teach
participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the
criteria that have to be set to the NGS analysis pipelines and on the use of international databases. The course will
build on expertise gained by EuroGentest and help in the translation of research tools to diagnostic applications (in
line with the IRDiRC objectives). The impact is on the quality and reliability of NGS results, obtained through rare
disease research. Over the years, the course content will shift to total genome interpretation, which will entail novel
molecular mechanisms for disease and further increase the complexity. Training courses typically host 20-30
participants and last 3-days. It is envisaged to provide the course every year. The courses will travel across Europe:
Rome, Warsaw, Istanbul, Tübingen and Leuven.
Previous experience relevant to the Tasks:
KU Leuven and the Center for Human Genetics have been the coordinator of EuroGentest, a project to harmonize
the process of genetic testing, from sampling to counselling, across Europe. It was funded as a Network of
Excellence (from 2005 to 2010) and as a Coordination action (2011-2013). The ultimate goal was to ensure that
all aspects of genetic testing are of high quality thereby providing accurate and reliable results for the benefit of
the patients. A major part of the activities concerned training and the generation of guidelines for good practice.
Hence, the courses will build on expertise gained by EuroGentest (www.eurogentest.org.
In 2014, EuroGentest has been integrated with the European Society for Human Genetics (ESHG).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The Center for Human Genetics has a genetic clinic, and different diagnostic and research facilities, including a
825575 – EJP RD – Part B 65
Next Generation Sequencing facility (the ‘Genomics Core’ or GC) and bio-informatics
Associated support.
with document Ref. Researchers
Ares(2018)6091977 have
- 28/11/2018
easy access to the animal breeding facilities, microscopy services etc. The laboratories are located on the Health
Sciences Campus in Leuven.
Short Profile of key Staff Members who will be undertaking the work
Gert Pharmacist, PhD in Pharmaceutical Sciences , Laboratory Geneticist. Head of laboratory at the
Matthijs Laboratory for Molecular Diagnosis, Center for Human Genetics .Professor at the Faculty of
(male) Medicine and Faculty of Pharmacy, University of Leuven;Molecular geneticist, involved in the
diagnostics of inherited diseases since 1994. The laboratory offers diagnostic for a large range on rare
diseases. His (translational) research activities deal with the development and validation of novel
technologies for diagnostic use. Currently, the focus is on the implementation of the newest massive
parallel sequencing platforms including whole-genome sequencing for mutation scanning and on the
interpretation of genetic variants. His (fundamental) research interest is in Congenital Disorders of
Glycosylation, a group of rare inborn errors of metabolism. His group has been focusing on the
systematic search for novel types of CDG since 1995. The success is partly due to the fact that the
group has committed itself, since 1999, to the coordination of EUROGLYCANET, a network that has
been funded by the Commission (FP5, FP6). He was the coordinator of EuroGentest, a network for
development, harmonization, validation and standardization of genetic testing in Europe, that was
funded by the European Commission from 2005 until 2013. He is a member of the Diagnostic
Scientific Committee of IRDiRC (International Rare Disease Research Consortium). He was an
alternate member of the Commission Expert Group on Rare Diseases (formally EUCERD). He has
been a scientific committee member for INSERM, AERES, INCa, FNRS, ANR and other granting
agencies. He was active on the steering committee of the Global Genomic Medicine Collaborative
(G2MC), created in 2014.
At the national level, he has been a thriving force for a revision of the reimbursement system for
genetic tests for rare diseases. At the University of Leuven, he has co-coordinated a workgroup on
legal, ethical and societal aspects of total genome analysis. In 2013 and 2014, he has published 2
books about genetics and genomics for the public. He is involved in MetabERN, the European
Reference Network for Hereditary Metabolic Disorders, wherein the Congenital Disorders of
Glycosylation are recognized as one of the disease groups.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Community activity towards the improvement of quality in genetic testing: The EuroGentest ‘Guidelines
for Diagnostic NGS’ have been prepared by a multidisciplinary group of experts and stakeholders.
Guidelines for diagnostic next-generation sequencing, Gert Matthijs et al.,European Journal of Human
Genetics (2016) 24, 2–5 and supplement.
2. Coordination of EuroGentest, a European network for quality in genetic testing, described in
EuroGentest NoE, the ESHG, and genetic services, Jean-Jacques Cassiman, European Journal of Human
Genetics (2017) 25, S47-S49)
3. Evaluation of the use and treats of patents in genetic testing
The European BRCA patent oppositions and appeals: coloring inside the lines, Matthijs G et al., Nature
Biotechnology, 31(8):704-10, 2013.
4. Books on genetics, genomics and rare diseases for a specialized and general readerships
‘Mes Gènes, Mon Identité’ (ISBN:9782804702144, Ed. Mardaga 2014). This book was translated from the
Flemish boek ‘Wat met genetica’ (ISBN 9789401411462, Ed. Lannoo Campus 2013) was written for medical
doctors and other professionals working in the medical field, for interested lay people and for policy makers. The
content was compiled from the work of a multidisciplinary ‘think thank’ about ‘Total genome analysis’ at the
University of Leuven in 2011-2012.
The Human Recipe’ (ISBN 9789462700727, Ed. University Press Leuven), translated from ‘Iedereen GENiaal’
(ISBN 978-94-62101-98-2, Ed. Ballon Media 2014 ), a book really directed towards the public and illustrated by 9
cartoonists, known in Flanders by their cartoons in the newspapers.
825575 – EJP RD – Part B 66
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal):
document Ref. Ares(2018)6091977 - 28/11/2018
Acronyme; Funder; starting year-ending year; role in the project; description
• EuroGentest; Eur.Comm.-FP6-7; Coordinator; 2005-2013
Community activity towards the improvement of quality in genetic testing , EuroGentest started in 2005 as an
network of excellence (NoE) for development, harmonization, validation and standardization of genetic testing
in Europe (www.eurogentest.org). From 2011 to 2013, it was funded as a coordination action (CA).
• TECHGENE; Eur.Comm.-FP7; Partner; 2009-2011
High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical
presentation.TECHGENE was a European integrated project (IP) for the introduction of next generation
sequencing tools in diagnostics.
• EURO-CDG, E-RARE, Coordinator, 2012-2014
A European research network for a systematic approach to CDG and related diseases.
• 3Gb-TEST; Eur.Comm.-FP7; WP Leader; 2013-2015
Introducing diagnostic applications of ‘3Gb-testing’ in human genetics
• EURO-CDG-2, E-RARE, Coordinator, 2016-2018
A European research network directed towards improving diagnosis and treatment of inborn errors of
glycosylation.
08-MEYS
Full legal name (Acronym) – Country Ministry of Education, Youth and Sports (MEYS), Czech
Republic
Principal investigator PhDr. Pavel Doleček, Acting Deputy Minister for Higher
Education, Science and Research
Relevant Network
Description of the legal entity/department/laboratory/group:
Ministry of Education, Youth and Sports (MEYS)
According to the Act No. 130/2002 Coll. on the Support of Research, Experimental Development and Innovation
from Public Funds and on the Amendment to Some Related Acts, MEYS is the central administration authority
responsible for R&D, particularly institutional funding for higher education sector, research infrastructures policy
and funding and international R&D collaboration.
Main tasks in the project per Pillar/WP:
MEYS as a member of EJP and a Beneficiary will contribute to the Pillar 1 in WP 6 as a funding agency
participating in a Joint Transnational Call. Its role and tasks are clearly defined by the description of tasks 6.1. Joint
Transnational Call 2019 – Call co-funded by the EC for three years and 6.2. Joint Transnational Call 2020 – Call
co-funded by the EC for two years. The MEYS will actively cooperate as a participants on following subtasks
analogous for both calls mentioned above:
• Topic selection
• Preparation of the call and establishment of the joint call secretariat
• Evaluation of the joint call and funding decision
• Quality management of call procedures
Previous experience relevant to the Tasks:
MEYS – Department of Research and Development participates in different initiatives supporting international
cooperation in R&D including participation in programme Horizon 2020, ERANets and JPIs (e.g. E-Rare, ERA-
Net QuantERA, HERA, JPND, JPICH, JPI AMR, JPI HDHL, JPI Facce).
Short Profile of key Staff Members who will be undertaking the work
Dr Lukáš Director of the Department of Research and Development in the MEYS. Lukáš Levák was
Levák (male) appointed Director of Department for Research and Development in 2014. His current duties and
responsibilities comprise particularly formulation and implementation of the strategy for cross-
border and international cooperation of the Czech Republic in R&D, mainly within the European
Research Area, and defying the research infrastructures policy of the Czech Republic.
Renata Hrubá Ing. Renata Hrubá works in the Department of Research and Development in the Unit of the
(female) European Research Area in the MEYES.
825575 – EJP RD – Part B 67
List of the most relevant publications and/or products, servicesAssociated
(including widely-used
with document datasets or software),
Ref. Ares(2018)6091977 - 28/11/2018
or other achievements :
In 2015, Lukáš Levák was the main co-author of “Roadmap of the Czech Republic of Large Infrastructures for
Research, Experimental Development and Innovation for the years 2016-2022”. In 2016 he was the main
coordinator of preparation of the “ERA Roadmap of the Czech Republic for the years 2016-2020”. Since 2014 he is
the leading delegate of the Czech Republic to the ERAC (European Research Area and Innovation Committee). His
major current tasks consist mainly in further alignment of the Czech research infrastructures policy with the ESFRI
(European Strategy Forum on Research Infrastructures) good practice examples and in updating the Czech national
large research infrastructures roadmap (to be accomplished in 2018). Regarding the further integration of the Czech
research and innovation system into the European Research Area, the major challenges of Department for Research
and Development comprise strengthening the participation of the Czech Republic in Joint Programming process.
As for the Czech national R&D policy, the Department of Research and Development will focus on preparation of
an overarching national strategy of the Czech Republic for development of human resources and gender equality in
R&D.
List of relevant previous projects or activities, connected to the subject of this proposal :
Department of Research and Development supports and funds the Czech research community in different
international initiatives, the most relevant to the EJP are ERANets and JPIs (e.g. E-Rare, JPND, JPI AMR,JPI
HDHL,).
09-MoSAE
Full legal name (Acronym) – Country Ministry of Social Affairs of Estonia (MOSAE), Estonia
Principal investigator Heli Paluste
Relevant Network
Description of the legal entity/department/laboratory/group:
The Ministry of Social Affairs (MOSAE) is a government agency. The MOSAE area of government includes the
preparation and implementation of national strategies in the field of public health and health care, social security
and welfare, employment, the labor market, the working environment, the promotion of equal treatment and the
promotion of equality between women and men and the coordination of children's rights and families promotion of
quality of life, promotion and support of sporting activities of people with disabilities and drafting of relevant
legislation.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will provide in cash contribution to Pillar 1 co-funded calls: earmarked funds for co-funded call 1: 25
000 euros for 2019, 25 000 euros for 2020, 25 000 euros for 2021 (task 6.1)
Previous experience relevant to the Tasks:
The tasks of the Ministry of Social Affairs of Estonia in the area of research and development are:
a) the organization of the research and development activities necessary for its area of government and its
financing, taking into account the results of the evaluations and the related assessments and
recommendations;
b) justification and appointment of funds necessary for the financing of R & D activities within its area of
government in the preparation of the budget draft of the government area and approval of budgets of
these research and development institutions in the amount of the state budget allocated to the amount
allocated to research and development within the area of government.
Short Profile of key Staff Members who will be undertaking the work
Dr/ Heli Head of Health Care Unit, MD
Paluste/F Department of Health System Development
MOSAE
Ms/ Angela Research Adviser for Health Policy,
825575 – EJP RD – Part B 68
Ivask/F Analysis and Statistics Department Associated with document Ref. Ares(2018)6091977 - 28/11/2018
MOSAE
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. National Health Plan 2009–2020
2. Estonian health system research and development and innovation strategy 2015-2020
3. Estonian eHealth Strategic Development Plan 2020
4. Estonian Rare Disease Development Plan
5. Estonian Health Care System Roadmap 2020
List of relevant previous projects or activities, connected to the subject of this proposal
2 hospitals from Estonia are the members of ERN-s.
Tartu University Hospital is a member of ERN-ENDO and ERN-BOND. East Tallinn Hospital is a member of
ERN-EYE.
10-AKA
Full legal name (Acronym) – Country Suomen Akatemia (AKA) - Finland
Principal investigator Heikki Vilen
Relevant Network
Description of the legal entity/department/laboratory/group:
The Academy of Finland’s mission is to fund high-quality scientific research, provide expertise in science and
science policy, and strengthen the position of science and research. We are an agency within the administrative
branch of the Finnish Ministry of Education, Science and Culture. We work to contribute to the renewal,
diversification and increasing internationalisation of Finnish research. Our activities cover the full spectrum of
scientific disciplines.
We support and facilitate researcher training and research careers, internationalisation and the utilisation of research
results. We are also keen to emphasise the importance of research impact and breakthrough research. We therefore
encourage researchers to submit boundary-crossing applications that involve risks but also offer promise and
potential for scientifically significant breakthroughs. Each year, our funding contributes to some 2 700 people’s
work (FTEs) at universities and research institutes.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will take part in the transnational research funding calls (task 6.1)
Previous experience relevant to the Tasks:
The Academy of Finland has participated in several ERA-NETs and joint calls. For example, in recent years the
Academy of Finland has participated in the calls of JPco-fuND, ERA-NEURON, E-RARE and JPI-AMR.
Short Profile of key Staff Members who will be undertaking the work
Dr. Heikki Vilen Science Adviser in Health Research Unit of the Academy of Finland, highly experienced in
(male) organizing peer-reviewed research panels. Currently, he is the AKA representative in the Call
Steering Committee of E-RARE3.
List of relevant previous projects or activities, connected to the subject of this proposal :
The Academy of Finland has participated / is currently participating in the JTC2017 and JTC2018 calls of the rare
diseases research Era-NET E-RARE3
11-ANR
Full legal name (Acronym) – Country French National Research Agency (ANR)
Principal investigator Dominique Dunon-Bluteau
Relevant Network E-Rare
Description of the legal entity/department/laboratory/group:
The French National Research Agency (ANR) was established by the French government in 2005 to fund research
projects, based on competitive schemes giving researchers the best opportunities to carry out their projects and
paving the way for ground-breaking new knowledge. The main mission of ANR is to fund the best basic research,
but also targeted and applied research in particular through partnerships between companies and public sector
laboratories. Its action is thus intended to support French research excellence at both academic and technological
825575 – EJP RD – Part B 69
levels by means of a rigorous selection process based on evaluation by peer
Associated withreview.
documentFinally, it is also the- ANR's
Ref. Ares(2018)6091977 28/11/2018
mission to strengthen international cooperation by contributing in particular to the funding of international
consortia in partnership with other funding agencies in Europe and beyond. ANR funds are available in all
scientific fields, for both fundamental and industrial research. Since 2010, ANR has also been the principal
operator of the Investments for the Future programme in the field of higher education and research. In this role it
ensures the selection, funding and monitoring of projects relating to the centres of excellence, health,
biotechnologies, and the transfer of technology and the creation of value from research. Since its inception in 2005,
the ANR agency awarded approximately 15,600 grants investing 6,5 billion €. In 2016 for example, 1,257 projects
were awarded for an amount of 595,5 M€.
Developing European and international collaborations is one of the priorities of the ANR. The ANR has
participated/is participating in multiple ERA-NETs, CSAs and JPIs. Currently the Health & Biology Department is
contributing to 13 ERA-Nets (JPI-EC-AMR, SEA-EU-NET, ERA-HDHL, HDHL INTIMIC, JPI-JPcofuND,
NEURON, FLAG-ERA II, ERA-CVD, ERACoSysMed, ERA PerMed, EuroNanoMedIII and E-Rare-3) and
coordinates two of them (E-Rare and ERA-HDHL). ANR also participates in 3 JPIs (JPND, JPAMR, JPI HDHL),
as well as other type of collaborative initiatives like IC PerMed or CRCNS (computational neurosciences).
In the context of rare diseases, the ANR has funded research projects through the generic programme and thematic
programmes not focused on rare diseases, but also thanks to a dedicated yearly thematic call (MRARE, in 2005,
2006 and 2007). Between 2005 and 2017 a total of 496 research projects related to rare diseases have been funded
with a budget of 177.6 M€. At the transnational level, the ANR participates in E-Rare since 2007 and coordinates
the programme since 2014. In this context, 89 E-Rare projects with French researchers were financed (17,74 M€ of
ANR budget + 2,24 M€ other resources [EC and DGOS]). In addition, the ANR is a member of the IRDiRC
Executive Committee since its inception. Through its involvement in the EJP RD, ANR will continue its strong
involvement and support for rare diseases research.
Main tasks in the project per Pillar/WP:
Pillar 1:
WP6: ANR intends to participate in the two EC co-funded joint transnational calls (2019, 2020) with the budget of
6 M€ (3 M€ per call) and two non-cofunded calls (2021, 2022; budget to be defined). In addition, ANR will act as
joint transnational call 2020 secretariat, which involves the preparation of the call, the establishment of the joint
call secretariat and the implementation of the call.
WP9: ANR will support WP and Task leaders in the monitoring activities by providing necessary information on
the financed projects with FR components.
Coordination and transversal activities
WP1 (Coordination): As future member of the EJP RD Consortium, ANR will participate in the prioritization
strategy, preparation of the Annual Work Plans and Summary Reports. ANR will be also involved in the activities
related to the translation of the EJP RD outcomes and alignment at national level (for example through its
participation in National Mirror Group).
WP5 (Communication and dissemination): ANR will contribute to the dissemination and communication activities
of the EJP RD in order to strengthen the capacity of outreach at national level.
Previous experience relevant to the Tasks:
As mentioned above ANR (Department of Health & Biology) is currently coordinating E-Rare-3. ANR was also
responsible for two JTC secretariats (2011, 2016) and in addition was actively involved in the preparation of all
previous E-Rare calls (calls documents’ preparation, selection, monitoring and evaluation of projects). Thus, the
experience necessary to overtake the responsibilities foreseen in Pillar 1 is already acquired and available at ANR.
In addition, ANR is an active actor in the field of rare diseases at national level by participating in the 2nd Rare
Diseases National Plan and as member of the Rare Diseases Mirror Group specifically created by the French
Ministry of Research to reflect the needs and align the activities of French stakeholders with EJP RD plans.
Short Profile of key Staff Members who will be undertaking the work
Prof. Dominique PhD, director of the Biology and Health Department at the ANR, worked for 20 years at the
Dunon-Bluteau University Pierre and Marie Curie (UPMC) and CNRS as a group leader in developmental cell
(male) biology. In parallel of his scientific activities, he was dean of the Faculty of Biology at UPMC
and member of the HCERES (French Agency for evaluation). He became scientific adviser at
the French Embassy in Switzerland and then member the Cabinet of Minister of French Higher
Education and Research as scientific adviser for Biology and Health. Recently, he was
scientific deputy director at Institute of Biology (CNRS) in charge of interdisciplinary research
programme implementation. As the head of department, he supervises the involvement of ANR
in 3 joint programs (JPI), 10 ERA-NETs and multilateral projects.
ANR scientific ANR scientific project manager (yet to be defined).
825575 – EJP RD – Part B 70
project manager Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Ms Blandine Ms Castrillo joined the ANR in 2016 as administrative & financial officer for ERA-NETs. She
Castrillo graduated in European Project Management from the University of Cergy-Pontoise (UCP) and
(female) has been working since then at ANR. She currently assists the ANR’s scientific project
managers and coordinators on the administrative and financial management of European
projects of the Biology and Health Department and the Digital Technology and Mathematics
Department of ANR. She will be the administrative and financial officer for EJP RD at ANR.
List of relevant previous projects or activities, connected to the subject of this proposal:
E-Rare-1 (2007 – 2011), GA036248
E-Rare-2 (2011 – 2014), GA266608
E-Rare-3 (2014 – 2019), GA643578
Member of IRDiRC, International Rare Diseases Research Consortium.
12-FFRD
Full legal name (Acronym) – Country French Foundation for rare diseases (FFRD)
Principal investigator Roseline Favresse
Relevant Network N.A.
Description of the legal entity/department/laboratory/group:
FFRD is a unique cooperative framework coordinating research resources and expertise in the RD field. Flagship of
the 2nd French National Rare Diseases Plan, with a growing team of 15 people, FFRD acts as a federative hub to
fund research and accelerate scientific, clinical and social innovation by stimulating cross-sector cooperation
towards effective healthcare to the benefit of RD patients. Its active financial support spans from biomedical
sciences to Social Sciences and Humanities. Since its creation in 2012, FFRD has funded 325 projects (out of 994
submitted) for a cumulated amount of 9,4M€ (30 calls for proposals). With headquarters located in Paris, FFRD
also relies on a team of seven regional field coordinators in direct contact with academic and clinical teams all over
the national territory to ensure that priorities are driven by grounded needs. FFRD main objectives include:
accelerating the translation of research into clinical development; detecting business development opportunities;
enhancing access to innovative technologies; facilitating cross-sector partnerships. With its close contacts with
academic researchers and clinicians in the field, FFRD is contributing to early identification of proofs of
therapeutic concept and making links with other partners in the research value chain, namely SMEs, Pharmas, and
TTOs.
Main tasks in the project per Pillar/WP:
Pillar 1:
- In WP6 (Joint Transnational Calls for collaborative research projects) FFRD will be task leader for Task 6.3 Joint
Transnational Call 2021 (JTC 2021): call not co-funded by the EC.
- In WP8 (Rare Disease Research Challenges), FFRD will coordinate the WP and be involved in task 8.1:
Development of the scheme as participant and as task leader for task 8.2: Set-up of challenges; task 8.3: Call for
proposals, evaluation and selection of proposed projects for solutions in first phase; task 8.4: Call for proposals,
evaluation and selection of proposed projects for solutions in second phase and task 8.5: Management of the
funding resources, establishment of contracts and distribution of funding to selected projects.
- In WP9 (Monitoring of funded projects), FFRD will participate to task 9.1: Monitoring of Joint Transnational
Calls for collaborative research projects and will co-lead task 9.3: Monitoring of Rare Disease Research Challenge
Pillar 3:
- In WP16 (Online academic education course), FFRD will coordinate the WP (task leader on task 16.1: Assess the
needs, target audience, main topics of the academic education course and task 16.2: Developing the online course
and task participant in task 16.3: Follow-up, assessment and monitoring of the course).
- In WP18 (Development and adaptation of training activities), FFRD will co-lead task 18.1: Evaluation of
developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities and
be task participant in task 18.2: Evaluation of strategic priorities and development of existing training activities
according to specific needs of EU-13 countries.
Pillar 4:
In WP19 (Facilitating partnerships and accelerating translation for higher patient impact), FFRD will be involved
as task participant in task 19.2: Development and exploitation plan and task 19.3: Follow-on funding.
Previous experience relevant to the Tasks:
FFRD has developed a French inter-University diploma on RD translational research in 2014-2015 together with 5
825575 – EJP RD – Part B 71
French Universities (hence its coordination of WP16/Pillar 3 and participation
Associated within WP18/Pillar
document 3).
Ref. Ares(2018)6091977 - 28/11/2018
FFRD coordinates a group of pharmaceutical and biotech companies that have an interest in the early identification
and promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic
Concepts” Club) (hence its coordination of WP8/Pillar 1 and participation in WP19/Pillar 4).
FFRD has successfully handled multiple calls for proposals both in Biomedical Sciences and Social Sciences and
Humanities (hence its involvement in Pillar 1 in the management and monitoring of Calls for proposals)
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work:
FFRD has a significant background in launching, managing and monitoring calls for proposals (from start to
closure). More than 325 grants have been awarded at the French national level for above 9,4M€ in approved
funding since the launch of FFRD in February 2012.
More than 1000 external experts have been involved in reviewing applications, more than 2500 evaluations have
been performed and 50 expert committees organised. FFRD is working with a renowned service provider (eVision)
for electronical submission of projects.
Short Profile of key Staff Members who will be undertaking the work
Ms.Roseline Favresse Roseline Favresse has an academic background in Social Sciences and Humanities in
(female) France and Canada (MA in Geopolitics from Sorbonne University and Ecole Normale
Supérieure (Paris). She is specialized in the set-up, development and management of
international research projects & capacity-building programs in Europe and worldwide.
While working for international organizations, NGOs and consulting companies, she has
developed a strong knowledge of EU public policies and funding schemes/instruments.
For 9 years now, she has been working in the RD field, first as a consultant by setting-up
and managing FP6/FP7/H2020 projects (incl. TREAT-NMD) in answer to EC Calls for
proposals; then, at FFRD since 2012 where she is coordinating international involvement
of FFRD and also acting as a Regional Coordinator helping clinicians and researchers
speeding up their RD development projects for new medicines.
Dr. Christine Fetro Dr Christine Fetro is a Pharm. D. specialized in Clinical Pharmacy, Regulatory Affairs
(female) (MSc) and Public Health. She started working at Canadian and French hospitals with
involvement in effective medication management and clinical trials. She then worked for
20 years in the pharmaceutical industry holding various positions in the area of public
and medical affairs at an international level. As a medical affairs manager (OPI/Eusa)
she had the opportunity to focus on RD and orphan drugs challenges and develop a
medical and regulatory strategy to register a drug in the Lambert Eaton syndrome. At
FFRD, she coordinates the group of pharmal companies with a common interest in RD
and early identification of PoC from academic researchers. The main objective is to build
successful partnerships between academia and industry.
Dr. Ingrid Zwaenepoel Dr Ingrid Zwaenepoel has obtained a PhD in Human Genetics with a Cell and Molecular
(female) Biology specialty. She managed research projects at the Pasteur Institute (Paris), the
Faculty of Medicine (Geneva) and Curie Institute (Paris). Since 2012, as the FFRD
Scientific policy officer, she animates and implements the Scientific Policy, by
coordinating in close interaction with the Scientific Advisory Board, calls for proposals
in Biomedical Sciences as well as Social Sciences and Humanities and by managing
partnerships with technological platforms and providers.
Prof. Daniel Scherman Prof Daniel Scherman is a Member of EURASC (European Academy of Sciences) and
(male) Head of its Division Medicine and Life Sciences. As FFRD Director, he is in close
relationship with the main EU pharmaceutical companies involved in RD, with which
common actions are undertaken, such as: co-development of PoC projects, research
funding and linking academics with pharma/biotech companies. His academic production
is of 490 publications, h index: 62, 16 000 quotations without self-citations. Most of his
recent works concern the field of RD, such as Mucopolysaccharidoses of types III-A
(Sanfilippo) and VII (Sly), Duchene Muscular Dystrophy, and Leber congenital
amaurosis. Prof Scherman has coordinated the FP6 MOLEDA Project (Molecular
optimization of laser/electrotransfer DNA administration into muscle and skin for gene
therapy) (2005-2008) and the TRANSPOSMART E-Rare2 Project (An innovating
platform using transposon and S/MAR for von Willebrand disease gene therapy) (2012-
2015).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
825575 – EJP RD – Part B 72
1. French inter-University diploma on RD translational research setAssociated
up in 2014
with with 5 French
document Universities. - 28/11/2018
Ref. Ares(2018)6091977
2. FFRD group of pharmaceutical and biotech companies that have an interest in the early identification and
promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic Concepts”
Club). Launched in April 2017, the club has led to a series of meetings and first partnerships are being concluded
between researchers and companies.
3. Five to seven annual calls for proposals for boosting RD research in the fields of NGS, animal model,
translational research, HTS and Social Siences and Humanities.
List of relevant previous projects or activities, connected to the subject of this proposal:
. RD-Connect; H2020, European Commission; 2012-2018; at FFRD, R. Favresse is responsible for inventorying
tools developed by RD-Connect in the "–omics" field within the Impact WP.
. IRDiRC: FFRD is a member of the IRDiRC Consortium Assembly as a Funding organisation.
13-AFM
Full legal name (Acronym) – Country AFM Téléthon (Association Française contre les Myopathies),
France
Principal investigator Alexandre MEJAT
Relevant Network ERN-EuroNMD, Orphanet
Description of the legal entity/department/laboratory/group:
AFM-Téléthon is a French neuromuscular disease patient association funding research on rare genetic diseases and
supporting development of innovative biotherapies such as cell and gene therapies. It also supports and manages
three Institutes of research: Genethon (Evry, France) dedicated to gene therapy development; I-Stem (Evry, France)
dedicated to stem cell therapy and drug screening; and the Institute of Myology (Paris, France) dedicated to clinical
research, medical follow-up and clinical trial management for neuromuscular diseases.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP8 (Rare Disease Research Challenges), we will participate to the workshops implicating industries and
stakeholders to identify the specific challenges related to research on rare diseases (Task 8.1) and to the committee
approving the Challenges (Task 8.2).
Pillar 4:
In WP19 (Facilitating Partnerships and accelerating translation for higher patient impact), we will provide our
expertise to advise and support projects approaching the end of EC funding (Task 19.2) and participate in the
definition of a funding platform dedicated to rare diseases in collaboration with FTELE and EATRIS (Task 19.4).
In WP20 (Accelerating the validation, use and development of innovative methodologies tailored for clinical trials),
AFM Telethon Medical Affairs department and Institute of Myology (Third party) will provide experts reinforcing
the “Task force group on clinical trials” (Task 20.1) and help more particularly in Subtask 20.1.3 “Mapping
existing methodologies and prioritize the needs for demonstration or innovative methodologies for clinical studies
in rare diseases”.
Previous experience relevant to the Tasks:
AFM-Téléthon has been creating and developing its own research and development platforms (Genethon and I-
Stem) dedicated to research on rare diseases to address unsolved issues in terms of innovative biotherapies
development (Pillar 1 – WP 8). It also initiated, in collaboration with the French Bank for Investment (BPI
France), its own investment fund investing 50M euros to support 6 start-ups companies dedicated to early stage
of research in rare diseases. Moreover, AFM Telethon established research partnerships with several
pharmaceutical companies in the field of rare diseases (Pillar 4 – WP 19).
AFM-Téléthon and its associated Institute of Myology have developed innovative devices (MyoTools)
generating new outcome measures dedicated to the validation of therapeutics approaches implicating mobility
limitations (Pillar 4 – WP20).
825575 – EJP RD – Part B 73
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
AFM-Téléthon manages and financially supports three Institutes dedicated to the development of innovative
biotherapies (Gene therapy in Genethon and Stem cells in I Stem) and to the clinical trials (Institute of Myology)
for rare genetic diseases.
Short Profile of key Staff Members who will be undertaking the work
Dr Alexandre Alexandre MEJAT is a patient and a PhD in molecular and cellular biology by training. He is in
MEJAT (Man) charge of the International Scientific Affairs at the scientific department of AFM Telethon. He
was a member of the Board of AFM Telethon (2010-2017) and of the I Stem Institute (2004-
2017).
Dr Sandrine Sandrine SEGOVIA-KUENY is Director of the Medical Affairs department at AFM-Telethon.
SEGOVIA- Medical doctor and PhD in legal affairs by training, Dr Segovia-Kueny has been previously vice-
KUENY director of a French Regional Health Agency (ARS).
(Woman)
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements (max 5)
1. MyoTools description and use: Upper limb strength and function changes during a one-year follow-up in non-
ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.
Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck
N, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Maincent K, Desguerre I, Thémar-Noël C, Cuisset JM,
Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L.
PLoS One. 2015 (Fév).10(2) : e0113999.
2. Motor Function Measure : http://www.motor-function-measure.org/home.aspx
3.
4.
5.
List of relevant previous projects or activities, connected to the subject of this proposal (max 5):
- AFM Téléthon has been at the initiative, in collaboration with INSERM, of the Orphanet portal.
- AFM Téléthon has been at the initiative of Eurordis creation.
14-IMAGINE
Full legal name (Acronym) – Country Institut des Maladies Génétiques Necker Enfants Malades
(IMAGINE), France
Principal investigator Stanislas Lyonnet
Relevant Network EURORDIS
Description of the legal entity/department/laboratory/group:
Imagine is a research institute dedicated to the study of genetic diseases. Its main objective is to integrate research
into clinical practice in order to better understand genetic diseases with unmet medical needs, and to propose and
validate diagnostic and therapeutic approaches. The study of genetic diseases is fed by knowledge of fundamental
biological mechanisms, and in reverse may uncover novel biological concepts. This vision can be considered
according to four core missions: patient-focused research; innovative care; education and training; and technology
transfer.
The Innovation and Technology Transfer Department of Imagine supports the development of public-private
partnership and the valorization of the academic research performed in the institute.
Main tasks in the project per Pillar/WP:
Pillar 3:
In WP14, we will provide a number of cases to ISS for the 3-day training course. We will also be involved in the
follow-up phase (task 14.3)
In WP15, we will provide in-kind facilities plus on-site visits to genetic labs, bioinformatics, animal facilities and
interactive discussions with research teams during the training for patient advocates on scientific innovation and
825575 – EJP RD – Part B 74
translational research aspects in rare diseases (task 15.2) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Previous experience relevant to the Tasks:
The institute is focused on genetic diseases and is involved in the organization of several courses dedicated to rare
genetic diseases, with academic and private partners.
Imagine institute already hosts the Eurordis Winter School. Indeed, Imagine institute for Genetic Disease is
perfectly relevant to the topic of this Winter School. The institute provides speakers and in-kind facilities.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work:
Imagine institute is located in the middle of Paris and is fully accessible to people with disabilities. The laboratories
and facilities are located in the same place and can be visited by all the participants of the training.
Short Profile of key Staff Members who will be undertaking the work
Pr.Lyonnet Stanislas Director of Imagine Institute
(male)
Marlange Romain Head of Innovation and Technology Transfer Department
(male)
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
- Hosting of the Eurordis Winter School
- Organization of a Master Class program on rare diseases with a large pharma company
- Participation to the training program EUR-GENE with Descartes University
- Organization of the Master “Bioentrepreneurs” with Ecole Polytechnique, HEC Paris and Descartes
University
List of relevant previous projects or activities, connected to the subject of this proposal:
- Several research projects focused on rare diseases are coordinated by Imagine, some funded by institutional
partners (RHU C’IL-LICO funded by ANR on ciliopathies, others by foundations such as MSD-Avenir on
developmental disorders.
- Imagine institute is coordinator of a DIM project, funded by the “Ile-de-France” region, which supports a
major interest area, the gene therapy, capitalizing on the expertise acquired by academic, hospital,
industrial, associative and socio-economic actors of the “Île-de-France” region.
- Imagine is partner of the SeqOIA (Sequencing, Omics, Information Analysis) pilot project for very high-
throughput health sequencing platforms, of the Plan France Médecine Génomique 2025 which promotes
the implementation and prospective over 10 years of the conditions of access to genetic diagnosis in
France.
15-DLR
Full legal name (Acronym) – Country Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Germany
Principal investigator Dr. Ralph Schuster
Relevant Network ERA-Net E-Rare
Description of the legal entity/department/laboratory/group:
DLR is a non-governmental, non-profit German research organisation. Its Project Management Agency DLR-PT is
mandated by the Federal Ministry of Education and Research (BMBF) and other ministries with regard to
implementation and management of governmental programmes for research funding. Being a trustee for the
funding budget, PT-DLR administrates, with a staff of over 1000, more than one billion € of research funding p.a.
Fields covered – amongst others – are information technology, education, environment, and life sciences. Within
the life sciences, the “health research” department of DLR-PT manages the areas of clinical research and
biomedical research for BMBF, administrating a total of more than 200 million € annually in several governmental
programmes aiming at fostering all areas of health research, health related research infrastructure as well as
internationally competitive research.
Main tasks in the project per Pillar/WP:
Pillar 1: we will be responsible for co-leading Pillar 1 activities
In WP6, we will be responsible for leading the WP and for leading and performing the first Joint Transnational Call
(task 6.1)
In WP8, we will contribute to planning and implementing the Rare Disease Challenge (tasks 8.1-8.3)
In WP9, we will contribute to the monitoring of the Joint Transnational Calls (task 9.1) and the Rare Disease
Research Challenge (task 9.3)
825575 – EJP RD – Part B 75
Pillar 0: Coordination and transversal activities: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
In WP1, we will contribute to the management as part of the operating group and the executive committee (task
1.2, 1.3, 1.4).
In WP2, we will we will contribute to the strategy development as part of the operating group and the executive
committee (task 2.2, 2.4)as well as one of the responsible task leaders for one of the Joint Transnational Calls (task
2.3).
In WP3, we will contribute to the sustainability development as part of the operating group (task 3.1).
In WP4, we will contribute to the ethical, regulatory, legal and IPR framework as part of the operating group and
(task 4.2).
In WP5, we will contribute to the communication and dissemination as part of the operating group (task 5.1).
Previous experience relevant to the Tasks:
On behalf of BMBF, the “health research” department of DLR-PT has already participated in E-Rare1-3 and
managed 3 of the 10 joint call secretariats for the transnational calls implemented within these three ERA-Nets.
Additionally, it is currently acting as coordinator of the ERA-Nets NEURON and ERA-CVD, and has participated /
is participating in a number of other health research related ERA-NETs (e.g. TRANSCAN, HIVERA, ERA
PerMed) and Joint Programming Initiatives (JPND, HDHL). Other departments of DLR-PT are coordinating or
participating in many other ERA-Nets, and there are regular meetings dedicated to discuss the experience with the
various ERA-Nets. DLR-PT is also involved as a partner in ERA-LEARN. Also, DLR-PT manages a large and
growing number of transnational calls both within and outside of ERA-Nets and JPIs for BMBF, and is serving as
call secretariat for many of them. Relevant know-how is pooled, and very experienced personnel available.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
DLR-PT has developed the online proposal submission and evaluation tool PT-Outline which has been and will be
used for managing the joint transnational calls. This tool is also available for the management of other research
funding schemes in the EJP RD.
Short Profile of key Staff Members who will be undertaking the work
Dr. Ralph Dr. Ralph Schuster obtained his PhD in biology at the University of Gießen in 2000 with studies
Schuster on the molecular biology of the hepatitis B virus. In 2001 he joined the DLR-PT as a scientific
(male) officer. Since then, he has been involved in several funding programmes including rehabilitation,
genomics and rare disease research. Since 2004, he is the coordinating scientific officer for the
national rare disease research funding programme. He participated from the start in setting up the
ERA-Net E-Rare and coordinates the German efforts in this network. He has been co-chair of the
E-Rare network steering committee since 2013. In addition, he is involved in the national action
league for people with rare diseases (NAMSE) which drafted the national plan for people with
rare diseases in Germany. He is also member of the IRDiRC consortium on behalf of the BMBF.
Dr. Michaela Dr. Michaela Fersch obtained her PhD in biomedicine at the University of Bonn in 2009 working
Fersch on immunoregulation in the liver. After a 2-year post-doc she joined the DLR Project
(female) Management Agency (DLR-PT) in 2011. Since then she has been involved in several funding
programmes including clinical studies, health services research on aging, integrated research and
treatment centers as well as rare disease research. Within the programmes of rare disease research
she worked on the national funding initiative as well as in the ERA-Net E-Rare. In addition, she is
involved in the national action league for people with rare diseases (NAMSE).
Dr. Katarzyna Dr. Katarzyna Saedler obtained her PhD in genetics at the University of Cologne in 2015 working
Saedler on the genetic mechanism of adipositas and cancer. Completing her PhD work during a short
(female) post-doc she joined the DLR Project Management Agency (DLR-PT) in 2017. Since then she has
been involved in several funding programmes including clinical studies, child and youth health,
integrated research and treatment centers as well as rare disease research. Within the programmes
of rare disease research she worked on the national funding initiative as well as in the ERA-Net E-
Rare.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Joint call secretariats for E-Rare calls in 2009, 2013, 2015
2. Participation in E-Rare 1-3
3. Participation in IRDiRC consortium
4. Involvement in drafting the national action plan for rare diseases
5. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I,
Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of
international collaboration for rare diseases research: a European perspective.
825575 – EJP RD – Part B 76
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal
document :
Ref. Ares(2018)6091977 - 28/11/2018
. E-Rare; European Commission; 2006-2010, participating in all activities and the 2 joint transnational calls,
management of the 2009 Joint Transnational Call
. E-Rare-2; European Commission; 2010-2014 participating in all activities and the 4 joint transnational calls,
management of the 2013 Joint Transnational Call, co-chair of the Network steering committee since 2013
. E-Rare-3 co-fund; European Commission; 2014-2019- participating in all activities and the 4 joint transnational
calls, management of the 2015 Joint Transnational Call, co-chair of the Network steering committee
16-UKA
Full legal name (Acronym) – Country Universitätsklinikum Aachen (UKA), Germany
Principal investigator Prof. Dr. rer. Nat. Ralf-Dieter Hilgers
Relevant Network IDeAl
The University Hospital Aachen combines consistent patient care, efficient teaching and innovative research. The
building of UKA combines the hospital, the Medical Faculty and dentistry and is a place for collaboration of
physicians, scientists and engineers. Currently around 2.700 students in medicine and dentistry are studying at the
Medical Faculty of RWTH Aachen University. At the moment 59 professors, 824 scientific assistants and 4.347
non-scientific employees work together in 34 clinical departments and 23 institutes and administration facilities.
The Department of Medical Statistics (IMSA) being part of the Medical Faculty of the RWTH Aachen University
was founded in 2001. Nowadays the team consists of 1 professor, 1 assistant professor, 3 scientist, 3 non scientific
employees, secretary and 10 student workers. Since 2013 the department coordinated the FP7 funded IDeAl project
(No. 602552).
Main tasks in the project per Pillar/WP:
Professor Ralf Dieter Hilgers is co-lead of WP20 in Pillar 4 and recognizes the corresponding responsibilities
resulting from the work and results of this work package.
He contributes as member of the TFG to task 20..1, and perhaps provides research in projects of task 20.3 and20. 4.
He also interacts with ECRIN in task 20.2.
Previous experience relevant to the Tasks:
Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical
methodologies in the design and analysis of small population clinical trials.
Among other dissemination activities IDeAl results in around 70 peer reviewed publications (www.ideal.rwth-
aachen.de).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical
methodologies in the design and analysis of small population clinical trials. He has IPP rights of the developments.
Within his department of medical statistics at UKA, computer resources are available to conduct the proposed
activities within the EJP. He will be assisted by Professor Dr. rer. medic Nicole Heussen the co-lead and senior
statistican of the IDeAl project.
Short Profile of key Staff Members who will be undertaking the work
Dr. Ralf Dieter Hilgers Professor who studied mathematics at RWTH Aachen University. He finished his
(male) doctoral thesis at the statistical faculty of the University of Dortmund in 1991.
In 2000 he received the Venia Legendi for Medical Statistics at the University of
Cologne. Since 2001 he is head of the Department of Medical Statistics (IMSA) at the
Medical Faculty, RWTH Aachen University. His research interest is in optimal design
of experiments, randomizations procedure and clinical trials. Since 1987 he gives
biostatistical advice to clinical and experimental trials in all clinical and preclinical
areas.
Professor Hilgers teaches 300 students in different bio-scientific areas per year and is
responsible for the education of investigators in clinical trials. He also acts as reviewer
for methodological and clinical journals with main focus on surgical trials. He was
coordinator of the IDeAl project funded by the European Community (www.ideal.rwth-
aachen.de) form 2013-2017, which established new methodologies for small population
group trials.
Pr. Nicole Heussen Professor Dr, Nicole Heussen (female) is a biostatistician. She graduated in Statistics at
825575 – EJP RD – Part B 77
(female) the University of Dortmund and received her PhD
Associated in theoretical
with document medicine (2004)
Ref. Ares(2018)6091977 and
- 28/11/2018
the habilitation with venia legendi for Medical Biometry and Clinical Epidemiology
(2012) from the Medical Faculty at RWTH Aachen University.
In April 2016, she was appointed to a professorship for Evidence Based Medicine at the
Medical School of the Sigmund Freud University in Vienna. Her research interest
centres around the design of pre-clinical studies and randomization based inference.
She provides statistical input into clinical development plan, project objectivities,
experimental design, and data analysis since 1998. Currently she is working as a
researcher and teacher for biostatistics and related areas in Aachen and Vienna.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. Hilgers RD., Bogdan M., Burman CF., Dette H., Karlsson M., König F., Male Ch., Mentré, F.,
Molenberghs, G., Senn, SJ.: Lessons learned from IDeAl — 33 recommendations from the IDeAl‐Net
about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases (under
review)
2. Hilgers, R.-D., Uschner, D., Rosenberger, W. F., Heussen, N.: ERDO – a framework to select an
appropriate randomization procedure for clinical trials. BMC Medical Research Methodology, 4. December
2017.
3. Hilgers, R.-D., König, F., Molenberghs, G., Senn, S.: Design and analysis of clinical trials for small rare
disease populations. Journal of Rare Diseases Research & Treatment. Volume 1. Issue 3. pages 53-60.
November 2016.
4. Reetz, K., Dogan, I., Hilgers, R.-D., Giunti, P., Mariotti, C., Durr, A., Boesch, S., Klopstock,
T., Rodriguez de Rivera, F., Schöls, S., Klockgether, T., Bürk, K., Rai, M., Pandolfo, M., Schulz,
J.: Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies
(EFACTS): a 2 year cohort study,The Lancet Neurology. Volume 15. pages 1346-1354. December 2016.
5. Hilgers, R. D., Roes, K., and Stallard, N.: Directions for new developments on statistical design and
analysis of small population group trials. Orphanet Journal of Rare Diseases. Volume 11. Issue 1. pages 78.
June 2016.
List of relevant previous projects or activities, connected to the subject of this proposal :
. Coordinator and WP1 an 2 lead of the IDeAl, FP7 funded IDeAl project (No. 602552)
. Persist a Innovative Training Networks (ITN) within MARIE SKŁODOWSKA‐CURIE ACTIONS (Call: H2020‐
MSCA‐ITN‐2018) proposal submit to EC 17th January 2018
17-CHARITE
Full legal name (Acronym) – Country Charité Universitätsmedizin Berlin (Charité), Germany
Principal investigator Andreas Kurtz, Sebastian Köhler
Relevant Network hPSCreg
Description of the legal entity/department/laboratory/group:
Charité (www.charite.de) is the joint medical faculty of the Humboldt University - and the Free University Berlin.
The Charité is one of Europe’s largest university hospitals with over 100 clinical departments and specialized
research institutions with 160.000 in-patients and a turnover of about 1 billion EUR per year. Innovative capacity
and responsible governance are the central tenets behind Charité research endeavors; with approximately
3,700 researchers developing innovations in the field of medicine. Committed to highest standards of quality
and sustainability, they work across 1,000 projects, working groups and collaborative projects. There is a
particular focus on the interface between basic and patient-oriented research, which seeks to foster
interdisciplinary collaborations with both national and international partners. High priority is given to
research areas that offer an interdisciplinary approach and close integration of basic and clinical research.
While to ensure that new research findings are quickly translated into clinical practice, training of the next
generation of physicians and researchers is equally important. The Berlin-Brandenburg Center for
Regenerative Therapies (BCRT – www.b-crt.de) and its associated graduate school is located at one of Charité's 4
campuses and associates more than 15 institutional partners. The BCRT is was established by the German Federal
Ministry of Education and Research as a translational center, and is a joint initiative between the Charité and
Germany’s largest research organization the Helmholtz-Association. The Laboratory for Stem Cell Research and
Knowledge Management at the BCRT coordinates the European human pluripotent stem cell registry
(https://hPSCreg.eu), a platform to collect, comprehend and make available data for human stem cells.
825575 – EJP RD – Part B 78
Main tasks in the project per Pillar/WP: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 2
In WP11, we will be working on the organization and integration into the consortium data framework of cell
related data and implement FAIR principles.
Task 11.1 : (HPO/Köhler group) Metadata and ontological model definition for cataloging resources for RD
research
11.1.2. Define an ontological model compatible with existing key databases and resources
Task 11.2 : (hPSCreg/Kurtz group) FAIR-compliant platform for discovery of RD resources
11.2.1. Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to
represent all key databases and resources
Task 11.3 : (hPSCreg/Kurtz group) Data deposition and access to data infrastructures for RD research
11.3.3. Adopt a Privacy-Preserving Record Linkage solution to enable data from the same individual to be
connected across resources
11.3.4. Provide data deposition guidelines and documentation
In WP12, we will Enabling sustainable FAIRness and Federation at the data record, patient and sample level for
RD
Task 12.1 : (hPSCreg/Kurtz group) Compare and align core interoperability standards of relevance management
12.1.5. Ontologies & semantics for record-level clinical and preclinical information
12.2.1. Semantic and syntactic harmonisation of data records
Task 12.3 : (hPSCreg/Kurtz group) Combining expertise for practical FAIRification support.
Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities.
Pillar 3:
In WP14, we will provide Training on data management & quality
Task 14.4: (hPSCreg/Kurtz group) Training for biobanks and researchers/clinicians on sample data
Previous experience relevant to the Tasks:
The Kurtz group (hPScreg) established and manages several cell focused databases (hPSCreg.eu, CellFinder.org)
on the international level and within consortia, and developed relevant tools for their exploitation, association,
standardization and improved accessibility (e.g. standard naming tool, ontologie tools, sample classifier). The
work involved the management of data of diverse formats, from different sources and multiple levels of
standardization, which are highly relevant for the proposed work.
The Köhler group has led the development of the Human Phenotype Ontology (HPO) and disease annotations,
developed several algorithms for matching of phenotypic profiles (i.e. sets of HPO terms) and provided
knowledge integration for phenotype-driven genomics. He personally has 9+ years experience as leader, major
developer, and maintainer of the HPO and HPO infrastructure, including maintaining and developing HPO-based
tools for clinical diagnostics and variant prioritisation.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
All necessary infrastructure for the proposed tasks, including IT hard and software as well as maintenance, data
safety and security implementations and governance structures are available. Also available are relevant training
data sets and infrastructure for training as part of the graduate school and the Einstein Center, both associated with
BCRT.
Short Profile of key Staff Members who will be undertaking the work
Prof. Andreas Dr. Kurtz, is managing the EU-hESCreg project (https://hescreg.eu). He is head of the Laboratory
Kurtz of Stem Cell Research and Knowledge Management at the BCRT. He established several national
Male and international communications-, information technology-, and infrastructure projects in the
field of stem cell research and regenerative medicine, including the European Bank of iPSC
(EBiSC), Regenerative Medicine Initiative Berlin (RMIB), the Regenerative Medicine Initiative
Germany (RMIG), the internet platforms CellFinder.de. He co-established the stem cell core at
the BCRT and conducts research in organ modelling for preclinical cell therapy assessment based
on iPSC. Prof. Kurtz became in 2006 founding PI of the BCRT and has previously worked as
Professor at Georgetown (1995-2000), Harvard (2000-2003) and Seoul National (2009-2016)
Universities.
Prof. Dr.Köhler recently been appointed as Junior Professor at Charité and before worked at a post-doc
Sebastian at NeuroCure in the group of Dr. Dominik Seelow. He is also a PI in the EU-funded project
Köhler Solve-RD (http://solve-rd.eu/). He participated in the EU-project HIPBI-RD lead by Orphanet.
Male The major focus of Dr. Köhler and his group is the phenotype-driven analysis of patients,
825575 – EJP RD – Part B 79
genomes, and cohorts using ontologies. He is one of thewith
Associated co-founders ofAres(2018)6091977
document Ref. the Human Phenotype
- 28/11/2018
Ontology (HPO) and has developed several algorithms and applications of HPO to data from
different areas, such as genomics and clinics.
Dr. Nancy Dr. Mah is a research scientist at the Berlin-Brandenburg Center for Regenerative Therapies at
Mah Charité University Medicine Berlin. As an experienced data wrangler and analyst of transcriptome
Female data, she has contributed to a number of publications in the development and stem cell fields,
including pluripotent stem cells (PSC) and their PSC-derived cell types. Concurrently, she is
developing bioinformatic methods to evaluate the cell identity of PSC-derived cell types
compared to their native counterparts. A member of the International Society for Stem Cell
Research (ISSCR) and German Stem Cell Network (GSCN), she is also involved in implementing
interchangeable data formats for the European Stem Cell Registry (hPSCreg.eu) and actively
represents hPSCreg at national and international stem cell conferences.
Dr. Stefanie Dr. Seltmann is a bioinformatician and has been implementing stem cell related ontologies and
Seltmann databases related to hPSCreg as well as the platform CellFinder. Her main activities are the concept
Female and implementation of the database management system (DBMS) behind the public hPSCreg
platform and development of long-term storage solutions. She will be responsible for implementing,
monitoring, updating the technical concept, database, interface and dissemination.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Kurtz A, Bairoch A, Bittner MS, Bruce K, Capes-Davis A, Clarke L, Crook JM, Daheron L, Dewender J,
Faulconbridge A, Fujibuchi W, Gutteridge A, Hei D, Kim YO, Kim JH, Kolb- Kokocinski A, Lekschas F,
Lomax G, Loring JF, Ludwig T, Mah N, Matsui T, Müller R, Parkinson H, Seltmann S (*), Sheldon M, Smith
K, Stachelscheid H, Stacey G, Streeter I, Veiga A, Xu RH. A standard nomenclature for referencing and
authentication of pluripotent stem cells. Stem Cell Reports Stem Cell Reports. 2018 Jan 9;10(1):1-6.
2. Amrani KE, Stachelscheid H, Lekschas F, Kurtz A*, Andrade-Navarro MA. MGFM: a novel tool for detection
of tissue and cell specific marker genes from microarray gene expression data. BMC Genomics. 2015 Aug
28;16:645.
3. Seltmann S, Lekschas F, Müller R, Stachelscheid H, Bittner MS, Zhang W, Kidane L, Seriola A, Veiga A,
Stacey G, Kurtz A. hPSCreg--the human pluripotent stem cell registry. Nucleic Acids Res. 2016 Jan
4;44(D1):D757-63.
4. Zemojtel*, Köhler*, Mackenroth*, Jager, Hecht, Krawitz, Graul-Neumann, Doelken, Ehmke, Spielmann, Oien,
Schweiger, Kruger, Frommer, Fischer, Kornak, Flottmann, Ardeshirdavani, Moreau, Lewis, Haendel, Smedley,
Horn, Mundlos and Robinson (2014). "Effective diagnosis of genetic disease by computational phenotype
analysis of the disease-associated genome." Sci Transl Med 6: 252ra123.10.1126/scitranslmed.3009262
5. Köhler, Vasilevsky, Engelstad, Foster, McMurry, et al. (2017). "The Human Phenotype Ontology in 2017."
Journal/Nucleic Acids Res 45: D865- D876.10.1093/nar/gkw1039
List of relevant previous projects or activities, connected to the subject of this proposal
. A. Kurtz is coordinator of hPSCreg, EU-funded since 2007: iPSC registry and data platform
. A. Kurtz is responsible for the Information Management System of the EU-Bank of iSC-lines (IMI-
EBiSC), since 2015
. A. Kurtz implemented the CellFinder database, a human cell atlas funded by German Research Foundation
2010-2013
. Dr Köhler is a PI within the Solve-RD project, responsible for phenotype-similarity calculation
between solved and unsolved cases.
. Dr Köhler was a postdoctoral researcher in the HIPBI-RD project, which aims at harmonising
phenomics information for a better interoperability in the rare disease field.
18-UKLFR
Full legal name (Acronym) – Country UNIVERSITAETSKLINIKUM FREIBURG (UKLFR)
Principal investigator Prof. Janbernd Kirschner
Relevant Network TREAT-NMD, EURO-NMD, ECRIN
Description of the legal entity/department/laboratory/group:
The Medical Faculty is one of the most prestigious research-driven medical schools in Germany and renowned for
experimental as well as clinical research. The Medical Center – University of Freiburg is an independent public
institution of the University of Freiburg. It is amongst the largest university hospitals in Germany. It collaborates
825575 – EJP RD – Part B 80
closely with the Medical Faculty, University of Freiburg according to Baden
Associated withWuerttemberg state law and engages
document Ref. Ares(2018)6091977 - 28/11/2018
in research, training and patient care as its core responsibilities, with the goal of offering its patients treatment
informed by latest scientific findings.
In 2009 UKLFR has established the Freiburg Center for Rare Disease and members of the center are involved in 10
different European Reference Networks for Rare Diseases including the EURO-NMD network for neuromuscular
diseases.
The Department of Neuropediatrics and Muscle Disorders has a long tradition in clinical research with special
focus on rare diseases. UKLFR was founding member of the German muscular dystrophy network MD-NET and
the TREAT-NMD network for translational research in neuromuscular disorders. The Department of
Neuropediatrics and Muscle Disorders delivers its activities in close close cooperation with the Clinical Trial Unit
(CTU) of UKLFR. The CTU is a central facility of UKLFR founded in 1997 which ensures compliance with
international quality standards and participates in a number of international joint research projects. The CTU is an
ECRIN certified center for data management.
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP11, the data of the CTSR will be linked to the EJP platform. In addition, the CTSR will be expanded further
or replicated, to include all rare diseases organised along the lines for the ERN Thematic Groupings, extending
beyond the original remit in TREAT-NMD. Participation in tasks 11.3.1, 11.3.3, 11.3.4, 11.4.4).
Previous experience relevant to the Tasks:
The Care and Trial Site registry (CTSR, PubMed 24148153) at Freiburg University – Medical Center is an
IRDiRC recognized resource contributing to the European data infrastructure for rare neuromuscular and
neurodegenerative disease and exposes highly phenotyped patient cohorts and specialist centres for clinical
research (linked to ERNs EURO-NMD and RND). The CTSR currently contains information on the personnel,
facilities and patient population of 320 centres in 48 countries, and site-reported data indicates that 60,000
patients are seen in these centres.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work:
The Care and Trial Site registry (CTSR, PubMed 24148153) at UKLFR is part of the TREAT-NMD activities
and contains information of more than 320 centres for neuromuscular and/or neurodegenerative disease in a
single database. The CTSR is also used to collect relevant information for the ERN EURO-NMD from
pariticipating centres. The information on patient numbers, investigators, infrastructure has been used in
numerous feasibility requests from academic partners and industry to plan and conduct clinical and health care
research projects.
The Clinical Trial Unit (CTU) of UKLFR has more than 50 employees and provides all services to plan, conduct
and evaluate clinical research projects. Together with the Department of Neuropediatrics and Muscle Disorders
the CTU has developed specific expertise in the area of rare diseases. CTU has been certified by ECRIN as a
European data management centre.
Short Profile of key Staff Members who will be undertaking the work
Pr.Janbernd Kirschner Acting Medical Director of the Department of Neuropediatrics and Muscle Disorders. As
(male) paediatric neurologist his main interest is clinical research in neuromuscular diseases and
other rare diseases. Under his leadership UKLFR has developed to one of the leading
institutions for clinical research in neuromuscular diseases in Germany. He has been
principal investigator for numerous clinical trials for spinal muscular atrophy and
Duchenne muscular dystrophy. These include IIT-trials as well as industry sponsored
trials. Kirschner was coordinator of the EU-funded project CARE-NMD which explored
the care situation of Duchenne patients in 7 EU countries. Kirschner has recently
established the SMArtCARE database to collect long-term observational data for patients
with spinal muscular atrophy. Kirschner is designated chair of the TREAT-NMD alliance
executive committee and member of the ERN EURO-NMD executive committee.
Kirschner has authored more than 100 peer-reviewed publications und is section editor of
the Orphanet Journal of Rare Diseases.
Dr. Hanns Lochmüller Hanns Lochmüller has joined the Department of Neuropediatrics and Muscle Disorders
(male ) at the UKLFR in February 2018. Previously, he held the Chair of Experimental
Myology at the Institute of Genetic Medicine, Newcastle University, where he is co-led
the MRC Centre for Neuromuscular Diseases. Recently, he set up and coordinated the
EU funded RD-Connect project, and chaired the Interdisciplinary Scientific Committee
of the International Rare Diseases Research Consortium (involving most major Rare
825575 – EJP RD – Part B 81
Disease funders such as the EuropeanAssociated
Commission and theRef.
with document NIH), which advises
Ares(2018)6091977 this
- 28/11/2018
global consortium on issues around data sharing, bioinformatics, registries and biobanks.
These roles place him at the heart of efforts to bring together data, analysis methods and
clinical bioinformatics tools applicable to rare disease. His research group has
successfully established zebrafish as a tool for investigating hereditary muscle disorders
and continues to publish basic and translational research in leading journals. Lochmüller
has been principal investigator for several natural history and clinical trials for spinal
muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy, and GNE
myopathy. He has authored more than 450 peer-reviewed publications and is the editor-
in-chief of the J of Neuromuscular Disease.
Kirsten König Kirsten König works as an IT specialist at the Clinical Trials Unit of the University of
(female) Freiburg – Medical Center. She has programmed registries such as the CTSR, of which
she is also curator, as well as other web-based investigational tools.
Adrian Tassoni Adrian Tassoni works as IT specialist and is responsible for the IT team at the Clinical
(male) Trials Unit of the University Freiburg – Medical Center.
He works in collaboration with the Department of Neuropediatrics since 2007 and is
responsible the technical aspects of the CTSR, the TREAT-NMD Regulatory Affairs
Database and the TREAT-NMD TACT Application Form. Within the Clinical Trials
Unit he is responsible for a working IT infrastructure including the GCP-compliant
development, validation and maintenance of computerized systems like data entry
systems, electronic CRFs, and the IT for data-managers, bio-statisticians and pharmaco-
vigilance.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.; ENDEAR Study Group.
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov
2;377(18):1723-1732.
2. Rodger S, Lochmüller H, Tassoni A, Gramsch K, König K, Bushby K, Straub V, Korinthenberg R, Kirschner J.
The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular
diseases. Orphanet J Rare Dis. 2013 Oct 23;8:171.
3. Boycott KM, Rath A, Chong JX, Hartley T, …, Lochmüller H. International Cooperation to Enable the
Diagnosis of All Rare Genetic Diseases. Am J Hum Genet. 2017 May 4;100(5):695-705.
4. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, … Lochmüller H, et al.; International Rare
Diseases Research Consortium (IRDiRC). Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective.
Clin Transl Sci. 2018 Jan;11(1):21-27
5. Lochmüller H, et al.; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. RD-Connect,
NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018 Feb 27.
List of relevant previous projects or activities, connected to the subject of this proposal :
. TREAT-NMD: EU-funded period 2007-2013; continuing as TREAT-NMD alliance
. MD-NET: German Ministry of Research and Education, 2004-2011, co-lead, coordination of clinical trials
. CARE-NMD: EU-funded, DG SANCO, 2010-2013, project lead, Evaluation of Care and Quality of Life of
patients with Duchenne muscular dystrophy
. CoordinateRare: German Ministry of Research and Education, 2011-2013, project lead, methodological centre
for clinical research in rare diseases.
. NEUROMICS: EU-funded; 2012-2017, sub investigator, Integrated European Project on Omics Research of
Rare Neuromuscular and Neurodegenerative Diseases
. ERN EURO-NMD: EU-funded reference network for neuromuscular diseases; since 2017, clinical site and
member of the executive committee
19-NKFIH
Full legal name (Acronym) – Country Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (NKFIH) –
Hungary
Principal investigator Gábor Tóth
Relevant Network
Description of the legal entity/department/laboratory/group:
825575 – EJP RD – Part B 82
The National Research, Development and Innovation Office (NKFIH, or NRDI
Associated Office)Ref.
with document was founded on 1 January
Ares(2018)6091977 - 28/11/2018
2015 by the Act on scientific research, development and innovation (Act 2014/LXXVI) of the Hungarian
Parliament (RDI Act) with the aim to create a stable institutional framework for the governmental coordination of
the national research, development and innovation ecosystem, provide predictable funding and implement efficient
and transparent use of available resources.
It is a national strategic and funding agency for scientific research, development and innovation, the primary source
of advice on RDI policy for the Hungarian government, and the primary RDI funding agency. It manages the
National Research, Development and Innovation Fund to provide state support for research, development and
innovation.
Its mission is to develop RDI policy and ensure that Hungary adequately invests in RDI by funding excellent
research and supporting innovation to increase competitiveness.
Its mandate is to prepare the RDI strategy of the Hungarian government, to handle the National Research,
Development and Innovation Fund, and represent the Hungarian government and the Hungarian RDI community in
international organisations.
Is vision is to be a world-class RDI funding agency, create an internationally attractive RDI environment in
Hungary, and a stronger link of RDI to the economy and society to increase growth and prosperity.
Main tasks in the project per Pillar/WP:
Pillar 1 (Funding Collaborative Research on Rare Diseases):
In WP6 NKFIH as a funding agency will participate in both co-funded Joint Translational Calls for collaborative
research projects. We will be involved in topic selection, call preparation, call secretariat tasks, evaluation and
funding decision.
Previous experience relevant to the Tasks:
With regard to supporting basic research, NKFIH administers open calls for proposals with a bottom-up approach
towards research proposals, postdoctoral research proposals, and proposals for international cooperation (often
based on bilateral agreements between NKFIH and foreign research funding agencies with the view of Europe and
Hungary investing in a knowledge-based society) – without thematic priorities and with a special emphasis on the
careers of talented young researchers and on the reintegration of Hungarian researchers returning from postdoctoral
trainings or research projects carried out abroad. Competition is intense: in recent years, the average support ratio
has been approximately thirty percent of the total number of proposals received. Their evaluation is based on a peer
review system where individual expert reviews are collected through an online electronic proposal review system
and proposals are further evaluated and ranked by a two-level system of review panels and scientific councils.
Previous experience also includes active participation in the call secretariats of the ERA-Chemistry and the M-
ERA.NET ERA-NET projects.
In the annual program strategy, a specific budget line is dedicated to the support of Hungarian participation in the
Horizon 2020 Programme, as well as in related ERA-NET projects such as FLAG-ERA, M-ERA.NET, Quantera,
Infect-ERA, E-Rare and ERA PerMed. Furthermore, NKFIH participates in the AAL Joint Programme, in the Joint
Programme – Neurodegenerative Disease Research (JPND) as well as in the ECSEL joint technology initiative, in
the EUREKA and in the EUROSTARS programmes, and has numerous bilateral international agreements for joint
programmes.
As a member of the E-Rare-3 ERA-NET consortium NKFIH participated in all joint transnational calls launched by
E-Rare-3.
Short Profile of key Staff Members who will be undertaking the work
Dr. Gábor Tóth Scientific background: bioengineering (MSc degree), molecular genetics (teaching and
(male) research experience), bioinformatics (teaching and research experience, PhD degree).
PhD in Biology (2001).
Recent positions: Head of Department of Life Sciences at the Hungarian Scientific
Research Fund, OTKA (2012–2014); Head of Unit of Medical and Biological Sciences
at NKFIH (2015); Head of Department of Research and Development at NKFIH
(2016–).
In the above positions, he has been responsible for the administrative management of
national funding programmes in the field of discovery (basic) research, coordinating
evaluation of research proposals and monitoring of funded projects.
He represents NKFIH in the ERA-NET consortium E-Rare-3.
He is the national administrative delegate in the ELIXIR Board.
Dr. Előd Nemerkényi PhD in Medieval Latin (2004).
(male) Positions: Assistant of International Affairs at the Hungarian Scientific Research Fund,
OTKA (2007–2014); Assistant of International Affairs in the Department of Research
825575 – EJP RD – Part B 83
and Development at NKFIH (2015–). Associated with document Ref. Ares(2018)6091977 - 28/11/2018
He represents NKFIH in the Working Group of the M-ERA.NET programme.
He is also involved in the administrative management of proposal evaluation and
project monitoring in national funding programmes.
Dr. Klára Horváth She studied Physics and has a PhD degree in Experimental Molecular Biophysics. She
(female) has been working with national and EU research programmes at NKFIH (and its legal
predecessors) since 2009. Between 2009 and 2012, she took part in the management
and monitoring tasks of major Hungarian programmes at the Department of Programme
Planning, at present she is working with H2020-related projects and programmes in the
field of Health at the Department of International Affairs. She is the national delegate
in the Health Programme Committee, in the Innovative Medicines Initiative (IMI)
States Representative Group, in the Joint Programme – Neurodegenerative Disease
Research (JPND) Management Board and takes part in the ERA PerMed ERA-NET
project.
List of relevant previous projects or activities, connected to the subject of this proposal :
E-Rare-3; Funder: European Commission; 2014-2019 participant; participation in the launching of joint
transnational calls, funding and monitoring of projects.
20-HRB
Full legal name (Acronym) – Country Health Research Board (HRB)- Ireland
Principal investigator Dr Annalisa Montesanti
Relevant Network
Description of the legal entity/department/laboratory/group:
The Health Research Board (HRB) is a state agency that supports research and provides evidence to prevent illness,
improve health and transform patient care.
Main tasks in the project per Pillar/WP:
Pillar 1:
WP6 Funding collaborative research on rare diseases
-earmarked funds for co-funded call 1: 370,000 three hundred and seventy thousands euros
-earmarked funds for co-funded call 2: 370,000 three hundred and seventy thousands euros
Previous experience relevant to the Tasks:
We have previous experience with the funding of JPI HDHL DEDIPAC which I managed from start to finish.
Also there is plenty of additional expertise in the organisation as we are involved in several JPIs activities.
Short Profile of key Staff Members who will be undertaking the work
Dr. Annalisa Montesanti Programme Manager managing the Health Research Careers portfolio at the Health
(Female) Research Board (HRB). She is responsible for developing and managing a portfolio
of training and career development initiatives through a number of mechanisms and at
many different levels – ranging from PhD students and mid-career researchers to
leaders in health research and other training courses or training initiatives - and
generally develop a coordinated approach to building capacity in health research in
Ireland. She has previous experience in managing a variety of initiatives, including
investigator-led projects, programmatic awards and several career development
schemes, including securing funding from European Commission under FP7 MSCA
COFUND. At international level she has represented the HRB in the steering
committee of funders of the EC Joint Programme Initiative (JPI) Healthy Diet for
Healthy Life (HDHL) and in the European Science Foundation (ESF) and Science
Europe Research Careers working group. Before joining the HRB in 2005, Annalisa
had 13 years’ experience in scientific research in institutions and Universities in Italy,
England and Ireland. She has a Bachelor of Science (Molecular Biology) from
Palermo University in Italy and a PhD in cancer biology from the Institute of
Molecular Medicine in Oxford, UK. She was also awarded a fellowship from the
Italian Association for Cancer Research while working in Italy and a Marie Curie
Training and Mobility for Researchers fellowship while in Oxford
825575 – EJP RD – Part B 84
21-IT MoH Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Ministry of Health – (IT- Moh) - Directorate of Research and
Innovation in Healthcare, Italy
Principal investigator Giselda Scalera
Relevant Network
Description of the legal entity/department/laboratory/group:
The Ministry of Health represents the central level of the Italian National Health Service and is responsible for
overall planning and control and to establish the Italian NHS targets and most important measures to be
implemented.
The Ministry is the leading body of the national information system on health, which includes data on hospital
admission and health interventions; the Ministry is also responsible for the overall coordination of Prevention
Programmes, including those for elderly and disabled people, in particular correct life-style promotion, surveillance
of chronic diseases and c.d. risk factors, promotion and surveillance of secondary prevention. The Ministry is
entitled of the resource management of operational Health research, and it is also the Governing body for the
legislation on Medical Devices and Health Professionals. The participating Department/Director General has as
general task the coordination of Health prevention, Health Research, International and EU Relations and External
Communication activities. It also promotes actions and grants in several fields of public health.
Main tasks in the project per Pillar/WP:
Pillar 1:
Task 2.3: Scientific programming of joint transnational calls (M1 – M36) Task 2.5: Translation/impact of
prioritization on national and EU strategies (M13 – M60)
Previous experience relevant to the Tasks:
The Ministry of Health is the main public body funding biomedical research and biomedical innovation in Italy. As
a strategic health policy instrument, the Italian the Ministry of Health runs two types of funding programmes in the
fields of biomedicine: one on current research and another on targeted research. Current research funding is
available to Scientific Institutes of Research, Hospitalisation and Healthcare (IRCCS), the yearly amount is around
170 Mio € and in the evaluation criteria used to allocate this type of research is included the results of the capacity
of these Institutions to enter in EU Research Consortium funding in Joint Activities as ERANET and JPIs. Whereas
the targeted research funding is open to all researchers of the National HealthSystem. Both programmes constitute
priority initiatives for the improvement of the population’s health through the rapid translation of research results
into new or improved preventive, diagnostic, and treatment products and processes, and incorporation into health
policies and practice.In the period 2011-2012, in line with what was implemented in previous years, efforts were
made to ensure transparency and competitive research with a call for proposals for "Targeted Research and Young
Researchers 2011-2012". Within the framework of such programme, the Italian Ministry of Health allocated a total
funding of about 135 Mio. €.
By means of the Ministry of Health research funding vital synergies between public research and private research,
including national research and research within and outside Europe are strengthened.
At present, the MoH-IT is involved in the following European health research programmes:
• E-Rare-3
• ERA PerMed
• ERA-CVD
• EuroNanoMed III
• GENDER NET Plus
• HBM4EU
• ICPerMed Secretariat
• JPco-fuND
• JPI-EC-AMR
• NEURON Cofund
• TO-REACH
• TRANSCAN-2
• ERA-NET for Latin American and Caribbean States II (ERA-NET-LAC II)
• Active and Assisted Living - 2 (AAL- 2)
The MoH-IT is also committed to support the ESFRI Research Infrastructures in the biomedical science sector,
ECRIN, EATRIS and BBMR.
Short Profile of key Staff Members who will be undertaking the work
Dr.Gaetano Guglielmi Dr. Gaetano Guglielmi (is the Head of the Office of Health Research, DG for Research
825575 – EJP RD – Part B 85
(male) and Innovation in Healthcare. He represents thewithItalian
Associated Ministry
document of Health in - all
Ref. Ares(2018)6091977 EU
28/11/2018
initiatives in which the DG for Research and Innovation in Healthcare is involved.
Dr. Giselda Scalera Head of the Office of Health Research, DG for Research and Innovation in Healthcare;
(female) she is involved for the Italian Ministry of Health in following EU initiatives: E-Rare-3;
EuroNanoMed III ;GENDER NET Plus ; JPI-EC-AMR ; Active and Assisted Living - 2
(AAL- 2)
List of relevant previous projects or activities, connected to the subject of this proposal:
ERA-Net for Research Programmes on Rare Diseases E-Rare: Funder.
.
22-TuscReg
Full legal name (Acronym) Regione Toscana (TuscReg) - Italy
– Country
Principal investigator Katia Belvedere, Head of Sector for legal advice, research and support for clinical
governance bodies, Directorate for Citizenship Rights and Social Cohesion,
Tuscany Region
Relevant Network These are the ERN where the Centre of Tuscany Region participates:
BOND - European Reference Network on Rare Bone Disorders
Endo-ERN - European Reference Network on Rare Endocrine Conditions
EpiCARE - European Reference Network on Rare and Complex Epilepsies
ERKNet - European Rare Kidney Diseases Reference Network
ERN-RND - European Reference Network on Rare Neurological Diseases
ERNICA - European Reference Network on Rare inherited and congenital
anomalies
ERN-LUNG - European Reference Network on Rare Respiratory Diseases
ERN-Skin - European Reference Network on Rare and Undiagnosed Skin
Disorders
EURACAN - European Reference Network on Rare Adult Cancers (solid tumors)
EuroBloodNet - European Reference Network on Rare Hematological Diseases
EURO-NMD - European Reference Network for Rare Neuromuscular Diseases
ERN-EYE - European Reference Network on Rare Eye Diseases
ITHACA - European Reference Network on Rare Congenital Malformations and
Rare Intellectual Disability
MetabERN - European Reference Network for Rare Hereditary Metabolic
Disorders
PaedCan-ERN - European Reference Network for Paediatric Cancer (haemato-
oncology)
ReCONNET - Rare Connective Tissue and Musculoskeletal Diseases Network
VASCern - European Reference Network on Rare Multisystemic Vascular
These are the Health care Providers involved in ERN's:
University Hospital Careggi
University Hospital of Siena
University Hospital of Pisa
University Hospital Meyer
Central Tuscany Local Health Authorities
Gabriele Monasterio Tuscany Foundation
Description of the legal entity/department/laboratory/group:
Tuscany is a region in central Italy with an area of about 23,000 square kilometres and a population of about 3.8
million inhabitants. Regione Toscana (Tuscany Region) is the regional authority and administrative body of the
region; it has legislative, administrative, and financial autonomy and is responsible, on a regional level, for issues
including education, social issues, healthcare, international cooperation, and the environment.
The Tuscan health system includes three Local Health Authorities and four university hospitals:
• Central Tuscany: Local Health Authorities (Florence, Prato, Pistoia, Empoli)
• Northwest Tuscany: Local Health Authorities (Lucca, Massa e Carrara, Versilia, Pisa and Livorno)
• Southeast Tuscany: Local Health Authorities (Siena, Arezzo and Grosseto)
• University hospital Careggi (Florence)
825575 – EJP RD – Part B 86
• University hospital Meyer (Florence) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
• University hospital of Pisa
• University hospital of Siena.
The health system is the sector to which the region commits the largest share of its budget and organizational
structure, and constitutes an infrastructure of services and activities that can generate positive effects throughout
the region. It is, in spite of and even more so in a period of economic crisis, a driving force of development for the
entire regional economy, in which economic development is seen not as an end in itself but also includes, in a
context of sustainability, measures tied to the social sector and the environment. Regione Toscana is also actively
involved in the promotion of the Tuscan Life Sciences Cluster for large and small companies operating in the
sector.
Regione Toscana has a long-standing tradition of activities to promote wellness, including healthy diets and
physical activity. The latest version of Regione Toscana’s multi-year health plan includes a major focus on “health
in all policies”, i.e. the promotion of healthy lifestyles across all sectors (urban planning, environment, welfare,
transportation, commerce, schools, culture, sport, etc.). The project team will include colleagues in other relevant
sectors of the regional government as well as the region’s associated health agencies for specific expertise on
obesity; expertise in the management of European projects will also be present.
Tuscany Region promotes health research and innovation policies to structure an integrated and synergistic
research and innovation system in a coordinated context among Tuscan university hospitals and other institutions
of the Regional Health Service.
Main activities in this field:
• calls for funding (using regional, national e structural funds);
• creation of UVaR - office for exploitation of research results – that is engaged in assessing, monitoring and
exploiting the results of research in terms of applicability and transferability. An activity to support the
Tuscan university hospitals and other institutions of the Regional Health Service, universities and public
research organizations in order to develop and leverage innovative capacity and technology transfer, also
through the creation of collaborative channels with companies and other stakeholders in the Life Sciences
sector;
• Support to Tuscany Life Sciences Cluster, founded in 2011 by an initiative of the Tuscany Region aimed at
creating an integrated Life Sciences system. Its mission is to act as the “glue” between the specialist
industrial dimension and the institutional and systemic one, promoting dialogue among companies and the
network of excellence present in the field of research and technology transfer in the region.
The Rare Diseases Regional Network in Tuscany is the result of a process started in Italy with DM 279/2001
almost 17 years ago when the Regional Coordination group for rare diseases was established to represent highly
specialized units, patients no-profit organizations, healthcare institutions. Tuscany region is implementing the
National Plan on Rare Diseases with the aim of better organising both the healthcare paths for patients affected by
rare diseases, and the regional network activity of the Centres of Expertise. The Centres for rare diseases must
ensure continuity with the recommendations through specialized units within the regional network. 6 Health Care
Providers in Tuscany are the seat of Centers of expertise on Rare diseases according the Recommendations of the
EUCERD committee (2011) on the quality criteria for the selection and the evaluation of the "Centres of expertise"
(CEs) for the rare diseases European Reference Networks (ERNs). This HCP partecipates with 28 specialised units
in 17 ERN’s and one of them (Reumatology Unit - AOU Pisana) coordinates the ERN ReConnect.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate in joint transnational calls of Pillar 1 task 6.1 with support of TLS (Linked Third Party)
Previous experience relevant to the Tasks:
Competence in the issue of calls for research using regional, national (MoH) e structural funds (ERDF)
Short Profile of key Staff Members who will be undertaking the work
Mrs Donatella Tanini Dontella Tanini has worked for Tuscany Region - Health Direction since 1990 in the
(female) dealing mainly health research and health system.
She is responsible of the posizione organizzativa "Health research and cooperation
international health".
Skills: Organization and coordination of activities related to health research, for the
development and funding of research-innovation projects financed by regional, state and
community funds. Relations with health research subjects and with regional directorates
interested in the research and innovation system. Relations with regional technical
structures of the European Union for the promotion and development of the Tuscan health
research system. Coordination of administrative activities related to international health
cooperation.
825575 – EJP RD – Part B 87
Mrs Ceclia Berni Middle manager in Tuscany Region, with a Master
Associated DiplomaRef.
with document in Ares(2018)6091977
Healthcare Management
- 28/11/2018
(female) with honours (Sant’Anna School of Advanced Studies – Pisa) after been graduated with
honours in Political Science. She supports the set up of regional policies and procedures
for the development of the regional network on rare diseases and on pregnancy and child
care. She is involved in the implementation of standards of diagnosis and care and of
mechanism for evaluation. She coordinates the work of the Regional group for rare
diseases and she is the regional representative in the Nationl working group for rare
diseases. She is also involved in the Regional Committee on pregnancy and birth and in
the National Committee on monitoring induced abortion.
Ms Teresa Vieri Master’s Degree in Art, Music and Performing Arts Disciplines, University of Bologna,
(female) graduated with honours; First Level Master in “Local human development and
International Cooperation: theories, methods and best practices”.
She has been Deputy Coordinator of the ART Secretariat for Decentralized Cooperation
UNOPS/PNUD in Florence; Area Manager in the Nusa Tengara Timur Province,
Indonesia for the ART Programme (Articulating Territorial and Thematic Networks for
Human Development) of UNDP (United Nations Development Programme), Public
Officer for International Relations and Cooperation in staff of the Mayor of Florence,
Municipality of Florence. She is currently Assistant for the Management of National and
European Funds, Directorate for Citizenship Rights and Social Cohesion, Tuscany
Region.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. The Rare Disease Regional Network
2.http://toscanaopenresearch.it/
3.http://www.meetthelifesciences.it/it/
List of relevant previous projects or activities, connected to the subject of this proposal :
Projects financed by RT in the field of rare diseases currently in progress:
. UNAVIR “Rare Viral Diseases: an innovative strategy to combat them with a single antiviral agent” UNIV.
Siena, UNIV. Florence, UNIV. Pisa
. GLIOMICS “Proteomic/genomic/metabolomics for biomarker detection and development of an ultra-sensitive
detection platform in peripheral body fluids: application to multiform glioblastoma” Scuola Normale Superiore
Pisa, Istituto Italiano di Tecnologia IIT, National Research Council CNR
. DIAMANTE “Innovative molecular diagnostics for the individual therapeutic choice of pancreatic ductal
adenocarcinoma” UNIV Pisa, National Research Council CNR, Scuola Normale Superiore Pisa, IIT NEST.
23-FRRB
Full legal name (Acronym) – Country Fondazione Regionale per la ricerca Biomedica (FRRB)- Italy
Principal investigator Gianni D’Errico
Relevant Network IC-PERMED, ERA-PERMED, TRANSCAN2
Description of the legal entity/department/laboratory/group:
The Lombardy Foundation for Biomedical Research (Fondazione Regionale per la Ricerca Biomedica - FRRB) is
an entity governed by public law, a non-for-profit organization, established in October 2011 by Regione
Lombardia, with the aim of promoting and supporting scientific research in Life Sciences in Lombardy (100
Million € from 2011 have been committed in innovative R&D projects so far). The Foundation represents the main
strategic platform for boosting progress, research, development and innovation within the health sector among the
regional academic and industrial life science players. Its raison d'être is to serve as support to and for implementing
the regional health care research policy, in order to place the Lombardy regional system in a leading position in
Europe within this field. In addition, the Foundation aims to distribute local and European resources to innovative
basic and translational research projects which enable a positive impact on the local health care eco-system and
citizens.
Main Activities:
• Promote research and innovation in Lombardy by assigning regional funds to basic and translational
research projects through public tenders and calls for proposals as to create a financially sustainable and
suitable environment for adding value to biomedical projects focused on different pathological conditions
including rare diseases.
825575 – EJP RD – Part B 88
• Through R&D infrastructures, support and coordinate theAssociated with document Ref. Ares(2018)6091977 - 28/11/2018
implementation of scientific research on disease
prevention, personalized medicine, medical devices and drug manufacturing and distribution.
• Support and promote local and national technological clusters in life sciences, thus enabling a better
coordination of research agendas in the biomedical field, as well as a more productive use of the available
funds.
• Attract European and International research funds to Lombardy by participating to European projects, as
those in the EU HORIZON 2020 research and innovation funding program, and international partnerships.
• Add value to funded projects derived research results through technology transfer activities in order to
support and promote the development of new treatments, therapies and devices for the diseases of interest.
• Promote the dissemination of scientific knowledge and culture including Responsible Research and
Innovation (RRI) principles and promoting a gender balance among Research Funding Organisation (RFOs
)and Research Performing Organisations (RPOs).
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6 - We will participate on all the tasks listed in WP6 (Tasks 6.1 -6.2 -6.3 -6.4)
Previous experience relevant to the Tasks:
We are building a strong experience in the participation, coordination and management of Transnational Caals
for Proposal. Particularly we are already part of the following networks:
Main National and International Projects:
1. IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the
implementation of the roadmap in liaison with the Italian ministry of Health;
2. ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016
and has committed 1 Million € for the call. The support is continuing in the JTC 2017 with 1,25 M€.
3. ERA-PERMED: FRRB is partner and Work package Leader of Era-PerMed Projects and has committed 4
Million € for the joint Transnational Call 2018
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
As a funding Agency we do not own Research/Innovation Infrastructure, nor technical equipment. We do use all
the IT tools for the correct execution of regional and transnational Calls for Proposals
Short Profile of key Staff Members who will be undertaking the work
Mrs Marina Gerini General Director at FFRB.She obtained her degree cum laude in classic literature in 1981 at
(Female) University of Florence. Since 1983 she became a civil servant and started her carrier in the
Public Administration. In 1997 she became manager in the Lombardy Government serving
at DG Family with responsibility of financial and human resources and between 2004 and
2005 she covered the interim position as responsible of public health interventions. In 2005
she was responsible of the Central DG for external and International Relations till
2009.Between 2009 and 2011 she became General Manager of Directorate General for
Social Associations and Volunteering Organisation Associations at the National Ministry of
Labour and Social Policy. Between 2011 and 2013 she covered the position of General
Secretary of the Lombardy Assembly and was responsible of coordinating the work between
the regional activities, the regional and national Government, as well as of realisation of the
activities and programmes of the national presidency of the council of ministries. From 2013
to 2014 she was director at Regional agency for transparency and anti-corruption. From
2014 to 2015 she was appointed as Special Manager at Melegnano General hospital.In 2015
she was appointed as Social Director of the at Primary Care Trust (the Italian Azienda
Sanitaria Locale) Milano 1 and in 2016 she was appointed as socio medical Director and
PCT West Milano. Since February, 2nd 2017 she is General Manager at Lombardy
Foundation for Biomedical Research
Gianni D’Errico After graduated cum laude at University Federico II in Napoli and obtained my post
(Male) graduate master’s degree in project management at SIOI in Rome, I started working in
Brussels and then in Maribor, where I got acquainted with R&D programmes and innovative
projects in Life Sciences. In Slovenia I cooperated with the University of Maribor, providing
lectures to PhD students on IP issues within R&D international projects (competences
certificated at University of Bonn). Since September 2015 I have been working at the
Regional Foundation for Biomedical Research (a strategic agency specialized in financing
highly scientific projects in Life Sciences), where I am in charge of the European strategy,
programmes and projects with the aim to create synergies between Lombardy and other
825575 – EJP RD – Part B 89
European regions’ R&D&I projects/programmes/policy. I am member
Associated with document of the IC-PERMED
Ref. Ares(2018)6091977 - 28/11/2018
(International consortium on Personalised Medicine)Executive Committee, main facilitator
of the ESTHER (Emerging and Strategic Technologies for Healthcare) Interregional
cooperation group, and I have been implementing the participation of the Lombardy Region
to TRANSCAN 2, ERA-PerMed (WP4 Leader – Monitoring of Cofunded projects)
Dr. Paola Larghi Scopus Author ID: 24740841600
(Female) ORCID: http://orcid.org/0000-0001-7074-1590
Paola, Since 2017 is Scientific Officer at Fondazione Regionale per la Ricerca Biomedica.
She got her degree in Biologic Sciences a University of Milan in 2005 followed by a PhD in
experimental Pathology and Neuropathology. She worked as immunologist at European
Institute of Oncology (2003-2005), Humanitas Clinical institute (2006-2010 e 2013-2014),
and l’Institut Curie in Paris (2010-2013), University of Padova (2015) and at National
Institute of Molecular Genetics (INGM) – University of Milan (2015-2017).
As researcher she has published different papers on peerrewied international magazines,
included Nature Immunology, and a book. (24 Scientific papers – h index 11).
List of relevant previous projects or activities, connected to the subject of this proposal :
. IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the
implementation of the roadmap in liaison with the Italian ministry of Health;
. ERA-PerMed: we are WP leader of the ERA-PerMed, and we have committed for the JTC 2018 4 Million
€
. ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016
and has committed 1 Million € for the call. The support will continue in the JTC 2017.
. TITTAN (Interreg Europe): Fostering the design, uptake and use of innovative technology based products
and solutions for a healthy and active ageing.
. TARGET: TAking a Reflexive approach to Gender Equality for institutional Transformation. We are
partner of the project whose aim is to contribute to the advancement of gender equality in research and
innovation (R&I) by supporting a reflexive gender equality policy in seven Gender Equality Innovating
Institutions (GEIIs) in the Mediterranean basin.
24-FGB
Full legal name (Acronym) – Country Fondazione per la Ricerca Farmacologica Gianni Benzi onlus
(FGB)- Italy
Principal investigator Viviana Giannuzzi
Relevant Network ENERCA, TEDDY
Description of the legal entity/department/laboratory/group:
Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus (FGB) is a registered not-for-profit scientific
research organisation promoting research in biological, medical and pharmaceutical areas, with particular reference
to patients affected by rare diseases and other populations with specific therapeutic needs. FGB aims are inspired to
the work of Professor Gianmartino Benzi, a scientist who dedicated a large part of his life to promoting the
translation of the emerging biological and pharmacological discoveries into new products for humans, as expert and
member of the EMA Management Board and COMP.
FGB main effort in the rare diseases field is EuOrphan, a database collecting regulatory and scientific information
on drugs having orphan designation and/or approval for rare diseases in the EU and US. Analyses of developmental
status, research results, marketing success and availability for patients are regularly produced. Originated by an
eTen grant (510774 2003/C 118/19), it is voluntarily managed by FGB since 2008.
FGB activities are mainly focused on the regulatory, ethical and methodological support to research. In the context
of national and international collaborative projects, FGB contributes to the plan and conduct of clinical studies and
project management. Besides research, FGB activities are addressed to training activities consolidating the existing
knowledge in regulatory sciences, including the annual ‘Foresight Training Courses’.
More recently, FGB has hosted an IT & Research laboratory applied to clinical and pharmaceutical research
formally acknowledged as Research Organisation/Laboratory in the list of Living Labs organisations (Apulia
Region). The laboratory is also working on the design and implementation of patient registries.
Main tasks in the project per Pillar/WP:
FGB will co-lead WP4 of transversal activities and will lead Tasks 4.1 and 4.2, coordinating regulatory and ethical
activities.
825575 – EJP RD – Part B 90
Pillar 3: In WP16, we will co-coordinate the e-learning module Associated
on social with
sciences andRef.
document humanities applied- 28/11/2018
Ares(2018)6091977 to RD
(task 16.2).
Pillar 4: In WP19, we will support the identification of suitable funding opportunities (task 19.2).
Previous experience relevant to the Tasks:
With regards to regulatory and ethics, FGB 1) has acted as a partner of the following projects to deal with the
compliance with the relevant requirements in interventional and non-interventional clinical studies, consent and
assent process, data collection and analysis, secondary use: ARPEC (2009 11 01, Health Programme), CloSed,
DEEP, EPIICAL (Viiv Healthcare grant), GAPP (FP7-HEALTH-2013-INNOVATION-1-602962), GRiP (FP7-
HEALTH–2010-261060), InNerMeD, SMART (H2020-TWINN-2015-692327), High-Technology District “Health
and Biotechnology” (H-BIO Puglia); 2) has organised training activities at national and international level: ten
annual ‘Foresight Training Courses’ devoted to create a critical mass of experts in the field of the regulatory
sciences and two international e-learning courses on registrative procedures and regulatory novelties; 3) has
participated in public consultations on European policies and regulations.
FGB will support and guide the identification of funding for projects as foreseen in Pillar 4 (WP1), thanks to the
consolidated experience in not-for-profit research networking, funds scouting and applications.
Finally, FGB participates in the c4c project, as responsible of WP5 dealing with research performance and quality,
utility, reusability, and uniformity of data gathered from the studies performed by c4c.
Overall, the robust expertise in the regulatory and ethical field as well as in the standardised collection of data on
rare diseases represents a key element to provide EJP with a well-addressed coordination of these activities
spanning from the conduction of clinical and non-clinical studies and regulatory validation procedures to the
collection of health data, guidance for researchers and protection of patient rights.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
FGB hosts an IT & Research laboratory that develops platforms, databases and other tools (e.g., surveys and e-
learning environment) to support research activities.
FGB manages two databases in the rare diseases field: 1) EuOrphan, developed on Windows Server 2008 operating
system and using SQL Express 2008 for data storage. Queries are designed for the advanced research by active
substance, therapeutic area, sponsor, trade name, type of disease; 2) HTA-THAL, a patients’ registry based on
electronic case report forms, one for adults and one for minors, written in HTML language using scripts in PHP and
JAVA language. Data are stored on MySQL database. It is hosted on servers with RAID 5 disks with HDSL
connection and daily backup. A user authentication system controls the access for data entry and standard security
measures have been adopted. According to the relevant rules, patient data are anonymised and securely stored in
each centre. Forms to obtain the patient's consent have been developed.
In the framework of InNerMeD project, FGB issued the IT platform containing regulatory, genetic, clinical and
therapeutic information, as collected through advanced crowling and data mining services from pre-selected public
databases after a validation process carried out by the network.
Short Profile of key Staff Members who will be undertaking the work
Dr Viviana Giannuzzi PharmD, PhD, post-graduate Degree Master in Clinical Research of Medicines,
(female) PDCO alternate member representing patients affected by rare
haemoglobinopathies. Researcher, ethical and regulatory expert, project manager
of EuOrphan, scientific director of Foresight Training Courses at FGB. She was
the Scientific Secretary of the Ethics Committee in Lecce (IT).
Eng Fedele Bonifazi Biomedical Engineer, post-graduate Master in HTA and Management, member
(male) of HTA working group in the Apulia Region Health Agency, expert for the
Health Dept of Basilicata Region. FGB Vice President. Project Manager of many
projects (GRiP, TEDDY, InNerMeD, HTA-Thal).
Mrs Annalisa Landi PharmD and student of the second level postgraduate Master in Regulatory
(female) Sciences “G.Benzi”. Research Assistant at FGB, where she is involved in
scientific and regulatory activities related to data protection and confidentiality,
patient registries and medicine databases management.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. Giannuzzi V, Landi A, Bosone E, et al. Failures to further developing orphan medicinal products after
designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs. BMJ Open.
2017;7(9):e017358.
2. Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of
patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017;12(1):64.
825575 – EJP RD – Part B 91
3. Giannuzzi V, Devlieger H, Margari L, et al. The ethical framework for with
Associated performing research
document Ref. with rare inherited
Ares(2018)6091977 - 28/11/2018
neurometabolic disease patients. Eur J Pediatr. 2017;176(3):395-405.
4. Ruggieri L, Giannuzzi V, Baiardi P, et al. Successful private-public funding of paediatric medicines research:
lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. 2015;174(4):481-91.
5. Bonifazi F, Conte R, Baiardi P, et al. on behalf of HTA-THAL Multiregional Registry. Pattern of complications
and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin. 2017; 33(8):1525-33.
List of relevant previous projects or activities, connected to the subject of this proposal:
1. InNerMeD-I-network; 2nd Health Programme 2008-2013 – G.A. n. 2012 12 12; 01/04/2013 - 31/05/2016. It was
aimed to create a network of information on diagnosis and treatment of inherited neurometabolic diseases, based
on the collection and exchange of information. FGB was in charge of developing the IT platform, preparing
ethical and methodological recommendations and supported the project management.
2. DEEP; FP7-HEALTH-2010 G.A. n. 261483; 01/01/2011 - 31/08/2016. Is aimed to study the efficacy and safety
of deferiprone in children affected by rare transfusion-dependent haemoglobinopathies. FGB was involved in
regulatory and ethical issues and pharmacoeconomic analyses.
3. c4c; H2020-JTI-IMI2-2016-10-04; proposal number 777389-2; 01/05/2018 (foreseen start date). It aims to
generate a sustainable infrastructure on paediatric trials. FGB co-leads WP5 “Data coordinating centre and data
quality standards” to contribute to implementing performance metrics, quality improvement plan of expert
groups, training materials, and awareness and dissemination campaign.
4. PEPPER; DETERMINAZIONE 22-12-2017, n. 162 “POR Puglia FESR-FSE 2014-2020 - “Innolabs”;
01/04/2018 - 01/09/2019 (foreseen). It is aimed to set up and validate methodologies and tools to evaluate
research performance and quality in all the different phases (trials, prototyping, basic research). The system will
suggest corrective/improvement measures for performance optimization.
5. CloSed; FP7-HEALTH-2013-INNOVATION-1 G.A. n. 602453; 01/12/2013 – ongoing. It is aimed to perform a
multinational paediatric trial on clonidine for sedation in the intensive care. FGB is involved in regulatory,
ethical and dissemination activities, and supports the project management.
25-FTELE
Full legal name (Acronym) – Country Fondazione Telethon (FTELE) - Italy
Principal investigator Lucia Faccio
Relevant Network UDNI, EuroBioBank, IRDiRC, NORD, Rete delle Associazioni Amiche
di Fondazione Telethon, ENMC, Alliance Regenerative Medicine
Description of the legal entity/department/laboratory/group:
Fondazione Telethon is an Italian charity founded in 1990 at the behest of a group of patients to support research on
rare genetic diseases. Research is the central activity that FTELE pursues to fulfil its mission. This is done through
both intramural research in three Telethon institutes (all focusing on rare genetic diseases) directly managed by
FTELE and research performed in extramural laboratories funded through competitive calls.
FTELE invests in the whole pipeline of research, from basic laboratory research up to clinical studies, as well as in
the support of infrastructures for research, such as the Telethon Network of Genetic Biobanks. As a charity, FTELE
has also built a strong expertise in drug development, including patenting, negotiation and management of
industrial alliances and regulatory affairs. Moreover, FTELE, being a reference for RD patients, works in
partnership with almost 200 Italian patient organizations.
Main tasks in the project per Pillar/WP:
Pillar 0:
In WP2 FTELE co-leads Task 2.1: Prioritization scheme for EJP-RD actions. FTELE is involved in Task 2.5:
Translation/impact of prioritization on national and EU strategies. FTELE also co-leads WP4 and is
responsible of Task 4.3: Managing legal and IPR issues
Pillar 2:
FTELE participates in a number of tasks related with the development, monitoring and management of
RD Biobanks data and related networking activities (WP10, WP11, WP12). Below listed 3rd parties will contribute
use cases.
Pillar 3:
In WP14, FTELE contributes to Task 14.3 and leads Task 14.4: Training for biobanks and
researchers/clinicians on sample data management. FTELE participates in activities of WP18 on Development and
adaptation of training activities.
Pillar 4:
FTELE co-leads WP19, participates in Task 19.1 and is responsible of Task 19.2: Support in exploitation and
825575 – EJP RD – Part B 92
follow-on funding Associated with document Ref. Ares(2018)6091977 - 28/11/2018
and co-responsible of Task 19.4: Roadmap for a European investment platform for RD.
Previous experience relevant to the Tasks:
IP and Research Exploitation: FTELE currently has a portfolio of 36 active patent families and is involved in 5
alliances with industrial partners for the development of therapies for 14 rare/genetic disorders. Moreover in 2017
FTELE in partnership with Sofinnova designed a technology transfer fund dedicated to RD in Italy that was
approved by the European Investment Fund Board of Directors in November of the same year.
Biobanking: FTELE has been supporting EuroBioBank since 2012, in the role of administrative coordinator and
more recently as general coordinator. EuroBioBank has become the biobank network of RD-Connect, whose
biobanking work-package is led by FTELE. Within RD-Connect, FTELE has continued to work towards alignment
of data models and FAIR principles, interoperability and quality protocols of EuroBioBank biobanks with new-
generation tools.
Patients’ empowerment: FTELE has set an informal network of 200 Patient Organizations called Telethon
Friends with the aim of sharing information on research. Since 2009 FTELE trained more than 1.000 patients
through annual meetings focusing on the mechanism of research and its tools (Clinical Trials, biobanks, registries,
etc.).
Short Profile of key Staff Members who will be undertaking the work
Lucia Faccio, Lucia is the Director of Research & Development at FTELE. She directs a team of 18
PhD, Female professionals in charge of the peer reviewed research evaluation process, monitoring of research
results, strategic analyses of performance and translational potential of the funded research,
technology transfer, intellectual property protection, regulatory affairs, negotiation and
management of alliances with partnering organizations. Lucia has more than 17 years of
technology transfer and business development experience in the life science field. Lucia obtained
a PhD in Biotechnology in association with the Harvard Medical School.
Simona Simona is the IP Manager at FTELE and has over 12 years of experience as a patent professional
Varani, in the life science field. Previously Simona was a partner of Zebra Ventures, a consultancy firm
Female dedicated to providing business development, licensing and IP support to life-science companies
and academic institutions. She also served as head of IP for Allozyne Inc, a US Biotech company
based in Seattle, and BioXell SpA, an Italian biopharmaceutical Company. Simona has a degree
in pharmaceutical chemistry obtained from the University of Milan.
Chiuhui Mary Mary has been working in the field of RD biobanking since 2014 and is managing the biobank
Wang, PhD, activities in RD-Connect and EuroBioBank. Mary is experienced in organising international
Female biobank training workshops and webinars. At Telethon she also oversees the program support for
the Telethon Network of Genetic Biobanks. Mary received her PhD in Cell Biology from
University College London, UK. After the completion of her PhD she worked as postdoctoral
researcher in the UK and Italy.
Lucia Lucia is the Head of Research Impact and Strategic Analysis of FTELE and was Telethon’s Chief
Monaco, PhD, Scientific Officer between 2008 and 2017. She is leading the biobanking WP of RD-Connect and
Female is the EuroBioBank coordinator. She represents FTELE in IRDiRC and is a member of the
Horizon 2020 Advisory Group for Societal Challenge 1 – Health, demographic change and well-
being.
Alessia Alessia is the manager of relations with Patient Organizations and coordinator of the Telethon
Daturi, helpline for RD. She has been working at FTELE since 2006 taking care of patients’ advocacy
Female and empowerment. She graduated in Philosophy at the Università Cattolica del Sacro Cuore of
Milan and specialized in Business and Social Communication for non profit organizations.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. L. Monaco, L. Faccio, Patient-driven search for rare disease therapies: the Fondazione Telethon success story
and the strategy leading to Strimvelis, EMBO Molecular Medicine, 2017
2. S. Gainotti, et.al., The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata
among rare disease researchers. Eur J Hum Genet. 2018
3. C. Baldo et.al., The alliance between genetic biobanks and patient organisations: the experience of the telethon
network of genetic biobanks. Orphanet J Rare Dis. 2016
4. M. Mora et.al., EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational
biobanking for rare diseases. Eur J Hum Genet. 2015
5. Willmann R., et. Al., 227th ENMC International Workshop:: Finalizing a plan to guarantee quality in
translational research for neuromuscular diseases Heemskerk, Netherlands, 10-11 February 2017, Neuromuscul
Disord. 2018
825575 – EJP RD – Part B 93
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal:
document Ref. Ares(2018)6091977 - 28/11/2018
1. RD-Connect; European Commission – FP7; 2012-2018, leader of the WP on biobanks.
2. Determinazione Rara; Ministero del Lavoro e delle Politiche Sociali; 2013-2014, FTELE has provided contents
and speakers for the experience-based training for Patient Organisations on clinical trials, registries and
biobabanks.
3. T2B – Translation to Business; Regione Lombardia, 2017-2018, coordinator of the feasibility study for a PoC-
like call at Regional level in the biomedical sector.
4. Sofinnova Telethon SCA; European Investment Fund, 2018-2030, Technology transfer fund focused on early
stage life sciences investments, primarily supporting the development of therapies and drugs for rare genetic
diseases, in Italy.
26-ISS
Full legal name (Acronym) – Country Istituto Superiore di Sanità (ISS), Italy
Principal investigator Domenica Taruscio
Relevant Network ECRIN, EATRIS, UDNI
Description of the legal entity/department/laboratory/group:
The Istituto Superiore di Sanità (ISS), Rome, Italy, is the scientific advisory body of the National Health System in
Italy, namely of the Ministry of Health, the Regions and the Local Health Unit. The National Health Fund allocates
to the ISS resources for research and action according to the objectives of the National Health Plan. The ISS
undertakes research funding, management and training functions in relation to public health in Italy.
The ISS: a) collaborates with the Minister of Health in preparing and implementing scientific and health planning;
b) promotes programmes in line with the objectives of the National Health Plan, and c) promotes
programmes of research on the relationship between environment and health, as well as programmes and clinical
trials of national interest. With regard to rare diseases, the ISS, through the National Centre for Rare Diseases, acts
as a coordinator of rare disease research, surveillance and public health actions at the national and international
levels. Actually, the ISS is one of the key bodies targeting health-related aspects of rare diseases in Italy; in
particular, the ISS coordinates the Italian Network on Rare Diseases; it is responsible for the organization and
implementation of the National Registry of Rare Diseases.
Main tasks in the project per Pillar/WP:
Pillar 0: COORDINATION & TRANSVERSAL ACTIVITIES
ISS will be co-leader in
- WP2 Integrative research and innovation strategy
- Task 2.2 Mapping the research and innovation needs
- Task 2.5: Translation/impact of prioritization on national and EU strategies of WP2
ISS will be Partner in
- Task 2.1: Prioritization scheme for EJP RD actions
- Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with
Task Forces of IRDiRC
Pillar 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR A
TRANSFORMATIVE RARE DISEASE RESEARCH
ISS will be leader of
- Subtask 13.1.8. Environmental toxicology of Task 13.1: Fill a number of pre identified gaps to allow
integrative systems biology approaches for rare diseases
ISS will be co-leader in
- Subtask 10.1.1 (“Whole-RD-community annual retreat”) of the Task 10.1 (“Convene yearly retreats
leading to Pillar 2 annual strategic plans”)
ISS will be partner
- Task 10.5: Sustainability and scaling up
- Task 11.3: Data deposition and access to data infrastructures for RD research
- Task 11.4: Provision of RD analysis and data sharing capabilities through online resources
ISS will participate in kind in the activities of WP12: Enabling sustainable FAIRness and Federation at the record
level for RD data, patients and samples
Pillar 3 CAPACITY BUILDING & EMPOWERMENT
ISS will be leader of
825575 – EJP RD – Part B 94
- WP 14: Training on data management & quality Associated with document Ref. Ares(2018)6091977 - 28/11/2018
- Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases
- Task 14.5: Training on rare disease registries and FAIRification of data at the source
ISS will be partner of:
- Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice
- Task 15.3: Training for patient representatives and advocates on leadership and communication skills
- Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant
adaptation of training activities
- Task 18.2: Evaluation of strategic priorities and development of existing training activities according to
specific needs of EU-13 countries
Previous experience relevant to the Tasks:
National Centre for Rare Diseases (CNMR) employs a wide range of scientific and technical expertise from
various fields (medicine, genetics, molecular biology, epidemiology, public health, psychology, sociology etc.)
and holds a network of national and international collaborations, which allow the development of a sound and
integrated approach to RDs. The history of the CNMR dates back to the institution of the National Registry for
Rare Diseases in 2001, which was the first nucleus of the Centre and now there are also specific rare disease
registries maintained by the CNMR. A number of national, European and international projects on RDs are
undertaken yearly by the Centre.
The CNMR holds a portal on RDs which provides topics of interest to RD patients, to the scientific community
and to anyone interested in RDs .
Every year, the CNMR organises a number of education and training activities on RD directed to various
stakeholders (patients and their families, patient organisations, physicians, nurse practitioners, paediatricians,
residents of professional schools, etc.)
Since 2013 the Center has organised and held a specific course on Rare Disease and Orphan drug registries for
health professionals, researchers, clinicians and representatives of patient associations engaged in rare disease
patient registries.
The Center is actively involved in undiagnosed rare diseases research at National and International level.
Since 2016, at National level the Center, is coordinator of a project (namely "Undiagnosed Rare Diseases: a joint
Italy - USA project" funded by Ministry of Foreign Affairs and International Cooperation) aimed at developing a
national strategy to foster undiagnosed rare diseases. At International level the Center is co-founder of the
"undiagnosed diseases network international" network established in 2014 across several countries to improve the
rate of definite diagnosis for persons living with undiagnosed conditions.
Short Profile of key Staff Members who will be undertaking the work
Dr. Domenica Degree in Medicine and Surgery. Post graduate Specialist in Histopathology. Post-doctoral fellow
Taruscio/F in Human Genetics (Yale University, USA) and Ethics. Director of the Italian National Centre for
Rare Diseases (Istituto Superiore di Sanità). Responsible of the Italian National Registry for Rare
diseases. Coordinator of the following EU projects: NEPHIRD, EUROPLAN, EPIRARE, RARE-
BestPractices. WP Leader: ADVANCE HTA, EUROCAT JA, E-RARE, RD-Connect. WP co-
Leader: Endo-ERN, EuRRECa. Member of: EU Task Force on Rare Diseases, Expert EU
Commission Group on Rare Diseases, EMQN Management Board. Coordinator of the Italy-USA
bilateral project “Undiagnosed Rare Diseases”. Advisory Member of SOLVE-RD. Co-Founder of
Undiagnosed Diseases Network International (UDNI, www.udni.org). Past President and Board
Member of ICORD (www.icord.se). Vice Chair of ISC IRDiRC (www.irdirc.org). Coauthor of
more the 150 peer reviewed publications
(https://www.ncbi.nlm.nih.gov/pubmed/?term=taruscio+d)
Prof. Degree in Medicine and Surgery-Postgraduate Specialist in Hygiene and Preventive Medicine
Gualtiero President of Istituto Superiore di Sanità (ISS) from September 2015 . Expert Panel Member on the
(Walter) Effective Ways of Investing in Health (EXPH) European Commission,DG SANTE. Coordinator
Ricciardi/M of TO-REACH consortium (producing research evidence supporting health care services and
systems to become more resilient, effective, equitable, accessible, sustainable and comprehensive
(in Europe, and abroad).
Dr Claudio Claudio has a PhD in Biomedical and Cytomorphological Sciences. His previous research was
Carta/M focused on the molecular basis of RASopathies caused by mutations affecting genes involved in
the RAS-MAPK pathway. Since October 2012, he has been working as a researcher at the
National Center for Rare Diseases, Istituto Superiore di Sanità. His current work focuses on data
management for rare disease registries and particularly on how to make registries Findable
Accessible Interoperable and Reusable (FAIR) for humans and computers with other registries,
biobanks and bioinformatics data
825575 – EJP RD – Part B 95
Dr Marco Researcher in Molecular Genetics at the National Center
Associated withRare Diseases,
document Istituto Superiore
Ref. Ares(2018)6091977 di
- 28/11/2018
Salvatore/M Sanità. His research is focused on rare diseases and on undiagnosed rare diseases; in particular he
studied i) the role of specific microRNAs in the biology of rare diseases (i.e. Hepatolastoma,
Hailey-Hailey disease; osteocondromas); ii) the role of specific genetic markers for diagnosis and
prognosis of rare tumours.
He is member of the coordination Team of National program for External Quality Assessment of
genetic test and for Sweat choloride test for cystic fibrosis. He attended at the Management Board
of the European Molecular Quality Network (EMQN) (2008-14, on behalf of Italian member). He
is member of Undiagnosed Diseases Network International (UDNI) and is member of the
coordination team of the Italian Project for Undiagnosed Rare Diseases (Italy-USA bilateral
framework). From 2016 he is member of the Scientific Committee of the Italian Cystic Fibrosis
(CF) Patient Registry.
Dr Alberto AM (DVM, MSc) is a senior scientist with a long-standing expertise in toxicology and
Mantovani/M toxicological risk assessment, mainly on endocrine disruptors,but encompassing also trace
elements, nanomaterials and pesticides . AM is a toxicology expert in EFSA Panels since 2003; in
particular he has been member of the PPR Panel (pesticides, 2012-5) where he has contributed to
the opinion on the use of AOP to elucidate the potential links between pesticide exposure and
human diseases (Parkinson's disease, childhood leukemia) (2017). He is principal investigator for
ISS in the H2020 project Eu-ToxRisk (wwww.eu-toxrisk.eu) pivoting on AOP development
Dr. Paola Graduated in Chemistry and Pharmaceutical Technologies, Researcher at the National Center for
Torreri /F Rare Diseases, Management of E-rare project: ERA-Net for Research Programmes on Rare
Diseases; collaboration on RD-Connect project especially for the activities of WP2 on rare disease
registries. Management of the Italian National Rare Disease Registry
Dr. MD, specialised in Epidemiology and Public Health and PhD in Public Health. She is a researcher
Yllka Kodra/F at the National Centre for Rare Diseases. Her key qualifications are: expertise in epidemiology
and public health, design/implementation of rare disease and congenital malformations registry,
biostatistical analysis, disease classification system, Patient-reported outcomes (PROs) studies,
design/implementation of neonatal screening programme
De Santis She’s researcher at the National Centre for Rare Diseases, where she’s the coordinator of the
Marta/F National Helpline for Rare Diseases and of the network of institutional helpline “R.I.C.A.Ma.Re”.
She's responsible for liaising with the Patient Associations; she participates as a speaker/teacher in
conferences and courses and promotes training&information initiatives for the general public and
specifically to the patients (e.g. Educational programs for patients on several issues on RD as
orphan drugs and expanded newborn Screening; Open Days on Rare Diseases, Parent training
courses to family members of people with rare disease, ecc). She's deputy representative of Dr.
Taruscio on the Italian Scientific Board of the EUPATI project ("European Patients' Academy on
Therapeutic Innovation"). Currently a member of the Coordinating Team of Task 2.5 "Sustainable
Health Systems for Rare Diseases" in Work package 2 - Joint Action "RD-ACTION. Data and
policies for rare diseases "(2015-2018).
Angela She’s a psychologist and works at the National Centre for Rare Diseases-Istituto Superiore di
Ruocco/F Sanità. She’s a counselor of the National Helpline for Rare Diseases and is a member of the
coordinating team of the network of institutional helpline “R.I.C.A.Ma.Re”. She collaborates in
open days on rare diseases and several training/informative initiatives aimed at patient
associations. She’s member of the organizational staff of “Volo di Pegaso”, artistic, literary and
musical contest on rare diseases. She's in the staff of an association that deals with the rights of
the weakest part of the population end leads self-help groups. She participates as speaker in
conferences and courses on social inclusion.
Federica Researcher at National Centre of Rare Diseases; Degree in Biology; specialist medical training in
Censi/F medical genetics. I have a broad background in human genetic, with specific expertise in Genetic
testing. She carried out the Organization of the Italian External Quality Assessment for nine
schemes of genetic testing included Oncology genetic, Cytogenetics and Molecular Genetics
Fabrizio Tosto Researcher at National Centre of Rare Diseases; Degree in Biology. He has a broad background in
/M genetic testing, with long experience in External Quality Assessment in Genetic Testing
Organization. He carried out the Organization of the Italian External Quality Assessment for nine
schemes of genetic testing included in the area of Oncology genetic, Cytogenetics and Molecular
Genetics.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
825575 – EJP RD – Part B 96
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
1.The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease
researchers. Eur J Hum Genet. 2018 Feb 2.
2. Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017; Adv Exp Med Biol. 2017;1031:149-164.
3. Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases
Lacking a Diagnosis. Adv Exp Med Biol. 2017;1031:25-38. doi: 10.1007/978-3-319-67144-4_2.
4. Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017
Nov;91(11):3477-3505
5. Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer. Biomed Res Int.
2017;2017:8327980.
List of relevant previous projects or activities, connected to the subject of this proposal :
. EPIRARE (European Platform for Rare Disease Registries); 2011-2013; is a three-year project co-funded by the
European Commission within the EU Program of Community Action in the field of Public Health. ISS was the
coordinator. The general objective of the EPIRARE project is to build consensus and synergies to address legal,
ethical and technical issues associated with the registration of RD patients and to elaborate a proposal for a EU
web-based multi-disease platform which, by sharing information and resources, can increase the sustainability of
registries, promotes the use of standards and of registry quality procedures and provides an effective way of
dissemination of the results.
. RD‐Connect; FP7; 2012-2018, ISS is WP leader " Databases/patient registries" in the European RD-Connect
project, and developed the online searchable catalogue that is meant to offer detailed information on the content
of the databases included
. E-rare3: "ERA-NET rare disease research implementing IRDiRC objectives", Horizon 2020, 2015-2020-ISS is
WP leader “Strengthening research collaboration and enhancing knowledge translation”
. RD-Action; EU Health Programme-2015-2018, promoting implementation of recommendations on policy,
information and data for RD; the ISS is co-leader, with EURORDIS, of Workpackage 2, focused on
"Communication and dissemination", and Leader of Task 2.5 (WP2) “Sustainable Health Systems for Rare
Diseases”. This Task aims to support national authorities to quantify the burden of RDs and available resources
for sustainable and resilient health systems, taking into account principles of equity, quality and efficiency, and
involving stakeholders, policy makers, and civil servants in charge of national strategies on RDs.
. TO-REACH is a coordination and support action (CSA) to prepare a joint European research programme aimed
at producing research evidence supporting health care services and systems to become more resilient, effective,
equitable, accessible, sustainable and comprehensive (in Europe, and abroad). ISS is the coordinator.
27-CVBF
Full legal name (Acronym) – Country Consorzio per Valutazioni Biologiche e Farmacologiche
(CVBF) - Italy
Principal investigator Giovanni Migliaccio
Relevant Network EPTRI, TEDDY, C4C, INCiPiT, Enpr-EMA, EUCROF,
AICRO
Description of the legal entity/department/laboratory/group:
Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a non-profit organization whose mission is to
perform research and education in the pharmaceutical field integrating regulatory, methodological, ethical, clinical,
epidemiological, economical and statistical expertise.
CVBF has a longlasting experience in performing paediatric clinical trials where CVBF a) acts as sponsor and
project coordinator of independent trials; b) provides specific services related to clinical trial management, data
collection and storage, clinical operations, drug management, monitoring and quality assurance, clinical study
reports and statistics, c) is registered in EudraVigilance to perform pharmacovigilance activities.
CVBF has also developed a European Paediatric Medicines Database (EPMD) including information on medicines
approved for children by EMA (indication, dosages, by age populations, studies and trials, etc).
CVBF has significant expertise in the project coordination, conducting research activities mainly in the context of
national and EU funded projects and being Coordinator of two FP7 projects (DEEP, GAPP) and Partner in many
other projects funded by the European Commission (DG-Research and DG-SANCO). CVBF will participate to the
825575 – EJP RD – Part B 97
conect4children (C4C) pan-European Paediatric Clinical Trial Network funded
Associated under theRef.
with document IMI2 call 10.
Ares(2018)6091977 - 28/11/2018
CVBF is the Coordinator of EPTRI (European Paediatric Translational Research Infrastructure), funded as a
Horizon 2020 project, a new complementary Research Infrastructure (RI) in the context of the existing RIs
intended to putting together and networking all the available competences and technologies useful to enhance
paediatric research in paediatric medicines from drug discovery and early development phases to be translated into
clinical phases and medicines uses. To harness efficiency in delivery of paediatric research activities and services,
EPTRI will act as a ‘Paediatric Common Service’ in the ESFRI (European Strategy Forum on Research
Infrastructures) scenario and will cover all the different scientific domains grouped in the following five thematic
platforms: 1. Pediatric Medicines Discovery and Preclinical Studies; 2. Biomarkers; 3. Paediatric Pharmacology, 4.
Formulation Science, 5. Underpinning Paediatric Studies.
EPTRI involves 26 partners from 19 EU and non-EU countries including consolidated research infrastructures, top-
level universities, research centers of excellence in Europe.
Main tasks in the project per Pillar/WP:
Pillar 0
WP1 Coordination and Management
CVBF will lead task 1.3 (Monitoring of the EJP RD activities and achievements), aimed to evaluate the quality of
the EJP RD activities and the achievement of the expected project goals.
The task is further divided into:
• subtask 1.3.1 (Identification of key performance indicators), leaded by ULIV
• subtask 1.3.2 (Implementation of the monitoring process), leaded by CVBF.
WP2 Integrative research and innovation strategy
CVBF will co-lead task 2.1 (Prioritization scheme for EJP RD actions).
Pillar 4
WP19 Facilitating partnerships and accelerating translation for higher patient impact
CVBF will co-lead task 19.1 (Accelerating translation). In particular, will lead subtask 19.1.1 (Innovation
Management Toolbox) contributing to structure and empower translational research in EU by providing key
paediatric competences into operational Platforms for enhancing and optimizing the use of key technologies to be
included in the rare diseases medicines developmental process, and will participate in the following subtasks:
• subtask 19.1.2 Assessment of translational research projects
• subtask 19.1.3 Real-time mentoring and technical support for translational research projects
CVBF will also participate in task 19.2 (Support in exploitation and follow-on funding).
Previous experience relevant to the Tasks:
CVBF is the Coordinator of EPTRI that is aimed to overcome fragmentation, leading to efficacious use of data and
resources and a faster scientific progress. Through EPTRI many dispersed and disaggregated paediatric research
expertise will be linked and integrated, increasing collaboration and sharing of facilities, resources and related
services. EPTRI will act as a “one-stop-shop” for advice in order to bridge the existing gaps in paediatric medicines
research and development and contribute to EJP RD by providing data from its operational Platforms, including
information on target drugs, new molecules, biomarkers, clinical and non-clinical innovative study results,
databases and repositories of research data. In this way, CVBF and EPTRI will contribute in accelerating discovery
by rapidly validating hypothesis that can give rise to further research and in producing interoperable re-usable data
for researchers.
CVBF has developed many surveys to increase the knowledge about different paediatric issues and currently is
developing within EPTRI a large inventory of existing paediatric research resources allowing to bridge dispersed
resources in a common interoperable infrastructure, including:
1) centers involved in new discovery and target identification for paediatric untreated diseases (mainly Rare
diseases);
2) available resources (including data and samples repositories/databases) related to paediatric disease and
pharmacological characteristics including neonates and placental research (paediatric PKPD population data and/or
modelling/simulation/extrapolation application, biobanks and databases collecting data and sample from children
affected by many rare pathologies including RPME data): the goal of this collection is to identify clinical,
demographic and genetic biomarkers possibly linked to clinical diagnostic and therapeutic data;
3) all available good methodological guidelines usable in each sector for new therapies identification, diagnosis
and treatment monitoring.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
CVBF manages several databases and registries such as the Inventory of the Ethical and Regulatory procedures for
paediatric clinical trial (CT) approval and conduction in EU and non-EU countries and the EPMD database related
825575 – EJP RD – Part B 98
to drugs for children authorised by the EMA under the centralised Associated
procedure.
with document Ref. Ares(2018)6091977 - 28/11/2018
CVBF has managed the certification process and the interoperability of a network of human biobanks in the project
RIMedRI (Integrated clinical and biological Network for Rigenerative Medicine).
CVBF has also created an e-learning platform to provide courses on medicines, regulatory issues and clinical
research. In particular, it is recognised provider of ICH-Good Clinical Practice (GCP) Training by TransCelerate
BioPharma with the e-learning “ICH-Good Clinical Practice (GCP) Training Course”. The course is based on the
international E6 ICH Good Clinical Practice (R2), revised in 2016, and is aimed at providing a guide for all
individuals that are involved in clinical research and clinical. It meets the Minimum Criteria for ICH GCP
Investigator Site Personnel Training identified by TransCelerate BioPharma, as necessary to enable mutual
recognition of GCP training among trial sponsors.
Short Profile of key Staff Members who will be undertaking the work
Donato Bonifazi/Mecon CVBF Chief Executive Officer, economist. Project manager and trial manager in FP7
(male) projects/clinical trials (DEEP – DEferiprone Evaluation in Paediatrics, GA n. 261483;
GAPP – GAbapentin in Paediatric Pain, GA n. 602962). PedCRIN (Paediatric Clinical
Research Infrastructure Network, GA n. 731046) work package leader. ID-EPTRI
(European Paediatric Translational Research Infrastructure, GA n. 777544)
Coordinator.
Pr.Ornella Pastoris President of CVBF, Master Degree in Biological Sciences, Associate Professor of
(female) Pharmacology at the University of Pavia, Department of Molecular Physiological
Pharmacology.
Pr.Lucia Margari Member of the Boards of Director at CVBF. Degree in Medicine and Surgery.
(female) Specialist in Neurology. Full Professor and Director of Specialization School in Child
and Adolescent Neuropsychiatry at University of Bari.
PhD Mariagrazia Felisi Coordinator of the Clinical Research Unit, responsible for the Quality Management
(female) System at CVBF. Master Degree in Pharmacovigilance, she is Qualified Person
(certified as QPPV in EudraVigilance).
Giovanni Migliaccio Senior Advisor at CVBF. He has been EATRIS Scientific Director from 2011 to end of
(male) 2017. He was the Italian National Delegate to the Committee for Advanced Therapies
at EMA from 2009 to 2011. He is currently the sitting member for Advanced Therapies
Medicinal Products in the committees delegated to the authorisation of clinical trials in
Italy.
Pr. Oscar della Pasqua Senior Advisor at CVBF. He holds the Chair of Clinical Pharmacology & Therapeutics
(male) at University College of London and is also affiliated with GlaxoSmithKline. He has
authored over 100 scientific peer-reviewed articles, an H-index of 17 and has a key
interest in drug development and personalised medicine.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Capone, F., Lombardini, L., Pupella, S., Grazzini, G., Costa, A. N., and Migliaccio, G. (2011) Cord blood stem
cell banking: a snapshot of the Italian situation. Transfusion 51, 1985-1994
2. Rubinstein, P., Dobrila, L., Rosenfield, R.E., Adamson, J.W., Migliaccio, G., Migliaccio, A.R., Taylor, P.E. and
Stevens, C.E. (1995) Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow
reconstitution. Proceedings of the National Academy of Sciences of the United States of America, 92, 10119-10122
3. Cella M, Danhof M, Della Pasqua O. Bridging strategies for drug combinations in pediatric indications. Clin
Pharmacol Ther. 2012; 91(4):726-33.
4. Ruggieri L, Giannuzzi V, Baiardi P, Bonifazi F, Davies EH, Giaquinto C, Bonifazi D, Felisi M, Chiron C,
Pressler R, Rabe H, Whitaker MJ, Neubert A, Jacqz-Aigrain E, Eichler I, Turner MA, Ceci A; on behalf of the
GRiP Consortium. Successful private-public funding of paediatric medicines research: lessons from the EU
programme to fund research into off-patent medicines. Eur J Pediatr. 2015 174(4):481-91.
5. Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci
A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP).
Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6
years. Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6.
List of relevant previous projects or activities, connected to the subject of this proposal :
. DEEP (DEferiprone Evaluation in Paediatrics); European Commission, Grant Agreement n°261483 - FP7-
HEALTH-F4-2010; 2011-2016; CVBF is the project Coordinator and provides the overall scientific strategy and
coordination of the project. It is responsible for the project management activities, the planning, designing,
implementation and analysis of the Efficacy/Safety Clinical Trial as well as the dissemination activities. DEEP is
825575 – EJP RD – Part B 99
a project involving EU and non-EU countries to study deferiprone, in children
Associated affected
with document by congenital anaemias
Ref. Ares(2018)6091977 - 28/11/2018
requiring chronic transfusion therapy and iron chelation, such as the β-thalassaemia major and the Sickle Cell
Disease (SCD) and develop a new formulation suitable for children. To this aim, the project has conducted three
multi-national paediatric studies. Results from paediatric clinical studies will be used for a PUMA (Paediatric
Use Marketing Authorisation) application. In the context of DEEP, for the first time the cardiac MRI T2* is
evaluated as primary endpoint and will be validated as biomarker.
. GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7‐HEALTH‐
2013‐INNOVATION‐1; 2013-2017, CVBF is the project Coordinator, responsible of the Project Management
activities, guaranteeing that the project plan is completed in due time with the contribution of all the participating
Beneficiaries and with the highest quality standards) and of the regulatory activities. GAPP is aimed to develop,
test and made available a new formulation of gabapentin for the treatment of neuropathic chronic pain in the
paediatric population. Results from paediatric clinical studies will be used for a PUMA application. Genomic
biomarkers are evaluated in the context of GAPP clinical trials.
. GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7-HEALTH-F5-
2010; 2011-2017. CVBF was partner in the project and was responsible for the development of innovative
methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of two of
the ten modules of the International Master of Science in “Paediatric Medicines Development and Evaluation”.
GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the development and
safe use of medicines in children. An International Master in Paediatric Clinical Pharmacology has been realised
and proposed at global level (Europe, USA, Canada, Japan, China, etc.).
. ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission, Grant
Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; CVBF is coordinator of the project; ID-
EPTRI is aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology-
driven paediatric research in discovery and early development phases to be translated into clinical research and
paediatric use of medicines
. PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement
n°731046 - H2020-INFRADEV-2016-1; 2017-2020; CVBF is partner in the project and is responsible for the
development of tools and databases specific for paediatric and neonatal clinical trials. PedCRIN is a four-year
project funded by the European Union’s Horizon 2020 programme, aimed to bring together the European Clinical
Research Infrastructure Network (ECRIN) and the founding partners of the European Paediatric Clinical Trial
Research Infrastructure (EPCT-RI) to develop capacity for the management of multinational paediatric clinical
trials. PedCRIN will effectively bridge paediatricians and other partners across Europe (and internationally) to
combine resources and expertise to conduct and manage robust studies, while minimising risk and protecting the
child participants
. SMART (Small Medicines Advanced Research Training), European Commission, Grant Agreement n°692327 -
H2020-TWINN-2015, 2016-2018. CVBF is partner in the project and acts as internationally-leading research
institutions providing specific expertise in paediatric clinical trial government and developing, M&S and
Extrapolation applications, new formulation generation. SMART is aimed at raising the Instytut Pomnik Centrum
Zdrowia Dziecka (IPCZD – Poland) staff’s research profile and increase capacity in providing innovative
paediatric research methods. A specific training programme is foreseen.
28-TEDDY
Full legal name (Acronym) – Country European Network of Excellence for Paediatric Clinical Research
(TEDDY) - Italy
Principal investigator Annagrazia Altavilla
Relevant Network Enpr-EMA, ENCePP, EPTRI, C4C, INCiPiT, RECLIP
Description of the legal entity/department/laboratory/group:
TEDDY European Network of Excellence for Paediatric Clinical Research is a scientific organisation arisen from
the Task-force in Europe for Drug Development for the Young, a consortium funded in 2005 as TEDDY project
(LSHB-CT-2005-005216) within the Sixth Framework Programme of the European Commission with the aim to
favour the integration of the paediatric pharmacological research activities, the implementation of adequate health
policies and a social awareness on the importance of the paediatric medicines across Europe covering different
specialty areas (haematology, oncology, infectious diseases, respiratory diseases, intensive care, pain,
endocrinology, rare diseases, neonatology).
At the end of the 5-years funding period, the consortium was further renewed and now TEDDY is operating as an
825575 – EJP RD – Part B 100
independent multidisciplinary, multinational network including 50 members
Associated with documentin
Ref.20 EU and non-
Ares(2018)6091977 EU
- 28/11/2018
countries. In June 2017 TEDDY has acquired an autonomous legal status allowing the Network to be fully
represented and consolidated in the paediatric research community framework.
The main objective of TEDDY network is to promote research on medicinal products in children
providing methodological expertise and implementing good practices, Standard Operating Procedures (SOPs) and
tools to plan, design and perform clinical studies at national and international level.
TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the
European Medicines Agency and registered at ENCePP (the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance), an initiative coordinated by the EMA with the aim of
strengthening post-authorisation research, pharmacoepidemiological research and risk-benefit monitoring of
medicines. TEDDY can count on the expertise and collaboration of researchers, scientists, health experts and
paediatric clinical research centers working together to identify the most appropriate research tools and procedures
that reflect the specificity of the paediatric patient population and collaborates with existing paediatric networks
and research organisations with the goal to promote and foster scientific and technological excellence in paediatric
research.
Thanks to the international recognition and the wide geographical representativeness, TEDDY is able to provide
the paediatric community of: easy dissemination of relevant information; consultation on paediatric drug
development issues; involvement in paediatric studies; documents and recommendations in the sector of paediatric
study methodology.
Moreover, TEDDY has developed many surveys to increase the knowledge about different paediatric issues
(Expert Groups and research priorities in 2007-8, Ethic and Regulatory in 2009 and 2011, Off-label use in 2010)
and currently is managing a Survey on the assessment of paediatric sites’ services and capacities. TEDDY is
particularly committed to setting up and implementing appropriate methodologies to conduct clinical research, with
reference to innovative and traditional studies including population PK study, Modeling & Simulation,
extrapolation. To this aim, TEDDY is both involved in the scientific discussion to prepare and disseminate
recommendations and publication on this issue and in the practical development and conduction of paediatric
national or multinational clinical trials using innovative methodologies.
TEDDY is also particularly engaged in favouring awareness on the topics of paediatric research, to spread
information on the rational use of paediatric medicines and to identify unmet medical needs in paediatrics.
Moreover, by developing ad hoc informative and educational tools, TEDDY aims to increase awareness on the
topics of paediatric research and to encourage the participation of children in all the relevant experimental
procedures.
Regarding the patients empowerment and the involvement in the paediatric clinical research, TEDDY has
promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons Advisory Group (YPAG).
Main tasks in the project per Pillar/WP:
Pillar 3:
In WP15, we will lead the task related to “Educational materials and activities for paediatric patients” (task 15.4)
dedicated to the development and organization of educational materials and activities for paediatric patients.
Several tools such as videos, cartoon and serious game for children and adolescents will be developed and
disseminated and a yearly face to face “paediatric patients experts training course’ will be organized.
Pillar 0: Transversal WP5 “Communication & Dissemination”:
We will be involved in Task 5.2: Integrating EJP-RD communication and dissemination strategies with the
strategies of involved stakeholders. We will be in charge of communication, dissemination and networking
activities, establishing a live mechanism of interactions and providing a link between the parties involved in the
project and the European scientific community.
Previous experience relevant to the Tasks:
Experience of the team relevant to the tasks in the proposal:
- Patients Advocacy on research: TEDDY provides support, education and information to patients and families
regarding their participation in clinical trials. Currently, we have designed different educational resources with
different format, e.g. serious games, comics, videos on the development of clinical trials.
- KIDS Bari and Albania: Regarding the patients empowerment and the involvement in the paediatric clinical
research, TEDDY has promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons
Advisory Group (YPAG) named respectively KIDS Bari (in collaboration with Consorzio per Valutazioni
Biologiche e Farmacologiche and the paediatric University Hospital Azienda Ospedaliero-Universitaria
Consorziale Policlinico di Bari – Ospedale Pediatrico “Giovanni XXIII”) and KIDS Albania (in collaboration with
the Albanian Branch Office of CVBF and the University Hospital Center Tirana “Mother Teresa”, Service of
Paediatrics) in order to provide the youths to be able to help researchers in trials design, prioritizing future
researches, improving communication with the target population and increase awareness on clinical research
825575 – EJP RD – Part B 101
through the different means of communication. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
- Communication and dissemination on clinical research: TEDDY is leading different projects on this field
developing different kind of activities: webinars, social media education, specific website about clinical trials for
patients and families, conferences, etc.
TEDDY has developed age-appropriate informative materials (age-tailored information booklets, assent forms and
videos) to duly inform children and families involved in clinical study, prepared in the framework of the DEEP and
GAPP projects, two EC-FP7 funded project. All the materials have been developed with a language and a wording
appropriate to age, psychological and intellectual maturity, taking into account the cultural and linguistic
differences, in a collaborative effort among pharmacologists, paediatricians, child psychologists and illustrators.
- Training: TEDDY has created an e-learning platform to provide courses on medicines, regulatory issues and
clinical research, realised in the context of the TEDDY FP6 project (http://www.teddylearning.org/).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
To conduct the networking and dissemination activities, TEDDY is able to provide communication and
dissemination activities such as websites and newsletter, in order to deliver relevant publications or guidelines
which were believed to be of interest for the Network and useful to stimulate scientific debate. TEDDY Network
pays particular attention to the theme of the empowerment of paediatric patients in the healthcare field and is
involved in several activities such as:
- Videos (a spoonful of info helps the medicine go down) and training material, specifically addressed to
children explaining some main concepts on drugs and their use.
- Development of age-appropriate informative material to duly inform children and families involved in
clinical studies (e.g. DEEP project informative material)
- Quality evaluation of informative materials addressed to paediatric patients involved in clinical trials
- Advisory group setup in the international paediatric project GAPP
- Analysis of existing Young Person Advisory Groups and improvement of strategies to involve
paediatric patients in the healthcare decisions (GRiP project activity)
- Participation to public consultations and roundtables on this topic.
Finally, TEDDY is always proactive to ensure a collaborative and continuous action involving paediatricians and
healthcare professionals, psychologists, families, children.
An e-learning Platform has been created by TEDDY aimed to distribute to different stakeholders updated
Information on Medicines for children with particular reference to their better use, valuable effects and possible
risks.
Short Profile of key Staff Members who will be undertaking the work
Mariangela Lupo/ M. Lupo has a Master’s Degree in Political Science, International Relations. Bachelor’s
Communication and Degree in Foreign Languages - Linguistic Mediation in the European Union. She is
Patient Advocacy responsible for Communication and Development at TEDDY and involved in the
Manager/ female communication and dissemination activities in several European projects (e.g. GAPP and
DEEP). She is responsible for the activities dedicated to patient’s advocacy and
coordinates the KIDS Bari and KIDS Albania, the first Young Persons Advisory Group in
Italy and in Albania.
Annagrazia Altavilla/ A. Altavilla Professor (PAST) at Aix-Marseille University – EEM (Bioethics Research
Lawyer and Ethicist/ Centre) and lawyer specialised in Health Law and Bioethics (LL.M. in Health Law and
female PhD Sciences –Ethics). Former member of the European Medicine Agency (EMA)
Paediatric Committee (2008/2011) and of the “Third countries clinical trials” EMA
Working Group; rapporteur on ethical and legal aspects of the “Reflection paper on ethical
and GCP aspects of clinical trials of medicinal products for human use conducted in third
countries and submitted to marketing Authorisation to EMA” (2009/2012). Author of a
book and about 40 publications in national and international journals.
Joana Claverol/ CTO Paediatric Clinical trials Unit Manager at FSJD, where she manages and oversees
Coordinator of more than 100 clinical trials in all paediatric specialities. She is paediatric clinical research
Clinical Trial Office consultant for pharmaceutical companies and lecturer of different masters of the University
at HSJD/female of Barcelona, ESAME business school and Moebio. She has over 13 years of medical and
clinical research experience in the pharmaceutical and biotechnology industry, particularly
in Drug Development, Clinical Operations, Commercial, Marketing, Regulatory, and
Medical Affairs functions. Together with Ms Begoña Nafria, she coordinates the Young
Patient’s Advisory Group KIDS Barcelona and the European network of YPAG
(eYPAGnet).
825575 – EJP RD – Part B 102
Begonya Nafría/ Experience in coordinating and managingAssociated
projectswith
in document
clinical Ref.
research on rare diseases.
Ares(2018)6091977 - 28/11/2018
Patient Advocacy Coordinator of YPAG-KIDS Barcelona and RareCommons platform. Fellow of the
Manager on Research EUPATI IMI2 project (first cohort), member of the Course Committee and member of the
at FSJD/ female Spanish National Platform and Course Committee of Eupati. Chair of the Educational
Committee of ICan.
Before her professional relationship with FSJD, she worked during two years as a research
technician of CIBERER (Biomedical Center for the Research on Rare Diseases Networks)
and during three years in a research project about the involvement on clinical research and
health education for patients’ associations in agreement with the Open University of
Catalonia (APTIC Project) and the Hospital Sant Joan de Déu.
Antonella Minervini/ She is responsible for the organization of meetings and training activities within TEDDY
Administrative and
organizational
Manager/ female
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour C, Otto A, Rastegari
M, Berry P. Investigating the roles and training of paediatric research nurses working across Europe: a
questionnaire-based survey. BMJ Paediatrics Open. 2017 August 11
2. Giannuzzi V, Altavilla A, Ruggieri L, Ceci A. Clinical Trial Application in Europe: What will change with the
new Regulation? Sci Eng Ethics. 2016 Apr;22(2):451-66. doi: 10.1007/s11948-015-9662-0. Epub 2015 Jun 3.
3. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A; TEDDY Network of Excellence. Innovative study design
for paediatric clinical trials. Eur J Clin Pharmacol. 2011 May; 67 Suppl 1:109-15.
4. Altavilla A, Manfredi C, Baiardi P, Dehlinger-Kremer M, Galletti P, Pozuelo AA, Chaplin J, Ceci A. Impact of
the new European paediatric regulatory framework on ethics committees: overview and perspectives. Acta Paediatr.
2012 Jan;101(1):27-32.
5. Armayones, M., Camino-León, R., Cantarín, V., De la Fuente, J., Families Lowe Syndrome, S.,
Gómez, B., Maldonado, E., Nafría, B., Ojea, T., Pascual, S., Pérez, B., Pousada, M., Serrano & M., Vidal-
Valls, J. (2013). Results of a families-researchers collaborative project in Lowe Syndrome: ten patients with
a wide neurological phenotype. Journal of Inherited Metabolic Disease, (2), 330. doi: 10.1007/s10545-013-
9635-x.
List of relevant previous projects or activities, connected to the subject of this proposal :
. ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission,
Grant Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; TEDDY is Third party of CVBF
in the project and is involved in the communication , networking and patients engagement; ID-EPTRI is
aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology-
driven paediatric research in discovery and early development phases to be translated into clinical research
and paediatric use of medicines
. GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7‐
HEALTH‐2013‐INNOVATION‐1; 2013-2017, TEDDY was involved in the preparation of age-appropriate
informative materials aimed to duly inform children and families involved in the clinical studies conducted
within the project: GAPP was aimed at designing paediatric studies with gabapentin for the treatment of
chronic pain of neuropathic origin in children.
. PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement
n°731046 - H2020-INFRADEV-2016-1; 2017-2020; TEDDY is involved in the project in developing or
adapting tools to be used for multinational paediatric and neonatal clinical trials. PedCRIN is aimed to
enrich the current ECRIN (European Clinical Research Infrastructure Network) tools and actions with
paediatric components in order to better address the real needs and the gaps of the paediatric research
community.
. GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7-
HEALTH-F5-2010; 2011-2017. TEDDY was involved in the project for the development of innovative
methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of
two of the ten modules of the International Master of Science in “Paediatric Medicines Development and
Evaluation”. GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the
development and safe use of medicines in children. An International Master in Paediatric Clinical
Pharmacology has been realised and proposed at global level (Europe, USA, Canada, Japan, China, etc.).
. RESPECT (Relating Expectations and Needs to the Participation and Empowerment of Children in Clinical
825575 – EJP RD – Part B 103
Trials - 201938 - FP7- HEALTH-2007-4.1-4), a project aimed toAssociated
identify with
thedocument
needs and
Ref.motivations of children
Ares(2018)6091977 - 28/11/2018
and their families participating in clinical trials in Europe. The project makes available recommendations for
researchers about how to empower children, respect their interests and motivate their participation in future
clinical trials. CVBF has provided an extensive knowledge on the ethical procedures with the current European
and national provision (guidance and control), on-line questionnaires (elaboration and validation), statistical
support.
29-MIUR
Full legal name (Acronym) – Country Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR)
- Italy
Main contact / Principal investigator Gianluigi Consoli
Relevant Network NA
Description of the legal entity/department/laboratory/group:
The Italian Ministry for Education, University and Research (MIUR) is the key RTD policy actor and funding
agency in Italy at state level. MIUR is in charge to prepare and to submit the National Research Programme (PNR –
Piano Nazionale della Ricerca) proposal to the Government and to directly manage it. Besides, the Ministry, in
charge of definition of strategic priorities in Research and higher education, has the following responsibilities:
• coordination, assessment and evaluation of the national university system and advanced training schools;
• supporting and fostering basic research in university and research institutions, programming intervention in
public research institutions;
• coordination, regulation and funding of national research institutions;
• coordination of the research activities promoted by other Ministries;
• monitoring and supporting the integration between the research system and industries;
• integration between public research and applied research;
• promoting and supporting research in the industry system;
• funding research programmes for southern regions;
• promoting initiatives such as the Funds for the diffusion of scientific culture;
• enforcement of EU and international rules on university education and research.
The Ministry also has key responsibilities for international co-operation. It concludes bi- and multilateral
agreements on research and technology collaboration and is in charge of co-ordinating Italy’s participation in the
European Union’s Framework Programme.
Main tasks in the project per Pillar/WP:
Pillar 1:
WP 6: Joint Transnational Calls for collaborative research projects.
Previous experience relevant to the Tasks:
MIUR has a large experience in joining Calls for proposals. MIUR has participated in 7 FP6 ERANETs, 11 FP7
ERANET and 3 FP7 ERANET PLUS. MIUR is participating also in more than 20 ERANET Cofund of which:
CoBioTech, CORE Organic, EMEurope, ENSUF, ERA4CS, ERA-HDHL, ERA-MIN 2, EURONANOMED III,
FACCE Surplus, FLAG-ERA II, GEOTHERMICA, HDHL INTIMIC, JPco-fuND, M-ERA.NET2, MANUNET
III, MarTERA, QuantERA, SUSFOOD2, TRANSCAN2, WaterWorks 2014, WaterWorks2015,
WaterWorks2017.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
NA
Short Profile of key Staff Members who will be undertaking the work
Dr Gianluigi Consoli Dr Gianluigi Consoli is in charge as a Head of Planning and promotion of international
(male) scientific research and coordination of aerospace research Office within MIUR. He is also
the Italian representative in several EU initiatives and he is the person in charge of the
administrative, legal and financial aspects in all the ERANET and ERANET+ projects in
which MIUR participates.
Dr Aldo Covello Dr Aldo Covello is a senior scientific advisor for MIUR and represents the ministry in
(male) several European initiatives and committees: JTI ECSEL, JPIs, ERANETs and ERANET+.
Dr Valeria Cardia Dr Valeria Cardia is a Project Officer at MIUR. She is involved in the administrative and
(female) financial management of several European initiatives: JPIs, CSAs, ERANETs, ERANET+
and ERANET Cofund.
825575 – EJP RD – Part B 104
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
30-VIAA
Full legal name (Acronym) – Country VALSTS IZGLITIBAS ATTISTIBAS AGENTURA (VIAA),
LATVIA
Principal investigator Dr. Janis Ancans
Relevant Network E-Rare-3, other subject related ERA NET/ EJP partnership
Description of the legal entity/department/laboratory/group:
VIAA ensures evaluation, administration and supervision of international cooperation programme projects in the
field of science and technology development in the Republic of Latvia.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP7 «Networking to share knowledge on rare diseases», Task 7.2. Evaluation of applications.
VIAA will participate in the Evaluation Committee that will evaluate the applications for network meetings,
workshops or conferences to share knowledge on rare diseases based on specific criteria and on a competitive basis.
This will be performed according to confidentiality and conflict of interest issues rules.
In WP9 Task «Monitoring of granted projects», Task 9.2. Monitoring of networking to share knowledge on rare
diseases (WP2).VIAA will participate in the follow-up, monitoring and assessment of results of the networking
grants funded by the Evaluation Committee under WP7, as the result of Task 7.2 activity.
Previous experience relevant to the Tasks:
VIAA responsibilities include Erasmus+ programme; joint programmes and joint technology initiatives stipulated
in Article 185 and 187 of the Treaty on the Functioning of the European Union as well as EU COST, EJP, JPI,
ERA-NET un ERA-NET+ projects; Euroguidance and Eurydice networks in accordance with the aims and tasks
set out in EU guidelines; administration of the European Economic Area financial instruments, Norway and
Swiss financial instrument programmes and projects; and other international and bilateral programmes. VIAA is
involved in nationwide management of the EU Structural Funds in education and science sector. The Agency
ensures implementation of EU policy initiatives in Latvia in the field of education and science policy.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Human resources with professional expertise relevant to abovementioned Pillar 1 tasks.
Short Profile of key Staff Members who will be undertaking the work
Dr. Janis Ancans Senior expert at VIAA Horizon 2020 National Contact point, responsible for Health,
(male) Demographic Change and Wellbeing since 2017. Previously served as Head of Laboratory
at University of Latvia, 2005-2017. Delegate from Latvia to the Committee for Advanced
Therapies at European Medicines Agency (EMA) 2009 - 2014; European expert at EMA
WPs. External expert at the national medicines agency for medical biotechnology and
biopharmaceutical products. Expert for medical biotechnology and pharmaceutical project
evaluation at Lithuanian Business Support Agency (LBSA) 2013 - 2016. Personal expertise
includes consulting for experimental medicinal, bioanalytical, biotech R&D services
biotechnology service and product development.
TBC (involvement VIAA personal or experts will be involved as required by specific Pillar 1 tasks, including
as required by networking project evaluation stage, and provide expertise on project management, financial
tasks) issues, monitoring and assessment, and related competencies.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
In Horizon 2020, VIAA has participated in 22 projects as ERA-NET/EJP/JU partner and funding agency.
List of relevant previous projects or activities, connected to the subject of this proposal :
VIAA is partner in the following projects:
E-Rare/ E-Rare-3. ERA-NET for research programmes on rare diseases which has been extended under Horizon
2020 to the third phase, implementing IRDiRC objectives 01.12.2014. - 30.11.2019.
TRANSCAN-2. ERA-NET aligning national/regional translational cancer research programmes and activities.
01.01.2015. - 31.12.2019.
NEURON. ERA NET in the area of brain-related diseases and disorders of the nervous system. 01.01.2016. -
31.12.2020.
HBM4EU. COFUND-EJP European Human Biomonitoring Initiative. 01.01.2017. - 31.12.2021.
ERA PerMed. ERA NET in Personalised Medicine. 01.12.2017. - 31.11.2022.
825575 – EJP RD – Part B 105
31-LMT Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Lietuvos mokslo taryba (LMT), Lithuania
Principal investigator Dr. Aistė Vilkanauskytė, Head of International Programmes Unit
(head of Department which is responsible for the implementation
of international programmes at LMT (Research Council of
Lithuania))
Relevant Network
Description of the legal entity/department/laboratory/group:
The Council is a counsellor of the Lithuanian Parliament and the Government on research and researchers training
issues, implements programme based competitive funding of research, administers most important Lithuanian
science development programmes, evaluates research performance and represents Lithuanian science in various
European institutions and other international organisations. The Council is the principal national institution
providing competitive R&D funding in Lithuania, focusing on financing high-level research projects. The Council
regularly holds competitions for R&D in every area, taking responsibilities of conducting (administrative)
verification, evaluation by experts, selection of winning projects and administrative management during
implementation.
Main tasks in the project per Pillar/WP:
Pillar 1:
WP6: participation in joint transnational calls for collaborative research projects.
Previous experience relevant to the Tasks:
Every year the Council publishes more than 30 calls for research proposals. The funding portfolio includes top-
down schemes with pre-define research topics, such as National Research Programmes, national Lithuanian studies,
as well as bottom-up schemes. The list of the programmes comprises in average 40 national and international
programmes and the EU funds' schemes designed to provide funding for different research, career, mobility and
dissemination activities.
The Council, as an institution implementing the national research programmes, is engaged in the international
initiatives of coordination of the national research programmes: the European research area networks developed
under the FP7 (such as ERA-NET), and the networks for cofunding European research (ERA-NET COFUND),
joint programming and the initiatives under Article 185 of the Treaty establishing the European Community. The
Council participates in seven ERA-NET/ERA-NET COFUND projects, engaged in the activities of Joint
Programming Initiatives (JPI) also organises the participation of Lithuanian researchers in the activities of the
COST programme.
Short Profile of key Staff Members who will be undertaking the work
Dr. Saulius Marcinkonis Chief officer at the international programmes unit of the Council in charge of
(male) international cooperation and bilateral agreements. He is programme manager for the
Lithuanian–Ukrainian Cooperation Programme in the Fields of Research and
Technologies, M-ERA.NET programme (ERA-NET COFUND project) and national
support scheme for preparation of Horizon 2020 proposals, also acting as national
contact point (NCP) for Health, demographic change and well-being (SC1) and ERC
under Horizon 2020.
Dr. Marcinkonis has extensive former researcher experience (over 20-years) also
worked as a strategist in leading institution of Lithuanian UAS sector.
List of relevant previous projects or activities, connected to the subject of this proposal:
. Research Council of Lithuania is the participant of 11 ongoing H2020 projects (JHEP2, FLAG-ERA II,
CHIST-ERA III, EuroNanoMed III, HERA JRP UP, BiodivScen, HERA-JRP-PS, DIAL, BiodivERsA3,
ENSUF and M-ERA.NET 2.
.
32-VUHSK
Full legal name (Acronym) – Country Vilnius University Hospital Santaros Klinikos (VUH SK) –
Lithuania
Principal investigator Birute Tumiene
825575 – EJP RD – Part B 106
Relevant Network ITHACA ERN Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Description of the legal entity/department/laboratory/group:
Vilnius University Hospital Santaros Klinikos (VUH SK) is one of the largest University hospitals in Lithuania and
Eastern Europe encompassing all main medical specialties. VUH SK is founded by Vilnius University and
Lithuanian Ministry of Health with three key assignments of highly specialized healthcare, research and
education/training. Considerable part of VUHSK human resources is active in research and education including >
320 PhD and 43 professors. All rare disease activities in VUH SK are coordinated by Joint Center for Competences
and Biomedical Research (JCCBR) that serves as a clinical and biomedical research hub providing IT
infrastructures, managerial, administrative and coordination services for 36 Competence centres for rare and
complex diseases. The volumes of JCCBR include approx. 7,000 rare disease patients/year and at least 90-100
clinical research studies for investigational medical products and devices at a time. VUH SK is a designated
national coordinator of Orphanet Lithuania, a hub of Human Biological Resource Center – a national biobanking
system integrated with BBMRI-ERIC, a true Member of 8 European Reference Networks (ERN; ITHACA ERN,
EuroBloodNet, MetabERN, ERN RND, ERKNet, eUROGEN, TransplantChild, PaedCanERN).
Main tasks in the project per Pillar/WP:
Pillar 0:
Coordination and transversal activities:
In WP1, we will carry out the overall management of EJP RD including HelpDesk activities as one of Pillar 3
leaders (Task 1.1; Task 1.2; Task 1.3)
In WP5, we will develop and implement EJP RD communication and dissemination strategy as one of Pillar 3
leaders (Task 5.1)
Pillar 2:
In WP11 VUSHK will represent ERN-ITHACA participate in Task 11.2 FAIR-compliant virtual platform for
discovery of RD resources
Pillar 3:
In WP14, we will perform national training on Orphanet nomenclature and RD ontologies as a LTP of Orphanet
(Task 14.1); training for biobanks and researchers/clinicians on sample data management as a LTP of FTELE (Task
14.4).
In WP16, we will participate in the development of on-line academic education course modules (Task 16.2)
In WP18, we will adapt Pillar 3 training activities according to the developing EJP RD needs (Task 18.1; Task
18.2; Task 18.3)
Previous experience relevant to the Tasks:
In collaboration with Vilnius University, Faculty of Medicine, VUH SK is the main provider of rare disease
education/training and research activities in Lithuania. From 2004, it is a national coordinator of Orphanet
Lithuania. Besides, it participates in multiple other international RD-related activities including RD-Action,
JARC, EORTC, BBMRI and ERNs, among others.
Short Profile of key Staff Members who will be undertaking the work
Pr. Birute Tumiene Clinical geneticist and Coordinator for Competence Centers at VUH SK, lecturer and
(female) researcher at Vilnius University, Faculty of Medicine, with special interests in clinical
genetics/rare diseases, epilepsy genetics and inborn errors of metabolism; Orphanet
Lithuania National Coordinator and a member of Orphanet Operating Committee
responsible for Northern Eastern European countries (LT, LV, EE, SK, SI, PL); RD-
Action WP6 (Policy Development for Rare Diseases and Integration), WP5 (Steering,
maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the
European database for Rare Diseases) partner; ERN Board of Member States Lithuanian
representative.
Pr. Algirdas Utkus Clinical geneticist, the Head of Medical Genetics Centre at VUH SK, the Dean of Faculty
(male) of Medicine, Vilnius University, the Chair of Lithuanian Society of Human Genetics.
Association of Medical Schools in Europe Board Member. Special interests: clinical
genetics, syndromology, dysmorphology.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Tumienė B, Maver A, Writzl K, et al. Diagnostic exome sequencing of syndromic epilepsy patients in clinical
practice. Clin Genet. 2017 Dec 29. doi: 10.1111/cge.13203. [Epub ahead of print]
2. http://kimg.eu/en/tools/epigene-database
3. Savickienė J, Matuzevičius D, Baronaitė S, et al. Histone Modifications Pattern Associated With a State of
Mesenchymal Stem Cell Cultures Derived From Amniotic Fluid of Normal and Fetus-Affected Gestations. J Cell
Biochem. 2017;118(11):3744-3755.
825575 – EJP RD – Part B 107
4. Inashkina I, Jankevics E, Stavusis J, et al. Robust genotyping Associated
tool for autosomal
with documentrecessive type of limb-girdle
Ref. Ares(2018)6091977 - 28/11/2018
muscular dystrophies. BMC Musculoskelet Disord. 2016;17:200.
5. Stavusis J, Inashkina I, Jankevics E, et al. CAV3 gene sequence variations: National Genome Database and
clinics. Acta Neurol Scand. 2015;132(3):185-90.
List of relevant previous projects or activities, connected to the subject of this proposal:
. Joint Action RD-Action; European Union’s Health Programme (2014-2020), 677024; 2015-2018; WP5 (Steering,
maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the European database for
Rare Diseases) partner
. Orphanet; supported by grants from EC; 2004-current; National Coordinator, Orphanet Lithuania
. COST EUCID Action; FP7/2007–2013, BM12082013-2017, partner
. UNIGENE; Lithuanian –Swiss cooperation programme; 2014-2016, partner.
33-FNR
Full legal name (Acronym) – Country Fonds National de la Recherche (FNR) - Luxembourg
Principal investigator Sean Sapcariu
Relevant Network
Description of the legal entity/department/laboratory/group:
The National Research Fund (FNR) was set up by the Law of 31 May 1999. Through the FNR, an additional
impetus was given to Luxembourg research, with the aim to create and strengthen competences and knowledge and
to develop national and international synergies in order to increase the attractiveness of Luxembourg as a scientific
and economic site of excellence.Since 2000, several multi-annual research programmes have been launched in
specific fields of interest to Luxembourg. Calls are addressed to public institutions, Luxembourg administrations
and public establishments authorised to undertake R&D activities or technology transfer in their respective fields of
activity.As an outcome of the 2007 Foresight Exercise and the subsequent choice of national research priorities by
the Government, the new thematic research programme CORE was launched in 2008 with the prime objective
fostering scientific quality in selected areas of Luxembourg public research. The FNR also regularly launches calls
in the three structural programmes: ATTRACT (Attract Researchers to Luxembourg), the PEARL (Excellence
Award for Research in Luxembourg) and the INTER (Promoting International collaboration. The FNR is also in
charge of the Luxembourg research grants for PhDs and post-docs. Furthermore, the FNR subsidises accompanying
measures, addressed to a larger public and aiming to strengthen the general framework of scientific research in
Luxembourg. The FNR also wishes to strengthen the links between science and society and the general public to
feel concerned with science. Activities for promoting scientific culture are mostly targeted to young people.FNR
funds running research projects within the biomedical field through its CORE programme, which has an annual
budget of approximately 4 Mio € and covers the following areas: Regenerative Medicine in Age-related,
Translational Biomedical Research and Public Health research.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP 6, we intend to participate in two co-funded and two non-cofunded joint transnational calls.
In WP 9, we will FNR will support the WP leaders in the monitoring of funded research projects.
FNR will participate in the co-funded call. It will contribute to the overall implementation of the co-funded call by
commenting on the proposed call text and other call documents, publication and promotion of the call, eligibility
check of candidates applying for FNR support and participation in funding decision. In addition, FNR will
participate in additional funding activities by contribution to the workshops in which the topics of the additional
activities will be determined
Previous experience relevant to the Tasks:
At an international level, the FNR currently participates to the following initiatives:
- ERA-Nets: TRANSCAN, NEURON I and II, ERA-SysAp, MATERA, MNT, ERA-SysBio, ERA-Age, HERA,
CHIST-ERA, CORE Organic.
- Coordinated Actions: CoA-SysMed, CoA-PerMed;
- JPND: Joint programming in neurodegenerative diseases;
- Agreements with 11 funding agencies in Europe to fund bilateral research projects.
By participating to these initiatives, the main objective of the FNR is foster cooperation and coordination of
research activities carried out across Europe, and to increase visibility of Luxembourg research in selected
domains.
Short Profile of key Staff Members who will be undertaking the work
825575 – EJP RD – Part B 108
Sean Sapcariu Sean Sapcariu, Ph. D. is a Programme ManagerAssociated
of the biomedical sciences
with document research programme
Ref. Ares(2018)6091977 - 28/11/2018
(male) (CORE BM) at the FNR. He has over 6 years of experience in the Luxembourgish research
ecosystem, involved in biomedical research, university administration and strategy, and
facilitation of funding agency programs.
34-ZonMw
Full legal name (Acronym) – Country ZORGONDERZOEK NEDERLAND ZON (ZonMw), The
Netherlands
Principal investigator Sonja van Weely
Relevant Network E-Rare, IRDiRC
Description of the legal entity/department/laboratory/group:
ZonMw, The Netherlands Organisation for Health Research and Development, funds health research and stimulates
use of the knowledge developed to help improve health and health care. Research on rare diseases is funded in
several clusters within ZonMw.
Main tasks in the project per Pillar/WP:
Pillar 1:
- Coleader of Pillar 1 “Funding Collaborative Research on Rare Diseases”
P1WP6
- Participant in WP6: “Joint Transnational Calls for collaborative research projects”
P1WP7
- Leader of WP7: “Networking to share knowledge on rare diseases”
- Co-taskleader WP7 task 7.1: “Development of the networking scheme”
- Taskleader WP7, task 7.2: “Implementation of networking scheme”
- Taskleader WP7, task 7.3: “Evaluation of applications”
P1WP8
- Participant in WP8, task 8.1: “Development of the scheme”
- Participant in WP8, task 8.2: “Set-up of challenges”
- Participant in WP8, task 8.3: “Call for proposals, evaluation and selection of proposed projects for solutions in
first phase”
- Participant in WP8, task 8.4: “Call for proposals, evaluation and selection of proposed projects for solutions in
second phase”
P1WP9
- Co-taskleader WP9, task 9.2: “Monitoring of networking to share knowledge on rare diseases”
Pillar 0: Coordination and Transversal activities
As Coleader of Pillar 1 involved in
- WP1 “Coordination and management”
- WP2 “Integrative research strategy”
- WP3 “Sustainability strategy and business plan”
- WP4 “Legal, ethical and regulatory framework of the EJP RD”
- WP5 “Communication and Dissemination”
Previous experience relevant to the Tasks:
ZonMw is a co-creating party in European research programming and is involved in four Joint Programming
Initiatives and many ERA-Nets related to health, and in four Research Infrastructures (BBMRI, BBMRI,
EATRIS, ELIXIR and EuroBioImaging).
From 2006 ZonMw is involved in the ERA-Net E-Rare and was leader of several work packages and/or tasks. In
the current programme E-Rare 3, ZonMw is co-chair of the Network Steering Committee, leader of the work
package “Strategy” and Call Secretariat for E-Rare Joint Transnational Call JTC 2018. ZonMw has executed
several national network subsidy programmes, including a specific network subsidy programme for rare diseases
research. ZonMw is member of the Consortium Assembly of the International Rare Disease Research Consortium
(IRDiRC) from 2011.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
ZonMw has its own online project portal (ProjectNet), which could be used for the submission of applications for
the networking scheme, for which ZonMw will be WP leader.
825575 – EJP RD – Part B 109
Short Profile of key Staff Members who will be undertaking the work with document Ref. Ares(2018)6091977 - 28/11/2018
Associated
Dr. Sonja Van Weely The professional career of Sonja van Weely is dedicated to rare diseases. After working for
(female) more than 10 years as scientist in the field of biochemistry of rare diseases, she became
scientific officer of the multidisciplinary Dutch Steering Committee on Orphan Drugs that
was installed by the Minister of Health (2001-2011). Subsequently, she was appointed as
senior programme officer dedicated to research and network programmes on rare diseases
and orphan drugs at ZonMw (2011-now). As representative of ZonMw she is involved in
E-Rare from 2006. In the current programme E-Rare 3 she is co-chair of the Network
Steering Committee, leader of the work package Strategy and takes part in the Call
Secretariat JTC 2018. She is also representative of ZonMw in the Consortium Assembly of
the International Rare Disease Research Consortium (IRDiRC) from 2011. Sonja is
involved in the preparation of the EJP RD from the beginning and will act as one of the
two coleaders on funding of rare disease research.
Dr. Harald Moonen Dr. Moonen was originally trained as a chemical engineer at the Eindhoven University of
(male) Technology. He then shifted his focus of interest towards biomedical research and
obtained his PhD at the University of Maastricht, after investigating the relationship
between dietary habits, the formation of endogenous formation of carcinogenic compounds
and colorectal cancer risk. Subsequently he worked for almost 4 years as a postdoctoral
researcher on the relationship between dietary factors and modulation of chronic oxidative
stress. In 2007 he continued his career in research management and –policy. Since 2009 he
has been working as senior programme officer at ZonMw on several programmes
including research and network programmes on rare diseases, both in a national and
international context (E-Rare).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I,
Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of
international collaboration for rare diseases research: a European perspective.
2. Results of Networking Subsidy scheme in ZonMw programme Priority Medicines Rare Diseases and Orphan
Drugs, page 131-132; https://www.zonmw.nl/fileadmin/documenten/Corporate/ZonMw_jaarverslag_2015.pdf
3. Report on E-Rare Strategic Workshop “Strategic Research Agenda of E-Rare in relation to other initiatives on
rare diseases”, organised by ZonMw on March 7, 2016 in Barcelona (Spain), http://www.erare.eu/sites/default/
files/Report%20E-Rare%20Strategic%20Workshop%20March%207%202016%20VFF.pdf
35-UMCG
Full legal name (Acronym) – Country Academisch Ziekenhuis Groningen (UMCG) - The Netherlands
Principal investigator Prof.Dr. Morris Swertz
Relevant Network BBMRI, ELIXIR
Description of the legal entity/department/laboratory/group:
The UMCG (Academisch Ziekenhuis Groningen) is the second largest academic hospital in the Netherlands with a
staff of 10,000 people in patient care, education & training and research, with a focus on ‘Healthy Ageing’. The
work is planned at the Genomics Coordination Center (GCC) a multi-discipliniary 25fte streong bioinformatics
core facility and big data stewardship hotel of the UMCG and University of Groningen on a mission to unlock big
data for personalized genomics using smart informatics software, methods and tools. GCC is part of the
Department of Genetics, having Prof. dr. Richard Sinke (male) - head of diagnostics and power user from
diagnostic perspective, Prof. dr. Nine Knoers (female) – head of department, Prof. dr. Cisca Wijmenga (female) –
head of BBMRI-NL 2.0, immune/complex disease, Mw Prof. dr. Irene van Langen MD (female) – head of clinic,
ELSI, power user from clinical perspective, Prof. dr. Lude Franke – head of research and leading in multi-omics
data integration, Prof. dr. Rolf Sijmons MD (male) – daily power user, national ontology expert, consultant to the
project.
Main tasks in the project per Pillar/WP:
In Pillar 2:
WP11 UMCG will participate in tasks on Metadata and ontological model definition for cataloging resources for
RD research (Task 11.1), FAIR-compliant virtual platform for discovery of RD resources (Task 11.2), Data
deposition and access to data infrastructures for RD research (Task 11.3), and Provision of analysis and data
sharing capabilities to the RD community through online resources (Task 11.4).
825575 – EJP RD – Part B 110
/WP12 UMCG will participate in tasks to Compare and align core interoperability
Associated standards
with document of relevance- 28/11/2018
Ref. Ares(2018)6091977 (Task
12.1), Multi-team software development to enable the FAIR ecosystem (Task 12.2), and Combining expertise for
practical FAIRification support (Task 12.3).
WP12 UMCG will participate in tasks to Fill a number of pre identified gaps to allow integrative systems biology
approaches for rare diseases (Task 13.1)
In Pillar 3:
WP14 UMCG will participate in tasks on Standards and quality of genetics/genomics data in laboratory and clinical
research practice (Task 14.2), Training on strategies to foster solutions of undiagnosed rare disease cases (Task
14.3), Training for biobanks and researchers/clinicians on sample data management (Task 14.4) and Training on
rare disease registries and FAIRification of data at the source (Task 14.5)
Previous experience relevant to the Tasks:
The GCC is and has been part of several national and EU Rare Disease and Infrastructure grants in which we
have developed tools to make biobank and registries data and samples findable and accessible and link it with
sample/data request workflows. We developed the MOLGENIS software that we used to build the BBMRI-ERIC
(Biobank) Directory and the RD-Connect Sample Catalogue. MOLGENIS is also used for Rare Disease patient
registries, e.g. CHARGE database (chd7.org) DEB central (www.deb-central.org) AIP (aip.fipapatients.org),
MVID (mvid-central.org). In particularly relevant the GCC develops and operates the UMCG facilities for large
scale DNA and RNA data processing for research and genome diagnostic health care. In addition, GCC is lead of
the BBMRI-NL Dutch national IT infrastructure for biobanking, the BBMRI-ERIC Directory (catalogue),
BBMRI-NL Dutch data and sample catalogue, LifeCycle large scale harmonization and federated analysis of EU
child cohort data; RD-connect sample catalogue, Solve-RD bioinformatics team, and task lead in EU CORBEL
access to sensitive project and RD-connect linked data project. All software is available as open source as part of
the MOLGENIS software platform for scientific data at http://www.molgenis.org. UMCG is ISO 9001 and ISO
27001 certified.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
GCC has a multi-discplinary team of 25 biologists, statisticians and computer scientist providing research, support,
large scale analysis and data management. Next to open source software MOLGENIS, GCC hosts a database cloud
consisting of 4 servers, 100 database servers and a computer cluster consisting of 20+ servers hosting >1500
Terabyte of NGS data, >1000 CPU cores and >5Terabyte of RAM. GCC is also host of the UMCG research IT
infrastructure, in particular big data. In addition, UMCG is partner in University of Groningen Center for
Information Technology, the second largest academic compute center in the Netherlands and part of SURF and
Excelerate, with ample of capacity to host big data compute projects.
Short Profile of key Staff Members who will be undertaking the work
Pr. Morris Swertz Adj. Prof. dr. Swertz coordinates large scale bioinformatics research and support to the Dept.
(male) of Genetics, other UMCG departments, and several (inter)national consortia. His research
lines focus on: (1) methods for DNA, RNA and phenotype data analysis, and (2) user-friendly
systems for large scale data management, analysis, interpretation and sharing. Swertz
developed a novel data framework (Bioinformatics 2012) and computational framework
(Molgenis/Compute) to enable large genome analyses, e.g. used in Genome of the
Netherlands (EJHG 2013, Nature Genetics 2014), discovery of novel human gene-disease
associations based on eQTL studies (NAR 2014), inconsistencies in the metabolic pathway
knowledge (BMC Systems Biology 2013), and to inform genetic variant interpretation in
various diseases (Human Mutation 2011-2015). Swertz also developed analysis methods to
call genotypes from RNA-sequencing that enables identification of (rare) variants affecting
gene- expression levels (Genome Med 2015) and a framework to estimate RD variant
pathogenicity classification for clinical application (Human Mutation 2015, Genome Biology
2017). Finally, Swertz is Co-Lead of BBMRI-NL 2.0 'IT', genetics datasharing in VKGL &
VKGN, Co-lead of UMCG Personalized Genomics Medicine programme Lead of UMCG
Research IT program, focus on big data.
David Van Before making the switch to bioinformatics in 2010 David van Enckevort has worked in
Enckevort different roles at commercial ICT providers in the Netherlands. From 2010 - 2013 he was a
(male) Senior Software Integration Engineer and Technical project lead (TPL) for the biobanking
task force at the Netherlands Bioinformatics Center (NBIC). As TPL he was responsible for
the day-to-day management of the development of BBMRI-NL catalogue and the day to day
management of the GoNL Imputation Working Group. In 2013 he joined the department of
Genetics at the UMCG as a project manager and he is responsible for the day to day
management of the BBMRI-ERIC CS-IT WP1 (development of the BBMRI-ERIC Directory),
825575 – EJP RD – Part B 111
BBMRI-NL catalogue, RD-Connect SampleAssociatedCatalogue and the Ref.
with document RD-Connect Data Linkage
Ares(2018)6091977 - 28/11/2018
plan (co-Lead by Marco Roos, LUMC) and the harmonisation effort as Dutch representative
in the MIABIS working group. He is a member of GA4GH and was a key participant in the
GA4GH/IRDiRC joint Privacy Preserving Record linkage working group and he is co-Chair
of the ISBER Resource Locator Working Group.
Dr. K. Joeri van K. Joeri van der Velde graduated as BSc Bioinformatics on pathway visualizations of kinase
der Velde activity at the Groningen Bioinformatics Centre in collaboration with the UMCG dept. of Cell
(male) Biology and then continued to work on MOLGENIS software infrastructure for multi-omics
research in Arabidopsis, mice and C. elegans at the Groningen Bioinformatics Centre. In 2018
he obtained his PhD at the UMCG dept. of Genetics, working on new methods for
downstream clinical analysis of next-generation sequencing data in the group of Prof. Swertz.
Now, as a postdoc amongst a unique crowd of clinicians, software developers, geneticists,
parallel computing experts, wet-lab technicians and statisticians, he aims to discover new
ways to revolutionarize the speed, yield and applications of genome interpretation for medical
genetics, powered by NL and EU collaborations (e.g. Solve-RD) and a wealth of untapped
resources available in the public domain.
Dr. Salome Salome Scholtens (PhD) is a programme manager and epidemiologist at the University
Scholtens (female) Medical Center Groningen in the Netherlands. She is expert on data management training and
the set-up of research data infrastructure.
Patrick Deelen Patrick Deelen completed his BASc bioinformatics at the Hanze University Groningen in
(male) 2010 and his MSc of bioinformatics at the VU University Amsterdam in 2012 with honors.
He is currently working on his PhD thesis at the genetics department of the UMCG. He
mostly works on DNA and RNA data of population’s cohorts. He worked on the Genome of
The Netherlands, Lifelines, and the BIOS cohort.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Holub, Swertz, Reihs, van Enckevort, Muller and Litton (2016). "BBMRI-ERIC Directory: 515 Biobanks
with Over 60 Million Biological Samples." Journal/Biopreserv Biobank 14: 559-562. DOI:
https://doi.org/10.1089/bio.2016.0088
2. Pang, Hendriksen, Dijkstra, van der Velde, Kuiper, Hillege and Swertz (2015). "BiobankConnect: software
to rapidly connect data elements for pooled analysis across biobanks using ontological and lexical
indexing." Journal/J Am Med Inform Assoc 22: 65-75. DOI: https://doi.org/10.1136/amiajnl-2013-002577
3. Van Diemen, et al, van der Velde, et al, Swertz, Sinke, van Langen, Wijmenga (2017) Rapid Targeted
Genomics in Critically Ill Newborns. Peadiatrics 140(4). DOI: https://doi.org/10.1542/peds.2016-2854
4. K. Joeri van der Velde, et al, Morris A. Swertz. “GAVIN: Gene-Aware Variant INterpretation for medical
sequencing.” Genome Biology, 201718:6. DOI: https://doi.org/10.1186/s13059-016-1141-7
5. Patrick Deelen, et al, Morris A Swertz and Lude Franke "Calling genotypes from public RNA-sequencing
data enables identification of genetic variants that affect gene-expression levels" Genome Medicine2015
7:30, DOI: https://doi.org/10.1186/s13073-015-0152-4
List of relevant previous projects or activities, connected to the subject of this proposal :
1. RD-Connect; European Union; 2012-2018; lead development of the RD-Connect Sample catalogue and
integrated it with the Registry and Biobanks finder; co-Lead of the RD-Connect data linkage plan to link
data from different sources; Data harmonisation and improving findability according to the FAIR
principles.
2. Solve-RD; European Union; 2018-2022; Development of the Solve-RD Sandbox environment for
development and piloting of innovative diagnostic tools; Data harmonisation and improving findability
according to the FAIR principles.
3. ADOPT; European Union; 2015-2018; As part of ADOPT and the BBMRI-ERIC Common Services for IT
we developed the BBMRI-ERIC biobank Directory and integrated the Directory with the BBMRI-ERIC
Negotiator tool.
4. SAID, E-RARE; European Union/ZonMW; 2016-2020; lead large scale data sharing, annotation and
integration for DNA variants, *omics and phenotypes from patients suffering from systemic
autoinflammatory diseases
5. CORBEL; European Union; 2016-2020; We focussed in particular on interoperability (e.g.
BiobankConnect) and systems to access sensitive human data.
825575 – EJP RD – Part B 112
36-UM Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Maastricht University (UM), The Netherlands
Principal investigator Prof. Chris Evelo
Relevant Network ELIXIR
Description of the legal entity/department:
Maastricht University (UM), the most international university in the Netherlands, stands out for its innovative
approach to learning and international outlook. With almost 16,000 students and 4,000 staff, UM offers a wide
choice of academic programs, all of which are designed to bring out the best in its students.
The Department of Bioinformatics – BiGCaT uses bioinformatics and integrative systems biology approaches to
answer questions in biology. Technologies and algorithms are continuously explored to make biological knowledge
and data more Findable, Accessible, Interoperable, and Reuseable (FAIR) and then actually reuse them for multi-
omics data integration to answer new questions. Pathway and network biology form the heart of the in silico
approaches used to explain health and disease issues with including the role of nutrients, the interaction of
(nano)materials with biological matter, and the role of metabolism and other small compounds in human health.
The unit comprises 6 FTE senior researchers and 8 PhD candidates, all doing research around biological data
integration and analysis.
Main tasks in the project per Pillar/WP:
Contribution in Pillar 2:
In WP10, we will contribute to the annual strategic plans for WP2&3 and to the bi-monthly progress reports and
strategy discussions with WP11 and 12 leaders .
In WP11 we will contribute to define ontological and metadata models for new relevant sources, to adapt the
ELIXIR’s bio.tools for the RD community, to enhance the catalogue platform for query capabilities and
collaboratively analysis multi-omics data from the selected use cases.
In WP 12, we will contribute to develop and improve metadata (and other data) models, and the federation
architecture, networks and registries
In WP13, we will act as WP leader; we will co-lead the gap filling task to help facilitate holistic approaches using
omics and genetics data in rare diseases ; we will participate in the proof principle studies to show and improve the
usability of the work flows from task 13.1; we will make a connection with pillar 3 to provide training in the usage
of the workflows developed in the WP.
Previous experience relevant to the Tasks:
Our work focuses on integrative (FAIR) data approaches in systems biology. This WP tries to make that approach
work for rare diseases and is thus exactly in line with our expertise and available skills and resources.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Servers to run WikiPathways and related tool and data collections
Short Profile of key Staff Members who will be undertaking the work
Pr. Chris Evelo Prof. Evelo is the founder and head of the department of Bioinformatics - BiGCaT and is a PI in
(male) the Maastricht Center for Systems Biology (MaCSBio). His research focus is on bioinformatics
for integrative systems biology; aiming at a better interpretation of experimental data through
integration in data models that build on structuring existing knowledge.
Integrative approaches are multi-faceted, and as a generalist he is involved in many projects
related to capturing and processing, integrating and understanding experimental data. This
includes the interoperability approaches underlying such efforts: standards, ontologies, mapping
tools and documentation of the origin of the data and methods used (the provenance). He is a co-
lead of the interoperability platform of ELIXIR which he represents in the rare disease use case.
WikiPathways and the accompanying mapping, analysis and network biology tools form his core
project. WikiPathways is a resource for community curation of biological pathways and
originates from collaboration with Alex Pico’s group at UCSF. He is a board member of the
Open PHACTS foundation for large-scale semantic web based knowledge structuring of relations
between chemicals, gene-products and diseases. Chris is scientific advisor for the IMI project for
translational quantitative systems biology (TransQST) and for two SME’s (Edgeleap and
Micelio). He is a.o. governing council member of the nutrigenomics organization NuGO, a
member of the micronutrient genomics organization for which he lead the IRSES project
Microgennet, involved in H2020 projects OpenRiskNet and EUToxRisk and a workpackage
leader in the COST CHARME for harmonization of standards in biology and a member of the
JPI ENPADASI that works on the development of a phenotype database that he helped
conceptualize and develop.
Dr. Friederike Dr. Friederike Ehrhart is currently post-doc researcher at the Department of Bioinformatics (head
825575 – EJP RD – Part B 113
Ehrhart of department: Prof. Dr. Chris Evelo) and the Dutch Rettwith
Associated Expertise
documentCentre-GKC (director:
Ref. Ares(2018)6091977 Prof.
- 28/11/2018
(female) Dr. Leopold Curfs). Educated and trained as cell and molecular biologist, working on tissue
engineering of neurological, pancreatic and liver tissue, and high throughput and omics data
approaches. Joining the Department of Bioinformatics at Maastricht University in 2015 she
works on systems biology and bioinformatics methods to analyze (single or multi) omics data,
especially within pathway and network analysis. Together with the Dutch Rett Expertise Centre
in Maastricht she is working since 2016 on the systems biology of Rett syndrome, a rare
neurological disorder with a genetic cause. Friederike has coordinated and co-coordinated 7
public and 3 industry funded projects and published 23 papers. Within ELIXIR (EU
bioinformatics infrastructure project) she coordinated an implementation study which analyses
and improves molecular data interoperability of rare diseases. She is a member of the SSBP
(Society for the Study of Behavioral Phenotypes) to investigate (rare) genetic syndromes and
their phenotypic outcome including fetal alcohol syndrome, Prader-Willi and Angelman
syndrome.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. WikiPathways and PathVisio biological pathway collections and related analytical tools including network
biology connections including BridgeDb database identifier mapping services and mappings for gene products and
gene variants.
2. WikiPathways: capturing the full diversity of pathway knowledge. 2015. M Kutmon et al. NAR 44 (D1), D488.
3. The FAIR Guiding Principles for scientific data management and stewardship. 2016. MD Wilkinson et al.,
Scientific data 3
4. Open PHACTS: semantic interoperability for drug discovery. 2012. AJ Williams et al., Drug discovery today 17
(21-22), 1188.
5. Rett syndrome–biological pathways leading from MECP2 to disorder phenotypes. 2016. F Ehrhart et al.
Orphanet journal of rare diseases 11 (1), 158.
List of relevant previous projects or activities, connected to the subject of this proposal:
. ELIXIR EXCELERATE; H2020; 2015-19; helps ELIXIR coordinate and extend national and international data
resources to ensure the delivery of world-leading life-science data services: co-leading the interoperability
platform and linking this to the rare disease use case.
. Open PHACTS; IMI; 2011-16; Open Pharmacological Concepts Triple Store for drug discovery: central tech
team, providing RDF formatted pathways, identifier mapping services & mappings, driver question resolution.
. OpenRiskNet; H2020; 2016-19; Open e-Infrastructure to support risk assessment: API & ontology development.
. EUToxRisk; H2020; 2016-21; ‘Flagship’ program driving mechanism-based toxicity testing and risk assessment:
Adverse Outcome Pathway development and use in analysis, link to Open PHACTS
. MICROGENNET; FP7/H2020; 2012-15; collaborations for a community-driven knowledge base for
micronutrient genomics, coordinator.
37-NCBR
Full legal name (Acronym) – Country The National Centre for Research and Development (NCBR),
Poland
Principal investigator Marcin Chmielewski
Relevant Network E-Rare-3 / EJP RD
Description of the legal entity/department/laboratory/group:
The National Centre for Research and Development is the implementing agency of the Minister of Science and
Higher Education. It was appointed in the summer 2007 as an entity in charge of the performance of the tasks
within the area of national science, science and technology and innovation policies. When if was founded, it was
the first entity of this type, created as the platform of an effective dialogue between the scientific and business
communities.
The main task of the National Centre for Research and Development is management and execution of strategic
research and development programs, which lead directly to the development of innovativeness. Among the tasks of
the National Centre for Research and Development, are the support of commercialization and other forms of
transfer of scientific research results, the management of applied research programs and the performance of
national security and defense projects. The Centre also attempts to provide young scientists with training and
825575 – EJP RD – Part B 114
development opportunities i.a. by implementing international scientific mobility
Associated programs.
with document Special attention- is
Ref. Ares(2018)6091977 paid
28/11/2018
to the participation of young scientists in research programs. The Centre enables young researchers to expand their
business and intellectual property management skills and to learn how to commercialize research results. At the
same time, via implemented initiatives, it draws attention to the necessity of rasing the R&D staff’s awareness of
the importance of industrial property protection to the commercialization of modern solutions and international
patent protection opportunities for research units.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate in JTCs for proposals as a programme partner (WP6.1, 6.2, 6.3 and 6.4).
Previous experience relevant to the Tasks:
NCBR is the most important research funding agency in Poland. Currently, it operates under the Act on National
Centre for Research and Development dated 30 April 2010 (Journal of Laws from 2010, No. 96 item 616). The
science reform adopted in the autumn 2010 gave the Centre more freedom to manage its financial assets, within
the scope of a strategic research programme. In addition, the National Centre for Research and Development
extended its activity with new initiatives and possibilities on 1 September 2011. Assigned by the Ministry of
Science and Higher Education the function of the Mediation Institution in three operational programmes: Human
Capital, Innovative Economy and Infrastructure and Environment, the Centre became one of the greatest
innovation centres in Poland. The activity of the Centre is funded by the national treasury and the European
Union. NCBR participates in more than 30 different international initiatives (ERA-NETs, JPIs, bilateral
cooperation programmes).
Short Profile of key Staff Members who will be undertaking the work
Dr Marcin Marcin Chmielewski, Chief expert in Programmes Management Department, studied
Chmielewski Biology at the University of Warsaw, specialisation - Parasitology. He got his PhD from the
/Male Warsaw Medical University on the thesis “Apoptosis during the course of infection with
hepatitis C virus (HCV) and human immunodeficiency virus (HIV).” Former lecturer at
Warsaw Medical University. Since summer 2011 employed in National Centre for Research
and Development (NCBR) as a Scientific officer. Currently responsible for coordination of
international programs in the field of medicine. Main task is to take care of the projects
during the whole funding period. It includes administrative and formal issues, but also
scientific reviews.
Matylda Matylda Marczak, Senior Expert in Financial Department of NCBR. Main responsibilities
Marczak/Female are: financial control of the projects financed from national and international programs.
38-MUW
Full legal name (Acronym) – Country Medical University of Warsaw (MUW) Poland
Principal investigator Associate Professor Maciej Kosieradzki
Relevant Network
Description of the legal entity/department/laboratory/group:
Department of General and Transplantation Surgery, Medical University of Warsaw is a clinical department that
has a great experience with organ’s transplantation and it is an active member of European Transplantation Society.
Our experience is based on transplantation liver, kidney and pancreas/ islet cells including patients with rare
disease. The Department has clinical facilities and laboratory space dedicated just for departments’’ needs,
diagnostic facilities are also included and High-class specialists with international experience.
Main tasks in the project per Pillar/WP:
Pillar 0:
WP2
Task 2.5: Translation/impact of prioritization on national and EU strategies-co-leader
Task 2.2 Mapping the research and innovation needs
- Verification of integrated and coordinated set of commitments and actions designed to exploit core competencies
on national level.
825575 – EJP RD – Part B 115
- Sharing the good practice. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
- Grouping, verifying of specific therapeutic needs.
- Identification of tasks during ongoing program, which were not included in the program.
- Monitoring and controlling of the ongoing activities.
- Analysis of risks and problems and adjusting the tools to solve them.
Pillar 2:
Task 12.1: Compare and align core interoperability standards of relevance
Task 12.2 : Multi-team software development to enable the FAIR ecosystem
We will
1) Identify diagnosis and standardization of procedures for international and interdisciplinary system which will
classify diseases based on geno-diagnosis.
2) Improve the diagnostic and therapeutical standards.
3) Verification of caring out the preclinical and clinical research within Rare Disease
4) Monitor of oncological patients with RD
5) Develop infrastructure of R&D based on research of ATMPs indicated to RD, Oncology and Personalized
Medicine.
6) Assessment of pharmacotherapy including safety and efficacy of medicinal products and analysis of benefit-risk
ratio
We will try to develop IT program together with centres, which have already existing data to harmonize diagnosis,
symptoms, clinical treatment and monitoring follow-up in patients with RD.
Development of clinical protocol to introduce as international standards for clinical study phase 1,2 and 3 including
primary and secondary points to evaluate the benefit/risk ratio.
Pillar 3:
Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research
We will take a part in scientific committee for training on the Orphanet nomenclature and RD ontologies for RD
research.
Previous experience relevant to the Tasks:
1) develop diagnosis and standardization of procedures for international and interdisciplinary system
2) set the diagnostic and therapeutical standards.
3) Monitor of oncological patients with RD
We have profound experience in transplantations of patients with RD proceeded from 2000:
PSC – 48, Wilson – 24, HEHE – 2, Frantz tumor – 2, FAP – 2
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work (if applicable):
We have full equipment and laboratory with specialization of ATMP research adequate to European standards for
developing research and clinical trails for advanced therapy medicinal products in patients with rare disease and/or
personalized medicine in oncology.
Short Profile of key Staff Members who will be undertaking the work
Associate Professor Maciej Head of the Department of General and Transplantation Surgery, Medical
Kosieradzki, University of Warsaw. High class specialist with international experiance, from
Male 2011 has been certified a European Board of Surgery Qualification in
Transplantation Surgery. Research intern in the Division of Transplantation,
Department of Surgery of the University of Wisconsin, Madison. President of an
NGO, Polish Union for Transplantation Medicine. He was involved in EC project
“Coordinationg a European Initiative among National Organizations for Organ
Transplantation”. He manages a department that treats 24 patients with Wilson
disease, nearly 50 patients with primary sclerotising cholangitis and some rare liver
tumors. He authored 51 articles indexed in Medline.
Professor Piotr Fiedor Prof. Piotr Fiedor, since 2010 up to 2017 held position of polish member of
Male Committee for Medicinal Products for Human Use (CHMP) in European Medicine
Agency (EMA). Prof. Fiedor is an clinicial professor hired by Medical University of
Warsaw and was Chief of Executive Officer at National Medicines Institute in
Warsaw, Poland. 2010-2013 – alternate member of Biological Working Party,
European Medicines Agency. Additionally, he is an active expert in Scientific
Advisory Group EMA. Professor Fiedor is clinical professor with long-term clinical
experience (surgery, oncology, transplantology, immunology). He was a member of
Orphan Diseases Group by the Ministry of Health and member of Medicinal
825575 – EJP RD – Part B 116
Product Commission by the President of The
Associated withOffice forRef.
document Registration of Medicinal
Ares(2018)6091977 - 28/11/2018
Products, Medical Devices and Biocides. Prof. Fiedor is a international Expert in
assessment and review of research programs and scientific collaboration by The
Ministry of Science and Higher Education. He published over 140 scientific papers.
Associate Professor Marek High class specialist, transplantologist with international experiance, involved in
Pacholczyk The European Society of Organ Transplantation, The Polish Hepatology Society,
Male Male The Polish Surgery Society. Currently he is working in the Department of General
and Transplantation Surgery, Medical University of Warsaw. Asc. Profesor with
long-term clinical experience. He authored 62 articles indexed in Medline.
PhD Karolina Maria PhD, currently MBA student at ESG University of Quebec at Montreal (ESG
Nowak UQAM) and Warsaw School of Economics, Internship in Stanford Biomaterials and
Female Advanced Drug Delivery Laboratory, School of Medicine, she finished with honors
Postgraduate Management Studies, Leadership 2.0 at the Warsaw School of
Economics. Participation in Science Management and Commercialization Program,
Stanford Centre for Professional Development, Stanford University. Previous
experience as a acting head of R&D office in National Medicine Institute. Eight
years of experience in research and development in Pharmaceutics.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Immune biomarkers and long-term graft survival: a prospective follow-up of 457 kidney transplant recipients.
Ciszek M, Mucha K, Foroncewicz B, Żochowska D, Kosieradzki M, Grochowiecki T, Durlik M, Górski A, Pączek
L. Pol Arch Intern Med. 2017 Feb 15;127(3):178-183. doi: 10.20452/pamw.3937.
2. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After
Introduction of Direct-Acting Antivirals: Our Experience and Literature Review Tronina. O, Ślubowska
K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M Lisik
W, Kosieradzki M, Durlik M. Transplant Proc. 2017 Jul - Aug;49(6):1409-1418.
doi:10.1016/j.transproceed.2017.01.077.
3. The effects of in vitro hemodilution and fibrinogen concentrate substitution on thromboelastometry analysis in
patients qualified for liver transplantation - Preliminary results. Nicińska B, Pluta J, Kosieradzki M, Lągiewska
B, Wasiak D, Lazowski T, Chmura A, Trzebicki J. Transplant Proc. 2014 Oct;46(8):2758-61. doi:
10.1016/j.transproceed.2014.09.048.
4. Regulatory evaluation of Glybera in Europe - two committees, one mission. Melchiorri D, Pani L, Gasparini P,
Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I, Leufkens HG, Müller-Berghaus J, Narayanan G,
Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK.Nat Rev Drug Discov. 2013 Sep;12(9):719.
doi: 10.1038/nrd3835-c1.
5. Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer. Annals of
Transplantation 2013; 18: 651-3.
List of relevant previous projects or activities, connected to the subject of this proposal :
• BIOOPA (Epidermolisis bullosa), NCBR; 2016- is pending – Coordinator of project, This project is the
world's first research project based on the use of allogeneic human skin matrix ADM seeded with
allogeneic stem cells and on a dressing of autologous cells taken from the areas of revertant mosaicism in
the epidermolysis bullosa treatment.
• International cooperation to develop new research for medicinal product in RD (preclinical study)
• Isolation/immunomodyfication of hepatocytes and pancreatic islets
National transplantation program-Polgraft, steam cells.
39-MUG
Full legal name (Acronym) – Country Medical University Gdansk (MUG),Gdanski Uniwersytet
Medyczny (GUMed), Poland
Principal investigator Aleksandra Zurowska
Relevant Network MUG members of ERKNet, PaedCan,eUROGEN, BBMRI.pl
Description of the legal entity/department/laboratory/group:
Medical University Gdansk teaches nearly 3000 students( including >800 international students) at its teaching
hospital which is the largest in Northern Poland (1300 beds) with all specialities represented and full diagnostic and
825575 – EJP RD – Part B 117
research facilities on site. Its Centre for Rare Diseases incorporates research,
Associated withteaching
document activities of the departments
Ref. Ares(2018)6091977 - 28/11/2018
which are members of several European Reference Networks.
Department of Pediatrics, Nephrology & Hypertension and Department of Nephrology, Transplantation &
Internal Medicine are members of ERKNet involved in the care of rare kidney diseases.
Department Surgery & Urology for Children and Adolescents , a member of PaedCan ERN, eUROGEN ERN
Department Pediatrics, Oncology & Hematology includes Infant Ward dedicated to rare diseases, member of
PaedCan ERN Department Clinical Analytics- Central Bank Frozen Tissues and Genetic Specimens – member
of BBMRI.pl
Main tasks in the project per Pillar/WP:
Pillar 3:
WP 14. Capacity Building and Empowerment. We will be one of task leaders for Training for biobanks and
researchers/clinicians on sample data management hosting 1 of annual workshops in Gdansk, Poland (Task 14.4)
WP 15. Capacity building and training of patients and researchers in Rare Disease research and processes.
We will be one of task leaders for Training for patient representatives and advocates on leadership and
communication skills supporting the development of the annual face-to-face 2 days training programme for 30
participants and organising 1 of the rotating location courses in Gdansk, Poland (Task 15.3)
Previous experience relevant to the Tasks: We have helped in the establishment of several patients organisations
for rare diseases e.g Tuberous Sclerosis Complex (TSC), Hemolytic Uremic Syndrome (aHUS), Alport Syndrome.
We have been long term cooperation with non-governmental organizations from all over Poland, including:
Cornelia de Lange Association, Parent Project ( DMD) , Williams Syndrome Association , Fra X Family, Prader
Willi Association, TSC, aHUS etc. We have organized a series of nationwide conferences on rare diseases with the
participation of representatives of patient organizations and two international conferences for Duchenne Disease
Families (Sobieszewo 2013 and 2015) as well as three conferences for Down Syndrome patients and families
from Pomeranian district for Phenyloketonuria and LCHADD. We participate in annual conferences for Cornelia
de Lange and William Syndrome Families and TSC Association.
The CBTFT&GS functions as an IT node biobank for the Polish biobanking network as well as for the Biobanking
and Biomolecular Resources Research Instructure (BBMRI) - European Research Instructure (ERIC). The
CBTFT&GS is a gating biobank of BBMRI.PL for retrieving data from health- and public-related country
databases (National Health Fund, Central Statistical Office, National Cancer Registry) as well as with the biobanks
databases of BBMRI.EU.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
we have well equipped lecture halls with multimedia support and simultaneous translation capabilities and modern
Biobank facilities (Fully automated and robotized repository, Omics labs, Cell biology unit , histochemical unit
with fully automated system for tissue staining procedures, IT scanning and telemetric transfer system of images,
TMA equipment, Unit for preclinical studies with modalities for in vivo imaging).
Short Profile of key Staff Members who will be undertaking the work
Prof Aleksandra Zurowska, professor in pediatric nephrology, head Department Paediatrics,
Aleksandra Nephrology & Hypertension, the President of The Polish Pediatric Nephrology Association,
Zurowska former council member of ESPN and IPNA. Organiser of Polish Registry for Renal
femle Replacement Therapy in Children closely collaborating with International Registries – ESPN
ERA/EDTA Registry and IPDN involving other ERKNet Centres . Poland’s national
representative in the ESPN/ERA-EDTA Registry, member of the European Pediatric Dialysis
Working Group which issues guidelines on the management of children with Chronic Kidney
Disease. Endorses multicentre activities like PolTube, Polish HUS Registry. Disseminates
knowledge and guidelines organising working groups for National Guidelines for both specialists
and the general practitioner. Organiser of national multicentre projects in rare diseases initiating
the Polish PODONET, Nephrosis Online, paediatric ADPKD Registry and Alport Registry.
International collaboration > 15years in the ESCAPE Clinical Research Network IPDN, PodoNet
and ESPN Registries. Author of > 200 publications ( 40 joint international publications).
Prof Ass Professor Jolanta Wierzba Pediatrician, Clinical Genetist, specialist of pediatric metabolism
Jolanta , Head of Department of Infant Pathology, Consultant of the Outpatients Genetic Department.
Wierzba Member of the World Scientific Advisory Council Cornelia de Lange syndrome. Member of
female board of Polish Society of Human Genetics .Author of > 200 publications mostly related to
genetically determined diseases.
Prof Alicja Slizien Debska, professor of nephrology. Head of the Department of Nephrology,
Alicja Debska Transplantology and Internal Medicine. Coordinator of Transplantation programme for Northern
Slizien Poland, organiser of Reference centre for Tuberous Sclerosis Complex, involved in setting
825575 – EJP RD – Part B 118
female national guidelines for ADPKD and kidney Associated
management in TSC.
with document Ref. Author of nearly
Ares(2018)6091977 500
- 28/11/2018
publications.
Prof Piotr Czauderna, professor paediatric surgery. Head Department Surgery and Urology for
Piotr Children and Adolescents and President of European Pediatric Surgeon's Office of European
Czauderna Union of Medical Specialists (UEMS).Former member of Scientific Committee of the
male International Society for Pediatric Oncology (SIOP), chairman of International Liver Tumors
Strategy Group in Children – SIOPEL, former president of the Polish Society of Pediatric
Surgeons. Involved in several European projects on rare paediatric cancers
(ENCA,EXPORNET). Author of >180 publications.
Prof Head of Department of Clinical Analytics at Faculty of Pharmacy and co-organiser of Central
Leszek Bank of Frozen Tissues and Genetic Specimens in MUG. Co-organiser and vice-national
Kalinowski coordinator of BBMRI.pl a partner of BBMRI-ERIC and a member of BBMRI.EU clinical
male biobank working group. Author of > 100 scientific publications in clinical analytics.
List of the most relevant publications and/or products, services (including widely-used datasets or software), or
other achievements
1.Members of 3 ERN’s: ERKNet, eUrogenERN, PedCanERN since 1st March 2017
2.Datasets : National Registries for: Renal Replacement Therapy in Children , Alport Syndrome, ADPKD,
PolishPODONET
(steroidresistant nephrotic syndrome- modern diagnostic genetic programme ), Hemolytic-Uremic Syndrome.
Close
collaboration with International Registries – ESPN ERA/EDTA Registry and IPDN which includes 16 other
ERKNet centres
3.International research activities and clinical trials ( ESCAPE, PREDICT, PODONET, Levamisol Trial in SDNS)
and national multicentre activities;. 10 year record of organising national workshops for promoting national
multicentre studies and dissemination of specialized guidelines in nephrology. National Reference Centre for
Tuberous Sclerosis Complex, Cornelia di Lange Syndrome and Williams Syndrome, National node for Pediatric
Liver Tumours affiliated with the SIOPEL [International Childhood Liver Tumors Strategy Group], internartional
projects on rare tumours ENCA,EXPORNET. 4. Publications : Kidney Versus
Combined Kidney and Liver Transplantation in Young People With ARPKD: Data From the
ESPN/ERA/EDTARegistry. Mekahli D, van Stralen KJ, ..Zurowska A, et al Am J Kidney Dis. 2016
Nov;68(5):782-788. European Reference Networks: Share, Care, and Cure-Future or Dream? Wijnen R,
Anzelewicz SM, Petersen C, Czauderna P. Eur J Pediatr Surg. 2017 Oct;27(5):388-394.
Organization of BBMRI.pl: The Polish Biobanking Network. Witoń M, Strapagiel D, .., Kalinowski L, et al.
Biopreserv Biobank. 2017 Jun;15(3):264-269.
List of relevant previous projects or activities, connected to the subject of this proposal :
1.ERKNet Registry for Rare Kidney Diseases [ERK-REG] grant [PARTNER} and ERN-PAEDCAN: Paediatric
Rare Tumours
Network - European Registry grant [PARTNER]: CHAFEA Health programme grants 1/1/2018-30/12/2020
2. Introduction of reimbursed Eculizumab drug programme for atypical Hemolytic Uremic in Poland in
cooperation with
aHUS patient organisation on 1st Jan 2018
3. International 2 day conferences for Duchenne Disease Families ( Poland, Sobieszewo 2013 and 2015)
3. National 2 day Conference “ Rare disorders”,Dec.2016,Gdansk,Poland:participation 15 patient organisations
5. co-organizer of BBMRI.pl partner with BBMRI-ERIC
40-IPCZD
Full legal name (Acronym) – Country “Instytut Pomnik- Centrum Zdrowia Dziecka” (IPCZD),
Poland
Principal investigator Prof. Krystyna Chrzanowska
Relevant Network Orphanet
825575 – EJP RD – Part B 119
Description of the legal entity/department/laboratory/group: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The Children's Memorial Health Institute is a research institute, and also one of the largest specialized pediatric
hospitals in Poland acting for the benefit of modern pediatrics. The aim of the Institute is to conduct research and
development activities and to provide medical services focused on the health needs of children, adolescents and
young adults. The Institute also undertakes teaching responsibilities aimed at adapting the results of research and
development into practice. The CMHI has been awarded category A+ by the Polish Ministry of Science and Higher
Education, a category granted only to research institutes with the highest quality R&D. The CMHI’s scientific and
clinical achievements are the result of nearly 40 years of work of its medical staff. The CMHI is one of the main
Polish reference centers for rare diseases- it leads two ERNs (transplantation and epilepsy).
The Department of Medical Genetics of the CMHI is focused on both diagnostics of a wide spectrum of rare
genetic diseases/syndromes to provide complete genetic counseling for families at risk, and on translational
research aimed at unravelling physiologic and disordered molecular mechanisms leading to a disease, with the
ultimate aim of improving patient care. Dysmorphic syndromes, inherited errors of metabolism (including
mitochondrial disorders), imprinting disorders, and chromosomal instability syndromes are of particular interest.
Various genetic techniques are used: cytogenetic, molecular (including NGS, i.e. targeted diagnostic panels, WES,
WGS), methylation analysis). In the period 1980-2017, over 110 research projects were realized, and over 215
peer-reviewed papers were published (IF=985.517).
Main tasks in the project per Pillar/WP:
Pillar 2: Orphanet LTP and Network will contribute to subtask 2.2.2. Create a catalog of research projects and
clinical trials, on an ongoing basis, to inform funders (IRDiRC Roadmap priority).
Pillar 3:
In WP14(Training on data management & quality):
• Task 14.1: Developement of a novel training modules for clinicians and scientists involved in various
rare disease research fields: After some adaptation to country-specific needs, the Orphanet Network
teams will organise trainings in their countries in their national language.
• CMHI (KCH) is a contributor of the Task 14.2: Standards and quality of genetics and genomics data
in laboratory and clinical research practice.
One of the courses will be organised by CMHI in Poland.
• CMHI (KCH/PS) is a contributor of the Task 14.3: Training on strategies to foster solutions of
undiagnosed rare disease cases.
CMHI will contribute in presenting one or two selected cases.
In WP18 (Development and adaptation of training activities):
• CMHI (KCH) is a Co-Leader of the Task 18.2 together with VUHSK: Evaluation of strategic
priorities and development of existing training activities according to specific needs of EU-13
countries.
Short Profile of key Staff Members who will be undertaking the work
Prof. Krystyna Chrzanowska Krystyna Chrzanowska MD, PhD: Paediatrician and Consultant in Clinical
(female) Genetics, Full Professor and Head of the Department of Medical Genetics and
Genetic Counseling Unit, CMHI, Warsaw, Poland. Special interest in clinical and
molecular aspects of dysmorphic syndromes, chromosomal instability syndromes
and imprinting disorders. Principal investigator (10) and investigator (16) in
national projects sponsored by government institutions, contributed in 7 EU
projects (PERFECT, EURO-PID-NAS, DYSCERNE, ORPHANET EUROPE, RD
ACTION, EUCID, EuroCID). Over 155 peer reviewed publications (125 indexed
in PubMed, IF >540, h-index 29, citations >3200); also review articles and book
contributions. Member of the Orphanet Poland since 2011.
825575 – EJP RD – Part B 120
Prof. Piotr Socha Professor of Pediatrics & Associated
Gastroenterology in Ares(2018)6091977
with document Ref. the Department of
- 28/11/2018
(male) Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics in CMHI and
the Director Deputy for Research. His research and clinical work were mainly
devoted to cholestatic liver disease, non-alcoholic fatty liver disease,rare
metabolic liver diseases (eg. Wilson disease, newly described PGM-1), nutrition
in hepatology and gastroenterology (eg. LCPUFA deficiency), obesity prevention
and therapy, feeding disorders, protracted diarrhoea of infancy and early
childhood. Piotr Socha was the chair of the Hepatology Committee of ESPGHAN
(2010-2013) and he was appointed Scientific Secretary of ESPGHAN in 2015.
Piotr Socha contributs/contributed to 7 EU projects (CHOP, EUROWILSON,
EARNEST, PERFECT, NUTRIMENTHE, TOYBOX, EARLY NUTRITION).
He was the president of the Polish Society for Pediatric Gastroenterology,
Hepatology and Nutrition. He published over 400 peer reviewed papers (160
indexed in pubmed) and contributed to 40 book chapters.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Krystyna Chrzanowska actively participated in EUCID (COST Action project BM 1280), and in writing
recommendations by 36 international Silver-Russell syndrome specialists: Diagnosis and management of
Silver-Russell syndrome: first international consensus statement. Wakeling EL, Brioude F, Lokulo-Sodipe O,
O'Connell SM, Salem J, Bliek J, Canton AP, Chrzanowska KH, et al. Nat Rev Endocrinol. 2017;13(2):105-
124.
Krystyna Chrzanowska initiated Nijmegen breakage syndrome registry in Poland (a world largest group of
patients with NBS), and continued international collaboration contributing in EURO-PIDNAS and EuroCID grants,
which resulted many publications, e.g.: Nijmegen Breakage Syndrome: clinical and immunological features, long-
term outcome and treatment options - a retrospective analysis. Wolska-Kusnierz B., Gregorek H., Chrzanowska
K., et al. on behalf of the Inborn Errors Working Party of the Society, for European Blood and Marrow
Transplantation, the European Society for Immune Deficiencies. J Clin Immunol. 2015;35(6);538-549
Piotr Socha- led the Polish group of experts in the EU EUROWILSON project, which was devoted to
construction of a European database for Wilson disease
3. Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for
Paediatric Gastroenterology, Hepatology and Nutrition.
Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, Iorio R, Vajro P, Houwen R, Fischler B,
Dezsofi A, Hadzic N, Hierro L, Jahnel J, McLin V, Nobili V, Smets F, Verkade HJ, Debray D. J Pediatr
Gastroenterol Nutr. 2018 Feb;66(2):334-344.
5. A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase. Kulecka M,
Wierzbicka A, Paziewska A, Mikula M, Habior A, Janczyk W, Dabrowska M, Karczmarski J, Lazniewski M,
Ginalski K, Czlonkowska A, Socha P (corresponding author), Ostrowski J (corresponding author).
J Hepatol. 2017 Nov;67(5):1026-1030.
List of relevant previous projects or activities, connected to the subject of this proposal :
Prof. Krystyna Chrzanowska:
. PERFECT; EC FP5; 2002-2005, leader WP4
. EURO-PID-NAS; 2003-2004; investigator
. DYSCERNE, 2007-2010; investigator
. ORPHANET EUROPE; EC 2nd Health Programme; 2011-2014; partner, Co-Coordinator in Poland
. RD ACTION; EC 3rd Health Programme EU; 2015-2018; partner, member of the Polish team
. EUCID; COST ACTION BM 1208; 2013-2016, member of the management board
. EuroCID, ERA-NET e-Rare; 2016-2019; investigator
Prof. Piotr Socha:
. CHOP; EC FP5, 2002-2006, investigator
. EUROWILSON; EC FP6, 2004-2008, principal investigator
. PERFECT; EC FP5, 2003-2005, investigator
. EARNEST; EC FP6, 2005-2010, investigator
. NUTRIMENTHE; EC FP7, 2008-2013, investigator
. Toybox; EC FP7, 2010-2014, principal investigator
825575 – EJP RD – Part B 121
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
.
41-FCT
Full legal name (Acronym) – Country Fundação para a Ciência e a Tecnologia (FCT), Portugal
Principal investigator Anabela Isidro
Relevant Network E-Rare-2, NEURON II, Infect-ERA, FLAG-ERA, BESTF Plus
Description of the legal entity/department/laboratory/group:
Fundação para a Ciência e a Tecnologia is the national funding agency that supports science, technology and
innovation, in all scientific domains, under responsibility of the Ministry for Science, Technology and Higher
Education, in Portugal.
FCT started its activity in August 1997, succeeding the Junta Nacional de Investigação Científica e Tecnológica
(JNICT). Since March 2012 FCT has coordinated public policies for the Information and Knowledge Society in
Portugal, after the integration of the Knowledge Society Agency-UMIC. In October 2013, FCT took over the
attributions and responsibilities of the Fundação para a Computação Científica Nacional (FCCN), [Foundation for
National Scientific Computation].
FCT’s mission is to continuously promote the advancement of knowledge in science and technology in Portugal,
attain the highest international standards in quality and competitiveness, in all scientific and technological domains,
and encourage its dissemination and active role in society and in economic growth.
FCT pursues its mission by funding fellowships, studentships and research contracts for scientists, research projects,
internationally competitive research centres and state-of-the-art infrastructures, via competitive calls with
international peer-review. FCT ensures Portugal’s participation in international scientific organisations, fosters the
participation of the scientific community in international projects and promotes knowledge transfer between R&D
centres and industry. Working closely with international organisations, FCT coordinates public policy for the
Information and Knowledge Society in Portugal and ensures the development of national scientific computing
resources.
The results of FCT accomplishments are, in essence, the outcome of the work carried out by the individual
scientists, research groups and institutions that are funded by FCT.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP9, we will participate, as contributors, in the monitoring exercise of the Joint Transnational Calls for
collaborative research projects (task 9.1), led by CSO-MOH (Israel) and co-led by DLR (Germany).
Previous experience relevant to the Tasks:
Over the last years, FCT team has been involved in the monitoring processes of the Joint Transnational Calls in
several ERA instruments and initiatives, from all scientific domains (Social Sciences and Humanities, Exact
Sciences and Engineering, Natural and Environmental Sciences, and Life and Health Sciences).
During the last years, FCT was involved in the monitoring of the funded projects of the E-Rare ERA-NET.
Short Profile of key Staff Members who will be undertaking the work
Dr. Anabela Isidro PhD in Molecular Biology in 2002 at the Institute for Chemical and Biological
(female) Technology, New University of Lisbon (PT). From 2002 to 2004 she got Postdoctoral
training period at the Centre National de la Recherche Scientifique (CNRS). From 2005 to
2009 she was a Post-doc at the Institute for Biological Chemistry, New University of
Lisbon (PT) and later got a principal investigator position at the Faculty for Veterinary
Medicine till 2010. Her current scientific officer position at the Department of
International Relations, FCT, involves the management of ERA-NETs in the field of
Medical and Life Sciences, and Engineering (e.g., E-Rare-2, NEURON II, Infect-ERA,
FLAG-ERA and BESTF Plus).
Dr Carlos Almeida PhD in Bioethics / Philosophy of Science, with a Master’s degree in Management of
Pereira Science, Technology & Innovation, a Specialization Course in Anthropology and Health,
(male) and a Post-Graduation Course in Neurosciences. Science Officer at the Department for
International Relations, FCT, since February 2013, taking various tasks and roles in
transnational funding programmes: JPIs (JPND; JPI CH); ERA-NETs (HERA; Neuron;
NORFACE, EuroNanoMed III; E-Rare); CSAs (JHEP2, ProSafe). Co-coordinator of the
Programme for Responsible Research of FCT. FCT’s representative in the European
Network of Research Integrity Offices (ENRIO). FCT’s representative in the National
Commission for the Protection of Animals Used for Scientific Purposes. Head of the
825575 – EJP RD – Part B 122
Thematic Group «Social Sciences and Humanities» (fordocument
Associated with the transnational cooperation).
Ref. Ares(2018)6091977 - 28/11/2018
List of relevant previous projects or activities, connected to the subject of this proposal:
. Neuron; funder: EC/national and regional partners; 2003-…; role in the project: partner
. E-Rare; funder: EC/national and regional partners; 2006-2019; role in the project: partner
. EuroNanoMed; funder: EC/national and regional partners; 2008-…; role in the project: partner
. Infect-ERA; funder: EC/national and regional partners; 2013-2016; role in the project: partner
. JPND; funder: EC/national and regional partners; 2011-…; role in the project: partner
42-INSA
Full legal name (Acronym) – Country Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA)- Portugal
Principal investigator Sandra Alves
Relevant Network
Description of the legal entity/department/laboratory/group:
INSA develops its activity as the Portuguese State Laboratory, National Reference Laboratory and National
Observatory of the health sector. INSA’s Human Genetics Department has contributed for more than three decades
now to the diagnosis and research of a large set of rare diseases (RD), such as thalassemias, cystic fibrosis,
hemophilias, mitochondrial and lysosomal storage disorders among others, being the major Portuguese centre in the
diagnosis of RD (including the Portuguese Newborn Screening Program). A great effort has also been put in
fostering the research activities involving all aspects of these pathologies: molecular and biochemical
characterization of the patients, establishment of genotype-phenotype correlations, study of the patophysiological
mechanisms, cell biology studies, development of novel therapies and monitoring of the efficacy of the already
available ones. As a consequence INSA’s team includes experts that have accumulated a large and very significant
experience on RD.
Main tasks in the project per Pillar/WP:
Pillar 2: In WP10, we will participate as contributors in the task 10.2. 2 (Survey and structured interview
approaches on technical and scientific matters, to monitor progress and inform strategic decisions) led by FTELE
(Italy).
Previous experience relevant to the Tasks:
Relevant experience for Pillar 2:
INSA Human Genetics Department research groups have widely contributed to the identification of the molecular
basis of many rare genetic diseases leading to an improvement in the functional annotation of the human genome
and in diagnosis precision and personalized medicine approaches.
Participation in the Joint Action N° 20112201 under EU Health Programme 2008-2013, EUCERD Joint Action:
working for rare diseases; INSA was responsible for the Evaluation Work package.
Participation in international networks and COST actions related to Rare Diseases. (e.g. E-HOD European Network
and Register and Cost action BM1207-Networking towards application of antisense-mediated exon skipping).
Relevant experience for Pillar 3:
Partner of the Portuguese Rare disease integrated strategy: interministerial, intersectorial and interinstitutional
cooperation towards the complementary usage of medical, social, educational and scientific resources for the
benefit of rare disease affected people and their caregivers.
Contribution to increased public awareness in health science through the regular reception of visitor groups from
schools and high schools, participation in public events such as the European Researchers' Night and summer
hands-on lab training initiatives. Furthermore a 10-minute educational video was produced for students at age 10 to
15 to explain basic genetics concepts. Special attention was given to the interaction with patient organizations for
rare or chronic diseases as well as the distribution of informative health guide leaflets on to promote health literacy
of patients, families and communities . Related Outreach activities also included: training and networking
initiatives such as “One day with the Newborn Screening Programme”.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work:
Next Generation Core facility
Short Profile of key Staff Members who will be undertaking the work
PhD. Sandra Alves PhD in Molecular Biology in 2002 at Faculty of Sciences of the University of Porto (PT).
(female) From 2002 to 2004 she had a PostDoctoral training period in the Institute of Molecular
Pathology and Immunology of the University of Porto. In 2004 she became Auxiliary
825575 – EJP RD – Part B 123
Researcher in the Department of HumanAssociated
Geneticswith
in document
the Instituto Nacional de Saúde
Ref. Ares(2018)6091977 Dr.
- 28/11/2018
Ricardo Jorge (INSA), Porto and Head of the Lysosomal Storage Diseases Research
Group in 2009.
Since 2013, she is the INSA’s representative in the Portuguese Commission for the
Treatment of Lysosomal Storage Diseases.. As principal investigator she conducted 8
R&D projects and has the authorship in more than 30 peer reviewed scientific
publications. Focused on biochemical and molecular aspects of inherited metabolic
diseases she has the domain of specialization in lysosomal storage diseases.
Dr. Glória Isidro Expert in Molecular Biology and Genetics. Coordinator of the Human Genetics
(female) Department (Instituto Nacional de Saúde Doutor Ricardo Jorge – INSA). She was
responsible for the Evaluation WP of the EUCERD Joint Action: Working for Rare
Diseases.
PhD.Laura Vilarinho PhD in Biomedical Sciences in 2000. She has over 130 articles published in peer
(female) reviewed journals and more than 150 lectures in scientific meetings. Responsible for the
Unit of Newborn Screening and Diagnosis of Inherited Metabolic Diseases (Department
of Human Genetics, Instituto Nacional de Saúde Dr. Ricardo Jorge - INSA).
Coordinator of the Executive Committee of the Portuguese Newborn Screening Program.
PhD. Olg Amaral PhD in Biomedical Sciences (Faculty of Sciences, University of Porto-UP) in 2001.
(female) Specialization domain: Human Molecular Genetics and Lysosomal Storage Disorders
(LSD). She has worked in research and diagnosis in the field of rare metabolic disorders,
having participated in several research projects, as well as being responsible for the set
up, coordination and supervision of molecular diagnosis of sphingolipidoses and
mucopolysaccharidoses at U.Enzimologia of IGMJM and Unilipe at IBMC-UP (1989-
2005). At INSA she´s a member of the Unit of Research & Development in the LSDs
Group (DGH). She’s been principal investigator of projects with competitive financing,
with 30 peer reviewed papers and over 80 peer reviewed presentations
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements (:
1.Vilarinho L1, Rocha H, Sousa C, Marcão A, Fonseca H, Bogas M, Osório RV. Four years of expanded newborn
screening in Portugal with tandem mass spectrometry J Inherit Metab Dis. 2010;33 Suppl 3:S133-8.
2. Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, Desviat LR, Pérez B, Pshezhetsky AV, Grinberg D,
Alves S, Vilageliu L. Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C
splicing mutations. Orphanet J Rare Dis. 2014; 9:180.
3. Matos L, Gonçalves V, Pinto E, Laranjeira F, Prata MJ, Jordan P, Desviat LR, Pérez B, Alves S. Functional
analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative
therapy for MPS II. Biochim Biophys Acta. 2015;1852:2712-21.
4. Cruz S, Taipa R, Nogueira C, Pereira C, Almeida LS, Neiva R, Geraldes T, Guimarães A, Melo-Pires M,
Vilarinho L. Clinical, biochemical, molecular, and histological features of 65 Portuguese patients with
mitochondrial disorders.
Muscle Nerve. 2017;56(5):868-872.
5. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia-
Cazorla A, la Marca G, Pasquini E, Vilarinho L, Weisfeld-Adams JD, Kožich V, Blom H, Baumgartner MR,
Dionisi-Vici C. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC,
cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48.
List of relevant previous projects or activities, connected to the subject of this proposal :Desvendar. NORTE-
2020. (2016-2018). Proponent. This project focuses the application of innovative methods of molecular biology for
the study of rare diseases. The main objective is the implementation of a Next Generation Core facility in INSA
Human Genetics Department in Porto.
. Joint Action N° 20112201 under EU Health Programme EUCERD Joint Action: working for rare diseases.
(2008-2013). General objectives: The EUCERD was mandated to assist the EC in formulating & implementing
the Community's activities in the RD field, to foster exchanges of relevant experience, policies & practices
between the MS & stakeholders. Specifically, the JA addressed the following: a) Enhanced visibility and
recognition of RD; b) Contributed to the development and dissemination of knowledge on RD; c) Contributed to
improvements in access to quality services and care, from diagnosis, through to care and social support and
innovative therapies. INSA was responsible for the Evaluation WP.
. Splicether. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project is in
the rare diseases disease field and makes the bridge between patient diagnosis and characterization of the
mutations found and the development of alternative therapeutic approaches (mutation-specific).
825575 – EJP RD – Part B 124
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
. CeMoLy. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project aims at
establishing cellular models for the investigation of rare diseases, through the use of iPSCs, in order to provide
alternative means for pathophysiology and therapeutic studies.
. Genetic Defects of Mitochondrial Diseases: a Next Generation Sequencing Approach. FCT (Fundação para a
Ciência e a Tecnologia). (2016-2018). Proponent. The overall aim of this project is the development of a Next
Generation Sequencing strategy to identify genetic defects in patients with a presumptive diagnosis of
Mitochondrial Disease.
43-SAS
Full legal name (Acronym) – Country Slovak Academy of Sciences (SAS) - Slovakia
Principal investigator Ján Barančik, PhD.
Relevant Network www.sav.sk
Description of the legal entity/department/laboratory/group:
The Slovak Academy of Sciences (SAS) a governmental research organization, is the recognized leading research
and scientific institution aimed at excellent basic, strategic and applied research in Slovakia. The SAS as a funding
body supports those scientific disciplines which have attained international level and which are deemed necessary
for the advancement of Slovakia. It consists of 70 organizations and publishes 54 scientific and professional
journals and 8 yearbooks. There are 49 scientific and scholarly associations, societies and unions affiliated with the
SAS. The Assembly, the Scientific Council, and the Presidium are the Academy’s self-governing bodies. The SAS
governs the total budget of more than 60 Mio. Euro. Significant part of this amount is distributed on the
competitive principle via annual project calls. The scientific policy of SAS supports interdisciplinary research and
collaboration with research teams at Universities and with the industry.The SAS together with the Slovak
universities operates the Scientific Grant Agency (VEGA – Vedecka grantova agentura) to which the project
proposals in different research fields including the Rare Diseases research can be submitted in the frame of
the “ Research in the field of biological, medical and farmaceutical sciences”. A part of the budget is reserved
for international research cooperation within the schemes such as FP EU, ERA-Net, Horizon 2020 COST, ESA etc.
The funding supports multidisciplinarity and synergy effects stemming from international cooperation with the
emphasis on incorporation of post docs and young researchers. The duration of funding is based on the
individual project needs (as a rule, several years).
SAS has an expertise concerning ERA.NET (Cofund) scheme in the various fields of science. The participation of
SAS in the ERA-Nets projects have been based on the official mandate of the Ministry of Education of the Slovak
Republic for the SAS to act as R&D programme owner and manager. Selection procedures for the applications
have been established and approved by the SAS Presidium.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate in task 1.1 – Joint Transnational Call 2019
In WP6, we will participate in task 1.2 – Joint Transnational Call 2020
SAS will actively participate in the project as committed partner in several tasks.
Previous experience relevant to the Tasks:
Participation of SAS in the “EJP Rare Diseases” project as committed partner will result from participation and
experience in many ERA.NETs (cofund) including the field of medicine e. i. TRANSCAN, NEURON,
ERACoSysMed, ERA-CVD, EuroNanoMed, etc.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work (if applicable):
Short Profile of key Staff Members who will be undertaking the work
825575 – EJP RD – Part B 125
Jan Barancik, PhD. Coordinating person responsible for the Associated
overall timely management
with document of the “EJP
Ref. Ares(2018)6091977 Rare
- 28/11/2018
Diseases project, comprising the content of the work plan, the finances and the
administration. He is the head of International Cooperation Dpt. at SAS. He has a
teorethical and working experience as a coordinator and project manager of many
European networks (ERA.NETs) and international projects not only in the field of
medicine e.g. TRANSCAN, NEURON II, EuroNanoMed II, ERACoSysMed,, ERA-CVD
but also in other scientific fields e.g. , M-ERA.NET, INCOMERA, ANIHWA,CONCERT
Japan, ERA.NET RUS Plus QuantERA, FLAG-ERA, ICT-CHIST ERA III etc.
Katarina Bibova Project Manager responsible for the day-to-day operational management of administrative
and organizational aspects in this project. He is engaged in several european and
international projects at SAS i.e NEURON, ERACoSysMed, EuroNanoMed and in the
SAS bilateral JRP Programmes related to the field of medicine and environment (Japan,
Korea, Russia)
Tbc Senior scientist. He/She will act as Scientific Manager responsible for scientific aspects in
this project.
List of relevant previous projects or activities, connected to the subject of this proposal (max 5):
SAS as a financing member of several consortia in the scheme of ERA-NETs (cofund) in the field of biological,
medical and farmaceutical sciences, as mentioned above.
.
44-ISCIII
Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII) − Spain
Principal investigator Eva Bermejo-Sánchez, PhD
Relevant Network
Description of the legal entity:
The Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is the main Public Research Entity
funding, managing and carrying out biomedical research in Spain. The Institute has been conducting research and
providing key services in the life and health sciences for over 25 years. Its mission focuses on basic, translational
and applied research as well as health technologies. ISCIII performs intramural activities and has a regulatory role
as far as accreditation of research centres is concerned. It is also the body responsible for managing Spain's Health
Research and Development Strategy within the framework of the National R+D+I Plan. Reports directly to the
Ministry of Economy, Industry and Competitiveness (Royal Decree 345/2012) and in operational terms to both this
Ministry and to the Ministry of Health, Social Services and Equality (Royal Decree 200/2012), has as its main
mission to support the development of scientific knowledge in the health sciences and to contribute to innovation in
treatment, healthcare and the prevention of disease. Putting patients and the public at the heart of all its activities
and objectives, the Institute promotes and coordinates biomedical research and provides scientific and technical
services of the highest quality in partnership with all the organizations forming part of the Spanish System of
Science, Technology and Innovation.
In terms of budget, the Institute is publicly funded (more than 270 M€ year 2016) and allocates funds to extramural
research, including competitive annual calls. Since its inception, through a rigorous selection process based on peer
review evaluation, ISCIII has awarded grants for research projects, networks, equipment, fellowships, technical
manpower and research contracts. Moreover, under the Horizon 2020 umbrella, the Institute has been actively
involved in the promotion of Spanish research excellence via its participation in key European transnational
initiatives such as: ERA-Net cofund, ERA-Nets, ERICs, ESFRI project preparatory phases, Art. 185 TFEU
initiatives, and Joint Programming Initiatives. The Institute also participates in other international research
consortia (e.g. IRDiRC, ICGC and the Personalized Medicine Coalition).
Departments involved in this EJP:
The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER
(Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And
Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC
will be also deeply involved. Both are included in “Team b” below.
There will be 2 main departments of ISCIII involved in this EJP:
- Team a: from the Sub-Directorate General for International Research Programmes and Institutional
825575 – EJP RD – Part B 126
Relations (SGPIIRI). Associated with document Ref. Ares(2018)6091977 - 28/11/2018
- Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There
will be mainly researchers from IIER, but also from other two units, as it will be detailed in a separate table, as
indicated in the instructions.
Team a: The specific team of the SGPIIRI involved in this EJP leads the follow-up of the international research
activities and programs, mainly the European ones. It has also leaded other like the Spanish participation in
multilateral and international organizations like IARC (International Agency for Research on Cancer), TDR
(Special Programme for Research and Training in Tropical Disease), IANPHI (International Association of
National Public Health Institutes), EuSANH (European Science Advisory Network for Health) and RIMAIS (Red
Interministerial de Aprendizaje e Investigación en Salud). Moreover,it has collaborated with European research
infrastructures in the development of the ESFRI roadmap (e.g. ECRIN, EATRIS, ELIXIR and ERINHA) and it has
also been involved in the reinforcement of cross-border cooperation of research programmes through Joint
Programme Initiatives: JPND, JP HDHL, JPAMR, JP MYBL; Article 185 TFEU (AAL and EDCTP); ERA-Net
cofund (ERACoSysMed, E-RARE-3, TRANSCAN 2, JPco-fuND); ERA-Nets (E-RARE, NEURON,
TRANSCAN, EuroNanoMed, Infect-ERA), JPIs to Co-Work and EULAC Health. Within the context of these
initiatives, the Institute has adopted a number of roles: Coordinator, National Contract Point and Joint Call
Secretariat.
[Details on “Team b” can be found in a separate table, as indicated in the instructions]
Main tasks in the project per Pillar/WP:
TEAM A will participate in:
Coordination & Transversal Activities:
In WP3: Co-leader, together with INSERM and EATRIS.
- Task Co-leader for tasks 3.1, 3.3 and 3.4
- Task 3.2: Participant.
Pillar 1:
In WP6: Participant, and
- Task 6.4: Leader, for the 4th Joint Transnational Call (JTC 2022) not co-funded by the EC
In WP9: Participant in Task 9.1 (Subtasks 9.1.1, 9.1.3 and 9.1.4), and Task 9.2.
Previous experience relevant to the Tasks:
ERA-Net Infect-ERA is an initiative in which ISCIII contributed to the development of Work Package 7. The
latter dealt with the design of a long-term collaboration framework, the set-up of the external scientific committee
and the generation of a network with similar initiatives.
ERA-Net Cofund ERACoSysMed aimed to enhance the implementation of Systems Medicine approaches in both
clinical research and medical practice throughout Europe and beyond. ISCIII was WP leader of the WP devoted to
the evaluation of the cofounded call and will be in charge on an additional call as Joint Call Secretariat.
ERA-Net Neuron II seeked to coordinate national and regional research programmes in neuroscience. ISCIII was
responsible for Neuron II’s Work Package 7, which dealt with the development of a long-term collaboration
framework. Additionally, ISCIII participated in the execution of Work Package 2, which dealt with the creation of
the strategic agenda; Work Package 5, intended to provide support to young researchers; and the monitorization of
the consortia’s communication activities.
ERA-Net EuroNanoMed III seeked to foster the competitiveness of European research centres engaged in
Nanomedicine. ISCIII was responsible of the Work Package that dealt with the development of the Research
Strategic Agenda, the drafting of joint call documents and the design of the long-term collaboration framework.
ERA-NET Cofund E-Rare-3, ISCIII was responsible of the management of the call secretariat of the third JTC.
In two occasions (2012 and 2014) ISCIII has been in charge of running the Joint Call Secretariat (ERA-Net E-Rare-
2). The tasks executed during both Calls included: drafting of call documents, design and coordination of the
assessment process, management of the IT platform, selection of reviewers and the organization of the evaluation
panels −among other things. Joint Call 2012 was focused on Young Investigators.
EU Joint Programme – Neurodegenerative Disease Research (JPND) ISCIII participated in kind in the
JUMPAHEAD project that supported the implementation of JPI to combat neurodegenerative diseases. It is a three
year project funded by an FP7 2 million euro grant GA no. 260774, in which ISCIII actively contributed with the
execution of organizational tasks.
In ERA-Net cofund JPco-fuND ISCIII mainly participated in the WP for additional activities and is co-leader in
825575 – EJP RD – Part B 127
the alignment of national research plans task. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
J-AGE is a Coordination Action for the implementation of the JPI "More Years, Better Lives - the Challenges and
Opportunities of Demographic Change". ISCIII was responsible of the management of the call secretariat of the
second and third JTC. ISCIII participated in the drafting of a non-comprehensive list of possible instruments that
could be used for the implementation of the Strategic Research Agenda (SRA) and the compilation of results of a
Workshop held in Madrid on 22/03/2013.
Short Profile of key Staff Members who will be undertaking the work
Mr./ Ignacio Project Officer managing and coordinating European transnational research collaborations at the
Baanante- EU and Internationalization Dept of SGPIIRI at ISCIII. In 2010 and 2012 he worked at the
Balastegui/ European Office of the Spanish Ministry of Science and Innovation, based in Brussels, where he
Male participated in the evaluation and monitoring of scientific policies at National, European and
International level, and contributed to drafting analytical documents (i.e. Impact Assessment). In
2008 he was involved and provided support in other initiatives [PRIOMEDCHILD, Art. 185
TFEU (AAL), ERA-Nets (TRANSCAN, INFECT-ERA), and JPI More Years Better Life and its
CSA (J-AGE), as well as in training activities in the biomedical field. Undertook several Joint
Call Secretariats (ERA-Net E-Rare, EuroNanoMed).
He will be in charge of call-4 secretariat and Pillar 1 activities of ISCIII, and will provide support
for the ones in transversal WP3, in this EJP.
Mrs./ María Project Officer at the Deputy Director’s Office for International Research Programmes and
Druet- Institutional Relations (SGPIIRI) at the National Institute of Health Carlos III. Ms Druet is
Ampuero/ actively involved in the coordination, management and follow-up of European transnational
Female collaborations European network of transnational collaborative RTD such as: EURONAOMED,
TRANSCAN, NEURON, and E-RARE. Ms Druet plays an instrumental role in the management
and coordination of E-RARE, TRANSCAN, NEURON and EURONANOMED Joint Call
Secretariat’s administrative and financial activities. A total of 21 funding agencies cooperate
within the novel EURONAOMED III where the Institute of Health Carlos III is the
coordinator.Previously, during 2011-2013, she worked in the European project office like the
Project Manager of the CSA Joint Programming Initiatives a process of mutual learning Toward a
Common adoption of framework Conditions, (VIIPM). She will support the call-4 secretariat and
Pillar 1 activities of ISCIII, as well as of the ones in transversal WP3 in this EJP.
Dr./ Carlos Carlos Segovia-Pérez has been involved in several European and international health research
Segovia- initiatives since 2007. He has been structural trainee at DG Research (EC) and National Focal
Pérez/ Male Point for the EC Health programme. He is the current chair of the Joint Programming Initiative on
Antimicrobial Resistance. He was Deputy Director of International Research Programmes (2009-
13) at ISCIII, and as such, Spain’s representative at IARC, TDR, IVI, RIMAIS, IANPHI,
Coordinator of FP7 ‘EU-LAC Health’ and ‘JPIs to Co-Work’, and President of EuSANH.
Technical Advisor of International Research Programmes (2006-2009) at ISCIII and National
Focal Point for EC-SANCO Health Programme. Technical Advisor at the Social and Health Care
Coordination Unit, at the Regional Department of Health Castilla y Leon.
Carlos Segovia is primary care physician and master of public health from Harvard University.
Before joining ISCIII, Carlos has been coordinator of a primary care centre for two years, deputy
director for primary care quality and research of a province for ten years, and expert for social and
health care coordination at a Regional Department of Health for two years.
He will be in charge of WP3, which is co-leaded by ISCIII.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
See above the cell on Previous Experience, that includes some achievements from a set of relevant activities of
similar nature to the one of this proposal.
List of relevant previous projects or activities, connected to the subject of this proposal
See above the cell on Previous Experience, that includes a set of relevant activities of similar nature to the one of
this proposal.
Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII) − Spain
Principal investigator Eva Bermejo-Sánchez, PhD
Relevant Network
825575 – EJP RD – Part B 128
Description of the legal entity: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
The description of the Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is included in a
separate table, where the description of ISCIII’s “Team a”, also involved in this EJP, is described.
Departments involved in this EJP:
The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER
(Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And
Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC
will be also deeply involved. Both are included in “Team b” below.
There will be 2 main departments of ISCIII involved in this EJP:
- Team a: from the Sub-Directorate General for International Research Programmes and Institutional
Relations (SGPIIRI).
[Details on “Team b” can be found in a separate table, as indicated in the instructions]
- Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There
will be mainly researchers from IIER, but also from UITeS (Telemedicine and eHealth Unit) and BU-ISCIII
(Bioinformatics Unit). These are the details on them:
The Institute of Rare Diseases Research (IIER) is a national center belonging to the ISCIII. It has two different
areas of work: Rare Diseases Epidemiology, and Human Genetics. The IIER was officially designed as a WHO
Collaborating Center for the epidemiology of diseases of unknown origin, between 1996 and 2011. It was also
responsible for the coordination of the Spanish Network for Epidemiological Research on Rare Diseases (REpiER)
and the Spanish National Rare Diseases Registry (SpainRDR). Currently, IIER is leading the National Rare
Diseases Biobank, being a founder of EuroBioBank network. On behalf of ISCIII, it assists the Ministry of Health,
Social Services and Equity in the development of its Strategy regarding Rare Diseases. Some members of the IIER
form part also as a research group of the Centre for Biomedical Research on Rare Diseases as a Network
(CIBERER). The IIER has also contributed to projects as RD-Connect, RIBERMOV, RareBestPractices,
EUROPLAN and EPIRARE, among others. It also takes part in the International Conference on Orphan Drugs and
Rare Diseases (ICORD) and the Undiagnosed RD Cases Network International (UDNI). Since 1981, IIER has been
responsible for the old Spanish cohort with more than 20,000 people involved and followed by more than 37 years
due to their affection by a rare disease, and at the same time IIER has contributed to the creation of some patient
RD registries or cohorts of patients.
UITeS (Telemedicine and eHealth Unit): Its mission is to promote and develop research, development and
innovation work in the field of ICT applied to health. Its work follows the priorities of the National R&D&I
Programme, the EU Framework Programme in ICT for health, public health and environmental health. Its main
areas of interest are: telemedicine; e-health; mobile systems, network service platforms, biomedical
instrumentation; wireless networks, electromagnetic security and compatibility, plus applications to support
assistance for people with chronic conditions and help to prevent dependence. Its work covers scientific and
technological research and the promotion of innovation in the National Health System by carrying out pilot
projects, demonstrations and clinical trials jointly with other research groups, healthcare institutions and relevant
industrial concerns.
BU-ISCIII (Bioinformatics Unit): It is a transversal unit at ISCIII that gives support to other of its units. Therefore,
BU-ISCIII will act supporting “Team b” of ISCIII for this EJP in what refers to the general analysis of data,
genomic data and big data of any nature, linked to research on rare diseases, as it has been doing since its inception
at ISCIII.
Main tasks in the project per Pillar/WP: (See details on ISCIII’s “Team a” in a separate table, according to the
instructions)
TEAM B will participate in:
Coordination & Transversal Activities:
In WP2: Co-leader, together with ISS.
- Task Co-leader for tasks 2.2 and 2.3
- Participant for Tasks 2.1, 2.4 and 2.5.
Pillar 2: (Costs of the in-kind contribution of ISCIII to Pillar 2 will be of at least 39,000.00 €, including
indirect costs)
- WP11: Participant for Tasks 11.1, 11.3, and 11.4
- WP12: Participant for Task 12.1
- WP13: Participant for Task 13.1
Pillar 3: (Costs of the in-kind contribution of ISCIII to Pillar 3 will be of at least 18,000.00 €, including
indirect costs)
- WP14: Participant for Tasks 14.3, 14.4 and 14.5
825575 – EJP RD – Part B 129
- WP16: Participant for Task 16.2 (Subtask 16.2.2) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Previous experience relevant to the Tasks:
More than 30 years working in the field of Rare Diseases (RD), in their research, development and coordination
of networks, creation of: the platform of the Spanish National Registry of RDs and the work for its
FAIRification, the Spanish National biobank for RD, a program for undiagnosed cases of RD, worldwide
contribution to the match-maker exchange approach to RD patients, leading and participation in numerous
research projects (either in Spain and at the international level –Europe and worldwide). Working on
biospecimen and patient registries, diagnosis, genomic studies, therapies development, orphan drugs, clinical
studies, and e-health. Hundreds of scientific papers. Contributing to the Spanish National Policy on RD. Very
close contact to the Spanish Federation of patients with Rare Diseases and their families (FEDER), and specific
patients’ associations. Member of the Steering Committee for the MOOC Course at Coursera “Preparing for an
Ageing Population” (Univ. of Melbourne). Chair of the Intl. Medical Informatics Association´s WG on
Exposome Informatics.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
- Platform: Spanish Rare Diseases Research Registries Network (SpainRDR)
- Platform: Spanish National Biobank for Rare Diseases (BioNER)
- On-line course on rare diseases for health professionals, developed by IIER at ISCIII.
- Computational infrastructure, High Performance Computing and Data storage, required for achieving the aims
of this project.
Short Profile of key Staff Members who will be undertaking the work
Dr. (MD, Director of IIER, member of the Executive Committee of the IRDiRC, President of the
PhD)/ Manuel International Conference on Orphan Drugs and Rare Diseases (ICORD), and Member of the past
Posada-de-la- European Commission’s Experts Group of RD (CEGRD) by designation. Director of BioNER
Paz/ Male (National Biobank on Rare Diseases). Chief of Research Group U-758 at CIBERER (Centre for
Biomedical Research as a Network). Director of the WHO Collaborating Centre in the
Epidemiology of Environment-Related Illnesses (1996-2011), Director of the Research Center
CISATER, International General Coordinator of the Research Programme on the Spanish Toxic
Oil Syndrome (WHO-Health Research Fund). Principal investigator for the Spanish Network for
Epidemiological Research on Rare Diseases (REpiER) and the Spanish Rare Diseases Research
Registries Network (SpainRDR). Leading one IRDIRC project and numerous projects funded by
the EU and main Spanish agencies, with hundreds of papers published.
Dr.(MSc, Tenured Scientist, Chief of Area of the Institute of Rare Diseases Research (IIER), ISCIII. Past
PhD)/ Eva President of the Executive Committee of ICBDSR, Chief of Research Group U-724 at CIBERER.
Bermejo- Scientific Coordinator of the Spanish Collaborative Study of Congenital Malformations
Sánchez/ (ECEMC), its registry, and its clinical network. Scientific Director of the National Biobank of the
Female Institute of Health Carlos III. Accredited in Human Genetics. Working in the field of
epidemiology, clinical genetics and clinical teratology, for congenital anomalies, and in the
Spanish Undiagnosed Rare Diseases Program of IIER (SpainUDP). 130 peer-reviewed papers
published (h-index: 24) and Principal Investigator of several research projects on congenital
anomalies and other rare diseases. Long participation in EUROCAT and JRC.
Dr. (PhD, Research Professor in Biomedical Informatics and Digital Health at ISCIII. Full Professor at the
FACHI, Division of Health Informatics at Weill Cornell Medicine and participated in the US Precision
FACMI, Medicine Initiative (2015-17). Former Chair of Health Informatics at the Melbourne Medical
CHIA, School and foundational Director of the Health and Biomedical Informatics Centre (HaBIC) at the
MIAHSI)/ University of Melbourne. PhDs in Informatics and Medicine; MSc in Knowledge Engineering
Fernando and BSc in Biochemistry and Molecular Biology. Served as Vice-President of the International
Martín- Medical Informatics Association and Chair of the Scientific Program Committee for the XV
Sánchez/ Male World Conference in Health and Biomedical Informatics, MEDINFO 2015. More than 180 peer-
reviewed publications (h-index: 25). 40 grants from the EC and main agencies from Spain,
Australia and the USA.
Dr.(MSc, Tenured Scientist at the Institute of Rare Diseases Research (IIER), of ISCIII. She is also part of
PhD)/ the Centre for Biomedical Network Research on Rare Diseases. Involved in different European
Verónica and national projects in Spain, her research is focused on Rare Diseases: morbidity and mortality
Alonso- studies, geographical analysis, population-base and patient registries, biobanking and
Ferreira/ interoperability, among other topics.
Female
Dr. (PhD)/ Researcher. PhD in Pharmacy. Skills in Pharmacy, Biochemistry, Microbiology, Environmental
825575 – EJP RD – Part B 130
Estrella Health and Rare Diseases research. Current postdoctoral
Associated position in IIER
with document of ISCIII, participating
Ref. Ares(2018)6091977 - 28/11/2018
López-Martín/ in several tasks related to the Spanish Undiagnosed Rare Diseases Program SpainUDP. Also
Female involved in activities derived from the European projects RD-Connect and Solve-RD, focused on
infrastructures and research on RD. Expertise within the rare diseases field: interoperability
strategies at international level, undiagnosed diseases programs, phenotype ontologies and
research projects.
Dr.(PhD)/ Leader of the Computational Biology Unit of the UFIEC in the Institute of Health Carlos III. She
Victoria has a Master of Biotechnology from the University of Madison Wisconsin (USA) and a PhD in
López- Biochemistry and Molecular Biology from the University of Valencia. Wide experience in
Alonso/ bioinformatics and system biology data analysis. She has participated in several research projects
Female related to new technologies at the intersection of biology and computer science.
Mrs.(PhD)/ Scientist and Bioinformatics Unit leader at ISCIII (BU-ISCIII). Master degree in Bioinformatics
Isabel Cuesta- and Computational Biology. Taught by Complutense University in partnership with National
Plaza/ Female Center of Biotechnology and ISCIII. Additional training visiting leading groups in Principe Felipe
Research Center Bioinformatic service (CIPF), European Bioinformatic Institute (EMBL-EBI).
She directs final master degree projects, organises and participates in courses on data mining and
high throughput sequencing data analysis at ISCIII. BUISCIII is involved in national and EU-
funded projects, among others, and is partner of Spanish Undiagnosed Rare Diseases Program
(SpainUDP), project leaded by IIER and integrated in RD-Connect European project, focusing on
the diagnosis of RD based on WES data analysis and sharing.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Spanish National Registry of Rare Diseases (SpainRDR): https://registroraras.isciii.es/
2. Spanish National Biobank for Rare Diseases (BioNER): http://bioner.isciii.es/
3. Spanish Program for Undiagnosed Rare Diseases (SpainUDP): http://portal-spainudp.isciii.es
4. Book: “Rare disease Epidemiology Book: Update and Overview” [2017]
http://www.springer.com/la/book/9783319671420
5. Martin-Sanchez FJ, Lopez-Campos GH. The New Role of Biomedical Informatics in the Age of Digital
Medicine. Methods Inf Med. 2016 Oct 17;55(5):392-402.
List of relevant previous projects or activities, connected to the subject of this proposal
REpIER (Spanish Network for Epi Research on RDs); Funder: ISCIII-Call for Networks of Thematic Cooperative
Research; 2002-05. Project Leader (MPP). Development of a program for epidemiological research on RDs in
Spain, for better orientation of social and health policies.
. SpainRDR; Funder: IRDiRC; 2012-14; Project Leader (MPP). Creation of the National Rare Diseases Registry
in Spain based on the input of two different strategies: patient registries addressed to patient outcome research
and population-based registries aimed at epidemiologic research and health-social planning.
. BioNER (Natl. Biobank on Rare Diseases); Funder: ISCIII; 2013-present. Creation and Manager (MPP). Spanish
National Biobank for RDS.
. NYC-PMI (New York City Precision Medicine Initiative); Funder: NIH. 2015-17. Co-investigator (FMS);
. BiomarkerCard; Funder: NICTA (National Information and Communications Technology Australia); 2013-14.
Principal investigator (FMS); Knowledge representation systems to assess the clinical relevance of biomarkers.
45-CNAG-CRG
Full legal name (Acronym) – Country Fundació Centre de Regulació Genòmica (CNAG-CRG),
Spain
Principal investigator Ivo Gut
Relevant Network ELIXIR
Description of the legal entity/department/laboratory/group:
The CRG is as a multidisciplinary research centre focusing on biomedicine. It is a first-class multidisciplinary
research center that hosts a total of 30 group leaders, of which ~half hold an ERC grant. The «Centro Nacional de
Análisis Genómico» (CNAG-CRG) is a non-profit organization founded in 2009 and integrated with the CRG.
CNAG-CRG is funded by the Spanish Ministry of Economy and Competitiveness and the Catalan Government.
CNAG-CRG’s mission is to carry out projects in DNA sequence analysis for the improvement of quality of life in
collaboration with the European and International Research Community. It has a staff of 79.
CNAG-CRG’s director, Dr. Ivo Gut, leads the Biomedical Genomics group. Its main line of research is mining,
825575 – EJP RD – Part B 131
analysis and re-analysis of genomic data from biomedical studies focussing
Associated on projects
with document in rare disease- 28/11/2018
Ref. Ares(2018)6091977 (RD),
common diseases and cancer. Dr. Sergi Beltran leads the Bioinformatics Unit at CNAG-CRG, composed by 21
people and devoted to the development and operation of tools and pipelines for the analysis and interpretation of
sequencing data. In 2017, the group analysed more than 250 projects in genomics, including germline variant
identification, somatic variant identification and differential gene expression analysis. Dr. Beltran leads the
development of the RD-Connect Genome-Phenome Analysis Platform (GPAP). Since 2013, the CRG is co-
managing the European Genome-phenome Archive (EGA) in partnership with the EBI. The CRG EGA group is led
by Jordi Rambla, and has expertise in different areas, especially software development and database design. The
EGA is hosting many studies and datasets from RD.
Main tasks in the project per Pillar/WP:
Pillar 2: In WP10, we will participate in Coordinating Pillar 2 Work Packages and aligning to RD community
needs (Task 10.1), Convene yearly retreats leading to Pillar 2 annual strategic plans (Task 10.2), Coordination of
technical GDPR implementation (Task 10.3), Quality oversight (Task 10.4) and Developing sustainable models
(Task 10.5).
In WP11, we will co-lead WP11 and lead Provision of analysis and data sharing capabilities to the RD community
through online resources (Task 11.4). We will also participate in tasks, FAIR-compliant platform for discovery of
RD resources (Task 11.2) and Data deposition and access to data infrastructures for RD research (Task 11.3).
In WP12, we will participate in Multi-site teams for software and tool development with respect to WP12 (Task
12.2) and Practical FAIRification support (Task 12.3).
In WP13 we will participate in Fill pre-identified gaps (Task 4.1).
Pillar 3: In WP14, we will participate in Standards and quality of genetics/genomics data in laboratory and clinical
research practice (Task 14.2) and Training on strategies to foster solutions of undiagnosed RD cases (Task 14.3)
Previous experience relevant to the Tasks:
PILLAR 2: The CNAG-CRG has been collaborating in sequencing and analysing RD patients since its foundation.
In 2014 the CNAG-CRG opened a call to sequence 300 exomes for RD research within Spain. In 2016, the CNAG-
CRG launched a call to sequence 900 exomes for RD research within the framework of the EU-FP7 project
BBMRI-LPC. Currently, the center is leading the sequencing and analysis of 1,000 RD whole genomes within the
NAGEN-1000 project (http://www.navarrabiomed.es).
Dr Sergi Beltran team has led the development of the RD-Connect platform (platform.rd-connect.eu) which, among
other, enables the standardised analysis and interpretation of genomic data linked to the corresponding clinical
information collected with controlled vocabularies and the Human Phenotype Ontology (HPO).
PILLAR 3: The CNAG-CRG provides training at several levels to researchers, clinicians, patients and students,
through dedicated hands-on workshops and courses on genome analysis and bioinformatics. Specifically for RD-
Connect, the CNAG-CRG has already led 14 hands-on workshops since 2015 in nine EU countries The CNAG-
CRG also generates online training materials and collaborates closely with the ELIXIR training platform through
Task 8.3 from ELIXIR-EXCELERATE and RD-Connect.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
To analyse the data the CNAG-CRG operates a 3,500 core supercomputer, with nodes carrying from 48 GB to 2
TB of RAM. CNAG-CRG uses CPUs, GPUs and FPGAs and has compute capacity in excess of 200 Tflops. The
computer has 7.6 PB of disk and tape storage. An internal 10 Gb/s network and multiple 10 Gb/s physical
connections to the Barcelona Supercomputing Center (BSC, www.bsc.es) which has over 50,000 compute cores
and provides backup.The RD-Connect cluster is hosted at the CNAG-CRG's Data Processing Center (DPC). The
cluster includes 19 nodes with a total of 304 cores, 4.8 TB of RAM, 336TB HDD and 19TB SDD.
The operation of CNAG-CRG is certified ISO9001 and accredited ISO17025.
Short Profile of key Staff Members who will be undertaking the work
PhD. Ivo Gut Ivo Gut is Director of the CNAG-CRG. He has more than 20 years’ experience in high-
(male) throughput nucleic analysis (genotyping and sequencing DNA, RNA and DNA
methylation), technology development in nucleic acid and protein analysis. He was Head of
Technology Development and Associate Director at the Centre National de Génotypage
(CNG) – CEA (1999-2009), where he established the highest throughput genotyping
platform in Europe, executed many genome-wide association studies, initiated and was the
coordinator of the EU-funded Project READNA. He is currently participating as principal
investigator in five FP7/ H2020 projects: BCAST, RD-CONNECT, ELIXIR-
EXCELERATE, SINGEK and SPIDIAP4P.
He is author of more than 350 research papers, 11 reviews and 12 book chapters, cited over
34,000 times (H-Index = 82, Google Scholar), inventor of 25 patents or patent applications,
founder of 4 biotech start-ups, and serves on numerous international advisory boards.
825575 – EJP RD – Part B 132
PhD.Sergi Beltran Sergi Beltran has over 15 years of experience withwith
Associated genomics and Ares(2018)6091977
document Ref. bioinformatics and has
- 28/11/2018
(male) participated in over 45 international publications. He leads the development of the RD-
Connect platform (platform.rd-connect.eu). His group participates in the IRDiRC/GA4GH
MatchMaker Exchange (MME) and GA4GH Beacon projects through RD-Connect and is
co-leading the development of the new MME API, which will enable more complex queries
while maintaining the same privacy standards. Within ELIXIR-EXCELERATE, Dr. Beltran
participates in the RD use case co-led from the CNAG-CRG and in benchmarking activities.
Jordi Rambla(male) Jordi Rambla is project manager for the EGA since 2013. He has 30 years of experience in
developing complex IT projects involving data integration, data cleansing, database
architecture and data warehousing exploitation.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements :
1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Lochmuller, H,
et al. including Gut, I and the RD-Connect consortium. Eur J Hum Genet. 2018 Feb 27.
2. From Wet-lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and
Whole Exome Sequencing. Laurie S, et al. including Gut I and Beltran S. (last author). Hum Mutat. 2016 Sep 8.
3. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Alioto
TS et al. including Beltran S and Gut I (last author). Nat Commun. 2015 Dec 9;6:10001.
4. The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery. Philippakis AA, Azzariti DR,
Beltran S et al. Hum Mutat. 2015 Oct;36(10):915-21. doi: 10.1002/humu.22858.
5. Genomic characterization of mutant laboratory mouse strains by exome sequencing and annotation lift-over.
Derdak S et al., including Beltran S. (last author). BMC Genomics. 2015 May 6;16:351.
List of relevant previous projects or activities, connected to the subject of this proposal:
1. RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare
disease research (Coordinator: Hanns Lochmüller). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 1,997,994 €;
timeline: nov12-oct18; Call: FP7-HEALTH.2012.2.1.1-1-C
2. SOLVE-RD: Solving the unsolved rare diseases (Coordinator: Olaf Riess). CNAG-CRG PI: Sergi Beltran;
CNAG-CRG budget: 1,505,132 €; timeline: jan18-dec22; Call H2020-SC1-2016-2017
3. ELIXIR-EXCELERATE: Fast-track ELIXIR implementation and drive early user exploitation across the life-
sciences. (Coordinator: Niklas Blomberg). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 200,000 €; timeline:
sep15-ago19; Call: H2020-INFRADEV-1-2015-1.
4. BBMRI-LPC: BBMRI – Large Prospective Cohorts (Coordinator: Markus Perola). CNAG-CRG PI: Ivo Gut;
CNAG-CRG budget: 535,660 €; timeline: feb13-ene17; Call: FP7-INFRA-2012-1.1.9. More than 900 exomes from
RD patients and their relatives sequenced and analysed through a transnational access call..
5. MatchMaker Exchange (www.matchmakerexchange.org, MME, IRDiRC and GA4GH) and Beacon project
(http://ga4gh.org/#/beacon, GA4GH) participants. Co-leaders of new MME API.
46-UPM
Full legal name (Acronym) – Country Universidad Politecnica de Madrid (UPM), Spain
Principal investigator Mark Wilkinson
Relevant Network none
Description of the legal entity/department/laboratory/group:
The Technical University of Madrid is the largest Spanish technological university as well as a renowned European
institution being twice recognized as a Campus of International Excellence. It boasts 114 Departments, more than
36,600 undergraduate students, more than 1,600 Masters’ Degree students and over 2,700 PhD Degree and
Postgraduate students, all under the supervision of nearly 3,300 teachers. UPM’s annual budget is 370 million
Euros. UPM heads the Spanish participation in the 7th Framework Program of the European Union for research
and technological development. More than 2,400 researchers carry out their activity at the UPM, which is
committed to technology transfer and startups, with a dedicated “incubator” facility, and staff dedicated to
commercialization of intellectual property.
CBGP has four primary objectives (i) generation of knowledge on the genomics and biotechnology of plants and
plant-interacting organisms; (ii) development of new technologies and tools for functional analyses (iii)
development of new products and processes relevant to the productive sectors; and (iv) transmission of information
and implementation of educational programmes for scientists and technicians. In the last few years, knowledge on
plant biology has progressed at an unprecedented pace. A major cause for this progress is the development of
innovative technologies that allow efficient and global analyses of genome structure, information and expression.
825575 – EJP RD – Part B 133
The new technologies are rooted in advances in the sequencing ofAssociated
DNA and withproteins, in the
document Ref. use of microchips,
Ares(2018)6091977 in
- 28/11/2018
the automation of many laboratory procedures, and in the possibility of handling large amounts of information
through bioinformatic tools. UPM is a leading center in Spain for pursuing both pure research and product
development, using these cutting-edge technologies.
Main tasks in the project per Pillar/WP:
Pillar 2
• We will contribute our expertise in FAIR data modelling in the BBMRI/ELIXIR RD Connect project to
guide the selection, design, and extension of data and metadata models. (Task 11.1.1, 11.1.3)
• We will apply our expertise in the domain of ontology building and use to define ontological models for
the project (Task 11.1.2)
• We will create FAIR Accessors and smartAPI meta-descriptors to help with accessing the ELIXIR
BioTools database (Task 11.2.3)
• We will use our expertise, as the inventors of the FAIR Discovery model (FAIR Accessors/Projectors) to
better enable dynamic discovery of appropriate catalogues to query, and facilitate metadata extraction from
these Accessor metadata documents (Task 11.2.4).
• We will align our data and metadata models with other biomedical initiatives globally (Task 12.1.1).
• We will implement our existing federation architecture (the FAIR Data Point) into the project infrastructure
to enable federated query and discovery (Task 12.1.2).
• We will implement the prototype of our semantic consent/privacy negotiation infrastructure, and evaluate
its utility; we will assist in the task of anonymising data outputs Task (12.1.3).
• We will ensure that all components are compliant with existing data and representation standards v.v.
federated query and data exchange, including the use of static and dynamic FAIR data sources. (Task
12.1.4)
• We will apply our expertise in clinical ontologies to the representation of clinical and pre-clinical
information
• We will oversee the harmonization between participating sites by harmonizing data models (Task 12.2.1)
• We will utilize our FAIR Accessor platform to enable metadata and sample-level discovery (Task 12.2.3)
• We will apply our FAIR Projector technology as a self-directed FAIRification service. (Task 12.3.3)
Previous experience relevant to the Tasks:
Our laboratory were lead authors on the FAIR Principles, and inventors and lead-authors on the first fully FAIR
platform that spanned from metadata to individual cells in an underlying spreadsheet. The laboratory head, Mark
Wilkinson, has spent more than a decade in clinical ontology creation, dynamic and automated discovery,
integration, and analysis clinical data, and the design of biomedical data systems that can support automated
workflow construction. Our flagship technologies – SADI and SHARE – were the first to use the global standard
SPARQL to drive the discovery, synthesis, and execution of analytical workflows that represented the solutions
to conceptual questions asked by biomedical researchers, and won the prize for best demonstration of semantic
technologies for their ability to support multi-lingual queries.
Short Profile of key Staff Members who will be undertaking the work
Dr. Mark For the past 15 years, my laboratory has focused on designing biomedical data/tool
Wilkinson, representation, discovery, and automated reuse infrastructures - what would now be called
FBBVA Chair in "FAIR". I am the EU technical lead of the FAIR "Skunkworks" initiative, charged with rapidly
Biotechnology prototyping cutting-edge FAIR infrastructures. I participate in the emergent GO FAIR initiative,
and Isaac Peral including being founding members of the FAIR Metrics working group, tasked with defining
Distinguished the precise, measurable behaviors that FAIR resources should exhibit. Beyond data
Researcher. integration, we have extensive machine-learning experience over a diverse range of data types
including longitudinal microbiome data, and were the first to identify shifting “states” in
microbiomes that could be attributed to specific interventions, opening-up approaches to
microbiome engineering.
Senior TBA
Technician
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Wilkinson MD; Dumontier M; Aalbersberg IjJ; et al. "The FAIR Guiding Principles for scientific data
825575 – EJP RD – Part B 134
management and stewardship". Sci. Data 3:160018. 2016. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
2. Wilkinson MD; Verborgh R; Bonino da Silva Santos LO; et al. "Interoperability and FAIRness through a
novel combination of Web technologies". PeerJ Comput. Sci. 3:e110. 2017.
3. Egaña Aranguren M; Wilkinson MD. “Enhanced reproducibility of SADI web service workflows with
Galaxy and Docker”, GigaScience 4(1), p59, 2015.
4. Wilkinson M, Vandervalk B, McCarthy L. “The Semantic Automated Discovery and Integration
(SADI) Web service Design-Pattern, API and Reference Implementation”. Journal of Biomedical
Semantics, 2:8, 2011.
5. Samadian S; McManus B; Wilkinson MD. Extending and encoding existing biological terminologies
and datasets for use in the reasoned semantic web. Journal of Biomedical Semantics, 3:6, 2012.
List of relevant previous projects or activities, connected to the subject of this proposal
1. Founding Member. FAIR Metrics Group. 2017-date. A group of 6 stakeholders representing researchers,
technologists, public databases, and journal editors, assembled to create quantifiable metrics to evaluate the
FAIRness of a resource.
2. Co-Chair, Common Repository Interfaces, Force11 Data Citation Implementation Group, 2012-2014.
3. European Lead, Data FAIRport Working Group 3 - “Skunkworks”, 2015-date.
4. Invited Expert – Semantics in Health Care and Life Sciences (HCLS) Working Group, World Wide Web
Consortium: May 2009 – 2015.
5. Board of Trustees, Identifiers.org Project: 2012 – date.
47-CIBER
Full legal name (Acronym) – Country Consorcio Centro de Investigación Biomédica en Red, M.P.
(CIBER) - Spain
Principal investigator Pablo Lapunzina
Relevant Network
Description of the legal entity/department/laboratory/group:
CIBER is a Public Research Consortium created in 2006 under the leadership of the Carlos III Health Institute
(ISCIII, the main Public Research Entity responsible of funding, managing and carrying out biomedical research in
Spain), to promote research excellence and build a critical mass of researchers in the field of Biomedicine and
Health Sciences. Organized in 11 research areas including Cardiovascular Diseases (CIBERCV), Bioengineering,
Biomaterials and Nanomedicine (CIBERBBN), Mental Health (CIBERSAM), Hepatic Diseases (CIBEREHD),
Diabetes and Metabolic Diseases (CIBERDEM), Rare Diseases (CIBERER), Respiratory Diseases (CIBERES),
Public Health and Epidemiology (CIBERESP), Obesity and Metabolic Diseases (CIBEROBN), Cancer
(CIBERONC), Fragility and Healthy Ageing (CIBERFES), CIBER is the largest Research Network in Spain.
CIBER counts with more than 800 dedicated employees and 6,000 associated researchers integrated in more than
400 leading-edge research groups. Thanks to its network structure, CIBER is capable of bringing together more
than 100 different associated institutions including Hospitals, Research Centers, Technology Centers, Private
Institutions and Universities selected to join CIBER consortium on the basis of their excellence.Within this
consortia CIBERER is the area of CIBER designed for the development and implementation of cooperative
research in the field of rare diseases (RD), to the study of Rare Diseases, integrating 61 research groups and 20
associated clinical groups, furthering scientific and technical research, stressing the aspects of genetic molecular,
biochemical and cellular research, with the aim of improving the understanding of causes and pathogenic
mechanisms of these disorders as a fundamental item for developing and implementing new diagnostic techniques
and therapeutic strategies. The following are specific aims of CIBERER: Contributing to research in the field of
RDs; Helping to solve healthcare problems connected with RD; Reinforcing the participation of research groups in
scientific-technical activities on an international scale; Promoting the transfer of research results to society and in
particular to the National Health System and to the pharmaceutical and biotechnological production sector; and
Supporting dissemination and participation in educational activities connected with RD.
Main tasks in the project per Pillar/WP:
In Pillar 2 we will contribute to:
- WP11: Common platform for discoverable data and resources for RD research
Task 11.1: Metadata and ontological model definition for cataloging resources for RD research
Task 11.2: FAIR-compliant platform for discovery of RD resources
Task 11.3: Data deposition and access to data infrastructures for RD research
Task 11.4: Provision of analysis and data sharing capabilities to the RD community through online resources
825575 – EJP RD – Part B 135
- WP12. Enabling sustainable FAIRness and Federation at the data record,
Associated patientRef.
with document andAres(2018)6091977
sample level for- 28/11/2018
RD
Task 12.1: Compare and align core interoperability standards with respect to WP3
- WP13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics
Previous experience relevant to the Tasks:
CIBERER research groups expertise range from basic genetic research to its clinical application in a day to day
context, so the whole chain from basic knowledge to bedside is tackled by our diverse groups. Such diversity
encompasses expertise in NGS data generation and interpretation, together with complementary physiological and
biochemical data, all applied in a clinical context to provide high quality diagnostic on rare diseases. As a result, we
act as catalysts between basic research and clinical practice (Both highly represented in our network), and
cooperate with industry to transforming the latest -omics technologies into useful tools for the clinical routine. In
their daily exercise many CIBERER groups face the challenges arising for the NGS and omics application to the
diagnosis of rare diseases, many of them as responsible of genetic testing services in the main hospitals of Spain.
Also involved in the definition of Good Clinical Practice guidelines form the technical, procedural and ethical
points of view. CIBERER groups have diagnostic activity on a wide range of rare diseases, most of them genetic
through genetic testing. Up to 48 CIBERER research groups have activity on this field, as part of their research
and/or in a clinical context, with more than 20 providing genetic clinical diagnostics and some being responsible of
Genetic Diagnostic Services of the main Spanish hospitals.
CIBERER is seriously involved in the new challenges associated with cross-border genetic testing for RD. With a
wide range of our staff (physicians, researchers, technicians, bioinformatics…) working to carry out large scale
projects in DNA sequencing and analysis in collaboration with researchers around the world, in order to ensure the
best implementation of this new technology in our hospitals genetics services.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
1. - CIBERER BIOBANK (CBK) is a public and non-profit-making biological sample repository which
centralices the reception of samples connected with rare diseases. It is a CIBERER initiative and it is located at the
Centro Superior de Investigación en Salud Pública (CSISP) in Valencia, Spain.
2- Bioinformatics Platform for Rare Diseases (BIER) (http://www.ciberer.es/BIER/?q=node/1), is a transversal
work group whose main task is to cooperate with the experimental groups working with genomic data, by giving
them I.T. and scientific support for the analysis and interpretation of this information.
3- CIBERER Exome Server (http://bioinfo.cipf.es/apps-beta/exome-server/beta/), a public, free online tool,
launched in 2014, designed to improve the filtering of potentially pathogenic genetic variants found in Spanish
individuals. As local variations could be significant, this server contributes to other international available exome
servers. Any researcher using CIBERER Exome Server will be able to obtain information about all variants
detected in the Spanish population. CIBERER aims to set up a repository of variant data contributed by all
investigators (academic, clinical or industrial) having sequenced exomes from Spanish individuals.
Short Profile of key Staff Members who will be undertaking the work
PhD. Pablo Lapunzina Specialist in pediatrics and medical genetics. Head of Department and Director of the
(male) Instituto de Genética Médica y Molecular (INGEMM), Hospital La Paz (Madrid, Spain).
Scientific director of CIBER on Rare Diseases (CIBERER).
Beatriz Gómez BSc in Nursing and BA in Journalism. CIBERER’s, WP7 EJA and RD-ACTION
(female) Manager.
Ingrid Mendes BSc in Biology. CIBERER’s Scientific Manager. Asst. to CIBERER´s Scientific
(female) Director.
Dr. Juan Luque PhD in Biology. CIBERER´s Scientific and Transfer Manager.
(male)
Dr. Andrés Medrano PhD in Biology. CIBERER´s Scientific and Training Manager.
(male)
Dr. Beatriz Morte PhD in Pharmacist CIBERER´s Scientific Manager of the Undiagnosed RD Programme.
(female)
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Technical and Institutional Committees. Rare Diseases Strategy of the National Health System. Spanish Ministry
of Health and Social Services. Madrid, 2009. NIPO: 840-09-0752-X.
2. “Report on the State of the Art of Rare Disease Activities in Europe”, 2011-2016.
3. Villanueva A, Woolley R, Corrochano V, Gómez B, Molas J, Barberá JD, Palau F. EUCERD Joint Action -
WP7: “Quality of Care and Centres of Expertise”. ECRD. Berlin, Germany, 8-10th May 2014.
825575 – EJP RD – Part B 136
4. EUCERD Joint Action Workshop. From Centers of ExpertiseAssociatedto European Reference
with document Networks. Ministry
Ref. Ares(2018)6091977 of
- 28/11/2018
Health, Social Services and Equality. Madrid, Spain 28-29 October, 2015.
5. RD Registries Workshop, Organized by CIBERER and financed by CHAFEA. Madrid, Spain, 21-22 March
2017.
List of relevant previous projects or activities, connected to the subject of this proposal:
- Programme for “Genes in non-diagnosed Rare Diseases”. Through this project, CIBERER has promoted
and enabled the application of the exome sequencing technique to discover new genes and variants
involved in pathologies such as metabolism disorders, neuromuscular pathologies, mitochondrial diseases,
polymalformation syndromes, birth defects or primary immunodeficiencies.
- Partner of EUCERD Joint Action: Working on Rare Diseases.2012-2015.
- Partner of RD-ACTION: Promoting Implementation of Recommendations on Policy, Information and Data
for RD. 2016-2018.
- Others describe in Orphanet-Spain description partner template.
48-SRC
Full legal name (Acronym) – Country Swedish Research Council (SRC), Stockholm, Sweden
Principal investigator Malin Eklund
Relevant Network Funder
Description of the legal entity/department/laboratory/group:
In 2001, the Swedish parliament enacted legislation to set up the Research Council “in order to support basic
research of the highest academic quality within all areas of knowledge", hence merging five councils into one. The
Swedish Research Council (SRC) has a leading role in developing Swedish research of the highest scientific
quality, thereby contributing to the development of society. The SRC is also responsible for coordinating
participation and funding of national and international research infrastructures.
The SRC is working to stimulate Swedish participation in European and international research cooperation. The
aim is a greater exchange of experience and collaboration. The SRC has a specific responsibility for research
cooperation within the EU, as well as a large commitment in Science Europe.
The Swedish Research Council tasks include also research policy analysis and research policy advice, as well as
communication about research and public understanding of science. The annual budget was around SEK 6 billion
for 2017.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate as funder in task 6.1 WP7
Previous experience relevant to the Tasks:
SRC, together with the Ministry of Education, has responsibility for programme committee work in seven areas of
the EU's current framework programme mainly within the excellence pillar but also within the Societal Challenge
pillar. SRC is also hosting the National Contact Point within these areas. SRC is taking part in three joint
programming initiatives JPI Climate, JPND and JPIAMR and is the coordinator of the latter. SRC participates in a
number of ERA-Net cofund such as ERA-PerMed, Gender-net Plus, Quant-ERA, Flag-ERA.
Short Profile of key Staff Members who will be undertaking the work
Dr Malin Eklund Senior Research Officer within the field of medicine and health. PhD in Biotechnology from
KTH, Stockholm. 10 years of experience as a researcher and project manager in the
pharmaceutical industry before joining SRC in 2014. SRC representative in IC PerMed and
ERA PerMed. Previously Policy Officer based in Brussels between 2015-2017.
49-VINNOVA
Full legal name (Acronym) – Country Vinnova - Sweden
Principal investigator Frida Lundmark
Relevant Network
Description of the legal entity/department/laboratory/group:
Vinnova is Sweden's government agency for innovation. Our mission is to contribute to sustainable growth by
825575 – EJP RD – Part B 137
improving the conditions for innovation. We do this mainly by funding innovation
Associated projects
with document and the research -needed
Ref. Ares(2018)6091977 28/11/2018
to develop new solutions. We also invest long term in strong research and innovation environments. We stimulate
collaborations between companies, universities and other higher education institutions, public services, civil society
and other actors. Our activities also focus on strengthening international cooperation.
Each year, Vinnova invests around SEK 3 billion in fostering innovation. Most of these funds are allocated via calls
for proposals in which companies, public sector actors and other organisations apply for funding. All investments
are continuously monitored and evaluated and we regularly analyse the impacts of our investments.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate as a funder (task 6.1)
Previous experience relevant to the Tasks:
Vinnova participate in several international initiatives and consortia such as “International consortia for
personalised medicine” (ICPerMed), “JPI More years better lives”, “Nordic call on personalised medicine”
(NordicPerMed), “Innovative medicines initiative” (IMI).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Not relevant
Short Profile of key Staff Members who will be undertaking the work
Frida Lundmark Doctoral degree in neurogenetics from Karolinska institute, Sweden. More than 12 years
(female) of experience from pharma industry focusing on translational science and precision
medicine. Before joining Vinnova several years of experience from public health sector
focusing on strategies for clinical research for Karolinska university hospital as well as
national strategies for biobanking in Sweden.
50-ULEIC
Full legal name (Acronym) – Country University of Leicester (ULEIC)
Principal investigator Anthony J Brookes
Relevant Network Solve-RD
Description of the legal entity/department/laboratory/group:
The University of Leicester (ULEIC) is a publicly funded university based in Leicester, UK. It is a research-
intensive university and was ranked in the top quartile of universities in the 2014 REF assessment of UK university
research. ULEIC contributions in this project will be led by the Department of Genetics and Genome Biology,
within the College of Medicine, Biological Sciences and Psychology - which is the largest and best-funded of the
University’s four Colleges, attracting substantial funding from the European Community. Notable discoveries made
in the Department of Genetics include the discovery and development of DNA fingerprinting (profiling) and, more
recently, the DNA-based identification of the remains of King Richard III. This Department also leads various
University wide initiatives, under the Directorship of lead applicant Anthony Brookes, namely: a) the 'NUCLEUS'
service group which provides a full spectrum of advanced genomics technology services to university researchers;
and b) the regional 'BINERI' network of health data science researchers and professionals, which brings together
and facilitates multi-disciplinary projects between mathematicians/statisticians, data analysts, bioinformaticians,
ethics/governance experts, healthcare providers, IT services, computer scientists and physicists.
Main tasks in the project per Pillar/WP:
ULEIC will contribute to many tasks in EJPRD, but has specific responsibility for leading or coleading the
following:
Pillar 2:
In WP10, we will co-lead the whole WP. Additionally we will coordinate all parties involved in drafting the
Annual Strategic Plan (SubTask 10.1.1) based on input from surveys, the user community, the VP developers, and
the outcomes of the Pillar 2 Annual Retreat. This will be enabled by our role as lead of Task 10.2, which will drive
and summarise regular TC discussions between Pillar 2 WP leaders, and in parallel undertake survey and structured
interview approaches on technical and scientific matters.
In WP11, we will make supportive contributions in Tasks 11.1, 11.2 and (mainly) 11.3.
In WP12, we will co-lead the whole WP. We will also lead Task 12.1 to compare and align core interoperability
standards relevant to the Pillar 2 mission. This will entail coordinating 5 subtask teams, of which we will lead two
concerning machine-readable access (Subtask 12.1.3) and query languages plus data exchange formats (Subtask
12.1.4). This will require us to find and engage relevant experts within and beyond EJPRD, and facilitate them to
work together to identify and align relevant standards needed by the VP and support their adoption by the project's
825575 – EJP RD – Part B 138
software developers. We will also lead Subtask 12.2.3, which is building
Associated withsoftware
document tools and modules for
Ref. Ares(2018)6091977 data
- 28/11/2018
discovery. This must be done as a multi-team effort, ensuring different technologies can interoperate. So as well as
developing our own contributions to this area we will be responsible for getting all the different development teams
to collaborate effectively. Additionally, within Task 12.3 we will lead Subtask 12.3.2. Thereby we and others will
enable people to make their data and samples and subjects safely and appropriately discoverable if they cannot do
that within their own data systems, and we will achieve this by providing a brokered hosting service with
concomitant data harmonisation support.
Previous experience relevant to the Tasks:
ULEIC researchers contributing to this project have wide-ranging expertise in areas including Human/Medical
Genetics and Informatics, relevant to the proposal, including:
(1) Leading a multi-disciplinary ‘Bio-Informatics Network for Education, Research and Industry (BINERI)’
across the UK Midlands to ensure data synergies, discoverability, and appropriate sharing across the regional
biomedical research and healthcare sectors by activities that entail interacting, not least, with Genomics England
Ltd for which we head up the national data analysis clinical interpretations partnership.
(2) Playing a central role in several major international initiatives for data standards development, not least the
GA4GH/IRDiRC Beacon, MatchMaker Exchange, and ADA-M Task Teams. The latter is a metadata standard
for the digitisation of conditions of use and consent, essential for future: (i) unambiguous communication of
conditions of use; (ii) inclusion of conditions of use considerations in resource discovery settings; and (iii)
automation of controlled access decision making.
(3) Creating Café Variome, a flexible data discovery platform with the ability to handle large, diverse and
complex datasets. It is agnostic regarding the types of entity it enables to be discovered, and it can be deployed as
a central through to a highly federated architecture. A core Oath2-based authorisation and authentication server,
compatible with the AAI from ELIXIR, enables fine-grained control of user permissions.
(4) Running large-scale databasing and data management projects, not least providing the world's largest public
domain GWAS database (GWAS Central), leading IT aspects of biomedical EU projects (GEN2PHEN,
BioShare, GCOF, Solve-RD), contributing 'discovery science' aspects of IMI projects (EMIF, eTOX, EPAD),
and direct translational medicine data management in large consortia (COPD-MAP (UK MRC), REQUITE
(EU)).
Short Profile of key Staff Members who will be undertaking the work
Professor Director BINERI, Director HDR-UK Leicester, Research Group leader.
Anthony J Qualifications in preclinical Medicine (Honors) and Medical Biochemistry (1st Class), creator of
Brookes / various technology patents, Founder of two biodata related companies, 30 year's experience as
Male academic researcher in leading institutions. Published >180 peer reviewed articles and reviews,
served two 3-year terms on the HUGO Council, co-founded the Human Variome Project and the
Human Genome Variation Society (now Vice-President)
Dr Colin Veal Senior bioinformatician and Brookes Research Group co-lead.
/ Male Biology degree plus 20 years experience as academic researcher conducting biomedical
informatics, human genomic technology innovation, and genetic disease studies. Additional
degree qualifications in mathematics and statistics
Dr Tim Beck / Current position: Independent 'Future Leaders' Research Fellow, associated with HDR-UK
Male Profile description: Biology degree plus 15 years experience as academic researcher in biomedical
informatics, spanning human and animal model investigations, operational lead on GWAS
Central, and with special expertise in semantics and ontologies.
Professor Professor in genetics
Raymond Support and guidance role as independent PI running several LSDBs, plus contribution and
Dalgleish / further development of the 'Variant Validator' platform for management of mutation nomenclature
Male
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. World’s largest public-domain GWAS database (http://www.gwascentral.org/)
2. Café Variome platform for federated data discovery (www.cafevariome.org)
3. Nature Reviews Genetics (2015) 16, 702-715. Human Genotype-Phenotype Databases: Aims, Challenges And
Opportunities. A.J.Brookes and P.N.Robinson.
4. Human Mutation (2012) 33, 867-873. Observ-OM and Observ-TAB: Universal Syntax Solutions for the
Integration, Search and Exchange of Phenotype And Genotype Information. . T.Adamusiak, H.Parkinson,
J.Muilu, E.Roos,
5. Nature Reviews Genetics (2009) 10, 9-18. Genotype-Phenotype Databases: Challenges and Solutions For The
Post-Genomic Era. G.A.Thorisson, J.Muilu and A.J.Brookes
825575 – EJP RD – Part B 139
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal
document :
Ref. Ares(2018)6091977 - 28/11/2018
1. GEN2PHEN (RTD): Genotype-To-Phenotype Databases: A Holistic Solution (HEALTH-F4-2007-20075): To
June 2013.
2. BioShaRE (RTD): Biobank Standardisation and Harmonisation for Research Excellence in the European
Union (261433): To November 2015.
3. GCOF: Stepping stone approach towards the Genetics Clinic of the Future (H2020-HCO-2014-643439): To
June 2017.
4. EMIF: A European Medical Information Framework of patient-level data to support a wide range of medical
research (115372-2): Ends June 2018.
5. Solve-RD: Solving the unsolved Rare Diseases (779257). To December 2022
51-ULIV
Full legal name (Acronym) – Country University of Liverpool (ULIV), United Kingdom
Principal investigator Mark Turner
Relevant Network EPTRI, PedCRIN (after 01 May conect4children)
Description of the legal entity/department/laboratory/group:
The University of Liverpool (ULIV) is one of the great centres of research, knowledge and innovation and one of
the UK’s leading research institutions with an annual turnover of £400 million, including £140 million for research.
The university’s pioneering reputation attracts students, experts and partners from around the world. Through
research, teaching and collaborations ULIV seeks to be life changing and world shaping. The University is globally
recognised for its research in health and life sciences, science and engineering, and humanities and social sciences.
ULIV is 75th in Europe according to the Times Higher Education rankings, is 61 – 100 in medicine according to
the global QS rankings and is the 78th most international university in the world.
The Department of Women’s and Children’s Health is internationally renowned for its research and has specialist
groups covering obstetrics, gynaecology, neonatology and medical and surgical paediatrics. The department’s
main research facilities are integrated with two of the largest specialist Women’s and Children’ hospitals in Europe
– Centre for Women’s Health research within the Liverpool Women’s Hospital and Institute in the Park within the
Alder Hey Hospital.
Main tasks in the project per Pillar/WP:
Pillar 0
WP1: Coordination
SubTask 1.1.2: Central Helpdesk;
Task 1.3: Monitoring of the EJP RD activities and achievements;
Leader of Subtask 1.3.1: Identification of key performance indicators
SubTask 1.3.2: Implementation of the monitoring process
Task 3.1: Service roadmap: alignement of needs, expectations and engagement of the different RD research
stakeholders in Europe with repsect to EJP RD sustainability;
Task 3.2: Preparation of sustainable EJP RD service calalogue;
Task 3.3: Preparation of the EJP RD sustainability plan with business plan;
Task 3.4: Sustaainability roadmap;
Task 5.2: Integrating EJP RD communication and dissemination strategies with the strategies of involved
stakeholders;
WP20: Task 20.1: Task Force Group (100% in kind contribution)
Previous experience relevant to the Tasks:
Mark Turner’s expertise is about developing new and improved medicines for children. This includes leadership of
clinical studies in neonates: Phase 0 microdosing; Phase 1 first-in-human; Phase 2 PK and PD, particularly for
antibiotics; excipient kinetics; Phase 3 studies. Other work includes mixed methods assessment of: adverse drug
reactions in children by professionals and parents; manipulations of drugs used by children; management of
stillbirth; induction of labour.
Turner has extensive experience bridging between research communities. He has chaired the UK NIHR AMR
Neonatal Clinical Studies Group (2007 – present); chaired the European Network for Paediatric Research at the
European Medicines Agency (2013 – present); been European Co-Director of the International Neonatal
Consortium (2014 – present). This includes developing relationships between all stakeholders in drug development
(families, regulators, industry, investigators) and at all stages of drug development (basic science, formulations,
clinical studies etc.).
825575 – EJP RD – Part B 140
He developed the European Paediatric Clinical Trials Research Infrastructure
Associated which
with document was recognised
Ref. Ares(2018)6091977 as a
- 28/11/2018
complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the
Conect4Children consortium that has applied to IMI2 Call 10 Topic 4 “European Paediatric Clinical Trials
Network”.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Mark Turner developed the European Paediatric Clinical Trials Research Infrastructure which was recognised as a
complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the
Conect4Children consortium that will receive the award for the IMI2 Call 10 Topic 4 “European Paediatric Clinical
Trials Network”. Collaborative Network for European Clinical Trials for Children (conect4children) will begin 01
May 2018.
Short Profile of key Staff Members who will be undertaking the work
Dr. Mark Turner Mark Turner BSc, MBChB, PhD, DRCOG, MRCP, MRCPCH, FFPM(Hon) is a
(male) Neonatologist at Liverpool Women’s Hospital and the University of Liverpool. He aims to
improve the access of newborn babies and children to high quality medicines. He has studied
the dosing, safety and efficacy of 12 medicines in neonates with rare conditions in the past 5
years. In older children his group is currently working on manipulations of medicines, the
avoidability of adverse drug reactions and the pharmacoeconomics of age-appropriate
formulations.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. A systematic review of the use of dosage form manipulation to obtain required doses to inform use of
manipulation in paediatric practice. Richey RH, Hughes C, Nunn AJ, Turner MA Int J Pharm. 2017
25:155-166
2. The International Neonatal Consortium: collaborating to advance regulatory science for neonates. Turner
MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson LD. Pediatr Res. 2016 80:462-4
3. Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates. Pandya HC,
Mulla H, Nunn AJ, Turner MA. Eur J Pediatr. 2016 175:841-7
4. Observational infant exploratory [(14) C]-paracetamol pharmacokinetic microdose/therapeutic dose study
with accelerator mass spectrometry bioanalysis. Garner CR, Park KB, Maruszak W, Turner MA. Br J Clin
Pharmacol. 2015 80:157-67
5. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Nellis G,
Metsvaht T,Turner MA, Lutsar I. Arch Dis Child. 2015 100:694-9.
List of relevant previous projects or activities, connected to the subject of this proposal
1. EPRTI WP 9 Lead funded by the European Commission H2020 INFRADEV programme from Jan 2018 –
Dec 2019
2. PedCRIN WP 2 Lead funded by European Commission H2020 from Jan 2017 – Dec 2019
3. Global Research in Paediatrics (GRIP): Scientific Coordinator of this FP7 Network of Excellence; funded
European Commission FP7 from Jan 2015-Jun 2017
4. European Study of Neonatal Excipient Exposure (ESNEE): Chief Investigator of this project, funded by
ERA-NET PRIOMEDCHILD from Jan 2011 – Mar 2014
5. Treat Infection in Neonates (TINN): Work Package Lead and Clinical Chief Investigator; European
Commission FP7 funded from Nov 2008 – Oct 2015
6. NeoVanc: Work Package 2 and 5 European Commission FP7Lead European Commission FP7 funded from
Feb 2014 – Jan 2019
52-UNEW
Full legal name (Acronym) – Country University of Newcastle upon Tyne (UNEW) -– UK
Principal investigator Volker Straub
Relevant Network TREAT-NMD
Description of the legal entity/department/laboratory/group:
The team at UNEW performing this work is based in the John Walton Muscular Dystrophy Research Centre
(JWMDRC), Institute of Genetic Medicine, Newcastle University. Newcastle University is one of the top research-
intensive universities in the UK: in the recent Research Excellence Framework (REF) evaluation, Newcastle
University was ranked 16th (out of 154) in the UK for research power. The university also ranks in the top 5 for
both hospital and laboratory based clinical subjects. Within the University, the JWMDRC is a clinical and research
825575 – EJP RD – Part B 141
reference centre led by Prof. Volker Straub, providing a depthAssociated
of clinical expertiseRef.inAres(2018)6091977
with document Muscular Dystrophies
- 28/11/2018
unparalleled elsewhere in the UK. Clinical management and drug development for Neuromuscular diseases
(NMDs) are core activities of the Centre, with national and international clinical trials funded via Wyeth, Sarepta,
GSK, Prosensa, BioMarin, Trophos, Roche, Ultragenyx, NIH, BHF, EU, NIHR and MRC. In addition, Newcastle
houses the MRC Translational Research Centre for Neuromuscular Diseases and Biobank, jointly established with
UCL (London). Over the least decade, the team in the JWMDRC has increasingly built a reputation for rare disease
expertise per se, from a disease-agnostic policy and infrastructure perspective (consolidated through leadership
positions in the EUCERD Joint Action for Rare Diseases, RD-Connect, and RD-ACTION (the Policy stream of
which is led from the JWMDRC)).
Main tasks in the project per Pillar/WP:
Pillar 4:
UNEW is a partner in P4 WP19 Facilitating partnerships and accelerating translation for higher patient impact.
Task19.1. The team will participate to the creation of an Innovation Management Tool Kit, by elaborating and
tailoring a ‘handbook’ for disease areas wishing to develop an ‘ACT’ (Advisory Committee on Therapeutics),
based upon the successful TACT model in the neuromuscular field. Most of the PM activity will be spent on
liaising with ERN communities (in greater detail where that ERN is able to dedicate person time, in-kind or funded
externally) to set-up an ACT in disease areas outside of the NMD field, based upon ERN thematic
groupings/subdomains. A workshop will be organised to support this broad ERN engagement.
Previous experience relevant to the Tasks:
TREAT-NMD has now been successfully operating for 10 years and has generated a number of tools and strategies
to support the development of therapies for rare neuromuscular diseases. Amongst these – and led from UNEW, at
present by V. Straub and C. Turner)- is the TREAT-NMD Advisory Committee for Therapeutics (TACT) model.
TACT is a model to convene a unique multidisciplinary international group of well recognized academic and
industry drug development experts, patient representatives and institutional governmental scientific research
centres, who meet twice a year to review development plans from academic groups and industry and provide
guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases with
large unmet need. By suggesting improvements or changes to pre-clinical research or trial design TACT can help
academics and industry to avoid potential pitfalls in the therapeutic development pipeline and facilitate the faster
development of therapies.
● Since its launch, TACT has formally reviewed 46 programme applications from both Industry (29) and
Academics (17) 21 of these reviews have been for novel compounds, 25 for repurposed drugs.
● The added-value is the approach is clear – in fact, some funders now request that a TACT review has been
completed before (co)-funding clinical trials
● The strength of the model lies in the assembly of bespoke panels for each application.
Thus, the UNEW team is ideally-placed to explore the expansion of this model to other disease areas, through
elaboration and deployment of a ‘Tool-Kit’ or handbook to support communities in embedding a model along these
lines. The ERNs are a logical ‘target’ for such discussions (and, as far as resources allow, more practical action)
and in this respect too, the UNEW team possesses the relevant experience and expertise to forge such synergies.
UNEW led a EU Joint Action dedicated to Rare Diseases (the EUCERD JA), and continues to lead the Policy
Strand of the current Joint Action, RD-ACTION – these initiatives have played a key role in supporting the
conceptualisation and implementation of ERNs, and as such the team currently led by V.Hedley developed robust
working relationships with many of the ERN coordinators and their teams, and understands the opportunities and
challenges for expansion of an ACT model into these communities.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
N/A
Short Profile of key Staff Members who will be undertaking the work
Pr. Volker Straub Current Director of the John Walton Centre, founding joint co-ordinator of TREAT-NMD
(male) (www.treat-nmd.eu), executive board member of the World Muscle Society and R&D
Director of the North Tees and Hartlepool NHS Foundation Trust. Trained as a paediatric
neurologist, Volker has a longstanding interest in the pathogenesis of muscular dystrophies
and is engaged in research using zebrafish and mouse models. He has a special interest in the
use of MRI in muscular dystrophies.
Catherine Turner Duchenne Liaison and TACT Coordinator. She oversees the running of TACT, solicits
(female) applications, works with expert panel members to facilitate the review process and ensures
funding and sustainability. She also provides the link between TACT and multiple
stakeholders including the patient community, industry and regulators.
825575 – EJP RD – Part B 142
Victoria Hedley Policy Manager (previously Thematic Coordinator) forwith
Associated RD-ACTION, the EU Joint Action
document Ref. Ares(2018)6091977 for
- 28/11/2018
(female) rare diseases. She leads on the RD-ACTION provision of policy support to ERNs, and is in
charge of generating the Resource on the State of the Art of Rare Disease Activities in
Europe.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. ‘Translational Research in Europe for the Assessment and
Treatment for Neuromuscular Disorders (TREAT-NMD)’. Neuropediatrics 2017 Aug;48(4):211-220. doi:
10.1055/s-0037-1604110. Epub 2017 Jul 6.
2. Heslop E. et. al. ‘The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking
model to foster orphan drug development’, Orphanet J Rare Dis. 2015 Apr 23;10:49. doi: 10.1186/s13023-015-
0258-1.
3. Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y, Bushby K, ‘The context for the thematic
grouping of rare diseases to facilitate the establishment of European Reference Networks’, Orphanet J Rare Dis
2016 (11) 10.1186/s13023-016-0398-y
4. Numerous outputs related to Policy support for ERNs (http://www.rd-action.eu/european-reference-networks-
erns/) Including Hedley et.al. Recommended Practices for Standardising Data in the Framework of the Operation of
ERNs (2017)
5. TGDOC – TREAT-NMD has established a global network of patient registries, with an agreed core data
set. This allows academia and industry to conduct feasibility and recruitment enquiries through the registries to
accelerate clinical trials.
List of relevant previous projects or activities, connected to the subject of this proposal :
TREAT-NMD: FP6, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’ with the remit of
‘reshaping the research environment’ in the neuromuscular field.
RD-ACTION : 3rd Public Health Programme, EC, 2015-2018, WP lead (WP6,Policy and Integration). Leading on
support for the implementation and (policy-oriented) development of ERNs, and on the generation of the State of
the Art resource.
EURO-NMD: 3rd Public Health Programme, EC, 2017-2021, Current coordinator. EURO-NMD is the ERN for
neuromuscular diseases.
EUCERD-JA: 2nd Public Health Programme, 2012-2015, Coordinator. Led the Joint Action to support EC and the
MS in formulating and implementing policies pertaining to rare diseases
53-CCRI
Full legal name (Acronym) – Country St. Anna Kinderkrebsforschung (CCRI) - Austria
Principal investigator Ruth Ladenstein
Relevant Network ERN-PaedCan
Description of the legal entity/department/laboratory/group:
The CCRI is owned by the private charity-based association St. Anna Kinderkrebsforschung, with the overall aim
to improve treatment options for children suffering from cancer through basic, translational and clinical research.
The CCRI is closely affiliated with the St. Anna Children’s Hospital, the largest clinical haemato-oncological
centre for the treatment of childhood cancer in Austria. The CCRI and the St. Anna Children´s Hospital have
formed a comprehensive cancer centre in order to address patient-relevant scientific questions to better
understand the disease and effective therapies through bidirectional knowledge exchange from research to
clinical applications and diagnostics. The CCRI hosts 12 research groups in the areas of molecular and cellular
biology, molecular genetics, genomics and epigenomics, immunology, cellular therapies and clinical research
with a focus on bone and soft tissue sarcomas, neuroblastoma and acute leukaemias. The CCRI is devoted to
bench to bedside research translational activities. The Unit for Clinical Trails and Statistics of the CCRI (S2IR:
Studies and Statistics for integrated Research Projects) under the leadership of Prof Dr Ruth Ladenstein serves as
the national trial centre for almost all childhood cancer trials and registries in Austria, but also is a recognised
international trial unit running several world-wide international phase 3 trials in the area of neuroblastoma,
Langerhans Cell Histiocytosis and Stem Cell transplantation as international academic sponsor. The unit has
major experience in setting up and running academic trials and has initiated and then supported a drug
development in partnership with industry achieving EMA approval in 2017 which made a new immunotherapy
for neuroblastoma accessible across Europe.
Main tasks in the project per Pillar/WP:
Pillar 2 - Coordinated access to data and services:
825575 – EJP RD – Part B 143
WP 11 Common virtual platform for discoverable data and resources for RD
Associated withresearch
document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 3 - Capacity building and empowerment:
WP 14 Training on data management & quality
WP 16 Online Academic education course
WP 18 Development and adaptation of training activities
Pillar 4 - Accelerating research translation & therapy development:
Accelerating the validation, use and development of innovative methodologies tailored for clinical:
.participation to Task force
.demonstration calls organization and FU (methodologists/Erns)
.new methodologies development calls (methodologists/ERNs/regulatory)
Previous experience relevant to the Tasks:
With Prof Dr Ruth Ladenstein acting as coordinator, the CCRI has acquired extensive experience in the
management of strategic EU-funded projects, namely large pan-European paediatric cancer networks such as:
SIOPEN-R-NET (QLRI-CT-2002-01768) - the SIOP European Neuroblastoma Research Network; ENCCA
(261474) - the European network for cancer research in children and adolescents; ExPO-r-Net (20131207) - the
pilot network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment; and of
particular relevance for this project, ERN-PAEDCAN - the European Reference Network for Paediatric
Oncology .
The CCRI has also played a leading role and coordinated other EU-funded projects such as MODICELL
(285875) - a Marie Curie Industry-Academia Partnerships and Pathways network aiming to improve the
understanding of the complexity of immune cell responses by studying cells designed for therapies in the settings
of cancer or transplantation; and FUNGITECT (602125) - an innovation project aiming at optimising
diagnostics for improved treatment stratification in invasive fungal diseases. In addition, the CCRI has also been
the initiator and key partner of other EU-funded projects, including AutoFLOW (610872) - a Marie Curie
Industry-Academia Partnerships and Pathways network aiming at developing innovative IT-based automation
tools for flow cytometric assessment of pediatric leukaemia; ASSET (259348) - an HEALTH project aimed at
tackling human diseases through systems biology approaches; and currently, the CCRI is also a partner in the
strategic IMI-2 consortium ITCC-P4 (116064), which will develop a large-scale platform comprising 400 novel
research tools based on cells and tissues from patients covering 10 common childhood cancers, including
neuroblastoma, high grade glioma, and osteosarcoma.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The Research Support Office of the CCRI (RSO) provides active assistance and expertise in the implementation of
national and international actions. A team of project managers, which also integrates the ERN-PAEDCAN network
manager, is involved in the day-to-day management of projects, monitoring the status of milestones and
deliverables, timely technical and financial reporting, and with the dissemination of results.
Short Profile of key Staff Members who will be undertaking the work
Professor/Ruth Head of the Studies and Statistics Department at the CCRI and a senior consultant in the St.
Ladenstein Anna Children’s Hospital. Chief investigator of the high risk neuroblastoma trial (HR-NBL-
(MD, MBA, 1/SIOPEN) with over 3000 patients enrolled. Past president of SIOPEN (SIOP Europe
cPM)/Female Neuroblastoma Group; 2007- 2011) and past president of SIOPE (2009- 2012) and Head of the
Austrian Paediatric Oncology Group (AGPHO) and Chair of OKIDS (Austrian medicines for
children network). She has 144 full publications in peer-reviewed journals and 20 published
book chapters. She coordinated the ERN Pilot project ExPO-r-Net (European Expert Paediatric
Oncology Reference Network for Diagnostics and Treatment, 2014 – 2017) and is now the
Coordinator of the ERN PaedCan (European Reference Network for Paediatric Cancer).
Nuno Andrade, Head of the Research Support Office at the CCRI. Manages and supervises the management of
(PhD, numerous international grants, including of the ERN PaedCan. He is experienced in the
MBA)/Male establishment of project management and procedures and has contributed in numerous initiatives
to acquire projects funded at the national and international levels.
Karoline ERN PaedCan Project Manager. She is responsible for the management and implementation of
Noworyta ERN´s non-clinical activities. She has experience with EU funded projects, coordination of
(B.Sc., communication and dissemination activities for European projects as well as advocacy and event
MPH)/Female organization.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Ladenstein R, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk
neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging.
825575 – EJP RD – Part B 144
2018 Feb;45(2):292-305 Associated with document Ref. Ares(2018)6091977 - 28/11/2018
2. Ladenstein R, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose
chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm,
open-label, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):500-514
3. Park JR, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From
the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-2587
4. Ranft A, et al. Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in
an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. J Clin Oncol. 2017 May
20;35(15):1704-1712
5. Abbasi MR, et al. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding
Clone. Clin Cancer Res. 2017 Aug 1;23(15):4224-4232
List of relevant previous projects or activities, connected to the subject of this proposal :
SIOPEN-R-NET (QLRI-CT-2002-01768) – funded under FP5, from 2002-11-01 to 2006-04-30 – Project
Coordinator of the SIOP European Neuroblastoma Research Network.
ENCCA (261474) – funded under FP7, from 2011-01-01 to 2015-12-31 – Project Coordinator of the European
network for cancer research in children and adolescents.
ExPO-r-Net (20131207) – funded under 2HP, from 2014-03-01 to 2017-08-31 – Project Coordinator of the pilot
network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment.
54-APHP (a)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Rima Nabbout (Hôpital Necker)
Relevant Network Reference centre for rare epilepsies (as ERN EPICARE
member)
Description of the legal entity/department/laboratory/group:
The group is composed by the team of the reference centre for rare epilepsies leaded by Pr Rima Nabbout.
Necker enfants Malades, AP-HP, Imagine Institute, Paris Descartes, Paris, France
Main tasks in the project per Pillar/WP:
Rima nabbout is a member of the steering group and leader of the Pillar 4 (WP19-20) together with A Ussi (Eatris)
Pillar 0:
Rima Nabbout will participate to all transversal activities as part of the operating group
Pillar 4:
Rima Nabbout is the leader of Pillar 4. She is leading also the task force group (WP20, task 1 and will participate to
task 20.1.1, task 20.1.2, 20.1.3 as well as tasks 20.3 and 20.4).
Her role will be to coordinate the work of the pillar, to chair the task force for mapping, dissemination, validation
and innovation in clinical studies dedicated to rare diseases.
Previous experience relevant to the Tasks:
PI in many orphan drugs development in rare epilepsies. Rima Nabbout is the coordinator of the French centre
for rare epilepsies and member of the steering committee of EPICARE (European network of rare and complex
epilepsies) where she is in charge for laboratory diagnosis and clinical trials.
She is involved in clinical trials since over 10 years and is PI in CT in rare epilepsies with new orphan drugs
designation and proposed recently a work on composite end points for a better evaluation in CTs. She is a
member of the regulatory task force for drugs in epilepsy in the International league against epilepsy.
Her expertise in genetics and phenotyping adds to the actual search for mechanisms for drugs and her close work
with patient groups help in a better understanding of patients centered outcome.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Short Profile of key Staff Members who will be undertaking the work
MD, PhD Pr. Rima Nabbout as supervision of the work
Pr. Rima Nabbout Pr. Rima Nabbout is Professor of Paediatric Neurology at Paris Descartes University as
Female well as Director of the Centre for Rare Epilepsies at Necker Enfants Malades Hospital,
Imagine Institute, Paris, France. She is a member of the steering committee of EPICARE
(European reference network on rare epilepsies) and of scientific committees of patients
associations on rare epilepsies.
Pr. Nabbout areas of research include electro clinical delineation of rare childhood
825575 – EJP RD – Part B 145
epilepsies, genetics of epileptic encephalopathies, clinical
Associated with documenttrials in rare epilepsies
Ref. Ares(2018)6091977 and
- 28/11/2018
transition from childhood into adulthood. She has authored or co-authored more than 150
peer-reviewed papers, and is presently leading a research group at Imagine in the group of
Dr. Kabashi Translational Research for Neurological Diseases, Institut des Maladies
Génétiques Imagine, Research Unit UMR1163 Inserm / Université Paris Descartes.
To be recruited Post doc to be assigned for the work under the supervision of Pr. Nabbout with an expertise
in trials and in research and bibliography.
Mrs Wenzel Coordination part time to help in the coordination of Pillar 4 and to organise the Task force
Female and the different groups meeting (face to face or webex…) and to do the secretary of the
group.
A person fluent in English, French and German is already previewed.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1) Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J,
Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R. New-onset refractory
status epilepticus (NORSE) and febrile infection-related epilepsy syndrome
(FIRES): State of the art and perspectives. Epilepsia. 2018 Apr;59(4):745-752.
doi: 10.1111/epi.14022. Epub 2018 Feb 24. Review. PubMed PMID: 29476535.
2) Nabbout R, Auvin S, Chiron C, Irwin J, Mistry A, Bonner N, Williamson N,
Bennett B. Development and content validation of a preliminary core set of
patient- and caregiver-relevant outcomes for inclusion in a potential composite
endpoint for Dravet Syndrome. Epilepsy Behav. 2018 Jan;78:232-242. doi:
10.1016/j.yebeh.2017.08.029. Epub 2017 Nov 4. PubMed PMID: 29108913.
3) Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE,
Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of
Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med.
2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PubMed PMID: 28538134.
4) French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de
Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive
everolimus therapy for treatment-resistant focal-onset seizures associated with
tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind,
placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153-2163. doi:
10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. PubMed PMID: 27613521
List of relevant previous projects or activities, connected to the subject of this proposal
. EPISTP FP7 Health project: 2013-2018
. DESIRE FP7 project 2013-2018
. Coordinator of the reference centre for rare epilepsies 2010-2022
. WP leader at EPICARE 2017-2022
54-APHP (b)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Guillaume Jondeau (Hôpital Bichat)
Relevant Network VASCERN (as ERN coordinator)
Description of the legal entity/department/laboratory/group:
The National Center de Reference located in the Bichat Hospital, 75018 Paris is the place where the patients are
seen. The hospital includes 1000 beds, and all the medical specialists are presents, including reanimation, heart and
lung transplantation. The radiological department possesses MRI, CT scanner, and all last imaging techniques.
In the same hospital, the research center, which is composed of more than 100 researchers, includes 5 teams. Team
2 is leaded by Guillaume Jondeau, and is dedicated to genetics in rare diseases (INSERM U1148 / Team 2).
Lastly, this HCP is coordinating VASCERN, the European Rare Disease Network devoted to vascular diseases,
which is present in 11 countries and includes 30 other HCPs.
[Other VASCERN team is involved in the project under the coordination of AP-HP: Radboudumc, Prof Leo
825575 – EJP RD – Part B 146
Schultze Kool - see Beneficiary Radboudumc description.] Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Main tasks in the project per Pillar/WP:
Pilar 3
In WP17
ERN RD training and support programme AP-HP/VASCERN, as contributor of “systemic” training
Previous experience relevant to the Tasks:
A long history of research in both the fundamental and clinical areas, with strong interaction between the 2: from
bedside to bench and back from bench to bedside, allowing discovery of new diseases, proposition of new
therapies.
Interaction with numerous HCPs and research teams within Europe through VASCERN.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Structuration of the clinical and research entities with strong interactions between the 2: Centre de Référence pour
le Syndrome de Marfan et appârentés (www.marfan.fr) and LVTS INSERM U 1148 (https://lvts.fr/).
Short Profile of key Staff Members who will be undertaking the work
Pr Guillaume Professor Jondeau has been a Professor of Cardiology since 1999, in Université Paris V, and has
Jondeau moved to Université Paris VII - Denis Diderot, since 2007. He is also leading a research team
(team 2 LVTS, INSERM U1148) focusing on aortic aneurysm, and has authored more than 200
publications in peer-reviewed international journals. Professor Jondeau’s research interests are in
the field of aortic aneurysms and heart failure.
He is leading the centre de reference for the Marfan syndrome (www.marfan.fr) and related
disorders, which is seeing more than 1000 patients every year, following >1200 patients with
FBN1 mutations, and is responsible for the organization of the care of these patients throughout
the country. Research units on genetics (co-leaded by Catherine Boileau) and pathophysiology
(leaded by JB Michel) in INSERM U1148 are closely linked to this centre de reference.
He is a funding member of the nucleus of the new ESC working group on Aorta and peripheral
vascular diseases.
He is leading the “Filière de Santé maladies rares” on rares vascular diseases, which is taking care
of patients with thoracic aortic aneurysms, aneurysms of systemic arteries, and HHT and
lymphatic pathologies throughout France, networking 3 reference centers, more than 30
competence centers, 5 diagnostic laboratories, 3 research units (www.favamulti.fr).
He is leading the European Rare Disease Network VASCERN (www.vascern.eu), gathering 31
centers from 11 European countries.
He is involved in studies in acute heart failure and chronic heart failure. He is a former president
of the Heart Failure Working Group of the French Society of Cardiology and has been a member
of the board of the Heart Failure Association of the European Society of Cardiology. He is a
fellow of the European Society of Cardiology, American College of Cardiology, and American
College of Chest Physicians and is a member of the board of the French Society of Cardiology.
Professor Jondeau participated in the steering or executive committees of international trials, and
was the principal investigator of investigator-driven and industry-sponsored clinical trials. He was
end-point committee’s member. Dr Jondeau has authored more than 200 articles in peer-reviewed
international journals.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1) Jondeau G, Boileau C, Milleron O. Marfan Syndrome: Always Evolving. Circ Cardiovasc Genet. 2017
Jun;10(3). pii: e001785. doi: 10.1161/CIRCGENETICS.117.001785. PubMed PMID: 28600389.
2) Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S,
Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE,
Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double-
blind, placebo-controlled trial. Eur Heart J. 2015 Aug 21;36(32):2160-6. doi: 10.1093/eurheartj/ehv151. Epub 2015
May 2. PubMed PMID: 25935877.
3) Aubart M, Gross MS, Hanna N, Zabot MT, Sznajder M, Detaint D, Gouya L, Jondeau G, Boileau C, Stheneur C.
he clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. Hum Mol
Genet. 2015 May 15;24(10):2764-70. doi: 10.1093/hmg/ddv037. Epub 2015 Feb 4. PubMed PMID: 25652400.
4) Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosolini L, Ho-Tin-Noe B, Regalado E, Varret
M, Abifadel M, Milleron O, Odent S, Dupuis-Girod S, Faivre L, Edouard T, Dulac Y, Busa T, Gouya L, Milewicz
DM, Jondeau G, Boileau C. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in
the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet. 2014 Dec 4;95(6):736-43.
825575 – EJP RD – Part B 147
doi: 10.1016/j.ajhg.2014.10.018. Epub 2014 Nov 26. PubMedAssociated PMID: with
25434006; PubMed
document Ref. Central PMCID:
Ares(2018)6091977 - 28/11/2018
PMC4259978.
5) Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy H,
Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C,
Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood
Institute (NHLBI) Go Exome Sequencing Project, Jondeau G, Milewicz DM. TGFB2 mutations cause familial
thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet.
2012 Jul 8;44(8):916-21. doi: 10.1038/ng.2348. PubMed PMID: 22772371; PubMed Central PMCID:
PMC4033668.
List of relevant previous projects or activities, connected to the subject of this proposal
1) ANR-05-PCOD-014 : « diversité génétique et monotonie phénotypique des anévrysmes artériels non
athéromateux » avec l’U 698 (Bichat), l’U 383 (Necker), l’U 36 (HEGP)
2) ANR-14-CE15-0012 (porteur de projet) : 420243 €
3) CRC 10 043 : Apport de la PET pour le suivi des patients présentant une dissection de l’aorte descendante
(porteur de projet) : 100 000 €
54-APHP (c)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Pierre Fenaux (Hôpital Saint Louis)
Relevant Network ERN EuroBloodNet (as ERN coordinator)
Description of the legal entity/department/laboratory/group:
Prof Pierre Fenaux moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical hematology
section for myeloid disorders in the elderly which he is currently chairing. He is involved in clinical and
laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially
promyelocytic leukemia). He is a founding member and chairman of the French speaking MDS group (Groupe
Francophone des Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit
1131 in Paris for his research
[Other EuroBlooNet teams are involved in the project under the coordination of AP-HP: AOUFIIN with Prof.
Achille Iolascon, CING with Prof. Marina Kleanthous, CHUM with Prof. Patricia Aguilar Martinez and
IRCCSCG with Dr. Paola Bianchi]
AP-HP remains coordinator but Pr. Achille Iolascon from AOUFIIN will be more involved in this EJP.
Since 1983 Prof. Iolascon Research group is currently an international reference group for genetics of rare
hemolytic anemias, either due to hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full
Professor of Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2
researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school of medical
genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy.
Main tasks in the project per Pillar/WP:
Pillar 2
Contribution to WP10 annual retreats to guide the priorities for Virtual Pltaform development and FAIRification
of resources.
Previous experience relevant to the Tasks:
The ERN EuroBloodNet coordinator Pierre Fenaux, AP-HP has contributed in RESEARCH ACTIVITIES
mainly concern acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS).
1° clinical research
- Coordinator of European clinical trials in Acute Promyelocytic Leukemia since 1990
- Founding member of the French MDS group (groupe francophone des
myélodysplasies –GFM-in 1992), Président (1992-1995, and since 1999) Vice-
Président (1996-1998). The GFM is sponsor of about 10 clinical trials in the field of myelodysplastic
syndromes
2° biological research
P Fenaux part of INSERM Unit 1131, Hôpital St Louis, Paris, where the main subject of our research is:
825575 – EJP RD – Part B 148
translational research in MDS and APL Associated with document Ref. Ares(2018)6091977 - 28/11/2018
For what concerns ERN-EuroBloodNet LTPs, some relevant experience:
LTP CING
- PKDeep 2017-2018. Funded by the FUNDACIÓ INSTITUT RECERCA CONTRA LA LEUCÈMIA JOSEP
CARRERAS
- H2020-INFRADEV-01-2017 – ID-EPTRI project European Paediatric Translation Research Infrastructure
(777554-ID-EPTRI) 2018-2020.
LTP AOUFIIN
- 2014-2017: PRIN research grant “Study of the molecular mechanisms of erythropoiesis for the identification
of therapeutic targets”
LTP CHUM
The principal investigator of CHUM has acted as a workpackage leader in the field of education and training in
3 European projects. We have developed several e-learning platforms and many of us are university
professors/teachers having participated to numerous educational programmes
The principal investigator of CHUM and her team are specialists in molecular biology applied to rare diseases,
including sequencing and next generation sequencing tools.
LTP IRCCSCG
-2016-present BBMRI-LPC Whole Exome Sequencing Call: “Sequencing the exome of 500 rare disease
samples in collaboration with EuroBioBank” (PI)
- 2013-2016 e-Health workplan for the European reference network on rare anaemias (e-ENERCA), EU
Executive Agency for Health and Consumers. (Italian Partner)
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
- The Cyprus Institute of Neurology and Genetics (CING) is a non-profit research organization, with the vision of
operating as a Regional Centre of Excellence, in the areas of Neurology, Genetics and Biomedical Sciences. With
a particular focus on rare diseases, the activities of the CING include delivery of state-of-the-art diagnostic and
clinical services, execution of innovative research programmes and participation in postgraduate education.
- The CHU of Montpellier is fully equipped with a platform of next generation sequencing (NGS) and all genetics
and genomics facilities which are shared by the different laboratories.
Short Profile of key Staff Members who will be undertaking the work
Prof. Pierre Pierre Fenaux, after training at the University Hospital of Lille, France, where he became
Fenaux Professor in Hematology in 1993, created and was head of the clinical hematology section at
Hôpital Avicenne/Paris 13 university (belonging to Assistance Publique- Hôpitaux de Paris) from
2002 to 2013. He moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical
hematology section for myeloid disorders in the elderly which he is currently chairing.
He is involved in clinical and laboratory research in the field of myelodysplastic syndromes
(MDS) and acute myeloid leukemia (especially promyelocytic leukemia ). He is a founding
member and chairman of the French speaking MDS group (Groupe Francophone des
Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit
1131 in Paris for his research.
Prof. Since 1983 Prof. Iolascon works in the field of rare anemias and he gradually gained international
Achille recognition in this field. Using continuously renewed methods in molecular biology and in
Iolascon medical genetics, he characterized a large number of previously unknown genes and mutations:
SPTA1, ANK1, AE1, SEC23B, ABCB6, KCNN4 and PIEZO1. Prof. Iolascon Research group is
currently an international reference group for genetics of rare hemolytic anemias, either due to
hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full Professor of
Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2
researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school
of medical genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy.
Dr. Paola Since 1993 she is involved in diagnosis and translational research on hemolytic anemias, both
Bianchi congenital (red cell membrane defects, erythroenzymopathies, congenital dyserythopoietic
anemias) and acquired (paroxysmal nocturnal hemoglobinuria), contributing to the identification
and characterization of more than 200 erythroenzymopathies, 50 CDAII and 30 PNH and some
825575 – EJP RD – Part B 149
peculiar cases of red cell membrane defects (HS,Associated
HE and with
HSt). As Head
document Biologist responsible
Ref. Ares(2018)6091977 of
- 28/11/2018
the molecular biology of “Pathophysiology of Anemia UOS”, she shared National and
International projects on moleculear characterization and genotype-phenotype correlation (by
mutagenesis and in vitro expression of recombinant mutants), and studied the epigenetic factors
that might influence clinical phenotype in these disorders. By NGS (whole exome sequencing,
targeted NGS platforms and genomic–proteomic approach she identified new genes responsible
for rare forms of hemolytic anemia (SEC23B, KCNN4, PARP4).
She is involved in molecular diagnonsis of mieloprolopherative disorders (qualitative
/quantitatative evaluation of JAK2V617 allele burden, JAK2, MPL sequencing) and rare forms of
congenital erythrocytosis, participating to the JakNet Italian Network.
List of the most relevant publications and/or products, services (including widely-used datasets or
software), or other achievements
1) Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, Caforio P, Pinto V, Pignataro P,
Radhakrishnan K, Unal S, Tomaiuolo G, Forni GL, Iolascon A. Multi-gene panel testing improves diagnosis and
management of patients with hereditary anemias. Am J Hematol. 2018 Feb 3. (LTP AOUFIIN)
2) De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in
adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017 Jul;42:16-23. (LTP
AOUFIIN)
3) Charitou G, Petousis V, Tsertos C, Parpottas Y, Kleanthous M, Phylactides M, Christou S. First study on iron
complexes in blood and organ samples from thalassaemic and normal laboratory mice using Mössbauer
spectroscopy. Eur Biophys J. 2017 Jul 10. doi: 10.1007/s00249-017-1234-6 (LTP CING)
4) Reorganisation of the WHO Human Genetics programme (HGN) website, during a mission at WHO
headquarter, Geneva (LTP CHUM)
5) *Grace RF, Bianchi P, van Beers E, Eber EW, Glader B, Ya ish HM, et al. The clinical spectrum of pyruvate
kinase deficiency: data from the Pyruvate kinase deficiency Natural History Study March 2018 Blood,
DOI10.1182/blood-2017-10-810796 (LTP IRCCSCG)
List of relevant previous projects or activities, connected to the subject of this proposal :
1) Non Invasive Prenatal Diagnosis of β-thalassaemia based on the detection of paternally inherited alleles using
Targeted Next Generation Sequencing2015-2018. Funded by Telethon grant. (LTP CING)
2) eENERCA; DG SANCO; 2009-2013-WP leader, WP: “Education and training”: organisation of European
Courses,(LTP CHUM)
3) 2011-2013: AIRC research grant “Targeting neuroblastoma tumours through the hypoxia-induced
dedifferentiation in cellular systems” (LTP AOUFIIN)
4) 2009-2012: European Network for Rare and Congenital Anaemias (LTP IRCCSCG)
5) 2009-2012: Telethon research grant “Congenital Dyserythropoietic Anemia Type II: genotype-phenotype
correlation, molecular mechanisms, animal model New insights in erythropoiesis and iron overload”(LTP
AOUFIIN)
54-APHP (d)
Full legal name (Acronym) Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Christine Bodemer (Hôpital Necker)
Relevant Network ERN-Skin (as ERN coordinator)
Description of the legal entity/department/laboratory/group:
Necker-Enfants Malades Hospital activity concerns more particularly patients with rare and chronic diseases and
its excellence is certified in the field of health care and research.
The Dermatology department is a referral dermatology department and prioritizes seeing patients with rare skin
diseases. We are recognized as National Referral Centre (MAGEC centre) for many rare and complex skin
diseases.
The expansion of the research activities in the department has led to close partnership with in house, national and
international research laboratory HCPs and benefits of the environment of 36 other national referral centres in its
institution, covering other specialities, with strong interaction.
Prof C Bodemer, MD, PhD is in charge of the Dermatology Department and lastly is coordinating ERN-Skin, the
European Rare Disease Network devoted to dermatological rare diseases, which is present in 18 countries and
includes 56 HCPs. She is also the coordinator of the French network for rare skin diseases
[Other ERN-Skin teams are involved in the project as LTP under the coordination of AP-HP: EBHS, Pr. Johann
825575 – EJP RD – Part B 150
Bauer and IRCCS, Pr. Maya El Hachem] Associated with document Ref. Ares(2018)6091977 - 28/11/2018
AP-HP remains coordinator but Pr. Johann Bauer from EBHS will be more involved in this EJP.
The EB House Austria which opened in November, 2005 is located as part of the hospital complex of the General
Hospital Salzburg and is closely aligned to the Paracelsus Medical University (PMU), Department of Dermatology.
It is the single point of contact for people who are suffering from Epidermolysis bullosa (EB). It consists of 3 units:
EB Outpatient Unit, EB Research Unit and the EB Academy.
Main tasks in the project per Pillar/WP:
ERN-Skin's (AP-HP/Christine Bodemer/Necker Hospital-Paris) main tasks in the project per Pillar/WP are :
Pillar 2:
In WP1, Johann Bauer from EBHS (LTP : EBHS / ERN-Skin) will take part to the management of the next-
generation data ecosystem strategic plan, by :
- optimizing and aligning WP1 and WP2 activities with real-world community needs, and taking part to 3-day
strategy meetings (annual retreat) (task 1.1.1).
- working on continuous monitoring and coordination of the usefulness of WP1 and WP2 activities, moreover on
survey and structured interview approaches on technical and scientific matters, to monitor progress and inform
strategic decisions (incl. Definition of indicators) (task 1.2.2).
- and by working on quality management system, on the design and deployment of the QMS processes,
documentation, internal tools and procedures, continuous improvement system, dysfunction tracing (task 1.3.1).
Christine Bodemer (Necker Hospital / ERN-Skin) and Johann Bauer will participate to the ERN task force in
Pillar2,
Pillar 3: Maya El-Hachem from IRCCS (LTP : IRCCS / ERN-Skin) and Christine Bodemer will participate to the
ERN task force.
Pillar4 :
in WP 20, Christine Bodemer will take part to Task 20.2: for “support in design and planning of RD clinical trials”
(M3 – M60)”.
Previous experience relevant to the Tasks:
Prof. C. Bodemer has participated to numerous Congress in the domain of rare diseases in Dermatology, and to
many selection committees, advisory boards, scientific committee for Grants in the same field, such as ESPD
congress, WCD congress, scientific board meeting of the Fondation René Touraine.
Dr J. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of Innsbruck, Austria.
After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined faculty of the Department of
Dermatology, Paracelsus Medical University Salzburg. In 2014 he was appointed Chairman of the Department of
Dermatology of the SALK, the University Hospital of the Paracelsus Medical University Salzburg. Concurrently he
is medical director of the EB House Austria, the accredited national center for patients with Genodermatoses.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Short Profile of key Staff Members who will be undertaking the work
Professor Professor Christine Bodemer (MD, PhD) is the head of the Department of Dermatology at the
Christine Necker Enfants- Malades Hospital, Paris, France.
Bodemer, She received her PhD on Cutaneous Biology in 1997, a qualification to direct Research in 2000,
MD,PhD and she is Professor in Dermatology at the Paris Descartes-Sorbonne Paris Cité University since
2001. She is regularly invited to give lecture in international congresses and is more particularly
specialized in Pediatric dermatology. Pr Bodemer has published more than 300 articles in
international Journals, and taken part in the main textbook of Pediatric dermatology as author. She
received regular grants to lead research programs. One of this main field of interest concerns rare
skin disorders in children and she coordinates a national certified centre for rare pediatric skin
diseases (mostly Genodermatoses) (MAGEC) the French national network (FIMARAD) and
European network (ERN-SKIN) for rare skin diseases. She is a member of many scientific
societies, associated editor of different journal, as the British Journal of Dermatology, and she is
actually the president of the French Society of Pediatric Dermatology and in the board of the
European Society of Pediatric Dermatology. She took part in the organization of the World
Congress of Pediatric Dermatology in Paris and organized recently the 13th congress of Pediatric
825575 – EJP RD – Part B 151
Dermatology (Paris, 2016). She developed regular international
Associated training
with document supported by European
Ref. Ares(2018)6091977 - 28/11/2018
Grants.
Professor Prof. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of
Johann Innsbruck, Austria. After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined
Bauer, faculty of the Department of Dermatology, Paracelsus Medical University Salzburg. In 2014 he
MD was appointed Chairman of the Department of Dermatology of the SALK, the University Hospital
of the Paracelsus Medical University Salzburg. Concurrently he is medical director of the EB
House Austria, the accredited national center for patients with Genodermatoses and Co-
coordinator of ERN-Skin.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
Christine Bodemer :
1) Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome.
Paluel-Marmont C, Bellon N, Barbet P, Leclerc-Mercier S, Hadj-Rabia S, Dupont C, Bodemer C.
J Allergy Clin Immunol. 2017 Jun;139(6):2003-2005.e1.
2) Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.El Hachem M,
Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, Diociaiuti A, Gouveia CF, Hernández-
Martín A, de Lucas Laguna R, Dolenc-Volj M, Tadini G, Salvatori G, De Ranieri C, Leclerc-Mercier S,
Bodemer C. Orphanet J Rare Dis. 2014 May 20;9(1):76
3) Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with
primary immunodeficiency.
Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, Debré M, Pellier I, Gagnieur L,
Fraitag S, Fischer A, Blanche S, Lecuit M, Eloit M.
Clin Microbiol Infect. 2014; 20):O656-63
4) Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from
a French national survey.
Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D,
Thomas C, Hoarau C, Lebranchu Y, Stephan JL, Cazorla C, Aladjidi N, Micheau M, Tron F, Baruchel A,
Barlogis V, Palenzuela G, Mathey C, Dominique S, Body G, Munzer M, Fouyssac F, Jaussaud R, Bader-
Meunier B, Mahlaoui N, Blanche S, Debré M, Le Bourgeois M, Gandemer V, Lambert N, Grandin V, Ndaga S,
Jacques C, Harre C, Forveille M, Alyanakian MA, Durandy A, Bodemer C, Suarez F, Hermine O, Lortholary O,
Casanova JL, Fischer A, Picard C.
Medicine (Baltimore). 2012 91:e1-19.
5) Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.
Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L,
Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF,
Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H,
Dubreuil P.
J Invest Dermatol. 2010;130: 804-15.
Johann Bauer :
1) Wally V, Lettner T, Peckl-Schmid D, Klausegger A, Murauer EM, Hintner H and Bauer JW. The pathogenetic
role of interleukin-1 beta in severe epidermolysis bullosa simplex. J Invest Dermatol 2013. 133(7):1901-3
2) Gruber C, Koller U, Murauer EM, Hainzl S, Hüttner C, Kocher T, South AP, Hintner H, Bauer JW. The design
and optimization of RNA trans-splicing molecules for skin cancer therapy. Mol Oncol 2013 Dec;7(6):1056-68
3) Bauer JW, Brandl C, Haubenreisser O, Wimmer B, Karl T, Klausegger A, Breitenbach M, Hintner H, von der
Haar T, Tuite M, Breitenbach-Koller H. Personalized ribosomes: a customized tool for selective mRNA
translation. PLOS one 2013 10.1371/journal.pone.0067609
4) Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, Bondanza ,S, Recchia A, Muss W, Diem A,
Mayr E, Schlager P, Gratz IK, Pellegrini G and De Luca M. Closure of a large chronic wound through
transplantation of gene-corrected epidermal stem cells. J Invest Dermatol 2016 Nov 10. pii: S0022-
202X(16)32636-7. doi: 10.1016/j.jid.2016.10.038
5) Hirsch T*, Rothoeft T*, Teig N*, Bauer JW*, Pellegrini G*, De Rosa L*, Scaglione D, Reichelt J, Klausegger
A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T,
Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M.
Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017 Nov 16;551(7680):327-
332. doi: 10.1038/nature24487. Epub 2017 Nov 8. PMID: 29144448
*shared first authors
825575 – EJP RD – Part B 152
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal
document Ref. Ares(2018)6091977 - 28/11/2018
Christine Bodemer :
Examples of recent research programs supported b grants
1) Phase II clinical trial using Humira in Nztherton syndrome (anti TNF-SN)
2) A replacement protein administrated to male infants with X-Linked hypohydrotic Ectodermal Dysplaisa (Phase
II)
3) A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related
Overgrowth
4) Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2
trial in children observational-phase designed
Johann Bauer :
1) GENESKIN Website; European Commission (contract LSHM-CT-2005-512117) between 2005 and 2008. In
2011 the EDF (European Dermatology Foundation) has taken over responsibility to manage the website. Co-
ordinator
2) EB House Austria; DEBRA Austria; 2006-ongoing; Medical director
54-APHP (e)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Dr. Belmatoug (Hôpital Beaujon)
Relevant Network ERN MetabERN (participation as ERN member)
Description of the legal entity/department/laboratory/group:
Assistance Publique-Hôpitaux de Paris (AP-HP) is the legal entity where all research projects including clinical
trials are administered. The Referral Centre for Lysosomal Diseases (RCLD) certified by the health ministry since
2004, is located at AP-HP, University Hospital, Paris-Nord Val de Seine, Department of internal medicine, Beaujon
Hospital. The characteristics of the centre are: multidisciplinarity, collaborative approach, coordination,
symptomatic and specific care for disabled patients, epidemiology and registries, reactivity to give expertise,
transition programme from childhood to adulthood, enzyme replacement therapy for outpatients, home therapy,
clinical trials, research. Various platforms are present. High-level specialized performances with multidisciplinary
meetings locally and with external consultants in structured national organizations that exist since 2000 : CETL
(Treatment Evaluation multidisciplinary Committee for Lysosomal Diseases). Our HCP contributes to the
continuous training for lysosomal diseases for nurses, dietitians, residents, interns, fellows and medical students
etc. Teaching courses in LD are organized by HCP locally and in many university hospitals. Beaujon hospital has a
3 research departments called DHU organizing teaching courses for trainees (medical and research :
http://hupnvs.aphp.fr/dhu/. Clinical research department in Beaujon Hospital give methodological assistance for
clinical trials, monitoring and coordinating data management (http://hupnvs.aphp.fr/liste-des-
specialites/epidemiologie-recherche-clinique-beaujon/). The centre is included in the French Inherited Metabolic
Diseases (IMDs) network “G2M” that integrates 19 rare diseases centres and was certified in 2013. 9 HCP of
“G2M” are members of MetabERN. MetabERN is being coordinated by Prof Maurizio Scarpa. MetabERN
represents 69 nationally certified healthcare providers from 18 European countries, 44 patients organisations and
is endorsed by the Society for the Inborn Errors of Metabolism (SSIEM).
The centre has numerous academic national registries: The French Gaucher registry, RaDiCo (MPS), Niemann
Pick. Bio-banks are affiliated to registries
Main tasks in the project per Pillar/WP:
Pillar 3
In WP16 : Online academic education course
Task 16.1 : Access the needs, target audience, main topics of the academic education course
Task 16.2 : Developing the online courses
Our main contribution will be based on our experience and model and find new concepts to give courses in the
field of rare diseases. Education of health care professionals outside the field of rare diseases is also crucial.
Previous experience relevant to the Tasks:
- Leader of work package : Education, Training and Capacity Building for MetabERN
- Organisation and participation of courses for rare diseases : inter-universitary diploma on lysosomal
diseases and metabolic diseases with Pascal de Lonlay (AP-HP Necker Hospital)
- Organisation and participation of education programmes for the patients and families in patient
825575 – EJP RD – Part B 153
associations. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
- Lessons for medical students at University Paris Diderot
- Responsible of rare diseases websites :
For Lysosomal Diseases : www.cetl.net
For the European working group on Gaucher: www.ewggd.com
For MetabERN website : the section on education and training : metabern-edu.eu
Since 2004, our HCP is interested in developing new tools to create original programmes and curriculum for
education and training in the field of rare diseases. The creation of a pilot programmes that integrates a
multidisciplinary approach with physicians, researchers, scientists, biologists, nurses, etc.), “around “patients and
families stories with the participation of patient associations is already set up and need evaluation.
Different perspectives on rare diseases must be offered and developed for the students.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Two members of the referral centre for lysosomal diseases and of MetabERN with an expertise in the field will be
dedicated to the tasks.
Short Profile of key Staff Members who will be undertaking the work
MD, MD, Rheumatologist-Internist, master of infectiology, 123 publications. Knight of the Order of
Belmatoug the Legion d’Honneur in 2010 given by the health ministry. Head of the outpatient unit in the
Nadia Female department of internal medicine. Involved in rare diseases since 1992. Coordinator of the Referral
Centre for Lysosomal Diseases since 2004. Coordinator of the French National Gaucher disease
Registry (600 patients) certified by Inserm. Head of the multidisciplinary committee CETL :
Comité d’Evaluation du Traitement des maladies Lysosomales, for the french filère « G2M”.
Investigator for clinical trials on enzyme replacement therapy and Substrate Reduction Treatment.
Clinical research on lysosomal diseases, collaboration with research units : laboratory of
excellence GR-Ex : Inserm U1149, Inserm U1134; university of Orsay (LETIAM) for basic
research on pathophysiology of Gaucher. Member of the scientific committee of the patient
association : Vaincre les Maladies Lysosomales. Member of the European Gaucher Alliance.
Member of Maladies Rares Info-services. Coordinator of TENALYS programme (Transition
from childhood to adulthood for Lysosomal Diseases). Expert at the social security for
reimbursement of care and approval of treatment for metabolic diseases since 1996. Expert and
copilote at the French Health Ministry for the second and third rare disease plans.
PhD Beaujon University Hospital
Khemiri Head of mission for the French « filière G2M » in charge of research and clinical trials
Azza
Female Education and training in MetabERN
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN,
Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak
CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018 Feb 8.
2. Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, Frenzel C
Malinová V, Naumann S, Arndt J, Mengel E, Reinke J, Strobl R, Strupp M. Oculomotor and Vestibular Findings in
Gaucher Disease Type 3 and Their Correlation with Neurological Findings.Front Neurol. 2018 Jan 15;8:711.
3. Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van
Kim C, Franco M, Karim Z. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.
Haematologica. 2018 Apr;103(4):587-596.
4. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K,
Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ,
Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with
Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017 Nov;122(3):122-129.
5. Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau
C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM. Management and monitoring recommendations for
the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017 Jan;37:25-32.
List of relevant previous projects or activities, connected to the subject of this proposal :
EUROPLAN National conferences 2010
825575 – EJP RD – Part B 154
EUCERD Joint Action April 2014 : Workshop on Centres of Expertise for Rare
Associated Diseases
with document Ref. Ares(2018)6091977 - 28/11/2018
RaDiCo MPS 2017
MetabERN : Leader of WP 7 : Education, training, Capacity building, 2017-2022.
French Health Ministry : Leader of the workpackage “Research and Treatment” for the construction of the 3 rd
French rare disease plan, 2017-2018
54-APHP (f)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Jérôme Bertherat (Hôpital Cochin)
Relevant Network ERN Endo (participation as ERN member)
Description of the legal entity/department/laboratory/group:
Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical
trials are administered in the field of endocrine diseases within the ERN Endo. AP-HP hosts the French Reference
Centre for Rare Adrenal Disease and the French Network for Rare Endocrine Diseases, Service d’Endocrinologie,
Hôpital Cochin, HUPC.
[ERN Endo is under the coordination of LUMC: PI Prof Alberto Pereira – See Beneficiary LUMC description]
Main tasks in the project per Pillar/WP:
Pillar 3:
We will contribute to assess the needs, target audience and main topics of the academic education course. (task
16.1)
We will co-coordinate the development of on-line course module: choice of the lecturers/speakers, the
harmonization and general design of the module's content (task 16.2)
We will participate in the follow-up, evaluation and monitoring of the course.
Previous experience relevant to the Tasks:
Professor of endocrinology, responsible for various post-graduate course dedicated to are endocrine diseases at
Paris 5 University, coordinator of the French reference center for rare adrenal disease and the French national
network for rare endocrine disease,
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Short Profile of key Staff Members who will be undertaking the work
Pr Jérôme MD, PhD, Head of the Endocrinology dept of Cochin hospital
Bertherat, M
Pr Lionel MD, PhD, Professor of endocrinology, Paris Descartes University, coordinator of the national
Groussin diploma on endocrine tumors
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. On line course on endocrine tumors (Paris Descartes University)
2. Web site of the French network for rare endocrine diseases (www.firendo.fr)
3. Assié G, Libé R, Espiard S, … Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5
mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov
28;369(22):2105-14.
List of relevant previous projects or activities, connected to the subject of this proposal :
1) Coordinator Work Package geneomics of adrenal tumors ENSAT-CANCER (FP7) : FP7-HEALTH-2010;
259735 (2011-2016)
2) Coordinator E-RARE Genomics and signalisation of cAMP in adrenal Cushing, (RARE 0008-01) (2014-2017)
3) Coordinator Work-Package 2, H2020 633983, ENSAT-HT (2015-2020)
54-APHP (g)
Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France
Principal investigator Marc Humbert (Hôpital Bicêtre)
Relevant Network ERN-LUNG (participation as ERN member)
825575 – EJP RD – Part B 155
Description of the legal entity/department/laboratory/group: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical
trials are administered in the field of pulmonary hypertension within the ERN LUNG. AP-HP hosts the French
Reference Centre for Pulmonary Hypertension, Service de Pneumologie, Hôpital Bicêtre, France.
ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head of the FRZSE, the clinical Rare Disease Unit of
Universitätsklinikum Frankfurt (UKF). ERN-LUNG is a project of building a clinical care network for all rare
diseases of the respiratory system. ERN-LUNG has been evaluated by the European Commission and on 15
December 2016 the European Reference Network Board of Member States approved ERN-LUNG. ERN-LUNG is
a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research
for the benefit of patients affected by rare respiratory diseases.
[ERN-LUNG is under the coordination of GUF : PI Prof TOF Wagner – See Beneficiary UKF description]
Main tasks in the project per Pillar/WP:
Pillar 2:
WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources – contributing
experience with metadata registries and minimum data sets (e.g. ERDRI)
WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate
metadata collection/curation– contributing experience and work done on federate search and inter-operability
WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records – contributing experience and work done
on federate search data and inter-operability
Pillar 4:
WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided– perform a
survey to understand the ERN community needs in terms of educational resources for translational research (to
inform the population of our virtual library), and then later to perform an evaluation of the translational and
partnering services provided in the WP.
WP 19 Task 19.3. Evaluation of Innovation Management and exploitation support tasks
Other activities:
Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy
(ERDRI).
Previous experience relevant to the Tasks:
AP-HP, represented by M. Humbert, and O. Sitbon has many years of experience in registry work by running
registries and registry infrastructure. The group has developed the national French Pulmonary Hypertension
Registry.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Short Profile of key Staff Members who will be undertaking the work
Pr. Marc Marc Humbert, MD, PhD, is Professor of Respiratory Medicine at the South Paris University
Humbert (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities,
he is the Director of the French Reference Centre for Pulmonary Hypertension, Department of
Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris,
France. Along with membership to several scientific councils and institutes, Marc Humbert is the
current Director of the INSERM Unit "Pulmonary Hypertension: Pathophysiology and Innovative
Therapies" and of the “Thorax Innovation” University Hospital Department. He has been the Chief
Editor of the European Respiratory Journal from 2013 to 2017.
Pr. Olivier Sitbon, MD, PhD, is Professor of Respiratory Medicine at the South Paris University
Olivier (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities,
Sitbon he is in charge of the French Pulmonary Registry, Hôpital Bicêtre, Assistance Publique Hôpitaux de
Paris, France.
825575 – EJP RD – Part B 156
List of the most relevant publications and/or products, servicesAssociated
(including widely-used
with document datasets or software),
Ref. Ares(2018)6091977 - 28/11/2018
or other achievements
1) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf
A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh
T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment
of pulmonary hypertension. Eur Respir J 2015; 46: 903-75.
2) Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le
Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M. Clinical phenotypes and
outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir
Med 2017; 5:125-34.
3) Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S,
Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat
for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Lancet Respir Med 2016; 4:361–71.
4) Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for
patients with pulmonary arterial hypertension. Circulation 2014; 130 :2189-208.
5) Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P,
Fadel E, Sitbon O, Simonneau G, Tregouet DA, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary
veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65-9.
List of relevant previous projects or activities, connected to the subject of this proposal
1)EFORT; Funder; PHRC (French MoH); 2011-2017: Biomarkers of outcomes in PAH
2)VIGIAPATH; ANSM (French EMA); 2013-2018: Pharmacovigilance of drugs inducing PAH
3)SNOOPY-2; (Inserm, Univ. Paris-Sud, Technion, AP-HP) 2015-2018: Associated International Laboratory
Technion – Univ. Paris-Sud - Inserm on the development on an electronic nose to detect pulmonary hypertension
4)ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory
system
5)RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry
infrastructure for ERN-LUNG
55-HUS
Full legal name (Acronym) – Country Hôpitaux Universitaires de Strasbourg (HUS) - France
Principal investigator Hélène Dollfus
Relevant Network ERN-EYE
Description of the legal entity/department/laboratory/group:
Ranked among the top French university hospitals, the University Hospital of Strasbourg (HUS) is renowned for
the quality of the care provided, the excellence of its level of clinical research, innovation expertise, and its
leadership in the primary or life-time training of the healthcare professionals in the Alsace region and beyond. The
HUS as a university hospital (CHU) providing primary, secondary, tertiary care, teaching and research works in
close in connection with the University of Strasbourg (IDEX label) . For the last 20 years, the HUS has developed
expertise for diagnosis, care, clinical research and scientific research in the field of Rare Eye Diseases (RED) and
since 2004 is a national centre for rare diseases (CARGO). Since then >6000 files have been opened and >1750
consultations for secondary and tertiary referral of pediatric and adult RED are done yearly. CARGO has
established a highly specialized multidisciplinary network for care of syndromic eye diseases (with pediatrics,
neurology, nephrology, dermatology…). CARGO has low vision aid expertise for poorly sighted or blind patients
of all ages with a regional and national network for specialized careers. CARGO is one of the 3 French centres
authorized to perform patient selection and rehabilitation for artificial retinal implantation. CARGO is highly
specialized in genetic counselling for RED in close collaboration with the HUS Medical genetics department.
CARGO deals with preimplanatory diagnosis (PID) as well as prenatal diagnosis (PND) for various RED in close
contact with the HUS pluridisciplinary centre for prenatal diagnosis. The Molecular Genetics Unit of is constantly
developing various NGS panels for retinitis pigmentosa and for ciliopathies. CARGO is embedded in the
stimulating environment of the IGMA (Institut de Génétique Médicale d’Alsace) that brings together biologists,
clinicians, ophthalmologists and bio informaticians. CARGO leads or participates in clinical research protocols (R=
regional or N=national; PHRC) as principal investigator: Bardet-Bield syndrome I and II, Alström syndrome, NGS
panel for retinitis pigmentosa (R); or as associated investigator: Leber’s congenital amaurosis (N), retinitis
pigmentosa autosomal recessive and dominant (N). CARGO is tightly linked to fundamental research laboratories
especially the INSERM UMRS_S1112 and other human genetics laboratories in Strasbourg and many others
825575 – EJP RD – Part B 157
worldwide. Since 2014, CARGO is the chair of the nationalAssociated networkwith
fordocument
rare sensory diseases in - France
Ref. Ares(2018)6091977 28/11/2018
(SENSGENE) providing medical coordination of RED care for France including: mapping social care, child to
adult transition, education, national molecular network. The HUS coordinates the European Reference Network
dedicated to RED, ERN-EYE constituted by 29 Healthcare providers through 13 European Member States.
Main tasks in the project per Pillar/WP:
ERN-EYE members carry research with highly heterogeneous (phenotype and
genotype) non-syndromic rare eye diseases (ie: eye developmental anomalies, retinal degenerations, corneal
dystrophies, optic neuropathies, ...) as well as syndromic conditions (i.e.: ciliopathies, ultra rare syndromes,
mitochondrial disorders etc. …) overlapping with other ERN’s fields prompting for ERNs close interactions. 43
research entities are collaborating with ERN-EYE members of which 25 are working in the close vicinity of the
ERN HCPs; a premise to an excellent setting for holistic approaches to be developed. Genomics research for rare
eye diseases is tackled by ERN-EYE members with a continuous effort for solving the unsolved leading to multiple
novel gene identifications and with regular novel pathway & biomarker discovery . ERN-EYE will share this
holistic systemic biology approach strategy in this project and will solicit our network members & their research
partners for this purpose. Most importantly, therapies are being elaborated in preclinical terms by many groups of
ERN-EYE (often based on system biology approaches) and tackles the very high degree of phenotypic variability
and as well as the high number of genes involved to date putting multi-omics and holistic research at the forefront
of our priorities in the next years. We will fulfil the here under described tasks in PILLAR 2:
WP 10. User-driven strategic planning and transversal activities for Pillar 2 data ecosystem
Task 10.1: Pillar 2 annual strategic plans (M1-M60) including participation to prioritization, elaboration of WP11
and 12 of the proof of concept demonstrators, active participation to the annual retreat (we will propose use case,
use testers , …)
Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60) where
will be involved in advising, designing and responding to the activities.
Task 10.4: Quality oversight (M1-M60). We will offer regular participation to the process.
WP 13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics
Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases
(M1-M60). We can contribute to most subtasks due to the ERN-EYE ongoing collaboration with platforms and
institutes focusing on a holistic approach to diagnosis, biomarker identification and design of novel therapies.
Task 13.2: Organize proof of principle studies to identify efficacy of the work done and identify remaining
(including new) gaps (M1-M60)
Previous experience relevant to the Tasks:
We are highly interested in next generation data infrastructure and can contribute with our expertise in the field
of RED. WP10 is of concern for members of ERN-EYE involved in genomics research in RED , especially in
solving the unsolved and having access to common validated datasets would be a tremendous resource. Many
collaborators (i.e: Germany, France, UK, the Netherlands) are leading world experts in the field of gene
identification and genotype-phenotype studies in the field of retinal dystrophies. Therapies are also at the fore
front of RED (i.e: gene therapy getting into market, retinal implants also on the market and pharmacological
therapies on the way) with many preclinical studies as well as ongoing clinical trials.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
These are the one from each institute member of ERN-EYE, for the coordinating HCP we lean on INSERM and the
university of Strasbourg facilities (i.e.: for bioinformatics for instance).
Short Profile of key Staff Members who will be undertaking the work
Pr. Hélène Dollfus Hélène Dollfus, MD, PhD is specialized in Medical Genetics and Ophthalmology. She is
(female) the head of the Medical Genetics Department of the Strasbourg University Hospitals
(HUS) since 2003, Coordinator of the Rare Diseases in Ophthalmic Genetics Reference
Center (CARGO) since 2004, as well as the national rare diseases network SENSGENE
since 2014, Director of the Medical Genetics Laboratory Inserm UMRS_S 1112 since
2002, Instigator of the future Institute of Medical Genetics of Alsace (IGMA), President of
the scientific council of Retina France and Coordinator of the European Reference
Network ERN-EYE since 2017.
Dr. Jean Muller Jean Muller, PhD is specialized in Human Genetics testing and Bioinformatics. Member of
(male) the diagnostic laboratory of the HUS since 2009, he is responsible of the post and prenatal
diagnosis of rare sensory diseases. He is coordinator of the French network “NGS-
825575 – EJP RD – Part B 158
Diagnostic” since 2014. Member of the Medical
AssociatedGenetics Laboratory
with document INSERM UMRS_S
Ref. Ares(2018)6091977 - 28/11/2018
1112 since 2015 is coordinating research around bioinformatics and rare ophthalmologic
diseases including ciliopathies as well as development of WES and WEGS in novel gene
identification and novel path way discoveries.
Dr. Dorothée Leroux Dorothée Leroux (PharmD, PhD) is the project Manager of ERN-EYE since its creation.
(female) She manages ERN-EYE operatatiosn with important interactions with patients and patient
groups. She is particularly involved in the ontology work organized last year and in the
development of a training program for ERN-EYE.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects IFT20 release from the cis-Golgi.Stoetzel
C, Bär S, De Craene JO, Scheidecker S, Etard C, Chicher J, Reck JR, Perrault I, Geoffroy V, Chennen K,
Strähle U, Hammann P, Friant S, Dollfus H.Nat Commun. 2016 Nov 24;7:13586
2. Mutations in TUBGCP4 alter microtubule organization via the γ-tubulin ring complex in autosomal-
recessive microcephaly with chorioretinopathy.Scheidecker S, Etard C, Haren L, Stoetzel C, Hull S, Arno
G, Plagnol V, Drunat S, Passemard S, Toutain A, Obringer C, Koob M, Geoffroy V, Marion V, Strähle U,
Ostergaard P, Verloes A, Merdes A, Moore AT, Dollfus H.Am J Hum Genet. 2015 Apr 2;96(4):666-74.
3. [Bardet-Biedl syndrome: cilia and obesity - from genes to integrative approaches].Chennen K, Scerbo MJ,
Dollfus H, Poch O, Marion V.Med Sci (Paris). 2014 Nov;30(11):1034-9
4. Insights into Ciliary Genes and Evolution from Multi-Level Phylogenetic Profiling.Nevers Y, Prasad MK,
Poidevin L, Chennen K, Allot A, Kress A, Ripp R, Thompson JD, Dollfus H, Poch O, Lecompte O.Mol
Biol Evol. 2017 Aug 1;34(8):2016-2034.
5. Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knockout one
highlights the link between renal defects and systemic inactivation in mice.Cognard N, Scerbo MJ,
Obringer C, Yu X, Costa F, Haser E, Le D, Stoetzel C, Roux MJ, Moulin B, Dollfus H, Marion V.Cilia.
2015 Aug 13;4:10.
List of relevant previous projects or activities, connected to the subject of this proposal
- RADICO Cohort COBBALT (Cohort for Bardet-Biedl and Alström syndrome); start 2016 first inclusion
2018 for next 7 years
- OCUTher project, Call H2020 –MSCA-ITN-2016 Maria SKLODOWSKA-CURIE Action ITN innovative
training Educational network in ocular drug delivery and therapeutics (PI: Pr Arto URTi University of
Eastern Finland (UEF).Ongoing, until 2020
- Identification of novel genes in ultra rare sensorial diseases, PI, various sources of funding, Hospital calls,
Fondation Maladies Rares, Retina France, on going since 2004
- ALSM1, PHRC national, for the study of Alström syndrome patients, PI, ends 2018
- PHRI retinopathies pigmentaires, PI, Panel sequencing for retinal dystrophies, 2016 ends 2018
56-CLB
Full legal name (Acronym) – Country Centre Leon Berard (CLB),FRANCE
Principal investigator Jean-Yves BLAY
Relevant Network ERN EURACAN
Description of the legal entity/department/laboratory/group:
The legal entity is the Centre Leon Berard, the comprehensive cancer center in Lyon France
The Participating department is the Department of Medicine within the Centre Leon Berard
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10, we will contribute to the definition of the needs of the rare cancer community to the RD analysis and
sharing capabilities
Pillar 4: EURACAN will participate in Task 19.2: Support in exploitation and follow-up funding
825575 – EJP RD – Part B 159
Previous experience relevant to the Tasks: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Development of shared facilities in the SIRIC program of the French NCI (INCA). Contribution to the
creation of training courses in rare cancers with ESO and ESMO
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Molecular platformes and bioinformatics, participation to rare cancer networks, national and international level,
in house department for education and training courses, links with the University of Lyon.
Short Profile of key Staff Members who will be undertaking the work
Prof Isabelle Professor of medical oncology, head of the subdomain rare ovarian cancer in the EURACAN
Ray-Coquard ERN
female
Prof Sylvie Professor of pathology, head of the translational pathology department in the CLBN
Lantuejoul
female
Dr Pierre MD, PhD, Head of the platform for molecular characterization of Cancer in the CLB
Saintigny
Male
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
11: Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger
P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT,
Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der
Graaf WT, Zalcberg JR, Litière S, Blay JY. Time to Definitive Failure to the
First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With
Imatinib As an Adjuvant: A European Organisation for Research and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in
Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER,
French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on
Sarcomas. J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi:
10.1200/JCO.2015.62.4304. Epub 2015 Nov 16. PubMed PMID: 26573069.
2: Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S,
Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F,
Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay
JY. Nilotinib in locally advanced pigmented villonodular synovitis: a
multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018 Mar 20.
pii: S1470-2045(18)30143-8. doi: 10.1016/S1470-2045(18)30143-8. [Epub ahead of
print] PubMed PMID: 29571946.
3: Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J,
Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz
JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S,
Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I,
Italiano A, Le Cesne A; NETSARC/RREPS and French Sarcoma Group–Groupe d’Etude des
Tumeurs Osseuses (GSF-GETO) networks. Improved survival using specialized
multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov
1;28(11):2852-2859. doi: 10.1093/annonc/mdx484. PubMed PMID: 29117335; PubMed
Central PMCID: PMC5834019.
4: Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I. The value of research
collaborations and consortia in rare cancers. Lancet Oncol. 2016
Feb;17(2):e62-e69. doi: 10.1016/S1470-2045(15)00388-5. Review. PubMed PMID:
26868355.
5: Blay JY, Brahmi M, Ray-Coquard I. European Journal of Cancer's Biennial report
on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts
in sarcomas. Eur J Cancer. 2017 Jan;70:83-86. doi: 10.1016/j.ejca.2016.07.028.
825575 – EJP RD – Part B 160
Epub 2016 Nov 24. Review. PubMed PMID: 27889671. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of relevant previous projects or activities, connected to the subject of this proposal:
. NETSARC ; INCA; 2009-ongoing, head/PI, national network for sarcoma management in France
. LYRIC/LYRICAN ; INCA; 20011-ongoing, head/PI, site of excellencenetwork for translational research
development
. EUROSARC : FP7; 2011-17, head/PI, Acadelic clinical trials in sarcoma
EURACAN ERN ; FEur Commission; 2017-22r-Director, ERN of rare adult cancers
AURAGEN: DGOS/INSERM, France Medecine Genomic 2025 platform in Lyon, scientific director
57-UKL-HD
Full legal name (Acronym) – Country Universitätsklinikum Heidelberg (UKL-HD) - Germany
Principal investigator Prof. Dr. Franz Schaefer
Relevant Network ERN ERKNet
Heidelberg University is ranked #42 globally, #13 in Europe and #1 in Germany in the field of life science and
medicine (World University Rankings 2017). Heidelberg University Center for Paediatrics and Adolescent
Medicine has a strong focus on clinical and translational research in rare diseases, in particular hereditary kidney
and metabolic disorders. The Pediatric Nephrology division, headed by Prof. Franz Schaefer, has an international
reputation in clinical, genetic and experimental research in pediatric kidney diseases. The unit has recently been
awarded the status of a European Reference Center for Rare Kidney Diseases.
Main tasks in the project per Pillar/WP:
Pillar 0:
In WP1, we will serve in the Operationg Group. In this function, we will be part of the Operating Group and
Central Helpdesk (Subtask 1.1.2), provide coordination and support within and across the pillars (Task 1.2),
participate in the writing of the Annual Progress Reports and Annual Work Plans (Subtask 1.2.1), contribute to the
development of key performance indicators (Subtask 1.3.1), and help updating the Data Management Plan (Task
1.4).
In WP2, we will participate in the mapping of the research and innovation needs of the RD community from the
ERN perspective (Task 2.2).
Pillar 2:
In WP10, we will participate in the annual retreats (task 10.1).
In WP11, we will participate in data FAIRification and in PPRL development (task 11.2).
In WP12, we will participate in the development of Federation architectures subserving the interoperabilty of ERN
patient registries Task 12.1).
In WP13, we will help organizing proof of concept studies by identifying and making available suitable data sets
from ERN partners (Task 13.2).
Pillar 3:
In WP16, we will be instrumental in assessing the needs of the ERNs and developing the contents of the academic
education course (Tasks 16.1, 16.2).
In WP17, we will lead the sub-network “Organs” within the ERN Training Network and will lead Task 17.2
“Development of training programs for the ERN training networks”.
Pillar 4:
In WP20, we will participate in the Task Force directing the topic selection for demonstrator projects regarding rare
disease clinical research methodologies and trial designs (task 20.1)
Previous experience relevant to the Tasks:
Prof. Schaefer’s unit has ample experience in organizing clinical and translational collaborative research projects.
Also we have created several international registries and cohort studies and have performed clinical trials in
children with rare diseases and cohort studies, and have carried out multi-level omics studies in rare kidney
diseases.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The unit is home to the Central Office of the European Rare Kidney Disease Network (ERKNet) and hosts several
large rare kidney disease registries (see below) with a team of project managers, IT experts, data managers and
825575 – EJP RD – Part B 161
biostatisticians. The unit runs a fully equipped laboratory for translational,
Associated withgenetic
documentand
Ref. clinical research- with
Ares(2018)6091977 a
28/11/2018
central biorepository containing more than 180,000 serum, plasma, urine and DNA aliquots from patients with rare
kidney diseases.
Short Profile of key Staff Members who will be undertaking the work
Dr. Franz Schaefer Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg
(male) University Hospital. His research interests include the genetic basis of hereditary kidney
diseases, the physiopathology and prevention of kidney disease progression, the
cardiovascular, metabolic and endocrine consequences of kidney disease in children, and the
mangement of end-stage kidney disease by renal replacement therapy.
Prof. Schaefer has a special interest in rare disease research. He established the PodoNet
Project for Research in Steroid Resistant Nephrotic Syndrome and coordinates the
EURenOmics Consortium for High-Throughput Research in Rare Kidney Diseases. He is a
member the Scientific Advisory Board of the Global aHUS Registry. Recently he founded
and currently coordinates the European Rare Kidney Disease Reference Network (ERKNet).
Furthermore, he conducted numerous collaborative clinical trials and established several
international research consortia including the European Study Group for Progressive
Chronic Kidney Disease in Children (ESCAPE), the International Pediatric Dialysis
Network (IPDN), coordinated the European registry for pediatric dialysis and
transplantation for six years and is the current chair of the Global IPNA Registry for
pediatric renal replacement therapy.
Dr. Schaefer has published more than 500 scientific articles and book chapters, is co-editor
of the standard textbooks ‘Pediatric Kidney Disease’ and ‘Pediatric Dialysis’ and is
Associate Editor of two leading nephrology journals.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
• Chesnaye NC, Schaefer F, Bonthuis M, et al. Mortality risk disparities in children receiving chronic renal
replacement therapy for the treatment of end-stage renal disease across Europe. Lancet 2017; 389:2128-2137
• Devuyst O, Knoers NVA, Remuzzi G, Schaefer F. Rare inherited kidney diseases: Challenges, opportunities
and perspectives. Lancet 2014; 383:1844-59
• Lemaire M, Frémeaux-Bacchi V, Schaefer F, .... Recessive mutations in DGKE cause atypical hemolytic-
uremic syndrome. Nat Genet 2013; 45:531-6.
• Lapeyraque AL, Malina M, Fremeaux-Bacchi V, ..., Schaefer F. Eculizumab in severe Shiga-toxin-associated
HUS. New Engl J Med 2011; 364: 2561-3.
• Wühl E, Trivelli A, Matteucci MC, ..., Schaefer F. Strict blood pressure control and progression of renal
failure in children. N Engl J Med 2009; 361: 1639-50.
List of relevant previous projects or activities, connected to the subject of this proposal
. EURenOmics; EU FP7; 2012-2017; Coordinator
. ERK-REG; EU/Chafea; Coordinator; 2018-2020
. RenalTract; Marie-Curie-ETN; 2016-2018; project leader
. NeoCyst; BMBF (German Reseach Ministry); 2016-2018; WP leader
. PodoNet; eRare; 2009-2011; Coordinator
58-EKUT
Full legal name (Acronym) – Country Eberhard Karls Universität Tübingen (EKUT), Germany
Principal investigator Holm Graessner
Relevant Network ERN-RND, Solve-RD
Description of the legal entity/department/laboratory/group:
EKUT is the coordinator and leading center of the ERN-RND (European Reference Network on Rare Neurological
Diseases). This ERN establishes a large patient-centred network to address the needs of patients with RND of all
age groups, with or without a definite diagnosis, by implementing an infrastructure for diagnosis, evidence-based
management, treatment and collection of patient data. It represents a large-scale network of expert centres
dedicated to rare neurological diseases (RND) and exploits all well-established international rare disease
infrastructures such as Orphanet, EURORDIS and RD-Connect. This ERN will provide a rich expertise network
and infrastructure resource for EJP-RD.
825575 – EJP RD – Part B 162
Additionally, EKUT is a world-leading cluster of expert institutions focussing
Associated on next-generation
with document genomics- of
Ref. Ares(2018)6091977 rare
28/11/2018
neurological diseases, bringing together the expertise and methodologies from the Centre for Rare Diseases,
Clinical Department of Neurodegeneration, the Hertie-Institute for Clinical Brain Research (HIH), the German
Center for Neurodegenerative Diseases (DZNE), and the Institute of Medical Genetics and Applied Genomics. This
renowned infrastructure provides the resources that allows EKUT to coordinate Solve-RD a H2020 diagnostic RD
research project that will interconnect and interlink with EJP-RD.
Furthermore, EKUT has been leading many prominent European consortia on rare diseases such as Solve-RD,
NeurOmics, MultiSyn, EUROSCA.
Main tasks in the project per Pillar/WP:
Pillar 2: In WP10, we will provide important contribution to the management of the next-generation data ecosystem
strategic plan.
In WP13, we will provide important contribution to
• Task 13.1: Identification of areas in which a holistic, systemic biology approach is needed to overcome the
diagnostic and therapeutic challenges of RD
Pillar 3:
In WP17, we will lead the WP and provide important contribution throughout.
In WP14, we will provide important contribution
• Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice
• Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases
In WP18, we will provide important contribution to the assessment and adaptation of the Pillar 3.
Furthermore, ERN-RND will be participating (as applicants) in the calls as issued by Pillars 1,2 and 4.
Previous experience relevant to the Tasks:
EKUT is coordinator of ERN-RND and Solve-RD, two main networks that will contribute to EJP-RD.
Furthermore with regards to training activities and besides the activities being pursued in ERN-RND and Solve-
RD as well as the seven EU Initial Training Networks that we have been coordinating in our group over the last
years, we have set up the German Academy for Rare Neurological Diseases (www.dasne.de) and the Academy
for Further Medical Education for rare diseases (www.fakse.info)
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
1. Centre for Rare Diseases Tübingen (www.zse-tuebingen.de)
2. Recognised German NGS centre
3. Neurobiobank with biomaterials from >22.000 patients with neurodegenerative diseases, in particular FTD,
ataxias, HSP, rare movement disorders
4. Coordinator of the international EOA registry (>350 patients included) and HSP registry (> 1400 patients
included)
Short Profile of key Staff Members who will be undertaking the work
Dr. Holm Graessner PhD, MBA, is coordinator of ERN-RND, managing director of the Rare Disease Centre
(male) Tübingen and head of the research management unit of the Institute of Medical Genetics and
Applied Genomics at the University Hospital Tübingen. He has profound experience in rare
disease research and care. He has been coordinating/been responsible for the project
management of collaborative projects such as the FP6, FP7 and H2020 EU projects
EUROSCA, MEFOPA, RATstream, SENSE-PARK, TreatPolyQ, MultISyn, NeurOmics
and Solve-RD.
Dr. Carola Reinhard PhD, is project manager of ERN-RND. She has previously been managing EU FP7 and
(female) H2020 projects like Moving-beyond, Keep-Control and TreatPolyQ.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases.
Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, Wood L, Harmuth T,
Durudas A, Graessner H, Schaefer F, Riess O; RD-Connect consortium; NeurOmics consortium;
EURenOmics consortium. Eur J Hum Genet. 2018 Feb 27. doi: 10.1038/s41431-018-0115-5. [Epub ahead
of print] PMID: 29487416
2. European Reference Networks : Consequences for healthcare in Germany. Graessner H, Schäfer F, Scarpa
M, Wagner TOF. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):537-
541. doi: 10.1007/s00103-017-2533-x. German.
3. Participatory design in Parkinson's research with focus on the symptomatic domains to be measured.
Serrano JA, Larsen F, Isaacs T, Matthews H, Duffen J, Riggare S, Capitanio F, Ferreira JJ, Domingos J,
Maetzler W, Graessner H; SENSE-PARK Consortium. J Parkinsons Dis. 2015;5(1):187-96. doi:
825575 – EJP RD – Part B 163
10.3233/JPD-140472. PMID: 25588357 Associated with document Ref. Ares(2018)6091977 - 28/11/2018
4. German Academy for Rare Neurological Diseases (www.dasne.de)
5. Academy for Further Medical Education for Rare Diseases (www.fakse.info)
List of relevant previous projects or activities, connected to the subject of this proposal
. ERN-RND; EU; 2017-2022; coordinator; the European Network of rare neurological diseases is a network of
care providers set up to share and enhance the knowledge and resources used for treating rare neurological
diseases.
. Solve-RD; EU-H2020; 2018-2022; coordinator; Solve-RD will work directly with four ERNs to improve the
diagnosis of RD. The main ambitions are to solve large numbers of RD for which a molecular cause is not known
yet by combined omics approaches, and to improve diagnostics of RD patients through a “genetic knowledge
web”.
. NeurOmics; EU-FP7; 2012-2017; coordinator; NeurOmics is a European –omics research project for diagnosis
and therapy in rare neuromuscular and neurodegenerative diseases.
. EUROSCA; EU-FP6; 2004-2009; coordinator; EUROSCA is a European project on spinocerebellar ataxias.
59-GUF
Full legal name (Acronym) – Country Johann Wolfgang Goethe-Universität Frankfurt am Main (GUF)
Principal investigator Thomas WAGNER
Relevant Network ERN-LUNG
Description of the legal entity/department/laboratory/group:
Universitätsklinikum Frankfurt (UKF) is the legal entity coordinating ERN-LUNG. Goethe University Frankfurt
(GUF) is the Legal entity where all research projects including clinical trials run at UKF are administered. There is
a clear legal link between both legal entities. All activities within EJP will be organized by GUF with UKF being a
linked third party, coordinated by TOF Wagner. ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head
of the FRZSE, the clinical Rare Disease Unit of UKF. Professors holding lead positions at the UKF are Professors
of GUF. ERN-LUNG is a project of building a clinical care network for all rare diseases of the respiratory system.
ERN-LUNG has been evaluated by the European Commission and on 15 December 2016 the European Referece
Network Board of Member States approved ERN-LUNG as one of the 23 ERNs for rare diseases. ERN-LUNG is a
network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for
the benefit of patients affected by rare respiratory diseases.
[Other ERN-LUNG teams involved in the project under the coordination of GUF: APHP, PI Prof Humbert – See
Beneficiary APHP description]
Main tasks in the project per Pillar/WP:
Pillar 2:
WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources (Co-Task Leader)
– contributing experience with metadata registries and minimum data sets (e.g. ERDRI)
WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate
metadata collection/curation (Task Leader) – contributing experience and work done on federate search and inter-
operability
WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records (Co-Task Leader) – contributing
experience and work done on federate search data and inter-operability
Pillar 4:
WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided (Sub-Task
leader) – In WP 19 we will perform a survey to understand the ERN community needs in terms of educational
resources for translational research (to inform the population of our virtual library), and then later to perform an
evaluation of the translational and partnering services provided in the WP.
Other activities:
Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy
(ERDRI).
Previous experience relevant to the Tasks:
The Frankfurt group, represented by TOF Wagner, Holger Storf, and Gernot Rohde has many years of experience
in registry work by running registries and establishing registry software and registry infrastructure. The group has
developed the national RD registry platform (OSSE) containing cutting edge open source modules for registry
development, registry of registry, meta data repository and pseudonymization. These modules have been used to
build the European Rare Disease Registry Infrastructure (ERDRI) which is being built at JRC, Ispra, Italy. All
825575 – EJP RD – Part B 164
structures developed and run respect the highest possible standards of with
Associated datadocument
safety Ref.
andAres(2018)6091977
data ownership- 28/11/2018
and
sovereignty. Another module built is the ‘bridgehead’ which allows interoperability of existing registries with the
European registry platform.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work : https://www.osse-register.de/de/
Short Profile of key Staff Members who will be undertaking the work
Pr. TOF Wagner Head of the Dept. for Rare Diseases of the Universitätsklinikum Frankfurt (UKF), pulmonary
(male) medicine, Cystic Fibrosis and Lung transplantation. Coordinator of ERN-LUNG; PI of the
ERN-LUNG RD registry data warehouse project
Dr. H. Storf Head of the Medical Informatics Group of the Universitätsklinikum Frankfurt (UKF) and
(male) project coordinator of OSSE and ERDRI and partner in ERN-LUNG RD registry data
warehouse project
Pr. G. Rohde Head of the Dept. of Pulmonary Medicine of the Universitätsklinikum Frankfurt. Leads the
(male) section on Rare Respiratory diseases of the Universitätsklinikum Frankfurt as well as the
Christiane Herzog Zentrum for Cystic Fibrosis in Children, Adolescents and Adults.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1: Storf H, Schaaf J, Kadioglu D, Göbel J, Wagner TOF, Ückert F. [Registries for rare diseases : OSSE - An open-
source framework for technical implementation]. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz. 2017 May;60(5):523-531.
2: Pauer F, Göbel J, Storf H, Litzkendorf S, Babac A, Frank M, Lührs V, SchauerF, Schmidtke J, Biehl L, Wagner
TO, Ückert F, Graf von der Schulenburg JM, Hartz T. Adopting Quality Criteria for Websites Providing Medical
Information AboutRare Diseases. Interact J Med Res. 2016 Aug 25;5(3):e24. doi: 10.2196/ijmr.5822.
3: Storf H, Hartz T, Tegtbauer N, Pfeiffer W, Schmidtke J, Graessner H, Wagner T, Uckert F. Vision and
challenges of a cartographic representation of expert medical centres for rare diseases. Stud Health Technol Inform.
2014;205:677-81.
4: Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M,
Wagner TO; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis.
Pulm Med. 2014;2014:621342.
5: Hirche TO, Bradley J, d'Alquen D, De Boeck K, Dembski B, Elborn JS, Gleiber W,Lais C, Malfroot A, Wagner
TO; European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) Study Group. Travelling with cystic
fibrosis: recommendations for patients and care team members. J Cyst Fibros. 2010 Dec;9(6):385-99.
List of relevant previous projects or activities, connected to the subject of this proposal :
. ECORN-CF; EC DR SANTE; 2012-2016-TOF Wagner Coordinator, Cross border online Expert advice for RD
. ENCE-CF-LAM-LTX; EC DG Research; starting year-ending year-TOF Wagner Coordinator, blueprint for
ERNs
. ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory
system
. RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry
infrastructure for ERN-LUNG
60-HSK
Full legal name (Acronym) – Country Helios Dr. Horst Schmidt Kliniken (HSK), Wiesbaden DE
Principal investigator MetabERN
Relevant Network MetabERN
Description of the legal entity/department/laboratory/group:
The HELIOS Dr. Horst Schmidt Kliniken in Wiesbaden is a highly qualified multidisciplinary center aimed at the
treatment of patients with rare diseases as a maximum care facility involving 22 specialized departments and 4
institutes. The team at the Center for Rare Diseases coordinates a multidisciplinary care aimed to satisfy patients´
need. As Health Care Provider HSK is coordinating the MetabERN, the first European Reference Network for
Hereditary Metabolic Diseases connecting 69 Center of excellence in rare diseases, in 18 EU countries and
following 43000 RD Patients.
The MetabERN is running the U-IMD, project, the first EU funded project to create registry for all metabolic
diseasesin Europe
Main tasks in the project per Pillar/WP:
825575 – EJP RD – Part B 165
WP 11, task 11.3 to serve the needs for depositing, integrating and storingwith
Associated quality controlled
document (meta)data produced
Ref. Ares(2018)6091977 - 28/11/2018
by the EJP and the overall RD community building on existing resources including registries, in particular HSK
will be involved in evaluating strategies to integrate registries from patients in charge of the MetabERN.
In WP14 task 14.5, we will participate in course for the FAIRification of rare diseasae registries
In WP19, task 19.2 we will participate together with other ERNs to support and guidance to projects approaching
the end of EC funding, in particular for the definition and implementation of a development and exploitation plan.
In WP 20, task 20.1 we will participate actively to the Task Force on clinical trial to joint discussion to identify the
areas of action to improve RD research on clinical trials, design and methodology on evaluation for safety and
efficacy of new treatments
Previous experience relevant to the Tasks:
The team is involved in the management of registries for rare disease since over 15 years, following at clinical
level 400 patients affected by rare disease. Furthermore the Team is coordinating the European Reference
Network for Metabolic Diseases at European level. Maurizio Scarpa and Christina Lampe are experienced with
the running of phase I-III clinical trials for lysosomal diseases.
Short Profile of key Staff Members who will be undertaking the work
Dr. Maurizio Prof. Dr. Maurizio Scarpa is the Director of the Institute for Rare Diseases at the
Scarpa Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. He is the Coordinator of
MetabERN. He will collaborate in the Coordination and the dissemination of the project
inside MetabERN. He will participate in all the tasks.
Dr. Christina Dr. Christina Lampe, MD is the ViceDirector of the Institute for Rare Diseases at the
Lampe Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. She is actively participating
in registries for lysosomal disease, she will participate to task 11.3 and 14.5
Dr. Cinzia Dr. Cinzia Bellettato PhD is the MetabERN Project Manager will coordinate the
Bellettato involvement of the MetabERN in the project
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases.
Bellettato CM, Hubert L, Scarpa M, Wangler MF. Pediatr Clin North Am. 2018 Apr;65(2):353-373
2. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, Giugliani R.
Mol Genet Metab. 2017 Dec;122S:25-34.
3. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A,
Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E,
Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman
Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG.
N Engl J Med. 2015 Sep 10;373(11):1010-20.
4. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an
international case series.
Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, Muschol N, Olson R, Mendelsohn NJ.J
Inherit Metab Dis. 2014 Sep;37(5):823-9
5. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age.
Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalhães TS, Martins
AM, Mendelsohn NJ, Muenzer J, Smith LD. JIMD Rep. 2014;14:99-113.
List of relevant previous projects or activities, connected to the subject of this proposal:
MetabERN: DGSANTE contract 769046 starting 2017-running
U-IMD: DGSANTE contract 777259 starting 2018-running
InnerMEd: DGSANTE contract 20121212, starting 2012- ending 2015
61-IOR
Full legal name (Acronym) – Country ISTITUTO ORTOPEDICO RIZZOLI – IRCCS (IOR), Italy
Principal investigator Dr. Luca Sangiorgi
Relevant Network ERN BOND
Description of the legal entity/department/laboratory/group:
The Rizzoli Orthopaedic Institute (Bologna) is the main Italian institute for orthopedics and traumatology. Since
1981, the Italian Ministry of Health recognized to Rizzoli Institute the status of a “Scientific Research Hospital”
825575 – EJP RD – Part B 166
due to its close integration between healthcare (about 150,000Associated
patients with
examined and
document Ref.over 20,000 orthopaedic
Ares(2018)6091977 - 28/11/2018
operations every year) and scientific research, which is carried out in nine different laboratories employing
physicians, biologists, engineers, physicists, statisticians and technicians. High expertise, organization aimed at
integration between research and treatment, high quality healthcare and innovative technologies in continuous
evolution – are the ingredients for Rizzoli’s success in Italy and worldwide. With reference to its specializations,
the following shall be mentioned: treatment of degenerative pathologies of the hip, knee and ankle joints; spine
pathologies; pathologies of the foot and upper limbs; sports related pathologies; tumours of the musculoskeletal
system; paediatric orthopaedic pathologies; diagnosis and treatment of rare skeletal diseases. Rizzoli also houses
the specialization school of Orthopedics and Traumatology and the specialization school of Physical Therapy and
Rehabilitation of University of Bologna; indeed, there is a special cooperation agreement between Rizzoli
Orthopedic Institute and the University. Furthermore, the Institute participates in the Emilia-Romagna Regional
High Technology Network (Tecnopolo) with additional six research laboratories oriented toward translational
research; their activities is characterized by strong relations with industrial partners of the area operating in the
following fields: regenerative medicine, biomedicine, biomedical device, pharmaceutics, biomechanics and clinical
IT.
The Department of Medical Genetics and Rare Orthopaedic Diseases directed by Dr. Luca Sangiorgi, is
accredited from the Emilia-Romagna region as centre of coordination for the Regional Hub and Spoke Network of
Rare Skeletal Diseases. The Department is composed of a) the Molecular Laboratory that performs diagnosis and
research on RDs, b) the Medical Genetics Outpatient Clinic, welcoming patients with suspected familiar syndromes
and offering counselling and c) the Biobank of Genetic Samples (BIOGEN) created in order to collect high quality
biological materials of patients affected by skeletal dysplasias and other rare diseases. The samples collected, more
than 6500 different biospecimens, cover many fields of genetic and genomic research applications; in fact, the
biobank includes human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the
samples are collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research
scopes, after reading and signing informed consent agreement. Other samples are collected only for research
finality, like tissues, urine and serum. The Department works also in concert with the Clinical Bioinformatics Lab -
CLIBI - (always under the direction of Dr. Sangiorgi) and performs activities of research, development and
consultancy in the field of Clinical Bioinformatics. Being part of the Regional Network of RareSkeletal Diseases,
mentioned above, means that the Dept. and BIOGEN are in a net which involves 11 hospitals/institutions in Emilia-
Romagna region.
Furthermore, the Rizzoli Institute is the Coordinator of European Reference Network on BONe rare Diseases
(ERN BOND) that involves 38 health care providers, from 10 EU countries. The main ambition of the ERN
BOND is to implement measures that facilitate multidisciplinary, holistic, continuous, patient-centred and
participative care provision to people living with rare bone diseases (RBD), supporting them in the full realisation
of their fundamental human rights. In particular, BOND ERN aims to ensure that people living with a RBD are
afforded the same standards of care and support as the ones available to other citizens with similar requirements.
To meet this goal, BOND ERN gathers European professionals highly specialized in the field of RBD for both
scientific research and multidisciplinary care to increase knowledge on RDs, to improve healthcare quality and
patient safety, to increase access to ultra specialized medical expertise and accessible information beyond national
borders, in accordance with Directive 2011/24/EU.
Main tasks in the project per Pillar/WP:
Comtribution to the following pillars
Pillar 2: Development of ontologies to facilitate implementation of clinical trials and research activity.
Pillar 3: Improvement of timely diagnosis and care.
Pillar 4: Implementation of a help desk to support implementation of clinical trials.
PILLAR 2.
In WP10 we will participate in annual retreats and in definition of priorities for Virtual Pltaform and FAIRification.
ERN BOND Research Working Group (WG2) is promoting good quality and safe care for those with rare bone
diseases, and clinical research in this field. The WG is mapping the ongoing clinical and research activity, to
understand where this research activity is complimentary and where there are areas of weakness, in order to
facilitate the development of new research programs and collaboration between different partners.
PILLAR 3.
In WP 14 we will contribute to Task 14.2 Standards and quality of genetics/genomics data in laboratory and
clinical research practice.
ERN BOND Training and Education Working Group (WG8) is increasing awareness and knowledge about Rare
Bone Diseases in order to prevent unacceptable diagnostic delays and their associated burden of potentially
disabling complications, and allow timely use of the best available therapeutic options.
825575 – EJP RD – Part B 167
PILLAR 4. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
In WP 20 we will contribute to Task 20.1 Task Force Group and lead the Task 20.3 Demonstration projects on
existing statistical methodologies to improve RD clinical trials
ERN BOND Clinical Trials Working Group (WG4) is engaging relevant ERN members and relevant professional
groups (eg ESPE, ECTS, ICCBH) and regulators (EMA) in order to ensure patient benefit, inclusion and
collaboration in clinical trials to liaise with patient groups to identify and prioritise the clinical trials needed in
relation to unmet need, To developing a robust process for interaction with industry.
Previous experience relevant to the Tasks:
The scientific area of interest covers the diagnosis and the genetic and genomic research on hereditary skeletal
diseases furthermore we collect also clinical and genetic data of our patients (disease registries), we integrate
clinical data and molecular results in a genotype‐phenotype correlation. To date 4 disease registries are active at
MGD (Osteogenesis Imperfecta, Multiple Exostoses, Ehlers-Danlos Syndrome & Ollier Maffucci).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Facilities: Biobank of Genetic Samples (BIOGEN): The samples collected are more than 6500 different
biospecimens, cover many fields of genetic and genomic research applications; in fact, the biobank includes
human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the samples are
collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research scopes, after
reading and signing informed consent agreement. Other samples are collected only for research finality, like
tissues, urine and serum.
Networks: EATRIS (European infrastructure for translational medicine), BBMRI-ERIC (Biobanking and
BioMolecular Resources Research Infrastructure – ERIC), TNGB (Telethon Network of Genetic Biobank).
Short Profile of key Staff Members who will be undertaking the work
Phd. Luca Sangiorgi Head of the Department of Medical Genetics, Rizzoli Orthopaedic Institute, Bologna,
(male) Italy and Head of the Clinical Bioinformatics Lab and Rare Disease. He is also the
coordinator of the Rizzoli Rare Disease Centre and responsible of 4 National Registers
of Rare Diseases (REM: Multiple Hereditary Exostoses, ROI: Osteogenesis Imperfecta
and RED: Ehlers-Danlos Syndrome, ROM: Ollier-Maffucci diseases). He was nominated
in December 2014 as Italian representatives to the expert group on the "Committee for
Advanced Therapies" of EMA (European Medicines Agency) by the Italian Minister of
Health. He is also a Member of the National Coordination Team for Clinical Genetics
Department and manages the National and Regional Hub and Spoke Network on Skeletal
Dysplasia. Luca Sangiorgi is a Member of HL7 interest group for bioinformatics.
Contributor of more than 50 articles published in peer-reviewed journals such as
American Journal of Human Genetics, Journal of Clinical Oncology, Human Mutation
and International Journal of Cancer, he is an active Member of several international
medical associations, serving on the Executive Committee of the CTOS as President.
Since 2013 he has been appointed as Italian government representative for the Assembly
of the Member States for BBMRI Italy in Europe and he is Member of the National
Node Coordination Office and coordinator of the Rare Disease Interest Group. He is also
Member of the BBMRI-ERIC Steering Committee and Vice‐Chair of the Financial
Committee. Expert Reviewer for the European Union Commission for the Framework
Projects 6 (FP6) and Framework Projects 7 (FP7) grants and Horizon 2020, he is the
coordinator of a European Project within the ERA‐NET on Translational Cancer
Research (TRANSCAN) on the Identification of molecular therapeutic targets and
diagnostic/prognostic biomarkers for malignant transformation of osteochondromas. He
has been an invited speaker in several national and international conferences and
workshops. Dr. Sangiorgi research interests are on clinical and molecular genetics and
correlation between genotype and phenotype in musculoskeletal genetic disorders and
bone sarcomas. He is also interested in bioinformatics applications that correlate
genomic alteration and occurrence of diseases.
Phd. Marina Mordenti Senior Research Scientist at MGD & CLIBI Lab (IOR) and she is, at present, Registry
(female) Manager of four disease registries of rare skeletal disorder (REM, ROI, RED and ROM)
and curator of data management and protection of BIOGEN, the Biobank of Genetic
Sample (at MGD, IOR). Her main domains of interest include the design of biomedical
platforms for disease registries, for genotype-phenotype correlation, for sample
management, imaging as well as software for quality and risk management procedures.
She acquired good knowledge of international standards in the biomedical field and
825575 – EJP RD – Part B 168
databases on-line related to the world Associated
of scientific researchRef.
with document and a good command
Ares(2018)6091977 of
- 28/11/2018
quality control processes and risk management and good preparation on the protection of
privacy and security. She has been involving in several European projects, such as
ADOPT-BBMRI and CORBEL and she is author of peer-reviewed articles.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
- Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, Nishimura G, Sangiorgi L,
Savarirayan R, Sillence D, Spranger J, Superti-Furga A, Warman M, Unger S Nosology and classification
of genetic skeletal disorders: 2015 revision American Journal of Medical Genetics, Part A (167), 2869-
2892 (2015) 10.1002/ajmg.a.37365
- Baldo C, Casareto L, Renieri A, Merla G, Garavaglia B, Goldwurm S, Pegoraro E, Moggio M, Mora M,
Politano L, Sangiorgi L, Mazzotti R, Viotti V, Meloni I, Pellico MT, Barzaghi C, Wang C, Monaco L,
Filocamo M. The alliance between genetic biobanks and patient organisations: the experience of the
telethon network of genetic biobanks. Orphanet J Rare Dis (11(1)), 142 (2016)
- Mordenti M, Ferrari E, Pedrini E, Fabbri N, Campanacci L, Muselli M, Sangiorgi L. Validation of a new
multiple osteochondromas classification through Switching Neural Networks Am J Med Genet A.
(161A(3)), 556-60 (2013)
- Gentile FV, Zuntini M, Parra A, Battistelli L, Pandolfi M, Pals G, Sangiorgi L. Validation of a quantitative
PCR-high-resolution melting protocol for simultaneous screening of COL1A1 and COL1A2 point
mutations and large rearrangements: application for diagnosis of osteogenesis imperfecta. Hum Mutat.
(33(12)), 1697-707 (2012)
- D'Eufemia P, Palombaro M, Lodato V, Zambrano A, Celli M, Persiani P, De Bari MP, Sangiorgi L. Child
abuse and osteogenesis imperfecta: how can they be still misdiagnosed? A case report. Clin Cases Miner
Bone Metab. (9(3)), 195-7 (2012)
List of relevant previous projects or activities, connected to the subject of this proposal :
1. “Ma.Tr.OC - Identification of molecular therapeutic targets and diagnostic/prognostic biormarkers for
malignant transformation of osteochondromas” - ERA-Net Transcan-2 JCT 2012 – Italian Ministry of
Health – Coordinator – 2014-2018
2. “ADOPT BBMRI-ERIC: implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC" -
Grant agreement n. 676550 - Horizon 2020- European Commission - beneficiary, WP Leader – 2015-2018;
3. "CORBEL: Coordinated Research Infrastructures Building Enduring Life-science services”– Grant
Agreement n.654248 – Horizon 2020 – European Commission - Linked third party – 2015-2019;
4. ERN BOND: European Reference Network on BONe rare Diseases – Framework Partnership Agreement
n. 739539 - 3rd Health Programme – European Commission – Coordinator – 2017-2022;
5. “MCDS-Therapy - Repurposing of carbamazepine for treatment of skeletal dysplasia” - Grant Agreement
n.754825 – Horizon 2020 – European Commission – beneficiary – 2018-2022.
62-AOUP
Full legal name (Acronym) – Country Azienda Ospedaliero Universitaria Pisana (AOUP), Italy
Principal investigator Prof. Marta Mosca
Relevant Network ERN ReCONNET
Description of the legal entity/department/laboratory/group:
The Rheumatology Unit is part of the University Department of Clinical and Experimental Medicine of University
of Pisa (Italy); patients care, clinical research and education are the three main objectives of the Unit. The Unit is
the coordinating Clinical Centre of the ERN-RECONNET, the European Reference Network on Rare Connective
Tissue and Musculoskeletal Diseases approved by the European Commission in 15th December 2016.
The clinical activity of the Unit is focused on inflammatory rheumatic diseases and it is the Tuscany referral center
for systemic autoimmune diseases including SLE, undifferentiated connective tissue disease, antiphospholipid
syndrome, Systemic Vasculitides, Inflammatory myopathies and Systemic Sclerosis.
The clinical activity of the Unit is structured in three levels of patient care: outpatients visits, day-hospital for daily
drug infusions and inpatients ward. The outpatients clinic provides 16 daily visits for first rheumatologic
assessment and disease-specific second-level clinics for SLE (Lupus clinic), Systemic sclerosis (Scleroderma
clinic), Sjogren’s Syndrome (Sjogren Clinic), rheumatoid arthritis, Inflammatory myopathies, systemic vasculitis
and fibromyalgia. All these dedicated clinics share common characteristics including the multidisciplinary
approach to the patients as several health professionals other than rheumatologists are involved in the clinics:
nurses, physical therapists, obstetrics and gynaecologists, nephrologists, ophthalmologists, psychiatrist,
cardiologists and orthopaedics. Moreover, all these clinics are characterized by a strong effort toward quality of
825575 – EJP RD – Part B 169
care and a patient-centered approach. Overall, 400 SLE, 350 UCTD, 350 SSc,
Associated 600 SS,Ref.
with document 200 SAPL, 2000 RA,
Ares(2018)6091977 250
- 28/11/2018
vasculitis and 650 fibromyalgia patients are regularly followed at the dedicated clinics of the Rheumatology Unit.
The research activity of the Unit is focused on epidemiological studies and prognostic factors of systemic
autoimmune diseases; quality of care, imaging studies, outcomes measures are other topics of the research activity
of the Rheumatology Unit. The research activity is documented in more than 500 published scientific articles over
40 years of activity, several participations to national and international congresses and a worldwide esteem of the
research activity. The Rheumatology Unit takes part and leads of several collaborative research studies with Italian
and European centers.
The educational mission of the Rheumatology Unit is achieved by several initiatives addresses to medical students,
internal and external rheumatologists in training, rheumatologists, nurses, general practitioners.
Among these initiatives, a particular mention goes to the bi-annual EULAR scientifically endorsed course on SLE
successfully arrived at its VIII edition and entirely organized by Prof. Marta Mosca and her staff. The Course is
aimed at 70 young rheumatologists (aged less than 40 years of age) coming from all over the world; the course is
aimed at providing a comprehensive and intensive training on various aspects of systemic lupus erythematosus
(SLE).
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10, we will contribute in 5x pan-RD-community, 3-day strategy meetings (annual retreat)(task 10.1.1), and in
carrying out survey and structured interview approaches on technical and scientific matters, to monitor progress
and inform strategic decisions - incl. Definition of indicators (task 10.2.2)
Pillar 3:
In WP17, we will contribute in the assessment of the needs and development of training activities for ERNs as
members of Group 2 Neoplasm and Malformation”.
Previous experience relevant to the Tasks:
Recently Prof. Marta Mosca has coordinated the development of “EULAR Recommendations for monitoring SLE
patients in clinical practice and observational studies”, of quality measures in SLE and of a core set of measures to
be used in clinical practice to standardize patients care. In addition, she is part of the Steering Committee for the
development of the "Treat to Target Recommendations in SLE" and for the definition of Remission in SLE. She is
also participating to a SLICC/ACR project aiming at defining flares in SLE. She is coordinating and has
coordinated entire projects and/or Research Units on SLE and other Musculoskeletal Disorders at a national and
international level. Since 2011, she is part of the medical panel of the European Lupus Patients Association LUPUS
EUROPE. Since 2013, she is member of the Ethical Committee of the district area of Western Tuscany (including
the Pisa University Hospital and other 15 hospitals).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The Rheumatology Unit (the day hospital section) includes 12 seats and 2 beds for daily intravenous drug-infusion;
two rheumatologists and three nurses are assigned to this section of the Unit.
The inpatients ward consists of 18 beds addressed to severely ill patients with rheumatology conditions; two
experienced rheumatologists and four rheumatologists in training are assigned to the inpatients care with two daily
nurses and a team of 12 shift worker nurses.
Short Profile of key Staff Members who will be undertaking the work
Pr. Marta Mosca Associate Professor of Rheumatology at the Department of Clinical and Experimental
(female) Medicine of the University of Pisa, Italy and chief of the Rheumatology Unit of the Azienda
Ospedaliero Universitaria Pisana. She graduated from the Medical School of the University
of Pisa in 1992 and in the same year she has started her fellowship in Rheumatology. In
1999 she has obtained a PhD in Immunology of Organ Transplantation. Her research
interests are represented by connective tissue diseases, with special interest in systemic
lupus erythematosus (SLE) and undifferentiated connective tissue diseases (UCTD), with
particular interest to clinimetrics. She is the Network Coordinator of ERN-RECONNET, the
European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases
approved by the European Commission in 15th December 2016.
Her clinical activity includes the follow up of patients with connective tissue diseases
followed at the Rheumatology Unit, where she runs the Lupus Clinic and the Pregnancy
Clinic.Prof. Marta Mosca has co-authored 176 papers published in peer reviewed journals
(at March 16th, 2018), with an H index of 40 (SCOPUS, March 16th, 2018), and 6684
citations.
Dr. Rosaria Talarico Rosaria Talarico, MD, PhD. Rheumatologist at the Rheumatology Unit of AOUP (Since
(female) March 2017). Employed under independent contract in the INFORMaR project, University
825575 – EJP RD – Part B 170
of Pisa, Italy. (from October 2013 to March2017)
Associatedand from September
with document 2011 to September
Ref. Ares(2018)6091977 - 28/11/2018
2013 she was employed under independent contract in the Rheumatology Division,
University of Pisa, Italy, within the Rare Diseases Regional Project.
Member of the Coordinating Centre for Rare Diseases at the “Azienda Ospedaliera
Universitaria Pisana (AOUP)”, University of Pisa, Italy, as epidemiological expert.
Experience in research. 2007-2009: Participation as Fellow for the research of the literature
for the EULAR project “Development of recommendations for monitoring systemic lupus
erythematosus (SLE) patients in clinical practice and in observational studies”. 2012:
Participation as Fellow for the research of the literature for the project “Systematic review of
2008-2012 literature and update of recommendations for the use of methotrexate in
rheumatic diseases, with a focus on rheumatoid arthritis”; 2012-ongoing: Participation as
Methodological coordinator for the research of the literature for the FIRMA project
“Development of recommendations for the clinical application of autoantibodies
determination in systemic autoimmune diseases”.
Rosaria Talarico has co-authored 150 papers published in peer reviewed journals (at March
21th, 2018), with an H index of 18 (SCOPUS, March 21th, 2018), and 943 citations.
Dr. Chiara Baldini MD, PhD. Associated Professor in Rheumatology (MED/16), Rheumatology Unit,
(female) University of Pisa, Italy. Her clinical research activity and interests are in the field of
clinical Research on connective tissue diseases and vasculitis. Lab Research identification
and validation of novel non-invasive diagnostic, prognostic and therapeutic proteomic
biomarkers for primary Sjogren’s syndrome and other systemic autoimmune disorders
which might eventually improve the diagnostic processes and the assessment of patients
affected by systemic autoimmune disorders. Principal investigator and co-investigator in
several phase III and IV clinical trials carried out in systemic autoimmune disorders; has co-
authored 150 papers published in peer reviewed journals (at March 21th, 2018), with an H
index of 26 (SCOPUS, March 21th, 2018), and 1541 citations.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus
erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus
Sci Med. 2018 Feb 27;5(1):e000234.
2. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa
E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L,
Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F,
Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X,
Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig
OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth
VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from
a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017
Mar;76(3):554-561.
3. Barsotti S, Zampa V, Talarico R, Minichilli F, Ortori S, Iacopetti V, D'ascanio A, Tavoni AG, Bombardieri S,
Mosca M, Neri R. Thigh magnetic resonance imaging for the evaluation of disease activity in patients with
idiopathic inflammatory myopathies followed in a single center. Muscle Nerve. 2016 Oct;54(4):666-72.
4. Luciano N, Baldini C, Tarantini G, Ferro F, Sernissi F, Varanini V, Donati V, Martini D, Mosca M, Caramella
D, Bombardieri S. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary
Sjögren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015
Dec;54(12):2198-204.
5. Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, Alijotas-Reig J, De Carolis S, Mekinian A,
Bertero MT, Canti V, Brucato A, Bremme K, Ramoni V, Mosca M, Di Poi E, Caramaschi P, Galeazzi M, Tincani
A, Trespidi L. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with
thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost.
2014 Oct;112(4):727-35. doi: 10.1160/TH14-03-0191. Epub 2014 Jul 10.
List of relevant previous projects or activities, connected to the subject of this proposal :
ERN RECONNET; Funder: European Commission (CHAFEA); 2017-2021; PI-Network Coordinator.
825575 – EJP RD – Part B 171
63-AOUS Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Azienda Ospedaliera Universitaria Senene (AOUS), Siena, Italy
Principal investigator Alessandra Renieri
Relevant Network ITHACA
Description of the legal entity/department/laboratory/group:
The mission of AOUS is to provide clinical care, training and research. AOUS delivers inpatients and outpatient
specialist services, emergency and urgency services and pursues the development of high medical specialization.
The Hospital operates within the Regional Health Service that guarantees to all users treatment and rehabilitation in
accordance with the principles of equality, fairness and compassionate care, free of charge or with a contribution
according to the National Health Service regulations. The main objective of AOUS is to achieve a high level of
response to the health demand, meant as recovery and preservation of physical, mental and social health.
Medical Genetics Unit provides genetic counselling, genetic tests, information and support to people who have, or
may be at risk for, genetic disorders and, in particular, for pediatric and adult patients with intellectual disability
and their families. During a consultation, a medical geneticist meets with an individual or family to discuss genetic
risks or to diagnose, confirm, or rule out a genetic condition and to evaluate the possibility to perform a prenatal
diagnosis. The AOUS offers molecular tests for a large number of genetic conditions characterized by intellectual
disability: Rett, Coffin Siris, Nicolaides Baraitser, Cohen, Angelman, Prader Willi, and Lesch Nyhan Syndromes
and others. Furthermore, it provides array-CGH analysis for Rare Chromosomal Disorders. All patients with other
rare intellectual disability syndromes and rare undiagnosed malformation syndromes hospitalized are evaluated by
several healthcare professionals, namely Geneticists, Child Neuropsychiatrists, Neuroradiologists,
Neurophysiopatologist, Cardiologists, Odontologists, Gastroenterologists, Physical Therapists and Pediatricians in
order to obtain a complete examination, to ameliorate health conditions and to obtain a defined diagnosis. Weekly
multidisciplinary discussions regarding specific cases are in place. The majority of these diseases do not have a
specific cure. However, providing specific diagnosis may help in patient daily care and rehabilitation therapy
including physiotherapy and speech therapy. Whenever the syndrome includes epileptic involvement, treatment
with specific antiepileptic drugs (even multidrug teraphy) in both pediatric and adult patients is administered.
The clinical service is complemented by a wide range of research activities, which include genetic and
experimental research in a dedicated laboratory as well as the coordination of national and international clinical
research consortia. Medical Genetics Unit is certified through a National Assessment Program concerning
specifically the ISO 9001:2008 certification released by ACCREDIA. Site visits are annually planned. It certifies
that the Management System of the Unit has been audited and found to be in accordance with the requirements of
the management system standard. Supplies services are Clinical Genetics, Genetics Biobank, Scientific research in
Medical Genetics and Laboratory of Medical Genetics including Molecular Genetics, Cytogenetics, Forensic
Genetics and Preimplantation Genetic Diagnosis. Furthermore, every year the Italian Society of Human Genetics
(SIGU) certifies that the above organisation has been audited and found to be in accordance with SIGU.
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP11, we will contribute to facilitate data generated from RD research to be deposited in existing repositories
by improving their capacity, interoperability, privacy protection and security compliance through the development
of a specific informatic tool, named “IVANA/FastPG”. The searching algorithm, based on a machine-learning
approach, will combine data from several sources (i.e. bibliometric databases, and specialized
biological databanks) using data-mining techniques.
Pillar 3:
In WP16, we will contribute in Online Academic education course. A streamlined education programme could be
made available to all stakeholders via an established e-learning service provider. The e-learning modules will be
created or adapted with the help of interested universities. Since Education is also part of the future activities to be
developed by the European Rare Disease Networks (ERNs), the EJP on RD will provide support, complimentary
access to the e-learning platform, and visibility to the research training activities and educational material
developed by the ERNs. The EJP will also develop its own educational material which should be complementary to
the ERN resources rather than overlapping. Specifically, we will contribute to assess the needs, target audience,
main topics of the academic education course (task 3.1 - VUH SK). This task will be performed through a thorough
benchmark of existing RD academic courses at EU level and through survey and audits of potential target
audiences and experts involved in those courses (not restricted to students) and the main topics to address, the most
relevant lecturers. The e-learning programme will be based on already existing initiatives such as the French inter-
university diploma.
The contribution will be also related to task 3.2 (CHU DIJON) in developing the online course. E-learning
approaches could combine different components: e-learning content, e-tutoring, collaborative learning, virtual
classroom. Activities can be synchronous or asynchronous. One key component to be addressed in this task will be
825575 – EJP RD – Part B 172
the status of this academic course (free-access or based on tuition Associated
fees fromwith
each partnered
document organisation; European
Ref. Ares(2018)6091977 - 28/11/2018
Credit Transfer System eligibility (ECTS); the most relevant length of the course; etc.). The identification of an
established e-learning service platform will be also performed (on going discussions with FutureLearn). The
platform will develop and implement the e-learning scholar content received from lecturers.
Pillar 4:
In WP20, we intend to contribute to Task 20.2 Support in design and planning of RD clinical studies . We will
also contribute to Task 20.4 Projects on innovative methodologies to improve RD clinical trials in limited
populations
Previous experience relevant to the Tasks:
Universities of beneficiary and LTP have developed specific academic courses for RD. There is a great need to
share this knowledge and make it available to the broader public including students, medical doctors, healthcare
providers or patients at the European level.
The beneficiary directs the Genetic Biobank of Siena (GBS, http://www.biobank.unisi.it), one of the few in Italy
certified SIGU-CERT and ISO9001, and funded by Telethon since 2002. GBS is the Italian Partner of BBMRI
(Biobanking and Biomolecular Resources Research Infrastructure), member of EuroBioBank and RD-Connect.
Since 2009, she coordinates the international Rett database network (http://www.rettdatabasenetwork.org). The
Medical Genetics of AOUS also coordinates the Italian Registry of Alport disease, an Italian network for Alport
disease. The beneficiary is leading for ERN ITHACA the Registry Work Package.
The beneficiary already experienced preclinical trials on gene therapy within four different genetic diseases. Thus,
we can contribute to develop a system devoted to assess if a disease can be treated more or less effectively with
gene therapy.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Beneficiary and LTP are equipped with the all major equipment relevant to the proposed work.
Short Profile of key Staff Members who will be undertaking the work
Pr.Francesca Mari Prof. Mari F. is currently Associate Professor of Medical Genetics at University of Siena
(female) and Medical Geneticist of AOUS. She contributed to the development of the genetic
counselling activity in the Medical Genetics Unit in Siena performing and supervising
thousands of genetic counselling clinics. Her main research interests are focused on
understanding the genetic bases of rare disorders mainly Intellectual disability, including
Rett syndrome, Alport syndrome, and rare cancers.
Dr.Simone Furini Dr. Furini S. is currently a Researcher / Assistant Professor at the Department of Medical
(male) Biotechnologies of the University of Siena. His main area of expertise is Systems Biology,
with a particular interest on how deterministic and stochastic models can be used to predict
the outcome of gene networks.
Dr.Elisa Frullanti Dr. Frullanti E. is currently a Researcher / Assistant Professor of Medical Genetics at
(female) University of Siena. Her main research interests were aimed to dissect the molecular and
genetic bases of lung cancer in never smoker young patients as well as genetic bases of rare
disorders following an innovative “omics” approach that will integrate genomic (Whole-
Exome/Genome Sequencing) and transcriptomic (RNA sequencing) data.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Ivanovski I, Djuric O, Caraffi SG, Santodirocco D, Pollazzon M, Rosato S, Cordelli DM, Abdalla E, Accorsi P,
Adam MP, Ajmone PF, Badura-Stronka M, Baldo C, Baldi M, Bayat A, Bigoni S, Bonvicini F, Breckpot J,
Callewaert B, Cocchi G, Cuturilo G, De Brasi D, Devriendt K, Dinulos MB, Hjortshøj TD, Epifanio R, Faravelli F,
Fiumara A, Formisano D, Giordano L, Grasso M, Grønborg S, Iodice A, Iughetti L, Kuburovic V, Kutkowska-
Kazmierczak A, Lacombe D, Lo Rizzo C, Luchetti A, Malbora B, Mammi I, Mari F, Montorsi G, Moutton S,
Møller RS, Muschke P, Nielsen JEK, Obersztyn E, Pantaleoni C, Pellicciari A, Pisanti MA, Prpic I, Poch-Olive
ML, Raviglione F, Renieri A, Ricci E, Rivieri F, Santen GW, Savasta S, Scarano G, Schanze I, Selicorni A,
Silengo M, Smigiel R, Spaccini L, Sorge G, Szczaluba K, Tarani L, Tone LG, Toutain A, Trimouille A, Valera ET,
Vergano SS, Zanotta N, Zenker M, Conidi A, Zollino M, Rauch A, Zweier C, Garavelli L. Phenotype and genotype
of 87 patients with Mowat-Wilson syndrome and recommendations for care. Genet Med. 2018 Jan 4. doi:
10.1038/gim.2017.221.
2. Mari F, Marozza A, Mencarelli MA, Lo Rizzo C, Fallerini C, Dosa L, Di Marco C, Carignani G, Baldassarri M,
Cianci P, Vivarelli R, Vascotto M, Grosso S, Rubegni P, Caffarelli C, Pretegiani E, Fimiani M, Garavelli L,
Cristofoli F, Vermeesch JR, Nuti R, Dotti MT, Balestri P, Hayek J, Selicorni A, Renieri A. Coffin-Siris and
Nicolaides-Baraitser syndromes are a common well recognizable cause of intellectual disability. Brain Dev. 2014
Sep 20. pii: S0387-7604(14)00212-5.
825575 – EJP RD – Part B 173
3. Grillo E, Villard L, Clarke A, Ben Zeev B, Pineda M, Bahi-Buisson N, Hryniewiecka-Jaworska
Associated A, Bienvenu
with document Ref. Ares(2018)6091977 T,
- 28/11/2018
Armstrong J, Martinez AR, Mari F, Veneselli E, Russo S, Vignoli A, Pini G, Djuric M, Bisgaard AM, Mejaški
Bošnjak V, PolgárN, Cogliati F, Ravn K, Pintaudi M, Melegh B, Craiu D, Djukic A, Renieri A. Rett networked
database: an integrated clinical and genetic network of Rett syndromedatabases. Hum Mutat. 2012 Jul;33(7):1031-
6.
4. Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A, Pollazzon M, Buoni S, Spiga
O, Ricciardi S, Meloni I, Longo I, Mari F, Broccoli V, Zappella M, Renieri A. FOXG1 is responsible for the
congenital variant of Rett syndrome. Am J Hum Genet. 2008 Jul;83(1):89-93.
5. Renieri A, Mari F, Mencarelli MA, Scala E, Ariani F, Longo I, Meloni I, Cevenini G, Pini G, Hayek G, Zappella
M. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain Dev. 2009
Mar;31(3):208-16.
List of relevant previous projects or activities, connected to the subject of this proposal
. “FoxG1 gene therapy using CRISPR/Cas9 technology and AAV9 iPSCs-derived neurons”; Blackswan
Foundation; 2017-2018 - PI: Renieri A. Building on the possibility of obtained and characterized iPSCs from skin
biopsy of Rett patients, we propose a combination of CRiSPR/Cas9 technology with AAV9 system to delete the
FOXG1 mutated gene and replace it with the “healthy”/wild type gene in FOXG1 mutated iPSCs. We plan to
apply this strategy on an ex-vivo model, to prove efficacy and safety of the method.
. “Development of an innovative strategy of personalized medicine for the diagnosis and therapy of kidney
diseases in children”; Tuscany Region; 2016-2018 - PI: Renieri A. We propose an innovative diagnostic strategy,
potentially extending to all pediatric nephropathies, for the diagnosis and therapy of kidney diseases in children.
. “Telethon Network of Genetic Biobanks”; Telethon; 2013-2017 – Unit PI: Renieri A. The goal is to realize the
first national, standardized biospecimen/genetic data Resource, creating a nationally coordinated network of
pathological biospecimens and related data collection as well as normal controls, and developing a centralized
bioinformatics system of rare diseases for improving links between the existing Telethon biobanks as well as for
facilitating Network presentation world−wide and external access to the collections.
64-LUMC
Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name
Leiden University Medical Centre (LUMC), The Netherlands,
(Team A): Human Genetics department / Biosemantics group
Principal investigator Dr. Marco Roos, team A
Relevant Network
Description of the legal entity/department/laboratory/group:
The LUMC is a university medical centre for research, education and patient care with a high-quality profile and a
strong scientific orientation and ranks as the 6th best medical research institute in Europe (Shanghai 2015/2014). It
has a unique research practice, ranging from pure fundamental medical research to applied clinical research. This
enables LUMC to offer patient care and education that is in line with the latest international insights and standards
– and helps it to improve medicine and healthcare both internally and externally. The LUMC participates in the
League of European Research Universities (LERU), a strong international network of 21 renowned research
universities based in 10 European countries (www.leru.org). LUMC’s well-structured and productive research and
training environment annually produces ~115 PhD theses and ~1750 scientific publications. Each year, LUMC
welcomes many visiting scientists and foreign MSc/PhD students, who will also be enrolled in the LUMC Graduate
School (now > 900 PhD-students). Currently, LUMC is active in 54 granted Horizon2020 projects (17 as
coordinator). Thus, LUMC has ample experience with the legal and financial implementation of these projects.
Website: https://www.lumc.nl/research/.
The department of Human Genetics (team A) is a broadly oriented research department with focus on the
(epi)genomic contribution to inherited and acquired diseases. HG has research focus on genome technology,
functional genomics, novel diagnostics, model systems and bioinformatics of human diseases. The department
provided leadership for the human genome project, BBMRI, and Orphanet-NL (professor emeritus dr. GJB van
Ommen, Dr. Petra van Overveld) to which it contributed information for the Netherlands. The BioSemantics group
(PIs Dr. M. Roos, Prof. Dr. B. Mons) focuses on the development and application of the FAIR data principles for
translational research, particularly in the domain of rare diseases, and the automated discovery of new biological
knowledge from FAIR data.
Main tasks in the project per Pillar/WP:
Team A
825575 – EJP RD – Part B 174
Pillar 0: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
In WP1, we will contribute to data management planning of the EJP RD (task 1.4) as per our responsibility as co-
lead of WP12 in Pillar 2.
For WP3, we will contribute to the communication between WP10 Task 1.5 (sustainability and scaling up of the
VP) and WP3.
Pillar 2
In WP10, we will contribute to:
- Coordination of Pillar 2 Work Packages and aligning to RD community needs (task 10.1)
- Convening yearly retreats leading to Pillar 2 annual strategic plans (task 10.2)
- Coordination of technical GDPR implementation (task 10.3)
- Quality oversight (task 10.4)
- Developing sustainable models (task 10.5)
In WP11, we will contribute to the following tasks:
- Metadata and ontological model definition for cataloguing resources for RD research (task 11.1)
- FAIR-compliant platform for discovery of RD resources (task 11.2)
- Provision of analysis and data sharing capabilities to the RD community through online resources (task 11.4)
In WP12, we will contribute to:
- Comparing and aligning core interoperability standards with respect to WP12 [in conjunction with other standards
bodies, & spanning RD patient data, biobanks, registries] (task 12.1)
- Multi-site teams for software and tool development with respect to WP3 (task 12.2)
- leading practical FAIRification support (task 12.3)
LUMC, team A, co-leads WP3.
In WP13 we will contribute to:
- Filling a number of pre-identified gaps to allow integrative systems biology approaches for rare diseases (task
13.1)
- Organising proof of principle studies (task 13.2)
Pillar 3
In WP14, we will contribute to training on rare disease registries and FAIRification of data at the source (task 14.5)
In WP15, we will contribute to the ExPRESS Expert Patients and Researchers EURORDIS Summer School (task
2.1)
Previous experience relevant to the Tasks:
LUMC team A will contribute significantly to the implementation and exploitation of FAIR data principles as core
elements of the Virtual Platform for the RD community via protocols, tools, training, and practical FAIRification
support. LUMC team A is one of the founders of the FAIR data principles and has extensive experience with
developing and applying technologies related to FAIR. It organised the meeting where the principles were first
conceived (Lorentz workshop, Leiden, 2014). It has a track record in activating communities towards better data
and knowledge management (PMID:18507872; PMID:21445068). It previously developed the nanopublication
model as a means to share research findings in a machine-readable format (PMID:26464783; nanopub.org), and
contributed to the development of the research object model to improve reproducibility of analysis (PMID:
25276335; researchobject.org). In recent years LUMC team A software engineers formed the core of the DTL-P led
FAIR engineering team that developed FAIRification protocols and a suite of FAIR data tools to create, publish,
index and annotate FAIR data sources (https://github.com/DTL-FAIRData). LUMC team A was one of the
initiators of OpenPHACTS, an IMI project that served as a milestone project on enabling queries over distributed
linkable data. Over the past 2 years, the Biosemantics group has (co)organized 10+ Bring Your Own Data
workshops: a combination of hackathon and training event to introduce techniques for making data linkable and
FAIR at the source. BYODs and hackathons in the rare disease domain, co-organised between DTL-P, ISS and
LUMC, have contributed significantly to the FAIR guiding principles (PMID:26978244). LUMC team A
successfully submitted the application for these guidelines as an IRDiRC recognized resource with several RD
community representatives also involved with this EJP proposal. Together with UMCG, LUMC team A is leading
the so-called ‘Rare Disease Data Linkage Plan’ that provides a starting point for WP3 in Pillar 2, and some tasks in
WP2 and WP4. The plan helps stakeholders make a rare disease registry or biobank FAIR ‘at the source’ by
temporarily providing FAIR data stewardship expertise to a group that manages RD data and would like to make
those more FAIR. The plan has been supported by RD-Connect, ELIXIR, ELIXIR-EXCELERATE, BBMRI-NL,
and stakeholders (currently it is running pilots with VASCERN, BOND-ERN, and DMD resources). LUMC team
A has a leading role in European-wide efforts to harmonize data and establish FAIR-compliant infrastructure,
particularly for rare diseases. PI Mons was co-lead of the interoperability platform in ELIXIR, was chair of the
high-level expert group for developing the European Open Science Cloud, and is leading the organisation that
825575 – EJP RD – Part B 175
supports starting Global Open FAIR implementation networks. Associated PI Rooswith
is document
co-leading
Ref. the Rare Disease- 28/11/2018
Ares(2018)6091977 Work
package within ELIXIR-EXCELERATE. Together with leaders from the RD-Connect community, such as V.
Bros-Facer from EURORDIS, A. Rath from Orphanet, Y. Rubinstein from NIH, PI Roos initiated the creation of a
rare disease GO FAIR implementation network to foster FAIR in the rare disease community. In addition, LUMC
team A has extensive experience in extracting and structuring knowledge from literature, and developed algorithms
that use structured knowledge for the purpose of finding novel genotype - phenotype relationships, drug targets and
drug repurposing, and multi-omics analysis, for rare and genetic diseases (PMID:26919047, PMID:27524956,
PMID:23356878, PMID:29441734, PMID:27476530). Finally, LUMC team A is also responsible for the Leiden
Open Variation Database software (IRDiRC recognized resources) and Mutalyzer.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
• Resource of gene-disease associations predicted from the literature:
https://datadryad.org//resource/doi:10.5061/dryad.gn219
• FAIR service suite: https://github.com/DTL-FAIRData
• Leiden Open Variation Database: http://www.lovd.nl/
• Mutalyzer sequence variant nomenclature checker: https://mutalyzer.nl/,
https://github.com/mutalyzer/mutalyzer
Short Profile of key Staff Members who will be undertaking the work
Dr. Marc Roos Dr. Marco Roos is group leader of the Biosemantics group of Prof. dr. Barend Mons. His
(male) background is in molecular biological research and computer science. He has expertise in
enhancing biomedical research by interdisciplinary collaboration and methods emerging
from computer science (e-Science), particularly Semantic Web, ontologies, and
computational workflows. He is currently interested in FAIR data stewardship and FAIR
data analytics to enhance translational research in the domain of rare diseases. He co-leads
the rare disease use case in ELIXIR-EXCELERATE, and (together with UMCG) he co-
leads the rare disease data linkage plan to make rare disease registries and biobanks
interoperable, and he chairs the Rare Disease Linked Data and Ontology task force that
originated from RD-Connect. He has initiated a Rare Disease GO FAIR implementation
network towards the implementation of FAIR principles in the rare disease community
Dr.Kristina Hettne Kristina is a senior research scientist in the Biosemantics group at the Human Genetics
(female) department of LUMC. She obtained her PhD in bioinformatics of toxicogenomics from the
University of Maastricht in 2012. She has developed resources and methods for in-silico
knowledge discovery in the biomedical domain and integrated prior knowledge from
literature with statistical pathway analysis methods to analyze and integrate -omics data. She
has contributed to setting standards for providing resources and methods to the research
community in a Findable, Accessible, Interoperable and Re-useable (FAIR) way through the
development and application of Research Objects (standard format for describing an in-
silico experiment), Nanopublications (standard format for stating an assertion), and
scientific research pipelines (workflows), within the EU FP7 project Workflow forever.
Since 2017, she leads the working group on integrating transcriptomics data with proteomics
and metabolomics data in the RD-Connect project.
Dr.Mark Thompson Mark Thompson is a senior research scientist in the Biosemantics group at the Human
(male) Genetics department of LUMC. He obtained a PhD in Computer Science from the
University of Amsterdam in 2012. He has expertise in hardware and software architecture
(co-)design, data management, data modeling, FAIR data infrastructure and computational
aspects of knowledge discovery. He serves as a Linked Data expert and trainer at Bring
Your Own Data (BYOD) events and FAIR Data hackathons. Currently he is developing a
FAIR data stewardship program for the LUMC. He leads local and international pilots
towards the adoption of FAIR principles in a translational research environment.
MSc.Annika Annika Jacobsen studied systems biology engineering at the Technical University of
Jacobsen Denmark. She did her PhD research computational modeling of biological networks at the
(female) Vrije Universiteit Amsterdam in an interdisciplinary setting (planned graduation in 2018).
Apart from technical skills, she has developed her organisational and communicative skills
as active member of the Dutch and international ISCB student council. She is currently the
FAIR data steward for the Rare Disease Data Linkage plan, where she has the central role in
the FAIRification process between registry managers and FAIR data software engineers and
ontology experts.
825575 – EJP RD – Part B 176
MSc.Rajaram Rajaram Kaliyaperumal studied biomedicalAssociated
engineering in IndiaRef.
with document and Linköping University
Ares(2018)6091977 - 28/11/2018
Kaliyaperumal in Sweden. Over the last four years he has worked as scientific software engineer at the
(male) LUMC as part of the FAIR software engineering team, contributing to prototyping and
stabilizing FAIR software services, and recently also as software project lead.
Prof.Barend Mons Barend Mons is Professor in Biosemantics at the Human Genetics department of Leiden
(male) University Medical Center, and leads the international GO FAIR office in the Netherlands.
He is a molecular biologist by training (PhD Leiden University 1986) and spent over 15
years in malaria research. After that he gained experience in computer-assisted knowledge
discovery. Barend has worked as head-of-node of ELIXIR-NL, Integrator Life Sciences at
the Netherlands eScience Center, board member of the Leiden Centre of Data Science, and
director of DTL Projects. In 2014, Barend initiated the FAIR data initiative and in 2015,
Barend Mons was appointed Chair of the European Commission's High Level Expert Group
for the “European Open Science Cloud”, DG Research and Innovation.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Wilkinson MD., Dumontier M., Aalbersberg IjJ., Appleton G., Axton M., Baak A., Blomberg N., Boiten J-
W., Da Silva Santos LB., Bourne PE., Bouwman J., Brookes AJ., Clark T., Crosas M., Dillo I., Dumon O.,
Edmunds S.,Evelo CT., Finkers R., Gonzalez-Beltran A., Gray AJG., Groth P., Goble C., Grethe JS.,
Heringa J., ’t Hoen PA.,Hooft R., Kuhn T., Kok R., Kok J., Lusher SJ., Martone ME., Mons A., Packer
AL., Persson B., Rocca-Serra P.,Roos M., van Schaik R., Sansone S-A., Schultes E., Sengstag T., Slater T.,
Strawn G., Swertz MA., Thompson M.,Van der Lei J., van Mulligen E., Velterop J., Waagmeester A.,
Wittenburg P., Wolstencroft K., Zhao J., Mons B. 2016. The FAIR Guiding Principles for scientific data
management and stewardship. Scientific Data 3:160018.
DOI: 10.1038/sdata.2016.18. (IRDiRC recognized resource)
2. Mark Thompson, Luiz Bonino, Mark D Wilkinson, Rajaram Kaliyaperumal, Kees Burger, Shamanou van
Leeuwen, Annika Jacobsen, Claudio Carta, Erik Schultes, David van Enckevort, Richard Finkers, Mascha
Jansen, Barend Mons, and Marco Roos Overview of a suite of middle-ware services for implementing
FAIR data principles, Proceedings of the 2017 edition of SWAT4HCLS, Rome, December 4-7, 2017
(http://CEUR-WS.org/Vol-2042) http://www.swat4ls.org/wp-content/uploads/2017/12/paper_23.pdf
3. B. Mons, H. Van Haagen, C. Chichester, P.-B. ’t Hoen, J. T. Den Dunnen, G. Van Ommen, E. M. Van
Mulligen, B. Singh, R. Hooft, M. Roos, J. Hammond, B. Kiesel, B. Giardine, J. Velterop, P. Groth, E.
Schultes, and J. T. Den Dunnen, The value of data., Nat. Genet., vol. 43, no. 4, pp. 281–283, 2011.
4. Hettne KM, Thompson M, van Haagen HH, van der Horst E, Kaliyaperumal R, Mina E, Tatum Z, Laros
JF, van Mulligen EM, Schuemie M, Aten E, Li TS, Bruskiewich R, Good BM, Su AI, Kors JA, den
Dunnen J, van Ommen GJ, Roos M, 't Hoen PA, Mons B, Schultes EA. The Implicitome: A Resource for
Rationalizing Gene-Disease Associations. PLoS One. 2016 Feb 26;11(2):e0149621. PMID: 26919047
5. Mastrokolias A, Pool R, Mina E, Hettne KM, van Duijn E, van der Mast RC, van Ommen G, 't Hoen PA,
Prehn C, Adamski J, van Roon-Mom W. Integration of targeted metabolomics and transcriptomics
identifies deregulation of phosphatidylcholinemetabolism in Huntington's disease peripheral blood
samples. Metabolomics.2016;12:137. PMID: 27524956
List of relevant previous projects or activities, connected to the subject of this proposal
ELIXIR-EXCELERATE, H2020-INFRADEV-1-2015-12, 2015-2019, co-lead work package rare disease use
case, contributor to work package interoperability, contributor to ELIXIR Bring Your Own Data workshops,
EXCELERATE helps ELIXIR coordinate and extend national and international data resources to ensure the
delivery of world-leading life-science data services. It supports a pan-European training programme, anchored in
national infrastructures, to increase bioinformatics capacity and competency. It provides efficiencies in
management and operation throughout the infrastructure, which is distributed amongst 17 countries.
Open Data Exchange for all, Data Science program NWO/e-Science Center. Project coordinator and contributor
to core FAIR service software development. The ODEX4all project focuses on the challenges associated with the
ever-growing amount of research data in the life sciences. In Next Generation Sequencing alone the data doubles
every 6-8 months and high-throughput datasets contain up to millions of new associations. Traditional ways of
publishing, retrieving and using these massive data sources are inadequate to provide researchers and computers
access to information in a manner needed for the scientific reasoning process. ODEX4all sets out to generate the
infrastructure for the comprehensive exploitation of available data sets in a continuous machine-mind interaction.
RD-Connect, FP7-HEALTH-2012-INNOVATION-1: contributor to bioinformatics services, registry
interoperability, and rare disease data linkage plan. RD-Connect develops an integrated platform connecting
registries, biobanks and clinical bioinformatics for rare disease research.
The Open Pharmacological Concepts Triple Store, Open PHACTS, grant agreement n° 115191, FP7/2007-2013
825575 – EJP RD – Part B 177
and EFPIA, contributor to nanopublication model and interoperability services.
Associated The Open
with document PHACTS Discovery
Ref. Ares(2018)6091977 - 28/11/2018
Platform has been developed to reduce barriers to drug discovery in industry, academia and for small businesses.
The integrated pharmacological data can be accessed via the Open PHACTS API, the Open PHACTS Explorer
and explorer apps.
BBMRI-NL2.0, Netherlands Organisation for Scientific Research (NWO) National Roadmap Large Research
Facilities program, contribution to development of FAIR and interoperability for biobanks and catalogues.
BBMRI-NL2.0 produces a collaborative hub between biobanks in the Netherlands.
Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name
Leiden University Medical Centre (LUMC), The Netherlands,
(team b): Coordinating Endo-ERN
Principal investigator Prof.dr. Alberto Pereira Arias
Relevant Network Endo-ERN
Description of the legal entity/department/laboratory/group:
See description in the Partner Description Form of team a.
Main tasks in the project per Pillar/WP:
Pillar 2
In WP10, we will contribute in optimising and aligning WP10 and WP11 activities with real-world community
needs (task 10.1), in utilisation of the EuRRECa platform to monitor the utility of these activities amongst the
Endo-ERN members (task 10.2), and in designing and deployment of the QMS (task 10.3). In WP2, we will
provide details to be used to serve the registry needs and to ensure that compatibility of ontological models can be
compared between ERN based registries and this project (task 11.1). We will utilise the EuRRECa platform to
provide metadata and create a catalogue of research projects (task 11.2) and ensure the EuRRECa platform acts as
an effective data deposition facility for core endocrine data including exploration of linkages to other datasets (task
11.3). We will contribute to the improvement of RD phenomics-genomics and multi-omics analysis capabilities
(task 11.4). In WP12, we will be instrumental in providing the EuRRECa platform as a model of a RD registry
which can be operated within a harmonised environment for registries to ensure maximum interoperability (task
12.1) and will ensure that our platform will achieve semantic and syntactic harmonisation of other parallel activities
(task 12.2). We will contribute to the practical FAIRification support process (task 12.3).
Pillar 3
In WP 14 we will participate and teach a course on International Registry Summer School (task 14.5) and provide
training on the European Rare Disease Registry Infrastructure (ERDRI) (task 14.6) through the experience of the
EuRRECa platform and the I-DSD and I-CAH Registries. In WP17, we will lead task 17.1 (development of online
survey) and contribute (task 17.2, 17.3 and 17.4) to the develop and deliver research training programs including
accreditation for the European Reference Networks (ERNs).
Pillar 4
In WP19, Endo-ERN will be surveyed enabling the development of an openly accessible Library of self-help
resources and materials for good RD translational research practice.
In WP20, Endo-ERN is ready to be included by providing specific additional scientific, clinical and methodological
experts for the Task Force Group (TFG) of experts . In Tasks 20.3 and 20.4, Endo-ERN will participate in the
preparation of innovative methodology projects calls.
Previous experience relevant to the Tasks:
Endo-ERN is the largest European Reference Network for Rare Diseases, encompassing the broadest range of rare
endocrine conditions from birth to senescence. Endocrine RDs are highly heterogeneous conditions of variable
origin, but with severe impact on development, well-being and life expectancy, and specific age-related phenotypic
and biochemical profiles. Several endocrine rare conditions have an unknown origin and/or lack therapeutic
options. Endo-ERN is founded on several EU networks and projects that have already in the past contributed to
data infrastructure, -omics strategies, model systems, and innovative therapies. In specific, we will contribute to all
proposed tasks, such as FAIRification processes, the operational management of the NGS-platform (linked to the
overarching registry. Endo-ERN is one of the few ERNs which was successful in securing a CHAFEA grant for the
development of a core registry for rare endocrine conditions (EuRRECa). Furthermore, Endo-ERN is officially
supported by ESE and ESPE, the main pan-European professional and scientific societies which, between them,
825575 – EJP RD – Part B 178
cover people of all ages for all the conditions covered withinAssociated
Endo-ERN. Finally,Ref.
with document Endo-ERN prioritizes
Ares(2018)6091977 the
- 28/11/2018
inclusion of ePAGs, training and capacity building of professionals, patients and support groups.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Short Profile of key Staff Members who will be undertaking the work:
Pr.Alberto Pereira Alberto M. Pereira is professor of medicine, and head of the division of Endocrinology at the
Arias (male) Leiden University Medical Center, the Netherlands. In addition, he is coordinator of the
European Reference Network on Rare Endocrine Conditions (2017-2022), and president of
the European Neuroendocrine Association (2016-2018). His research focusses on the long-
term effects of pituitary tumours and of its treatment, and in specific on the effects of stress
hormones on the central nervous system. He (co)authored more than 250 papers and book
chapters, and supervised 15 PhD students.
Pr. O. Hiort Professor Hiort specialised in Paediatrics and the subspecialities Neonatology, Paediatric
(male) Endocrinology and Diabetes, as well as in Laboratory Medicine. He was appointed as
Professor of Paediatrics in 2001 at the University of Lübeck. He is heading the Division of
Paediatric Endocrinology and Diabetes at the University Hospital of Schleswig-Holstein in
Lübeck. His scientific interest is with the natural history and pathophysiology of complex rare
conditions, namely with disorders of sex development and calcium and phosphate
metabolism.
Pr.F.Ahmed Professor Faisal Ahmed was appointed in 2000 as a consultant at the Royal Hospital for Sick
(male) Children, Yorkhill, Glasgow. In 2012 he was appointed to the Samson Gemmell Chair of
Child Health at the University of Glasgow where he leads the Developmental Endocrinology
Research Group and has published over 230 scientific communications, with a focus on rare
conditions. In addition, he coordinates the long-standing International DSD (I-DSD) Registry
and a new EU CHAFEA project, the European Registries for Rare Endocrine Conditions
(EuRRECa). Professor Ahmed currently serves as the Chair of the Science Committee of the
European Society for Paediatric Endocrinology (ESPE) and leads the e-Health & ICT
Working Group within the European Reference Network for Rare Endocrine Conditions
(Endo-ERN).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Cox K, Bryce J, Jiang J, RodieM, Sinnott R, Alkhawari M, Arlt W, Audi L, Balsamo A, Bertelloni S, Cools M,
Darendeliler F, Drop S, Ellaithi M, Guran T, Hiort O, Holterhus P-M, Hughes I, Krone N, Lisa L, Morel Y, Soder
O, Wieacker P, Ahmed SF. Novel associations in disorders of sex development: findings from the I-DSD Registry.
J Clin Endocrinol Metab. 2014;99:e348-355.
2. Lucas-Herald A, Bertelloni S, Juul A, Bryce J, Jiang J, Rodie M1, Sinnott R, Boroujerdi M, Lindhardt-Johansen
M, Hiort O, Holterhus PM, Cools M, Guaragna-Filho G, Guerra-Junior G, Weintrob N, Hannema S, Drop S,
Guran T, Darendeliler F, Nordenstrom A, Hughes IA, Acerini C, Tadokoro-Cuccaro R, Ahmed SF. The long term
outcome of boys with partial androgen insensitivity syndrome and androgen receptor gene mutations. J Clin
Endocrinol Metab. 2016 Nov;101(11):3959-3967.
3. Doehnert U, Bertelloni S, Werner R, Dati E, Hiort O. Characteristic features of reproductive hormone profiles in
late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 2015;9(2):69-74. doi:
10.1159/000371464. Epub 2015 Jan 20.
4. Bas-Hoogendam JM, Andela CD, van der Werff SJA, Pannekoek JN, van Steenbergen H, Meijer OC, van
Buchem MA, Rombouts SA, van Mast RC, Biermasz NR, van der Wee NJ, Pereira AM. Altered neural
processing of emotional faces in remitted Cushing's disease. Psychoneuroendocrinology 2015;59:134-46
5. Andela CD, Repping-Wuts H, Stikkelbroeck NMML, Pronk MC, Tiemensma J, Hermus AR, Kaptein AA,
Pereira AM, Kamminga NGA, Biermasz NR. Enhanced self-efficacy after a self-management programme in
pituitary disease: a randomized controlled trial. Eur J Endocrinol. 2017 Jul;177(1):59-72. doi: 10.1530/EJE-16-
1015.
List of relevant previous projects or activities, connected to the subject of this proposal
. Endo-ERN; EU/CHAFEA, 2017-2022, Coordinator (LUMC), European Reference Network on Rare Endocrine
Conditions, grant agreement nr. 739527 / 769031
. CEF Telecom: EU/INEA, 2018-2019, Coordinator (LUMC), Operational Helpdesk for Endo-ERN to ensure
structured and tailored Use of Collaborative Platform and CPMS
. EuRRECa: EU/CHAFEA, 2018-2021, Coordinator (UoG), European Registries For Rare Endocrine Conditions,
grant agreement nr. 777215
825575 – EJP RD – Part B 179
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
. DSDnet: EU-H2020, COST Action, Coordinator (UzL/USKH), Systematic elucidation of Differences of Sex
Development
65-Raboudumc
Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands
Principal investigator Nicoline Hoogerbrugge
Relevant Network ERN GENTURIS
Description of the legal entity/department/laboratory/group:
Radboud University Medical Center (Radboudumc) is a leading academic center with expertise in medical science
and healthcare. Expertise plays an essential part in our organization and connects research, education and patient
care. Our more than 8,500 staff and 3,000 students are committed and ambitious, helping to shape the future of
healthcare and medical science.
Team (a): The department of Human Genetics is one of its largest departments, employing 300+ staff (including
clinicians, diagnosticians, and scientific researchers), treating over 5,000 patients annually. The department of
Human Genetics is nationally and internationally acknowledged for the implementation of genomic medicine, at
the levels of patient care, genetic diagnostics and research, using expert knowledge and innovation to reach this
goal. With this mission, the department of Human Genetics is recognized as one of the centers of expertise for rare
Diseases in the Netherlands and Europe.
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10 we will participate in Task 10.1: regular retreats with ERNs
Pillar 3:
In WP16 (Online Education Course), we will participate in:
Task 16.1.: Assess the needs, target audience, main topics of the academic education course (Inst. Curie)
Task 16.2.2.: Developing the online course Diagnostic of rare diseases (Inst. Curie).
In WP17, we will contribute to:
Task 17.1.: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem
Task 17.2.: Development of training programs for the ERN training networks based on the results of survey
Task 17.3.: Deliver training programs through the ERN training networks
Task 17.4.: Accreditation by universities (Radboudumc, KI, CMFT)
Previous experience relevant to the Tasks:
N. Hoogerbrugge is coordinator of ERN GENTURIS and initiator and chair of national and international teaching
programs, such as the Dutch Up-to-date in hereditary cancer thematic days
(http://www.vkgn.org/files/190/2017Up-to-date%20LYnch%20syndroom.pdf) and the Spring Course in
Hereditary Cancer Genetics in Bertinoro, Italy (http://www.ceub.it/default.asp?id_c=772&id=436#.WqlNY6-
ouHs).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The Radboud Health Academy is specifically equipped to develop and organise training programs.
Short Profile of key Staff Members who will be undertaking the work
Prof.dr. Nicoline Hoogerbrugge (female) is currently full professor hereditary cancer and head of the
multidisciplinary expert center in hereditary cancer RadboudUMC. She has initiated and conducted many research
projects on innovation of care and on genetic predisposition of cancer. She has published more than 250 peer-
reviewed manuscripts. She is coordinator of the European Reference Network on Genetic Tumour Risk Syndromes
(ERN GENTURIS).
825575 – EJP RD – Part B 180
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands
Principal investigator Wout Feitz
Relevant Network ERN eUROGEN
Description of the legal entity/department/laboratory/group:
Team (b) Department of Urology
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10 we will participate inTask 10.1: regular retreats with ERNs
Previous experience relevant to the Tasks:
Prof. Wout Feiz is the coordinator of ERN eUROGEN for rare and complex urogenital diseases and conditions.
eUROGEN aims to improve diagnosis, create more equitable access to high-quality treatment and care for
patients with rare urogenital diseases and complex conditions needing highly specialised surgery.
Short Profile of key Staff Members who will be undertaking the work
Prof.dr. Wout Feitz (male) works as a pediatric urologist at Radboudumc (including Amalia children’s Hospital)
which is one of the 8 University Hospitals in The Netherlands and has been involved in more than 200 scientific
publication and mentored students, PHD’s, post docs and Fellows for paediatric urology. Radboudumc Pediatric
urology care and research has been recognized by the ministry of Health as an expertise center for congenital
urogenital anomalies. He participates in the Radboudumc Urology Research Laboratory (Heads Prof. J. Schalken
and Dr. E. Oosterwijk) which is one of the leading urological research laboratories in Europe and is the coordinator
for the Radboudumc Research Theme Reconstructive and Regenerative Medicine (13 departments). He has
coordinated FP6 Integrated project EuroSTEC with 15 European partners including 5 SME’s, a Marie Curie
program and EU funded regional urology directed research collaborations (7 partners including 5 SME). He is a
member of the EUMS/JCPU Board for the fellowship programs in paediatric urology and a member of the EAU
Scientific Congress Office for Paediatric Urology. He is the director of the EUMS/JCPU fellowship program for
Pediatric Urology, coordinator for the EBU-EAU Host Center for Pediatric Urology, Radboudumc health care
representative in the Strategic Board of the ERN eUROGEN (11 EU countries with 29 HCP partners), Member of
the operational board of eUROGEN, Workstream 1 coordinator for the disease areas for rare congenital uro-recto-
genital anomalies (23 HCP partners).
Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands
Principal investigator Leo Schultze Kool
Relevant Network ERN VASCERN
Description of the legal entity/department/laboratory/group:
Team (c) Department of Radiology and Nuclear Medicine: The group of Schultze Kool at the Radboudumc is a
mutlidisciplinairy team composed of 12 different disciplines focussed on the treatment of vasculair malformations
in adults and children. On a yearly basis approx 5000 patients are seen and treated. The HCP is part of the ERN
vascern which covers mulitsystemic vasculair diseases like rendu osler weber, lymfatic diseases HTAD and MSA.
The group has a close collaboration with the patient organizations for the development of patient centered and
patient controlled health systems. In collaboration with the biosemantic group in Leiden a FAIR based patient
signal bank has recently been developed. A pilot for a FAIR based registry among the vasculair malformations
centers in europe is in progress.
The group is closely related to the DTL and the bioinformatics group of the Radboudumc with focus on
interoperability and federated data management
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10, we will participate in:
Task 10.1.1: 5 x pan-RD community, 3 days strategy meetings
Task 10.1: regular retreats with ERNs
825575 – EJP RD – Part B 181
Task 10.2.2: Survey and structured interview approaches on technical and scientific
Associated matters
with document Ref. Ares(2018)6091977 - 28/11/2018
In WP11, we will participate in:
Task 11.1.1: Defíne metadata model compatible with existing key databases and resources
Task 11.2.1: Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to
represent all key databases and resources
In WP12, we will participate in:
Task 12.3.3: FAlRification service for data from Pillar 1 studies, from Pillar 2-WP10 activities, and prioritized EU
data sources
Radboud umc will actively participate in the above mentioned WP with our partners in the Radboudumc (‘t Hoen)
and the biosementics (Roos) group in Leiden. The work will be building on already existing partnerships. Joint
datastewards will ensure that an optimal collaboration effort is obtained.
Previous experience relevant to the Tasks:
Schultze Kool is part of the FAIR group of the Radboud umc, chair of the registry WG of VASCERN and co
chair of the vasculair malformations WG. He developed several new innovative treatments (2 patents), was co
director of the digital research group of the university of leiden (1986-1993) and is the chair of the Biodatabank
congenital anomalies.
He has recently been proposed as a boardmember of the steering committee Research data management of the
Radboud University.
Short Profile of key Staff Members who will be undertaking the work
Prof.dr. Leo J Schultze Kool (male) is a full professor of Interventional Radiology of the Radboud University
Medical Center. Before he was head of the radiology department of the Dutch Cancer Institute in Amsterdam. His
main topic is the further development of main innovative treatments for patients with vasculair malformations and
further development of personalized care for these groups.
Interests are the development of FAIR based registries, linking with FAIR based biodatabanks and EHR to allow
datamining.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
A FAIR compliant registry for the vascular malformation centres within the European Reference Networks.
How it was done. Author(s): Leo Schultze Kool, Alan IRVINE, Päivi Salminen, Nader Ghaffarpour, Andrea
Diociaiuti, Jochen Rössler, C.T. van den Bosch, Eulalia Baselga, Anne Dompmartin, Laurence Boon, Miikka
Vikkula, Luiz Bonino, Mark Thompson, Annika Jacobsen, David van Enckevort and Marco Roos. ISSVA meeting
2018
Enrichment of rare disease patient registries by FAIRification. Authors: Annika Jacobsen, Mark Thompson,
Erik A. Schultes, Ronald Cornet, Mark Wilkinson, Rachel Thompson, Marina Mordenti, Luca Sangiorgi, Claudio
Carta, Karlijn Groenen, Martijn Kersloot, Leo Schultze Kool, David van Enckevort, Marco Roos. ECRD meeting
2018
Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands
Principal investigator Peter-Bram ‘t Hoen
Relevant Network DTL / ELIXIR / Solve-RD / RD-Connect / EATRIS / EURO-
NMD
Description of the legal entity/department/laboratory/group:
Team (d) Centre for Molecular and Biomolecular Informatics: The group of ‘t Hoen focuses on the identification
of diagnostic, prognostic and therapeutic biomarkers from multi-omics profiles through innovative data integration
methods. They are implementing and further developing FAIR data stewardship approaches to increase reusability
of data and tools.
Radboudumc is a member of the Dutch Techcentre for the Life Sciences (DTL, the Dutch ELIXIR node) and
actively contributes to DTL services on FAIR data infrastructures, stewardship and training.
Main tasks in the project per Pillar/WP:
825575 – EJP RD – Part B 182
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Pillar 2:
In WP10, we will participate in:
Task 1.1.: regular retreats with ERNs
In WP11 we will participate in:
Task 11.4.1.: Provide RD phenotype-genotype analysis and data sharing capabilities through the RD-Connect
platform for molecular diagnostics and gene discovery
Task 11.4.4.: User-driven implementation of new analysis functionalities and tools
We will be collecting and modeling experimental metadata for RD studies and contribute to method development
for knowledge discovery through integration of FAIR data resources relevant to the RD field.
In WP12, we will participate in:
Task 12.2.4.: Consent and data use management, plus automated access control
Task 12.3.3.: FAIRification service for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU
data sources.
We will co-develop federated architectures and systems recording patient consent and enabling the use of patient-
related data in a privacy-protective manner.
In WP13, we will contribute to the development of integrative systems biology approaches for rare diseases, we fill
a number of pre-identified gaps, allowing linkage of external FAIR data sources, and discovering environmental
factors influencing disease (task 13.1), and lead task 13.2 to organize proof-of-concept studies around these gaps.
Previous experience relevant to the Tasks:
Developing new methods for interpreting -omics information in the context of health and disease is the core
activity of the group. In the context of RD-Connect, we have developed workflows for mapping and integration
of multi-level -omics data and applied these to the study of rare neuromuscular, neurodevelopmental disorders
and thalassemias. I emphasise data interoperability to facilitate data integration and professional software
engineering, as to make my research and data optimally useful for the community, and are actively contributing
to the principles and metrics for FAIR data management. I am actively contributing to the Personal Health Train,
an infrastructure that facilitates health data exchange, is fully based on FAIR data architecture and empowers
patients / citizens to be in control of their data. In the context of the Personal Health Train and a BBMRI-funded
project, we developed a prototype for a machine readable consent systems that is based on FAIR data architecture
and is a way for patients to provide dynamic consent to the use of their data by researchers and/or health care
providers.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Digital Research Environment, FAIR data infrastructure, Personal Health Train
Short Profile of key Staff Members who will be undertaking the work
Prof.dr. Peter-Bram ’t Hoen (male) started in February 2018 as full professor in bioinformatics at Radboudumc
(Centre for Molecular and Biomolecular Informatics). Before that, he was postdoc, assistant and associate professor
in the Human Genetics department at Leiden University Medical Center. His group studied the aetiology of rare
muscular dystrophies using state-of-the-art molecular technologies. He was among the first researchers in the
Netherlands to implement microarray and (novel) RNA-sequencing technologies, and organized many
(inter)national courses on these topics. With these new technologies, he identified major players and mechanisms in
the transcriptional and post-transcriptional regulation of gene expression in health and disease. His main drive is to
optimally analyze and interpret large -omics data sets to facilitate diagnosis, patient stratification and personalized
medicine approaches.. In their interpretation, he typically goes beyond standard (pathway) analysis methods and
develops and employs automated knowledge discovery approaches and new statistical routines. This resulted in the
prediction and validation of novel biomarkers, novel protein:protein interactions, and new candidate drugs. ‘t Hoen
is member of the International Rare Diseases Research Consortium (IRDiRC ) taskforce on data mining and drug
repurposing, board member of the research working group European Reference Network on neuromuscular
diseases (EURO-NMD) and management team member of the Personal Health Train consortium, developing a data
infrastructure to advance healthcare and biomedical science through interoperable and federated data management.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
825575 – EJP RD – Part B 183
1. Daria V. Zhernakova, Patrick Deelen, Martijn Vermaat, Maarten vanwith
Associated Iterson, Michiel
document van Galen, Wibowo
Ref. Ares(2018)6091977 - 28/11/2018
Arindrarto, Peter van 't Hof, Hailiang Mei, Freerk van Dijk, Harm-Jan Westra, Marc Jan Bonder, Jeroen van Rooij,
Marijn Verkerk, P. Mila Jhamai, Matthijs Moed, Szymon M. Kielbasa, Jan Bot, Irene Nooren, René Pool, Jenny
van Dongen, Jouke J. Hottenga, Coen D.A. Stehouwer, Carla J.H. van der Kallen, Casper G. Schalkwijk,
Alexandra Zhernakova, Yang Li, Ettje F. Tigchelaar, Niek de Klein, Marian Beekman, Joris Deelen, Diana van
Heemst, Leonard H. van den Berg, Albert Hofman, André G. Uitterlinden, Marleen M.J. van Greevenbroek, Jan H.
Veldink, Dorret I. Boomsma, Cornelia M. van Duijn, Cisca Wijmenga, P. Eline Slagboom, Morris A. Swertz,
Aaron Isaacs, Joyce B.J. van Meurs, Rick Jansen, Bastiaan T. Heijmans*, Peter A.C. ’t Hoen*, Lude
Franke*. * shared last author. Identification of context-dependent expression quantitative trait loci in whole blood.
Nature Genetics 49:139-145 (2017) IF:31.6
2. Kristina M. Hettne, Mark Thompson , Herman H. H. B. M. van Haagen,Eelke van der Horst,Rajaram
Kaliyaperumal, Eleni Mina, Zuotian Tatum, Jeroen F. J. Laros, Erik M. van Mulligen, Martijn Schuemie,
Emmelien Aten, Tong Shu Li, Richard Bruskiewich,Benjamin M. Good, Andrew I. Su, Jan A. Kors, Johan den
Dunnen, Gert-Jan B. van Ommen, Marco Roos, Peter A.C. ‘t Hoen, Barend Mons, Erik A. Schultes
The Implicitome: A Resource for Rationalizing Gene-Disease Associations
PLoS One 11:e0149621 (2016) IF: 3.057
3. F. Cynthia Martin, Monika Hiller, Pietro Spitali, Stijn Oonk, Hans Dalebout, Magnus Palmblad, Amina
Chaouch, Michela Guglieri, Volker Straub, Hanns Lochmüller, Erik H. Niks, Jan J.G.M.Verschuuren, Annemieke
Aartsma-Rus, André M. Deelder, Yuri E.M. van der Burgt, Peter A.C. ’t Hoen
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
Proteomics 8:269-78 (2013) IF: 4.079
4. Harish Dharuri, Peter Henneman, Ayse Demirkan, Jan Bert van Klinken, Dennis Owen Mook-Kanamori, Rui
Wang-Sattler, Christian Gieger, Jerzy Adamski, Kristina Hettne, Marco Roos, Karsten Suhre, Cornelia M. Van
Duijn, EUROSPAN consortia, Ko Willems van Dijk, Peter A.C. ’t Hoen
Automated workflow-based exploitation of pathway databases provides new insights into genetic associations of
metabolite profiles.
BMC Genomics 14:865 (2013) IF: 3.867
5. Peter A.C. ’t Hoen, Marc R. Friedländer, Jonas Almlöf, Michael Sammeth, Irina Pulyakhina, Seyed Yahya
Anvar, Jeroen F.J. Laros, Henk P.J. Buermans, Olof Karlberg, Mathias Brännvall, The GEUVADIS Consortium,
Johan T. den Dunnen, Gert-Jan B. van Ommen, Ivo G. Gut, Roderic Guigó, Xavier Estivill, Ann-Christine
Syvänen, Emmanouil T. Dermitzakis, Tuuli Lappalainen. Reproducible mRNA and small RNA sequencing across
laboratories. Nature Biotechnol 31:1015-22 (2013) IF 32.4
List of relevant previous projects or activities, connected to the subject of this proposal :
. RD-Connect, EU-FP7, 2012-2018,
. BIO-NMD, EU-FP7, 2013-2015, identification of biomarkers for neuromuscular disorders, workpackage leader
66-AMC
Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team a)
Principal investigator Arthur A.M. Wilde
Relevant Network ERN GUARD-Heart
Description of the legal entity/department/laboratory/group:
In 1996, the Cardiogenetics team of the AMC was one of the first worldwide to start a specialized cardiogenetic
outpatient clinic where cardiologists, clinical genetic counsellors, and molecular geneticists act synergistically. Our
Cardiogenetics team aims to identify the diagnosis and to provide timely often presymptomatic treatment to the
carriers of pathogenic mutations. These carriers are, for the greater part, followed, supported, and treated in our
outpatient clinic, according to state-of-the-art methods. At the same time, specific molecular-genetic expertise has
been deployed to determine whether gene variants thus found can be regarded as the disease-causing gene defects.
This knowledge and expertise is extremely important in the light of the great technological advances in DNA
testing in recent years. With the advent of NGS techniques (e.g., whole-exome sequencing), the number of DNA
variants to be found, both disease-causing mutations and rare variants of unknown significance in known and
825575 – EJP RD – Part B 184
unknown genes, increased drastically. We anticipate, that with the enormous
Associated amountRef.
with document of Ares(2018)6091977
molecular-genetic data,
- 28/11/2018
intensive collaboration between cardiologists, genetic counsellors, and (molecular) geneticists who combine
research and patient care in specialized cardiogenetics centres and share their knowledge in international databases
will become even more important. In addition, the Cardiogenetics team of the AMC has a strong national and
international position in clinical research. A biobank has been implemented. Since 2004, patients with a familial
heart disease are included in a national (GENCOR) database.
Main tasks in the project per Pillar/WP:
Pillar 2: In WP11, we will participate in the process of optimising and align the activities of EJP with real-world
community needs by taking active part in annual strategy meetings with other stakeholders in the rare disease
community and discuss the management of the next-generation data ecosystem strategic plan) and the setup of a
common platform for discoverable data and resources for rare diseases research (Pillar 2 WP11)). In WP10, we will
also provide experts to assist in monitoring and coordination of the progress and the usefulness of the activities of
Pillar 2 WP10.
Previous experience relevant to the Tasks:
The Cardiogenetics team of the AMC consists of a dedicated group of cardiologists, clinical geneticists,
counsellors, a psycho-social worker and molecular geneticists with expertise in the management of patients with
rare and low prevalence diseases of the heart. Since 1996, members of our Cardiogenetics team work together to
diagnose and treat patients with familial electrical diseases and familial cardiomyopathies. This design has allowed
us to adopt a candidate-gene approach to find the familial-disease gene variant, often driven by specific knowledge
about familial electrical diseases and familial cardiomyopathies. The yearly number of counselees increased to
reach ~1100 in the last few years. In addition, our team has established a strong position in basic, clinical and
translational research and has participated in many national and international research projects, databases and
patient registries. In addition, since March 2017, AMC coordinates the activities of the European Reference
Network for rare diseases of the heart (ERN GUARD-Heart). It is for these reasons that our Cardiogenetics team is
an ideal partner for the EJP to optimise and align Pillar WP 1 and WP2 activities with real-world community needs
(which are very well identified by our team members), and to assist in monitoring and the usefulness of WP1 and
WP2 activities, according to the needs and the requirements of the rare disease community.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The Cardiogenetics team of the AMC consists of 7 (paediatric) cardiologists, 6 clinical geneticists / genetic
counsellors, a psycho-social worker and 3 molecular geneticists, all of them being specialized in the management
of patients with rare and genetic heart diseases. The team members work together in multidisciplinary teams
according to a strategic work plan, in which the tasks and responsibilities of each team member are well described.
The care is provided according to national and international guidelines and patient pathways with the use of
specialised and state-of-the-art equipment, infrastructure, and information technology. The team discusses patients
who suffer from high complex rare conditions within the ERN GUARD-Heart using the Clinical Patient
Management System (CPMS).
Short Profile of key Staff Members who will be undertaking the work
Prof. Dr. Arthur A.M. Wilde is a cardiologist-electrophysiologist and head of the Department of Clinical
Arthur A.M. and Experimental Cardiology at the AMC, Amsterdam, the Netherlands. He is the Coordinator of
Wilde, MD, the European Reference Network for rare and complex diseases of the heart (ERN GUARD-
PhD, Male Heart). He is a member of the Dutch Academy of Science. His research interest includes the
genetic basis of cardiac arrhythmias, ranging from the monogenetic diseases to more broader
healthcare problems as sudden cardiac death in the setting of ischemic heart disease. Recent
studies centre on genotype-phenotype relationships in these disorders and the role of clinical and
genetic modifiers in establishing the phenotype.
Dr. Ahmad S. Ahmad Amin is a cardiologist at AMC, Amsterdam, the Netherlands. He is project manager of the
Amin, MD, ERN GUARD-Heart. His research interest includes the genetic basis of familial electrical diseases
PhD, Male and familial cardiomyopathies. In his recent studies, he investigates the role of genetic and
clinical modifies on the phenotype in order to explain phenotypic variability in patients with these
orders (even in families affected with the same pathogenic ‘familial’ mutation).
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Priori SG,* Wilde AA,* et al. Heart Rhythm. 2013;10:1932-63.
2. Ackerman MJ, …, Wilde AA, et al. Heart Rhythm. 2011;8:1308-1339.
3. Postema PG, Wolpert C, Amin AS, …, Wilde AA. Heart Rhythm. 2009;61335-1341.
4. Hofman N, …, Wilde AA. Circulation. 2013;128:1513-1521.
5. Amin AS, …, Wilde AA, et al. European Heart Journal. 2012;33:714-723.
825575 – EJP RD – Part B 185
List of relevant previous projects or activities, connected to theAssociated
subject with
of this proposal
document Ref. Ares(2018)6091977 - 28/11/2018
. ERN GUARD-Heart; European Union; 2017-2022 - Network coordinator (Wilde), European Reference Network
for rare and complex diseases of the heart.
. Improve CPVT; European Union (ERA-Net E-Rare); 2016-2020 - Project Coordinator (Wilde), improving
diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia: integrating clinical and basic
science.
. PREDICT; Dutch Heart Foundation; 2013-2018 - Principal Investigator (Wilde), predicting sudden cardiac death.
. Netherlands Organisation for health Research and Development; 2012-2016 - Principal Investigator (Wilde),
preventing arrhythmias & sudden cardiac death in LQTS3 through pharmacological late sodium current inhibition.
. Dutch Heart Foundation; 2014-2017- Principal Investigator (Amin), variants in the 3'UTR modify disease severity
in inherited cardiac diseases by altering microRNA binding.
Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team b)
Principal investigator Ronald Cornet
Relevant Network
Description of the legal entity/department/laboratory/group:
The Department of Medical Informatics at the Academic Medical Centre (AMC) in Amsterdam is one of the
leading Medical Informatics departments in the Netherlands and Europe. It is one of the few groups that provides
Medical Informatics training and research at BSc, MSc and PhD level, as well as MSc-level Health Informatics
training for healthcare professionals. These training programs deliver a continuous stream of young academics and
provide a fertile ground for collaboration with clinical partners.
The department has a strong track record in research on standardization of healthcare information, combining a
demand-driven perspective with strong theoretical foundation. Research encompasses application of description
logic, semantic modelling using information models and ontologies, structured data capture, and use of structured
data.
The department is based in the AMC, one of the major health and care research institutions in the Netherlands, and
one of its largest hospitals. Over 7,000 people work here to provide integrated patient care, fundamental and
clinical scientific research, and teaching.
Main tasks in the project per Pillar/WP:
Pillar 2: In WP11, we will contribute to the metadata and ontological model definition for cataloguing resources
for RD research. Our focus in this will be on the clinical resources.
In WP12, we will lead subtasks on FAIRification of data. These tasks consist of a) development and application of
methods for semantic and syntactic harmonisation of data records, and b) a coordinated effort to define strategies to
move towards generating data that is FAIR from the start, rather than post-hoc FAIRification. These tasks will be
led using the experience gained in the subtasks in which interoperability standards are compared and aligned.
Pillar 3: In WP14, we will contribute to the training on rare disease registries and FAIRification of data at the
source. In the last years, we have successfully contributed to this course, which has consisted of a summer school
and a hands-on tutorial.
Previous experience relevant to the Tasks:
The department of Medical Informatics of the AMC has previously been involved in standardization and
harmonization efforts in various domains, including intensive care, nephrology, anaesthesiology, oncology, and
HIV/AIDS-care. The department has been involved in various national efforts towards standardized and structured
data capture, predominantly the introduction of SNOMED CT in the Netherlands, and raising awareness of the
importance of point-of-care clinical data capture.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
The department has a variety of semantic resources in place, as well as knowledge, skills and permission to access
even more resources. Furthermore, the department has a broad network, via active or past involvement in national,
international and global data harmonisation efforts.
Short Profile of key Staff Members who will be undertaking the work
Dr. Ronald Ronald Cornet holds a position as associate professor at the department of Medical Informatics in
Cornet, PhD, the Amsterdam Public Health research institute, Academic Medical Center - University of
Male Amsterdam. His research focuses on semantic interoperability, both from a technical perspective
and from a users' point of view, including natural language processing. This research has resulted
in over 40 journal publications and over 70 peer-reviewed conference proceedings.
Ronald is involved in the Modelling Advisory Group of SNOMED International, the organisation
that is responsible for maintenance and further development of SNOMED CT. He chairs the IMIA
825575 – EJP RD – Part B 186
working group on Language and Meaning in Biomedicine.
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Zini EM, Lanzola G, Quaglini S, Cornet R. Standardization of immunotherapy adverse events in patient
information leaflets and development of an interface terminology for outpatients' monitoring. J BIOMED
INFORM 2018;77:133-144
2. Burger G, Abu-Hanna A, de Keizer N, Cornet R. Natural language processing in pathology: a scoping
review. J CLIN PATHOL 2016;69 (11):949-955
3. Dentler K, Cornet R. Intra-axiom redundancies in SNOMED CT. ARTIF INTELL MED 2015;65 (1):29-34
4. Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. J AM MED INFORM ASSN
2014;21 (E1):E11-E19
5. Geller J, Perl Y, Halper M, Cornet R. Special issue on auditing of terminologies. J BIOMED INFORM
2009;42 (3):407-411
List of relevant previous projects or activities, connected to the subject of this proposal
• International Summer School on Rare Disease and Orphan Drug Registries, organized by the Italian
National Centre for Rare Diseases (CNMR) in collaboration with Services and Centre for International
Affairs (ISS), RD-Connect, Elixir, RD-Action, EURORDIS and endorsed by ICORD; 2016-2017 - faculty
• ASSESS-CT - Assessing SNOMED CT for Large Scale eHealth Deployments in the EU; European Union;
2015-2016; participant.
• SemanticHealthNet; European Union; 2013-2014; Advisory board member.
• NephroQUEST Initiative; European Union; 2007-2010; Workpackage leader
67-Erasmus MC
Full legal name (Acronym) – Country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC),
The Netherlands (Team a)
Principal investigator Prof. dr. I.M.J. Mathijssen
Relevant Network ERN CRANIO
Description of the legal entity/department/laboratory/group:
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department of Plastic and Reconstructive Surgery
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP10, we will work on 5x pan-RD-community, 3-day strategy meetings (annual retreat) (task 10.1.1)
In WP10, we will work on Survey and structured interview approaches on technical and scientific matters, to
monitor progress and inform strategic decisions (incl. Definition of indicators) (task 10.2.2)
Previous experience relevant to the Tasks:
I am leading the craniofacial team of the Erasmus MC and involved in care, research and training regarding
craniofacial anomalies. As secretary-treasurer of the International Society of Craniofacial Surgery I have a large
network within the field.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
We have all the medical specialties and all relevant equipment for this project, ranging from a electronic patient
file, data bases for research, multidisciplinary teams for providing care, educational programs for all care providers,
close interaction with the patient society, training programs for fellows from all over the world.
Short Profile of key Staff Members who will be undertaking the work
Pr. Irene M.J. MBA-Health,Head of department of Plastic and Reconstructive Surgery, and Hand Surgery
Mathijssen Erasmus MC, Rotterdam
(female)
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Cornelissen MJ, Softeland M, Apon I, Ladfors L, Mathijssen IMJ, Cohen-Overbeek TE, Bonsel GJ, Kolby L
Perinatal complications in patients with unisutural craniosynostosis: An international multicentre retrospective
cohort study. J Craniomaxilofac Surg 45: 1809-14, 2017
2. . Van Veelen MLC, Kamst N, Touw C, Mauff K, Versnel S, Dammers R, De Jong THR, Prasad V, Mathijssen
IM. Minimally invasive, spring-assisted correction of sagittal suture synostosis. Technique, outcome and
825575 – EJP RD – Part B 187
complications in 83 cases. Plast Reconstr Surg 141: 423-33, 2018 Associated with document Ref. Ares(2018)6091977 - 28/11/2018
3. Miller KA, Twigg SR, McGowan SJ, Phipps JM, Fenwick AL, Johnson D, Wall SA, Noons P, Rees KE, Tidey
EA, Craft J, Taylor J, Taylor JC, Goos JA, Swagemakers SM, Mathijssen IM, van der Spek PJ, Lord H, Lester T,
Abid N, Cilliers D, Hurst JA, Morton JE, Sweeney E, Weber A, Wilson LC, Wilkie AO. Diagnostic value of
exome and whole genome sequencing in craniosynostosis. J Med Genet. 54: 260-8, 2017.
4. Spruijt B, Mathijssen IM, Bredeo-Boelhouwer HH, Cherian PJ, Corel LJ, Van Veelen ML, Hayward RD, Tasker
RC, Joosten KF. Sleep architecture linked to airway obstruction and intracranial hypertension in children with
syndromic craniosynostosis. Plast Reconstr Surg 138: 1019e-1029e, 2016.
5. Mathijssen IM. Guideline for care of patients with the diagnoses of craniosynostosis: Working group on
craniosynostosis. J Craniofac Surg 26: 1735-1807, 2015.
List of relevant previous projects or activities, connected to the subject of this proposal:
OCT; Stichting Lijf en Leven; 2017-2020, the use of OCT for detection of raised intracranial pressure in
craniosynostosis
CRISPR-CAS; Dalijn Stichting; 2014-2017, repair of craniosynostosis genetic defects
BRAIN; JANIVO stichting; 2016-2019, study into brain anomalies in congenital craniofacial defects
Ultra; Nuts Ohra Foundation; 2013-2017, prenatal and perinatal findings in craniosynostosis
68-SERMAS
Full legal name (Acronym) – Country SERVICIO MADRILEÑO DE SALUD-HOSPITAL
UNIVERSITARIO LA PAZ (SERMAS) - Spain
Principal investigator Eduardo López Granados
Relevant Network ERN TransplantChild
Description of the legal entity/department/laboratory/group:
TransplantChild is the only ERN focused on a highly complex procedure: Pediatric Transplantation, both solid
organ (SOT) and hematopoietic stem cell transplantation (HSCT).
Transplantation is yet the only curative option for many paediatric rare diseases that compromise organ anatomy
and function, or hematopoietic and immunological capacity and control. Transplanted patients overcome their
severe primary disease, but acquire a life-long medical condition, that yet fulfills many characteristics of RD as low
prevalence, and favors the appearance of transplant-related rare diseases (e.g. graft versus host disease) and
complications (e.g. rejection, opportunistic infections). Many of these complications share a common pathogenic
root, the immunosuppressed status of the transplanted individual, appear in all type of transplants, or even
aggravate when several organs or SOT and HSCT are accomplished. Immune-mediated conditions present
challenges because of their complexity and variety; however, they also provide research opportunities as biomarker
discovery and novel therapeutics.
Current transplantation outcomes in children, in terms of quality of life, morbidity and mortality can be improved.
This requires better clinical management of associated complications by implementation of prognostic and
diagnostic tools, for a precise and patient-centered monitoring of the transplantation process based on novel -omics
and the development of innovative preventive and therapeutic procedures at all stages of transplant. The
identification of patients likely to respond to novel procedures, as operational tolerance induction, would be
important both in terms of health, and in terms of cost‐effectiveness.
Innovative efforts are particularly challenging in paediatric transplantation, and requires dedicated coordinated
efforts across pediatric-experienced institutions to overcome major challenges that are shared with others areas of
research in RD: 1) existing fragmentation of efforts, data and resources in single organ-oriented efforts; 2)
difficulties to re-use results of funded research; 3) the need for optimization of tools and resources that already
exists and that can be adapted from their original design for primary disease diagnosis to the transplantation-related
complications.
Main tasks in the project per Pillar/WP:
Pillar 0:
WP1: Coordination and management
Support of the ERN TransplantChild in the tasks.
Pillar 2:
WP 10: User-driven strategic planning and transversal activities
Attending, participating and making decisions on the strategy at the annual retreats.
Also depending on the strategic decisions, TransplantChild may be connected to the virtual platform and also may
conduct POCs in WP13 depending on the POCs prioritised.
Pillar 3:
825575 – EJP RD – Part B 188
WP 16: On line education course: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Task 16.1 "Assess the needs, target audience, main topics of the academic education course”. This task will be
performed through a thorough benchmark of existing RD academic courses at EU level and through survey and
audits of potential target audiences and experts involved in those courses (not restricted to students) and the main
topics to address, the most relevant lecturers.
Task 16.2 Developing the online course as Co-coordinators of development of training. E-learning approaches
could combine different components: e-learning content, e-tutoring, collaborative learning, virtual classroom. The
platform will develop and implement the e-learning scholar content received from lecturers.
Pillar 4:
WP20: Accelerating the validation, use and development of new methodologies tailored for clinical studies in
RDs.
As coordinators of the ERN TransplantChild and representing it, will participate in all the tasks related to the
objectives of the WG.
Previous experience relevant to the Tasks:
TransplantChild would provide coordinated access to a comprehensive, accessible and interoperable suite of
tools. We collaborate with FAIR clinical and standardized routine analytical data (collected in a pan-trasplant
dedicated registry following recommendations of the DG Joint Research Centre (JRC), with identified relevant
cohorts). With the aim to create a critical mass of collected biological samples, based on recommended and
harmonized quality based banking procedures in each ERN HCP to increase and accelerate research
opportunities. Stimulating a collaborative bridging of existing advanced data analytics services for generation and
exploitation of –omics data, seeking the integration with existing European platforms, for the precise monitoring
of the transplant procedure for children with rare diseases.
TransplantChild provides effective interaction between patients, healthcare professionals, academics and
researchers to support training activities to bridge the gap between patient needs, clinical practice and new
treatment strategies at European, national and regional levels. We´ve created a best expertise knowledge platform
(online) and Training Programs, based on e-learning modules, specific sessions in online courses. Collaboration
with other ERNs focused on disease groups that require transplantation will be favored.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Biobank facility at Hospital premises, dedicated registry for all types of pediatric transplant procedure), integrative
platform for collection and exploitation of clinical, routine lab and research data. Clinical simulation platform
oriented to learn and train in the approach of the patient in critical clinical situations with the highest standards and
equipment. Clinical Research Unit of Clinical Trials (UCICEC) with staff specialized in the management and
development of clinical investigation and clinical trials including Phase I unit accredited.
Short Profile of key Staff Members who will be undertaking the work
Eduardo López Consultant Clinical Immunologist and PhD with 20 years’ experience in the diagnosis, genetic
Granados and immunological characterization of Primary Immunodeficiencies (PIDs), a large group of
(male) RD. Previous clinical and Research positions at NIAID/NIH and Human Immunology Unit at
MRC Weatherall Institute of Molecular Medicine, Univ. of Oxford. Head of La Paz University
Clinical Immunology Department. From the experience of PIDs, we are introducing cellular
and molecular biomarkers for better definition of the secondary immunodeficiency and
immune dysregulation generated by transplant procedures, for better clinical management of
complications. TRANSPLANTChild Research Working Group Coordinator
Antonio Pérez Paediatric Hemato-Oncologist with experience in hematopoietic stem cell Transplantation and
Martínez Associated Professor of Paediatric at La Paz University Hospital (HULP), and Faculty of
(male) Medicine of the Autonoma University, respectively, in Madrid, Spain. ERN
TRANSPLANTChild Education and training Working Group Coordinator.
Juan M.Torres MD, specialist in Clinical Immunology. Medical Supervisor of ERN-TRANSPLANTChild,
Canizales participating in the organizational management and orientation of Research and Education and
(male) Training, together with the rest of the network working groups.
List of the most relevant publications and/or products, services or other achievements
1.Scientific communications about the ERN vision and orientation at: Third IRDiRC Conference on February 8-9,
2017 in Paris
2.Communication at European Conference on Rare Diseases & Orphan Products 2018
3. Oral presentation at the 5th National Congress of the Spanish Society of Transplantation 30 June 1 July 2018.
4. Continuous training course in paediatric transplantation focused on physicians, emphasizing a transversal and
825575 – EJP RD – Part B 189
holistic approach. The model used is a mixed platform: through Associated
face-to-face training Ref.
with document combined with multimedia
Ares(2018)6091977 - 28/11/2018
and audio-visual materials available on the e-learning platform.
5. We promoted the short-term secondees program for medical specialists and specialist trainee who are currently
dedicated to paediatric transplantation in any of any of the members for best practices sharing.
List of relevant previous projects or activities, connected to the subject of this proposal
- TRANSMIT: European TRAining Network on perSonalised Medicine for Tolerance in PaedIatric
Transplantation; Innovative Training Networks (ITN) Call: H2020-MSCA-ITN-2018 (Submitted, on evaluation);
Through multidisciplinary and multicentric approach strengthened by European-level cooperation and
coordination, TRANSMIT will exploit immunological signatures in tolerance, alloreactivity and
immunosuppression related biomarkers, allowing to centres of expertise and professionals in different countries
to share knowledge of personalised medicine in PT recipient patients.
- PRICISION: European Network on Paediatric transplantation Risk stratification by Immunological
biomarkers-driven Clinical ImmunoSuppressIon decisiONs; COST Action OC-2017-1 (Submitted, on
evaluation); The Aim of this Action is to establish a European-led multidisciplinary network of researchers
collaborating in the validation and standardization of immune biomarkers for personalized immunosuppressive
therapy in paediatric transplantation.
- PETER: PaEdiatric Transplantation European Registry; HP-PJ-06-2016; The overall objective of the project is
to create a new rational, efficient, interoperable, open, accessible and predictive paediatric transplant registry; the
first that includes jointly solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT).
69-NUTH
Full legal name (Acronym) – Country Newcastle-Upon-Tyne Hospitals NHS Foundation Trust (NUTH)
Principal investigator Kate Bushby (as coordinator EURO-NMD) and Teresinha
Evangelista
David Jones (as coordinator RARE-LIVER)
Andrew Cant (as Coordinator ERN RITA)
Relevant Network ERN-EURO-NMD , ERN-Rare-Liver ,ERN-RITA
Description of the legal entity/department/laboratory/group:
NUTH has been providing patient-centred healthcare to communities in the North East of England and beyond for
over 250 years. NUTH is one of the largest NHS trusts in the UK, offering a wider range of specialist services than
any other. NUTH has a great deal of expertise in rare disease research and is the coordinator of three European
Reference Networks (ERN):
• ERN-EURO-NMD, the ERN for rare and complex neuromuscular diseases;
• ERN-Rare-Liver for rare and complex hepatological diseases
• ERN-RITA for Rare Immunodeficiency, auto inflammatory and autoimmune diseases.
ERN-EURO-NMD is part of the Institute of Genetic Medicine (IGM). It is coordinated by Katie Bushby who is an
honorary consultant at the world leading John Walton Muscular Dystrophy Research Centre. Her team based at the
Institute of Genetic Medicine, Newcastle University and its associated hospitals work together towards the
development and application of genomic and translational medicine to improve the health outcomes of people
living with neuromuscular diseases.
ERN-Rare-Liver (coordinated by Prof. Andrew Cant) and ERN-RITA (coordinated by Prof. David Jones) are part
of the Institute of Cellular Medicine (ICM).
Main tasks in the project per Pillar/WP: IGM
PILLAR 2:
WP10-Strategy. EURO-NMD and RITA will put themselves forward to join the monthly stakeholder board and
annual meetings. The decision on exactly which ERNs will be represented on the board will be made at the up-
coming ERN coordinators meeting.
PILLAR 3
WP16 – Online Education course
EURO-NMD has been approached by the WP lead (FFRD) and agreed to be involved in the development of an
academic course this will include contributing to task 16.1-Assess the needs, target audience and main topics of
825575 – EJP RD – Part B 190
the academic training course. We will also contribute to task 16.2.2with
Associated – document
IdentifyRef.
and work with relevant
Ares(2018)6091977 - 28/11/2018
European Universities, learned societies and other institutions to develop the content of the academic course.
WP17 – ERN RD Training and support Programme. Under this WP the ERN’s have been organized into four
thematic diseases groupings.
EURO-NMD will participate in Group 1 “Neuro”.
ERN-RITA will participate in Group 2 ‘Neoplasm and Malformation”.
ERN-Rare-Liver will participate in Group 3 “Organs”.
Previous experience relevant to the Tasks:
Within the IGM the team coordinates a number of relevant rare disease projects. Katie Bushby was a co-
coordinator for TREAT-NMD and the coordinator of the EUCERD joint action on Rare diseases. The centre has
the expertise and over 12 years of experience in the management and participation in EU funded initiatives.
From 2006 to 2009, Andrew Cant was President of the European Society for Paediatric Infectious Diseases
(ESPID). He is also a member of the Medical Advisory Board of the International Patient Organisation for
Primary Immunodeficiencies (IPOPI). He has thus contributed strongly to the success of the ESID registry. He
also has access (through ERN-RITA) to specific expertise in database interoperability.
Short Profile of key Staff Members who will be undertaking the work - across all three departments
Prof. David ICM, Coordinator of ERN-RARE-LIVER
Jones David Jones is a NIHR Dean for Faculty Trainees and an active researcher in the area of
Professor of Autoimmune Liver Disease, with a particular focus on the impact of the diseases on patients and
Liver how we can improve outcomes through the development and evaluation of new treatment
Immunology approaches. He co-wrote the European treatment guidelines for autoimmune liver disease upon
which all current therapy is based. I lead the UK PBC Consortium which brings together all
Male centres in the UK with the goal of improving therapy for everybody with autoimmune liver
disease. David Jones is the coordinator of ERN-Rare Liver
Prof. Andrew ICM, Coordinator of ERN-RITA
Cant As Consultant in Newcastle for 24 years, he set up one of two national referral centres for the
Hon Clin Prof treatment of children with severe immunological disorders and I am a world leader in the field of
Paediatric childhood infection, immune disorders, and bone marrow transplantation, also holding clinics in
Immunology Leeds, Scotland and Ireland he is a past President of the European Society for Paediatric
Infectious Diseases and President Elect of the European Society for Immunodeficiencies.
Male
Professor Cant is a leading researcher and teacher of international repute, and in the last 28 years
he has been awarded grants of over £7 million to support research into childhood tuberculosis,
meningococcal disease, the epidemiology and pathology of primary immune deficiencies,
defining the role of bone marrow transplantation as a treatment for primary immune deficiencies,
viral infection in the immunocompromised host, polysaccharide antibody responses following
solid organ transplantation and vaccine responses in preterm infants; leading to over 200 peer
reviewed papers, his most recent leading work on the delineation of Activated Protein Kinase
Delta syndrome.
Dr. Teresinha IGM, Acting Coordinator of ERN-EURO-NMD
Evangelista. Dr Teresinha Evangelista has over 20 years’ experience working as a Neurologist. Dr Teresinha
Acting Evangelista played an important role in the development of a diagnostic network for
EURO-NMD Neuromuscular Diseases during the years working in Portugal and was appointed as President of
coordinator the Portuguese Society for The Study of Neuromuscular Diseases in 2009 in recognition of status
as a leading reference for Neuromuscular Diseases in Portugal.
Female
Her work currently focuses on clinical and research work on hereditary muscle diseases, FSHD
and Congenital Myasthenic Syndromes. Simultaneously as a member of the Joint Actions for rare
diseases (EUCERD Joint Action and RD-Action), developed a particular interest on Rare
Diseases policies. As a result of the policy work become responsible for the concept and setting
up of the neuromuscular ERN (EURO-NMD) that integrates 61 healthcare providers from across
Europe.
825575 – EJP RD – Part B 191
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Thus far, she has published over 70 peer-reviewed papers and 5 book chapters. She has given
many invited lectures at meetings, symposiums and workshops as well as patient/parent
organizations meetings.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1.Translational Summer School and wider NMD training programme
2. Neuropediatrics. 2017 Aug;48(4):211-220. doi: 10.1055/s-0037-1604110. Epub 2017 Jul 6.
Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD).
Leary R, Oyewole AO, Bushby K, Aartsma-Rus A.
3. Muscle Nerve. 2018 Mar;57(3):380-387. doi: 10.1002/mus.25991. Epub 2017 Nov 7.
Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy.
Morís G, Wood L, FernáNdez-Torrón R González Coraspe JA, Turner C, Hilton-Jones D, Norwood F, Willis T,
Parton M, Rogers M, Hammans S, Roberts M, Househam E, Williams M Lochmüller H, Evangelista T.
4. Non-PTLD Malignancy post HSCT in patients with Primary Immunodeficiency: UK experience.
Unni MNM, Elfeky R, Rao K, Nademi Z, Chiesa R, Amrolia P, Skinner R, Slater O, Worth A, Flood T, Abinun M,
Hambleton S, Qasim W, Gaspar HB, Cant AJ, Gennery AR, Veys P, Slatter MA.
J Allergy Clin Immunol. 2018 Mar 7. pii: S0091-6749(18)30391-9. doi: 10.1016/j.jaci.2018.02.038.
5. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR,
Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva
A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R,
Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G,
Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S,
Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM,
Cant AJ.
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.
List of relevant previous projects or activities, connected to the subject of this proposal :
TREAT-NMD: FP6, European commission, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’
with the remit of ‘reshaping the research environment’ in the neuromuscular field.
EURO-NMD: Third Health Programme, EC, 2017-2021, Current coordinator of the Network. EURO-NMD is one
of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. EURO-NMD
facilitates discussion on complex or rare neuromuscular diseases and conditions that require highly specialised
treatment, and concentrated knowledge and resources.
ERN-Rare Liver and ERN-RITA: Third Health Programme, EC, 2017-2021, Current coordinators of the
Network. EURO-NMD and ERN RITA are two of the 24 European Reference Networks (ERNs) approved by the
ERN Board of Member States.
70-GOSH
Full legal name (Acronym) – Country Great Ormond Street Hospital for Children NHS Trust (GOSH)
Principal investigator Professor J Helen Cross
Relevant Network EpiCARE
Description of the legal entity/department/laboratory/group:
Great Ormond Street Hospital (GOSH) is a large children’s hospital providing tertiary and quaternary services to
children from across the UK and overseas. We provide the widest range of specialist paediatric health services on
one site found in the UK. Together with our research partner, UCL Great Ormond Street Institute of Child Health
we form the UKs only academic Biomedical Research Centre specialising in paediatrics
Main tasks in the project per Pillar/WP:
Pillar 2:
In WP 10.2 & 10.4 (MEYER) Professor Renzo Guerrini, will to the annual retreats and guidance on priorities for
Virtual Platform and FAIRification
In WP11 (MEYER) we will contribute through Professor Renzo Guerrini with his knowledge and development of
existing genetic epilepsy expertise, specifically his involvement in existing genetic epilepsy platform)
825575 – EJP RD – Part B 192
Pillar 3 Associated with document Ref. Ares(2018)6091977 - 28/11/2018
WP16.1 (GHE-HCL) Through Professor Alexis Arzimanoglou, assess the needs, target audience, main topics of
the academic education course" as well as task 16.2.2. "Identify and work with relevant European Universities,
learned societies and other institutions to develop the content of the academic course"
Professor Arzimanoglou will also contribute, together with EATRIS, to Module 8 on Regulatory affairs. In the
domain of the epilepsies there has been a regular collaboration between International League Against Epilepsy
representatives and the EMA/FDA.
Pillar 4
Task 20.1: Task Force Group
WP 20 (GOSH) as a participant and contributor, and contributory to C4C, with regard to the set up and
methodologies for clinical studies
Previous experience relevant to the Tasks:
Great Ormond Street Hospital (GOSH) is a major referral centre for rare and complex epilepsies in the UK, and
coordinates the European Reference Network EpiCARE. With its partner organisation UCL-GOSH Institute of
Child Health, it is part of the clinical trial network C4C and has participated in several European Funded research
projects.
Professor Renzo Guerrini has extensive experience in coordination of global epilepsy genetics projects including
Epi4K, EuroEPINOMICS, Epi25 and as leader of the FP7 funded project DESIRE (Development and Epilepsy:
Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat
Epilepsy)
Professor Alexis Arzimanoglou leads the educational workpackage of EPiCARE. He is editor of the International
League Against Epilepsy Educational journal Epileptic Disorders and leads on several course initiatives in rare
and complex epilepsies.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
All participants are centres within the European Reference Network for Rare and Complex Epilepsies EPiCARE.
Short Profile of key Staff Members who will be undertaking the work
Pr.Helen Cross Professor Helen Cross is The Prince of Wales’s Chair of Childhood Epilepsy and Head of the
(female) Developmental Neuroscience Programme at UCL-Great Ormond Street Institute of Child
Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for
Children NHS Foundation Trust, London and Young Epilepsy, Lingfield, UK. Her research
has been targeted at improving outcomes in early onset epilepsy, specifically in assessing the
role of surgery and ketogenic diet She leads the European Reference Network for Rare and
Complex Epilepsies, EpiCARE
Pr.Renzo Guerrini Renzo Guerrini is Medical Doctor; Neurologist; Child Neurologist and Psychiatrist; Clinical
(male) Neurophysiologist. Current position: Professor of Child Neurology and Psychiatry, Director
of Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer-University of
Florence. He was previously appointed Clinical Professor at Department of Neurology, GKT
Medical, London, King’s College Hospital (1999-2001): Professor Pediatric Neurology,
Institute of Child Health, University College London and Great Ormond Street Hospital
(2001-2003).
Pr.Alexis Alexis Arzimanoglou is currently consultant and Coordinator of the Epilepsy Program of the
Arzimanoglou Epilepsy Unit at SJD Barcelona Children's Hospital and Director of the Epilepsy, Sleep and
(male) Pediatric Neurophysiology Department at the University Hospitals of Lyon, France. He is also
member of the DYCOG research team at the Centre de Recherche en Neurosciences de Lyon
(France). His clinical and research activities are focused on: the pharmacological and surgical
management of childhood epilepsies, the cognitive development and emotional regulation
disorders in children with focal epilepsies
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. https://epi-care.eu/
2. Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG, Pfäfflin M, Elger C, Widman G, Schramm J,
Becker A, Braun KP, Leijten F, Baayen JC, Aronica E, Chassoux F, Hamer H, Stefan H, Rössler K, Thom M,
Walker MC, Sisodiya SM, Duncan JS, McEvoy AW, Pieper T, Holthausen H, Kudernatsch M, Meencke HJ,
Kahane P, Schulze-Bonhage A, Zentner J, Heiland DH, Urbach H, Steinhoff BJ, Bast T, Tassi L, Lo Russo G,
Özkara C, Oz B, Krsek P, Vogelgesang S, Runge U, Lerche H, Weber Y, Honavar M, Pimentel J, Arzimanoglou A,
825575 – EJP RD – Part B 193
Ulate-Campos A, Noachtar S, Hartl E, Schijns O, Guerrini R,Associated
Barba with
C, document
Jacques Ref.
TS,Ares(2018)6091977
Cross JH, Feucht M,
- 28/11/2018
Mühlebner A, Grunwald T, Trinka E, Winkler PA, Gil-Nagel A, Toledano Delgado R, Mayer T, Lutz M, Zountsas
B, Garganis K, Rosenow F, Hermsen A, von Oertzen TJ, Diepgen TL, Avanzini G; EEBB
Consortium.Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med. 2017
Oct 26;377(17):1648-1656.
3. Whelan CD, Altmann A, Botía JA, Jahanshad N, Hibar DP, Absil J, Alhusaini S, Alvim MKM, Auvinen P,
Bartolini E, Bergo FPG, Bernardes T, Blackmon K, Braga B, Caligiuri ME, Calvo A, Carr SJ, Chen J, Chen S,
Cherubini A, David P, Domin M, Foley S, França W, Haaker G, Isaev D, Keller SS, Kotikalapudi R, Kowalczyk
MA, Kuzniecky R, Langner S, Lenge M, Leyden KM, Liu M, Loi RQ, Martin P, Mascalchi M, Morita ME,
Pariente JC, Rodríguez-Cruces R, Rummel C, Saavalainen T, Semmelroch MK, Severino M, Thomas RH, Tondelli
M, Tortora D, Vaudano AE, Vivash L, von Podewils F, Wagner J, Weber B, Yao Y, Yasuda CL, Zhang G,
Bargalló N, Bender B, Bernasconi N, Bernasconi A, Bernhardt BC, Blümcke I, Carlson C, Cavalleri GL, Cendes F,
Concha L, Delanty N, Depondt C, Devinsky O, Doherty CP, Focke NK, Gambardella A, Guerrini R, Hamandi K,
Jackson GD, Kälviäinen R, Kochunov P, Kwan P, Labate A, McDonald CR, Meletti S, O'Brien TJ, Ourselin S,
Richardson MP, Striano P, Thesen T, Wiest R, Zhang J, Vezzani A, Ryten M, Thompson PM, Sisodiya SM.
Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain. 2018 Feb
1;141(2):391-408.
4. http://epilepsydesireproject.eu/
5. http://www.jle.com/en/revues/epd/revue.phtml
List of relevant previous projects or activities, connected to the subject of this proposal
ERN EpiCARE; coordination funded through Chafea grant 769051 — EpiCARE
71-EORTC
Full legal name (Acronym) – Country European Organisation for Research and Treatment of Cancer
(EORTC)- BE
Principal investigator Sandrine Marreaud, Saskia litière, Stéphane Lejeune
Relevant Network EORTC, ERN EURACAN, IRCI, IRDIRC
Description of the legal entity/department/laboratory/group:
The EORTC is a non-profit international research organization created under Belgian law in 1962. Since its
creation, the EORTC has contributed to improve the survival rates for several types of cancer through translational
and clinical research. Over 50 EORTC sponsored clinical trials are open to patient recruitment at any given time.
Both multinational and multidisciplinary, the EORTC Network comprises more than 4,000 collaborators from all
disciplines involved in cancer treatment and research in more than 700 university hospitals in over 30 countries.
The EORTC provides the know-how and the capacities to develop, perform, analysis and publish clinical research
projects including clinical trial protocol development, trial design, trial coordination, medical review, translational
research, pharmacovigilance, regulatory affairs management, contracts and insurances, Quality of Life/ PRO
investigation, imaging platform, radiotherapy QA, CDISC compliant database development and data management,
biostatistics, monitoring, QA/QC, etc.. The scientific activities of EORTC are strictly peer-reviewed and subject to
quality assurance/quality control programs. The EORTC operates on an independent basis, and in this capacity is
able to work in partnership with the pharmaceutical industry in evaluating innovative molecules. EORTC has
contributed to several success stories in terms of new anti-cancer drug development including registrations by the
FDA and the EMA. The EORTC has a proven track record in establishing new clinical standards, e.g. Response
Evaluation Criteria In Solid Tumours (RECIST), quality of life of cancer patients, etc. The EORTC is running the
SPECTA program to enable efficient access to molecular screening platforms for efficient biomarkers-driven
clinical trials access in lung, colorectal, melanoma, brain, and rare cancers. EORTC works in partnership with
various clinical research groups from Europe, America, Asia and Australia.
Main tasks in the project per Pillar/WP:
Pillar 2 – WP11 Multi-omics pipelines and reference maps for rare diseases research: pilot project in rare cancers if
funded.
Pillar 4 – WP20 Support office for clinical study: EORTC will provide advice and guidance to EURACAN selected
clinical studies in rare cancers.
Previous experience relevant to the Tasks:
The EORTC holds a strong track record in the field of rare diseases. The EORTC has performed 62 international
clinical trials over the past 15 years accruing a total of more than 20,123 patients in various rare disease entities
such lymphomas, melanoma, leukemia, sarcoma, brain, lung, urogenital, head and neck, male breast, cutaneous T
825575 – EJP RD – Part B 194
cell lymphoma, mesothelioma, thymoma, and anal cancers. TheseAssociatedclinical with
trials are multidisciplinary
document and -involve
Ref. Ares(2018)6091977 28/11/2018
various treatment modalities (chemotherapy, radiotherapy, surgery, hormonotherapy, targeted agent) alone or in
combination. Recognizing the challenge of the complex diagnosis of rare cancers, mandatory central pathology
review is enforced by EORTC and supported by international network of pathologists. Thanks to database
centralization, consistent data collection, and strict quality control procedure, the EORTC has accumulated unique
repositories of fully documented patient data and biological samples accessible for future research. Since 2011, the
US National Cancer Institute, the UK National Clinical Research Network, Cancer Research UK and the EORTC
decided to join force within the International Rare Cancers Initiative to perform new international clinical trials in
rare cancers otherwise lacking infrastructural support. EORTC is member of IRDIRC.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
Located in Brussels, the EORTC Headquarters with its 220 professionals is a unique facility in Europe. It provides
scientific, legal, logistic, and administrative support to EORTC clinical and translational research activities with
strong track record in the field of rare diseases. SPECTA is a standardized, quality-assured pan-European
infrastructure collecting clinically annotated human biological material (HBM) and characterizing tumors for the
purpose of biomarker discovery and ultimately integrating these newly discovered biomarkers into clinical trials.
SPECTA is built on existing EORTC resources and expertise in clinical research. Amongst common cancer types,
SPECTA is targeting rare cancers i.e., cancers with an incidence of less than 6/100,000 in the adult and
teenager/young adult populations. Rare anal, biliary tract, neuroendocrine, endometrium, cervical, vulvar, lung,
mesothelioma, thyroid, brain and sarcoma cancers will be considered in priority. The range of targeted cancer types
is adapted according to the medical needs, the progress of science and the requirements from downstream research
projects using SPECTA. Longitudinal patient follow-up with both clinical/pathological data and HBM collection
take place for all consented SPECTA patients until death or loss to follow-up, irrespective of the patients' treatment
as part of routine clinical care or participation in clinical trials within or outside the SPECTA structure
(downstream clinical trial or any other clinical trial). Long-term patient follow-up (annually) enables continued
acquisition of clinical data after all lines of treatment as part of routine clinical care or participation in a clinical
trial. A systematic histopathological central assessment of the patient tissue sample is performed to confirm the rare
cancer diagnosis and also to confirm that the quality of the material is adequate for further molecular testing(s). All
analyses are centrally performed by high-quality laboratories selected according to the needs.
Short Profile of key Staff Members who will be undertaking the work
Msc Sandrine Head of the EORTC Medical Dept. She is a medical doctor specialized in pharmaceutical medicine
Marreaud research with extensive experience in various types of cancers. She is supervising the Clinical
(female) Research Physicians who coordinate and provide clinical and methodological support to EORTC
clinical trials.
PhD Saskia Biostatistician and associated head of the EORTC statistics Dept. Saskia has in depth expertise in
Litière the design and analysis of clinical trials in various types of rare cancers. She is also a member of
(female) the Response Criteria In Solid Tumors (RECIST) Working Group and is involved in the ongoing
update of RECIST.
MSc Head of European Program. Stephane is responsible for coordinating EORTC participation in EU
Stephane funded projects. He will be the liaison person. He is experienced in various aspects of clinical
Lejeune research operations. Stephane contributes to contract preparation with research group, and
(male) laboratory.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Van den Bent M et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with
concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-
label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653.
2 Schöffski P et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET
alterations: EORTC phase II trial 90101 ‘CREATE’. Annals of Oncology, Volume 28, Issue 12, 1 December 2017,
Pages 3000–3008,
3. Perry J, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med
2017 Mar 16;376(11):1027-1037.
4. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC
22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov;17(11):1521-1532
5. BOGAERTS J et al. Clinical trial designs for rare diseases: Studies developed and discussed by the International
Rare Cancers Initiative. Eur J Cancer 2014; 51 (3):271-281.
List of relevant previous projects or activities, connected to the subject of this proposal
825575 – EJP RD – Part B 195
- FP7 EUROSARC (European Clinical trials in Rare SarcomasAssociated
within anwith
integrated translational
document Ref. trial network).
Ares(2018)6091977 - 28/11/2018
EORTC is performing clinical trial.
- FP7 EEC (EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing
Sarcoma). EORTC is performing clinical trials.
- H2020 MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced
newly molecular defined subtypes of colorectal cancer). EORTC is performing clinical trials.
- Associated partner to the ERN EURACAN in rare adult solid cancers, EORTC is the research infrastructure.
- Collaborating partner to the Joint Action in rare cancers. EORTC is providing its expertise.
72-INFRAFRONTIER
Full legal name (Acronym) – Country INFRAFRONTIER GmbH, Germany
Principal investigator Martin Hrabe de Angelis
Relevant Network INFRAFRONTIER
Description of the legal entity/department/laboratory/group:
INFRAFRONTIER is the European research infrastructure for the development, phenotyping, archiving and
distribution of mammalian models. It is a distributed research infrastructure with partners in 15 European countries.
The core services of INFRAFRONTIER comprise the development and systemic phenotyping of mammalian
disease models, and the archiving and distribution of mouse mutant lines by the European Mouse Mutant Archive
(EMMA). All INFRAFRONTIER resources and services can be accessed at www.infrafrontier.eu. The
INFRAFRONTIER GmbH was established in April 2013 as management and coordination unit of the
INFRAFRONTIER Research Infrastructure. It is based in Germany at the Helmholtz Zentrum München. The
INFRAFRONTIER GmbH is responsible for developing the INFRAFRONTIER GmbH resources and services, for
providing transnational access and for operating the INFRAFRONTIER IT infrastructure. It is also the contact
point for all stakeholders of the INFRAFRONTIER Research Infrastructure and coordinates the networking and
outreach activities.
Main tasks in the project per Pillar/WP:
Pillar 2:
WP11: Common platform for discoverable data and resources for RD research; contribution of metadata and
ontological models related to INFRAFRONTIER mouse mutant resources (task 2.1) to a FAIR compliant platform
for discovery of RD resources (tasks 2.2 and 2.3)
Previous experience relevant to the Tasks:
INFRAFRONTIER operates the EMMA database and actively compiles Rare Disease relevant mouse mutant
resources, which will be contributed to the common EJP RD platform for discoverable data and resources for RD
research. Furthermore, INFRAFRONTIER has considerable expertise in running EU funded Trans-national Access
service calls, which will inform the set-up of the EJP RD brokerage system e.g. regarding service contributors,
proposal evaluation and service call administration.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
INFRAFRONTIER GmbH operates the EMMA database and hosts the INFRAFRONTIER web portal at
www.infrafrontier.eu.
Short Profile of key Staff Members who will be undertaking the work
Pr. Martin Hrabé Full professor and chair at the Technical University in Munich and holds the chair of
De Angelis Experimental Genetics. At the same time he serves as director of the European Mouse
(male) Mutant Archive (EMMA). His research focus is on large-scale mutagenesis, functional
genomics, stem cell biology and metabolic research. He founded the German Mouse Clinic
(GMC) for systemic analysis of human diseases. He is member of the Project Committee of
the German National Genome Network (NGFN) for which he served as spokesman from
2006 to 2009. Prof. Dr. Hrabé de Angelis coordinated the INFRAFRONTIER preparatory
phase project and other national and international research consortia funded by the German
government and the European Commission (FP6/7). He is member of the Executive Steering
Committee of the International Mouse Phenotyping Consortium (IMPC) and founding
member and member of the Board of the German Center for Diabetes Research (DZD).
Since April 2014 he serves as Scientific Director of the INFRAFRONTIER GmbH. Prof.
Dr. Dr. h.c. Martin Hrabè de Angelis received numerous awards and honours.
Dr. Michael Räß, Trained biologist and research manager. He did his PhD thesis in behavioral physiology in
825575 – EJP RD – Part B 196
(male) 2006. After working for two years as a postdoc
Associatedinwith
this field, Ref.
document he changed in 2008- 28/11/2018
Ares(2018)6091977 to the
Helmholtz Zentrum München as lead project manager for the INFRAFRONTIER
Preparatory Phase and head of the INFRAFRONTIER Project Office. In 2010 he received a
MSc degree in „Science Communications and Marketing“. Since 2014 he is Head of
General Management of the INFRAFRONTIER GmbH. Michael Raess is the Leader of the
CORBEL Work Package 5 (Common Solutions for User Access).
Dr Sabine Fessele Dr. Sabine Fessele studied Technical Biology at the University of Stuttgart. After doing her
(female) PhD in cellular and molecular immunology at LMU Munich, she worked as project manager
for NascaCell GmbH in the department of Functional Biology. In another biotech start-up
company, EPIDAUROS Biotechnologie AG, she held the position of Data Manager. She
started to work as project manager for the Helmholtz Zentrum München in 2006 and
coordinated several areas of the European Mouse Mutant Archive (EMMA). Since 2013
Sabine Fessele is a PMI-certified Project Management Professional (PMP®) and since 2015
she is the Head of Unit - Operations and IT of the INFRAFRONTIER GmbH.
Philipp Gormanns Philipp Gormanns studied bioinformatics at the universities LMU and TUM in Munich. He
(male) worked as a bioinformatics scientist in the Max-Planck Institute of Psychiatry in the field of
biomarker discovery for depression and anxiety from 2007 to 2011. From 2012 to 2015 he
was working at the Helmholtz Zentrum München as an IT scientist for the German Mouse
Clinic and technical project lead for BioMedBridges. Since 2016 he is Senior Developer at
the INFRAFRONTIER GmbH.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Meehan TF, et al. 2017. Disease model discovery from 3,328 gene knockouts by The International Mouse
Phenotyping Consortium. Nature genetics, 2017-06-26
2. Meehan TF, et al. 2015. INFRAFRONTIER – providing mutant mouse resources as research tools for the
international scientific community. Nucleic Acids Research 43, D1171-1175
3. Hrabě de Angelis M, et al. 2015. Analysis of mammalian gene function through broad-based phenotypic
screens across a consortium of mouse clinics. Nature Genet 47(9), 969-978
4. INFRAFRONTIER portal providing access to EMMA mouse mutant resources www.infrafrontier.eu
5. IMPC portal providing access to IMPC phenotyping data www.mousephenotype.org
List of relevant previous projects or activities, connected to the subject of this proposal
. INFRAFRONTIER2020, Horizon2020, 2017-2020 - Towards enduring mouse resources and services
advancing research into human health and disease
. CORBEL, Horizon2020, 2015-2019 - Coordinated Research Infrastructures Building Enduring Life-science
Services
. IPAD-MD, Horizon2020, 2015-2019 - Research Infrastructures for Phenotyping, Archiving, and Distribution
of Mouse Disease Models - Promoting International Cooperation and User Engagement to Enhance Biomedical
Innovation
. RItrain, Horizon2020, 2015-2019 - Research Infrastructures Training Program
. INFRAFRONTIER-I3, FP7, 2013-2016 - Development of mouse mutant resources for functional analyses of
human diseases - Enhancing the translation of research into innovation
73-BBMRI
Full legal name (Acronym) – Country Biobanking and BioMolecular resources Research Infrastructure -
European Research Infrastructure Consortium (BBMRI-ERIC),
AT
Principal investigator Erik Steinfelder
Relevant Network BBMRI-ERIC
Description of the legal entity/department/laboratory/group:
The pan-European Biobanking and BioMolecular resources Research Infrastructure - European Research
Infrastructure Consortium (BBMRI-ERIC) improves the accessibility and interoperability of the existing
comprehensive collections, either population-based or clinical-oriented, of biological samples from different
(sub)populations of Europe. These collections include the attached data on factors such as health status, nutrition,
lifestyle, and environmental exposure of the study subjects. Combined with the expertise of the clinicians,
825575 – EJP RD – Part B 197
pathologists, bio-informaticians, and molecular biologists involved, a globally
Associated unmatched,
with document Europe-wide platform
Ref. Ares(2018)6091977 - 28/11/2018
for translational medical research is envisaged with the aim to develop personalized medicine and disease
prevention for the benefit of European citizens.
To reach this goal, also biotech and pharmaceutical industry must have a possibility to collaborate with academic
researchers in order to fully realize the enormous potential of European biobanking. In addition to clinical, ethical
and legal experts, patient communities are involved to achieve standards and guidelines that properly balance
individual values, such as protection of privacy and informed consent, with shared values of facilitated access to
progress in health care and disease prevention.
On 3 December 2013, BBMRI was officially awarded the Community legal framework for a European Research
Infrastructure Consortium (ERIC). This specific legal form is designed to facilitate the joint establishment and
operation of research infrastructures of European interest. The ERIC status allows pulling together biobanks and
biomolecular resources into a pan-European facility and providing access to collections of partner biobanks and
biomolecular resources, their expertise and services on a non-economic basis.
BBMRI-ERIC shall establish, operate and develop a pan-European distributed research infrastructure of biobanks
and biomolecular resources in order to facilitate the access to resources as well as facilities and to support high
quality biomolecular and medical research. BBMRI-ERIC operates on a non-economic basis.
BBMRI-ERIC is set up as a distributed research infrastructure in most, if not all European Member States.
BBMRI-ERIC consists of 19 Member States and one International Organisation, making it one of the largest
research infrastructures for health research in Europe.
Members: Austria, Belgium, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Malta, the
Netherlands, Norway, Poland, Sweden, and the United Kingdom. Observer Countries: Cyprus, Switzerland,
Turkey, IARC/WHO
Main tasks in the project per Pillar/WP:
Pillar 2 Petr Holub
BBMRI-ERIC will lead tasks on technical GDPR implementation (Task 10.3) and Quality oversigth (Task 10.4),
and it will contribute to federated searches architectures (Tasks 11.2 and 12.1), machine readable access (Task
12.1), integration of existing services into Orphanet catalog (Task 11.1), and brokering hosting services for FAIR
data provisioning (Task 12.3).
Pillar 3 Michaela Th. Mayrhofer
Within Pillar 3, BBMRI-ERIC will contribute with its expertise in ethical, legal and societal matters related to rare
diseases. In particular, it will share its experience in operating the custom based ELSI Helpdesk and self-service
Knowledge Base. Additionally, BBMRI-ERIC commits to host a 3-day training workshop in Graz ensuring
awareness raising and appropriate knowledge transfer (Task 14.4).
Previous experience relevant to the Tasks:
BBMRI-ERIC designs, implements and operates its IT services via its Common Service IT (CS IT), with particular
attention to biobanks dealing with human biological material and data. It delivers both centralized and distributed
findability (Directory and Locator services), accessibility (Negotiator), interoperability (MIABIS data model), and
reusability (common inteoperable provenance model developed within ISO TC276 WG5). Together with BBMRI-
ERIC Rare Diseases Working Group it delivers services specific to RD community, such as RD section of BBMRI-
ERIC Directory and Helpdesk for Rare Diseases. BBMRI-ERIC has also commitment to sustainably operate
selected outcomes of RD-Connect, namely Registry & Biobank Finder (aka ID-cards) and Sample Catalogue.
BBMRI-ERIC Negotiator is also being extended by the RD-Connect to implement the access pipeline for rare
disease resources within RD-Connect.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
BBMRI-ERIC Common Services form a key element for the research infrastructure as they provide the biobanking
community and biobank users with expertise, services and tools specific to biobanking. The Common Services are
established under BBMRI-ERIC and under the responsibility of its Director General. The ELSI Helpdesk is a
personalised support service assisting researchers who have ethical, legal and societal questions in the context of a
research project. We offer assistance on topics that are crucial in biobanking, such as informed consent and data
protection amongst others, in order to promote compliance with regulatory requirements and best practice
principles
Short Profile of key Staff Members who will be undertaking the work
Dr Petr Holub Associate Professor of computer science at Masaryk University, the second largest
(male) university in the Czech Republic. He has background both in sciences (MSc with
specialization on computational quantum chemistry in 2001) and computer science (PhD in
2005, specializing on computer networks, self-organizing systems and multimedia
processing). He was head of the Division of Communication Technologies at Institute of
825575 – EJP RD – Part B 198
Computers Science, Masaryk University, as well aswith
Associated architect
documentof advanced
Ref. multimedia
Ares(2018)6091977 and
- 28/11/2018
collaborative systems of the Czech national e-infrastructure developed and operated by
CESNET. His research in computer networks and multimedia processing has lead to more
than 40 research papers in established computer science journals and ranked conferences, as
well as to practical software systems and patents. Since 2011, he has been responsible for
design and development of IT infrastructure of the Czech BBMRI, as well as its subsequent
operation using national research cloud e-infrastructure CERIT-SC. He is also responsible
for the IT and data management infrastructure of the ongoing EU THALAMOSS project,
focusing on data collection and processing for stratification of patients suffering from
thalassaemia. He has been a contributor to a number of international and national projects
linking computer science and biomedicine. He joined BBMRI-ERIC as its IT/Data
Protection Manager in January 2015.
Dr. Michaela Political scientist and historian by training. She was educated in Vienna, Louvain-la-Neuve,
Mayhofer Essex and Paris. In 2010, she has earned her PhD from both the Ecole des Hautes Etudes en
(male) Sciences Sociales and the University of Vienna, which was shortlisted by the Austrian
Society for Political Science for 'best thesis 2010'. Prior to her involvement in BBMRI-
ERIC, she was investigator in several national and international research projects focusing
on the politics of biotechnology and the life sciences, especially the governance of biobanks.
Her academic career led to various positions at the Centre de Recherche Médecine,
Sciences, Santé et Société, the University of Vienna, the Institute of Science, Technology
and Society Studies at Alpen-Adria-Universität Klagenfurt/ Vienna/Graz, the Technical
University of Vienna and the Medical University of Graz. Today, she serves as the Chief
Policy and Coordination Officer of BBMRI-ERIC and leads the Code of Conduct for Health
Research Initiative.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. Michaela Th. Mayrhofer (2013): About the New Significance and the Contingent Meaning of Biological
Material and Data in Biobanks. IN: Hist. Phil. Life Sci 35, 449‐467.
2. Michaela Mayrhofer (2008): Patient Organisations as the (Un)Usual Suspects in Biomedical Research, IN H.
Gottweis & A. Petersen (Ed.): Biobanks: Governance in Comparative Perspective, Routledge, p. 71‐87.
3. Mayrhofer MT, Holub P, Wutte A, Litton JE (2016): BBMRI-ERIC: the novel gateway to biobanks. From
humans to humans. IN: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Mar;59(3):379-84.
doi: 10.1007/s00103-015-2301-8.
4. Holub, P., Mayrhofer MT, Wutte, A et.al. (2018): Enhancing Reuse of Data and Biological Material in Medical
Research: From FAIR to FAIR-Health. IN: Biopreservation and Biobanking, see
https://doi.org/10.1089/bio.2017.0110
List of relevant previous projects or activities, connected to the subject of this proposal
. 1. BioSHaRE: https://www.bioshare.eu/
. 2. BBMRI-LPC: http://www.bbmri-lpc.org/
. 3. SPIDIA4P: http://www.bbmri-eric.eu/scientific-collaboration/spidia4p/
. 4. BioMedBridges: http://www.biomedbridges.eu/
. 5. CORBEL: http://www.corbel-project.eu/home.html
74-ECRIN/PedCRIN
Full legal name (Acronym) – Country European Clinical Research Infrastructure Network
(ECRIN)- France
Principal investigator Jacques Demotes
Relevant Network ECRIN, PEDCRIN project
Description of the legal entity/department/laboratory/group:
The European Clinical Research Infrastructure Network (ECRIN, www.ecrin.org) is a sustainable, not-for-profit,
distributed infrastructure with the legal status of a European Research Infrastructure Consortium (ERIC). ECRIN
provides support for the planning and implementation of multinational clinical research projects in Europe.
ECRIN currently has eight Member Countries (France, Germany, Spain, Italy, Portugal, Hungary, Czech Republic
and Norway) and one Observer Country (Switzerland). Additional countries are about to join.
ECRIN provides services for the management of multinational -investigators initiated and SME sponsored- trials;
825575 – EJP RD – Part B 199
central services (data management through ECRIN certified data centres, central
Associated vigilance)
with document and distributed services
Ref. Ares(2018)6091977 - 28/11/2018
provided by the ECRIN partner in each country involved (regulatory and ethical submissions and follow-up,
monitoring, local vigilance, project management etc.).
As part of its trial support activities, ECRIN develops and maintains freely accessible tools such as databases on
regulatory and ethical issues, outcome measures, and risk-based monitoring. ECRIN contributes to capacity
building projects aiming to establish shared services in biomedical areas, and to foster international cooperation in
non-commercial trials.
ECRIN organisation:
ECRIN’s ‘distributed infrastructure’ includes a Core Team based in Paris, France (headquarters) and European
Correspondents (EuCos) working in each Member and Observer Country and hosted by the national scientific
partners (networks of academic clinical trial units (CTUs) and/or clinical research centres (CRCs)). ECRIN
scientific partners (a total of 80 CTUs and CRCs) are the final service providers for ECRIN-supported clinical
trials; they provide services and expertise under the coordination of ECRIN.
ECRIN has also partners in other countries in Europe and internationally with which it collaborates.
Main tasks in the project per Pillar/WP:
In WP 20, ECRIN will be in charge of the clinical trial helpdesk (tasks 20.1 and 20.2).
ECRIN will also provide its regulatory and ethical expertise in the WP4 task 4.2.
Previous experience relevant to the Tasks:
-Development of tools and operational services for multinational clinical trials in Europe and in particular for rare
diseases through the ECRIN-IA project
-Leader of the Medical Infrastructure work package in the CORBEL cluster project
-Co-secretariat (with US NIH) of the CRIGH (clinical research initiative for global health) promoting
international cooperation in clinical trials.
Short Profile of key Staff Members who will be undertaking the work
Jacques Director General of ECRIN. Professor of cell biology, clinical neurologist. Dr Demotes was
Demotes, MD, the coordinator of ECRIN’s four FP6- and FP7-funded projects, which supported the
PhD, MBA (male) sustainable development of ECRIN as a pan-European infrastructure with “ERIC” status
(awarded in 2013). He has participated in more than 50 FP6, FP7, H2020 and IMI-funded
projects.
Christine Operations Director of ECRIN. She holds a PhD from University Paris XI in pharmaceutical
Kubiak, PharmD, sciences. She has more than 20 years’ experience in the planning, setup, and management of
PhD (female) multinational clinical trials and in the coordination of clinical programmes in the
pharmaceutical industry. At ECRIN since 2006, she played a key role in ECRIN’s FP6 and
FP7 funded projects. She currently oversees projects development and implementation, and
contributes to strategy and business development.
Sabine Kläger, ECRIN Clinical Operations Manager since October 2017. She has over 30 years of experience
PhD, MSc (Biol.), in biomedical research, initially in the field of tropical diseases, including drug development
MSC programmes from P1 to P3, and the use of new medicines in mass treatment programmes
(Epidemiology), across endemic areas (Africa, South America), and later in the planning, setup, and
DLSHTM management of multi-national clinical trials in various therapeutic areas in the UK and
(female) Europe. Since 2003 she was working for academic Sponsors, ensuring the implementation of
necessary regulatory requirements to comply with the EU Directives on Clinical Trials,
including the set-up and operational and strategic management of a CTU for Cambridge
University-Hospital partnership. Currently, she is also chairing the DMECs for 3 drug trials,
running across several Sub-Saharan countries
Salma Malik, PEDCRIN project manager. Holds a PhD in paediatric clinical endocrinology and has
PhD (female) experience in the development and conduct of paediatric clinical trials and paediatric research
projects.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1.European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical
825575 – EJP RD – Part B 200
research. Demotes-Mainard J, Ohmann C. Lancet. 2005 Jan 8-14;365(9454):107-8
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
2.Cloud computing' and clinical trials: report from an ECRIN workshop. Ohmann C et al. Trials. 2015 Jul
29;16:318. doi: 10.1186/s13063-015-0835-6.
3 A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and
real barriers for improving the evidence and how can they be overcome? Ana Rath et al. Trials. 2017 Nov
22;18(1):556. doi: 10.1186/s13063-017-2287-7.
4.Global health: Boost multinational clinical research. Demotes-Mainard J et al. Nature 545:289 (2017)
doi:10.1038/545289b
5.Sharing and reuse of individual participant data from clinical trials: principles and recommendations. Christian
Ohmann et al. BMJ Open. 2017 Dec 14;7(12):e018647. doi: 10.1136/bmjopen-2017-018647
List of relevant previous projects or activities, connected to the subject of this proposal :
-ECRIN-IA: European Clinical Research Infrastructures Network - Integrating Activity, including a competitive
call to support multinational trials (FP7 Infrastructure 2011; grant number 284395) (ECRIN coordinator)
-PedCRIN: Paediatric Clinical Research Infrastructure Network (H2020-INFRADEV-2016-2017; grant number
731046) (ECRIN coordinator)
-CORBEL: Coordinated Research Infrastructures Building Enduring Life-science Services (H2020 INFRADEV-4-
2014/2015; grant number 654248)
-CRIGH: Clinical Research Initiative for Global Health (Collaboration Agreement between international partners in
order to promote and develop international collaboration)
-TRANSVAC: European Vaccines Research and Development Infrastructure (H2020 INFRAIA-2016-1- grant
number 730964)
75-EATRIS
Full legal name (Acronym) – Country EATRIS-ERIC (EATRIS)- The Netherlands
Principal investigator Toni Andreu (MD, PhD)
Relevant Network EPTRI, CORBEL
Description of the legal entity:
EATRIS, the European Infrastructure for Translational Research offers a new collaboration model for fostering
innovation. The infrastructure plays a fundamental role in the advancement of knowledge and technology in
translational research and drug development. With over 90 leading institutes, across 12 EU Member States,
EATRIS provides access to the entire pipeline of academic translational infrastructure and expertise, and optimises
the route from discovery to proof-of-concept in medicines development. It provides a new development pathway,
open to academic researchers and companies in need of support for advancing biomedical innovations.
The EATRIS ‘Coordination & Support’ office employs 14 people, with expertise ranging from project
management, marketing, and technology transfer to translational product development. EATRIS is a European
Research Infrastructure Consortium (ERIC) since 2013, a legal entity established by the European Commission to
facilitate the operation of international research infrastructures.
Main tasks in the project per Pillar/WP:
Pillar 0 - Coordination and Transversal activities
In WP1, we will support the coordinator with the overall management of the project by being part of the operating
group (tasks 1.1; 1.2; 1.3)
In WP2, we will be involved in the development of EJP RD research and innovation strategy by contributing to the
mapping exercise (tasks 2.2; 2.4)
In WP3, we will co-lead WP activities, contribute to the design of a service roadmap and catalogue and lead the
task aiming at preparing the EJP-RD sustainability plan with business plan (tasks 3.1; 3.2; 3.3)
In WP4, we will provide advice on regulatory procedures (task 4.2)
In WP5, we will contribute to the implementation of the communication and dissemination strategy of the project
(task 5.1)
Pillar 1
In WP8, we will co-develop the rare disease research challenges (tasks 8.1; 8.2; 8.3; 8.4)
Pillar 3
In WP16, we will contribute to the development of online courses (task 16.2)
Pillar 4
In WP19, we will act as co-WP leader and will be involved in all tasks to provide researchers with the right support
825575 – EJP RD – Part B 201
to conduct translational research (tasks 19.1; 19.2; 19.3; 19.4) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
Previous experience relevant to the Tasks:
Examples of services provided by the Coordination Office of EATRIS since 2013:
EATRIS Matchmaking: EATRIS matches clients’ needs to the specific capabilities and expertise of the
institutions, relying on a sophisticated and detailed database outlining EATRIS institutional capabilities. The
EATRIS operational model in which a large consortium operates under harmonized conditions and a framework
agreement, offers user the same reach of a consortium, but with the safety and effectiveness of a bilateral
relationship. This service lies at the heart of EATRIS operations, has been offered to an increasing number of users
since 2013, ranging from biotech companies to academia and pharmaceutical industry.
EATRIS Inside: EATRIS has worked together with funders and charities to bring the European-wide EATRIS
expertise and infrastructure ‘inside’ their funding procedure. Principal Investigators, shortlisted by the funder, are
invited by the funding agency or the charity to contact EATRIS for translational optimisation of their proposal.
EATRIS then performs a preliminary assessment of the translational feasibility of the project based on the
elements available: unmet medical need and clear end-product definition; preliminary analysis of the intellectual
property status; technical feasibility and regulatory pathway. Based on this potential assessment, the PI completes
their full proposal for subsequent review by the funder. EATRIS has already piloted successful collaboration with
several funders and charities (for instance, ZonmW - The Netherlands Organisation for Health Research and
Development- and Rheumafonds).
Innovation Management: EATRIS has been responsible for the facilitation of multiple public-private
collaboration, involving SME’s and also large pharma. Additionally, since 2015, it has been leading the WP
dedicated to Accelerating Innovation of CORBEL (see below), and set up an Innovation Helpdesk, providing
partnering, legal, IP support to other biological and medical research infrastructures.
Business planning: EATRIS has been in charge of drafting the sustainability plan of TRANSVAC-2 (see
below), as well as the business plan of EPTRI (see below).
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work :
N/A
Short Profile of key Staff Members who will be undertaking the work
Anton Ussi Operations & Finance Director for EATRIS C&S. Anton Ussi has a background in engineering
(male) and SME administration. He is a specialist in the establishment and execution of strategic public-
private and public- public collaborations based on the deployment of high value translational
research infrastructure for medicine. Anton has been co-responsible for the development of
several ongoing public private partnerships and spin-out companies, among which the €130
million VU University Medical Imaging Center Amsterdam, and the Dutch Imaging Hub, a
public-private translational initiative with Roche-Genentech and three Dutch university medical
centers.
Tim Moser EATRIS industry partnering specialist, educated in biology, later combining an MBA in Supply
(male) Chain Management. His work experience includes scientific research, evolving into operational
and site management in life sciences companies. Since 2010 he works in technology transfer and
specializes in industry partnering. As former business developer for Industry Alliance Office of
Neuroscience Campus Amsterdam, Tim has developed and negotiated collaboration agreements
with many different companies ranging from biotech to international big pharma. He specializes
in identifying the frontier areas in academic translational medicine that spark interest for industry
and pursuing ideal routes toward partnership.
Rosan Vegter After graduating and working as an emergency vet for several years, she has worked in
(female) pharmaceutical industry where she completed a PhD on the Challenges in the Clinical
Development of Orphan drugs. At EATRIS, she is in charge of the coordination and
implementation of training activities. One of her main activities has been developing curricula for
PhDs and Postdocs involved in translational medicine for the Erasmus+ funded C-COMEND
project. Furthermore, she is part of the communication team as content writer.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements
1. G.A.M.S. van Dongen, et al. EATRIS, a European initiative to boost translational biomedical research.
Am J Nucl Med Mol Imaging. 3, 166-174 (2013).
2. CT. Gilliland, et al. Putting translational science on to a global stage. Nat. Rev. Drug Discov. 15, 217–8
(2016).
3. A.E. Ussi, et al. In Search of System-Wide Productivity Gains - The Role of Global Collaborations in
825575 – EJP RD – Part B 202
Preclinical Translation. Clin. Transl. Sci. 10, 423–425 (2017).
Associated with document Ref. Ares(2018)6091977 - 28/11/2018
4. A.J. Van Gool, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev
Drug Discov, (2017).
List of relevant previous projects or activities, connected to the subject of this proposal
1. CORBEL (H2020, 654248) (2015-2019): Coordinated Research Infrastructures Building Enduring Life-
science Services project of thirteen biological and medical research infrastructures (BMS RIs), creating a
platform for harmonised user access to biological and medical technologies, biological samples and data
services required by cutting-edge biomedical research. EATRIS is leading the Innovation WP, which
provides support for RI on public-private collaboration and industry partnering.
2. C-COMEND (Erasmus Plus, 2015-1-NL01-KA203-008986) (2015-2017): Project coordinated by
EATRIS along with academic and SME partners to develop a competency profile, e-learning and face-to-
face courses on medicines development for PhD students and PostDocs.
3. ID-EPTRI (H2020, 777554) (2018-2020): the project aims at designing the business and governance
model for an infrastructure for pediatrics translational research. EATRIS leads the WP dedicated to
Governance and is responsible for delivering the business and governance models.
76-ELIXIR
Full legal name (Acronym) – Country European Molecular Biology Laboratory (EMBL) (ELIXIR,
EMBL-EBI)
Principal investigator Niklas Blomberg
Relevant Network ELIXIR
Description of the legal entity/department/laboratory/group:
The European Molecular Biology Laboratory (EMBL; http://www.embl.org/ ) was established in 1974 and is
supported by over twenty countries. EMBL is a centre of excellence for research in molecular biology.
EMBL is a centre of excellence for research in molecular biology. It is a distributed international research
organization (24 member states) with its main laboratory in Heidelberg. Research at EMBL emphasizes
experimental analysis at multiple levels of biological organisation, from the molecule to the organism. One of
EMBL’s five core missions is to develop and make available new technologies for the Life Sciences. Accordingly,
EMBL has an extensive success record in developing new biology-driven technologies and providing service-
oriented user infrastructures including the Advanced Light Microscopy Facility (ALMF) offering external user
access, a high-throughput light microscopy screening facility, the Centre for Bioimage Analysis, the Electron
Microscopy Core Facility (EMCF) and the EMBL-EBI data resources. Another core mission of EMBL is to
provide advanced training to researchers, which is organized by the EMBL International Centre for Advanced
Training (EICAT) and encompasses the EMBL International PhD Programme (EIPP), the EMBL Postdoctoral
Programme and the Visitors Programme as well as a large number of workshops, courses and conferences. EMBL
maintains strong interactive relationships to the major life science research institutions in Europe and has more than
40 years of experience in integrating European research.
In addition to EMBL in Heidelberg, the European Bioinformatics Institute (EMBL-EBI) in Hinxton is involved
in Euro-BioImaging and will host the general data services of EuBI ERIC. Established in 1996, EMBL-EBI
(http://www.ebi.ac.uk/ ) is an outstation of the EMBL and has a long-standing mission to collect, organise and
make available databases for biomolecular science. EMBL-EBI makes available a collection of databases along
with tools to search, download and analyse their content. These databases include nucleotide sequences (European
Nucleotide Archive), protein sequences (UniProt), structures (PDBe), genome annotation (Ensembl), gene
expression information (ArrayExpress), molecular interactions (Intact) and pathways (Reactome). Connected to
these are linking and descriptive data resources such as protein motifs (InterPro), ontologies and many others. In
many of these efforts the EMBL-EBI is a European node in global data-sharing agreements.
ELIXIR (https://www.elixir-europe.org/) is an inter-governmental organisation, which builds on existing life
sciences data resources and services within Europe to orchestrate the collection, quality control and archiving of
large amounts of biological data. It follows a hub-and-nodes model, with a single Hub located at EMBL-EBI in
Hinxton, Cambridge, UK (with EMBL providing the legal entity) and a growing number of Nodes located at
centres of excellence throughout Europe. ELIXIR is an ESFRI Research Infrastructure in permanent operations
phase since 2013. The ELIXIR Consortium Agreement established ELIXIR as an independently governed entity
within the legal framework of EMBL. To date, 21 countries plus EMBL have signed the consortium agreement:
Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Israel,
Luxembourg, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, UK and Greece. In May
825575 – EJP RD – Part B 203
2014 ELIXIR was one of only three priority projects identified by ESFRI
Associated as mature
with document enough to support
Ref. Ares(2018)6091977 for
- 28/11/2018
implementation in 2015-2016.
Governments and ministries of ELIXIR Member States are responsible for contributing funding for the ELIXIR
Hub and coordinating the scientific community in their country into a national Node that provides services to the
ELIXIR community, including data resources, tools, Compute provision, Standards development, Training and
support to Industry.
Main tasks in the project per Pillar/WP, Description of Beneficiaries and Third Parties involvement.
Pillar 0 Transversal activities:
In WP1: Coordination and management
● ELIXIR Hub will be co-leading Task 1.3 Monitoring of the EJP RD activities and achievements KPI
definition and Subtask 1.3.1 Identification of key performance indicators
In WP2: Integrative research and innovation strategy
● DTL-Projects(ELIXIR-NL) will contribute to Task 2.1 Prioritization scheme for EJP RD actions and
Task 2.2 Mapping the research and innovation needs
In WP4: Ethical, regulatory, legal and IPR framework of the EJP RD
● ELIXIR Hub will be contribute to Task 4.2 Managing ethical and regulatory issues
Pillar 2:
In WP10: User-driven strategic planning and transversal activities for Pillar 2 data ecosystem
● ELIXIR Hub will be co-leading Task 10.3 Coordination of technical implementation of General Data
Protection Regulations (GDPR) task.
● ELIXIR Hub will be co-leading Task 10.4 Quality oversight task
● DTL-Projects (ELIXIR-NL) will be leading Task 10.5 Developing sustainable models. ELIXIR Hub
will be contributing to this task also.
In WP 11: Common virtual platform for discoverable data and resources for RD research
● EMBL-EBI will be leading Task 11.1 Metadata and ontological model definition for cataloging resources
for RD research task. SIB(ELIXIR-CH) will also be contributing in this task, to define an ontological
model compatible with existing key databases and resources.
● DTU(ELIXIR-DK) and BSC(ELIXIR-ES) will be contributing to the Subtask 11.2.3 To make relevant
RD analysis tools and methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation
for the RD community initiated in EXCELERATE
● EMBL-EBI will be leading Task 11.3 Data deposition and access to data infrastructures for RD research.
CSC(ELIXIR-FI) and MU-CERIT-SC (ELIXIR-CZ) will be contributing to Subtask 11.3.2 Implement a
unified authentication and authorisation mechanism, based on ELIXIR’s AAI. EMBL-EBI, ELIXIR Hub,
CSC(ELIXIR-FI), BSC(ELIXIR-ES) and UU(ELIXIR-SE) will be contributing to Subtask 11.3.4
develop data deposition guidelines and documentation.
● BSC(ELIXIR-ES) and SIB(ELIXIR-CH) will be contributing to Task 11.4 Provision of analysis and
data sharing capabilities to the RD community through online resources to Provide RD phenotype-
genotype analysis and data sharing capabilities through the RD-Connect platform for molecular diagnostics
and gene discovery. EMBL-EBI, CSC(ELIXIR-FI), BSC(ELIXIR-ES), UU(ELIXIR-SE) and
SIB(ELIXIR-CH) will contribute to Subtask 11.4.2 collaborative integrated analysis of multi-omics data
from selected use cases. BSC(ELIXIR-ES) will contribute to Subtask 11.4.3 provide capabilities for
custom analyses through cloud-based solutions. EMBL-EBI, BSC(ELIXIR-ES) and UU(ELIXIR-SE)
will contribute to Subtask 11.4.4 user-driven implementation of new analysis functionalities and tools task.
In WP12: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples
● EMBL-EBI will contribute to Subtask 12.1.2 federation architectures, and networks registers.
CSC(ELIXIR-FI) will also contribute to Subtask 12.1.3 implement machine readable access (e.g., consent
& use conditions, governance, identifiers, security, anonymization). EMBL-EBI will contribute to Subtask
12.1.4 Query languages and Subtask 12.1.5 data exchange formats and ontologies & semantics for record-
level clinical and preclinical information.
● EMBL-EBI will contribute to Subtask 12.3.2 Brokered hosting service for FAIR data provision,
discovery and matchmaking. SIB(ELIXIR-CH) will contribute to Subtask 12.3.3 FAIRification service
for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU data sources.
In WP13: Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics
EMBL-EBI and SIB(ELIXIR-CH) will contribute to Subtask 13.1.3 the Mapping (combinations) of
variants to protein function task.
825575 – EJP RD – Part B 204
Pillar 3: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
In WP14: Training on data management & quality
● CNR (ELIXIR-IT) and DTL-Projects(ELIXIR-NL) will contribute to Task 14.5 training on rare disease
registries and FAIRification of data at the source.
In WP16: Online Academic education course
● UL(ELIXIR-SI) will be co-leading the Biotechnologies & bioinformatics: databases, NGS and -omics
interpretation tools module of the online academic course.
● UCAM(ELIXIR-UK) will be leading Task 16.3 Follow-up, evaluation and monitoring,
UNIMAN(ELIXIR-UK) will be also contributing to this task
Previous experience relevant to the Tasks:
The utility of the EMBL-EBI to the scientific community today is evidenced by massive use of its services. EMBL-
EBI’s web portals receive over 27 million requests per day from 5 million unique IP addresses, 12 million compute
jobs per month are executed on EMBL’s cores.The community served ranges from basic academic researchers
through to applied research in diverse areas including pharmaceuticals, agriculture and nutrition. Alongside the
core service activities, the EMBL-EBI is a basic research institute, with bioinformaticians regularly publishing the
biological findings of computational investigations of biomolecular information. The constituency of the EMBL-
EBI most emphatically includes the commercial sector as well as academic research. It has a flourishing Industry
Programme and SME engagement activities for European companies involved in bioinformatics. EMBL-EBI also
provides a substantial proportion of EMBL's external training.
ELIXIR is an inter-governmental organisation, which builds on existing life sciences data resources and services
within Europe. It currently works across 21 member states and the EMBL-EBI, collectively reaching nearly 200
institutes involved in Bioinformatics research or service provision. ELIXIR’s core role is to orchestrate the
collection, quality control and archiving of large amounts of biological data, with a strong focus on ensuring that
these data are made as FAIR (Findable, Accessible, Interoperable and Reusable) as possible. During the past 4
years, ELIXIR has sought to be guided by the scientific community through the establishment of Use Cases, which
have included Human Data, Rare Diseases, Plant Sciences and Marine Metagenomics. Through these efforts
ELIXIR has ensured that the key Bioinformatic services and resources are increasingly accessible to and embedded
across LIfe Science Research in the EU.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work:
EMBL-EBI manages large-scale biological databases, which are available to clients via web services 24/7/365.
The demand for rapid access to all publicly available biological databases is constantly growing, as is the volume
of biological information held within the databases. To support these needs, EMBL-EBI manages an infrastructure
of extensive, high-performance compute infrastructure along with large data-storage farms. EMBL-EBI's state-of-
the-art technical architecture is secure and robust, and is distributed in four discrete, Tier 3+ security data centres in
different geographical locations to assure long-term security. This gives our data very high protection through
redundancy, and provides sufficient capacity and reserve to ensure our management of the rising influx of data and
compute requests. In August 2013 our main compute farm has ~17,000 cores and the installed disk based storage
capacity is above 30 Petabytes.
Part of EMBL-EBI’s core mission is to maintain large life science archives hosting critical reference data for
research. This includes ENSEMBL and genome archives; the EGA for human genomes and UniProt.
The ELIXIR Hub is charged with coordination activities, whilst the Nodes provide the service delivery of the key
bioinformatics resources. The largest ELIXIR Node is EMBL-EBI and delivers some of Europe’s key
bioinformatics services, which are described above.
Further information can be found at: www.ebi.ac.uk
Short Profile of key Staff Members who will be undertaking the work
Dr. Niklas ELIXIR Director, Project Coordinator. Dr. Blomberg joined ELIXIR as Director in 2013
Blomberg following 14 years in the pharmaceutical industry with AstraZeneca. He led the global
(M) cheminformatic function from 2006-2011 with responsibility for global delivery of novel
computational approaches and external partnerships in screening, and in 2011-2013 led the build
of new computational biology / computational chemistry unit for the AZ inflammatory research
area. He has also previously been the Chairman of the board for Bioinformatics for Life Science
in Sweden (BILS), Chair of the advisory board for the Swedish e-Science for Cancer prevention
and cure project, Advisory board member for the Swedish eScience center and the IMI eTRIKS
project. He was co-chair for IMI OpenPHACTS, a project with 24 industrial and academic
825575 – EJP RD – Part B 205
partners to develop standards and infrastructure for with
Associated effective
document data-interoperability across
Ref. Ares(2018)6091977 - 28/11/2018
chemistry and biology for drug-discovery research
Dr. Helen EMBL-EBI, Team Leader: Head of Molecular Archives comprising three teams and 85 people
Parkinson (F) delivering core databases, data coordination activities, semantic data integration tools. Her team
deliver the BioSamples database, the Ontology Lookup Service, the Knockout Mouse Project 2
informatics, PDX resources and the Human Cell Atlas Data Coordination. She is a also partner in
Infrafrontier.
Dr Johanna EMBL-EBI, Team Leader: Literature services. Dr. McEntyre has been Team Leader for
McEntyre (F) Literature Services at EMBL-EBI since 2009. She is the PI for Europe PMC - the database of
abstracts and full-text articles for the life sciences. Prior to joining EMBL-EBI, Jo was a staff
scientist at the NCBI, National Library of Medicine, NIH, USA, and was the Editor at Trends in
Biochemical Sciences (TiBS), Elsevier. Jo is active in the Force 11 Data Citation Implementation
Group, and is interested in text mining as a means to improve the integration of literature with
public data resources.
Dr Steven EMBL-EBI, Head of Technical Services. Dr Newhouse leads 5 teams comprising over 85 people
Newhouse supporting EMBL-EBI’s various IT functions. This includes the teams delivering the 200+PB of
(M) storage and over 30,000 cores of cloud, HTC and HPC analysis platforms, the database, desktop
and cloud support functions, hosting of public web services and tools, development of web sites
and more general open-source software development and operations which include the EBI Cloud
Portal and GA4GH compatible task-based analysis platforms.
Dr Thomas EMBL-EBI, Team Leader: European Genome Phenome Archive (EGA), the European Variation
Keane (M) Archive (EVA), as well as the Archival Infrastructure for the European Nucleotide Archive
(ENA) at EMBL-EBI. He is responsible for strategic planning for EGA, ENA (AI) and EVA, is a
member of the Global Alliance for Genomics and Health (GA4GH) steering committee and leads
the Large Scale Genomics workstream. He is the scientific lead for the Mouse Genomes Project, a
collaboration with the Wellcome Sanger Institute.
Sandra EMBL-EBI, Team Leader: Protein Function Content team. Responsible for the curation of
Orchard (F) UniProt at EMBL-EBI, and annotation of the Gene Ontology, carrying out manual annotation and
producing the rules for automated annotation. The team also create and maintain value-added
interfaces for exploring protein data, for example the Enzyme Portal and Complex Portal. Sandra
additionally works on standards development in protein data capture and annotation and is Co-
Chair of the HUPO Proteomics Standards Initiative
Claire EMBL-EBI, Head of Metabolomics. Provides the biomedical community with information on
O'Donovan metabolism: small molecules and their interplay with biological systems. Responsible for
(F) MetaboLights, a resource for data from metabolomics experiments and derived information. The
database is cross-species, cross-technique and covers metabolite structures and their reference
spectra as well as their biological roles, locations and concentrations, and experimental data from
metabolic experiments. Also responsible for PhenoMeNal, a comprehensive and standardised e-
infrastructure that supports the data processing and analysis pipelines for molecular phenotype
data generated by metabolomics applications.
Dr Fiona EMBL-EBI, Team Leader: Variation Annotation team. Fiona is part of the senior management for
Cunningham Ensembl (www.ensembl.org), a genome information system. Her team developed Ensembl's
(F) Variant Effect predictor (VEP), the software tool for annotating variation data, and led the
creation of the variation and phenotype data in Ensembl. Fiona works very closely with the
GENCODE project to improve transcript annotation for clinically relevant genes. Her team
deliver robust and reliable reference resources for consistent variant annotation in any species.
She is also a co-PI on the NHGRI-EBI GWAS Catalog project.
List of the most relevant publications and/or products, services (including widely-used datasets or software),
or other achievements:
1. Postmitotic nuclear pore assembly proceeds by radial dilation of small ER membrane openings. Otsuka
S, Steyer AM, Schorb M, Heriche JK, Hossain MJ, Sethi S, Schwab Y, Beck M, Ellenberg J. Nat Struct
Mol. Biol. 2018 Jan; 25(1):21-8. Epub 2017 Nov 27.
2. Sister chromatid resolution is an intrinsic part of chromosome organization in prophase. Nagasaka K,
Hossain MJ, Roberti MJ, Ellenberg J, Hirota T. Nat Cell Biol. 2016 Jun;18(6):692-9. doi:
10.1038/ncb3353. Epub 2016 May 2.
3. Inverted light-sheet microscope for imaging mouse pre-implantation development. Strnad P, Gunther S,
Reichmann J, Krzic U, Balazs B, de Medeiros G, Norlin N, Hiiragi T, Hufnagel L, Ellenberg J. Nature
825575 – EJP RD – Part B 206
Methods. 2016 Feb;13(2):139-42. Epub 2015 Dec 14. Associated with document Ref. Ares(2018)6091977 - 28/11/2018
4. High-throughput fluorescence correlation spectroscopy enables analysis of proteome dynamics in living
cells. Wachsmuth M, Conrad C, Bulkescher J, Koch B, Mahen R, Isokane M, Pepperkok R, Ellenberg J.
Nat Biotechnol. 2015 Apr;33(4):384-9. Epub 2015 Mar 16.
5. Nuclear Pore Scaffold Structure Analyzed by Super-Resolution Microscopy and Particle Averaging
Szymborska A, de Marco A, Daigle N, Cordes VC, Briggs JAG, Ellenberg J. Science. 2013 Aug
9;341(6146):655-8. Epub 2013 Jul 11.
6. van Gool, A. J., Bietrix, F., Caldenhoven, E., Zatloukal, K., Scherer, A., Litton, J.-E., et al. (2017).
Bridging the translational innovation gap through good biomarker practice. Nature Reviews Drug
Discovery, 16(9), 587–588. http://doi.org/10.1038/nrd.2017.72
7. Durinx, C., McEntyre, J., Appel, R., Apweiler, R., Barlow, M., Blomberg, N., et al. (2016). Identifying
ELIXIR Core Data Resources. F1000Research, 5, 2422. http://doi.org/10.12688/f1000research.9656.1
8. Auffray, C., Balling, R., Barroso, I., Bencze, L., Benson, M., Bergeron, J., et al. (2016). Making sense of
big data in health research: Towards an EU action plan. Genome Medicine, 8(1), 860.
http://doi.org/10.1186/s13073-016-0323-y
9. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., et al. (2016).
The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3,
160018. http://doi.org/10.1038/sdata.2016.18
10. Budd, A., Corpas, M., Brazas, M. D., Fuller, J. C., Goecks, J., Mulder, N. J., et al. (2015). A quick guide
for building a successful bioinformatics community. PLoS Computational Biology, 11(2), e1003972.
http://doi.org/10.1371/journal.pcbi.1003972
11. CE Cook, MT Bergman, G Cochrane, R Apweiler, E Birney. 2018. The European Bioinformatics
Institute in 2017: data coordination and integration. Nucleic acids research 46 (D1), D21-D29 DOI:
10.1093/nar/gkx1154
List of relevant previous projects or activities, connected to the subject of this proposal:
. Project coordinator of ELIXIR-EXCELERATE (2015-2019): an H2020 project (H2020-INFRADEV-
1-2015-1) Fast-track ELIXIR implementation and drive early user exploitation across the life sciences,
Grant number: 676559, 2015-2019
. Project Coordinator of CORBEL (2015-2019): an H2020-funded cluster project of the thirteen ESFRI
biological and medical research infrastructures (BMS RIs), which together have created a platform for
harmonised user access to biological and medical technologies, biological samples and data services
required by cutting-edge biomedical research. EMBL is co-leading the WP4 on the open call for users to
common service pipelines commonly offered by the ESFRI BMS RIs.
. Project Coordinator of BioMedBridges (2011-2015): a joint effort of twelve biomedical sciences research
infrastructures on the ESFRI roadmap to develop the shared e-infrastructure—the technical bridges—to
allow data integration in the biological, medical, translational and clinical domains.
. Project Coordinator of Euro-BioImaging Preparatory Phase I: an ESFRI infrastructure project that will
provide open user access to state-of-the-art imaging technologies in biological, molecular and medical
imaging for life scientists in Europe and beyond, including advanced light microscopy and electron
microscopy technologies. EMBL-HD (ALMF) participated in Euro-BioImaging Proof-of-Concept
studies in 2012 during which it hosted external Euro-BioImaging users.
. Partner in iNEXT consortium (infrastructure for NMR, EM and X-rays for Translational research),
providing access to Advanced light microscopy and Electron microscopy techniques.
. Project Coordinator of Euro-BioImaging Preparatory Phase II: EuBI PPII project aims not only at
submitting the ERIC application to the European Commission but also at enabling the rapid finalization
of the legal, financial, managerial and technical documents, tools and procedures to start the operation of
the EuBI ERIC on the day of the signature of the ERIC statutes by all its member states.
. Project Coordinator of Global BioImaging: Funded by the European Commission’s Horizon 2020
Programme it has received 1.78M €, to achieve multi-lateral international cooperation between Euro-
BioImaging and its infrastructure counterparts in six countries (Argentina, Australia, India, Japan, South
Africa, the USA) in the field of life sciences - including biological sciences, marine biology, biodiversity,
medical sciences and agricultural sciences. GBI enables Euro-BioImaging to exchange best practice with
its international infrastructure partners on open user access to their various services, and in the long term to
pursue international agreements on the reciprocal use of these services
Third parties involvement:
1. BSC (ELIXIR-ES)
2. CSC (ELIXIR-FI)
825575 – EJP RD – Part B 207
3. CNR (ELIXIR-IT) Associated with document Ref. Ares(2018)6091977 - 28/11/2018
4. DTU (ELIXIR-DK)
5. MU-CERIT-SC (ELIXIR-CZ)
6. SIB (ELIXIR-CH)
7. UCAM (ELIXIR-UK)
8. UU (ELIXIR-SE)
9. UNIMAN (ELIXIR-UK)
10. DTL-Projects (ELIXIR-NL)
11. UL (ELIXIR-SI)
77-EURORDIS
Full legal name (Acronym) – Country EURORDIS-Rare Diseases Europe (EURORDIS)
Principal investigator Virginie Bros-Facer
Relevant Network EURORDIS
Description of the legal entity/department/laboratory/group:
EURORDIS-Rare Diseases Europe is a non-governmental patient-driven alliance of patient organisations representing
792 rare disease patient organisations in 69 countries and is the voice of the estimated 30 million patients affected by
rare diseases throughout Europe. EURORDIS’ vision is to enable better lives and cures for people living with a rare
disease and its mission is to work across borders and diseases to improve the lives of people living with a rare disease.
Since its creation in 1997, EURORDIS has gained significant and well-recognised experience in networking and
capacity building for patient organisations, in information sharing as well as in policy development, regulatory affairs,
medicines development and patient engagement in RD research and research infrastructure projects. EURORDIS
promotes, supports and coordinates the patient engagement with most of the stakeholders involved during the lifetime
of a medicinal product.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP8 (RD Research challenges), EURORDIS will be the co-leader (leader FFRD) of this WP, responsible for the
development of the scheme (leader of task 8.1) and participant in task 8.2 and 8.3 to set up the challenges and support
the evaluation of funded projects.
Pillar 3: EURORDIS is co-leader of Pillar 3 with VUHSK
In WP15, we will lead task 15.1 “ExPRESS Expert Patients and Researchers EURORDIS Summer School”
In WP15, we will lead task 15.2 “Training for patient advocates on scientific innovation and translational research”
In WP15, we will lead task 15.3 “training for patient advocates and representatives on leadership and communication
skills”. In WP15, we are also participant in task 15.4 co-lead by TEDDY and FSJD to develop education materials and
activities for paediatric patients.
In WP18, we are co-leader with CHMI, supporting VUH as leader of this WP and we lead task 18.1 with FFRD on
“Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training
activities”.
Coordination & Transversal activities:
As Pillar 3 leader, EURORDIS is a member of the Operating Group and is involved as a participant in Pillar 0 WP1,
WP2, WP3, WP4 and WP5.
Previous experience relevant to the Tasks:
Virginie Bros-Facer (VBF) previously worked for the NC3Rs in the UK, the organisation who pioneered the
CRACK IT challenges which is the funding model to be used to develop the RD Research challenge in Pillar 1 WP3
and therefore has a deep and detailed understanding of the mechanisms used in this innovative funding scheme.
Furthermore, as Scientific Director, VBF represent EURORDIS is RD research and research infrastructure projects
(see below) as well as other relevant European and international initiatives (IRDiRC, UDNI, SWAN Europe, Go
FAIR RD Network, BBMRI-ERIC Stakeholders forum), bringing the RD patient voice & perspectives and
developing specific capacity building programmes to engage and support RD patient representatives in these
projects and initiatives.
Description of any significant infrastructure and/or major items of technical equipment, relevant to the
proposed work : N/A
825575 – EJP RD – Part B 208
Short Profile of key Staff Members who will be undertaking the work with document Ref. Ares(2018)6091977 - 28/11/2018
Associated
Dr. Virginie Bros- Virginie Bros-Facer is Scientific Director at EURORDIS-Rare Diseases Europe. Her
Facer responsibilities include monitoring the European landscape on rare disease research from a
(female) strategy, policy and action perspectives, overseeing and managing all activities related to rare
disease research, diagnostics, infrastructures and technologies as well as related ethical issues.
Prior to joining EURORDIS, she worked for several research funding organisations in the UK,
including as Director of Medical Research for Sparks, a children's medical research charity based
in London and as Research Funding Programme Manager for the NIHR and the National Centre
for Replacement, Reduction and Refinement of Animals in Research (NC3Rs under the MRC
umbrella). Virginie holds an MSc and a PhD in Neuroscience from King's College London and
also worked for 7 years at the UCL Institute of Neurology in London on several research projects
aiming to develop new therapeutic strategies for motor neuron disease and other neuromuscular
disorders.
Nancy Hamilton Nancy Hamilton is part of the EURORDIS Operations team, her work is centred around
(female) empowering patients’ advocates. She coordinates the organisation of the capacity-building
EURORDIS Summer School, Winter School and the EURORDIS e-learning tools. She is the
contact person at EURORDIS for the EUPATI and ECRIN projects respectively to develop a
European Patients Academy and to set up a European Clinical Research Infrastructure Network.
Her previous experience includes working as Education Resource Coordinator at the European
Haematology Association in Rotterdam where she played a key role in the development of the
European Haematology CME system. Nancy has a passion for human rights and volunteers at
Amnesty International France and is currently completing a legal diploma (Capacité en Droit) at
the Faculté de Droit of the University of Paris Sorbonne Panthéon. Nancy has a B.A. in medical
sociology and an M.A in French literature.
List of the most relevant publications and/or products, services (including widely-used datasets or software), or
other achievements
1.The voice of 12.000
patientshttp://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf
2. Position paper of EURORDIS on Rare Diseases Research (2012)
http://www.eurordis.org/sites/default/files/EURORDIS_Rapport_Research_2012.pdf
3. International Joint Recommendations to address specific needs of Undiagnosed Rare Disease Patients (2016)
https://www.eurordis.org/publication/international-joint-recommendations-address-specific-needs-undiagnosed-rare-
disease-patients
4. Rare disease patients’ participation in research: a report on the results of the Rare Barometer survey on rare disease
patients' participation in research (2018). https://www.eurordis.org/publication/rare-disease-patients-participation-
research
List of relevant previous projects or activities, connected to the subject of this proposal
. IRDiRC; Virginie Hivert (EURORDIS Therapeutic Development Director) is co-chair of the Therapeutic Scientific
Committee and Virginie Bros-Facer (EURORDIS Scientific Director) is a member of the Patient Advocacy
Constituent Committee
. RD-Connect; FP7; 2013-2018- EURORDIS is WP8 leader (patient engagement), member of the Executive
Management Committee and chair the Patient Advisory Council comprised of 16 rare disease patient representatives
representing 15 rare diseases and European countries supporting their active involvement in the different WPs of the
project (Biobanks, registries, bioinformatics tools, communication and the phenome-exome analysis platform). RD-
Connect’ s resources are represented throughout the EJP in Pillar 2 and Pillar 3.
. Solve-RD; H2020; 2018-2022- EURORDIS is a partner in several WPs and is responsible for the creation and
animation of the Community Engagement Task Force aiming at supporting the interaction and the engagement with
the different initiatives and networks currently existing in the field of diagnosis at the European and International
levels. EURORDIS will also develop the first 2 editions of the Winter School (Patient Capacity Building Programme
on Scientific Innovation and Translational Research in 2018 and 2019, to be developed further in Pilar 3, WP2.2
from 2020).
. European Reference Networks; EC; 2017-2021-EURORDIS is responsible for the creation of all 24 European
Patient Advocacy Groups (ePAGs) involved in the different ERNs. EURORDIS actively supports the activities of
the 24 ePAGs communities in all ERNs and provides capacity building for these RD patient representatives within
the different networks (link with future training activities in Pillar 3, WP2.3).
. Connect for Children (C4C); IMI2; 2018-2023- EURORDIS is a partner involved in 6 work packages and will work
together with the Sant Juan de Deu Foundation (co-leader of WP2.4 with Teddy in Pillar 3) to specifically engage
825575 – EJP RD – Part B 209
young rare disease patients in the development of the pan-European
Associated with paediatric
document Ref.clinical trials network
Ares(2018)6091977 and
- 28/11/2018
infrastructure.
78-CSO-MOH
Full legal name (Acronym) – Country Chief Scientist Office, Ministry of Health (CSO-MOH), Israel
Principal investigator Irit Allon
Relevant Network https://www.health.gov.il/English/Pages/HomePage.aspx
Description of the legal entity/department/laboratory/group:
If the Beneficiary is composed of several teams (a, b, c) and you decide to replicate this table several times, there is
no need to repeat the “legal entity” description in each of the tables.
Main tasks in the project per Pillar/WP:
Pillar 1:
In WP6, we will participate in the Joint Transnational Calls
In WP7, we will lead Task 7.1 Public Call document for networking scheme
In WP9, we will lead the WP on Monitoring of the funded projects and be the leaders of Tasks 9.1, 9.2, 9.3
Previous experience relevant to the Tasks:
In the last 14 years, CSO-MOH has been actively involved in several health- related Era-Nets and JPIs. In
particular, CSO-MOH has been responsible for science to society issues, communication and dissemination and
young scientists. In the last year CSO-MOH has added another field of interest, monitoring, which is currently
done in the framework of E-RARE-3 and ERA-Net Per-Med. In the EJP, it will be the first time that CSO-MOH
leads the entire WP and responsible for all the tasks within it.
Short Profile of key Staff Members who will be undertaking the work
Pr. Abraham Prof. Avi Israeli, MD, is the Chief Scientist at the Ministry of health. He is a specialist in internal
Israeli medicine and the current head of the Department of Health Policy, Health Care Management and
(male) Health Economics at the Hebrew University – Hadassah Faculty of Medicine. Prior to this he was
the Director General of the Israel Ministry of Health (2003-2009) and the Director – General of
Hadassah Medical Organization (1998 -2001).Prof. Israeli is an NSC member in several ERA-
Nets, CSAs and JPIs.
Dr. Irit Allon Dr. Irit Allon, DMD, Ph.D is the director of the medical research department.She is the previous
(female) national coordinator of several ERA-Nets and JPIs in the CSO-MOH. She is a specialist in Oral
pathology and since 2005 has gained experience in managing ERA-Nets and leading the Science
to Society and Communication & Dissemination activities. She is the former national coordinator
of ERA-NET PathoGenoMics, ERA-Age1 and 2, FUTURAGE and the current liaison of E-
RARE, Infect-ERA, EuroNanoMed2, and JPIAMR at the CSO-MOH.
Dr. Nava Dr. Nava Levine, PhD, is the national coordinator of several ERA-Nets in the CSO-MOH. She is
Levin the projects manager in the Israeli association for cardiovascular research and has coordinated
(female) ERA-Nets in the CSO-MOH during 2006-2013 mainly focused on the Science to Society and
Communication & Dissemination activities.
Ms. Elina Ms. Elina Kushnir is the- ICT director in CSO-MOH, supporting the technical and financial
Kushnir aspects of ERA-NET activities.
(female)
79-SNSF
Full legal name (Acronym) – Country Swiss National Science Foundation (SNSF), Switzerland
Principal investigator None
Relevant Network ERANET E-RARE
Description of the legal entity/department/laboratory/group:
Mandated by the federal government, the Swiss National Science Foundation (SNSF) supports basic science in all
academic disciplines, from history to medicine and the engineering sciences. The SNSF is Switzerland’s foremost
research funding organisation. The SNSF was established as a private foundation in 1952.
Main tasks in the project per Pillar/WP:
The tasks of the SNSF is to participate in the implementation and execution of four Joint Transnational Calls for
collaborative research projects.
825575 – EJP RD – Part B 210
Pillar 1: Associated with document Ref. Ares(2018)6091977 - 28/11/2018
In WP6, we will participate in:
Task 6.1 Joint Transnational Call 2019 (JTC 2019): Call co-funded by the EC for three years
Task 6.2 Joint Transnational Call 2020 (JTC 2020): Call co-funded by the EC for two years
Task 6.3 Joint Transnational Call 2021 (JTC 2021): call not co-funded by the EC
Task 6.4 Joint Transnational Call 2022 (JTC 2022): call not co-funded by the EC
Previous experience relevant to the Tasks:
The SNSF is a longstanding funding partner in the ERANET E-RARE and member of the E-RARE Steering
Committee.
Short Profile of key Staff Members who will be undertaking the work
Dr. Christoph Meier Head of Section Clinical, Social and Preventive Medicine SNSF
(male)
Dr. Ayşim Yilmaz Head of Department Biology and Medicine SNSF
(male)
List of relevant previous projects or activities, connected to the subject of this proposal
. The SNSF has participated in ERANET E-RARE Joint Transnational Calls since 2013.
80-BLACKSWAN
Full legal name (Acronym) – Country BLACKSWAN Foundation, Switzerland
Principal investigator Olivier Menzel
Relevant Network E-Rare, Eurordis, NIH, RDI, UDNI, IRDiRC, ProRaris
Description of the legal entity/department/laboratory/group:
The BLACKSWAN Foundation was established in Switzerland in 2010 to contribute to the development of
research on rare and orphan diseases worldwide. The Foundation supports research on all different types of rare
and orphan disease, which makes its vision unique and helps in finding new solutions that can assist a large variety
of projects. Besides its funding research mission, the Foundation organizes every two years the RE(ACT)
Congress, which became an international reference point for rare disease experts. In 2014, the BLACKSWAN
Foundation launched the RE(ACT) Community a crowdfunding and a knowledge sharing digital platform that
connects researchers, patients and other rare disease stakeholders. Since 2015, BLACKSWAN Foundation has also
started an international advocacy and awareness campaign called #RAREvolution to ensure rare diseases are
recognized as an international public health and research priority.
Main tasks in the project per Pillar/WP:
Pillar 0: Transversal WP (WP5 external